<SEC-DOCUMENT>0000950123-19-011700.txt : 20200127
<SEC-HEADER>0000950123-19-011700.hdr.sgml : 20200127
<ACCEPTANCE-DATETIME>20191202171733
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-19-011700
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		25
FILED AS OF DATE:		20191202
<PUBLIC-REL-DATE>20200127
DATE AS OF CHANGE:		20191202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alector, Inc.
		CENTRAL INDEX KEY:			0001653087
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				462702363
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02936
		FILM NUMBER:		191263918

	BUSINESS ADDRESS:	
		STREET 1:		151 OYSTER POINT BLVD., SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		415-231-5660

	MAIL ADDRESS:	
		STREET 1:		151 OYSTER POINT BLVD., SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alector LLC
		DATE OF NAME CHANGE:	20150915
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>Draft Registration Statement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on December 2, 2019.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>This draft registration statement has not been filed publicly with the Securities and Exchange Commission, and all information herein
remains strictly&nbsp;confidential. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration
No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Under </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>The
Securities Act of 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>ALECTOR, INC. </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name
of Registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">82-2933343</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>131 Oyster Point Blvd. Suite&nbsp;600 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>South San Francisco, California 94080 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">415-231-5660</FONT></FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Arnon Rosenthal, Ph.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alector, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>131 Oyster
Point Blvd. Suite&nbsp;600 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>South San Francisco, California 94080 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">415-231-5660</FONT></FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kenneth A. Clark</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Michael E. Coke</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Wilson&nbsp;Sonsini&nbsp;Goodrich&nbsp;&amp;&nbsp;Rosati,&nbsp;P.C.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>650 Page Mill Road</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Palo
Alto, California 94304</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-493-9300</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stephanie Yonker, Ph.D.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vice President, Legal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alector, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>131 Oyster
Point Blvd. Suite&nbsp;600</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>South&nbsp;San&nbsp;Francisco,&nbsp;California&nbsp;94080</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">415-231-5660</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alan F. Denenberg</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stephen Salmon</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Davis
Polk&nbsp;&amp; Wardwell LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1600 El Camino Real</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, California 94025</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-752-2000</FONT></FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this registration
statement. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to
Rule&nbsp;415 under the Securities Act of 1933, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this form is filed to register additional
securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount<BR>to&nbsp;be<BR>Registered(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering
Price</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Per Share(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering Price(1)(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration Fee</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common stock, $0.0001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Includes offering price of any additional shares of our common stock that the underwriters have the option to
purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of computing the amount of the registration fee. In accordance with Rule 457(c)
under the Securities Act of 1933, as amended, the maximum price per share and maximum aggregate offering price are based on the average of the $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(high)
and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(low) sale price of the registrant&#146;s common stock as reported on The Nasdaq Global Select Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2019, which date is within five business days prior to filing this Registration Statement. </P></TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration
Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#eb0029"><B>The information in this preliminary prospectus is not complete and may be changed.
These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#eb0029"><B>SUBJECT TO COMPLETION, DATED </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#eb0029"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2019 </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g96o97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is a public offering of
shares of common stock by Alector, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the NASDAQ Global Select Market under the symbol &#147;ALEC.&#148;
On&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, the last reported sale price of our common stock on the NASDAQ Global Select Market was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined under the
federal securities laws and, as such, have elected to comply with certain reduced reporting requirements for this prospectus and may elect to do so in future filings. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common
stock involves risks. See the section titled &#147;<A HREF="#rom838337_4">Risk Factors</A>&#148; beginning on page 11 to read about factors you should consider before buying shares of our common stock. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities, or passed upon the accuracy
or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:13%;border-bottom:1px solid #000000; width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the section titled &#147;Underwriting&#148; for a description of the compensation payable to the
underwriters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock at the public offering price less underwriting discounts and commissions. The underwriters can exercise this
option at any time within 30 days after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares of common stock to purchasers on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="bottom"><B>Morgan Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Goldman Sachs&nbsp;&amp; Co. LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_2">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_3">Summary Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_5">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_6">Market, Industry and Other Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_8">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc838337_22">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc838337_23">A Letter from Arnon</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_12">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_13">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_14">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_15">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_16">Material U.S. Federal Income and Estate Tax Considerations for <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of our Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_17">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_18">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_19">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_20">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_21">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without
charge by following the instructions under the section of this prospectus entitled &#147;Where You Can Find More Information.&#148; You should carefully read this prospectus as well as additional information described under the section of this
prospectus entitled &#147;Incorporation of Certain Information by Reference,&#148; before deciding to invest in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and
the underwriters have not authorized anyone to provide you any information other than that contained or incorporated by reference in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you.
We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or
sale is not permitted. The information contained or incorporated by reference in this prospectus is accurate only as of the date of this prospectus or the date of the applicable document incorporated by reference, regardless of the time of the
delivery of this prospectus or any sale of shares of our common stock. Our business, financial condition, results of operations, and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: we have not and the underwriters have not done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about,
and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained in greater detail elsewhere in this prospectus and in the documents incorporated by
reference. This summary is not complete and does not contain all of the information you should consider in making your investment decision. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should carefully consider, among other things, our consolidated financial statements and related notes incorporated by reference into
this prospectus from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018, or our 2018 Annual Report, our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the three
and nine months ended September&nbsp;30, 2019, or our 2019 Quarterly Report, and the sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included in our
2018 Annual Report and 2019 Quarterly Report and incorporated by reference into this prospectus. In this prospectus, unless context requires otherwise, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;Alector,&#148; or &#147;the
Company&#148; refer to Alector, Inc. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALECTOR, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our mission is to develop therapies that
empower the immune system to cure neurodegeneration. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a
novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to
simultaneously counteract these pathologies by restoring healthy immune function to the brain. Supporting our scientific approach, our Discovery Platform enables us to advance a broad portfolio of product candidates, validated by human genetics,
which we believe will improve the probability of technical success over shorter development timelines. As a result, in the last six years, we have identified over forty immune system targets, progressed over ten programs into preclinical research,
and advanced three product candidates, AL001, AL002, and AL003, into clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AL001, our first program in the clinic,
modulates progranulin (PGRN), a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer&#146;s disease, and Parkinson&#146;s disease. AL001 is initially
designed to treat FTD, a severe, rapidly progressing neurodegenerative disorder that affects approximately 170,000 individuals in the United States and the European Union alone, with potentially higher prevalence in Asia and Latin America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our AL001 program is aimed at treating a genetic subset of patients with FTD who have a known genetic mutation that causes a deficiency in
PGRN, which is called <FONT STYLE="white-space:nowrap">FTD-GRN.</FONT> AL001 has successfully achieved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> in the Phase 1b portion of the study in <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> subjects by restoring PGRN levels in plasma and cerebrospinal fluid back to the normal range. In the third quarter of 2019, we advanced AL001 into a Phase&nbsp;2 study with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients expected in the first half of 2020, which also includes an additional genetic subset of FTD patients <FONT
STYLE="white-space:nowrap">(FTD-C9orf72).</FONT> In addition, in consultation with the U.S. Food and Drug Administration (FDA), we plan to advance AL001 into a Phase&nbsp;3 study in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients in 2020.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing AL101, our second product candidate in our PGRN program, for patients suffering from more prevalent neurodegenerative
diseases including Alzheimer&#146;s disease and Parkinson&#146;s disease, in addition to FTD. In line with our therapeutic hypothesis for FTD, mutations that moderately reduce the expression levels of PGRN have been shown to increase the risk of
developing Alzheimer&#146;s disease and Parkinson&#146;s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models. AL101 received orphan drug designation from the FDA for treatment of FTD in July
2019 and we expect to initiate a Phase 1 study of AL101 in the fourth quarter of 2019. We expect proof-of-mechanism data in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own
worldwide rights to both AL001 and AL101. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our next development programs, AL002 and AL003, focus on modulating check-point receptors on
the brain&#146;s immune cells, with AL002 targeting Triggering Receptor Expressed on Myeloid cells&nbsp;2 (TREM2) and AL003 targeting sialic acid binding <FONT STYLE="white-space:nowrap">Ig-like</FONT> lectin&nbsp;3 (SIGLEC&nbsp;3), respectively.
The AL002 and AL003 programs are aimed at treating Alzheimer&#146;s disease patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the third quarter of 2019, we completed the
Phase 1a portion of the study in healthy subjects with AL002 and a dose dependent change in the target engagement biomarker in cerebrospinal fluid was observed upon treatment. In the second quarter of 2019, based on safety and tolerability observed
in the Phase 1a study, we initiated the Phase 1b portion of the study with AL002 in Alzheimer&#146;s disease patients. We expect <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> data from
Alzheimer&#146;s disease patients in the first half of 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2019, we initiated a Phase 1a study in healthy
subjects with AL003, a product candidate targeting Alzheimer&#146;s disease. Thirty-eight (38)&nbsp;healthy subjects were dosed over eight dose cohorts in the AL003 Phase 1a dose escalation trial. A dose dependent change in target engagement in the
blood was observed upon treatment. One subject treated with the second highest dose experienced aseptic hip monoarthritis and a second subject treated with the highest dose experienced an adverse drug reaction characterized by rash, fever, and
thrombocytopenia, which were both deemed treatment-related serious adverse events. The subjects were treated with corticosteroids and recovered. Based on the safety and tolerability observed in the Phase 1a study, we identified a dose and initiated
screening for the Phase 1b portion of the study with AL003 in Alzheimer&#146;s disease patients in the fourth quarter of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
partnered with AbbVie Biotechnology, Ltd. (AbbVie), a leader in neuroscience drug development, for the global development and potential commercialization of AL002 and AL003. We are responsible for execution of the Phase&nbsp;1 and Phase&nbsp;2
studies. Following AbbVie&#146;s potential exercise of its option, Alector and AbbVie will share the development costs and will split global profits after marketing approval. However, following AbbVie&#146;s option exercise for a program, we may opt
out of sharing in development costs and profits or losses from that program and instead receive a tiered royalty on sales of products from that program. As part of this partnership, we received $205.0&nbsp;million in upfront payments, of which
$5.0&nbsp;million and $200.0&nbsp;million was received by us in October 2017 and January 2018, respectively, $20.0&nbsp;million from the sale of shares of our preferred stock in October 2017 and are eligible for up to an additional
$985.6&nbsp;million in option exercise and milestone payments and a global profit share with AbbVie upon commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Discovery
Platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system targets that play a critical role in the development of multiple
neurodegenerative diseases. Our Discovery Platform focuses on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Target Selection</I></B><B>. </B>We identify mutations in genes that control the brain&#146;s immune
system, which we believe are the root cause of neurodegeneration, employ a suite of genetic tools to elucidate the immune dysfunction caused by these mutations, and then engineer immune modulating antibodies to counteract the harmful consequences of
these genetic mutations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Biomarker Selection</I></B><B>. </B>We are able to identify and employ molecular biomarkers, assays, and
precise imaging techniques to confirm target engagement and measure the effect of our product candidates, allowing us to potentially obtain clinical data earlier than would otherwise be expected using traditional clinical measures.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Patient Selection</I></B><B>. </B>We utilize genetic screening and other biomarkers to better align a
patient&#146;s specific diagnosis with the targeted intervention in our clinical studies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our immuno-neurology approach
and our Discovery Platform are designed to broadly address multiple neurodegenerative disorders. The breadth of our opportunity is reinforced by our ability to engineer therapeutics </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capable of modulating a broad array of immune targets, validated by human genetics, across multiple mechanisms of action, including product candidates that activate, block, inhibit, or
down-regulate a given target as therapeutically needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table highlights our preclinical and clinical programs. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g78f41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table highlights ten of our identified programs in our research and development pipeline.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g39b98.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above table reflects that we currently have ten research programs identified in our research and
development pipeline focused on targeting Alzheimer&#146;s disease, Parkinson&#146;s disease, amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis and oncology. Currently, we estimate that these programs are one to three years or more
away from entering preclinical studies assuming that these programs meet our requirements for advancement into the preclinical stage. For each of our programs in our research and development pipeline we are working to identify biomarkers to be
utilized in preclinical studies for each program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Immune System is Central to Neurodegeneration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss of healthy immune function in the brain, due to cellular aging or mutations of genes that regulate key immune cells, underlies the
onset and progression of multiple neurodegenerative disorders. Genomic analyses have shown that there is a strong correlation between genetic mutations that predispose individuals to neurodegeneration and dysfunction in the immune system. For
example, 22 of the top 25 risk genes identified by evaluating large-scale data on tens of thousands of Alzheimer&#146;s disease patients regulate immune function in the </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
brain. As a result of these genetic mutations, the brain&#146;s immune function deteriorates and subsequently would fail to carry out critical activities, which include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clearing or counteracting pathological neurodegenerative proteins such as amyloid-beta, TAU, alpha-synuclein, and
<FONT STYLE="white-space:nowrap">TDP-43;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing metabolic and functional support to nerve cells; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulating synaptic connections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protecting nerve cells by stimulating the regeneration of myelin sheaths around nerve fibers; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlling the neurotoxic activities of activated astrocytes and rogue microglia. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that restoring the immune system&#146;s ability to perform all of these vital functions in the brain is crucial to addressing
neurodegeneration given that past approaches focusing on single degenerative pathologies have proved inadequate to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the early
20<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> century, the root cause of neurodegeneration has been thought to be misfolded and aggregated pathological proteins. Other observable pathologies, including destruction of synapses,
accelerated nerve cell death, and dysfunction of the brain support cells, were all thought to be consequences of these pathological misfolded proteins. As a result, attempts to develop therapies for neurodegeneration have been centered on blocking
the synthesis of, and removing or <FONT STYLE="white-space:nowrap">dis-aggregating</FONT> misfolded proteins. These attempts have been largely unsuccessful, as the disease continues to progress despite significant clearance of the misfolded protein.
We believe that the multiple pathologies found in degenerative brain disorders become independent of the misfolded proteins, and each other, at early disease stages and are driven primarily by dysfunction of the brain&#146;s immune system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, the brain&#146;s immune system undergoes gradual deterioration of functional characteristics as part of normal
biological&nbsp;aging or due to harmful genetic mutations that are linked to neurodegeneration and are associated with accelerated senescence of the brain immune cells. These cells are no longer capable of executing their beneficial and protective
roles and instead often become harmful and destructive to the brain. Based on our understanding of the role of genetic mutations in neurodegeneration, we have designed our product candidates to target the mutated genes linked to neurodegeneration,
with the goal of slowing or reversing the deterioration of the brain&#146;s immune cells to achieve therapeutic benefit. By restoring healthy immune function in the brain, we believe we can simultaneously counteract the multiple independent
pathologies responsible for neurodegeneration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Team </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is led by seasoned executives with a proven track record of drug discovery and development in neuroscience, as well as substantial
operational and business expertise. Our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer, Arnon Rosenthal, Ph.D., has spent over 35&nbsp;years developing therapeutics in neuroscience and led teams responsible for the
development of the <FONT STYLE="white-space:nowrap">non-addictive</FONT> pain drug tanezumab and the migraine drug AJOVY, and multiple other programs in clinical development. He also held several leadership roles over a <FONT
STYLE="white-space:nowrap">16-year</FONT> career at Genentech, where he led the team that discovered the target for the cancer drug Erivedge. Our Chief Medical Officer, Robert Paul, M.D., Ph.D., served as the Therapeutic Area Lead for Neuroscience
at Genentech, where among other projects, he oversaw the clinical development of several product candidates, including the amyloid-beta antibody crenezumab in Alzheimer&#146;s disease, <FONT STYLE="white-space:nowrap">GDC-0134</FONT> in ALS, and <FONT
STYLE="white-space:nowrap">GDC-0276</FONT> and <FONT STYLE="white-space:nowrap">GDC-0310</FONT> in pain. Our Chief Development Officer, Robert King, Ph.D., previously served as the Senior Vice President of development and supply chain at SciClone
Pharmaceuticals. Our Chief Business Officer, Sabah Oney, Ph.D., previously served as the Head of Global Sales and Business Development at Ariosa Diagnostics until and through its acquisition by Roche. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to develop therapies that empower the immune system to cure neurodegeneration. The key tenets of our business strategy to achieve
this goal include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">building the leading, fully-integrated company focused on delivering innovative immuno-therapies, validated by
human genetics, for the treatment of neurodegeneration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applying our proprietary development capabilities to rapidly advance our product candidates through clinical <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies and beyond; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maximizing the therapeutic potential of our existing targets and product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing to focus on discovering new targets and product candidates, validated by human genetics, to prosecute
the full power of our insights and platform. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks and uncertainties that you should consider before investing in our company. These risks are described
more fully in the section titled &#147;Risk Factors&#148; in this prospectus. These risks include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are in the early stages of clinical drug development and have a limited operating history and no products
approved for commercial sale. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant net losses in each period since our inception and anticipate that we will continue
to incur net losses for the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our share price has been and may continue to be highly volatile, and you could lose all or part of your
investment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Drug development is a highly uncertain undertaking and involves a substantial degree of risk.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need to obtain substantial additional financing to complete the development and any commercialization of
our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Due to the significant resources required for the development of our products, and depending on our ability to
access capital, we must prioritize development of certain product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Research and development of biopharmaceutical products is inherently risky. Our business is heavily dependent on
the successful development of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be successful in our efforts to continue to create a pipeline of product candidates from our Discovery
Platform or to develop commercially successful products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be successful in our efforts to expand indications for approved product candidates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have concentrated a substantial portion of our research and development efforts on the treatment of
neurodegenerative diseases, a field that has seen limited success in drug development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our
clinical trials on the timelines we expect, if at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product
candidates, which would prevent, delay, or limit the scope of regulatory approval and the commercialization of our product candidates. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial Public Offering (IPO) Transaction </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, we issued and sold 9,739,541 shares of common stock at a public offering price of $19.00 per share, including 489,541 shares
sold pursuant to the underwriters&#146; partial exercise of their option to purchase additional shares. We received aggregate net proceeds from the offering, net of underwriting discounts and commissions and offering expenses, of
$168.2&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were initially formed as a limited liability company in Delaware in May 2013 under the name Alector LLC and completed our restructuring to a
corporation in October 2017 under the name Alector, Inc. Our principal executive offices are located at 131&nbsp;Oyster Point Boulevard, Suite&nbsp;600, South San Francisco, California 94080. Our telephone number is <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">415-231-5660.</FONT></FONT> Our website address is www.alector.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus and should not be considered
to be part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use Alector, the Alector logo, and other marks as trademarks in the United States and other countries.
This prospectus contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork, and other visual displays,
may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or TM&nbsp;symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or the
rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#146; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any
other entity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (JOBS Act). We will
remain an emerging growth company until the earliest to occur of: the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; the date we qualify as a &#147;large accelerated filer,&#148; with at least
$700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> the issuance, in any three-year period, by us of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt
securities; and December&nbsp;31, 2024, which is the last day of the fiscal year ending after the fifth anniversary of our initial public offering. As a result of this status, we have taken advantage of reduced reporting requirements in this
prospectus and may elect to take advantage of other reduced reporting requirements in our future filings with the Securities and Exchange Commission. In particular, in this prospectus, we have not included or incorporated by reference all of the
executive compensation related information that would be required if we were not an emerging growth company. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with
new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and we have adopted and will continue to adopt
new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies that are not emerging growth companies. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common&nbsp;stock&nbsp;offered&nbsp;by&nbsp;us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to purchase
additional shares in full) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase additional shares of common stock from us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from the sale of the shares of our common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional shares in full, based upon an offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the last
reported sale price of our common stock on the NASDAQ Global Select Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 and after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering, together with our existing resources, as follows: (1)&nbsp;to fund Phase&nbsp;2 and Phase 3 clinical trials for AL001 in
<FONT STYLE="white-space:nowrap">FTD-GRN</FONT> and expand into <FONT STYLE="white-space:nowrap">FTD-C9orf72</FONT> and other potential indications; (2)&nbsp;to fund Phase 1 and Phase 2 clinical trials for AL002 and AL003; (3) to advance AL101 in
and through Phase 1 clinical trials; (4)&nbsp;to continue to advance our preclinical development pipeline into Phase 1 clinical trials; (5)&nbsp;to further develop our Discovery Platform; and (6)&nbsp;to fund working capital and other general
corporate activities. See the section titled &#147;Use of Proceeds&#148; for more information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See the section of this prospectus titled &#147;Risk Factors&#148; beginning on page&nbsp;11 and other information included or incorporated by reference in this prospectus for a discussion of factors you should carefully consider before deciding
to invest in shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">NASDAQ trading symbol </P></TD>
<TD>&#147;ALEC&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on the
68,922,249 shares of our common stock outstanding as of September&nbsp;30, 2019, and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,822,524 shares of common stock issuable upon exercise of options to purchase shares of our common stock
outstanding as of September&nbsp;30, 2019 under our 2017 Stock Option and Grant Plan (2017 Plan), at a weighted-average exercise price of $8.97 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,095,600 shares of common stock issuable upon exercise of options to purchase shares of our common stock
outstanding as of September&nbsp;30, 2019 under our 2019 Equity Incentive Plan (2019 Plan), at a weighted-average exercise price of $19.15 per share; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,604,971 shares of common stock issuable upon exercise of options to purchase shares of our common stock that we
granted after September&nbsp;30, 2019 under our 2019 Plan, at a weighted-average exercise price of $17.12 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,911,739 shares of common stock reserved for future issuance under our 2019 Plan as of September&nbsp;30, 2019,
as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,478,492 shares of common stock reserved for issuance under our 2019 Employee Stock Purchase Plan as of
September&nbsp;30, 2019, as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, this prospectus reflects and assumes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of outstanding options after September&nbsp;30, 2019; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of common stock from us in this
offering. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our consolidated financial data for the periods and as of the dates indicated. We derived the consolidated
statement of operations data for the years ended December&nbsp;31, 2018, 2017, and 2016 from our audited consolidated financial statements included in our 2018 Annual Report, which is incorporated by reference in this prospectus. We derived the
consolidated statement of operations data for the nine months ended September&nbsp;30, 2019 and 2018, and the consolidated balance sheet data as of September&nbsp;30, 2019, from our unaudited interim condensed consolidated financial statements
included in our 2019 Quarterly Report, which is incorporated by reference in this prospectus. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as our annual audited consolidated financial
statements and, in the opinion of management, reflect all adjustments, which include only normal, recurring adjustments that are necessary to present fairly the unaudited interim condensed consolidated financial statements. Our historical results
are not necessarily indicative of the results that may be expected in the future, and our interim results are not necessarily indicative of the results to be expected for the full year or any other period. You should read the following summary
consolidated financial data in conjunction with our consolidated financial statements and the related notes and the information in the sections titled &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; included in our 2018 Annual Report and 2019 Quarterly Report and incorporated by reference into this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,302,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,142,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,173,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,663,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,154,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 381,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The as adjusted consolidated balance sheet data reflects our receipt of net proceeds from the sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which was
the last sale price of our common stock as reported by the NASDAQ Global Select Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other
information contained or incorporated by reference in this prospectus, including our financial statements and the related notes and the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; included in our 2018 Annual Report and 2019 Quarterly Report and incorporated by reference into this prospectus, before deciding whether to invest in our common stock. The occurrence of any of the events or developments described
below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties
not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business, Financial Condition, and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are in the early stages of clinical drug development and have a limited operating history and no products approved for commercial sale, which may make
it difficult to evaluate our current business and predict our future success and viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biopharmaceutical company with a limited operating history, focused initially on developing therapeutics for neurodegenerative diseases, including frontotemporal dementia (FTD), Alzheimer&#146;s disease, and Parkinson&#146;s disease. We commenced
operations in May&nbsp;2013. To date, we have only generated revenue from our collaboration arrangements and a government grant. We have no products approved for commercial sale and have not generated any revenue from product sales. Drug development
is a highly uncertain undertaking and involves a substantial degree of risk. We have begun a Phase 2 clinical trial for one product candidate, AL001, and two product candidates, AL002 and AL003, are currently in Phase&nbsp;1 clinical trials, but to
date, we have not initiated or completed a pivotal clinical trial, obtained marketing approval for any product candidates, manufactured a commercial scale product or arranged for a third party to do so on our behalf, or conducted sales and marketing
activities necessary for successful product commercialization. Our short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we
have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable
future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses in each reporting period since our inception, including net losses of $52.2&nbsp;million,
$32.5&nbsp;million, and $15.1&nbsp;million for the years ended December&nbsp;31, 2018, 2017, and 2016, respectively, and $74.9&nbsp;million and $34.9&nbsp;million for the nine months ended September&nbsp;30, 2019 and 2018, respectively. As of
September&nbsp;30, 2019, we had an accumulated deficit of $189.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have invested significant financial resources in
research and development activities, including for our preclinical and clinical product candidates. We do not expect to generate revenue from product sales for several years, if at all. The revenue we currently generate from our collaboration
arrangement with AbbVie Biotechnology, Ltd. (AbbVie) is variable and limited in amount based on such arrangements. For our collaboration with AbbVie, we recognize collaboration revenue by measuring the progress towards complete satisfaction of the
performance of obligation measured as the program costs are incurred. The amount of our future net losses will depend, in part, on the level of our future expenditures and revenue. Moreover, our net losses may fluctuate significantly from quarter to
quarter and year to year, such that a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good indication of our future performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and increasingly higher operating losses
for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our research and discovery activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance our Discovery Platform, including our target, patient, and biomarker selections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">progress our current and any future product candidates through preclinical and clinical development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and conduct additional preclinical, clinical, or other studies for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">work with our contract development and manufacturing organizations (CDMOs) to scale up the manufacturing
processes for our product candidates or, in the future, establish and operate a manufacturing facility; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change or add additional contract manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals and marketing authorizations for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish sales, marketing, and distribution infrastructure to commercialize any products for which we obtain
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty, or other payments due under any license or collaboration agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take steps to seek protection of our intellectual property and defend our intellectual property against
challenges from third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, protect, and enforce our intellectual property portfolio, including intellectual property
obtained through license agreements, including as a result of the arbitration proceeding that we have initiated against our former consulting <FONT STYLE="white-space:nowrap">co-founder;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, hire, and retain qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide additional internal infrastructure to support our continued research and development operations and any
planned commercialization efforts in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays or encounter other issues related to our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement additional internal systems and infrastructure related to cybersecurity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meet the requirements and demands of being a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defend against any product liability claims or other lawsuits related to our products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#146; equity and working
capital. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug development is a highly uncertain undertaking and involves a substantial degree of risk. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no products approved for commercial sale. To obtain revenues from the sales of our product candidates that are significant or large
enough to achieve profitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing, and marketing therapies with significant commercial success. Our ability to generate revenue and
achieve profitability depends on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completing research and preclinical and clinical development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully
complete clinical development and clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing
and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, assessing, acquiring, and/or developing new product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching and successfully commercializing product candidates for which we obtain regulatory and marketing
approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing, and distribution infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining an adequate price for our product candidates, both in the United States and in foreign
countries where our products are commercialized; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining adequate reimbursement for our product candidates from payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining market acceptance of our product candidates as viable treatment options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receiving milestones and other payments under our current and any future collaboration arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining, protecting, expanding, and enforcing our portfolio of intellectual property rights, including
patents, trade secrets, and <FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attracting, hiring, and retaining qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our
expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the U.S. Food and Drug Administration
(FDA) or foreign regulatory agencies, to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our future collaborators&#146; clinical trials or the development of any of our product
candidates. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with launching and commercializing any approved product candidate and ongoing compliance efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to obtain substantial additional financing to complete the development and any commercialization of our product candidates, and a failure
to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have required substantial amounts of cash since inception, and we expect our expenses to increase significantly in the
foreseeable future. To date, we have financed our operations primarily through the sale of equity securities and through our government grant and upfront payments received in connection with our collaboration arrangement with AbbVie. Developing our
product candidates and conducting clinical trials for the treatment of neurodegenerative diseases, including FTD, Alzheimer&#146;s disease, and Parkinson&#146;s disease, will require substantial amounts of capital. We will also require a significant
amount of capital to commercialize any approved products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, we had cash, cash equivalents, and marketable
securities of $381.4&nbsp;million. In February 2019, we received $168.2&nbsp;million of net proceeds from the issuance of common stock upon the completion of our initial public offering (IPO), net of underwriting discounts and commissions and
offering expenses. Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our projected operations through at least the next 12&nbsp;months. Our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
estimate as to how long we expect our existing cash, cash equivalents, and marketable securities to be available to fund our operations is based on assumptions that may be proved inaccurate, and
we could use our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than
currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will require additional capital for the further development and, if approved, commercialization of our product candidates. Additional
capital may not be available when we need it, on terms acceptable to us or at all. We have no committed source of additional capital. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, scale
back, or discontinue our research and development programs or the commercialization of any product candidates, if approved, or be unable to continue or expand our operations, or otherwise capitalize on our business opportunities, as desired, which
could materially affect our business, financial condition, results of operations, and growth prospects and cause the price of our common stock to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our
stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements
with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or grant licenses on terms that may not be favorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Due to the significant resources required for the development of our programs, and depending on our ability to access capital, we must prioritize
development of certain product candidates. Moreover, we may expend our limited resources on programs that do not yield a successful product candidate or fail to capitalize on product candidates or indications that may be more profitable or for which
there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have identified over forty immune system targets. In the last six years, we
have progressed over ten programs into preclinical research. By the end of 2019, we expect to have four product candidates in clinical trials. Together, the development of these programs and product candidates require significant capital investment.
Due to the significant resources required for the development of our programs and product candidates, we must focus our programs and product candidates on specific diseases and disease pathways and decide which product candidates to pursue and
advance and the amount of resources to allocate to each. Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in indications in which we believe there is the most evidence that we will be able
to quickly generate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data. We then intend to expand to clinical testing and seek regulatory approvals in other neurodegenerative indications based on
genetic and mechanistic overlap with the primary indication. However, even if our product candidates are able to gain regulatory approval in one indication, there is no guarantee that we will be able to expand to other indications, and we may expend
significant resources in seeking such approvals. In addition, we may focus resources on pursuing indications outside of neurodegeneration based on the same genetic and mechanistic rationale we utilize in determining on which of our discovery
programs to focus. Our decisions concerning the allocation of research, development, collaboration, management, and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable
commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate, or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and
could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the biopharmaceutical industry, in particular for
neurodegenerative diseases, our business, financial condition, and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial
potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing, or other royalty arrangements in cases in which it would have been advantageous for us to invest additional
resources to retain sole development and commercialization rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Discovery, Development, and Commercialization of Our Product
Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development of biopharmaceutical products is inherently risky. Our business is heavily dependent on the successful
development of our product candidates, which are in the early stages of preclinical and clinical development. We cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary
before they can be commercialized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are at the early stages of development of the product candidates currently in our programs.
To date, we have invested substantially all of our efforts and financial resources to identify, procure intellectual property for, and develop our programs, including conducting preclinical studies and clinical trials in our programs for our product
candidates, AL001, AL002, AL003, and AL101, and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully
commercialize our product candidates, and we may fail to do so for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our product candidates may not successfully complete preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may on further study be shown to have harmful side effects or other characteristics that
indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors may develop therapeutics that render our product candidates obsolete or less attractive;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product candidates that we develop may not be sufficiently covered by intellectual property for which we hold
exclusive rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product candidates that we develop may be covered by third parties&#146; patents or other intellectual
property or exclusive rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market for a product candidate may change so that the continued development of that product candidate is no
longer reasonable or commercially attractive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at
all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing
capabilities, or successfully market such approved product candidate, to gain market acceptance; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party
payors, if applicable. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these events occur, we may be forced to abandon our development efforts for a program
or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be
successful in our efforts to further develop our current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and
we may never receive such regulatory approval for any of our product candidates. Each of our product candidates is in the early stages of development and will require significant additional clinical development, management of preclinical, clinical,
and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never completed a clinical development program. We currently have one product
candidate, AL001, in a Phase 2 clinical trial and two product candidates, AL002 and AL003, in Phase&nbsp;1 clinical trials. None of our product candidates have advanced into late-stage development or a pivotal clinical trial and it may be years
before any such trial is initiated, if at all. Further, we cannot be certain that any of our product candidates will be successful in clinical trials. We may in the future advance product candidates into clinical trials and terminate such trials
prior to their completion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates successfully complete clinical trials, we generally plan to seek regulatory
approval to market our product candidates in the United States, the European Union, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an application seeking
regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would adversely affect our viability. To
obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, manufacturing and controls, clinical trials, commercial sales,
pricing, and distribution of our product candidates. We may also rely on our collaborators or partners to conduct the required activities to support an application for regulatory approval, and to seek approval, for one or more of our product
candidates. For example, for our AL002 and AL003 product candidates, our collaboration arrangement with AbbVie provides that we are responsible for the execution of the Phase&nbsp;1 and Phase&nbsp;2 studies. We cannot be sure that our collaborators
or partners will conduct these activities or do so within the timeframe we desire. Even if we (or our collaborators or partners) are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other
jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our business, financial condition, results of operations, and our growth prospects could be negatively affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive regulatory approval to market any of our product candidates, whether for the treatment of neurodegenerative diseases or
other diseases, we cannot assure you that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate
efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if
approved, successfully commercialize any of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to continue to create a pipeline of
product candidates from our Discovery Platform or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates from our Discover Platform, our commercial opportunity may be limited.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of our strategies is to identify and pursue clinical development of additional product candidates. Our Discovery Platform has
helped us identify over forty immune system targets. In the last six years, we have progressed over ten programs into early preclinical development. By the end of 2019, we expect to have four product candidates in clinical trials. Identifying,
developing, obtaining regulatory approval, and commercializing additional product candidates for the treatment of neurodegenerative diseases will require substantial additional funding beyond the net proceeds of this offering and is prone to the
risks of failure inherent in drug development. We cannot provide you any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development
process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire, develop, or, if approved, commercialize additional product candidates. If we are unable to successfully
identify, acquire, develop, and commercialize additional product candidates, our commercial opportunity may be limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to expand indications for approved product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in indications in
which we believe there is the most evidence that we will be able to quickly generate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data. We then intend to expand to clinical testing and seek
regulatory approvals in other neurodegenerative indications based on genetic and mechanistic overlap with the primary indication. Conducting clinical trials for additional indications for our product candidates requires substantial technical,
financial, and human resources and is prone to the risks of failure inherent in drug development. We cannot provide you any assurance that we will be successful in our effort to obtain regulatory approval for our product candidates for additional
indications even if we obtain approval for an initial indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, our product candidate AL001 is initially targeting <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> patients. In the third quarter of 2019, we advanced AL001 into a Phase&nbsp;2 study with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data in <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> patients expected in the first half of 2020, which also includes an additional genetic subset of FTD patients <FONT STYLE="white-space:nowrap">(FTD-C9orf72).</FONT> If we are unable to successfully identify,
develop, obtain regulatory approval for, and commercialize AL001 for other indications, our commercial opportunity for AL001 may be limited.&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have concentrated a substantial portion of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen
limited success in drug development. Further, our product candidates are based on new approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory
approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have focused a substantial portion of our research and development efforts on addressing neurodegenerative diseases.
Collectively, efforts by biopharmaceutical companies in the field of neurodegenerative diseases have seen limited success in drug development. There are few effective therapeutic options available for patients with FTD, Alzheimer&#146;s disease,
Parkinson&#146;s disease, and other neurodegenerative diseases. Our future success is highly dependent on the successful development of our product candidates for treating neurodegenerative diseases. Developing and, if approved, commercializing our
product candidates for treatment of neurodegenerative diseases subjects us to a number of challenges, including obtaining disease modifying activity and efficacious dose in target tissue and obtaining regulatory approval from the FDA and other
regulatory authorities who have only a limited set of precedents to rely on. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our approach to the treatment of neurodegenerative diseases
aims to identify and select targets enriched in microglia and other myeloid immune cells which are genetically associated with neurodegenerative diseases, identify and develop product candidates that cross the blood brain barrier in sufficient
quantity and potency to enable efficacious dosing in the brain and engage the intended target, identify and develop biomarkers that are signs of a disease or condition, to select the right patient population, and to demonstrate target engagement,
pathway engagement, and impact on disease progression of our product candidates. This strategy may not prove to be successful. We cannot be sure that our approach will yield satisfactory therapeutic products that are safe and effective, scalable, or
profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the
timelines we expect, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee
that any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an investigational new drug application (IND) or a clinical trial application (CTA) will result in the FDA or European
Medicines Agency (EMA), as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical
trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of clinical trials include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the
initiation or continuation of clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in confirming target engagement, patient selection, or other relevant biomarkers to be utilized in
preclinical and clinical product candidate development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching a consensus with regulatory agencies on study design; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and
clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying, recruiting, and training suitable clinical investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining required Institutional Review Board (IRB) approval at each clinical trial site;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of delays to clinical trials, including as a result of temporary or permanent clinical hold by
regulatory agencies for a number of reasons, including: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after review of an IND or amendment, CTA or amendment, or equivalent application or amendment;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as a result of a new safety finding that presents unreasonable risk to clinical trial participants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as a result of modifications to clinical trial protocols or related documentation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a negative finding from an inspection of our clinical trial operations or study sites; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the finding that the investigational protocol or plan is clearly deficient to meet its stated objectives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying, recruiting, and enrolling suitable patients to participate in our clinical trials, and
delays caused by patients withdrawing from clinical trials, or failing to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty collaborating with patient groups and investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by our CROs, other third parties, or us to adhere to clinical trial requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with the FDA&#146;s or any other regulatory authority&#146;s current good
clinical practices (cGCPs) requirements, or applicable EMA or other regulatory guidelines in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential
benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care on which a clinical development plan was based, which may require new or
additional trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates being greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates producing negative or inconclusive results, which may result in our
deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of
our product candidates for use in clinical trials or the inability to do any of the foregoing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any inability to
successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we
may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may
harm our business and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the
data safety monitoring board for such trial or by the FDA, EMA, or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and
sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of
the clinical trial operations or trial site by the FDA, EMA, or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product
candidate, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
may in the future advance product candidates into clinical trials and terminate such trials prior to their completion, which could adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Histopathological analysis of a <FONT STYLE="white-space:nowrap">26-week</FONT> toxicology study of AL002 in
<FONT STYLE="white-space:nowrap">non-human</FONT> primates identified minimal to marked granulomatous inflammation in the&nbsp;ciliary body&nbsp;and/or&nbsp;choroid&nbsp;of&nbsp;the eye. There were no other AL002- related gross or histopathological
findings in this toxicology study in the retina or any other tissues or organs. We have observed no drug-related, serious adverse events in the AL002 Phase 1 trial with over 50&nbsp;subjects. In response to FDA feedback, we have implemented
additional ophthalmological assessments in our AL002 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thirty-eight (38)&nbsp;healthy subjects were dosed over eight dose
cohorts in the AL003 Phase 1a dose escalation trial. One subject treated with the second highest dose experienced aseptic hip monoarthritis and a second subject treated with the highest dose experienced an adverse drug reaction characterized by
rash, fever, and thrombocytopenia, which were both deemed treatment-related serious adverse events. The subjects were treated with corticosteroids and recovered. Based on the safety and tolerability observed in the Phase 1a study, we identified a
dose and initiated screening for the Phase 1b portion of the study with AL003 in Alzheimer&#146;s disease patients in the fourth quarter of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development
and approval process and delay, or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also
ultimately lead to the denial of regulatory approval of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter difficulties enrolling patients in our clinical
trials, and our clinical development activities could thereby be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timely completion of
clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our
clinical trials for a variety of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient eligibility criteria defined in the protocol, including biomarker-driven identification and/or
certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have
biomarker-driven patient eligibility criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the study population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to a trial site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing clinical trials for similar therapies or targeting patient populations meeting our patient eligibility
criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages and side effects of the product
candidate being studied in relation to other available therapies and product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patient consents; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will not complete such trials, for any reason.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical trials may reveal significant adverse events, toxicities, or other side effects and may fail to demonstrate
substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex,
and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. For those product candidates that are subject to regulation as biological drug products, we will need to
demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time
during the clinical trial process. The results of preclinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our product candidates may
not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability
in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes
in and adherence to the dosing regimen, and other clinical trial protocols and the rate of dropout among clinical trial participants. Open-label extension studies may also extend the timing and cost of a clinical test substantially. Product
candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have
suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. This is particularly true in neurodegenerative diseases, where failure rates
historically have been higher than in many other disease areas. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing
approval. We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the
prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will
interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a
marketing application, we may be required to expend </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of
our product candidates, the terms of such approval may limit the scope and use of our product candidates, which may also limit its commercial potential. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may
achieve regulatory approval before us or develop therapies that are safer, more advanced, or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and
ultimately harm our financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and commercialization of new drug products is highly competitive.
Moreover, the neurodegenerative field is characterized by strong and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or
commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private
research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the
treatment of neurodegenerative diseases, including FTD and Alzheimer&#146;s disease. Many of these current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in
research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may
result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established
companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies
complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more
convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of neurodegenerative disease indications, which could give such products
significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA, or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan
drug exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed
by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity, and/or enforceability of our
patents relating to our competitors&#146; products and our competitors may allege that our products infringe, misappropriate, or otherwise violate their intellectual property. The availability of our competitors&#146; products could limit the
demand, and the price we are able to charge, for any products that we may develop and commercialize. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of our product candidates is complex, and we may encounter difficulties in production.
If we or any of our third-party manufacturers encounter such difficulties, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or our products for patients, if
approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The processes
involved in manufacturing our drug and biological product candidates are complex, expensive, highly-regulated, and subject to multiple risks. Further, as product candidates are developed through preclinical studies to late-stage clinical trials
towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will
not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to conduct clinical trials of our product candidates, or supply commercial products, if approved, we will need to manufacture them in
large quantities. Our CDMOs may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during <FONT
STYLE="white-space:nowrap">scale-up</FONT> activities. If our CDMOs are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product
candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. The same risk would apply to our internal manufacturing
facilities, should we in the future decide to build internal manufacturing capacity. In addition, building internal manufacturing capacity would carry significant risks in terms of being able to plan, design, and execute on a complex project to
build manufacturing facilities in a timely and cost-efficient manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the manufacturing process for any products that we may
develop is subject to FDA, EMA, and foreign regulatory authority approval processes, and continuous oversight, and we will need to contract with manufacturers who can meet all applicable FDA, EMA, and foreign regulatory authority requirements,
including complying with current good manufacturing practices (cGMPs) on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce products to specifications acceptable to the FDA, EMA, or other regulatory authorities,
we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CDMOs will be able to manufacture the approved
product to specifications acceptable to the FDA, EMA, or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these
challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts,
increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If, in
the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and
when they are approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing, or
distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third
parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to
perform these services. For example, recruiting and training a sales force or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish
marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot
retain or reposition our commercialization personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize any approved product on our
own include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer
service, medical affairs, and other support personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to
prescribe any future approved products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and
other acceptance by payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of
profitability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the
patient population; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent commercialization organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution
services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to
commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our
products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients,
healthcare payors, and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial success of any of our
product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail
to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number
of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety of such product candidates as demonstrated in clinical trials and published in
peer-reviewed journals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential and perceived advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sufficient third-party coverage or reimbursement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to offer appropriate patient access programs, such as <FONT STYLE="white-space:nowrap">co-pay</FONT>
assistance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which physicians recommend our products to their patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convenience and ease of dosing and administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which the product candidate is approved by FDA, EMA, or other regulatory agencies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or product insert requirements of the FDA, EMA, or other comparable foreign regulatory
authorities, including any limitations, contraindications, or warnings contained in a product&#146;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on how the product is distributed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity concerning our products or competing products and treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenue, and we
may not become profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any products we commercialize may become subject to unfavorable pricing regulations, third-party reimbursement
practices, or healthcare reform initiatives, which would harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulations that govern marketing approvals,
pricing, and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted or potential future legislation may significantly change the approval requirements in ways that could involve additional costs and
cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign
markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to
price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our
ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for
these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health
maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted
to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid and Veterans Affairs hospitals, and
may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list
prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement
may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to get reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to
standard of care </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
drugs, including lower-priced generic versions of standard of care drugs. If reimbursement is not available or is available only to limited levels, we may not be able to successfully
commercialize any product candidate for which we obtain marketing approval. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can
differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor
separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for
which the medicine is approved by the FDA, EMA, or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including
research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of
the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory
discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.
Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors
for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates, and our overall financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates for which we intend to seek approval may face competition sooner than anticipated. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are successful in achieving regulatory approval to commercialize a product candidate ahead of our competitors, our product
candidates may face competition from biosimilar products. In the United States, our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these product candidates pursuant to the Biologics License
Application (BLA) pathway. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal
authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#147;interchangeable&#148; based on its similarity to an existing brand product. Under the BPCIA, an application for a
biosimilar product cannot be approved by the FDA until 12&nbsp;years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact,
implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects
for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for
the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be
reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference
products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biologic</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. In
addition, a competitor could decide to forego the biosimilar approval path and submit a full BLA after completing its own preclinical studies and clinical trials. In such cases, any exclusivity to which we may be eligible under the BPCIA would not
prevent the competitor from marketing its product as soon as it is approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Europe, the European Commission has granted marketing authorizations for several
biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In Europe, a competitor may reference data supporting approval of an innovative biological product, but
will not be able to get it on the market until 10 years after the time of approval of the innovative product. This <FONT STYLE="white-space:nowrap">10-year</FONT> marketing exclusivity period will be extended to 11 years if, during the first eight
of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilar
products in other countries that could compete with our products, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If competitors are able to obtain marketing approval for
biosimilars referencing our product candidates, if approved, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to
immediately compete with us in each indication for which our product candidates may have received approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are
brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk
when and if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such
product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, or a breach of warranties. Claims could also be asserted under state
consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit testing and commercialization of our product candidates. Even successful defense
would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased or interrupted demand for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants and inability to continue clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing, or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exhaustion of any available insurance and our capital resources; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any product candidate. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims
could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to
pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements
with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA, EMA, and comparable foreign regulatory authorities are lengthy, time consuming, and inherently
unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain approval by the FDA, EMA, and comparable foreign regulatory authorities is unpredictable, typically takes many
years following the commencement of clinical trials, and depends upon numerous factors, including the type, complexity, and novelty of the product candidates involved. In addition, approval policies, regulations, or the type and amount of clinical
data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory
authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. We have not submitted
for, or obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control. For example, a U.S.
federal government shutdown or budget sequestration, such as ones that occurred during 2013, 2018, and 2019, may result in significant reductions to the FDA&#146;s budget, employees, and operations, which may lead to slower response times and longer
review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applications for our product candidates could fail to receive regulatory approval in an initial or subsequent indication for many reasons,
including but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA, or comparable foreign regulatory authorities may disagree with the design, implementation, or
results of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA, or comparable foreign regulatory authorities may determine that our product candidates are not safe
and effective, only moderately effective or have undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy
and safety in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product
candidate&#146;s risk-benefit ratio when compared to the standard of care is acceptable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA, or comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission
of a new drug application (NDA), BLA, or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the FDA, EMA, or comparable foreign regulatory authorities that a product
candidate&#146;s risk-benefit ratio for a proposed indication is acceptable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA, or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test
procedures, and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA, EMA, or comparable foreign regulatory authorities may
significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This lengthy approval process, as well as the unpredictability of the results of clinical
trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory
approval, limit their commercial potential, or result in significant negative consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse events or other undesirable
side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA, or other
comparable foreign regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drug-related side effects could affect patient recruitment, the ability of enrolled patients
to complete the study, and/or result in potential product liability claims. We are required to maintain product liability insurance pursuant to certain of our development and commercialization agreements. We may not be able to maintain insurance
coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect our results of operations, business, and
reputation. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical trial participants, costs due to related litigation, distraction of
management&#146;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates, and decreased demand for our
product candidates, if approved for commercial sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if one or more of our product candidates receives marketing approval,
and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw approvals of such product and cause us to recall our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way the product is administered or conduct additional clinical trials or
post-approval studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to create a Risk Evaluation and Mitigation Strategy plan, which could include a medication
guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements, such as boxed warning on the packaging, to assure safe use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and
could significantly harm our business, financial condition, results of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may in the future conduct clinical
trials for our product candidates outside the United States, and the FDA, EMA, and applicable foreign regulatory authorities may not accept data from such trials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future choose to conduct one or more of our clinical trials outside the United States, including in Europe or Australia. The
acceptance of study data from clinical trials conducted outside the United&nbsp;States or another jurisdiction by the FDA, EMA, or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign
clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foreign data alone unless (i)&nbsp;the data are applicable to the United States population and United States medical practice; and (ii)&nbsp;the trials were performed by clinical investigators of
recognized competence and pursuant to cGCP regulations. Additionally, the FDA&#146;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar
approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA, or any applicable foreign regulatory
authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, EMA, or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional
trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory approval of our product
candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the
regulatory approval process in others. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of
the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical
trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be
approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties,
and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any partner we work with fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing
approvals, our target market will be reduced, and our ability to realize the full market potential of our product candidates will be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even
if we obtain regulatory approval for a product candidate, our products will remain subject to extensive regulatory scrutiny. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission
of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers and manufacturers&#146; facilities are required to comply with extensive requirements imposed by the FDA, EMA, and comparable
foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance
with cGMP and adherence to commitments made in any NDA, BLA, or marketing authorization application (MAA). Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including
manufacturing, production, and quality control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our product candidates will be subject to
limitations on the approved indicated uses for which the product may be marketed and promoted or to the conditions of approval (including the requirement to implement a Risk Evaluation and Mitigation Strategy), or contain requirements for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potentially costly post-marketing testing. We will be required to report certain adverse reactions and production problems, if any, to the FDA, EMA, and comparable foreign regulatory authorities.
Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. The FDA and other agencies, including the Department of Justice, closely regulate and
monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed, and distributed only for the approved indications and in accordance with the provisions of the approved labeling. We will have to comply
with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the
product&#146;s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. The holder of an approved NDA, BLA, or MAA must submit new or supplemental applications and obtain approval for
certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. If
original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure
to complete such a study could result in the withdrawal of marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a regulatory agency discovers previously unknown
problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may
impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue warning letters that would result in adverse publicity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose civil or criminal penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend or withdraw regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend any of our ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to approve pending applications or supplements to approved applications submitted by us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose restrictions on our operations, including closing our contract manufacturers&#146; facilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seize or detain products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require a product recall. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory
approval is withdrawn, the value of our company and our operating results will be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have received orphan drug designation from
the FDA for AL001 and AL101 for treatment of FTD and plan to seek orphan drug designation for some of our other product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status,
including market exclusivity, which may cause our revenue, if any, to be reduced. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant
orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the
United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation
must be requested before submitting an NDA or BLA. In the United States, orphan drug designation entitles a party to financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. After the FDA grants orphan drug
designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. While we
have obtained orphan drug designation from the FDA for AL001 and AL101 for treatment of FTD, we may be unable to reap the benefits associated with orphan drug status. In addition, we plan to seek orphan drug designations for some of our other
product candidates in the future but may be unable to obtain an orphan drug designation for any additional product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a
product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the
FDA may not approve any other NDA or BLA applications to market the same drug or biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan exclusivity or if
FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. As a
result, even though the FDA has approved orphan drug status for AL001 and AL101 for treatment of FTD, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. Furthermore, the
FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative measures aimed at
reducing healthcare costs may have a material adverse effect on our business and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors,
whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and
regulatory changes to the healthcare system that could impact our ability to sell our products profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, or Affordable Care Act (ACA) was enacted, which, among other things,
subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled,
implanted, or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed
care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#146;s comparative effectiveness research. The U.S.
administration could repeal or change some or all of the ACA, and complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business. Until
the ACA is fully implemented or there is more certainty concerning the future of the ACA, it will be difficult to predict its full impact and influence on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at
containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to
contain or reduce costs of healthcare and/or impose price controls may adversely affect: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand for our product candidates, if we obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to receive or set a price that we believe is fair for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of taxes that we are required to pay; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of capital. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the ACA, as well as other healthcare reform measures that may be adopted in
the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for any approved product. Any
denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue,
attain profitability, or commercialize our product candidates, if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial
partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial
partners, and vendors. Misconduct by these parties could include intentional, reckless, and negligent conduct that fails to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with the laws of the FDA, EMA, and other comparable foreign regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide true, complete, and accurate information to the FDA, EMA, and other comparable foreign regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with manufacturing standards we have established; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">report financial information or data accurately or to disclose unauthorized activities to us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United
States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education, and other business arrangements in
the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and
promotion, sales and commission, certain customer incentive programs, and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical
trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and third parties, and
the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in
compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of
significant fines or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations,
and financial conditions could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we obtain FDA approval for any of our product candidates and begin
commercializing those products in the United States, our operations will be subject to various federal and state fraud and abuse laws. The laws that may impact our operations include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Anti-Kickback Statute, prohibits, among other things, persons from knowingly and willfully
soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the
purchase, lease, order, or recommendation of any good, facility, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute
constitutes a false or fraudulent claim for purposes of the False Claims Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act,
impose criminal and civil penalties, including through civil &#147;qui tam&#148; or &#147;whistleblower&#148; actions, against individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from
Medicare, Medicaid, or other third-party payors that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease, or conceal an obligation to pay money to the federal government. Similar to the federal Anti-Kickback
Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) created new federal criminal
statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property
owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any
materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and
their respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use,
or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of individually identifiable health information without appropriate authorization. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Physician Payment Sunshine Act, created under the ACA, and its implementing regulations, require
manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services under
the Open Payments Program, information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities
that potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer
protection, and unfair competition laws may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements, as well as submitting claims involving healthcare items or services
reimbursed by any third-party payer, including commercial insurers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary
compliance guidelines, and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State laws also require drug manufacturers to file reports with states regarding pricing and marketing
information, such as the tracking and reporting of gifts, compensations and other remuneration, and items of value provided to healthcare professionals and entities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State and foreign laws also govern the privacy and security of health information in certain circumstances, many
of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of
our business activities could, despite our efforts to comply, be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is
possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and
regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal, and
administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and
curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will
also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or any contract manufacturers
and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety
laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous
materials into the ground, air, and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous
waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous
materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and
at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with
applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development, and manufacturing efforts. In addition, we cannot entirely eliminate the risk of
accidental injury or contamination from these materials or wastes. Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous
materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically
exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding
our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is subject to complex and evolving U.S. and foreign laws and regulations relating to
security, privacy and data protection. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, or monetary penalties, and otherwise may harm our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A wide variety of state, national, and international laws and regulations apply to security and cybersecurity requirements and the
collection, use, retention, protection, disclosure, transfer, and other processing of personal data. These security and data protection and privacy-related laws and regulations are evolving and may result in ever-increasing regulatory and public
scrutiny and escalating levels of enforcement and sanctions. We are working to comply with the such laws, and we anticipate needing to devote significant additional resources to our compliance efforts. It is possible that the new legislation may
impose new obligations and requirements on similarly situated companies, and these laws may be interpreted and applied in a manner that is inconsistent from jurisdiction to jurisdiction or inconsistent with our current policies and practices. Our
actual or perceived failure to adequately comply with applicable laws and regulations relating to security, privacy and data protection, or to protect our systems, personal data and other data we process or maintain, could result in regulatory
fines, investigations and enforcement actions, penalties and other liabilities, claims for damages by affected individuals, and damage to our reputation, any of which could materially affect our business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inadequate funding for the FDA and other government agencies could hinder our ability to hire and retain key leadership and other
personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could
negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors,
including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a
result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In the past, the U.S. government has experienced
budgetary shutdowns and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability
of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public
markets and obtain necessary capital in order to properly capitalize and continue our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business activities may be subject to the
Foreign Corrupt Practices Act (FCPA) and similar anti-bribery and anti-corruption laws. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business activities may be subject to
the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything
of value, either directly or indirectly, to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and
keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant
interaction with public officials, including officials of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government,
and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Recently the Securities and Exchange Commission (SEC) and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There
is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these
laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries,
implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our
brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
expect to depend on collaborations with third parties for the research, development, and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market
potential of those product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently use and expect to continue to use third-party collaborators for the research,
development, and commercialization of certain of the product candidates we may develop. For example, we have entered into the <FONT STYLE="white-space:nowrap">Co-Development</FONT> and Option Agreement with AbbVie (the AbbVie Agreement) for the
global development and potential commercialization of AL002 and AL003. We also collaborate with Adimab and others to further our development of product candidates and to enhance our research efforts directed to better understanding neurodegenerative
diseases. For additional information on our relationships with AbbVie and Adimab, LLC (Adimab), see the sections titled &#147;Business&#151;Strategic Alliance with AbbVie&#148; and &#147;Business&#151;Collaboration Agreements with Adimab.&#148; Our
likely collaborators for any other collaboration arrangements include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies, biotechnology companies, and academic
institutions. Such arrangements with any third parties, generally provide us with shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product
candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these
arrangements. We cannot predict the success of any collaboration that we enter into. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaborations involving our research programs, or
any product candidates we may develop, pose the following risks to us: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators generally have significant discretion in determining the efforts and resources that they will apply
to these collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly obtain, maintain, enforce, or defend intellectual property or proprietary rights
relating to our product candidates or research programs or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope,
ownership, validity, and enforceability of our intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our
product candidates or research and development programs that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates or research
programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to
or that arises out of our collaborations, which may not be provided to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may control certain interactions with regulatory authorities, which may impact our ability to
obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between the collaborators and us that result in the delay or termination of the research,
development, or commercialization of our product candidates or research programs or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may decide to not pursue development and commercialization of any product candidates we develop or
may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#146;s strategic focus or available funding or external factors such as an acquisition that diverts resources
or creates competing priorities or collaborators may elect to fund or commercialize a competing product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our product candidates or research programs if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may restrict us from researching, developing, or commercializing certain products or technologies
without their involvement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient
resources to the marketing and distribution of such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo
a change of control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may grant sublicenses to our technology or product candidates or undergo a change of control, and
the sublicensees or new owners may decide to take the collaboration in a direction which is not in our best interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may become bankrupt, which may significantly delay our research or development programs, or may
cause us to lose access to valuable technology, <FONT STYLE="white-space:nowrap">know-how,</FONT> or intellectual property of the collaborator relating to our products, product candidates, or research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with
our collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may require us to incur short and long-term expenditures, issue securities that dilute our
stockholders, or disrupt our management and business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if our collaborators do not satisfy their obligations under our agreements with them, or if they terminate our
collaborations with them, we may not be able to develop or commercialize product candidates as planned; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may require us to share in development and commercialization costs pursuant to budgets that we do
not fully control, and our failure to share in such costs could have a detrimental impact on the collaboration or our ability to share in revenue generated under the collaboration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated in their entirety or with respect to certain product candidates or technologies
and, if so terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or technologies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaboration agreements may not lead to development or commercialization of product candidates in the most
efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our development or commercialization program under such collaboration could be delayed,
diminished, or terminated. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may face significant competition in seeking appropriate collaborations. Recent business
combinations among biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a
timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other
development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase
our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to
further develop product candidates or bring them to market and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not realize the benefit of collaborations
if we or our collaborator elects not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. In addition, if our agreement
with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing
the collaborator&#146;s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and
our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Many of the risks relating to product development, regulatory approval, and commercialization described in this
&#147;Risk Factors&#148; section also apply to the activities of our collaborators and any negative impact on our collaborators may adversely affect us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may
not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical
trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it would delay our product development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us
of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with
cGCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible, reproducible, and accurate and that the rights, integrity, and confidentiality of trial participants are protected.
We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal
sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our
clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be
delayed in our efforts to, successfully commercialize our medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect to rely on other third parties to store and
distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors, including with the shipment of any drug supplies, could delay clinical development or marketing approval of any product candidates we may
develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We contract with third parties for the manufacture of materials for our research programs, preclinical
studies, clinical trials, and for commercialization of any product candidates that we may develop. This reliance on third parties carries and may increase the risk that we will not have sufficient quantities of such materials, product candidates, or
any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any manufacturing facilities. We currently rely on CDMOs for the manufacture of our materials for preclinical studies and
clinical trials and expect to continue to do so for preclinical studies, clinical trials, and for commercial supply of any product candidates that we may develop. We currently have established relationships with several CDMOs for the manufacturing
of our product candidates. We may be unable to establish any further agreements with CDMOs or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on CDMOs entails additional risks,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or
inconvenient for us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and
related reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to produce required volume in a timely manner and to quality standards. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our
failure, or the failure of our CDMOs, to comply with applicable regulations could result in clinical holds on our trials, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals,
license revocations, seizures, or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial
condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any medicines that we may develop may compete with other product candidates and products
for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development or marketing
approval. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, securing and
reserving production capacity with contract manufacturers may result in significant costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and anticipated future dependence
upon others for the manufacture of any product candidates we may develop or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their
inability to supply us with adequate raw materials could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third-party suppliers for the supply of the
raw materials required for the production of our product candidates, and we expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. Our dependence on
these third-party suppliers and the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing, availability, quality, and delivery schedules. As a small company, our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
negotiation leverage is limited, and we are likely to get lower priority than our competitors who are larger than we are. We do not have long-term supply agreements, and we purchase our required
drug product on a development manufacturing services agreement or purchase order basis. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated
specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and
qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of
our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
are unable to obtain and maintain patent protection for any product candidates we develop, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we
may develop may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to obtain and maintain patent protection
in the United States and other countries with respect to our proprietary product candidates and other technologies we may develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad relating to
our core programs and product candidates, as well as other technologies that are important to our business. Given that the development of our product candidates is at an early stage, our intellectual property portfolio with respect to certain
aspects of our product candidates is also at an early stage. For example, we have filed or intend to file patent applications on aspects of our technology and core product candidates; however, there can be no assurance that any such patent
applications will issue as granted patents. Furthermore, in some cases, we have only filed provisional patent applications on certain aspects of our technology and product candidates and each of these provisional patent applications is not eligible
to become an issued patent until, among other things, we file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. Furthermore, in
some cases, we may not be able to obtain issued claims covering compositions relating to our core programs and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent
applications with claims covering a method of use and/or method of manufacture for protection of such core programs, product candidates, and other technologies. There can be no assurance that any such patent applications will issue as granted
patents, and even if they do issue, such patent claims may be insufficient to prevent third parties, such as our competitors, from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our core programs and
product candidates could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any of our
patent applications, or those of our collaborators, do not issue as patents in any jurisdiction, we may not be able to compete effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our
inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents or those of our collaborators with respect to our product
candidates. With respect to both our intellectual property and that of our collaborators related to our product candidates, we cannot predict whether the patent applications we and our collaborators are currently pursuing will issue as patents in
any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, time-consuming, and complex, and we or our collaborators may not be able to file, prosecute,
maintain, enforce, or license all necessary or desirable patent applications at a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we
enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators,
CROs, CDMOs, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our
ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the
scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be
certain that we or our collaborators were the first to make the inventions claimed in any of our or our collaborators&#146; patents or pending patent applications, or that we or our collaborators were the first to file for patent protection of such
inventions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to
prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions,
and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our or our collaborators&#146; pending and future patent
applications may not result in patents being issued which protect our product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be
reinterpreted after issuance. Even if patent applications we or our collaborators license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or
other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents to which we or our collaborators have rights may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we
do not know whether product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative
technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner which could materially adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in
the courts or patent offices in the United States and abroad. We or our collaborators may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office (USPTO) or become involved in opposition,
derivation, revocation, reexamination, post-grant and <I>inter partes </I>review, or interference proceedings or other similar proceedings challenging our or our collaborators&#146; patent rights. An adverse determination in any such submission,
proceeding, or litigation could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our product candidates or other technologies and compete directly with us, without payment to us, or
result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our collaborators, may have to participate in interference proceedings declared by the USPTO to determine priority
of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our collaborators&#146; priority of invention or other features of patentability with respect to our or our
collaborators&#146; patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from
using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates and other technologies. Such proceedings also may result in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we or our collaborators are unsuccessful in any such
proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses
may not be available on commercially reasonable terms or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and
commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical
technology and products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, given the amount of time required for the development, testing, and regulatory review of new
product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from
commercializing products similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our patents and patent applications may in the future be <FONT
STYLE="white-space:nowrap">co-owned</FONT> with third parties. In addition, collaborators or future licensors may <FONT STYLE="white-space:nowrap">co-own</FONT> their patents and patent applications with other third parties with whom we do not have
a direct relationship. Our rights to certain of these patents and patent applications may be dependent, in part, on inter-institutional or other operating agreements between the joint owners of such patents and patent applications, who are not
parties to our license agreements. If our collaborators or future licensors do not have exclusive control of the grant of licenses under any such third-party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent
applications or we are otherwise unable to secure such exclusive rights, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors, and our competitors could market
competing products and technology to the extent such products and technology are not also covered by our intellectual property. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our patents in
order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our rights to develop and commercialize our product candidates are subject, in part, to the terms and conditions of agreements with
others. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are heavily reliant upon option rights to certain patent rights and proprietary technology from third parties that are
important or necessary to the development of our product candidates and are subject to the terms and conditions of certain collaboration agreements with third parties. For example, in 2013 we entered into the Adimab Collaboration Agreement with
Adimab. Under the Adimab Collaboration Agreement, we are developing antibodies discovered by Adimab in our AL001 and AL101 product candidates, and we are developing antibodies optimized by Adimab in our AL002 and AL003 product candidates.
Additionally, in October&nbsp;2017, we entered into the AbbVie Agreement to <FONT STYLE="white-space:nowrap">co-develop</FONT> and commercialize medicines with AbbVie to treat Alzheimer&#146;s disease and other neurodegenerative diseases. In August
2019, we entered into a new Adimab collaboration agreement for development of antibodies for use in future programs. For additional information on the Adimab Collaboration Agreement and the AbbVie Agreement, see the sections titled
&#147;Business&#151;Adimab Collaboration Agreements&#148; and &#147;Business&#151;Strategic Alliance with AbbVie.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our agreements
with Adimab and AbbVie and other agreements we enter into in the future may not provide exclusive rights to use certain intellectual property and technology retained by the collaborator in all relevant fields of use and in all territories in which
we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products that utilizes technology
retained by such collaborators to the extent such products are not also covered by our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, subject to the
terms of any such agreements, we do not have the right to control the preparation, filing, prosecution, and maintenance, and we may not have the right to control the enforcement and defense of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain patents and patent applications retained by the collaborator and provided to us under a limited license. For example, under the Adimab Collaboration Agreements, patent rights relating to
improvements to Adimab&#146;s background platform technology that are invented in the course of the research under the Adimab Collaboration Agreements are assigned to Adimab. We also have an exclusive option under the Adimab Collaboration Agreements
to obtain with respect to a specified number of antibodies directed against such target and discovered or optimized by Adimab, ownership of certain patent rights relating to such antibodies, including certain patent rights. Until we exercise such
option, we and Adimab each grant each other a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to the relevant intellectual property. We cannot be certain that patents and patent applications that are controlled by our collaborators
will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our collaborators fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those
patents or patent applications, the limited rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of our product candidates that are subject of such licensed rights could be adversely affected, and we may
have a reduced ability to prevent competitors from making, using, and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from collaborators,
we may still be adversely affected or prejudiced by actions or inactions of our collaborators that took place prior to the date upon which we assumed control over patent prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our or our collaborators&#146; patents may be subject to a reservation of rights by one or more third parties. For example, we
received an award from the National Institute of Health in support of our research into the production and characterization of novel therapeutic antibodies against the neurotrophic factor PGRN degrading receptor Sortilin (SORT1). As a result, the
U.S. government may have certain rights to resulting intellectual property. When new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. The U.S. government&#146;s rights may also permit it to disclose the funded inventions
and technology to third parties and to exercise <FONT STYLE="white-space:nowrap">march-in</FONT> rights to use or allow third parties to use the technology developed using U.S. government funding. The U.S. government may exercise its <FONT
STYLE="white-space:nowrap">march-in</FONT> rights if it determines that action is necessary because we fail to achieve the practical application of the government funded technology, or because action is necessary to alleviate health or safety needs,
to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in facilities in the United
States in certain circumstances and if this requirement is not waived. Any exercise by the U.S. government of such rights or by any third party of its reserved rights could have a material adverse effect on our competitive position, business,
financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the agreements under which we option or
license intellectual property rights from our collaborators or future licensors or otherwise experience disruptions to our business relationships with our collaborators or future licensors, we could lose intellectual property rights that are
important to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into agreements with our collaborators to option or license certain intellectual
property and may need to obtain additional intellectual property rights from others to advance our research or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain additional intellectual
property rights at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or
license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial
condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future
methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, each of our agreements with collaborators do, and we expect our future agreements will, impose various economic, development,
diligence, commercialization, and other obligations on us. Certain of our collaboration agreements also require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products. In spite
of our efforts, our collaborators might conclude that we have materially breached our obligations under such agreements and might therefore terminate or seek damages under the agreements, thereby removing or limiting our ability to develop and
commercialize products and technology covered by these agreements. If termination of these agreements causes us to lose the rights to certain patents or other intellectual property, or if the underlying patents fail to provide the intended
exclusivity, competitors or other third parties may have the freedom to seek regulatory approval of, and to market, products similar to or identical to ours and we may be required to cease our development and commercialization of certain of our
product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, disputes may arise regarding intellectual property subject to a collaboration agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of the option or license rights granted under the agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our technology and processes infringe on intellectual property of the collaborator that is
not subject to the option or license rights granted under the agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other rights under our collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our collaborators and us and our other partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we currently have rights to option or license intellectual property or technology from third parties
are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the
relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of
operations, and growth prospects. Moreover, if disputes over intellectual property that we have optioned or licensed prevent or impair our ability to maintain our current arrangements on commercially acceptable terms, we may be unable to
successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property and proprietary rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, and defending patents on our product candidates and other technologies in all countries throughout the world would be
prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from
selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and,
further, may export otherwise infringing products to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems
in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual
property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary
rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at
risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other
remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant
licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the
value of such patent. If we, our collaborators or any of our future licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial
condition, results of operations, and prospects may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance
with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these
requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications
will be due to be paid to the USPTO and various government patent agencies outside of the United&nbsp;States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our collaborators or licensing
partners to pay these fees due to U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government agencies require compliance with several procedural,
documentary, fee payment, and other similar provisions during the patent application process. We also are dependent on our collaborators or licensors to take the necessary action to comply with these requirements with respect to our licensed
intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which
<FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential
competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs
surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March&nbsp;2013, in the United&nbsp;States, the first to invent the claimed
invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March&nbsp;2013, under the Leahy-Smith America Invents Act (the America Invents Act) enacted in
September&nbsp;2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent
application in the USPTO after March&nbsp;2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going
forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the
first to either (i)&nbsp;file any patent application related to our product candidates or other technologies or (ii)&nbsp;invent any of the inventions claimed in our patents or patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may
affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including
post-grant review, <I>inter partes</I><B><I> </I></B>review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a
patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court
action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America
Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our
business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the development
and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations.
This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing
patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before
administrative bodies in the United States or abroad. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we initiated legal proceedings against a third party to enforce a patent
covering our product candidates or other technologies, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are
commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an
unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims challenging the
validity or enforceability of our patents before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review,
<I>inter partes</I><B><I> </I></B>review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or
amendment to our patents in such a way that they no longer cover our product candidates or other technologies. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for
example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or
unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates or other technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition,
results of operations, and growth prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain patent term extension and data exclusivity for any product candidates we may
develop, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration, and specifics of any FDA marketing approval
of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for
patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims
covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and
territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise due diligence during the
testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the
scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products
following our patent expiration, and our business, financial condition, results of operations, and growth prospects could be materially harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may be subject to claims challenging the inventorship of our patents and other intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims
that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, we may have inventorship
disputes arise from conflicting obligations of employees, consultants, or others who are involved in developing our product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging
inventorship or ownership of our patents, trade secrets, or other intellectual property. If the defense of any such claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership
of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to
management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for our product candidates and other technologies, we also rely on trade secrets and confidentiality agreements
to protect our unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology, and other proprietary information and to maintain our competitive position. We consider trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to be
one of our primary sources of intellectual property. Trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We expect our trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to over time be
disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to protect these trade secrets and other proprietary technology, in part, by entering into
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and
other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, train our employees not to bring or use proprietary information or technology from former employers to us or in
their work, and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary
information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. For example, on June&nbsp;18, 2019, we initiated a confidential arbitration proceeding against Dr.&nbsp;Asa Abeliovich, our former
consulting <FONT STYLE="white-space:nowrap">co-founder,</FONT> related to alleged breaches of his consulting agreement and the improper use of our confidential information learned during the course of rendering services to us as our consulting Chief
Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome. Enforcing a claim that a party illegally disclosed or
misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade
secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be
disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may not be successful in obtaining, through acquisitions or otherwise, necessary rights to our product candidates or other technologies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many pharmaceutical companies, biotechnology companies, and academic institutions are competing with us in the field of neurodegeneration
therapy may have patents and have filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents
from such third-party intellectual property holders. We may also require licenses from third parties for certain technologies for use with future product candidates. In addition, with respect to any patents we
<FONT STYLE="white-space:nowrap">co-own</FONT> with third parties, we may wish to obtain licenses to such <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest to such patents. However, we may be unable to secure such licenses or
otherwise acquire any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our future product candidates. The licensing or acquisition of third-party intellectual
property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a
competitive advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.
We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party
intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial
condition, results of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants, or advisors have wrongfully
used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other biotechnology or
pharmaceutical companies, including our competitors and potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of
others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer.
Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who may be
involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops
intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims
that they may bring against us, to determine the ownership of what we regard as our intellectual property, such as with our arbitration claims against Dr.&nbsp;Asa Abeliovich, our former consulting Chief Scientific Officer/Chief Innovation Officer.
Such claims could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party
claims of intellectual property infringement, misappropriation, or other violation against us or our collaborators may prevent or delay the development and commercialization of our product candidates and other technologies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The field of discovering treatments for neurodegenerative diseases is highly competitive and dynamic. Due to the focused research and
development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is in flux, and it may remain uncertain in the future. Additionally, the technology used in our product
candidates is still in its infancy and no products utilizing similar technology have yet reached the market. As such, there may be significant intellectual property related litigation and proceedings relating to our, and other third party,
intellectual property and proprietary rights in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our and our collaborators&#146;
ability to develop, manufacture, market, and sell any product candidates that we develop and to use our proprietary technologies without infringing, misappropriating, and otherwise violating the patents and other intellectual property rights of
third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including
interference, derivation, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may become party to, or threatened with, such actions in the future, regardless of their merit. As
discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including <I>inter partes</I> review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of
challenge to our patents in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties
exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates and other technologies may give rise to
claims of infringement of the patent rights of others. Although we believe that we do not infringe a valid claim of any third party&#146;s patents or other intellectual property, we cannot assure you that our product candidates and other
technologies that we have developed, are developing or may develop in the future will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a
competitor in the fields in which we are developing product candidates, and other technologies might assert are infringed by our current or future product candidates or other technologies, including claims to compositions, formulations, methods of
manufacture or methods of use or treatment that cover our product candidates or other technologies. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or
other technologies, could be found to be infringed by our product candidates or other technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in
issued patents that our product candidates or other technologies may infringe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may have patents or obtain patents in the
future and claim that the manufacture, use or sale of our product candidates or other technologies infringes upon these patents. In the event that any third-party claims that we infringe their patents or that we are otherwise employing their
proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competent jurisdiction could hold that such patents are valid, enforceable and infringed by our product candidates or other technologies. In this case, the holders of such patents may be able to
block our ability to commercialize the applicable product candidate or technology unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may
not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could
result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our product candidates or other
technologies, or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion
of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing our infringing product
candidates or other technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, and/or redesign our
infringing product candidates or technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates or other technologies, which
could harm our business significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Engaging in litigation to defend against third parties alleging that we have infringed,
misappropriated, or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or
administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of
patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and
growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be
expensive, time consuming, and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or the patents of our licensing partners, or we
may be required to defend against claims of infringement. In addition, our patents or the patents of our licensing partners also may become involved in inventorship, priority, or validity disputes. To counter or defend against such claims can be
expensive and time consuming. In an infringement proceeding, a court may decide that a patent in which we have an interest is invalid or unenforceable, the other party&#146;s use of our patented technology falls under the safe harbor to patent
infringement under 35&nbsp;U.S.C. &#167;271(e)(1), or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could
put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure during this type of litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or
other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of
hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or
proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to
conduct such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial
resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the
marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of
interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our registered or unregistered trademarks or trade names may be challenged,
infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers
in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be
potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to
establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade
secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations, and growth
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are similar to our product candidates or utilize similar technology but
that are not covered by the claims of the patents that we license or may own; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our current or future licensors or collaborators, might not have been the first to make the inventions
covered by the issued patent or pending patent application that we license or own now or in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our current or future licensors or collaborators, might not have been the first to file patent
applications covering certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our owned or licensed intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our current or future pending owned or licensed patent applications will not lead to issued
patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal
challenges by our competitors or other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors or other third parties might conduct research and development activities in countries where we do
not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent covering such intellectual property. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on our business,
financial condition, results of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may
not be able to successfully implement our business strategy. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to compete in the highly competitive biotechnology and
pharmaceutical industries depends upon our ability to attract, motivate, and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our management, particularly our Chief Executive Officer, Dr.&nbsp;Arnon
Rosenthal, and our scientific and medical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in
delays in the development of our product candidates and harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conduct our operations at our facility in South San
Francisco, California, in a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our
ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region and doing so may be costly and difficult. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided restricted stock and stock
option grants that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more
lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our employees could
leave our employment at any time, with or without notice. If we are unable to attract and incentivize quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, we had 109 full-time employees. As our development plans and strategies develop, and as we continue to implement
the requirements applicable to operating as a public company, we must add a significant number of additional managerial, operational, financial, and other personnel. Future growth will impose significant added responsibilities on members of
management, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting, integrating, retaining, and motivating additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing our internal development efforts effectively, including the clinical and FDA review process for our
current and future product candidates, while complying with our contractual obligations to contractors and other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanding our operational, financial and management controls, reporting systems, and procedures; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing increasing operational and managerial complexity. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in
part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
activities in order to manage these growth activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely, and for the foreseeable future will continue to rely, in
substantial part on certain independent organizations, advisors, and consultants to provide certain services. There can be no assurance that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the services of these independent organizations, advisors, and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In
addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may
not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on
economically reasonable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not able to effectively expand our organization by hiring new employees and expanding
our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and, accordingly, may not achieve our research, development, and commercialization goals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have engaged in strategic collaborations and may in the future engage in acquisitions, collaborations, or strategic partnerships, which may increase
our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have engaged in strategic collaborations in the past, such as our strategic collaboration with AbbVie, and we may engage in various
acquisitions, collaborations, and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any acquisition, collaboration, or strategic partnership may
entail numerous risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">volatility with respect to the financial reporting related to such arrangements, such as our expected variability
in the recognition of revenue each quarter from the AbbVie Agreement based on the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">percentage-of-completion</FONT></FONT> basis under the applicable accounting rules;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumption of indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuance of our equity securities which would result in dilution to our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assimilation of operations, intellectual property, products, and product candidates of an acquired company,
including difficulties associated with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of our management&#146;s attention from our existing product programs and initiatives in pursuing such
an acquisition or strategic partnership; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that
party and their existing products or product candidates and regulatory approvals; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to generate revenue from acquired intellectual property, technology, and/or products sufficient to
meet our objectives or even to offset the associated transaction and maintenance costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we undertake
such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses, and acquire intangible assets that could result in significant future amortization
expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or
consultants, may fail or suffer other breakdowns, cyberattacks, or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development
programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems and those of our future CROs and other contractors and
consultants may be vulnerable to damage from computer viruses and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unauthorized access. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication, and intensity, and are becoming increasingly difficult to detect. Such attacks
could include the use of key loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering, and/or other means. If a breakdown,
cyberattack, or other information security breach were to occur and cause interruptions in our operations, it could result in a misappropriation of confidential information, including our intellectual property or financial information, and a
material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed, ongoing, or future clinical trials could result in delays in our regulatory approval efforts and significantly
increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates
and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data
or systems, or inappropriate disclosure of confidential, financial, or proprietary information, including data related to our personnel, we could incur liability or risk disclosure of confidential, financial, or proprietary information, and the
further development and commercialization of our product candidates could be delayed. There can be no assurance that we and our business counterparties will be successful in efforts to detect, prevent, or fully recover systems or data from all
breakdowns, service interruptions, attacks, or breaches of systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive data, which could result in financial, legal, business, or reputational
harm to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations, and those of our third-party research institution collaborators, CROs, CDMOs, suppliers, and other contractors and consultants,
could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT>
disasters or business interruptions, for which we are partly uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by
government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and
process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other
business interruption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of our operations including our corporate headquarters are located in a facility in South San
Francisco, California. Damage or extended periods of interruption to our corporate, development, or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry, or other events could cause us to cease or
delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business may
be seriously harmed by such delays and interruption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is subject to economic, political, regulatory, and other risks associated with
international operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to risks associated with conducting business internationally. Some of our CDMOs
are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> economies and markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing and changing regulatory requirements in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that
do not respect and protect intellectual property rights to the same extent as the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in compliance with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws and regulations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulations and customs, tariffs, and trade barriers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency exchange rates and currency controls;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in a specific country&#146;s or region&#146;s political or economic environment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shipping of biologics/drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trade protection measures, import or export licensing requirements, or other restrictive actions by U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> governments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative consequences from changes in tax laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties associated with staffing and managing international operations, including differing labor relations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential liability under the FCPA, UK Bribery Act, or comparable foreign laws; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including
war and terrorism, or natural disasters including earthquakes, typhoons, floods, and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other risks
associated with our planned international operations may materially adversely affect our ability to attain profitable operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to
use our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had
federal and state net operating loss (NOL) carryforwards of approximately $17.5&nbsp;million and $17.1&nbsp;million, respectively, which will begin to expire in 2037, if not utilized. In addition, due to tax reform, we also have federal NOL
carryforwards of $42.9&nbsp;million generated after December&nbsp;31, 2017, which do not expire. Under Sections&nbsp;382 and 383 of the United States Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an
&#147;ownership change&#148; (generally defined as a greater than <FONT STYLE="white-space:nowrap">50-percentage-point</FONT> cumulative change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the
corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change taxable income or taxes
may be limited. As a result of our initial public offering in February 2019, and other transactions that have occurred since our incorporation, we may have experienced, and in connection with this offering may experience, such an ownership change.
We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> net
operating loss carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset post-change taxable income or taxes may be subject to limitation. In addition, the enacted legislation commonly referred to as the Tax
Cuts and Jobs Act of 2017 (the Tax Act) imposes certain limitations on the deduction of NOLs, including a limitation on the use of NOLs generated in tax years beginning after December&nbsp;31, 2017 to 80% of current year taxable income. The Tax Act
also eliminates the carryback and permits the indefinite carryforward of NOLs arising in tax years ending after December&nbsp;31, 2017, whereas NOLs arising in tax years ending prior to that date continue to have a
<FONT STYLE="white-space:nowrap">two-year</FONT> carryback and twenty-year carryforward. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering and Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not be sustained. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to our initial public offering in February 2019, there was no public trading market for our common stock. Although our common stock is
listed on the NASDAQ Global Select Market, the market for our shares has demonstrated varying levels of trading activity. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our
results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our common stock may continue to be volatile, which could result in substantial losses for investors, including investors purchasing
shares in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of our common stock has been and may continue to be highly volatile and could be
subject to wide fluctuations in response to various factors, some of which are beyond our control. We priced our initial public offering at $19.00 per share on February&nbsp;6, 2019 and, our common stock reached a high of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share during&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and a low of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share during&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
On&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, the last reported sale price of our common stock was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. Some of the factors that may cause the market price of our common stock to fluctuate include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of existing or new competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and results of clinical trials for our current product candidates and any future product candidates
that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement or termination of collaborations for our product development and research programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to achieve development, regulatory, or commercialization milestones under our collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure or discontinuation of any of our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our
competitors, or announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents, or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our research programs, clinical development programs, or product
candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to develop additional product candidates or products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock by us, our insiders, or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expiration of market standoff or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry, and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced
significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors
may seriously affect the market price of our common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. Following periods of such
volatility in the market price of a company&#146;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation
in the future. Securities litigation could result in substantial costs and divert management&#146;s attention and resources from our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If
securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our
business. If one or more of the analysts covering our business cease to cover us or downgrade their evaluations of our stock or if we fail to meet their operating results estimates for us, the price of our stock could decline. If one or more of
these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could cause the market price of
our common stock to decline significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our
common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amount of our common stock in the public market, the market price of our common stock
could decline significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain holders of shares of our common stock have rights, subject to conditions, to require us to file
registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming
freely tradeable in the public market, subject to the restrictions of Rule 144 in the case of our affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price for our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You will incur immediate and substantial dilution as a result of this offering. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase common stock in this offering, you will incur immediate and substantial dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing the difference between the assumed offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the last reported sale price of our common stock on the NASDAQ Global Select Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, and the as adjusted net
tangible book value per share of our common stock as of September&nbsp;30, 2019, because the price that you pay will be substantially greater than our net tangible book value per share of the common stock that you acquire. As of September&nbsp;30,
2019, there were 5,918,124 shares subject to outstanding options with a weighted-average exercise price of $10.84 per share. To the extent that these outstanding options are ultimately exercised or the underwriters exercise their option to purchase
additional shares, you will incur further dilution. See the section titled &#147;Dilution&#148; for a further description of the dilution you will experience immediately after this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or
require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to seek additional capital through a
combination of public and private equity offerings, debt financings, strategic partnerships and alliances, and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our
decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our<B> </B>control, we cannot predict or estimate the amount, timing, or nature of any future offerings. To the extent that
we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of
indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property
rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow
and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant
licenses on terms unfavorable to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders and management own a significant percentage of our stock and will be able to
exercise significant influence over matters subject to stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors, executive officers, holders of more
than 5% of our outstanding stock and their respective affiliates beneficially owned 58.1% of our outstanding common stock as of November&nbsp;1, 2019. As a result, these stockholders, if they act together, may significantly influence all matters
requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company that our other
stockholders may believe is in their best interests. This in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the board of directors or management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock
less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act
of 2012 (JOBS Act). For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These
exemptions include not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (SOX), not being required to comply with any requirement that may be adopted by the Public Company
Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive
compensation, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide
stockholders will be different than the information that is available with respect to other public companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our
common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new
or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of
this exemption from new or revised accounting standards, and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred and will continue to incur significant additional costs as a result of operating as a
public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we are no longer an emerging growth company, we have incurred and will continue to incur
significant legal, accounting, and other expenses that we did not incur as a private company. The SOX, the Dodd-Frank Wall Street Reform, and Consumer Protection Act, the listing requirements of NASDAQ, and other applicable securities rules and
regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We have hired, and expect that we will need to continue to hire,
additional accounting, finance, and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel have devoted and will continue to devote a
substantial amount of time towards maintaining compliance with these requirements. These requirements have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.
For example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to maintain director and officer liability insurance, which could make it more difficult for us to
attract and retain qualified members of our board of directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and
regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could
result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to SOX Section&nbsp;404, we will be required to furnish a report by our management on our internal control over financial reporting
beginning with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC after we become a public company. However, while we remain an emerging growth company, we will not be required to include an
attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&nbsp;404 within the prescribed period, we will be engaged in a process to document
and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess
and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and
improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective
as required by SOX Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to maintain effective internal controls, our business, financial position, and results of operations could be adversely affected.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we are subject to reporting and other obligations under the Exchange Act, including the requirements of SOX
Section&nbsp;404, which require annual management assessments of the effectiveness of our internal control over financial reporting. However, our auditors will not be required to formally attest to the effectiveness of our internal control over
financial reporting pursuant to SOX Section&nbsp;404 until we are no longer an emerging growth company if we continue to take advantage of the exemptions available to us through the JOBS Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and
require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act of 2002. These reporting and other obligations place significant demands on our
management and administrative and operational resources, including accounting resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with accounting principles generally accepted in the United States. Any failure to maintain effective internal controls could have an adverse effect on our business, financial position, and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot specify with certainty the particular uses of the net proceeds we will receive from this offering. Our management will have broad
discretion in the application of the net proceeds, including for any of the purposes described in the section titled &#147;Use of Proceeds.&#148; Our management may spend a portion or all of the net proceeds from this offering in ways that our
stockholders may not desire or that may not yield a favorable return. The failure by our management to apply these funds effectively could harm our business, financial condition, results of operations and prospects. Pending their use, we may invest
the net proceeds from this offering in a manner that does not produce income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not expect to pay any dividends for the
foreseeable future. Investors may never obtain a return on their investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely on an investment in our common
stock to provide dividend income. We do not anticipate that we will pay any dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any
future credit facility may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never
occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might discourage, delay, or prevent a change in control
of our company or changes in our management and, therefore, depress the trading price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our
amended and restated certificate of incorporation and bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a
premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among
other things, our charter documents: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish that our board of directors is divided into three classes, Class&nbsp;I, Class&nbsp;II, and
Class&nbsp;III, with each class serving staggered three-year terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office,
even though less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our directors may only be removed for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eliminate cumulative voting in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of
those shares, including preferences and voting rights, without stockholder approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created
directorship; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit stockholders from calling a special meeting of stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholders give advance notice to nominate directors or submit proposals for consideration at
stockholder meetings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors, by a majority vote, to amend the bylaws; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many
of the provisions described above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;203 of the General Corporation Law of the State of
Delaware (DGCL), prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our
voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws, or Delaware law that has the effect of
delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes
between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of
Delaware is the exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of us, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our
stockholders, (iii)&nbsp;any action arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws (as either may be amended from time to time), or (iv)&nbsp;any action asserting a claim governed by the internal affairs
doctrine, except, in each case, (A)&nbsp;any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of
such court within 10 days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than such court, or (C)&nbsp;for which such court does not have subject matter jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These exclusive-forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for
disputes with us or our directors, employees, control persons, underwriters, or agents, which may discourage lawsuits against us and our directors, employees, control persons, underwriters, or agents. Additionally, a court could determine that the
exclusive forum provision is unenforceable, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. If a court were to find these provisions of our amended and
restated bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect
our business, financial condition, or results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference in this prospectus contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained or incorporated by reference in this prospectus, including statements regarding our future results of operations and financial
position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of
management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance,
or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148;
&#147;would,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148; &#147;contemplate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148;
&#147;potential,&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. Forward-looking statements contained in this prospectus and the documents incorporated by reference in this prospectus include, but are not
limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other
positive results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and focus of our future clinical trials, and the reporting of data from those trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to commercializing our product candidates, if approved, including the geographic areas of
focus and sales strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expected potential benefits of strategic collaborations with third parties and our ability to attract
collaborators with development, regulatory, and commercialization expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of the number of patients in the United States who suffer from the diseases we are targeting and
the number of patients that will enroll in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the market opportunity for our product candidates in each of the diseases we are targeting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to expand our product candidates into additional indications and patient populations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals, including our expectation to seek special
designations, such as orphan drug designation, for our product candidates for various diseases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to the further development and manufacturing of our product candidates, including additional
indications that we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">existing regulations and regulatory developments in the United States and other jurisdictions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for
the manufacture of our product candidates for preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent
terms where available and the outcome of our ongoing arbitration proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need to hire additional personnel and our ability to attract and retain such personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional
financing; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital
expenditure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS
Act; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of our existing resources and the proceeds from this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which
we operate and financial trends that we believe may affect our business, financial condition, results of operations, and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking
statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties, and assumptions described in the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus and the documents incorporated by
reference in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future
events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we
do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information, future events, or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not
be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_6"></A>MARKET, INDUSTRY, AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains estimates, projections, and other information concerning our industry, our business, and the markets for our product
candidates, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market, and similar dataset forth in this prospectus from our internal estimates and research and from
academic and industry research, publications, surveys, and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly refer to the sources from which this information is derived. In that regard, when we
refer to one or more sources of this type of information in any paragraph, you should assume that other information of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context
otherwise requires. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and
circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not
been verified by any third party. You are cautioned not to give undue weight to any such information, projections, and estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some
cases, we do not expressly refer to the sources from which data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is
derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sources of industry and market
data contained or incorporated by reference in this prospectus are listed below: ` </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Alzheimer&#146;s Association. &#147;2018 Alzheimer&#146;s Disease Facts and Figures.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Alzheimer&#146;s Association. &#147;Costs of Alzheimer&#146;s to Medicare and Medicaid.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Boeve, B., Baker, M., Dickson, D., Parisi, J., Giannini, C., et al. &#147;Frontotemporal dementia and
parkinsonism associated with the <FONT STYLE="white-space:nowrap">IVS1+1G-&gt;A</FONT> mutation in progranulin: a clinicopathologic study.&#148; <I>Brain: a Journal of Neurology</I>. Volume 129, Issue 11, November 2006. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Hansen, D., Hanson, J., Sheng, M. &#147;Microglia in Alzheimer&#146;s disease.&#148; <I>Journal of Cell
Biology</I>. Volume 217, Number 2, February 2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kao, A., McKay, A., Singh, P., Brunet, A., Huang, E. &#147;Progranulin, lysosomal regulation and
neurodegenerative disease.&#148; <I>Nature Reviews Neuroscience.</I> Volume 18, Number 6, June 2017. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parkinson&#146;s Disease Foundation. &#147;Statistics.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sha, S., Miller, Z., Min, S., Zhou, Y., Brown, J., et al. &#147;An
<FONT STYLE="white-space:nowrap">8-week,</FONT> open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations.&#148; <I>Alzheimer&#146;s</I><I></I><I>&nbsp;&amp; Dementia: Translational
Research</I><I></I><I>&nbsp;&amp; Clinical Interventions</I>. Volume 3, Issue 4, November 2017. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">World Health Organization. &#147;Neurological Disorders: Public Health Challenges.&#148; <I>World Health
Organization Press</I>. 2007. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Arthur, K., Calvo, A., Price, T. et al. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040.
Nat Commun 7, 12408 (2016). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds to us from the sale of the shares of our common stock in this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters
exercise their option to purchase additional shares in full, based on an assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the last reported sale price of
our common stock on the NASDAQ Global Select Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, and after deducting estimated underwriting discounts and commissions and estimated offering
expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purposes of this offering are to obtain additional capital to support our operations. We currently
anticipate that we will use the net proceeds from this offering, together with our existing resources, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund Phase&nbsp;2 and Phase 3 clinical trials for AL001 in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients and expand into <FONT
STYLE="white-space:nowrap">FTD-C9orf72</FONT> and other potential indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund Phase 1 and Phase 2 clinical trials for AL002 and AL003; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to advance AL101 in and through Phase&nbsp;1 clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to continue to advance our preclinical development pipeline into Phase 1 clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to further develop our Discovery Platform; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder to fund working capital and other general corporate activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe opportunities may exist from time to time to expand our current business through license or acquisitions of, or investments in,
complementary businesses, products or technologies. While we currently have no agreements or commitments to complete any such transaction at this time, we may use a portion of the net proceeds for these purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating expenses have increased and we expect them to continue to increase in 2020 and beyond as we advance our development pipeline and
accelerate our efforts to conduct clinical trials. Accordingly, we will need additional funds to complete our currently planned and future clinical trials and development programs. Based on our current operating plans and assumptions, we believe our
existing cash, cash equivalents, and marketable securities, together with the expected net proceeds from this offering, will enable us to meet our financial needs at least into the second half of 2022. The net proceeds from this offering, together
with our cash, cash equivalents, and marketable securities, will not be sufficient for us to fund any of our product candidates through regulatory approval, our preclinical development pipeline through Phase 1 clinical trials, or any product
candidates resulting from our Discovery Platform into preclinical studies and clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion
over the use of the net proceeds from this offering. The amounts and timing of our expenditures will depend upon numerous factors including the results of our research and development efforts, the timing and success of preclinical studies and any
ongoing clinical trials or clinical trials we may commence in the future, the timing of regulatory submissions, the amount of cash obtained through our existing collaborations and future collaborations, if any, and any unforeseen cash needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending their uses, we plan to invest the net proceeds of this offering in short-term, interest-bearing, investment-grade instruments,
certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to
finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of our board of directors after taking into account
various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements and contractual restrictions of then-existing debt instruments, and other factors that our board of directors deems relevant.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc838337_22"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash, cash equivalents, and marketable securities and capitalization as of September&nbsp;30, 2019, as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an as adjusted basis to further reflect our issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering at the assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the
last reported sale price of our common stock on the NASDAQ Global Select Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2019 after deducting the estimated underwriting discounts and commissions and estimated
expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this table in conjunction with our consolidated financial statements and the
related notes and the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; that are incorporated by reference in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September 30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(In&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and<BR>per&nbsp;share&nbsp;data)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">381,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, par value $0.0001 per share; 20,000,000 shares authorized and no shares issued
and outstanding, actual and as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.0001 per share; 200,000,000&nbsp;shares authorized and
68,922,249&nbsp;shares issued and outstanding, actual; 200,000,000 shares authorized and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">218,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on the 68,922,249
shares of our common stock outstanding as of September&nbsp;30, 2019, and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,822,524 shares of common stock issuable upon exercise of options to purchase shares of our common stock
outstanding as of September&nbsp;30, 2019 under our 2017 Stock Option and Grant Plan (2017 Plan), at a weighted-average exercise price of $8.97 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,095,600 shares of common stock issuable upon exercise of options to purchase shares of our common stock
outstanding as of September&nbsp;30, 2019 under our 2019 Equity Incentive Plan (2019 Plan), at a weighted-average exercise price of $19.15 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,604,971 shares of common stock issuable upon exercise of options to purchase shares of our common stock that we
granted after September 30, 2019 under our 2019 Plan, at a weighted-average exercise price of $17.12 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,911,739 shares of common stock reserved for future issuance under our 2019 Plan as of September&nbsp;30, 2019,
as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,478,492 shares of common stock reserved for issuance under our 2019 Employee Stock Purchase Plan (ESPP) as of
September 30, 2019, as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net tangible book value per share is determined by dividing our total tangible assets less our total liabilities by the number of shares of
our common stock outstanding. Our net tangible book value as of September&nbsp;30, 2019 was $218.6&nbsp;million, or $3.17 per share, based on the total number of shares of our common stock outstanding as of September&nbsp;30, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving further effect to our sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is
the last reported sale price of our common stock on the NASDAQ Global Select Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of September&nbsp;30, 2019 would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an immediate increase in as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to our existing stockholders and an immediate
dilution in as adjusted net tangible book value per share of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to new investors purchasing common stock in this offering. Dilution per share to new investors purchasing common stock
in this offering is determined by subtracting as adjusted net tangible book value per share after this offering from the public offering price per share paid by new investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in as adjusted net tangible book value per share attributable to new investors purchasing
shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the last reported sale price of our common stock on the NASDAQ Global Select Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, would increase (decrease) the as adjusted net tangible book value per share after this offering or dilution per share to new investors by
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option
to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock in this offering in full at the assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the last reported sale price of our common stock on the NASDAQ Global Select Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, the as adjusted net
tangible book value per share after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and the dilution in as adjusted net tangible book value per share to new investors purchasing common stock in this offering would
be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, on an as adjusted basis, as of
September&nbsp;30, 2019, the number of shares of common stock purchased from us on an as converted to common stock basis, the total consideration paid, or to be paid and the weighted-average price per share paid, or to be paid, by existing
stockholders and by new investors in this offering at the assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the last reported sale price of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our common stock on the NASDAQ Global Select Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, before deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,922,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">379,531,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information discussed above is illustrative only and will change based on the actual offering
price, the number of shares we sell and other terms of this offering that will be determined at pricing. The table above assumes no exercise of the underwriters&#146; option to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares in this offering. If the underwriters&#146; option to purchase additional shares is exercised in full, the number of shares of
our common stock held by existing stockholders would be reduced to &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering, and the number of shares of common stock held by new investors
participating in the offering would be increased to &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares outstanding after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on the 68,922,249 shares of our common stock
outstanding as of September&nbsp;30, 2019, and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,822,524 shares of common stock issuable upon exercise of options to purchase shares of our common stock
outstanding as of September&nbsp;30, 2019 under our 2017 Plan, at a weighted-average exercise price of $8.97 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,095,600 shares of common stock issuable upon exercise of options to purchase shares of our common stock
outstanding as of September&nbsp;30, 2019 under our 2019 Plan, at a weighted-average exercise price of $19.15 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,604,971 shares of common stock issuable upon exercise of options to purchase shares of our common stock that we
granted after September&nbsp;30, 2019 under our 2019 Plan, at a weighted-average exercise price of $17.12 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,911,739 shares of common stock reserved for future issuance under our 2019 Plan as of September&nbsp;30, 2019,
as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,478,492 shares of common stock reserved for issuance under our ESPP as of September&nbsp;30, 2019, as well as
any automatic increases in the number of shares of common stock reserved for future issuance under this plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the
extent that any outstanding options are exercised or new options are issued under the equity benefit plans, or we issue additional shares of common stock or other securities convertible into or exercisable or exchangeable for shares of our capital
stock in the future, there will be further dilution to investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc838337_23"></A>A LETTER FROM ARNON </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prospective Alector co-owner, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At Alector, we do
not view diseases of aging as immutable facts. We are on a mission to slow down their progression and prevent their occurrence. We envision a world where each individual retains his or her full brain function and cognitive faculties throughout
life&#151;a world where dementia and neurodegeneration are illnesses of the past just as smallpox, diphtheria, rubella, and polio have become. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the early 20<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> century, the root cause of neurodegeneration has been considered to
be misfolded proteins such as amyloid-beta plaques and TAU tangles in Alzheimer&#146;s disease, alpha-synuclein in Parkinson&#146;s disease and TDP-43 in FTD and amyotrophic lateral sclerosis (ALS). Other pathologies that typify neurodegeneration,
including the dysfunction and destruction of neuronal connections, the accelerated death of nerve cells, and the dysfunction of the brain support cells, were thought to be consequences of these misfolded proteins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our founding six years ago, we have challenged this widely held belief. We made the case that multiple pathologies that typify
neurodegeneration become autonomous of the misfolded proteins and of each other at early disease stages, and that for therapeutic purposes, these pathologies should be viewed as independent causes of the disorder. With this understanding, we
searched for an underlying biological process that these pathologies share. Discoveries on the genetic underpinning of neurodegeneration and on the functions of the brain immune system led us to conclude that these parallel pathologies are primarily
caused by a dysfunctional brain immune system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific scientific advances that enabled our conclusion were: (1)&nbsp;the
identification of harmful genetic mutations that increase the risk of developing Alzheimer&#146;s disease; (2)&nbsp;the revelation that the majority of these mutations are in proteins that regulate the brain immune system; and (3)&nbsp;the findings
that the immune cells in the brain are responsible for a myriad of functions, which include compacting and disposing of misfolded proteins, the regulation of neuronal connections, and the survival and function of the brain&#146;s support cells and
neurons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since most neurodegenerative diseases are diseases of aging, we postulated that the brain immune cells lose their competence
with time and are no longer able to support normal brain function or to repair avoidable brain pathologies. In futile attempts to act, the senescing immune cells may further exacerbate the disease by secreting toxic immune mediators and by
indiscriminate scavenging. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With this understanding, we devoted the last six years to the development of novel therapeutics that harness
the brain&#146;s immune system to treat neurodegeneration. We have advanced four of our product candidates into clinical trials and plan to test the impact of these product candidates initially in patients suffering from Alzheimer&#146;s disease and
FTD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I have invested much of my 35&nbsp;years in the biotech industry into building teams that develop innovative therapeutics in
neuroscience. During my 16&nbsp;years with Genentech, I built a team that discovered multiple neuronal survival factors and receptors in order to prevent degenerative nerve cell death. As the Founder, President, and Chief Science Officer of Rinat
Neuroscience, my team and I discovered clinical antibodies designed to target misfolded proteins. As a Co-Founder and the former Chief Executive Officer of Annexon Biosciences, my team and I developed clinical antibodies that prevent destruction of
neuronal connections. I am a named inventor on over 350 issued patents and patent applications and am an author on over 100 peer reviewed publications. My teams and I discovered the target for the approved cancer drug, Erivedge, and were responsible
for the development of the non-addictive antibody pain drug candidate, tanezumab, and the approved migraine antibody drug, AJOVY. Our work at Alector is based upon our understanding of the basic biology of degenerative brain disorders and how to
translate this understanding into effective therapeutics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The World Health Organization estimates that up to&nbsp;1&nbsp;billion people are affected
by neurological disorders. There are currently over 50&nbsp;million people with neurodegeneration worldwide, with over 10&nbsp;million new cases each year. The Alzheimer&#146;s Association projected that the cumulative total cost of Medicare and
Medicaid for individuals living with Alzheimer&#146;s disease will total $750&nbsp;billion by 2050 in the United States alone, an increase of over 300% from projected 2018 spending levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Degenerative brain disorders are among the last medical frontiers that have yet to be conquered. If we are successful in our mission to treat
neurodegeneration, Alector will have a profound social and economic impact on humanity. We invite you to join us and become a partner in this meaningful venture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Best Regards, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arnon Rosenthal, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Co-Founder and Chief Executive Officer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our mission is to develop therapies that
empower the immune system to cure neurodegeneration. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a
novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to
simultaneously counteract these pathologies by restoring healthy immune function to the brain. Supporting our scientific approach, our Discovery Platform enables us to advance a broad portfolio of product candidates, validated by human genetics,
which we believe will improve the probability of technical success over shorter development timelines. As a result, in the last six years, we have identified over forty immune system targets, progressed over ten programs into preclinical research,
and advanced three product candidates, AL001, AL002, and AL003, into clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AL001, our first program in the clinic,
modulates progranulin (PGRN), a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer&#146;s disease, and Parkinson&#146;s disease. AL001 is initially
designed to treat FTD, a severe, rapidly progressing neurodegenerative disorder that affects approximately 170,000 individuals in the United States and the European Union alone, with potentially higher prevalence in Asia and Latin America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our AL001 program is aimed at treating a genetic subset of patients with FTD who have a known genetic mutation that causes a deficiency in
PGRN, which is called <FONT STYLE="white-space:nowrap">FTD-GRN.</FONT> AL001 has successfully achieved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> in the Phase 1b portion of the study in <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> subjects by restoring PGRN levels in plasma and cerebrospinal fluid back to the normal range. In the third quarter of 2019, we advanced AL001 into a Phase&nbsp;2 study with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients expected in the first half of 2020, which also includes an additional genetic subset of FTD patients <FONT
STYLE="white-space:nowrap">(FTD-C9orf72).</FONT> In addition, in consultation with the FDA, we plan to advance AL001 into a Phase&nbsp;3 study in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients in 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing AL101, our second product candidate in our PGRN program, for patients suffering from more prevalent neurodegenerative
diseases including Alzheimer&#146;s disease and Parkinson&#146;s disease, in addition to FTD. In line with our therapeutic hypothesis for FTD, mutations that moderately reduce the expression levels of PGRN have been shown to increase the risk of
developing Alzheimer&#146;s disease and Parkinson&#146;s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models. AL101 received orphan drug designation from the FDA for treatment of FTD in July
2019 and we expect to initiate a Phase 1 study of AL101 in the fourth quarter of 2019. We expect proof-of-mechanism data in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own
worldwide rights to both AL001 and AL101. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our next development programs. AL002 and AL003, focus on modulating check-point receptors on
the brain&#146;s immune cells, with AL002 targeting Triggering Receptor Expressed on Myeloid cells&nbsp;2 (TREM2) and AL003 targeting sialic acid binding <FONT STYLE="white-space:nowrap">Ig-like</FONT> lectin&nbsp;3 (SIGLEC&nbsp;3), respectively.
The AL002 and AL003 programs are aimed at treating Alzheimer&#146;s disease patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the third quarter of 2019, we completed the
Phase 1a portion of the study in healthy subjects with AL002 and a dose dependent change in the target engagement biomarker in cerebrospinal fluid was observed upon treatment. In the second quarter of 2019, based on safety and tolerability observed
in the Phase 1a study, we initiated the Phase 1b portion of the study with AL002 in Alzheimer&#146;s disease patients. We expect <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> data from
Alzheimer&#146;s disease patients in the first half of 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2019, we initiated a Phase 1a study in healthy
subjects with AL003, a product candidate targeting Alzheimer&#146;s disease. Thirty-eight (38)&nbsp;healthy subjects were dosed over eight dose cohorts in the AL003 Phase 1a dose escalation trial. A dose dependent change in target engagement in the
blood was observed upon treatment. One subject treated with the second highest dose experienced aseptic hip monoarthritis </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and a second subject treated with the highest dose experienced an adverse drug reaction characterized by rash, fever, and thrombocytopenia, which were both deemed treatment-related serious
adverse events. The subjects were treated with corticosteroids and recovered. Based on the safety and tolerability observed in the Phase 1a study, we identified a dose and initiated screening for the Phase 1b portion of the study with AL003 in
Alzheimer&#146;s disease patients in the fourth quarter of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have partnered with AbbVie, a leader in neuroscience drug
development, for the global development and potential commercialization of AL002 and AL003. We are responsible for execution of the Phase&nbsp;1 and Phase&nbsp;2 studies. Following AbbVie&#146;s potential exercise of its option, Alector and AbbVie
will share the development costs and will split global profits after marketing approval. However, following AbbVie&#146;s option exercise for a program, we may opt out of sharing in development costs and profits or losses from that program and
instead receive a tiered royalty on sales of products from that program. As part of this partnership, we received $205.0&nbsp;million in upfront payments, of which $5.0&nbsp;million and $200.0&nbsp;million was received by us in October 2017 and
January 2018, respectively, $20.0&nbsp;million from the sale of shares of our preferred stock in October 2017 and are eligible for up to an additional $985.6&nbsp;million in option exercise and milestone payments and a global profit share with
AbbVie upon commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Discovery Platform leverages large scale human genetic datasets, advanced tools in bioinformatics and
imaging, and insights into neurodegeneration and immunology to identify immune system targets that play a critical role in the development of multiple neurodegenerative diseases. Our Discovery Platform focuses on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Target Selection</I></B><B>. </B>We identify mutations in genes that control the brain&#146;s immune
system, which we believe are the root cause of neurodegeneration, employ a suite of genetic tools to elucidate the immune dysfunction caused by these mutations, and then engineer immune modulating antibodies to counteract the harmful consequences of
these genetic mutations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Biomarker Selection</I></B><B>. </B>We are able to identify and employ molecular biomarkers, assays, and
precise imaging techniques to confirm target engagement and measure the effect of our product candidates, allowing us to potentially obtain clinical data earlier than would otherwise be expected using traditional clinical measures.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Patient Selection</I></B><B>. </B>We utilize genetic screening and other biomarkers to better align a
patient&#146;s specific diagnosis with the targeted intervention in our clinical studies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our immuno-neurology approach
and our Discovery Platform are designed to broadly address multiple neurodegenerative disorders. The breadth of our opportunity is reinforced by our ability to engineer therapeutics capable of modulating a broad array of immune targets, validated by
human genetics, across multiple mechanisms of action, including product candidates that activate, block, inhibit, or down-regulate a given target as therapeutically needed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 1. The following table highlights our preclinical and clinical programs. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g55e46.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 2. The following table highlights ten of our identified programs in our research and development
pipeline. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g39b98.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above table reflects that we currently have ten research programs identified in our research and
development pipeline focused on targeting Alzheimer&#146;s disease, Parkinson&#146;s disease, ALS, progressive multiple sclerosis, and oncology. Currently, we estimate that these programs are one to three years or more away from entering preclinical
studies assuming that these programs meet our requirements for advancement into the preclinical stage. For each of our programs in our research and development pipeline we are working to identify biomarkers to be utilized in preclinical studies for
each program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Immune System is Central to Neurodegeneration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss of healthy immune function in the brain, due to cellular aging or mutations of genes that regulate key immune cells, underlies the
onset and progression of multiple neurodegenerative disorders. Genomic analyses have shown that there is a strong correlation between genetic mutations that predispose individuals to neurodegeneration and dysfunction in the immune system. For
example, 22 of the top 25 risk genes identified by evaluating large-scale data on tens of thousands of Alzheimer&#146;s disease patients regulate immune function in the brain. As a result of these genetic mutations, the brain&#146;s immune function
deteriorates and subsequently would fail to carry out critical activities, which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clearing or counteracting pathological neurodegenerative proteins such as amyloid-beta, TAU, alpha-synuclein, and
<FONT STYLE="white-space:nowrap">TDP-43;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing metabolic and functional support to nerve cells; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulating synaptic connections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protecting nerve cells by stimulating the regeneration of myelin sheaths around nerve fibers; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlling the neurotoxic activities of activated astrocytes and rogue microglia. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that restoring the immune system&#146;s ability to perform all of these vital functions in the brain is crucial to addressing
neurodegeneration given that past approaches focusing on single degenerative pathologies have proved inadequate to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the early
20<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> century, the root cause of neurodegeneration has been thought to be misfolded and aggregated pathological proteins. Other observable pathologies, including destruction of synapses,
accelerated nerve cell death, and dysfunction of the brain support cells, were all thought to be consequences of these pathological misfolded proteins. As a result, attempts to develop therapies for neurodegeneration have been centered on blocking
the synthesis of, and removing or <FONT STYLE="white-space:nowrap">dis-aggregating</FONT> misfolded proteins. These attempts have been largely unsuccessful, as the disease continues to progress despite significant clearance of the misfolded protein.
We believe that the multiple pathologies found in degenerative brain disorders become independent of the misfolded proteins, and each other, at early disease stages and are driven primarily by dysfunction of the brain&#146;s immune system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, the brain&#146;s immune system undergoes gradual deterioration of functional
characteristics as part of normal biological&nbsp;aging or due to harmful genetic mutations that are linked to neurodegeneration and are associated with accelerated senescence of the brain immune cells. These cells are no longer capable of executing
their beneficial and protective roles and instead often become harmful and destructive to the brain. Based on our understanding of the role of genetic mutations in neurodegeneration, we have designed our product candidates to target the mutated
genes linked to neurodegeneration, with the goal of slowing or reversing the deterioration of the brain&#146;s immune cells to achieve therapeutic benefit. By restoring healthy immune function in the brain, we believe we can simultaneously
counteract the multiple independent pathologies responsible for neurodegeneration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Team </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is led by seasoned executives with a proven track record of drug discovery and development in neuroscience, as well as substantial
operational and business expertise. Our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer, Arnon Rosenthal, Ph.D., has spent over 35 years developing therapeutics in neuroscience and led teams responsible for the
development of the <FONT STYLE="white-space:nowrap">non-addictive</FONT> pain drug tanezumab and the migraine drug AJOVY, and multiple other programs in clinical development. He also held several leadership roles over a <FONT
STYLE="white-space:nowrap">16-year</FONT> career at Genentech, where he led the team that discovered the target for the cancer drug Erivedge. Our Chief Medical Officer, Robert Paul, M.D., Ph.D., served as the Therapeutic Area Lead for Neuroscience
at Genentech, where among other projects, he oversaw the clinical development of various product candidates, including the amyloid-beta antibody crenezumab in Alzheimer&#146;s disease, <FONT STYLE="white-space:nowrap">GDC-0134</FONT> in ALS, and <FONT
STYLE="white-space:nowrap">GDC-0276</FONT> and <FONT STYLE="white-space:nowrap">GDC-0310</FONT> in pain. Our Chief Development Officer, Robert King, Ph.D., previously served as the Senior Vice President of development and supply chain at SciClone
Pharmaceuticals. Our Chief Business Officer, Sabah Oney, Ph.D., previously served as the Head of Global Sales and Business Development at Ariosa, Inc. until and through its acquisition by Roche. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we grow our company, we will continue to bolster our team by attracting people and partners committed to transforming the neurodegenerative
treatment landscape. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to develop therapies that empower the immune system to cure neurodegeneration. The key tenets of our business strategy to achieve
this goal include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Building the leading, fully-integrated company focused on delivering innovative immuno-therapies, validated
by human genetics, for the treatment of neurodegeneration. </I></B>We believe that building a fully integrated company will allow us to more rapidly and efficiently develop therapies for patients as well as create value for our stakeholders. We are
focused on building an independent research, development, clinical, and ultimately commercial organization in order to prosecute the full potential of our immuno-neurology approach and Discovery Platform. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Applying our proprietary development capabilities to rapidly advance our product candidates through
clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies and beyond.</I></B><B> </B>We are focused on maximizing the probability of success of our product candidates by leveraging immunology,
neurobiology, and human genetics, as well as our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> bioinformatics, to enable better and earlier target selection.
In addition, we are also focused on a biomarker-driven approach, including proprietary tools and assays, to confirm target engagement, inform patient selection, and follow clinical outcomes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Maximizing the therapeutic potential of our existing targets and product candidates. </I></B>Given the
central physiological roles played by the distinct targets of our product candidates, we believe that there is significant potential for us to address multiple indications with single targets. Our goal is to expand the therapeutic and commercial
potential of our existing targets and product candidates to additional indications. However, we will remain disciplined about advancing this strategy, leveraging </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
our Discovery Platform capabilities to inform expansion areas of maximum value and highest probability of success. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continuing to focus on discovering new targets and product candidates, validated by human genetics, to
prosecute the full power of our insights and platform. </I></B>Our Discovery Platform is central to our efforts to rapidly identify new product candidates with compelling clinical promise. We will continue to invest in our Discovery Platform,
including evolving our proprietary analytical tools and assays, to further investigate several of our identified immune system targets as well as generate additional targets and product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Role of the Innate Immune System
and Microglia in Neurodegeneration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant evidence in the last decade has shown that neurodegenerative diseases, such as
Alzheimer&#146;s disease, Parkinson&#146;s disease, FTD, and ALS, are linked to a dysfunctional brain immune system. In contrast to the dual adaptive and innate components that characterize the broader human immune system, the brain&#146;s immune
system consists primarily of innate immune cells, known as microglia. These brain resident macrophages account for 10% to 15% of all cells found within the brain and are responsible for many aspects of brain health and maintenance. As the key innate
immune cells in the brain, microglia respond to infection and damage, clear cell debris and pathological proteins, nurture neurons and the brain support cells, and control the number and functionality of inter-neuronal connections. Microglia have
been our initial focus and new scientific advances have made it possible to understand how these key innate immune cells in the brain represent a crucial focal point for intervening, treating, or preventing neurodegenerative diseases
(Figure&nbsp;3). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g21u52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;3. Our antibody product candidates target microglia to harness their many potential beneficial roles in
treating neurodegenerative diseases. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant Scientific Data Support Our Hypothesis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Understanding how the brain&#146;s immune cells affect its structure and function, in both normal and diseased states, is in our view, the key
to understanding many neurological diseases. Human genetic evidence, especially in the last five years, has supported the importance of the interactions between the brain and the innate immune system. For example, 22 of the top 25 risk genes for
Alzheimer&#146;s disease, identified using genetic linkage studies, candidate gene analysis, genome-wide association (GWAS) studies, and whole-genome or whole-exome sequencing, regulate immune function in the brain. Many of these risk genes have
been shown to express predominantly in microglia and to control the function of these cells (Figure&nbsp;4). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g14g22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;4. Expression of genes linked to Alzheimer&#146;s disease is highly enriched in microglia.<SUP
STYLE="font-size:85%; vertical-align:top">1</SUP> * Red box added to highlight microglia. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Microglia have been shown to be key cells
in overall brain maintenance, health, and function and are the brain&#146;s first line of immune defense. These innate immune cells are tooled with &#147;microglial sensomes&#148; which enable them to constantly survey brain cells to identify and
respond to subtle signs of pathology or dysfunction. Microglia scavenge the brain for&nbsp;toxic misfolded proteins, cell debris, damaged or unnecessary nerve cells, dysfunctional or aged synapses, and infectious agents. In addition, microglia
support the generation of new neurons and synapses and remodel neuronal circuits. Microglia also control the survival and function of astrocytes and oligodendrocytes, the main brain support cells which control brain metabolism and blood supply and
replenish aged or damaged nerve fibers after injury. Further, microglia have been shown to modulate the permeability of the blood brain barrier allowing access to peripheral immune cells, to assist against infection or injury. Microglia can also
change their morphology, functionality, and number in response to changing brain environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent analysis of gene transcription at
the single-cell level in microglia from normal and diseased brains revealed that multiple microglia subtypes exist which may respond to specific disease pathologies in the brain. Our product candidates are designed to recruit microglia subtypes by
targeting microglia check-point proteins that control their survival, proliferation, migration, and function. This allows us to differentially modulate microglia activity as needed to counteract a given degenerative brain disorder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent findings in the fields of human genetics, immunology, and neuroscience have indicated that as a result of normal aging or genetic
mutations, the beneficial functions of the microglia deteriorate leading to massive death of neurons and consequently to neurodegeneration. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Hansen, D., Hanson, J., Sheng, M. &#147;Microglia in Alzheimer&#146;s disease.&#148; <I>Journal of Cell
Biology</I>. Volume 217, Number 2, February 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table outlines the key impact of functional and dysfunctional microglia: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Functional Microglia</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Dysfunctional
Microglia</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt" BGCOLOR="#d8d8d8">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Clear/counteract and form a barrier around pathological proteins such as
amyloid-beta</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Reduced ability to remove, or to limit the damage caused by pathological
proteins leading to dysfunction of neuronal connections and ultimately leading to neuronal cell death</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Provide metabolic and functional support to nerve cells</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Reduced ability to provide nourishing factors to neurons leading to neuronal
cell death</P></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#d8d8d8">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Regulate healthy synaptic connections</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Indiscriminate destruction of synapses leading to reduced number of synapses
and dysfunctional neuronal connections</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Control the function of astrocytes, the brain&#146;s star shaped support cells
that help maintain the&nbsp;blood-brain barrier, provide nutrients to neurons, repair the nerve tissue following injury, and facilitate neurotransmission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Inducement and conversion of beneficial astrocytes to toxic astrocytes leading
to neuronal cell death</P></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#d8d8d8">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Control the survival and function of oligodendrocytes that provide protective
myelin sheaths around nerve fibers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Failure to support oligodendrocytes, leading to neuronal
dysfunction</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Discovery Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Discovery Platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and
immunology to: (1)&nbsp;identify immune system targets that play a critical role in the development of multiple neurodegenerative diseases, and&nbsp;rapidly develop antibody therapeutics to these targets, (2)&nbsp;interrogate and prioritize those
targets for activity using biomarkers and related proprietary assays and preclinical models, and (3)&nbsp;clinically test product candidates in genetically defined patient populations that are most likely to respond to treatment. We believe that
these platform capabilities provide us with the tools to solve the conceptual and technical challenges associated with development of drug candidates for neurodegeneration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on proprietary immuno-neurology bioinformatics algorithms and methodologies to analyze large genetic datasets from diseased and
healthy individuals, brain-based gene expression profiling, brain-based proteomics, and human pathology. These proprietary capabilities allow us to rapidly identify tractable targets, pharmacodynamic biomarkers, and patient populations associated
with aberrant immune function which lead to neurodegeneration. Specifically, the three priorities of our platform efforts are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Target Selection</I></B><B>. </B>Our target selection capabilities address a wide array of factors that we
believe inform efficient, optimized therapeutic outcomes, including genetic and mechanistic rationale. We leverage our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> bioinformatics to identify genetic mutations in the brain immune system that we believe are the root cause of
neurodegeneration. We employ a suite of genetic tools to elucidate the immune dysfunction caused by these mutations. We then seek to engineer immune modulating antibody product candidates to functionally counteract the harmful consequence of these
genetic mutations. We leverage <I>in vitro </I>and <I>in vivo </I>functional tools to validate the activity of our product candidates and their ability to cross the blood brain barrier at sufficient quantities to be therapeutically effective.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Biomarker Selection</I></B><B>. </B>We are able to identify and employ molecular biomarkers, assays, and
imaging techniques that are tailored to our product candidates to confirm target engagement and quantify their therapeutic impact, allowing us to potentially obtain clinical data earlier than would be expected using traditional clinical measures.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Patient Selection</I></B><B>. </B>We utilize genetic screening and biomarkers to better align a
patient&#146;s specific diagnosis with the targeted intervention in our clinical studies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ gene expression
profiling, proteomics, brain imaging, and data on disease pathology as well as our own preclinical and clinical data to continually refine our proprietary immuno-neurology algorithms and methodologies. Using our Discovery Platform to identify
targets that are validated by human genetics, disease biomarkers, and responsive patient populations, we believe that we are positioned for greater probability of technical success on more efficient timelines relative to historical drug development
in neurodegeneration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the last six years, we have identified over forty immune system targets through genetic analysis and efficiently
advanced more than ten programs to preclinical research. Our AL001 program, initially aimed at treating a genetic subset of patients with FTD carrying a PGRN loss of function mutation <FONT STYLE="white-space:nowrap">(FTD-GRN),</FONT> has
successfully achieved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> in the central nervous systems of healthy volunteers and FTD patients. By the end of 2019, we expect to have four product
candidates in clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Progranulin Program </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our first
development program is focused on modulating levels of PGRN, a key regulator of microglia function in the brain with strong genetic links to FTD and other neurodegenerative disorders. Healthy individuals carry two copies of PGRN that function
together to produce healthy levels of PGRN throughout the body. Mutations in both copies of the PGRN gene lead to a neurodegenerative disease called neuronal ceroid lipofuscinosis, which is typified by childhood dementia, vision loss, and epilepsy.
Mutations in a single copy of PGRN lead to a drop of between 50% and 70% in the level of PGRN and consequently lead to development of FTD with greater than 90% probability. Moreover, large scale human genetic studies have shown that mutations in the
gene for PGRN, which leads to a more modest decrease in the level of PGRN, increases the risk for Alzheimer&#146;s disease and Parkinson&#146;s disease, making PGRN a significant risk gene for these disorders as well. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthy levels of PGRN are associated with many cellular processes that include, but are not limited to, normal microglial activities,
neuronal survival, and lysosome function. As shown in the figure below (Figure&nbsp;5), PGRN deficiency disrupts microglia-neuronal homeostasis in the brain and promotes neurodegeneration through the release of cytotoxic cytokines and complement
factors by dysfunctional microglia. Moreover, these microglia activate astrocytes, which in turn, damage neurons. Thus, lack of PGRN leads to disrupted health and function of both neurons and microglia and if not corrected, rapid neurodegeneration.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g28j20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;5. PGRN deficiency disrupts homeostasis between microglia and neurons, and promotes neurodegeneration during
aging.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </B></P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kao, A., McKay, A., Singh, P., Brunet, A., Huang, E. &#147;Progranulin, lysosomal regulation and
neurodegenerative disease.&#148; <I>Nature Reviews Neuroscience.</I> Volume&nbsp;18, Number&nbsp;6, June 2017. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SORT1 Controls PGRN Levels in the Body </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human and mouse genetic studies have identified the neurotrophic factor PGRN degrading receptor SORT1 as a major negative regulator of PGRN
levels in plasma and the brain. SORT1 is a sorting receptor on the cell surface and on the endoplasmic reticulum-Golgi apparatus within the cell. SORT1 binds to extracellular PGRN in the plasma and brain and transports it into the cells for
degradation by the lysosome resulting in decreasing levels of extracellular PGRN. SORT1 deficiency increases PGRN plasma and brain levels by two to three-fold in mouse models, while variants that modestly reduce expression of SORT1 increase the
level of PGRN in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, genetic loss of SORT1 in mice does not lead to the adverse effects associated with genetic loss of
PGRN, and PGRN continue to function as expected in the absence of SORT1. These studies and others have indicated to us that blocking SORT1 with a pharmacological agent would be a safe and effective approach in increasing the level of functional PGRN
in the brain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed two distinct product candidates that target SORT1, AL001 and AL101, designed to increase PGRN levels in
the brain of patients to counteract the damage sustained due to low PGRN levels in neurodegenerative disorders. Our first product candidate, AL001, is initially intended to target orphan disorders, including genetic forms of FTD such as in patients
that are missing a functional copy of the PGRN gene <FONT STYLE="white-space:nowrap">(FTD-GRN).</FONT> Our second PGRN product candidate, AL101, is intended to target widely prevalent neurodegenerative disorders such as Alzheimer&#146;s disease and
Parkinson&#146;s disease, in addition to FTD. We have worldwide development and commercial rights to our PGRN product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL001 for the
Treatment of FTD </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our first product candidate, AL001, is a humanized recombinant monoclonal antibody that is intended to be
delivered by intravenous, peripheral infusion to the blood stream to increase the levels of PGRN in the brains of <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients. AL001 functions by shutting down the SORT1 degradation mechanism for PGRN and
increasing the circulating half-life of the functional PGRN in the brain. AL001 received orphan drug designation from the FDA for the treatment of FTD in 2018. Generally, if a product with an orphan drug designation subsequently receives the first
marketing approval for the indication for which it has such designation, the product is entitled to a period of market exclusivity. This exclusivity precludes the FDA from approving another marketing application for the same indication for that time
period, unless the later product is clinically superior. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of FTD </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FTD is a rapidly
progressing and severe degenerative brain disease with no approved treatment. FTD is a form of dementia found most frequently in individuals less than 65&nbsp;years old at time of diagnosis. Patients with FTD exhibit a range of symptoms including
personality changes including compulsive behavior, lack of restraint, apathy, and anxiety as well as language and behavioral problems. Average life expectancy in FTD patients is seven to 10&nbsp;years after the start of symptoms. FTD symptoms have
an insidious onset with clinical symptoms usually appearing between 45 to 65&nbsp;years of age at an average age of 58. Hence, FTD is considered an early-onset dementia as compared to late-onset Alzheimer&#146;s disease, and is more common than
Alzheimer&#146;s disease in early-onset dementia under the age of 60 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although FTD was poorly understood and thought to be rare,
over the past decade the scientific community has gained a knowledge about the biology of FTD as well as an awareness of disease prevalence. FTD affects 50,000 to 60,000 individuals in the United States and roughly 110,000 individuals in the
European Union. There are multiple heritable forms of FTD, such as <FONT STYLE="white-space:nowrap">FTD-GRN,</FONT> which represent 5% to 10% of all patients with FTD, and approximately 22% of heritable FTD cases. Healthy individuals carry two
copies of PGRN that function together to produce sufficient levels of PGRN throughout the body. Mutations in a single copy of PGRN lead to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
50% or greater decrease in the level of PGRN and lead to development of FTD with a greater than 90% probability. Researchers have identified over 70 inherited loss of function mutations in PGRN
that lead to FTD to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rate of disease progression in FTD is faster than in Alzheimer&#146;s disease, suggesting that clinical
trials with disease-modifying agents have the potential to obtain clinical data more quickly and with fewer subjects in FTD than in Alzheimer&#146;s disease. For example, the median survival from symptom onset in FTD is shorter than in
Alzheimer&#146;s disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we can establish rapid clinical
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients given its genetically-defined patient population, fast rate of disease progression, and our
ability to leverage fluid and imaging biomarkers. In <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients, inhibition of SORT1 through AL001 represents a potential mechanism to compensate for the over 50% reduction of PGRN. AL001 is intended to
reduce the ability of SORT1 to bind to and degrade PGRN, leading to increases in the levels of PGRN through increasing its circulating half-life (Figure&nbsp;6). We have tested our PGRN program antibodies in various animal models, including mice,
rats, and non-human primates as well as in healthy volunteers and <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients and have achieved significantly elevated, long-lasting levels of PGRN in the brain after intravenous administration. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g02g68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;6. Mechanism of action for our PGRN programs. AL001 binds to SORT1 and prevents degradation of PGRN,
increasing its circulating half-life significantly. A similar mechanism of action is also applicable for AL101. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL101 for the Treatment of
Alzheimer&#146;s Disease and Parkinson&#146;s Disease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a second product candidate in our PGRN program, AL101,
that targets SORT1 for large patient populations such as Alzheimer&#146;s disease and Parkinson&#146;s disease. AL101 received orphan drug designation from the FDA for the treatment of FTD in July 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mutations that moderately reduce the amount of PGRN in the brain increase the risk for
Alzheimer&#146;s disease and Parkinson&#146;s disease. Moreover, some Parkinson&#146;s disease patients have been shown to have reduced levels of PGRN. In line with our therapeutic hypothesis, we plan to target PGRN as a potential disease modifying
therapeutic for patients suffering from Alzheimer&#146;s disease and/or Parkinson&#146;s disease following <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in FTD patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Alzheimer&#146;s Disease </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alzheimer&#146;s disease is a chronic neurodegenerative&nbsp;disease that usually starts slowly in people over 65&nbsp;years of age and worsens
over time.&nbsp;It is the most common cause of dementia, accounting for 60% to 70% of all cases. The most common early symptom of Alzheimer&#146;s disease is difficulty in remembering recent events. As the disease advances, symptoms can include
problems with language, disorientation, mood swings, loss of motivation, failure to manage self-care, and behavioral issues. As a person&#146;s condition declines, they often withdraw from family and society.&nbsp;Gradually, bodily functions are
lost, leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is eight to ten years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While estimates of the prevalence of Alzheimer&#146;s disease vary, the Alzheimer&#146;s Association estimates that, in 2018, there are
5.7&nbsp;million people in the United States suffering from Alzheimer&#146;s disease and that number is projected to rise to nearly 14&nbsp;million by 2050. Alzheimer&#146;s disease is the sixth leading cause of death in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to its debilitating effect on patients&#146; cognition and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> functioning, Alzheimer&#146;s disease places a significant burden on the healthcare system. According to the Alzheimer&#146;s Association, the aggregate cost
of care in 2018 for patients with Alzheimer&#146;s disease and other types of dementia in the United States was estimated to be $232&nbsp;billion, over half of which is borne by the Medicare system. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Parkinson&#146;s Disease </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parkinson&#146;s disease is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. Early in the
disease, the most obvious symptoms are shaking, rigidity, slowness of movement, and difficulty with walking. Cognitive and behavioral problems may also occur. Dementia becomes common in the advanced stages of the disease. Depression and anxiety are
also common, occurring in more than a third of people with Parkinson&#146;s disease. Other symptoms include sensory, sleep, and emotional problems. Parkinson&#146;s disease typically occurs in people over the age of 60. The average life expectancy
following diagnosis is between three to 10 years after the onset of symptoms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no disease modifying treatment for
Parkinson&#146;s disease, and the options for patients are limited to treatments that improve symptoms. Initial treatment is typically with the anti-Parkinson&#146;s drug medication levodopa, with dopamine agonists being used once levodopa becomes
less effective. As the disease progresses and neurons continue to be lost, these medications become less effective while at the same time they produce a complication marked by involuntary writhing movements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Parkinson&#146;s Foundation, more than 10&nbsp;million people worldwide are living with Parkinson&#146;s disease. An
estimated 930,000 people in the United States will be living with Parkinson&#146;s disease by the year 2020. This number is predicted to rise to 1.2&nbsp;million by 2030. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our PGRN Preclinical Data </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
conducted safety and efficacy studies of AL001 in <FONT STYLE="white-space:nowrap">non-human</FONT> primates, also referred to as NHPs, and completed preclinical chronic good laboratory practice (GLP) toxicology testing through 26 weeks with no test
article related adverse findings. In <FONT STYLE="white-space:nowrap">non-human</FONT> primates, AL001 recognizes and binds to SORT1 with potency similar to that seen in the binding between AL001 and human SORT1. In these <FONT
STYLE="white-space:nowrap">non-human</FONT> primate experiments, AL001 delivered by intravenous injection to the blood stream blocked SORT1 and increased levels of PGRN in both plasma and the CSF (Figure&nbsp;7). These experiments indicated that
there were therapeutic levels of AL001 in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the brain following delivery to the bloodstream systemically. These effects were observed after a single dose of AL001 as well as during and after multiple dosing. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g14o83.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;7. AL001 blocks SORT1 and increases the levels of PGRN in plasma and the cerebrospinal fluid in NHP
following injection to the bloodstream, indicating that peripherally injected AL001 elicits the desired biological response in the brain (n=4) (* indicates p&lt;0.05 and ** indicates p&lt;0.01 by <FONT STYLE="white-space:nowrap">T-test).</FONT>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AL101 is able to cross-react and bind to murine, rat, <FONT STYLE="white-space:nowrap">non-human</FONT> primate as well as human
SORT1. AL101 binds SORT1 with similar potency in multiple animal models. Following injection, AL101 was shown to block SORT1 and increase the levels of PGRN in the plasma and cerebrospinal fluid of mice (Figure&nbsp;8), rats, and <FONT
STYLE="white-space:nowrap">non-human</FONT> primates, demonstrating again that administration of AL101 is effective in increasing PGRN levels in the brain in multiple animal models. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g72l82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;8. AL101 blocks SORT1 and increases the levels of PGRN in the plasma and cerebrospinal fluid in normal mice
following intraperitoneal injection, indicating that peripherally injected AL101 elicits the desired biological response in the brain (* indicates p&lt;0.05 and *** indicates p&lt;0.001 by <FONT STYLE="white-space:nowrap">T-test).</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have conducted preclinical tests with AL101 in a mouse model created by introducing a mutation in one of the two copies for
the mouse version of PGRN <FONT STYLE="white-space:nowrap">(FTD-GRN</FONT> mice). AL101 blocked SORT1 and increased levels of PGRN in both the plasma and CSF of the <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mice (Figure&nbsp;9). These changes
support </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the hypothesis that targeting SORT1 by administration of anti-SORT1 antibodies would lead to an increase of PGRN in the brains of <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g74r49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 9. AL101 blocks SORT1 and increases the levels of PGRN in the plasma and CSF in
<FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mice following intraperitoneal injection, indicating that peripherally injected AL101 elicits the desired biological response in the brain (* indicates p&lt;0.05 and *** indicates p&lt;0.001 by <FONT
STYLE="white-space:nowrap">T-test).</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mice also exhibit behavioral changes
such as an increase in submissiveness and social aversion. This can be assessed in a social aversion test in which mice are introduced at opposite ends of a tube. Normal mice will approach each other in the tube until one of them retreats on average
50% of the time. When an <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mouse is placed into the tube together with a normal mouse, it is about three times more likely to retreat first. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We tested our hypothesis that increasing levels of PGRN, through inhibition of SORT1, would slow disease progression and lead to a beneficial
therapeutic effect in the <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mouse model. In this experiment, administration of the <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mice with AL101 for four weeks increased PGRN levels in the brains of <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> mice and significantly reduced the social deficit symptoms of FTD and restored healthy behavior in this social aversion test. Moreover, no adverse effects were observed in either <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> mouse model or normal mice after the treatment with AL101. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our PGRN Product Candidates Development Plan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing two PGRN product candidates, AL001 and AL101. Our AL001 product candidate has demonstrated target engagement and
increases in the disease associated pharmacodynamic marker PGRN in the brains of primates, healthy volunteers, and <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients.&nbsp;Our second PGRN product candidate, AL101 has demonstrated target
engagement, increases in the disease associated pharmacodynamic marker PGRN in the brains of mice, rats and <FONT STYLE="white-space:nowrap">non-human</FONT> primates, as well as reduction of social deficit symptoms of FTD in a social aversion test
using <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mice following intravenous injection.&nbsp;We expect to initiate a Phase 1, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study with AL101 in the
fourth quarter of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AL001 successfully demonstrated
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> in a dose-escalating Phase 1a study in healthy volunteers and in the Phase 1b portion of the study in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT>
patients by showing a statistically significant increase in PGRN levels relative to baseline when compared to pooled placebo in plasma and in CSF at the <FONT STYLE="white-space:nowrap">pre-specified</FONT>
<FONT STYLE="white-space:nowrap">follow-up</FONT> time point. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AL001 was dosed in a randomized, double-blind, placebo-controlled,
dose-escalating Phase&nbsp;1a study in the United States with healthy volunteers being randomized and receiving a single dose of AL001 or placebo. Each of the dose levels consisted of a cohort of eight healthy volunteers, with six receiving AL001
and two receiving </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
placebo, representing a six to two randomization ratio of AL001 to placebo. The primary endpoints of the study are safety and tolerability. The secondary endpoints include pharmacokinetic and
pharmacodynamic measurements, including changes of PGRN in serum and the CSF. Pharmacodynamic characteristics include the biochemical and physiological effects of a product candidate, and pharmacokinetic characteristics describe the time course, for
example, product candidate absorption, distribution, metabolism, and excretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The subjects were dosed in five cohorts in escalating
dose levels of AL001. There were no drug-related serious adverse events or dose limiting adverse events reported in the study, achieving the primary endpoint. Moreover, statistically significant increases in plasma and CSF PGRN levels relative to
baseline were also observed, and the magnitude and duration of the effect in plasma and CSF PGRN levels appeared to be dose dependent. Results in this dose-escalating Phase 1a study in healthy subjects successfully demonstrate <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> for AL001 in both plasma and CSF. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g65e64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 10. AL001 increases the level of PGRN in CSF in healthy volunteers in measured cohorts at the <FONT
STYLE="white-space:nowrap">pre-specified</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> time point (the thirteenth day following injection) compared to pooled placebo in CSF (**** indicates p&lt;0.0001 by
<FONT STYLE="white-space:nowrap">T-test).</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Phase 1b portion of the study, a total of 14
<FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mutation carriers, six asymptomatic <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> <FONT STYLE="white-space:nowrap">(aFTD-GRN)</FONT> patients and eight symptomatic
<FONT STYLE="white-space:nowrap">FTD-GRN</FONT> <FONT STYLE="white-space:nowrap">(FTD-GRN)</FONT> patients, were dosed with AL001 over a <FONT STYLE="white-space:nowrap">one-month</FONT> period. There were no drug-related serious adverse events or
dose limiting adverse events reported in the study, achieving the primary endpoint. In addition, an approximately <FONT STYLE="white-space:nowrap">two-fold</FONT> increase in CSF PGRN levels from baseline was observed in all 14 <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> mutation carriers dosed with AL001, successfully demonstrating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> for AL001 in this patient population. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g84w86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 11. AL001 elevates the level of PGRN in CSF compared to baseline in aFTD-GRN (purple bar) and FTD-GRN (blue bar)
mutation carriers after receiving one month of dosing with AL001 (* indicates p &lt; 0.05 by T-test and ** indicates p &lt; 0.01 by T-test). </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the chart below, after receiving their infusion of AL001, all 14 <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mutation
carriers&#146; <FONT STYLE="white-space:nowrap">CSF-PGRN</FONT> levels increased up to the normal range observed in healthy volunteers. In the <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients, their
<FONT STYLE="white-space:nowrap">CSF-PGRN</FONT> levels remained elevated for <FONT STYLE="white-space:nowrap">one-month</FONT> following their final infusion of AL001 (Day 57). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g47g23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 12. AL001 increases the level of PGRN in cerebral spinal fluid (CSF) from baseline level of <FONT
STYLE="white-space:nowrap">aFTD-GRN</FONT> and <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mutation carriers, who initially have fifty-percent or less (grey bars) compared to healthy volunteers (green bar), up to the normal range of PGRN (purple
and blue bars). </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the third quarter of 2019, we advanced AL001 into a Phase&nbsp;2 study. We plan to have Phase 2 trial <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients in the first half of 2020 and expect to include multiple CSF biomarkers, including
neurofilament light chain (NfL), multiple types of brain imaging, including volumetric MRI, and multiple cognitive and behavioral tests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g53l12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;13. Decreasing clinical risk with volumetric brain imaging. The change in brain volume loss was driven by
symptomatic mutation carriers.<SUP STYLE="font-size:85%; vertical-align:top">2</SUP><SUP STYLE="font-size:85%; vertical-align:top">,</SUP><SUP STYLE="font-size:85%; vertical-align:top">3</SUP> </B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g58a33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;14. Clinical plan for AL001 in <FONT STYLE="white-space:nowrap">FTD-GRN.</FONT> (Figure not to scale.)
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Additional Applications for Our PGRN Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial PGRN program is currently targeted only at patients with <FONT STYLE="white-space:nowrap">FTD-GRN,</FONT> which is a subset of the
total FTD patient population. Beyond <FONT STYLE="white-space:nowrap">FTD-GRN,</FONT> we believe AL001 has the potential to treat other rare diseases </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Boeve, B., Baker, M., Dickson, D., Parisi, J., Giannini, C., et al. &#147;Frontotemporal dementia and
parkinsonism associated with the <FONT STYLE="white-space:nowrap">IVS1+1G-&gt;A</FONT> mutation in progranulin: a clinicopathologic study.&#148; Brain: a Journal of Neurology. Volume 129, Issue 11, November 2006. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sha, S., Miller, Z., Min, S., Zhou, Y., Brown, J., et al. &#147;An
<FONT STYLE="white-space:nowrap">8-week,</FONT> open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations.&#148; <I>Alzheimer&#146;s</I><I></I><I>&nbsp;&amp; Dementia: Translational
Research</I><I></I><I>&nbsp;&amp; Clinical Interventions</I>. Volume&nbsp;3, Issue 4, November 2017. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that share pathological mechanisms with <FONT STYLE="white-space:nowrap">FTD-GRN.</FONT> In order to treat any other rare diseases and the broader FTD patient population, we will be required to
conduct additional clinical studies in order to obtain the applicable approvals for that specific patient population. We are enrolling an additional genetic subset of FTD patients <FONT STYLE="white-space:nowrap">(FTD-C9orf72)</FONT> in our Phase 2
clinical trial of AL001. Following <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data in <FONT STYLE="white-space:nowrap">FTD-GRN,</FONT> we intend to expand to additional FTD subpopulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, polymorphic mutations that moderately reduce the expression levels of PGRN have also been shown to increase the risk of
developing Alzheimer&#146;s disease and Parkinson&#146;s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models. We are developing AL101 ultimately to target these large chronic
neurodegenerative diseases (Figure&nbsp;15). For our other programs, we anticipate following a similar development approach to expand into additional patient populations as appropriate. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g17w57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;15. Our PGRN programs have broad therapeutic potential, including FTD and other more prevalent
neurodegenerative diseases such as Parkinson&#146;s disease and Alzheimer&#146;s disease. (Figure not to scale.) </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our TREM2 Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TREM2 is a transmembrane receptor protein that is expressed on a subset of innate immune cells and selectively on microglia in the brain. TREM2
on microglia cells is thought to promote improved cell migration to the site of injury, improved cell survival, increased phagocytosis, and increased cell proliferation. Rare individuals with homozygous TREM2 mutations, or mutations on both
chromosomal copies, may develop neurodegeneration by the age of 40 with an average lifespan of 10&nbsp;years following diagnosis. A gene variant in one of the two copies of TREM2 is found to increase the risk of Alzheimer&#146;s disease by
threefold. Not only do mutations in a single copy of TREM2 increase the risk of Alzheimer&#146;s disease significantly, but Alzheimer&#146;s disease patients with TREM2 mutations exhibit an earlier onset of symptoms by three years and an increased
rate of brain volume loss compared to individuals without such mutation. Evidence also suggests that gain of function mutation leading to increased extension of TREM2 confer a protective phenotype against Alzheimer&#146;s disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discovery of strong genetic linkage of TREM2 to Alzheimer&#146;s disease in 2013 was one of the first examples in which large scale
genomic analyses were used to identify a rare gene variation and link it to an increase in the risk of late-onset Alzheimer&#146;s disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TREM2 binds to membrane lipids and lipoproteins such as Apolipoprotein E (ApoE) which are normally found in the brain. Mutations in the gene
for ApoE are also known to significantly increase the risk of development of Alzheimer&#146;s disease and is the single highest risk factor for Alzheimer&#146;s disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL002 for the Treatment of Alzheimer&#146;s Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidate, AL002, is a humanized, TREM2 activating, monoclonal antibody that is intended to be delivered by intravenous, peripheral
infusion into the blood stream (Figure&nbsp;16). AL002 is a microglia cell regulator that modulates the TREM2 receptor<B> </B>and is being developed for the treatment of Alzheimer&#146;s disease in collaboration with AbbVie. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g15f12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;16. Mechanism of action of our TREM2 activating product candidate AL002. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are currently no cures or approved disease-modifying therapies for Alzheimer&#146;s disease and there are only two classes of approved
therapies for symptomatic treatment: acetylcholinesterase inhibitors and glutamatergic modulators. These drugs are designed to help preserve neuronal communication, but only provide temporary benefit and do not slow or halt neuronal death. In
addition, antidepressants and antipsychotics are often prescribed <FONT STYLE="white-space:nowrap">off-label</FONT> to treat the symptoms of severe Alzheimer&#146;s disease in patients suffering from agitation, aggressive behaviors, psychosis, and
depression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent drug candidates under development for Alzheimer&#146;s disease include those focused on blocking synthesis, enhancing
clearance or disaggregating misfolded amyloid-beta or TAU proteins in the brain, reversing chronic inflammation, and repairing vascular dysfunction, metabolic dysregulation, as well as neurotoxicity. Almost all of these candidates were designed to
target just one of the multiple Alzheimer&#146;s disease pathologies, and most of these drug candidates have so far failed to demonstrate any significant benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although amyloid-beta plaques and TAU protein in the brain represent physical pathologies of the disease and are believed to cause a loss of
neuronal connectivity in the brain and neuronal death, recent scientific data paints a more complex picture. Therapeutic approaches that address only one of the multiple pathologies observed in Alzheimer&#146;s disease, for example,
pathology-directed therapies that clear amyloid-beta or TAU proteins, have had limited efficacy. More efficacious therapies will require addressing additional pathologies which we believe are associated with microglial failure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our TREM2 Preclinical Data </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AL002
binds to TREM2 on the surface of microglia and is designed to optimize microglial activity through the phosphorylation of Spleen Associated Tyrosine Kinase (Syk). We have demonstrated that AL002s, an antibody that is functionally similar to AL002
but cross-reacts to the mouse TREM2, can normalize gene </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expression signature associated with Alzheimer&#146;s disease, induce microglial proliferation, increase microglial survival, increase the number of microglia surrounding amyloid-beta plaques,
and increase the compaction, insulation, and phagocytosis of these pathological proteins (Figure&nbsp;17). Moreover, AL002s following intraperitoneal injection increases migration of microglia to sites of neurodegenerative damage, and restores
cognitive ability in animal models (Figure&nbsp;18). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g33c68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;17. AL002s statistically significantly increases the number of microglia around amyloid-beta plaques (left)
and reduces the area occupied by amyloid-beta plaques (right) in a mouse model of Alzheimer&#146;s disease (**** indicates p&lt;0.0001 by <FONT STYLE="white-space:nowrap">T-test).</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g77r31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;18. AL002s statistically significantly improves cognitive deficit in a mouse model of Alzheimer&#146;s
disease (**** indicates p&lt;0.0001 by <FONT STYLE="white-space:nowrap">T-test).</FONT> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL002 Development Strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the third quarter of 2019, we completed a Phase 1a study of AL002 in healthy subjects and a dose dependent change in target engagement
biomarker in cerebrospinal fluid was observed upon treatment.&nbsp;In the second quarter of 2019, based on safety and tolerability observed in the Phase 1a study, we initiated the Phase 1b portion of the study with AL002 in Alzheimer&#146;s disease
patients. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Histopathological analysis of a
<FONT STYLE="white-space:nowrap">26-week&nbsp;toxicology</FONT> study of AL002 in <FONT STYLE="white-space:nowrap">non-human</FONT> primates identified minimal to marked granulomatous inflammation in the&nbsp;ciliary
body&nbsp;and/or&nbsp;choroid&nbsp;of&nbsp;the eye. There were no other AL002- related gross or histopathological findings in this toxicology study in the retina or any other tissues or organs. We have observed no drug-related, serious adverse
events in the AL002 Phase 1 trial with over 50 subjects. In response to FDA feedback, we have implemented additional ophthalmological assessments in our AL002 clinical trial. We expect proof of mechanism data from Alzheimer&#146;s disease patients
in the first half of 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Phase&nbsp;1 study, we intend to initiate a double-blind placebo-controlled Phase&nbsp;2 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in Alzheimer&#146;s disease patients in early stages of the disease (Figure 19). In addition to measuring molecular and genetic biomarkers, we will also
employ imaging techniques focused on pathological proteins and neuronal health for an early <FONT STYLE="white-space:nowrap">read-out</FONT> on various molecular and genetic biomarkers, imaging assessments and clinical measures to establish <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> enabling pivotal Phase&nbsp;3 studies. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g29t30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;19. Clinical plan for AL002 in Alzheimer&#146;s disease. (Figure not to scale.) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These clinical trials have been designed in close collaboration with AbbVie. Our desired outcome is to achieve informative endpoints to enable
efficient Phase&nbsp;3 clinical trial design and a rapid advancement towards marketing approval. For more information on our collaboration with AbbVie see the section titled &#147;Business&#151;Strategic Alliance with AbbVie.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our SIGLEC&nbsp;3 Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Large scale
genomic profiling of datasets from Alzheimer&#146;s disease patients has been used to identify the association between certain variants of SIGLEC&nbsp;3, also known as CD33, and increased risk to develop Alzheimer&#146;s disease. SIGLEC&nbsp;3 is an
inhibitory receptor expressed on microglia and acts as the brakes of the immune system in the brain, slowing down microglial activity. Excessive inhibition of the microglia by the disease risk variant of SIGLEC&nbsp;3, which increases expression of
the inhibitory SIGLEC&nbsp;3 receptor on microglia, leads to reduced functionality of the myeloid cells, and consequently, increased deposition of amyloid-beta plaques, and accelerated loss of tissue in the brain of Alzheimer&#146;s disease patients
that carry this risk variant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our analysis further showed that the natural inhibitory ligands for SIGLEC&nbsp;3, which are required for
activation of SIGLEC&nbsp;3, are upregulated in the brain of Alzheimer&#146;s disease patients, further reducing the functionality of the microglia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with the genetic findings in humans, Alzheimer&#146;s disease mouse models, in which the gene for SIGLEC&nbsp;3 was genetically
ablated, have microglia with improved phagocytosis of beta amyloid and displayed fewer amyloid-beta plaques compared to the same Alzheimer&#146;s disease model that expressed the mouse SIGLEC&nbsp;3 gene. In line with the findings that the presence
of SIGLEC&nbsp;3 increased the severity of Alzheimer&#146;s disease, a reduced number of certain disease associated microglia that are thought to counteract the progression of Alzheimer&#146;s disease was observed when the human SIGLEC&nbsp;3 in
Alzheimer&#146;s disease mouse models was over-expressed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Taken together, this data supports the hypothesis that blocking the function of
SIGLEC&nbsp;3 would increase the number of beneficial microglia and elicit a therapeutic benefit in Alzheimer&#146;s disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL003 for Treatment of Alzheimer&#146;s Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidate, AL003, is a SIGLEC&nbsp;3 blocking, monoclonal antibody (Figure&nbsp;20) that is intended to be delivered by
intravenous, peripheral infusion into the blood stream. The function of SIGLEC&nbsp;3 on microglia is similar to the inhibitory function of <FONT STYLE="white-space:nowrap">PD-1</FONT> on <FONT STYLE="white-space:nowrap">T-cells.</FONT> AL003 acts
similarly to <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitors that have been employed successfully in immunotherapy of cancer. Both approaches aim to remove the &#147;brakes&#148; on the immune system to allow the system to work at its full
capacity. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g59z81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;20. Mechanism of action of our SIGLEC&nbsp;3 blocking product candidate AL003. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our SIGLEC&nbsp;3 Preclinical Data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The activity of AL003 in mice was assessed in immunodeficient mice containing human immune cells to recapitulate the human immune system as
closely as possible. AL003 injected into the bloodstream of these mice blocks SIGLEC 3 on immune cells. In addition, a single intraperitoneal injection of AL003 into mice that express the human SIGLEC 3 in microglia leads to a long lasting,
statistically significant blockade of SIGLEC 3 on the cell surface of microglia in the brain, indicating that AL003 is able to cross the blood brain barrier and exert its desired activity (Figure&nbsp;21). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g94e00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;21. AL003 blocks SIGLEC 3 on microglia in mouse brain following injection to the blood stream (****
indicates p&lt;0.0001 by <FONT STYLE="white-space:nowrap">T-test).</FONT> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL003 Development Strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our AL003 product candidate follows a similar clinical development plan to AL002 with some modifications. In the first quarter of 2019, we
initiated a Phase 1a study in healthy subjects with AL003, a product candidate targeting Alzheimer&#146;s disease. Thirty-eight (38)&nbsp;healthy subjects were dosed over eight dose cohorts in the AL003 Phase 1a dose escalation trial. A dose
dependent change in target engagement in the blood was observed upon treatment. One subject treated with the second highest dose experienced aseptic hip monoarthritis and a second subject treated with the highest dose experienced an adverse drug
reaction characterized by rash, fever, and thrombocytopenia, which were both deemed treatment-related serious adverse events. The subjects were treated with corticosteroids and recovered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the safety and tolerability observed in the Phase 1a study, we identified a dose and initiated screening for the Phase 1b portion of
the study with AL003 in Alzheimer&#146;s disease patients in the fourth quarter of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following positive results in this trial, we
intend to launch a double-blind placebo-controlled Phase&nbsp;2 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in Alzheimer&#146;s disease patients (Figure&nbsp;22). During this planned
Phase&nbsp;2 trial, in addition to measuring molecular and genetic biomarkers, we intend to employ imaging techniques focused on pathological proteins and neuronal health for an early read out on various molecular and genetic biomarkers, imaging
assessments and clinical measures to establish <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> enabling pivotal Phase&nbsp;3 studies. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g77n88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;22. Clinical plan for AL003 in Alzheimer&#146;s disease. (Figure not to scale.) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These clinical trials have been designed in close collaboration with AbbVie. Our desired
outcome is to achieve informative endpoints to enable efficient Phase&nbsp;3 clinical trial design and a rapid advancement towards marketing approval. For more information on our collaboration with AbbVie see the section titled
&#147;Business&#151;Strategic Alliance with AbbVie.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expansion of Our Discovery Platform to Other Indications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Immuno-oncology </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Microglia display
similar gene expression signature and function to the innate cells of the peripheral immune system. These peripheral innate cells such as macrophages, NK cells and others, likely play a significant role in multiple chronic diseases including cancer,
inflammation, and autoimmune disorders. We are leveraging our expertise in innate immune system to develop additional innate immune&nbsp;check-point&nbsp;focused programs, including programs targeting the Siglec protein family and the SIRP protein
family, for peripheral disorders, particularly cancer. We believe that products focused on innate&nbsp;immune biology will complement and expand the efficacy of current&nbsp;immuno-oncology drugs that target the&nbsp;adaptive&nbsp;immune system.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Combination Therapies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
therapies are also likely to act in conjunction with each other or with other experimental drugs that are designed to remove pathological proteins.&nbsp;Therapies such as antibodies against amyloid-beta, the TAU filaments or misfolded
alpha-synuclein protein are designed to tag the pathological proteins and recruit microglia to dispose of the drug pathological protein complex. Aging microglia are less likely to perform this function effectively and our&nbsp;immuno-neurology
therapies could ameliorate this deficiency. We are continuing to explore various combination strategies in preclinical models and will, in the future, consider moving this strategy into the clinic based upon results from preclinical models. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic Alliance with AbbVie </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2017, we entered into the AbbVie Agreement. The primary goal of our global strategic collaboration with AbbVie is to <FONT
STYLE="white-space:nowrap">co-develop</FONT> and commercialize therapeutics to treat Alzheimer&#146;s and other neurodegenerative diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the AbbVie Agreement, we granted AbbVie an exclusive option to global development and commercialization for our TREM2 and SIGLEC&nbsp;3
programs. The terms of the AbbVie Agreement included initial upfront payments of&nbsp;$205.0&nbsp;million and $20.0&nbsp;million from the sale of shares of our Series&nbsp;E preferred stock, and if AbbVie exercises its option for both programs, we
are eligible for up to an additional $985.6&nbsp;million in option exercise and milestone payments. Following AbbVie&#146;s exercise of its option, Alector and AbbVie will share the development costs and will split global profits after marketing
approval. However, following AbbVie&#146;s option exercise for a program, we may opt out of sharing in development costs and profits or losses from that program and instead receive a tiered royalty on sales of products from that program. We are
responsible for the design and execution of Phase&nbsp;1 and Phase&nbsp;2 studies, taking advantage of our significant <FONT STYLE="white-space:nowrap">in-house</FONT> expertise in running clinical trials in Alzheimer&#146;s disease. Following its
exercise of an option for a program, AbbVie will be responsible for certain development activities and global commercialization, taking advantage of its global clinical trial expertise and commercialization networks. Through this partnership, we aim
to leverage the strengths of both organizations efficiently to best achieve the desired outcome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exercise of options.</I></B>
AbbVie may exercise its option for a program at any time until the expiration of an option term for that program. For each program, the option term ends following a fixed period after AbbVie&#146;s receipt of the data package that includes certain
information relating to the applicable program&#146;s research and development activities. If AbbVie fails to exercise its option during the option term for a product candidate, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will retain all rights to that program. If AbbVie exercises its option for a program, then AbbVie will lead development and commercialization activities worldwide. Once AbbVie opts in with
respect to a given product candidate, AbbVie must use commercially reasonable efforts to develop and commercialize the corresponding product globally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Governance.</I></B> The collaboration is governed by a joint steering committee (JSC). The JSC may establish additional subcommittees to
oversee particular projects or activities. Subject to limitations specified in the AbbVie Agreement, if the applicable governance committee is unable to make a decision by consensus and the parties are unable to resolve the issue through escalation
to specified senior executive officers of the parties, then the issue is escalated to an alternative dispute resolution subject to final decision-making rights retained by each party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exclusivity.</I></B> During the term of the AbbVie Agreement, each of Alector and AbbVie are subject to exclusivity requirements
prohibiting certain activities outside of the AbbVie Agreement directed to targets under the AbbVie Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual
Property.</I></B> Ownership of intellectual property created in connection with the AbbVie Agreement is generally determined on the basis of inventorship. Generally, each party has the first right to prosecute and maintain its own patents. We
generally have the first right to prosecute and maintain joint patents prior to AbbVie&#146;s exercise of its option for the program relating to such patent, and AbbVie has the right following its exercise of such option. AbbVie has the first right
to prosecute any infringement of jointly held patents developed under the AbbVie Agreement and our patents that are licensed under the AbbVie Agreement. Additionally, AbbVie has the sole right to prosecute its own patents. AbbVie has the first right
to defend against claims that a product developed under either of the programs that are the subject of the AbbVie Agreement infringe third-party intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Term and Termination.</I></B> At any point during the term of the AbbVie Agreement, including during the research, development, and
clinical trial process, AbbVie can terminate the AbbVie Agreement in its entirety, or with respect to either program under the AbbVie Agreement, for convenience. In that event, all rights related to the applicable program revert to us. Additionally,
AbbVie or we and can terminate the AbbVie Agreement in connection with a material breach of the AbbVie Agreement by the other party that remains uncured for a specified period of time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adimab Collaboration Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview &#151;
2014 Adimab Collaboration Agreement (2014 Adimab Agreement)</I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2014, we entered into the 2014 Adimab Collaboration Agreement.
Under the 2014 Adimab Agreement, we are required to fund, and we and Adimab are required to use commercially reasonable efforts to conduct, certain research to discover and optimize antibodies directed against targets selected by us. We are
developing antibodies discovered by Adimab in our AL001 and AL101 product candidates, and we are developing antibodies optimized by Adimab in our AL002 and AL003 product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Governance.</I></B> Our collaboration with Adimab is governed by a research committee consisting of at least two representatives from
each party. The research committee prioritizes among research programs and prepares and finalizes new proposed research plans, among other activities. If the research committee is unable to make a decision by consensus and the parties are unable to
resolve the issue through escalation to specified senior executive officers of the parties, then either party may seek arbitration of the matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exclusivity.</I></B> Pursuant to the 2014 Adimab Agreement, each party is subject to limitations on its ability to use information or
material provided by the other outside the scope of the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property.</I></B> Ownership of intellectual
property arising from the research is generally owned by the party that invents or creates the applicable intellectual property, although certain categories of intellectual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property are specifically assigned to one party or the other. For example, patent rights relating to improvements to Adimab&#146;s background platform technology that are invented in the course
of the research are assigned to Adimab. Prior to our exercise of the option described below, we and Adimab each grant the other a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to the relevant intellectual property we own to allow
each party to carry out its rights and obligations in connection with the research; and except for Adimab&#146;s retained rights to continue using and licensing its own libraries, each party agrees not to practice or license the patents arising out
of the research that it owns for any purpose other than to carry out its rights and obligations in connection with the research. Generally, each party has the obligation to prosecute, maintain, defend, and enforce its own patents, but we are subject
to certain contractual restrictions on our ability to prosecute, practice, and license certain of our patents that arose out of the research. These restrictions are lifted once we exercise the option described below as to such patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exercise of Options.</I></B> The 2014 Adimab Agreement granted us an exclusive option to obtain certain rights relating to a specified
number of antibodies discovered or optimized by Adimab directed against the targets we selected. The option extended to ownership of patent rights specifically covering the sequences of such antibodies, and the right to obtain worldwide,
royalty-bearing, sublicensable licenses under certain technology owned or developed by Adimab to research, develop, make, have made, use, sell, offer to sell, import and export such antibodies and products based on such antibodies for all human
therapeutic, prophylactic and diagnostic uses. These licenses are exclusive, except as to Adimab background and platform technology and Adimab&#146;s retained rights to continue using and licensing its own libraries, as to which the licenses are <FONT
STYLE="white-space:nowrap">non-exclusive.</FONT> We have confirmed with Adimab in writing that key patents we have filed relating to the programs partnered with AbbVie claim inventions owned solely by us, and do not include any such background or
platform technology of Adimab. All of our options under the 2014 Adimab Agreement have either expired, are in the process of being exercised, or, with respect to multiple targets and hundreds of antibodies (including the target programs partnered
with AbbVie), have already been exercised. Upon our exercise of the option with respect to a target, we are subject to an obligation to devote commercially reasonable efforts to commercialize products using the optioned rights to such target. The
assigned and licensed patent rights we obtained from these option exercises are described in more detail above under the section titled &#147;Business&#151;Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financial terms.</I></B> We fund Adimab&#146;s research in connection with our collaboration, in accordance with the terms and
limitations described in the 2014 Adimab Agreement. We also have potential milestone payments per program for use of antibodies and <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-single</FONT> digit royalty
payments for commercial sales of products incorporating such antibodies. However, if we enter into any transaction granting rights to the inventions or sell products created as a result of a collaboration with a third party, we have a choice to pay
a share of the resulting revenue instead of royalties from such sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Term and Termination.</I></B> We are able to terminate the
2014 Adimab Agreement, in its entirety or with respect to a products or antibodies directed to particular targets, on three months prior written notice to Adimab. In addition, either party can terminate the 2014 Adimab Agreement in its entirety, or,
subject to certain limitations, with respect to specific optioned rights, for material breaches that remain uncured after 90 days&#146; notice to the breaching party. In the case of a termination before expiration of the 2014 Adimab Agreement, we
would have certain continuing payment obligations to Adimab, or would be required to adhere to certain restrictions as to the fruits of the collaboration. The 2014 Adimab Agreement expires on the twelfth anniversary of the first commercial sale of
the products created under the collaboration, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. The licenses we and Adimab granted to each other do not survive, subject to certain limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview&#151;2019 Adimab Collaboration Agreement (2019 Adimab Agreement) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019, we entered into another Adimab collaboration agreement. Under the 2019 Adimab Agreement, we are required to fund, and we and Adimab
are required to use commercially reasonable efforts to conduct, certain research to discover and optimize antibodies directed against targets selected by us. We have not yet identified any research programs under the 2019 Adimab Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Governance.</I></B> Our collaboration with Adimab is governed by a research committee
consisting of at least two representatives from each party. The research committee facilitates communication regarding research under the 2019 Adimab Agreement and has the limited authority to amend a research plan in a manner not substantially
affecting the resources required from a party. If the research committee is unable to make a decision by consensus , no decision will be taken. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exclusivity.</I></B> Pursuant to the 2019 Adimab Agreement, each party is subject to limitations on its ability to use information or
material provided by the other outside the scope of the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property.</I></B> Ownership of intellectual
property arising from the research is generally owned by the party that invents or creates the applicable intellectual property, although certain categories of intellectual property are specifically assigned to one party or the other. Certain
intellectual property relating to Adimab&#146;s background platform technology including any improvements thereto that are invented in the course of the research are assigned to Adimab. Patents covering antibodies that are the subject of the
collaboration are owned by us; however, prior to our exercise of the option described below, we are prohibited from practicing such patents for any purpose other than to perform our research obligations under the 2019 Adimab Agreement. Upon the
expiration of the option term described below, in the event we elect not to exercise our option right with respect to an antibody, ownership of such patents is transferred to Adimab. Prior to our exercise of the option described below, we and Adimab
each grant the other a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to the relevant intellectual property we own to allow each party to carry out its rights and obligations in connection with the research. Generally, each party has
the obligation to prosecute, maintain, defend, and enforce its own patents, but we are subject to certain contractual restrictions on our ability to prosecute, practice, and license certain of our patents that arose out of the research. These
restrictions are lifted once we exercise the option described below as to such patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exercise of Options.</I></B> The 2019
Adimab Agreement granted us an exclusive option to obtain certain rights relating to a specified number of antibodies discovered or optimized by Adimab directed against the targets we selected. The option extends to ownership of the applicable
optioned antibody, and the right to obtain worldwide, royalty-bearing, sublicensable <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses under certain technology owned or developed by Adimab to research, develop, make, have made, use,
sell, offer to sell, import and export such antibodies and products based on such antibodies for all human therapeutic, prophylactic and diagnostic uses. Upon our exercise of the option with respect to a target, we are subject to an obligation to
devote commercially reasonable efforts to commercialize products using the optioned rights to such target. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financial terms.</I></B>
We fund Adimab&#146;s research in connection with our collaboration, in accordance with the terms and limitations described in the 2019 Adimab Agreement. We are also responsible for certain development fees and, in the event we exercise the option
right, we are obligated to pay an option fee. We also have potential milestone payments per product for use of antibodies, subject to certain limitations on total payments owed on any given target, and
<FONT STYLE="white-space:nowrap">low-single</FONT> digit royalty payments for commercial sales of products incorporating such antibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Term and Termination.</I></B> We are able to terminate the 2019 Adimab Agreement, in its entirety or with respect to a products or
antibodies directed to particular targets, on 60 days&#146; prior written notice to Adimab. In addition, either party can terminate the 2019 Adimab Agreement in its entirety for material breaches that remain uncured after 90 days&#146; notice to the
breaching party. In the case of a termination before expiration of the 2019 Adimab Agreement, we would be prohibited from using the fruits of the collaboration. The 2019 Adimab Agreement expires, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, on the later of the twelfth anniversary of the first commercial sale of such
product in such country and expiration of the last patent covering such product in such country, or, in the event no product is optioned under the 2019 Adimab Agreement, upon the last to expire option period. Upon expiration, the licenses Adimab
granted to us with respect to products for which we have exercised our option will continue on a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must manufacture our product candidates for clinical trial use in compliance with cGMP regulations. The cGMP regulations include
requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution,
laboratory controls, records and reports, and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and FDA or comparable foreign regulatory authority&#146;s satisfaction before any
product is approved for human clinical trial use. Our third-party manufacturers will also be subject to periodic inspections of their respective facilities for general cGMP compliance by the FDA and other foreign authorities. These inspections may
include review of procedures and operations used in the testing and manufacture of our products to assess compliance with applicable regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have the infrastructure or internal capability to manufacture our product candidates for use in clinical trials and
commercialization. We rely, and expect to continue to rely, on third-party cGMP manufacturers for the production of our products for human clinical trials in compliance with FDA and other foreign authority regulations for such products. We rely on
CDMOs to manufacture and supply our preclinical and clinical materials to be used during the preclinical and clinical development of our product candidates. As part of our broad manufacturing strategy to expedite the manufacturing of our product
candidates and minimize manufacturing risk, we currently have established relationships with several CDMOs for the manufacturing of our drug substance or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have long-term supply agreements and we purchase our required drug product on a development manufacturing services agreement or
purchase order basis. We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We have personnel with significant technical, manufacturing,
analytical, quality, regulatory, including cGMP, and project management experience to oversee our third-party manufacturers and to manage manufacturing and quality data and information for regulatory compliance purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including warning
letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. Contract manufacturers often encounter difficulties involving
production yields, quality control and quality assurance, as well as shortages of qualified personnel. Any of these actions or events could have a material impact on the availability of our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not
currently have any approved drugs and we do not expect to have any approved drugs in the near term. Therefore, we have no sales, marketing or commercial product distribution capabilities and have no experience as a company in marketing drugs. When,
and if any of our product candidates are approved for commercialization, we intend to develop a commercialization infrastructure for those products in the United States, Europe, Asia, and potentially in certain other key markets. We may also rely on
partnerships, such as our AbbVie collaboration, to provide commercialization infrastructure, including sales and marketing and commercial distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success
depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and <FONT STYLE="white-space:nowrap">know-how,</FONT> to operate without infringing the proprietary rights of others and to prevent
others from infringing our proprietary rights. Our strategy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outside of the United States related to our proprietary technology, inventions, improvements and product candidates that are important to the development and implementation of our business. Our
patent portfolio is intended to cover our product candidates and related components, their methods of use and processes for their manufacture, our proprietary reagents and assays and any other inventions that are commercially important to our
business. We also rely on trademarks as well as trade secret protection of our confidential information and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to our proprietary technology, platforms and product candidates. We believe that we
have substantial <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets relating to our technology and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio contains over 30 families, which include three issued patents and over 185 pending patent applications, directed to over
15 different targets and/or technologies, that are solely owned or exclusively licensed by us. For our product candidates, we generally pursue multilayered patent protection covering the composition of matter based on binding epitopes of the product
candidates on the target protein, functional characteristics of the product candidates, degenerative sequence of the product candidates, and/or specific sequence of the product candidates. In addition to composition of matter coverage, we also
generally pursue claims directed to methods of making, nucleic acids, formulations, and methods of use of the product candidates. The method of use claims further include claims directed to patient selection criteria, biomarkers, disease subgroups,
pharmacodynamic and clinical <FONT STYLE="white-space:nowrap">end-points,</FONT> and dosage regimes. As further described below, we intend to strengthen the patent protection of our product candidates and technologies through additional patent
application filings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PGRN Programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own four patent families directed to our PGRN programs, AL001 and AL101, which include three issued U.S. patents, covering the compositions
and uses of our PGRN program product candidates. Two patent families are expected to expire in 2036, the third family is expected to expire in 2039, and the fourth patent family, assuming that the necessary
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications are timely filed and all other applicable requirements are satisfied for the U.S. provisional patent application, in 2040, in all cases excluding any patent term adjustments
and any patent term extensions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>TREM2 Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own three patent families directed to the TREM2 program covering the compositions and uses of our TREM2 program product candidates. The
patent families are expected to expire in 2035, 2036, and 2038, respectively, in all cases excluding any patent term adjustments and any patent term extensions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>SIGLEC&nbsp;3 Program </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own four patent
families directed to the SIGLEC&nbsp;3 program covering the compositions and uses of our SIGLEC&nbsp;3 program product candidates. Two patent families are expected to expire in 2036, the third patent family in 2038, and the fourth patent family in
2039, in all cases excluding any patent term adjustments and any patent term extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the
legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application in the applicable country. In the United States, a patent&#146;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for
administrative delays by the U.S. Patent and Trademark Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier
expiration date. The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) permits a patent term extension of up to five years beyond the expiration date of a U.S. patent as partial compensation for the length of time the
drug is under regulatory review while the patent is in force. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the date of product approval, only one patent applicable to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it or a method for
manufacturing it, may be extended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar provisions are available in the European Union and certain other foreign jurisdictions to
extend the term of a patent that covers an approved drug. In the future, if and when our product candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those
products, depending upon the length of the clinical trials for each drug and other factors. Expiration dates referred to above are without regard to potential patent term extension or other market exclusivity that may be available to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek
to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade
secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. For example, on June&nbsp;18, 2019, we initiated confidential arbitration proceedings against Dr.&nbsp;Asa
Abeliovich, our former consulting <FONT STYLE="white-space:nowrap">co-founder,</FONT> related to alleged breaches of his consulting agreement and the improper use of our confidential information learned during the course of rendering services to us
as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and
pharmaceutical industries, including in the neurodegenerative disease field, are characterized by rapidly advancing technologies, strong competition and an emphasis on intellectual property. We face substantial competition from many different
sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. Some of the pharmaceutical and biotechnology companies that are
currently pursuing the development of products for the treatment of the neurodegenerative disease indications for which we have research programs, including FTD, Alzheimer&#146;s disease and Parkinson&#146;s disease, include large companies with
significant financial resources, such as Biogen, Eli Lilly, GlaxoSmithKline, Merck and Roche Holding AG. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, safety profile, method
of administration, cost, level of promotional activity and intellectual property protection.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates will compete with
current therapies approved for the treatment of neurodegenerative diseases, which to date have been primarily targeted at treating the symptoms of such diseases rather than halting or slowing the progression of the disease. However, in addition to
such currently approved therapies, we believe that our product candidates, if approved, may also compete with other potential therapies intended to halt or slow the progression of neurodegenerative disease that are being developed by a number of
companies and institutions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the
research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and
biological products. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review
and approved by the regulatory authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Drug Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Food, Drug, and Cosmetic Act (FDCA) and biologics under the FDCA and the Public Health
Service Act (PHSA). Both drugs and biologics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign
statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an
applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#146;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls
or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement
action could have a material adverse effect on us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future product candidates must be approved by the FDA through either a biologics
license application (BLA) or NDA process before they may be legally marketed in the United States. The process generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completion of extensive preclinical studies in accordance with applicable regulations, including studies
conducted in accordance with GLP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approval by an independent IRB, or ethics committee at each clinical trial site before each trial may be
initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations,
good clinical practice (GCP), requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission to the FDA of a NDA or BLA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the filing for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Satisfactory completion of a FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the
manufacturing facility or facilities where the drug or biologic will be produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#146;s identity,
strength, quality and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of
the NDA or BLA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee,
prior to any commercial marketing or sale of the drug or biologic in the United States; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compliance with any post-approval requirements, including the potential requirement to implement a Risk
Evaluation and Mitigation Strategy (REMS), and the potential requirement to conduct post-approval studies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The data
required to support an NDA or BLA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be
certain that any approvals for any future product candidates will be granted on a timely basis, or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies and IND </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies
to evaluate toxicity in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a
proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as<I> in vitro</I> and animal studies to
assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies.
An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND.
Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time
the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a
result, submission of an IND may not result in the FDA allowing clinical trials to commence. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the
supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for
their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used
to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each
institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent
form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical
trial results to public registries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not,
obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or BLA. The FDA will accept a
well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials in the United States generally are conducted in three sequential phases, known as Phase&nbsp;1, Phase&nbsp;2, and
Phase&nbsp;3, and may overlap. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase&nbsp;1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients
who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase&nbsp;2 clinical trials involve studies in disease-affected patients to determine the dose required to
produce the desired benefits. At the same time, safety and further pharmacokinetic and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase&nbsp;3 clinical trials generally involve a large number of patients at multiple sites and are designed to
provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These trials
may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase&nbsp;4 clinical trials, may be conducted after initial marketing approval. These trials
are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&nbsp;4 clinical trials as a condition of approval of an NDA or BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and
written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug or biologic, findings from
animal or<I> in vitro</I> testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase&nbsp;1, Phase&nbsp;2, and Phase&nbsp;3 clinical trials may not be completed successfully within any specified period, if at all. The FDA
or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval
of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical
trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated
check-points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the
drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among
other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that
our product candidates do not undergo unacceptable deterioration over their shelf life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NDA/BLA Review Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of the clinical trials, data is analyzed to assess whether the investigational product is safe and effective for the
proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA or BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other
relevant data. In short, the NDA or BLA is a request for approval to market the drug or biologic for one or more specified indications and must contain proof of safety and efficacy for a drug or safety, purity, and potency for a biologic. The
application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#146;s
use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational
product to the satisfaction of FDA. FDA approval of an NDA or BLA must be obtained before a drug or biologic may be marketed in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA or BLA must be
accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. According to the FDA&#146;s FY 2020 fee schedule for prescription drug user fees, which became effective on October&nbsp;1, 2019, and will remain in effect through
September&nbsp;30, 2020, the user fee for an application requiring clinical data, such as an NDA or BLA, is approximately $2.9&nbsp;million. PDUFA also imposes an annual program fee for each marketed human drug or biologic ($325,424 in 2020) and an
annual establishment fee on facilities used to manufacture prescription drugs and biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small
business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews all submitted NDAs and BLAs before it accepts them for filing, and may request additional information rather than accepting
the NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the NDA
or BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of a new molecular-entity NDA or original BLA and respond to the applicant, and six months
from the filing date of a new molecular-entity NDA or original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs or BLAs, and the review process is often extended by FDA requests for
additional information or clarification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA or BLA, the FDA will conduct a
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the
manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with
GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts,
for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making
decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA or BLA, it will issue an approval
letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is
complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The Complete Response Letter may require additional
clinical data, additional pivotal Phase&nbsp;3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may
either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for
approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drugs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan
Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than
200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the
product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the
identity of the therapeutic agent and its potential orphan use are disclosed publicly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. However,
competitors may receive approval of either a different product for the same indication or the same product for a different indication but that could be used <FONT STYLE="white-space:nowrap">off-label</FONT> in the orphan indication. Orphan drug
exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if a product candidate is
determined to be contained within the scope of the competitor&#146;s product for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication broader than that which is designated,
it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that meet certain
criteria. Specifically, new drugs and biologics are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs
for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for fast track status any time before receiving NDA or BLA
approval, but ideally no later than the <FONT STYLE="white-space:nowrap">pre-NDA</FONT> or <FONT STYLE="white-space:nowrap">pre-BLA</FONT> meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended
to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in
safety and effectiveness compared to available therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product may also be eligible for accelerated approval, if it treats a serious
or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint
that can be measured earlier than irreversible morbidity or mortality (IMM), which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic
receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted, it may require such
post-marketing restrictions as it deems necessary to assure safe use of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, a drug or biologic may be eligible for
designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may
demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from
the FDA to ensure an efficient drug development program. Fast track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval
process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Abbreviated Licensure Pathway of Biological Products as Biosimilar or Interchangeable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, or ACA, signed into law in 2010, includes the BPCIA, which created an abbreviated approval
pathway for biological products shown to be highly similar to an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. The BPCIA attempts to minimize duplicative testing, and thereby lower development costs and increase
patient access to affordable treatments. An application for licensure of a biosimilar product must include information demonstrating biosimilarity based upon the following, unless the FDA determines otherwise: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analytical studies demonstrating that the proposed biosimilar product is highly similar to the approved product
notwithstanding minor differences in clinically inactive components; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">animal studies (including the assessment of toxicity); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a clinical trial or trials (including the assessment of immunogenicity and pharmacokinetic or pharmacodynamic)
sufficient to demonstrate safety, purity and potency in one or more conditions for which the reference product is licensed and intended to be used. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, an application must include information demonstrating that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed biosimilar product and reference product utilize the same mechanism of action for the condition(s)
of use prescribed, recommended or suggested in the proposed labeling, but only to the extent the mechanism(s) of action are known for the reference product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the condition or conditions of use prescribed, recommended or suggested in the labeling for the proposed
biosimilar product have been previously approved for the reference product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the route of administration, the dosage form and the strength of the proposed biosimilar product are the same as
those for the reference product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the facility in which the biological product is manufactured, processed, packed or held meets standards designed
to assure that the biological product continues to be safe, pure, and potent. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biosimilarity means that the biological
product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and that there are no clinically meaningful differences between the biological product and the reference product in terms of the
safety, purity, and potency of the product. In addition, the law provides for a designation of &#147;interchangeability&#148; between the reference and biosimilar products, whereby the biosimilar may be substituted for the reference product without
the intervention of the healthcare provider who prescribed the reference product. The higher standard of interchangeability must be demonstrated by information sufficient to show that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed product is biosimilar to the reference product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed product is expected to produce the same clinical result as the reference product in any given
patient; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for a product that is administered more than once to an individual, the risk to the patient in terms of safety or
diminished efficacy of alternating or switching between the biosimilar and the reference product is no greater than the risk of using the reference product without such alternation or switch. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA approval is required before a biosimilar may be marketed in the United States. However, complexities associated with the large and
intricate structures of biological products and the process by which such products are manufactured pose significant hurdles to the FDA&#146;s implementation of the law that are still being worked out by the FDA. For example, the FDA has discretion
over the kind and amount of scientific evidence&#151;laboratory, preclinical and/or clinical&#151;required to demonstrate biosimilarity to a licensed biological product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA intends to consider the totality of the evidence provided by a sponsor to support a demonstration of biosimilarity, and recommends
that sponsors use a stepwise approach in the development of their biosimilar </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products. Biosimilar product applications thus may not be required to duplicate the entirety of preclinical and clinical testing used to establish the underlying safety and effectiveness of the
reference product. However, the FDA may refuse to approve a biosimilar application if there is insufficient information to show that the active ingredients are the same or to demonstrate that any impurities or differences in active ingredients do
not affect the safety, purity or potency of the biosimilar product. In addition, as with BLAs, biosimilar product applications will not be approved unless the product is manufactured in facilities designed to assure and preserve the biological
product&#146;s safety, purity and potency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The submission of a biosimilar application does not guarantee that the FDA will accept the
application for filing and review, as the FDA may refuse to accept applications that it finds are insufficiently complete. The FDA will treat a biosimilar application or supplement as incomplete if, among other reasons, any applicable user fees
assessed under the Biosimilar User Fee Act of 2012 have not been paid. In addition, the FDA may accept an application for filing but deny approval on the basis that the sponsor has not demonstrated biosimilarity, in which case the sponsor may choose
to conduct further analytical, preclinical or clinical studies and submit a BLA for licensure as a new biological product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of
final FDA approval of a biosimilar for commercial distribution depends on a variety of factors, including whether the manufacturer of the branded product is entitled to one or more statutory exclusivity periods, during which time the FDA is
prohibited from approving any products that are biosimilar to the branded product. The FDA cannot approve a biosimilar application for 12&nbsp;years from the date of first licensure of the reference product. Additionally, a biosimilar product
sponsor may not submit an application for four years from the date of first licensure of the reference product. A reference product may also be entitled to exclusivity under other statutory provisions. For example, a reference product designated for
a rare disease or condition (an orphan drug) may be entitled to seven years of exclusivity, in which case no product that is biosimilar to the reference product may be approved until either the end of the twelve-year period provided under the
biosimilarity statute or the end of the seven-year orphan drug exclusivity period, whichever occurs later. In certain circumstances, a regulatory exclusivity period can extend beyond the life of a patent, and thus block biosimilarity applications
from being approved on or after the patent expiration date. In addition, the FDA may under certain circumstances extend the exclusivity period for the reference product by an additional six months if the FDA requests, and the manufacturer
undertakes, studies on the effect of its product in children, a <FONT STYLE="white-space:nowrap">so-called</FONT> pediatric extension. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first biological product determined to be interchangeable with a branded product for any condition of use is also entitled to a period of
exclusivity, during which time the FDA may not determine that another product is interchangeable with the reference product for any condition of use. This exclusivity period extends until the earlier of: one year after the first commercial marketing
of the first interchangeable product; 18&nbsp;months after resolution of a patent infringement against the applicant that submitted the application for the first interchangeable product, based on a final court decision regarding all of the patents
in the litigation or dismissal of the litigation with or without prejudice; 42&nbsp;months after approval of the first interchangeable product, if a patent infringement suit against the applicant that submitted the application for the first
interchangeable product is still ongoing; or 18 months after approval of the first interchangeable product if the applicant that submitted the application for the first interchangeable product has not been sued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including,
among other things, monitoring and record-keeping requirements, requirements to report adverse experiences and comply with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient
populations, known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;, and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs for <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
modifications to the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a
new NDA/BLA or NDA/BLA supplement, which may require the development of additional data or preclinical studies and clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
FDA may also place other conditions on approvals including the requirement for REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be
withdrawn for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards or if problems occur following initial marketing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other
potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market, or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applications, or suspension or revocation of product license approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics may
be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of
<FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. Regulatory Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory
authorities in the United States in addition to the FDA, including the Centers for Medicare&nbsp;&amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration,
the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the Environmental Protection Agency, and state and local governments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in the United States, sales, marketing and scientific and educational programs also must comply with state and federal fraud and
abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any
remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.
Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. Moreover, the ACA provides that the government may assert that
a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S.
Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply.
Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and
unfair competition laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of biologic and pharmaceutical products is subject to additional requirements and regulations,
including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on
the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or
withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur
significant legal expenses and divert our management&#146;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for
example: changes to our manufacturing arrangements; additions or modifications to product labeling; the recall or discontinuation of our products; or additional record-keeping requirements. If any such changes were to be imposed, they could
adversely affect the operation of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Patent-Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible
for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process.
Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The <FONT STYLE="white-space:nowrap">patent-term</FONT> restoration period is generally <FONT
STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the submission date of an NDA or BLA plus the time between the submission date of an NDA or BLA and the approval of that application, except that the review
period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration
of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add
patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a
five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to gain approval of a NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not
previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug
application (ANDA), or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted
after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> The FDCA also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing NDA
if new clinical investigations, other than bioavailability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an
existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year
exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical
trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reference biological product is granted 12 years of data exclusivity from the
time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product.
&#147;First licensure&#148; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for)
a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest or other related entity) for a
change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the
structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change
in safety, purity or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#147;first licensure&#148;
of a biological product is determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis with data submitted by the sponsor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Union Drug Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant
regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member
States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the
EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority (NCA), and one or more Ethics Committees (ECs). Under the current regime all suspected unexpected serious adverse reactions to the investigated
drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU clinical
trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing
their transparency. Recently enacted Clinical Trials Regulation EU No&nbsp;536/2014 ensures that the rules for conducting clinical trials in the EU will be identical. In the meantime, Clinical Trials Directive 2001/20/EC continues to govern all
clinical trials performed in the EU. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Union Drug Review and Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Economic Area (EEA), which is comprised of the 27 Member States of the European Union (including Norway and excluding Croatia),
Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (MA). There are two types of marketing authorizations. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of
the Committee for Medicinal Products for Human Use (CHMP), of the EMA, and is </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products,
advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes,
auto-immune and other immune dysfunctions and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific
or technical innovation or which are in the interest of public health in the EU. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their
respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in
another Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized
Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (RMS). The
competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics (SPC), and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States
Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling or packaging proposed by the RMS, the product is subsequently granted a national
MA in all the Member States (i.e., in the RMS and the Member States Concerned). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the above described procedures,
before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales
of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance, and managed healthcare organizations. In the United States, no uniform policy
of coverage and reimbursement for drug or biological products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products
to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States government,
state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement, and requirements
for substitution of generic products for branded prescription drugs. For example, the ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of
Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&nbsp;D beneficiaries and annual fees based on pharmaceutical companies&#146; share of sales to federal health care programs. Adoption of general controls
and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceutical drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the
Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#146;s outpatient drugs furnished to Medicaid </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#146; rebate liability by raising the minimum basic Medicaid rebate
on most branded prescription drugs from 15.1% of average manufacturer price (AMP), to 23.1% of AMP and adding a new rebate calculation for &#147;line extensions&#148; (i.e., new formulations, such as extended release formulations) of solid oral
dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical
manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits. The Centers for Medicare&nbsp;&amp; Medicaid Services (CMS), have proposed to expand Medicaid rebate
liability to the territories of the United States as well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003
(MMA), established the Medicare Part&nbsp;D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part&nbsp;D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide
coverage of outpatient prescription drugs. Unlike Medicare Part&nbsp;A and B, Part&nbsp;D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part&nbsp;D prescription drug plan
sponsors are not required to pay for all covered Part&nbsp;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part&nbsp;D prescription drug formularies must
include drugs within each therapeutic category and class of covered Part&nbsp;D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part&nbsp;D prescription drug plan must be developed and reviewed by a
pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part&nbsp;D
prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in
setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from <FONT STYLE="white-space:nowrap">non-governmental</FONT> payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a drug product to receive federal reimbursement under the Medicaid or Medicare Part&nbsp;B programs or to be sold directly to U.S.
government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by
the manufacturer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, the marketability of any products for which we receive regulatory approval for commercial sale may
suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. An increasing emphasis on cost containment measures in the United States has increased and we expect will continue to increase the pressure on
pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable
coverage policies and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in most foreign countries, the proposed pricing
for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the
range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may
instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly
lower. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific Advisory Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled a highly qualified scientific advisory board comprised of advisors who have, collectively, deep expertise in
neurodegenerative diseases, genomics, protein engineering, drug development, and drug discovery as well as translational medicine. Our scientists work in collaboration with these advisors to identify new disease targets, develop a biomarker
strategy, and accelerate discovery and development. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Affiliated Entity</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adam Boxer, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director of UCSF Neuroscience Clinical Research Unit</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Colonna, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Washington University School of Medicine in St. Louis</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Hauser, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chair of the Department of Neurology at UCSF</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Heneka, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chair of the Department of Neurology at University of Bonn</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lewis Lanier, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chair of the Department of Microbiology and Immunology at UCSF</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liqun Luo, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member of National Academy of Sciences, Stanford University</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Scheller, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member of National Academy of Sciences,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas&nbsp;Christian&nbsp;S&uuml;dhof,&nbsp;M.D.,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Nobel Laureate, Stanford University</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Vassar, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Northwestern University Feinberg School of Medicine</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Berislav Zlokovic, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chair of the Department of Physiology&nbsp;&amp; Neuroscience at USC Feinberg School of Medicine</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, we had 109 full-time employees, over 70% of whom were engaged in research and development activities. None of
our employees are represented by a labor union or covered under a collective bargaining agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are currently located in South San Francisco, California, where we lease approximately 105,000 square feet of
office, research and development, engineering, and laboratory space pursuant to a lease agreement that expires in April 2029, with an option to extend the term of the lease for an additional 10&nbsp;years. The new lease agreement also provides us a
right of first offer to expand into available office space in the building. We lease 8,763 square feet of additional office and laboratory space in Milpitas, California. We believe that these facilities will be adequate for our near-term needs. If
required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal
Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any
litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. We have initiated an arbitration against a third party as set forth below. Regardless of outcome, litigation can
have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;18, 2019, we initiated a confidential arbitration proceeding against Dr.&nbsp;Asa Abeliovich, our former consulting <FONT STYLE="white-space:nowrap">co-founder,</FONT> related to alleged breaches of his consulting agreement and the
improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable
to assess or provide any assurances regarding its possible outcome. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the names, ages, and positions of our executive officers and directors as of September&nbsp;30, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arnon Rosenthal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Co-Founder,&nbsp;Chief&nbsp;Executive&nbsp;Officer,&nbsp;and&nbsp;Director</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Paul, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert King, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Development Officer</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sabah Oney, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Business Officer</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calvin Yu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Finance</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tillman Gerngross, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chairperson</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis J. Lavigne, Jr.*<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terry McGuire<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Scheller, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wehner<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Yaffe, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lead independent director </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the corporate governance and nominating committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Arnon Rosenthal,
Ph.D., <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> Chief Executive Officer, and Director. </I>Dr.&nbsp;Rosenthal <FONT STYLE="white-space:nowrap">co-founded</FONT> Alector in 2013 and has served as a member of our board of directors, as
Chief Executive Officer, and as our President since 2013. Dr.&nbsp;Rosenthal <FONT STYLE="white-space:nowrap">co-founded</FONT> Annexon Biosciences, Inc. and served as its acting Chief Executive Officer from August 2011 to December 2014 and served
as a member of the board of directors, including as Chairman from August 2011 February 2017. Dr.&nbsp;Rosenthal <FONT STYLE="white-space:nowrap">co-founded</FONT> Rinat Neuroscience Corporation (acquired by Pfizer Inc. in August 2006), and served as
President, Chief Scientific Officer and as a member of the board of directors from August 2001 to August 2006. From January 1985 to August 2001, Dr.&nbsp;Rosenthal served in various roles at Genentech, Inc., where he ultimately served as Staff
Scientist and was appointed as a permanent member of Genentech&#146;s Research Review Committee where his team discovered the target for the cancer drug Erivedge. Dr.&nbsp;Rosenthal conducted his post-doctoral fellowship at Genentech, Inc. He holds
a Ph.D. in biology from the Hebrew University of Jerusalem. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Rosenthal is qualified to serve on our board of directors
because of the perspective and experience he provides as one of our founders and as our Chief Executive Officer, his experience as a founder and director of other life sciences companies, his educational background, as well as his broad experience
within the pharmaceutical industry, particularly in the area of neuroscience and drug discovery and development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Robert Paul, M.D.,
Ph.D., Chief Medical Officer.</I> Dr.&nbsp;Paul has served as our Chief Medical Officer since October 2016. Dr.&nbsp;Paul joined Alector from Genentech, Inc., where he held various roles of increasing responsibility between 2009 and 2016, including
as Assistant Group Medical Director and TA Head Neuroscience Early Clinical Development gRED from October 2015 to October 2016, as Senior Medical Director from October 2013 to September 2015, as Medical Director from September 2011 to October 2013,
and as Associate Medical Director from January 2009 to September 2011. From May 2002 to December 2008, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dr.&nbsp;Paul served as a Neurologist at the University of Munich. Dr.&nbsp;Paul is a board certified neurologist in Germany. He received a M.D. and a Ph.D. from Ludwig-Maximilians
Universit&auml;t M&uuml;nchen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Robert King, Ph.D., Chief Development Officer.</I> Dr.&nbsp;King has served as our Chief Development
Officer since January 2017. Dr.&nbsp;King joined Alector from SciClone Pharmaceuticals, Inc. (acquired by a consortium led by GL Capital Partners, LLC), a biotechnology company, where he served as Senior Vice President of Product Development and
Supply Chain from June 2011 to January 2017. Prior to SciClone Pharmaceuticals, Dr.&nbsp;King served as VP of Product Development and Manufacturing at Bayhill Therapeutics, Inc., a biotechnology company from 2006 to 2011. Dr.&nbsp;King served as VP
Product Development and Manufacturing at Rinat Neuroscience Corp. (acquired by Pfizer), a biotechnology company, from 2003 to 2006. Dr.&nbsp;King served in positions of increasing responsibility at COR Therapeutics, Inc. (acquired by Millennium
Pharmaceuticals, Inc. in 2002) from 1993 to 2003. From 1991 to 1993, Dr.&nbsp;King served as a Scientist in the Purification and Pharmaceutical Sciences groups at California Biotechnology/Scios. From 1988 to 1991, Dr.&nbsp;King was a Scientist at
Molecular Devices Corporation. Dr.&nbsp;King received a Ph.D. in Chemical Engineering from the University of California, Berkeley, and a B.S. in Chemical Engineering from the University of Washington. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sabah Oney, Ph.D., Chief Business Officer.</I> Dr.&nbsp;Oney joined Alector in October 2016. He has served as our Chief Business Officer
since January 2018 and previously as our Vice President of Business Development and Operations since October 2016. From January 2016 until October 2016, Dr.&nbsp;Oney served as a consultant to a number of biotechnology companies. Dr.&nbsp;Oney
previously served as Head of Global Sales and Business Development at Ariosa Diagnostics, Inc. (now a member of Roche Holding AG), a biotechnology company, from October 2015 to January 2016, and as Director of Business Development from September
2012 to October 2015. Dr.&nbsp;Oney received a Ph.D. in Genetics and Genomics from Duke University, an M.B.A. from Stanford University Graduate School of Business, and a B.S. in Genetics from the University of Kansas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Calvin Yu, Vice President, Finance.</I> Mr.&nbsp;Yu has led our Finance team since June 2017. Mr.&nbsp;Yu joined Alector from Stemcentrx,
Inc. (acquired by AbbVie), a biotechnology company, where he served as Corporate Controller from February 2016 to June 2017. Prior to Stemcentrx, Mr.&nbsp;Yu held several senior level finance roles at publicly traded biotechnology companies,
including Senior Director of Finance and SEC Reporting at Adverum Biotechnologies, Inc. from September 2014 to February 2016, and Controller at Five Prime Therapeutics, Inc. from March 2010 to September 2014. Mr.&nbsp;Yu received his B.S. in
Accounting from San Francisco State University, College of Business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Tillman Gerngross, Ph.D., <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chairperson. </I>Dr.&nbsp;Gerngross <FONT
STYLE="white-space:nowrap">co-founded</FONT> Alector in 2013 and has served as a member of our board of directors and as Chairperson since 2013. Dr.&nbsp;Gerngross is a founder, director, and executive officer of numerous biotechnology companies. He
is a founder and currently serving as Chief Executive Officer and as a director of Adimab, LLC. He is also a founder and Chairman of the board of directors of Avitide, Inc. and a founder and the Chairman of the board of directors of Arsanis, Inc.
Dr.&nbsp;Gerngross is currently a Venture Partner at SV Life Sciences Advisors, LLC, which he joined in 2006. Dr.&nbsp;Gerngross <FONT STYLE="white-space:nowrap">co-founded</FONT> GlycoFi, Inc. and served as its Chief Scientific Officer from 2000 to
2006 until it was acquired by Merck&nbsp;&amp; Company, Inc. Dr.&nbsp;Gerngross currently teaches in the departments of Biology and Chemistry, as well as at the School of Engineering at Dartmouth College, where he has taught since 1998.
Dr.&nbsp;Gerngross attended the Technical University of Vienna, Austria, where he received a B.S. and M.S. in Chemical Engineering and a Ph.D. in Molecular Biology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Gerngross is qualified to serve on our board of directors because of the perspective and experience he provides as one of
our founders, his expertise and experience in antibody drug discovery and development, his experience as a founder and director of other life sciences companies, his educational background, and his experience working in the venture capital industry.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Louis J. Lavigne, Jr.</I> Mr.&nbsp;Lavigne has served as a member of our board of
directors and as our Lead Independent Director since October 2018. Mr.&nbsp;Lavigne has been a Managing Director of Lavrite, LLC, a management consulting firm specializing in the areas of corporate finance, accounting, growth strategy, and
management, since 2005. Mr.&nbsp;Lavigne served in various executive capacities with Genentech, Inc. for over 20 years, including, Chief Financial Officer from 1988 to 2005, Executive Vice President from 1997 to 2005, Senior Vice President from 1994
to 1997, Vice President from 1986 to 1994, and Controller from 1983 to 1986. He has served as a director, chair of the audit committee, and member of the compensation committee of DocuSign Inc., an eSignature transaction management company, since
July 2013; as a member of the board of directors of Zynga&nbsp;Inc., a social game company, since 2015, including as audit committee chairman and compensation committee member since 2015 and as Lead Director since 2017; and as chairman of the board
of directors and chairperson of the compensation committee of Accuray Incorporated, a radiation oncology company, since September 2009. Within the last five years, Mr.&nbsp;Lavigne also served on the board of directors, the audit committee, and the
science and technology committee of Allergan, Inc., a global health care company, from 2005 until its acquisition by Actavis plc in 2015; as a director and chair of the audit committee of NovoCure Limited, an oncology company, from 2013 until
October 2018; as a director, chair of the compensation committee and member of the audit committee of Assertio Therapeutics, Inc., a pharmaceutical company, since July 2013 until his resignation in May 2019; as a director and chair of the audit
committee of SafeNet, Inc., a private information security company, from 2010 until its acquisition by Gemalto NV in 2015; and as a director and chair of the audit committee of BMC Software, Inc., an enterprise systems software vendor, from 2004 to
2007 and from 2008 to 2013, when it was acquired by a private investor group. Mr.&nbsp;Lavigne serves as a board member and is the former chairman of the UCSF Benioff Children&#146;s Hospitals and the UCSF Benioff Children&#146;s Hospitals
Foundation where he is also a member of the audit and finance committees. Mr.&nbsp;Lavigne holds a B.S. in Business Administration from Babson College and an M.B.A. from Temple University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Lavigne is qualified to serve on our board of directors because of his extensive experience in business operations and
management, strategy, finance, accounting, and public company governance as a chief financial officer of a large, complex publicly-traded company and his extensive board leadership positions with a number of public company boards and audit
committees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Terry McGuire. </I>Mr.&nbsp;McGuire has served as a member of our board of directors since 2013. Additionally,
Mr.&nbsp;McGuire is a Founding Partner of Polaris Partners, a venture capital firm investing in technology and healthcare companies across all stages of development, where he has worked since 1996. Mr.&nbsp;McGuire serves on the board of directors
of Cyclerion, Inc., a publicly traded biotechnology company, since January 2019 and Pulmatrix, Inc., a publicly traded biopharmaceutical company, where he has served since May 2016. Mr.&nbsp;McGuire served on the board of directors of Trevena, Inc.,
a publicly traded biopharmaceutical company, from January 2008 to July 2014; on the board of Ironwood Pharmaceuticals, Inc., a publicly traded drug manufacturer, from 1998 to 2019 and on the board of directors of Arsanis, Inc., a publicly traded
biopharmaceutical company, from 2011 to 2019. Mr.&nbsp;McGuire is emeritus Chairman of the National Venture Capital Association, Chairman of the Global Ventures Capital Congress and chairs the board of the Thayer School of Engineering at Dartmouth
College. He also sits on the boards of Massachusetts Institute of Technology&#146;s The David H. Koch Institute for Integrative Cancer Research, The Arthur Rock Center for Entrepreneurship at Harvard Business School and The Healthcare Initiative
Advisory Board. Mr.&nbsp;McGuire holds an M.B.A. from Harvard Business School, and a M.S. in engineering from the Thayer School at Dartmouth College, and a B.S. in physics and economics from Hobart College. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;McGuire is qualified to serve on our board of directors because of his expertise and experience in the biotechnology
industry through his role as a Founding Partner of Polaris Partners and his cumulative career in venture capital over a period spanning over 35 years, in which he has been involved in the evaluation, investment and oversight of numerous
biotechnology companies, as well as his experience as a director of several biotechnology companies, including other public companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Richard Scheller, Ph.D. </I>Dr.&nbsp;Scheller has served as a member of our board of directors since October 2018. Dr.&nbsp;Scheller has
served as the Chairman of Research and Development at BridgeBio Pharma LLC since January </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2019 and as a member of its board of directors since January 2018. Dr.&nbsp;Scheller previously served as Chief Scientific Officer at 23andMe, a personal genetics company, from April 2015 to
April 2019. Previously, Dr.&nbsp;Scheller was the Executive Vice President of Research and Early Development and a member of the Executive Committee at Genentech, Inc. from February 2001 to December 2014. From January 2009 to December 2014,
Dr.&nbsp;Scheller was also a member of the Enlarged Executive Committee at <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche&nbsp;Ltd. Since February 2015, Dr.&nbsp;Scheller has served as a member of the board of directors for ORIC
Pharmaceuticals, Inc. Since March 2015, Dr.&nbsp;Scheller has served as a member of the board of directors for Xenon Pharmaceuticals Inc. Since January 2018, Dr.&nbsp;Scheller has served as a member of the board of directors of BridgeBio Inc.
Dr.&nbsp;Scheller&#146;s research on elucidating the molecular machinery and regulatory mechanism that underlie the release of neurotransmitters earned him the 2013 Albert Lasker Basic Medical Research Award. He is a member of the National Academy
of Sciences and a member of the National Academy of Medicine. Dr.&nbsp;Scheller holds a Ph.D. in Chemistry from the California Institute of Technology and B.Sc. in Biochemistry from the University of Wisconsin-Madison. He completed his
post-doctorate in Molecular Neurobiology at Columbia University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Scheller is qualified to serve on our board of
directors because of his scientific background and his senior management experience in the pharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>David Wehner</I>.
Mr.&nbsp;Wehner has served as a member of our board of directors since October 2018. He has served as Chief Financial Officer of Facebook, Inc. since June 2014. Mr.&nbsp;Wehner joined Facebook, Inc. in November 2012 as Vice President, Corporate
Finance and Business Planning. From August 2010 until November 2012, Mr.&nbsp;Wehner served as Chief Financial Officer at Zynga Inc., a provider of social game services. From February 2001 to July 2010, Mr.&nbsp;Wehner served in various positions at
Allen&nbsp;&amp; Company, an investment bank, including as a Managing Director from November 2006 to July 2010 and as a director from December 2005 to November 2006. Mr.&nbsp;Wehner holds an M.S. in applied physics from Stanford University and a
B.S. in chemistry from Georgetown University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Wehner is qualified to serve on our board of directors based on his
substantial executive, strategy, finance, and operational experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Kristine Yaffe, M.D.</I> Dr.&nbsp;Yaffe has served as a member
of our board directors since August 2019. Dr.&nbsp;Yaffe is currently a professor of psychiatry, neurology and epidemiology at the University of California, San Francisco (UCSF) and has served in that role since 2007. Dr.&nbsp;Yaffe has also served
as the Roy and Marie Scola Endowed Chair since 2009 and Vice Chair in Psychiatry at UCSF since 2016. Dr.&nbsp;Yaffe has received numerous awards for her groundbreaking contributions to the field including the American Academy of Neurology Potamkin
Prize for Research in Pick&#146;s, Alzheimer&#146;s, and Related Diseases. Dr.&nbsp;Yaffe holds a B.S. in biology-psychology from Yale University, an M.D. from the University of Pennsylvania School of Medicine and has completed residencies in
neurology and psychiatry at the University of California, San Francisco. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Yaffe is qualified to serve on our board of
directors based on her experience as an internationally recognized expert in the field of cognitive aging, neurodegeneration and dementia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board
Composition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists of seven members. The number of directors will be fixed by our board of
directors, subject to the terms of our amended and restated certificate of incorporation and amended and restated bylaws. Each of our current directors will continue to serve as a director until the election and qualification of his or her
successor, or until his or her earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that
our board of directors is divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of stockholders, with the other classes continuing for the remainder of their respective three-year terms. Our current directors are divided among the three classes as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors consist of Dr.&nbsp;Rosenthal and Mr.&nbsp;Wehner, and their terms will expire at the
annual meeting of stockholders to be held in 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors consist of Mr.&nbsp;McGuire and Dr.&nbsp;Yaffe, and their terms will expire at the
annual meeting of stockholders to be held in 2020; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors consist of Drs. Gerngross and Scheller and Mr.&nbsp;Lavigne, and their terms will
expire at the annual meeting of stockholders to be held in 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders, upon the
expiration of the term of a class of directors, the successor to each such director in the class will be elected to serve from the time of election and qualification until the third annual meeting following his or her election and until his or her
successor is duly elected and qualified, in accordance with our amended and restated certificate of incorporation. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so
that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of our directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
classification of our board of directors may have the effect of delaying or preventing changes in control of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the NASDAQ Global Select Market (NASDAQ). Under the rules of NASDAQ, independent directors must comprise
a majority of a listed company&#146;s board of directors within one year of the completion of our initial public offering. In addition, the rules of NASDAQ require that, subject to specified exceptions, each member of a listed company&#146;s audit,
compensation and corporate governance, and nominating committees be independent. Audit committee members and compensation committee members must also satisfy the independence criteria set forth in
<FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> and <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1,</FONT> respectively, under the Exchange Act. Under the rules of NASDAQ, a director will only qualify as an &#147;independent director&#148;
if, in the opinion of that company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be considered to be independent for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> and under the rules of NASDAQ, a
member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory or
other compensatory fee from the listed company or any of its subsidiaries or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be considered independent for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1</FONT> and under the rules of NASDAQ, the board
of directors must affirmatively determine that each member of the compensation committee is independent, including a consideration of all factors specifically relevant to determining whether the director has a relationship to the company which is
material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: (1)&nbsp;the source of compensation of such director, including any
consulting, advisory, or other compensatory fee paid by the company to such director and (2)&nbsp;whether such director is affiliated with the company, a subsidiary of the company or an affiliate of a subsidiary of the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors undertook a review of its composition, the composition of its committees, and the independence of our directors and
considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each
director concerning his background, employment, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affiliations, including family relationships, our board of directors has determined that Drs. Scheller and Yaffe and Messrs. Lavigne, McGuire, and Wehner do not have a relationship that would
interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#147;independent&#148; as that term is defined under the rules of NASDAQ. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In making these determinations, our board of directors considered the current and prior relationships that each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital
stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director, and the transactions involving them described in the section titled &#147;Certain Relationships and Related Party Transactions&#148; incorporated by reference into this
prospectus. There are no family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lead Independent Director </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has appointed Louis J. Lavigne, Jr. to serve as our Lead Independent Director. As a general matter, our board of
directors believes that appointing a Lead Independent Director, when either our Chief Executive Officer serves as Chairman or when our Chairman is not independent, creates an environment that encourages objective oversight of management&#146;s
performance and enhances the effectiveness of our board of directors as a whole. As Lead Independent Director, Mr.&nbsp;Lavigne will preside over periodic meetings of our independent directors, serve as a liaison between our Chairperson, Chief
Executive Officer, and our independent directors and perform such additional duties as our board of directors may otherwise determine and delegate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
board of directors has an active role, as a whole and also at the committee level, in overseeing the management of our risks. Our board of directors is responsible for general oversight of risks and regular review of information regarding our risks,
including credit risks, liquidity risks, and operational risks. The compensation committee is responsible for overseeing the management of risks relating to our executive compensation plans and arrangements. The audit committee is responsible for
overseeing the management of risks relating to accounting matters and financial reporting and potential conflicts of interest. The corporate governance and nominating committee is responsible for overseeing the management of risks associated with
the independence of our board of directors. Although each committee is responsible for evaluating certain risks and overseeing the management of such risks, our entire board of directors is regularly informed through discussions from committee
members about such risks. Our board of directors believes its administration of its risk oversight function has not negatively affected the board of directors&#146; leadership structure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors
has an audit committee, a compensation committee, and a corporate governance and nominating committee, each of which has the composition and the responsibilities described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of
our audit committee are Messrs. Lavigne, McGuire and Wehner. Mr.&nbsp;Lavigne is the chairperson of our audit committee and both Mr.&nbsp;Lavigne and Mr.&nbsp;Wehner have been designated as audit committee financial experts, as that term is defined
under the SEC rules implementing Section&nbsp;407 of SOX, as each possesses financial sophistication, as defined under the rules of NASDAQ. Our audit committee oversees our corporate accounting and financial reporting process and assists our board
of directors in monitoring our financial systems. Our audit committee will also: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">select and hire the independent registered public accounting firm to audit our financial statements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">help to ensure the independence and performance of the independent registered public accounting firm;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services and fees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review financial statements and discuss with management and the independent registered public accounting firm our
annual audited and quarterly financial statements, the results of the independent audit and the quarterly reviews and the reports and certifications regarding internal controls over financial reporting and disclosure controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prepare the audit committee report that the SEC requires to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review reports and communications from the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review the adequacy and effectiveness of our internal controls and disclosure controls and procedure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review our policies on risk assessment and risk management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and monitor conflicts of interest situations, and approve or prohibit any involvement in matters that may
involve a conflict of interest or taking of a corporate opportunity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review related party transactions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish and oversee procedures for the receipt, retention, and treatment of accounting related complaints and
the confidential submission by our employees of concerns regarding questionable accounting or auditing matters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
audit committee operates under a written charter, which satisfies the applicable rules of the SEC and the listing standards of NASDAQ. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation
Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our compensation committee are Dr.&nbsp;Scheller and Mr.&nbsp;Lavigne. Dr.&nbsp;Scheller is the
chairperson of our compensation committee. Our compensation committee oversees our compensation policies, plans, and benefits programs. The compensation committee will also: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">oversee our overall compensation philosophy and compensation policies, plans, and benefit programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and approve or recommend to the board of directors for approval compensation for our executive officers
and directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prepare the compensation committee report that the SEC will require to be included in our annual proxy statement;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administer our equity compensation plans. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee operates under a written charter, which satisfies the applicable rules of the SEC and the listing standards of
NASDAQ. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Governance and Nominating Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our corporate governance and nominating committee are Drs. Scheller and Yaffe and Mr.&nbsp;McGuire. Mr.&nbsp;McGuire is the
chairperson of our corporate governance and nominating committee. Our corporate governance and nominating committee oversees and assists our board of directors in reviewing and recommending nominees for election as directors. Specifically, the
corporate governance and nominating committee will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify, evaluate, and make recommendations to our board of directors regarding nominees for election to our
board of directors and its committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consider and make recommendations to our board of directors regarding the composition of our board of directors
and its committees; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review developments in corporate governance practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate the adequacy of our corporate governance practices and reporting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate the performance of our board of directors and of individual directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate governance and nominating committee operates under a written charter, which satisfies the applicable rules of the SEC and the
listing standards of NASDAQ. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific Advisory Board Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also reimburse each member of our scientific advisory board for all reasonable and necessary expenses in connection with the performance of
his or her services. In addition, we grant each new member an option to purchase shares of our common stock and in the future, we may make additional grants or may make cash compensation payments to our scientific advisory board members for
continued service on the scientific advisory board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors who are also our employees receive no additional compensation for their service as directors. Dr.&nbsp;Rosenthal was our only
employee director during 2018. See the section titled &#147;Executive Compensation&#148; for additional information about Dr.&nbsp;Rosenthal&#146;s compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the total compensation each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors received during
the year ended December&nbsp;31, 2018. Dr.&nbsp;Yaffe is not included in this table, as she joined our board of directors in August 2019. Other than as set forth in the table, we did not pay any compensation, make any equity awards or <FONT
STYLE="white-space:nowrap">non-equity</FONT> awards to or pay any other compensation to any of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or&nbsp;Paid&nbsp;in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tillman Gerngross, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christine Brennan, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis J. Lavigne, Jr.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">501,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carl Gordon, Ph.D., C.F.A.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terry McGuire</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Scheller, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">583,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">583,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wehner<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts disclosed represent the aggregate grant date fair value of the award as calculated in accordance
with ASC 718. The assumptions used in calculating the grant date fair value of the award disclosed in this column are set forth in the notes to our audited financial statements incorporated by reference in this prospectus. These amounts do not
correspond to the actual value that may be recognized by the directors upon vesting of the applicable awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We paid Dr.&nbsp;Gerngross $25,000 in consulting fees in 2018. As of December&nbsp;31, 2018, Dr.&nbsp;Gerngross
held 70,208 restricted shares of our common stock. <FONT STYLE="white-space:nowrap">One-fourth</FONT> of the total number of shares subject to the restricted stock grant vested on the one year anniversary of July&nbsp;15, 2015, and an additional
1/48th of the total number of shares subject to the restricted stock grant vested, and continue to vest, on the same day of each month thereafter, subject to Dr.&nbsp;Gerngross&#146; continued status as a service provider through each such vesting
date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Brennan resigned from our board of directors in February 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2018, Mr.&nbsp;Lavigne held an option to purchase 70,000 shares of our common stock. <FONT
STYLE="white-space:nowrap">One-fourth</FONT> of the total number of shares subject to the option grant vest on the one year anniversary of October&nbsp;25, 2018, and an additional 1/48th of the total number of shares subject to the option grant vest
on </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the same day of each month thereafter, subject to Mr.&nbsp;Lavigne&#146;s continued status as a service provider through each such vesting date. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Gordon resigned from our board of directors in June 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2018, Dr.&nbsp;Scheller held an option to purchase 70,000 shares of our common stock. <FONT
STYLE="white-space:nowrap">One-fourth</FONT> of the total number of shares subject to the option grant vest on the one year anniversary of October&nbsp;22, 2018, and an additional 1/48th of the total number of shares subject to the option grant vest
on the same day of each month thereafter, subject to Dr.&nbsp;Scheller&#146;s continued status as a service provider through each such vesting date. As of December&nbsp;31, 2018, Dr.&nbsp;Scheller held an option to purchase 11,834 shares of our
common stock. The shares subject to this option vest one forty-eighth per month beginning on the one month anniversary of October&nbsp;22, 2018, subject to Dr.&nbsp;Scheller&#146;s continued status as a service provider on each such vesting date. As
of December&nbsp;31, 2018, Dr.&nbsp;Scheller held 19,981 restricted shares of our common stock. <FONT STYLE="white-space:nowrap">One-fourth</FONT> of the total number of shares subject to the restricted stock grant vested on the one year anniversary
of July&nbsp;31, 2015, and an additional 1/48th of the total number of shares subject to the restricted stock grant vested, and continued to vest, on the same day of each month thereafter, subject to Dr.&nbsp;Scheller&#146;s continued status as a
service provider through each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2018, Mr.&nbsp;Wehner held an option to purchase 70,000 shares of our common stock. <FONT
STYLE="white-space:nowrap">One-fourth</FONT> of the total number of shares subject to the option grant vest on the one year anniversary of October&nbsp;9, 2018, and an additional 1/48th of the total number of shares subject to the option grant vest
on the same day of each month thereafter, subject to Mr.&nbsp;Wehner&#146;s continued status as a service provider through each such vesting date. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have retained Radford, a national compensation consultant, to provide our board of directors with an analysis of market data compiled from
certain comparable public companies and assistance in determining compensation of directors. Our board of directors has adopted our Outside Director Compensation Policy. Our Outside Director Compensation Policy provides that all <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors will be entitled to receive the following cash compensation for their services: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$35,000 retainer per year for each <FONT STYLE="white-space:nowrap">non-employee</FONT> director;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$20,000 retainer per year for service as <FONT STYLE="white-space:nowrap">non-executive</FONT> chairman of the
board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$20,000 retainer per year for service as lead <FONT STYLE="white-space:nowrap">non-employee</FONT> director;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$15,000 retainer per year for the chairman of the audit committee or $7,500 retainer per year for each other
member of the audit committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$10,000 retainer per year for the chairman of the compensation committee or $5,000 retainer per year for each
other member of the compensation committee; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$8,000 retainer per year for the chairman of the nominating and corporate governance committee or $4,000 retainer
per year for each other member of the nominating and corporate governance committee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director who serves as the chair of a committee will receive only the additional annual fee as the chair of the committee and will not receive the additional annual fee as a member of the committee. All
cash payments to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are paid quarterly in arrears on a prorated basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to the cash compensation structure described above, our Outside Director Compensation Policy provides the following equity incentive compensation program for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director who first joins us (other than&nbsp;a director who becomes a <FONT STYLE="white-space:nowrap">non-employee&nbsp;director</FONT> as a&nbsp;result of terminating employment with us)
automatically&nbsp;will be&nbsp;granted on the first trading date on or after&nbsp;his or her&nbsp;start date as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director a <FONT STYLE="white-space:nowrap">one-time,</FONT> initial option
covering 40,000 shares&nbsp;of our common stock. Further, on the date of each of our annual stockholder meetings, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is continuing as a director
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
following our annual stockholder meeting automatically will be granted an annual option covering 20,000 shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each initial option&nbsp;will vest&nbsp;as to 1/4th of the underlying shares on the <FONT STYLE="white-space:nowrap">one-year</FONT>
anniversary of the date the director&#146;s service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director started and as to 1/48th of the underlying shares each following month, subject to continued service through each relevant vesting
date. Each annual option will vest as to 1/12th of the underlying shares each month after the award&#146;s grant date and will vest in full on the earlier of the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary of the date of grant or on
the date of our annual stockholder meetings following the date the annual option is granted, subject to continued service through each relevant vesting date. In the event of&nbsp;a change in control of our company, all equity awards granted to a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director (including those granted pursuant to our Outside Director Compensation Policy) will fully vest&nbsp;and become immediately exercisable,&nbsp;subject to&nbsp;continued service&nbsp;through such
date. Each initial option and annual option will have a term of 10 years and will have an exercise price per share equal to 100% of the fair market value of a share of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any fiscal year, a <FONT STYLE="white-space:nowrap">non-employee</FONT> director may be paid, issued, or granted cash compensation and
equity awards with a total value of no greater than $750,000 (increased to $1,000,000 in the fiscal year of his or her initial service as an outside director) with the value of an equity award based on its grant date fair value for purposes of this
limit (annual director limit). Equity awards or cash compensation granted to a <FONT STYLE="white-space:nowrap">non-employee</FONT> director for his or her service as an employee or consultant (other than a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director) will not count toward the annual director limit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Outside Director
Compensation Policy also provides for the reimbursement of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for reasonable, customary and documented travel expenses to attend meetings of our board of directors and committees of our
board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors is&nbsp;not limited to&nbsp;the
equity awards and payments set forth in our Outside Director Compensation Policy. Our <FONT STYLE="white-space:nowrap">non-employee&nbsp;directors</FONT> will&nbsp;remain&nbsp;eligible to receive equity awards&nbsp;and cash or other compensation
outside of the Outside Director Compensation Policy, as may be provided from time to time at the discretion of our board of directors. For further information regarding the equity compensation of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, see the section of this prospectus titled &#147;<I>Executive Compensation&#151;Employee Benefit and Stock Plans&#151;2019 Equity Incentive Plan</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Inside Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee is or has been an officer or employee of our company. None of our executive officers
currently serves, or in the past fiscal year has served, as a member of the board of directors, or compensation committee (or other board committee performing equivalent functions or, in the absence of any such committee, the entire board of
directors) of any entity that has one or more executive officers serving on our board of directors or compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct
and Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a written code of business conduct and ethics that applies to our directors, officers, and employees,
including our principal executive officer, principal financial officer, principal accounting officer or controller or, persons performing similar functions. The code of business conduct and ethics is available on our website at www.alector.com. We
intend to disclose future amendments to such code, or any waivers of its requirements, applicable to any principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions, or
our directors on our website identified above. Information contained on the website is not incorporated by reference into this prospectus and should not be considered to be part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers for the year ended December&nbsp;31, 2018, which consist of our principal executive officer and the next two most
highly compensated executive officers, are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arnon Rosenthal, Ph.D., our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Robert Paul, M.D., Ph.D., our Chief Medical Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Robert King, Ph.D., our Chief Development Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth information regarding the compensation of our named executive officers for the year ended December&nbsp;31, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards ($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arnon Rosenthal, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">396,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">237,540</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,816,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,564</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,453,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">370,001</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">140,600</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">2,881,057</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">3,564</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">3,395,222</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert King, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">352,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,800</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,570,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,323</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,072,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Development Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">316,898</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">103,700</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">1,309,005</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">1,730,783</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Paul, M.D., Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">326,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">180,670</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,707,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,243</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,216,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts disclosed represent the aggregate grant date fair value of the award as calculated in accordance
with ASC 718. The assumptions used in calculating the grant date fair value of the award disclosed in this column are set forth in the notes to our audited financial statements incorporated by reference in this prospectus. These amounts do not
correspond to the actual value that may be recognized by the named executive officers upon vesting of the applicable awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent a bonus earned upon the achievement of company objectives for the fiscal year
ended December&nbsp;31, 2018, which is expected to be paid in March 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported include life insurance premiums paid by us on behalf of our named executive officers.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent a bonus based upon the achievement of company objectives for the year ended
December&nbsp;31, 2017, which was paid in March 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount included in the &#147;Bonus&#148; column includes a portion of a signing bonus earned and paid in
2018 to Dr.&nbsp;Paul in the aggregate amount of $43,750. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning outstanding equity awards held by each of our named executive officers as of
December&nbsp;31, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares<BR>of Stock<BR>That<BR>Have Not<BR>Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value of<BR>Shares of<BR>Stock That<BR>Have Not<BR>Vested<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arnon Rosenthal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/10/2015</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,370</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/17/2015</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,716</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/09/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,905</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,986,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/09/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,655</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,233,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/02/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,083</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">447,917</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/02/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/06/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/06/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert King, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/26/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279,853</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,837,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/02/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,625</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,375</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/02/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/06/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/06/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Paul, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/04/2016</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,123</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,329,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/09/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,761</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/02/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,458</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,542</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/02/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/06/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(18)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/06/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column represents the fair market value of a share of our common stock on the date of grant, as determined
by our board of directors or its authorized committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Because our common stock was not traded on a public market on December&nbsp;31, 2018, the market value has been
calculated based on an estimated fair market value of $10.14 per share as of December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This restricted stock grant of our common stock was granted pursuant to our 2017 Plan and was converted from
restricted units and profit interest units of Alector LLC pursuant to the Conversion (as defined and discussed in Note 1 of the notes to our consolidated financial statements included in the 2018 Annual Report incorporated by reference into this
prospectus). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the total number of shares subject to the restricted
stock grant vested on January&nbsp;15, 2016, and an additional 1/16th of the total number of shares subject to the restricted stock grant vested, and continued to vest, quarterly thereafter, subject to Dr.&nbsp;Rosenthal&#146;s continued status as a
service provider through each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the total number of shares subject to the restricted
stock grant vested on July&nbsp;17, 2016, and an additional 1/48th of the total number of shares subject to the restricted stock grant vested, and continued to vest, on the same day of each month thereafter, subject to Dr.&nbsp;Rosenthal&#146;s
continued status as a service provider through each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to the restricted stock grant vested, and continue to vest, 1/48th per month beginning on
the one month anniversary of August&nbsp;1, 2017, subject to Dr.&nbsp;Rosenthal&#146;s continued status as a service provider on each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This restricted stock grant of our common stock was granted outside of the 2017 Plan, but is subject to the
terms of the 2017 Plan as if the grant was made under the 2017 Plan (except with respect to the forfeiture of unvested shares). The applicable grant listed above was converted from grants of restricted units of Alector LLC pursuant to the
Conversion. For more information regarding the Conversion, see Note&nbsp;1 of the notes to our consolidated financial statements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to the restricted stock grant vested, and continue to vest, 1/48th per month beginning on
the one month anniversary of August&nbsp;1, 2017, subject to Dr.&nbsp;Rosenthal&#146;s continued status as a service provider on each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option to purchase shares of our common stock was granted pursuant to our 2017 Plan.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to this option vested, and continue to vest, 1/48th per month beginning on the one month
anniversary of July&nbsp;2, 2018, subject to Dr.&nbsp;Rosenthal&#146;s continued status as a service provider on each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the total number of shares subject to the option grant
vest on the one year anniversary of November&nbsp;1, 2018, and an additional 1/48th of the total number of shares subject to the option grant continue to vest, on the same day of each month thereafter, subject to Dr.&nbsp;Rosenthal&#146;s continued
status as a service provider through each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the total number of shares subject to the restricted
stock grant vested on January&nbsp;26, 2018, and an additional 1/48th of the total number of shares subject to the restricted stock grant vested, and continued to vest, on the same day of each month thereafter, subject to Dr.&nbsp;King&#146;s
continued status as a service provider through each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to this option vested, and continue to vest, 1/48th per month beginning on the one month
anniversary of July&nbsp;2, 2018, subject to Dr.&nbsp;King&#146;s continued status as a service provider on each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the total number of shares subject to the option grant
vest on the one year anniversary of November&nbsp;1, 2018, and an additional 1/48th of the total number of shares subject to the option grant continue to vest, on the same day of each month thereafter, subject to Dr.&nbsp;King&#146;s continued
status as a service provider through each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the total number of shares subject to the restricted
stock grant vested on October&nbsp;3, 2017, and an additional 1/48th of the total number of shares subject to the restricted stock grant vested, and continued to vest, on the same day of each month thereafter, subject to Dr.&nbsp;Paul&#146;s
continued status as a service provider through each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to the restricted stock grant vested, and continue to vest, 1/48th per month beginning on
the one month anniversary of August&nbsp;1, 2017, subject to Dr.&nbsp;Paul&#146;s continued status as a service provider through each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to this option vested, and continue to vest, 1/48th per month beginning on the one month
anniversary of July&nbsp;2, 2018, subject to Dr.&nbsp;Paul&#146;s continued status as a service provider on each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the total number of shares subject to the option grant
vest on the one year anniversary of November&nbsp;1, 2018, and an additional 1/48th of the total number of shares subject to the option grant continue to vest, on the same day of each month thereafter, subject to Dr.&nbsp;Paul&#146;s continued
status as a service provider through each such vesting date. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements with Our Named Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;Arnon Rosenthal </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
entered into a confirmatory employment letter with Arnon Rosenthal, our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer. The confirmatory employment letter has no specific term and provides that Dr.&nbsp;Rosenthal is
an <FONT STYLE="white-space:nowrap">at-will</FONT> employee. Dr.&nbsp;Rosenthal&#146;s current annual base salary is $525,000 and he is eligible for an annual target cash incentive payment equal to 50% of his annual base salary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;Robert King </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered
into a confirmatory employment letter with Robert King, our Chief Development Officer. The confirmatory employment letter has no specific term and provides that Dr.&nbsp;King is an <FONT STYLE="white-space:nowrap">at-will</FONT> employee.
Dr.&nbsp;King&#146;s current annual base salary is $362,500 and he is eligible for an annual target cash incentive payment equal to 40% of his annual base salary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;Robert Paul </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered
into a confirmatory employment letter with Robert Paul, our Chief Medical Officer. The confirmatory employment letter has specific term and provides that Dr.&nbsp;Paul is an <FONT STYLE="white-space:nowrap">at-will</FONT> employee.
Dr.&nbsp;Paul&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
current annual base salary is $392,100 and he is eligible for an annual target cash incentive payment equal to 40% of his annual base salary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Change in Control and Severance Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a change in control and severance agreement for each of our named executive officers, which agreement would provide for certain
severance and change in control benefits as described below. Each change in control and severance agreement will supersede any prior agreement or arrangement the named executive officer may have had with us that provides for severance and/or change
in control payments or benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a named executive officer&#146;s employment is terminated outside the period beginning on the date of
a change in control and ending 12 months following that change in control (the Change in Control Period) either (1)&nbsp;by the Company or any of its subsidiaries (the Company Group) without &#147;cause&#148; (excluding by reason of death or
disability) or (2)&nbsp;by the named executive officer for &#147;good reason&#148; (as such terms are defined in the named executive officer&#146;s change in control and severance agreement), the named executive officer will receive the following
benefits if he or she timely signs and does not revoke a release of claims in our favor: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment equal to 9 months (or 12 months in the case of
Dr.&nbsp;Rosenthal) of the named executive officer&#146;s annual base salary as in effect immediately prior to such termination (or if such termination is due to a resignation for good reason based on a material reduction in base salary, then as in
effect immediately prior to the reduction); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of premiums for coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended
(COBRA), for the named executive officer and the named executive officer&#146;s eligible dependents, if any, for up to 9 months (or 12 months in the case of Dr.&nbsp;Rosenthal), or taxable monthly payments for the equivalent period in the event
payment of the COBRA premiums would violate or be subject to an excise tax under applicable law. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, within the Change
in Control Period, the named executive officer&#146;s employment is terminated either (1)&nbsp;by the Company (or any of its subsidiaries) without cause (excluding by reason of death or disability) or (2)&nbsp;by the named executive officer for good
reason, the named executive officer will receive the following benefits if the named executive officer timely signs and does not revoke a release of claims in our favor: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment equal to 12 months (or 18 months in the case of
Dr.&nbsp;Rosenthal) of the named executive officer&#146;s annual base salary as in effect immediately prior to such termination (or if such termination is due to a resignation for good reason based on a material reduction in base salary, then as in
effect immediately prior to the reduction) or if greater, at the level in effect immediately prior to the change in control); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment equal to 100% (or 150% in the case of
Dr.&nbsp;Rosenthal) of the named executive officer&#146;s target annual bonus as in effect for the fiscal year in which such termination occurs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of premiums for coverage under COBRA for the named executive officer and the named executive
officer&#146;s eligible dependents, if any, for up to 12 months (or 18 months in the case of Dr.&nbsp;Rosenthal), or taxable monthly payments for the equivalent period in the event payment of the COBRA premiums would violate or be subject to an
excise tax under applicable law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">100% accelerated vesting and exercisability of all outstanding equity awards and, in the case of an equity award
with performance-based vesting, unless otherwise specified all performance goals and other vesting criteria generally will be deemed achieved at 100% of target levels. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the amounts provided for under these change in control and severance agreements or otherwise payable to our named executive officers
would constitute &#147;parachute payments&#148; within the meaning of Section&nbsp;280G of the Internal Revenue Code and could be subject to the related excise tax, the named executive officer would be entitled to receive either full payment of
benefits under his or her change in control or severance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement or such lesser amount which would result in no portion of the benefits being subject to the excise tax, whichever results in the greater amount of
<FONT STYLE="white-space:nowrap">after-tax</FONT> benefits to the named executive officer. The change in control and severance agreements do not require us to provide any tax <FONT STYLE="white-space:nowrap">gross-up</FONT> payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under each named executive officer&#146;s change in control and severance agreement, the following definitions are used: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Cause&#148; means: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the named executive officer&#146;s dishonest statements or acts with respect to any Company Group member, or any
current or prospective customers, suppliers vendors or other third parties with which such entity does business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the named executive officer&#146;s commission of (1)&nbsp;a felony or (2)&nbsp;any misdemeanor involving moral
turpitude, deceit, dishonesty or fraud; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the named executive officer&#146;s failure to perform his assigned duties and responsibilities to the reasonable
satisfaction of the applicable Company Group member, which failure continues, in the reasonable judgment of the Company Group member, after written notice given to him by the Company Group member; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the named executive officer&#146;s gross negligence, willful misconduct or insubordination with respect to any
Company Group member; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the named executive officer&#146;s material violation of any provision of any agreement(s) between him and any
Company Group member relating to <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and/or assignment of inventions (such as the <FONT
STYLE="white-space:nowrap">at-will</FONT> employment, confidential information, invention assignment, and arbitration agreement with the named executive officer or any written Company Group policy or procedure to which the named executive officer is
subject). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Good Reason&#148; means that the named executive officer resigns from a Company Group member if one of the
following events occurs without his consent: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a material reduction of his duties, authorities, or responsibilities relative to his duties, authorities, or
responsibilities in effect immediately prior to the reduction, provided that (1)&nbsp;any change that results in Dr.&nbsp;Rosenthal not serving as the chief executive officer of, or reporting directly to the board of directors of, the parent
corporation in a group of controlled corporations including the Company or its assets (Parent) following a change in control (other than as the result of his voluntary resignation not at the request of the successor or the Parent) will be deemed to
constitute a material reduction in his duties, authorities, and responsibilities constituting &#147;Good Reason&#148; and (2)&nbsp;that continued employment of a named executive officer (other than Dr.&nbsp;Rosenthal) following a change in control
with substantially the same duties, authorities, or responsibilities with respect to the Company Group&#146;s business and operations will not constitute &#147;Good Reason&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a material diminution in his base salary except for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions similarly affecting all or substantially all similarly situated employees of the applicable Company Group member, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a change of more than 50 miles in the geographic location at which he provides services to the applicable Company
Group member. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For &#147;Good Reason&#148; to be established, the named executive officer must provide written notice to
our Chief Executive Officer (or our board of directors in the case of Dr.&nbsp;Rosenthal) and the applicable Company Group member within 90 days immediately following such alleged events, the applicable Company Group member must fail to materially
remedy such event within 30 days after receipt of such notice, and the named executive officer&#146;s resignation must be effective not later than 90 days from the occurrence of the alleged triggering event, and must not be effective until after the
expiration of the notice and cure periods described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Incentive Compensation Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted our Executive Incentive Compensation Plan (the Incentive Compensation Plan). The Incentive Compensation Plan
will be administered by a committee appointed by our board of directors. Unless and until our board of directors determines otherwise, our compensation committee will be the administrator of the Incentive Compensation Plan. The Incentive
Compensation Plan allows our compensation committee to provide cash incentive awards to selected employees, including our named executive officers, determined by our compensation committee, based upon performance goals established by our
compensation committee. Our compensation committee, in its sole discretion, will establish a target award for each participant under the Incentive Compensation Plan, which may be expressed as a percentage of the participant&#146;s average annual
base salary for the applicable performance period, a fixed dollar amount, or such other amount or based on such other formula as our compensation committee determines to be appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Incentive Compensation Plan, our compensation committee will determine the performance goals applicable to awards, which goals may
include, without limitation: attainment of research and development milestones, bookings, business divestitures and acquisitions, cash flow, cash position, contract awards or backlog, customer renewals, customer retention rates from an acquired
company, subsidiary, business unit or division, earnings (which may include earnings before interest and taxes, earnings before taxes, and net taxes), earnings per share, expenses, gross margin, growth in stockholder value relative to the moving
average of the S&amp;P 500 Index or another index, internal rate of return, market share, net income, net profit, net sales, new product development, new product invention or innovation, number of customers, operating cash flow, operating expenses,
operating income, operating margin, overhead or other expense reduction, product defect measures, product release timelines, productivity, profit, retained earnings, return on assets, return on capital, return on equity, return on investment, return
on sales, revenue, revenue growth, sales results, sales growth, stock price, time to market, total stockholder return, working capital, and individual objectives such as peer reviews or other subjective or objective criteria. As determined by our
compensation committee, the performance goals may be based on GAAP or <FONT STYLE="white-space:nowrap">non-GAAP</FONT> results and any actual results may be adjusted by our compensation committee for <FONT STYLE="white-space:nowrap">one-time</FONT>
items or unbudgeted or unexpected items and/or payments of actual awards under the Incentive Compensation Plan when determining whether the performance goals have been met. The goals may be on the basis of any factors our compensation committee
determines relevant, and may be on an individual, divisional, business unit, segment or company-wide basis. Any criteria used may be measured on such basis as our compensation committee determines. The performance goals may differ from participant
to participant and from award to award. Our compensation committee also may determine that a target award or a portion thereof will not have a performance goal associated with it but instead will be granted (if at all) in the compensation
committee&#146;s sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee may, in its sole discretion and at any time, increase, reduce or eliminate a
participant&#146;s actual award, and/or increase, reduce or eliminate the amount allocated to the bonus pool. The actual award may be below, at or above a participant&#146;s target award, in our compensation committee&#146;s discretion. Our
compensation committee may determine the amount of any increase, reduction or elimination on the basis of such factors as it deems relevant, and it will not be required to establish any allocation or weighting with respect to the factors it
considers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual awards will generally be paid in cash (or its equivalent) in a single lump sum only after they are earned and approved
by our compensation committee. Our compensation committee has the right, in its sole discretion, to settle an actual award with a grant of an equity award under our then-current equity compensation plan, which equity award may have such terms and
conditions, including vesting, as our compensation committee determines in its sole discretion. Unless otherwise determined by our compensation committee, to earn an actual award, a participant must be employed by us (or an affiliate of us, as
applicable) through the date the actual award is paid. Payment of bonuses occurs as soon as administratively practicable after the end of the applicable performance period, but no later than the dates set forth in the Incentive Compensation Plan.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority to amend or terminate the Incentive Compensation
Plan provided such action does not alter or impair the existing rights of any participant with respect to any earned actual award without the participant&#146;s consent. The Incentive Compensation Plan will remain in effect until terminated in
accordance with the terms of the Incentive Compensation Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefit and Stock Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
2019 Plan provides for the grant of incentive stock options, within the meaning of Section&nbsp;422 of the Code, to our employees and any of our parent and subsidiary corporations&#146; employees, and for the grant of nonstatutory stock options,
restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to our employees, directors, and consultants and our subsidiary corporations&#146; employees and consultants. As of September&nbsp;30,
2019, options to purchase 1,095,600 shares of our common stock remained outstanding under our 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. A
total of 7,688,156 shares of our common stock were initially reserved for issuance pursuant to our 2019 Plan. In addition, the shares reserved for issuance under our 2019 Plan will also include (1)&nbsp;those shares reserved but unissued under our
2017 Plan as of the date of stockholder approval of the 2019 Plan and (2)&nbsp;shares of our common stock subject to or issued pursuant to awards granted under our 2017 Plan that, after the date our stockholders approved the 2019 Plan, expire or
otherwise terminate without having been exercised in full or are forfeited to or repurchased by us (provided that the maximum number of shares that may be added to the 2019 Plan pursuant to (1)&nbsp;and (2) is 5,184,750 shares). The number of shares
available for issuance under our 2019 Plan will also include an annual increase on the first day of each fiscal year beginning with our 2020 fiscal year, equal to the least of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7,096,760 shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5% of the outstanding shares of our common stock as of the last day of the immediately preceding fiscal year; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such other amount as our board of directors may determine. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant to an exchange program, or, with
respect to restricted stock, restricted stock units, performance units or performance shares, is forfeited to or repurchased by us due to failure to vest, the unpurchased shares (or for awards other than stock options or stock appreciation rights,
the forfeited or repurchased shares) will become available for future grant or sale under the 2019 Plan (unless the 2019 Plan has terminated). With respect to stock appreciation rights, only the net shares actually issued will cease to be available
under the 2019 Plan and all remaining shares under stock appreciation rights will remain available for future grant or sale under the 2019 Plan (unless the 2019 Plan has terminated). Shares that have actually been issued under the 2019 Plan will not
be returned to the 2019 Plan except if shares issued pursuant to awards of restricted stock, restricted stock units, performance shares, or performance units are repurchased by or forfeited to us, such shares will become available for future grant
under the 2019 Plan. Shares used to pay the exercise price of an award or satisfy the tax withholding obligations related to an award will become available for future grant or sale under the 2019 Plan. To the extent an award is paid out in cash
rather than shares, such cash payment will not result in a reduction in the number of shares available for issuance under the 2019 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. Our board of directors or one or more committees appointed by our board of directors will administer our 2019
Plan. The compensation committee of our board of directors will administer our 2019 Plan. In addition, if we determine it is desirable to qualify transactions under our 2019 Plan as exempt under
<FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> of the Exchange Act, such transactions will be structured to satisfy the requirements for exemption under <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3.</FONT> Subject to the provisions of
our 2019 Plan, the administrator has the power to administer our 2019 Plan and make all determinations deemed necessary or advisable for administering the 2019 Plan, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
but not limited to, the power to determine the fair market value of our common stock, select the service providers to whom awards may be granted, determine the number of shares covered by each
award, approve forms of award agreements for use under the 2019 Plan, determine the terms and conditions of awards (including, but not limited to, the exercise price, the time or times at which awards may be exercised, any vesting acceleration or
waiver or forfeiture restrictions and any restriction or limitation regarding any award or the shares relating thereto), construe and interpret the terms of our 2019 Plan and awards granted under it, prescribe, amend and rescind rules relating to
our 2019 Plan, including creating <FONT STYLE="white-space:nowrap">sub-plans,</FONT> modify, or amend each award, including but not limited to the discretionary authority to extend the post-termination exercisability period of awards (except no
option or stock appreciation right will be extended past its original maximum term), and allow a participant to defer the receipt of payment of cash or the delivery of shares that would otherwise be due to such participant under an award. The
administrator also has the authority to allow participants the opportunity to transfer outstanding awards to a financial institution or other person or entity selected by the administrator and to institute an exchange program by which outstanding
awards may be surrendered or cancelled in exchange for awards of the same type, which may have a higher or lower exercise price and/or different terms, awards of a different type, and/or cash or by which the exercise price of an outstanding award is
increased or reduced. The administrator&#146;s decisions, interpretations, and other actions are final and binding on all participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options</I>. Stock options may be granted under our 2019 Plan. The exercise price of options granted under our 2019 Plan must at
least be equal to the fair market value of our common stock on the date of grant. The term of an option may not exceed ten years. With respect to any participant who owns more than 10% of the voting power of all classes of our (or any parent or
subsidiary of ours) outstanding stock, the term of an incentive stock option granted to such participant must not exceed five years and the exercise price must equal at least 110% of the fair market value on the grant date. The administrator will
determine the methods of payment of the exercise price of an option, which may include cash, shares or other property acceptable to the administrator, as well as other types of consideration permitted by applicable law. After the termination of
service of an employee, director, or consultant, he or she may exercise his or her option for the period of time stated in his or her option agreement. In the absence of a specified time in an award agreement, if termination is due to death or
disability, the option will remain exercisable for 12 months following the termination of service. In all other cases, in the absence of a specified time in an award agreement, the option will remain exercisable for three months following the
termination of service. An option, however, may not be exercised later than the expiration of its term. Subject to the provisions of our 2019 Plan, the administrator determines the other terms of options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>. Stock appreciation rights may be granted under our 2019 Plan. Stock appreciation rights allow the recipient
to receive the appreciation in the fair market value of our common stock between the exercise date and the date of grant. Stock appreciation rights may not have a term exceeding ten years. After the termination of service of an employee, director,
or consultant, he or she may exercise his or her stock appreciation right for the period of time stated in his or her stock appreciation rights agreement. In the absence of a specified time in an award agreement, if termination is due to death or
disability, the stock appreciation rights will remain exercisable for 12 months following the termination of service. In all other cases, in the absence of a specified time in an award agreement, the stock appreciation rights will remain exercisable
for three months following the termination of service. However, in no event may a stock appreciation right be exercised later than the expiration of its term. Subject to the provisions of our 2019 Plan, the administrator determines the other terms
of stock appreciation rights, including when such rights become exercisable and whether to pay any increased appreciation in cash or with shares of our common stock, or a combination thereof, except that the per share exercise price for the shares
to be issued pursuant to the exercise of a stock appreciation right will be no less than 100% of the fair market value per share on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock</I>. Restricted stock may be granted under our 2019 Plan. Restricted stock awards are grants of shares of our common stock
that vest in accordance with terms and conditions established by the administrator. The administrator will determine the number of shares of restricted stock granted to any employee, director, or consultant and, subject to the provisions of our 2019
Plan, will determine the terms and conditions of such awards. The administrator may impose whatever vesting conditions it determines to be appropriate (for example, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the administrator may set restrictions based on the achievement of specific performance goals or continued service to us), except the administrator, in its sole discretion, may accelerate the
time at which any restrictions will lapse or be removed. Recipients of restricted stock awards generally will have voting and dividend rights with respect to such shares upon grant without regard to vesting, unless the administrator provides
otherwise. Shares of restricted stock that do not vest are subject to our right of repurchase or forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units.
</I>Restricted stock units may be granted under our 2019 Plan. Restricted stock units are bookkeeping entries representing an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2019 Plan, the
administrator determines the terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. The administrator may set vesting criteria based upon the achievement of company-wide, divisional, business unit or
individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws or any other basis determined by the administrator in its discretion. The administrator, in its sole discretion, may pay
earned restricted stock units in the form of cash, in shares or in some combination thereof. In addition, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Performance Units and Performance Shares</I>. Performance units and performance shares may be granted under our 2019 Plan. Performance
units and performance shares are awards that will result in a payment to a participant only if performance objectives established by the administrator are achieved or the awards otherwise vest. The administrator will establish performance objectives
or other vesting criteria in its discretion, which, depending on the extent to which they are met, will determine the number or the value of performance units and performance shares to be paid out to participants. The administrator may set
performance objectives based on the achievement of company-wide, divisional, business unit, or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws or any other basis
determined by the administrator in its discretion. After the grant of a performance unit or performance share, the administrator, in its sole discretion, may reduce or waive any performance objectives or other vesting provisions for such performance
units or performance shares. Performance units will have an initial value established by the administrator on or prior to the grant date. Performance shares will have an initial value equal to the fair market value of our common stock on the grant
date. The administrator, in its sole discretion, may pay out earned performance units or performance shares in cash, shares, or in some combination thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Outside Directors</I>. All outside <FONT STYLE="white-space:nowrap">(non-employee)</FONT> directors will be eligible to receive all types
of awards (except for incentive stock options) under our 2019 Plan.&nbsp;To provide a maximum limit on the&nbsp;cash compensation and equity awards that can be made to our outside directors, our 2019 Plan provides that in any given fiscal year, an
outside director will not be granted&nbsp;cash compensation and equity awards with an aggregate value greater than $750,000 (increased to $1,000,000 in the fiscal year of his or her initial service as an outside director), with the value of each
equity award based on its grant date fair value as determined according to GAAP for purposes of this limit. Any cash compensation paid or awards granted to an individual&nbsp;for his or her&nbsp;services as&nbsp;an employee&nbsp;or
consultant&nbsp;(other than as an outside director) will not count toward this limit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Awards</I>. Unless the administrator provides otherwise, our 2019 Plan
generally does not allow for the transfer of awards and only the recipient of an award may exercise an award during his or her lifetime. If the administrator makes an award transferrable, such award will contain such additional terms and conditions
as the administrator deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments</I>. In the event of certain changes in our capitalization, to prevent
diminution or enlargement of the benefits or potential benefits available under our 2019 Plan, the administrator will adjust the number and class of shares that may be delivered under our 2019 Plan and/or the number, class, and price of shares
covered by each outstanding award and the numerical share limits set forth in our 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dissolution or Liquidation</I>. In the
event of our proposed liquidation or dissolution, the administrator will notify participants as soon as practicable and, to the extent not exercised, all awards will terminate immediately prior to the consummation of such proposed transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Merger or Change in Control</I>. Our 2019 Plan provides that in the event of a merger or
change in control, as defined under our 2019 Plan, each outstanding award will be treated as the administrator determines, without a participant&#146;s consent. The administrator is not required to treat all awards, all awards held by a participant
or all awards of the same type similarly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a successor corporation does not assume or substitute for any outstanding award,
then&nbsp;the participant will fully vest&nbsp;in and have the right to exercise all of his or her outstanding options and stock appreciation rights, all restrictions on&nbsp;restricted stock&nbsp;and&nbsp;restricted stock&nbsp;units will lapse, and
for awards with performance-based vesting, unless specifically provided for otherwise under the applicable award agreement or other agreement&nbsp;or policy applicable to the participant, all performance goals or other vesting criteria&nbsp;will be
deemed achieved at 100% of target levels and&nbsp;all other terms and conditions met. If an option or stock appreciation right is not assumed or substituted&nbsp;in the event of a change in control, the administrator will notify the participant in
writing or electronically that such option or stock appreciation right will be exercisable for a period of time determined by the administrator in its sole discretion and the option or stock appreciation right will terminate upon the expiration of
such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For awards granted to an outside director, in the event of a change in control,&nbsp;the outside director will fully vest in
and have the right to exercise all of&nbsp;his or her&nbsp;outstanding options and stock appreciation rights, all restrictions on restricted stock and restricted stock units will lapse and, for awards with performance-based vesting, unless
specifically provided for otherwise under the applicable award agreement or other agreement or policy&nbsp;applicable to&nbsp;the participant, all performance goals or other vesting&nbsp;criteria will be deemed achieved at 100% of target levels and
all other terms and conditions met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clawback</I>. Awards will be subject to any clawback policy of ours, and the administrator also
may specify in an award agreement that the participant&#146;s rights, payments, and/or benefits with respect to an&nbsp;award will&nbsp;be subject to reduction, cancellation, forfeiture, and/or recoupment upon the occurrence of certain specified
events. Our board of directors may require a participant to forfeit, return, or reimburse us all or a portion of the award and/or shares issued under the award, any amounts paid under the award, and any payments or proceeds paid or provided upon
disposition of the shares issued under the award in order to comply with such clawback policy or applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment;
Termination</I>. The administrator has the authority to amend, alter, suspend, or terminate our 2019 Plan, provided such action does not materially impair the rights of any participant. Our 2019 Plan automatically will terminate in 2029, unless we
terminate it sooner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Stock Option and Grant Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2017 Plan was adopted by our board of directors and approved by our stockholders approved in 2017 and was most recently amended in November
2018. Our 2017 Plan permitted the grant of incentive stock options, within the meaning of Section&nbsp;422 of the Code, to our employees and our subsidiary corporations&#146; employees, and the grant of nonstatutory stock options, restricted stock
awards, unrestricted stock awards, and restricted stock units to officers, employees, directors, consultants, and key employees of ours and any of our subsidiary corporations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. Our 2017 Plan was terminated in connection with our initial public offering, and accordingly, no new awards will be
granted under the 2017 Plan. Our 2017 Plan continues to govern outstanding awards granted thereunder. As of September&nbsp;30, 2019, options to purchase 4,822,524 shares of our common stock and 1,191,750 shares of unvested restricted stock remained
outstanding under our 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. Our board of directors or a committee appointed by our board of directors
administers our 2017 Plan. Subject to the provisions of our 2017 Plan, the administrator has the powers and discretion necessary or appropriate to administer the 2017 Plan and to control its operation. The administrator&#146;s powers
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include the power to modify the terms and conditions of any award, not inconsistent with the terms of the 2017 Plan including the number of shares to be covered, price, exercise price, conversion
ratio or other price relating thereto, any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any award. The administrator may at any time adopt, alter and repeal such rules, guidelines and
practices for administration of the 2017 Plan and for its own acts and proceedings as it deems advisable; interpret the terms and provisions of the 2017 Plan and any award (including award agreements); make all determinations it deems advisable for
the administration of the 2017 Plan; and decide all disputes arising in connection with the 2017 Plan. In addition, the administrator may modify the terms and procedures relating to the 2017 Plan and establish
<FONT STYLE="white-space:nowrap">sub-plans</FONT> for the purpose of satisfying applicable foreign laws. The administrator also has the authority to allow participants the opportunity to transfer outstanding awards to a financial institution or
other person or entity selected by the administrator and to institute an exchange program by which outstanding awards may be surrendered or cancelled in exchange for awards of the same type, which may have a higher or lower exercise price and/or
different terms, awards of a different type and/or cash, or by which the exercise price of an outstanding award is increased or reduced. The administrator&#146;s decisions and interpretations are final and binding on all persons, including us, all
participants, and any other persons holding awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Options</I>. Stock options were granted under our 2017 Plan. The exercise price of
options granted under our 2017 Plan must have been at least equal to the fair market value of our common stock on the date of grant. The term of an incentive stock option could not exceed 10 years, except that with respect to any employee who owned
more than 10% of the voting power of all classes of our (or any subsidiary of ours) outstanding stock, the term could not exceed five years, and the exercise price must have been equal to at least 110% of the fair market value on the grant date.
Subject to the provisions of our 2017 Plan, the administrator will determine the methods of payment of the exercise price of an option. After termination of the participant&#146;s service, a participant may exercise any portion of his or her vested
or exercisable option for the period of time as determined by the administrator and specified in the applicable option agreement. If termination is due to death or disability, the option generally will remain exercisable for at least twelve months.
In all other cases, the option will generally remain exercisable for at least three months. However, an option agreement may provide that the option will terminate immediately upon the termination of the participant&#146;s service for cause (as
defined in the 2017 Plan), and in no event may an option be exercised later than the expiration of its term. Subject to the provisions of our 2017 Plan, the administrator determines the other terms of options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards</I>. Restricted stock awards were granted under our 2017 Plan. Restricted stock awards are grants of shares of our
common stock that vest in accordance with terms and conditions established by the administrator. The administrator determined the number of shares of restricted stock granted to any employee, director, or consultant and, subject to the provisions of
our 2017 Plan, determined the terms and conditions of such awards. The administrator could impose whatever conditions for lapse of the restriction on the shares it determined to be appropriate (for example, the administrator could set restrictions
based on the achievement of <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals or continued service to us), except the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be
removed. Recipients of restricted stock awards generally have voting and dividend rights with respect to such shares upon grant without regard to the restriction, unless the administrator provided otherwise. Shares of restricted stock as to which
the restrictions have not lapsed are subject to our right of repurchase or forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Awards</I>. Unless the administrator provides otherwise, our 2017 Plan
generally does not allow for the transfer of awards other than by will or the laws of descent and distribution, and only the recipient of an award may exercise an award during his or her lifetime. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments</I>. In the event of certain changes in our capitalization, the administrator will make an appropriate and proportional
adjustment to the number of shares that may be delivered under our 2017 Plan and the number, kind, and price of shares covered by each outstanding award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sale Events</I>. Our 2017 Plan provides that in the event of a sale event, as defined under the 2017 Plan, (1)&nbsp;the 2017 Plan and all
outstanding options will terminate upon the effective time of the sale event, and (2)&nbsp;all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unvested restricted stock and restricted stock unit awards will be forfeited prior to the effective time of the sale event, in each case unless such awards are assumed or continued by the
successor entity, or new stock awards of the successor entity or parent thereof are substituted therefore. In the event of termination of the 2017 Plan and all outstanding options pursuant to a sale event, each optionholder will be permitted, within
a period of time prior to the sale event as specified by the administrator, to exercise all such options which are then exercisable or will become exercisable as of the effective time provided that the exercise of options not exercisable prior to
the sale event shall be subject to the consummation of the sale event. In the event of forfeiture of restricted stock pursuant to a sale event, such restricted stock will be purchased from the holder at a price per share equal to the original per
share purchase price paid by the holder. In the event of a sale event, the company will have the right, but not the obligation, to make a cash payment to a holder of an award, without the consent of the holder, in exchange for the cancellation of
such award, in an amount equal to (1)&nbsp;the number of shares subject to the award multiplied by the value as determined by the administrator of the consideration payable per share of our common stock under the sale event, minus (2)&nbsp;the
aggregate exercise price for such shares (if any). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment; Termination</I>. Our board of directors has the authority to amend or
alter the 2017 Plan, provided such action will not impair the existing rights of any participant without the consent of the participant. As noted above, our 2017 Plan has been terminated and no further awards will be granted thereunder. All
outstanding awards will continue to be governed by their existing terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted, and our stockholders have approved, our 2019 ESPP. We believe that allowing our employees to participate in
our 2019 ESPP provides them with a further incentive towards promoting our success and accomplishing our corporate goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized
Shares</I>. A total of 1,478,492 shares of our common stock are available for sale under our 2019 ESPP. The number of shares of our common stock that will be available for sale under our 2019 ESPP also includes an annual increase on the first day of
each fiscal year beginning with our 2020 fiscal year, equal to the least of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">591,397 shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the outstanding shares of our common stock as of the last day of the immediately preceding fiscal year; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such other amount as the administrator may determine. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>2019 ESPP Administration</I>. The compensation committee of our board of directors administers our 2019 ESPP and has exclusive
discretionary authority to construe, interpret, and apply the terms of the 2019 ESPP, delegate ministerial duties to any of our employees, designate separate offerings under the 2019 ESPP, designate our subsidiaries and affiliates as participating
in the 2019 ESPP, determine eligibility, adjudicate all disputed claims filed under the 2019 ESPP, and establish procedures that it deems necessary for the administration of the 2019 ESPP, including, but not limited to, adopting such procedures <FONT
STYLE="white-space:nowrap">and&nbsp;sub-plans&nbsp;as</FONT> are necessary or appropriate to permit participation in the 2019 ESPP by employees who are foreign nationals or employed outside the United States. The administrator&#146;s findings,
decisions and determinations are final and binding on all participants to the full extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>.
Generally, all of our employees will be eligible to participate if they are customarily employed by us, or any participating subsidiary or affiliate, for at least 20 hours per week and more than five months in any calendar year. The administrator,
in its discretion, may, prior to an enrollment date, for all options to be granted on such enrollment date in an offering, determine that an employee who (i)&nbsp;has not completed at least two years of service (or a lesser period of time determined
by the administrator) since his or her last hire date, (ii) customarily works not more than 20 hours per week (or a lesser period of time determined by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
administrator), (iii) customarily works not more than five months per calendar year (or a lesser period of time determined by the administrator), (iv) is a highly compensated employee within the
meaning of Section&nbsp;414(q) of the Code, or (v)&nbsp;is a highly compensated employee within the meaning of Section&nbsp;414(q) of the Code with compensation above a certain level or is an officer or subject to disclosure requirements under
Section&nbsp;16(a) of the Exchange Act, is or is not eligible to participate in such offering period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, an employee may not be
granted rights to purchase shares of our common stock under our 2019 ESPP if such employee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after the grant would own capital stock and/or hold outstanding options to purchase such stock
possessing 5% or more of the total combined voting power or value of all classes of capital stock of ours or of any parent or subsidiary of ours; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holds rights to purchase shares of our common stock under all employee stock purchase plans of ours or any parent
or subsidiary of ours that accrue at a rate that exceeds $25,000 worth of shares of our common stock for each calendar year in which such rights are outstanding at any time. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Offering Periods</I>. Our 2019 ESPP includes a component that allows us to make offerings intended to qualify under Section&nbsp;423 of the
Code and a component that allows us to make offerings not intended to qualify under Section&nbsp;423 of the Code to designated companies, as described in our 2019 ESPP. Our 2019 ESPP provides for consecutive,
<FONT STYLE="white-space:nowrap">overlapping&nbsp;6-month&nbsp;offering</FONT> periods. The offering periods will be scheduled to start on the first trading day on or after June&nbsp;1 and December&nbsp;1 of each year, except the first offering
period commenced on February&nbsp;7, 2019 and will end on the first trading day on or before December&nbsp;1, 2019, and the second offering period will commence on the last trading day on or after December&nbsp;1, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Contributions</I>. Our 2019 ESPP permits participants to purchase shares of our common stock through contributions (in the form of payroll
deductions or otherwise to the extent permitted by the administrator) of up to 15% of their eligible compensation, which includes a participant&#146;s base straight time gross earnings but excludes payments for incentive compensation, bonuses,
payments for overtime and shift premium, equity compensation income and other similar compensation. Unless otherwise determined by the administrator, a participant may make a <FONT STYLE="white-space:nowrap">one-time</FONT> decrease (but not
increase) to the rate of his or her contributions to 0% during an offering period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exercise of Purchase Right</I>. Amounts contributed
and accumulated by the participant will be used to purchase shares of our common stock at the end of each offering. A participant may purchase a maximum of 2,000 shares of our common stock during an offering period. The purchase price of the shares
will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the exercise date. Participants may end their participation at any time during an offering period and will be paid their
accrued contributions that have not yet been used to purchase shares of our common stock. Participation ends automatically upon termination of employment with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Transferability</FONT></I>. A participant may not transfer contributions credited to his or her
account nor any rights granted under our 2019 ESPP other than by will, the laws of descent and distribution or as otherwise provided under our 2019 ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Merger or Change in Control</I>. Our 2019 ESPP provides that in the event of a merger or change in control, as defined under our 2019 ESPP,
a successor corporation (or a parent or subsidiary of the successor corporation) will assume or substitute each outstanding purchase right. If the successor corporation refuses to assume or substitute for the outstanding purchase right, the offering
period with respect to which the purchase right relates will be shortened, and a new exercise date will be set that will be before the date of the proposed merger or change in control. The administrator will notify each participant that the exercise
date has been changed and that the participant&#146;s option will be exercised automatically on the new exercise date unless prior to such date the participant has withdrawn from the offering period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment; Termination</I>. The administrator has the authority to amend, suspend or
terminate our 2019 ESPP. Our 2019 ESPP automatically will terminate in 2039, unless we terminate it sooner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>401(k) Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a 401(k) retirement savings plan for the benefit of our employees, including our named executive officers, who satisfy certain
eligibility requirements. Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or
<FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan authorizes employer safe harbor contributions. The 401(k) plan is intended to qualify under Sections&nbsp;401(a) and 501(a) of
the Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan, <FONT STYLE="white-space:nowrap">pre-tax</FONT> contributions to the 401(k) plan and earnings on those <FONT STYLE="white-space:nowrap">pre-tax</FONT>
contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our directors and executive officers have adopted, and may adopt, written plans, known as Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they have contracted or will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a
broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, without further direction from them. The director or executive officer may amend a Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> plan in some circumstances and may terminate a plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material nonpublic information subject to compliance with the terms of our insider trading policy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and
officers, and may indemnify our employees and other agents, to the fullest extent permitted by Delaware law. Delaware law prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or to our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payment of dividends or unlawful stock repurchases or redemptions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the
liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated certificate of incorporation does not eliminate a director&#146;s duty of care and, in appropriate
circumstances, equitable remedies, such as injunctive or other forms of <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, remain available under Delaware law. This provision also does not affect a director&#146;s responsibilities under
any other laws, such as the federal securities laws or other state or federal laws. Under our amended and restated bylaws, we will also be empowered to purchase insurance on behalf of any person whom we are required or permitted to indemnify. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the indemnification required in our amended and restated certificate of incorporation and amended and restated bylaws, we
intend to enter into an indemnification agreement with each member of our board of directors and each of our officers prior to the completion of the offering. These agreements provide for the indemnification of our directors and officers for certain
expenses and liabilities incurred in connection with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any action, suit, proceeding, or alternative dispute resolution mechanism or hearing, inquiry, or investigation that may lead to the foregoing, to which they are a party, or are threatened to be
made a party, by reason of the fact that they are or were a director, officer, employee, agent or fiduciary of our company, or any of our subsidiaries, by reason of any action or inaction by them while serving as an officer, director, agent or
fiduciary, or by reason of the fact that they were serving at our request as a director, officer, employee, agent, or fiduciary of another entity. In the case of an action or proceeding by or in the right of our company or any of our subsidiaries,
no indemnification will be provided for any claim where a court determines that the indemnified party is prohibited from receiving indemnification. We believe that these charter and bylaw provisions and indemnification agreements are necessary to
attract and retain qualified persons as directors and officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended
and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation
against directors and officers, even though an action, if successful, might benefit us and our stockholders. Moreover, a stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and
officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or
otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. There is no pending litigation or proceeding naming any of our
directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_13"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the beneficial ownership of our common stock as of November&nbsp;1, 2019 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC, and thus it represents sole or shared voting or investment
power with respect to our securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to
community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections&nbsp;13(d) and 13(g) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based our calculation of the percentage of beneficial ownership prior to this offering on 68,923,730 shares of our common stock
outstanding as of November&nbsp;1, 2019. We have based our calculation of the percentage of beneficial ownership after this offering on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our
common stock outstanding immediately after the completion of this offering, assuming no exercise by the underwriters of their option to purchase additional shares. We have deemed shares of our common stock subject to stock options that are currently
exercisable or exercisable within 60&nbsp;days of November&nbsp;1, 2019, to be outstanding and to be beneficially owned by the person holding the stock option for the purpose of computing the percentage ownership of that person. We did not deem
these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated,
the address of each beneficial owner listed in the table below is c/o Alector, Inc., 131&nbsp;Oyster Point Boulevard, Suite&nbsp;600, South San Francisco, California 94080. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;Prior&nbsp;to&nbsp;this&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;After&nbsp;this&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,545,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with OrbiMed Private
Investments<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,532,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Polaris Venture
Partners<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,858,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arnon Rosenthal, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,317,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert King, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Paul, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tillman Gerngross, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,620,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis J. Lavigne, Jr.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terry McGuire<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Scheller, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wehner<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Yaffe<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (11&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,083,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information contained in a Schedule 13G filed on February&nbsp;14, 2019. Consists of 3,545,719 shares
held of record by MRL Ventures Fund LLC (MRL). All shares are held directly by MRL, which is a subsidiary of Merck Sharp&nbsp;&amp; Dohme Corp. The address for MRL is 320 Bent Street, Cambridge, Massachusetts 02141. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information contained in a Schedule 13D/A filed on August&nbsp;12, 2019. Consists of (a) 9,272,225
shares held of record by OrbiMed Private Investments <FONT STYLE="white-space:nowrap">IV-AL,</FONT> LP (OrbiMed <FONT STYLE="white-space:nowrap">IV-AL),</FONT> (b) 2,968,604 shares held of record by OrbiMed Private Investments <FONT
STYLE="white-space:nowrap">IV-AL</FONT> (Feeder), LP (OrbiMed <FONT STYLE="white-space:nowrap">IV-AL</FONT> (Feeder)), (c) 203,200 shares held of record by OrbiMed Partners Master Fund Limited (OPM) and (d) 88,300 shares held of record by The
Biotech Growth Trust PLC (BIOG). OrbiMed Capital GP IV LLC (OrbiMed GP), is the general partner of OrbiMed <FONT STYLE="white-space:nowrap">IV-AL</FONT> and OrbiMed <FONT STYLE="white-space:nowrap">IV-AL</FONT> (Feeder). OrbiMed Advisors LLC, or
OrbiMed Advisors, is the managing member of OrbiMed GP. Dr.&nbsp;Carl Gordon is a managing partner at OrbiMed Advisors and is also a former member of our board of directors. OrbiMed Advisors exercises investment and voting power through a management
committee comprised of Dr.&nbsp;Gordon, Sven H. Borho, and Jonathan T. Silverstein. Each of OrbiMed GP, OrbiMed Advisors, Dr.&nbsp;Gordon, Sven H. Borho, and Jonathan T. Silverstein disclaims beneficial ownership of the shares held by OrbiMed <FONT
STYLE="white-space:nowrap">IV-AL</FONT> and OrbiMed <FONT STYLE="white-space:nowrap">IV-AL</FONT> (Feeder), except to the extent of its or his pecuniary interest therein, if any. OrbiMed Capital is the sole investment advisor of OPM and BIOG.
OrbiMed Capital exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of Orbimed Capital, Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein disclaims
beneficial ownership of the shares held by OPM or BIOG, except to the extent of its or his pecuniary interest therein, if any. The address of the individuals and entities listed above is 601 Lexington Avenue, 54th Floor, New York NY 10022.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 9,350,877 shares held of record by Polaris Venture Partners VI (AIV), L.P. (PVP VI AIV), (b)
709,917 shares held of record by Polaris Venture Partners Founders&#146; Fund VI, L.P. (PVPFF VI), (c) 498,468 shares held of record by Polaris Venture Partners VI, L.P. (PVP VI), and (d) 2,298,932 shares held of record by PVP VI (AIV) Feeder Corp.
Holding Partnership, L.P. (PVP VI Feeder, and together with PVP VI AIV, PVPFF VI, and PVP VI, the Funds). Polaris Venture Management Co. VI, L.L.C. (PVM) is the general partner of the Funds and may be deemed to have sole power to vote and dispose of
the shares held by the Funds. Amir Nashat, Brian Chee, David Barrett, Bryce Youngren, Jon Flint, and Terry McGuire are the managing members of PVM who collectively make voting and investment decisions with respect to the shares held by the Funds.
The address of the individuals and entities listed above is One Marina Park Drive, 10th Floor, Boston, Massachusetts 02210. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 1,305,226 shares held of record by Dr.&nbsp;Rosenthal, of which 208,396 shares are subject to
repurchase by us at the original purchase price as of November&nbsp;1, 2019, (b)&nbsp;712,500 shares held of record by Adi Rosenthal 2007 Trust dated March&nbsp;27, 2007, for which Dr.&nbsp;Rosenthal serves as trustee, of which no shares are subject
to repurchase by us at the original purchase price as of November&nbsp;1, 2019, (c)&nbsp;712,500&nbsp;shares held of record by Noam Rosenthal 2007 Trust dated March&nbsp;27,&nbsp;2007, for which Dr.&nbsp;Rosenthal serves as trustee, of which no
shares are subject to repurchase by us at the original purchase price as of November&nbsp;1, 2019, (d)&nbsp;712,500 shares held of record by Shani Rosenthal 2007 Trust dated March&nbsp;27, 2007, for which Dr.&nbsp;Rosenthal serves as trustee, of
which no shares are subject to repurchase by us at the original purchase price as of November&nbsp;1, 2019, (e)&nbsp;2,612,500 shares held of record by The Rosenthal Family Revocable Trust Dated November&nbsp;4, 1994, as restated on June&nbsp;9,
1999, for which Dr.&nbsp;Rosenthal serves as trustee, of which no shares are subject to repurchase by us at the original purchase price as of November&nbsp;1, 2019, and (f)&nbsp;775,000 shares subject to options held by Dr.&nbsp;Rosenthal, of which
262,395&nbsp;shares are vested and exercisable within 60&nbsp;days of November&nbsp;1, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 537,317 shares held of record by Dr.&nbsp;King, of which 167,912 shares are subject to
repurchase by us at the original purchase price as of November&nbsp;1, 2019 and (b) 250,000 shares subject to options held by Dr.&nbsp;King, of which 80,208 shares are vested and exercisable within 60 days of November&nbsp;1, 2019.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 333,719 shares held of record by Dr.&nbsp;Paul, of which 92,371 shares are subject to
repurchase by us at the original purchase price as of November&nbsp;1, 2019 and (b) 444,000 shares subject to options held by Dr.&nbsp;Paul, of which 148,166 shares are vested and exercisable within 60&nbsp;days of November&nbsp;1, 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,608,610 shares held of record by Dr.&nbsp;Gerngross, of which no shares are subject to repurchase
by us at the original purchase price as of November&nbsp;1, 2019 and 20,000 shares subject to an option held by Dr.&nbsp;Gerngross, 11,666 of which shares are vested and exercisable within 60&nbsp;days of November&nbsp;1, 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 10,552 shares held of record by Lavrite, LLC, for which Mr.&nbsp;Lavigne serves as managing
director, and (b) 90,000 shares subject to an option held by Mr.&nbsp;Lavigne, of which 32,082 shares are vested and exercisable within 60 days of November&nbsp;1, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 20,000 shares subject to an option held by Mr.&nbsp;McGuire, of which 11,666 shares are vested and
exercisable within 60 days of November&nbsp;1, 2019. Mr.&nbsp;McGuire, who is one of our directors, is a managing member of PVM. Mr.&nbsp;McGuire has no voting or investment power over the shares held by the Funds described in Footnote 3 above. The
address for Mr.&nbsp;McGuire is c/o PVM, One Marina Park Drive, 10th Floor, Boston, Massachusetts 02210. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 19,981 shares held of record by Dr.&nbsp;Scheller, of which no shares are subject to repurchase
by us at the original purchase price as of December&nbsp;31, 2018 and (b) 101,834 shares subject to options held by Dr.&nbsp;Scheller, of which 35,533 shares are vested and exercisable within 60&nbsp;days of November&nbsp;1, 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 24,621 shares held of record by Mr.&nbsp;Wehner and (b) 90,000 shares subject to options held
by Mr.&nbsp;Wehner, 32,082 of which shares are vested and exercisable within 60 days of November&nbsp;1, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 40,000 shares subject to an option held by Dr.&nbsp;Yaffe, none of which shares are vested and
exercisable within 60 days of November&nbsp;1, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 11,083,468 shares beneficially owned by our current executive officers and directors as of
November&nbsp;1, 2019, of which 718,609 shares may be repurchased by us at the original purchase price as of such date and (b) 724,230 shares subject to options vested and exercisable within 60 days of November&nbsp;1, 2019. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_14"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended
and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws. Copies of these documents were filed with the SEC and referenced in the exhibits to our
registration statement, of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 200,000,000 shares of common
stock, par value $0.0001 per share, and 20,000,000 shares of convertible preferred stock, par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the
completion of this offering and the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering, there will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock outstanding. As of September&nbsp;30, 2019, we had 50 stockholders of record. As of September&nbsp;30, 2019, there were
5,918,124 shares of common stock subject to outstanding options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of
common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our certificate of incorporation and bylaws do not provide for cumulative voting rights. Because of
this, the holders of a plurality of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. With respect to matters other than the election of
directors, at any meeting of the stockholders at which a quorum is present or represented, the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at such meeting and entitled to vote on the
subject matter shall be the act of the stockholders, except as otherwise required by law. The holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for
the transaction of business at all meetings of the stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be applicable to any then-outstanding convertible preferred stock, holders of our common stock are entitled to
receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution, or winding up, holders of our common stock will be entitled to share ratably in the net assets
legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of convertible preferred stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no preemptive, conversion, subscription, or other rights, and there are no redemption or sinking fund
provisions applicable to our common stock. The rights, preferences, and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our convertible preferred
stock that we may designate in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and Nonassessable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering, upon payment and delivery in
accordance with the underwriting agreement, will be fully paid and nonassessable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors have the authority, without further action by the stockholders, to issue up to 20,000,000 shares of preferred stock in
one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences,
sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of
holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control
or other corporate action. Upon closing of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2019, we had outstanding options to purchase an aggregate of 5,918,124 shares of our common stock, with a weighted-average exercise price of $10.84 per share, under our 2017 Plan and 2019 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion
of this offering, under our registration rights agreement, as amended, certain holders&nbsp;of&nbsp;shares of common stock or their transferees, have the right to require us to register the offer and sale of their shares, or to include their shares
in any registration statement we file, in each case as described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of this offering, certain holders of shares of our common stock will be entitled to certain demand registration rights. At
any time beginning 180 days after the effective date of this offering, the holders of at least 25% of the shares (or a lesser percent for which the anticipated aggregate offering price would be at least $15 million) having registration rights then
outstanding can request that we file a registration statement to register the offer and sale of their shares. We are only obligated to effect up to two such registrations. Each such request for registration must cover securities the anticipated
aggregate public offering price of which, before deducting underwriting discounts and commissions, is at least $15&nbsp;million. These demand registration rights are subject to specified conditions and limitations, including the right of the
underwriters to limit the number of shares included in any such registration under certain circumstances. If we determine that it would be seriously detrimental to us and our stockholders to effect such a demand registration, we have the right to
defer such registration, not more than once in any twelve month period, for a period of up to 60 days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form
<FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of this offering, certain holders of shares
of our common stock will be entitled to certain Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights. At any time when we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> the holders
of the shares having these rights then outstanding can request that we register the offer and sale of their shares of our common stock on a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> so long as the request covers
securities the anticipated aggregate public offering price of which is at least $3&nbsp;million. These stockholders may make an unlimited number of requests for registration on a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3.</FONT> However, we will not be required to effect a registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we have effected two such registrations within the twelve month period preceding the date
of the request. Additionally, if we determine that it would be seriously detrimental to us and our stockholders to effect such a demand registration, we have the right to defer such registration, not more than once in any twelve month period, for a
period of up to 60 days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of this offering, certain holders of shares of our common stock will be entitled to certain &#147;piggyback&#148;
registration rights. If we propose to register the offer and sale of shares of our common stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the Securities Act, all holders of these shares then outstanding can request that we include their shares in such registration, subject to certain marketing and other limitations, including
the right of the underwriters to limit the number of shares included in any such registration statement under certain circumstances. As a result, whenever we propose to file a registration statement under the Securities Act, other than with respect
to (1)&nbsp;a registration related to any employee benefit plan or a corporate reorganization or other transaction covered by Rule&nbsp;145 promulgated under the Securities Act, (2)&nbsp;a registration in which the only stock being registered is
common stock issuable upon conversion of debt securities also being registered, or (3)&nbsp;a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering
the sale of our common stock, the holders of these shares are entitled to notice of the registration and have the right, subject to certain limitations, to include their shares in the registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of Registration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
pay all expenses relating to any demand registrations, Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations, and piggyback registrations, subject to specified exceptions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration
rights terminate upon the earliest of (1)&nbsp;the date that is five years after the closing of our initial public offering and (2)&nbsp;a deemed liquidation event (as defined in our amended and restated certificate of incorporation, in effect prior
to the completion of our initial public offering). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Certain Provisions of Delaware Law, Our Amended and Restated Certificate
of Incorporation and Our Amended and Restated Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law and certain provisions that are included in
our amended and restated certificate of incorporation and amended and restated bylaws summarized below may be deemed to have an anti-takeover effect and may delay, deter, or prevent a tender offer or takeover attempt that a stockholder might
consider to be in its best interests, including attempts that might result in a premium being paid over the market price for the shares held by stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and
restated certificate of incorporation contains provisions that permit our board of directors to issue, without any further vote or action by the stockholders, shares of preferred stock in one or more series and, with respect to each such series, to
fix the number of shares constituting the series and the designation of the series, the voting rights (if any) of the shares of the series and the powers, preferences, or relative, participation, optional, and other special rights, if any, and any
qualifications, limitations, or restrictions, of the shares of such series. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that our board of directors is divided into three classes, designated
Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Each class will be an equal number of directors, as nearly as possible, consisting of <FONT STYLE="white-space:nowrap">one-third</FONT> of the total number of directors constituting the entire board of
directors. The term of initial Class&nbsp;I directors shall terminate on the date of the 2023 annual meeting, the term of the initial Class&nbsp;II directors shall terminate on the date of the 2020 annual meeting, and the term of the initial
Class&nbsp;III directors shall terminate on the date of the 2021 annual meeting. At each annual meeting of stockholders, successors to the class of directors whose term expires at that annual meeting will be elected for a three-year term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended
and restated certificate of incorporation provides that stockholders may only remove a director for cause by a vote of no less than a majority of the shares present in person or by proxy at the meeting and entitled to vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation authorizes only our board of directors to fill vacant directorships. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Cumulative Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended
and restated certificate of incorporation provides that stockholders do not have the right to cumulate votes in the election of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special
Meetings of Stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws provides that,
except as otherwise required by law, special meetings of the stockholders may be called only by the Chairperson of our board of directors, the Chief Executive Officer, the President, or our board of directors acting pursuant to a resolution adopted
by a majority of the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advance Notice Procedures for Director Nominations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws provide that stockholders seeking to nominate candidates for election as directors at an annual or special meeting of stockholders
must provide timely notice thereof in writing. To be timely, a stockholder&#146;s notice generally will have to be delivered to and received at our principal executive offices before notice of the meeting is issued by the secretary of the company,
with such notice being served not less than 90 nor more than 120 days before the meeting. Although the amended and restated bylaws will not give the board of directors the power to approve or disapprove stockholder nominations of candidates to be
elected at an annual meeting, the amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a
solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Action by Written Consent
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws provide that any action to be taken by the
stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by written consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amending our
Certificate of Incorporation and Bylaws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation may be amended or altered in any
manner provided by the DGCL. Our amended and restated bylaws may be adopted, amended, altered, or repealed by stockholders only upon approval of at least majority of the voting power of all the then outstanding shares of the common stock, except for
any amendment of certain provisions set forth in the bylaws, which would require the approval of a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of our then outstanding common stock. Additionally, our amended and restated certificate
of incorporation provides that our bylaws may be amended, altered, or repealed by the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Authorized but Unissued Shares
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized but unissued shares of common stock and preferred stock will be available for future issuances without stockholder
approval, except as required by the listing standards of NASDAQ, and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized
but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of the company by means of a proxy contest, tender offer, merger, or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Jurisdiction </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of
Delaware, or if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware, is the exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of us, (ii)&nbsp;any action
asserting a claim of breach of a fiduciary duty owed by any director, officer, or other employee to the us or our stockholders, (iii)&nbsp;any action arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws (as
either may be amended from time to time), or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine, except, in each case, (A)&nbsp;any claim as to which such court determines that there is an indispensable party not
subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum
other than such court, or (C)&nbsp;for which such court does not have subject matter jurisdiction. Although our amended and restated bylaws will contain the exclusive of forum provisions described above, it is possible that a court could find that
such provision is inapplicable for a particular claim or action or that such provision is unenforceable, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combinations with Interested Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are governed by Section&nbsp;203 of the DGCL. Subject to certain exceptions, Section&nbsp;203 of the DGCL prohibits a public Delaware
corporation from engaging in a business combination (as defined in such section) with an &#147;interested stockholder&#148; (defined generally as any person who beneficially owns 15% or more of the outstanding voting stock of such corporation or any
person affiliated with such person) for a period of three years following the time that such stockholder became an interested stockholder, unless (i)&nbsp;prior to such time the board of directors of such corporation approved either the business
combination or the transaction that resulted in the stockholder becoming an interested stockholder; (ii)&nbsp;upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
at least 85% of the voting stock of such corporation at the time the transaction commenced (excluding for purposes of determining the voting stock of such corporation outstanding (but not the outstanding voting stock owned by the interested
stockholder) those shares owned (A)&nbsp;by persons who are directors and also officers of such corporation and (B)&nbsp;by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held
subject to the plan will be tendered in a tender or exchange offer); or (iii)&nbsp;at or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of stockholders (and not
by written consent) by the affirmative vote of at least 66 2/3% of the outstanding voting stock of such corporation not owned by the interested stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we must indemnify our directors and
officers to the fullest extent authorized by the DGCL. We are expressly authorized to, and do, carry directors&#146; and officers&#146; insurance providing coverage for our directors, officers and certain employees for some liabilities. We believe
that these indemnification provisions and insurance are useful to attract and retain qualified directors and executive directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
limitation on liability and indemnification provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect
of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we
pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Listing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the NASDAQ Global Select Market&nbsp;under the symbol &#147;ALEC.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer Agent and Registrar </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. The transfer agent and
registrar&#146;s address is 6201 15th Avenue, Brooklyn, New York 11219. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_15"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of substantial amounts of common stock in the public market, including shares issued upon exercise of outstanding options, or the
perception that such sales may occur, however, could adversely affect the market price of our common stock and also could adversely affect our future ability to raise capital through the sale of our common stock or other equity-related securities of
ours at times and prices we believe appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, based on our shares outstanding as of
September&nbsp;30, 2019,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be outstanding,
or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock if the underwriters exercise their option to purchase additional shares in full. All of the shares of common stock expected to
be sold in this offering will be freely tradable without restriction or further registration under the Securities Act unless held by our &#147;affiliates,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act. The remaining
outstanding shares of our common stock will be deemed &#147;restricted securities&#148; as that term is defined under Rule&nbsp;144. Restricted securities may be sold in the public market only if their offer and sale is registered under the
Securities Act or if the offer and sale of those securities qualify for an exemption from registration, including exemptions provided by Rules 144 and 701 under the Securities Act, which are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below and the provisions of Rules 144 or 701 and no
exercise of the underwriters&#146; option to purchase additional shares, the shares of our common stock that will be deemed &#147;restricted securities&#148; will be available for sale in the public market following the completion of this offering
as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares will be eligible for sale on the date of this prospectus; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares will be eligible for sale upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements and market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions described below, beginning more than 90 days after the date of this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, our executive officers, directors, and certain of our other stockholders affiliated with certain of our
directors have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for
shares of common stock during the period from the date of this prospectus continuing through the date 90 days after the date of this prospectus, except with the prior consent of Morgan Stanley&nbsp;&amp; Co. LLC and Goldman Sachs&nbsp;&amp; Co. LLC.
See the section titled &#147;Underwriting&#148; for additional information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule&nbsp;144, as currently in effect, generally provides that, once we have been subject to the public company reporting requirements of
Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, a stockholder who is not deemed to have been one of our affiliates at any time during the preceding 90 days and who has beneficially owned the shares of our capital
stock proposed to be sold for at least six months is entitled to sell such shares in reliance upon Rule&nbsp;144 without complying with the volume limitation, manner of sale or notice conditions of Rule&nbsp;144. If such stockholder has beneficially
owned the shares of our capital stock proposed to be sold for at least one year, then such person is entitled to sell such shares in reliance upon Rule&nbsp;144 without complying with any of the conditions of Rule&nbsp;144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule&nbsp;144 also provides that a stockholder who is deemed to have been one of our affiliates at any time during the preceding 90 days and
who has beneficially owned the shares of our common stock proposed to be sold for at least six months is entitled to sell such shares in reliance upon Rule&nbsp;144 within any three month period beginning 90 days after the date of this prospectus a
number of shares that does not exceed the greater of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our capital stock then outstanding, which will
equal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after the completion of this offering, assuming no exercise by the underwriters of their option to purchase additional shares; or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock during the four calendar weeks preceding the filing of a
notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our capital stock made in reliance upon Rule&nbsp;144 by a
stockholder who is deemed to have been one of our affiliates at any time during the preceding 90 days are also subject to the current public information, manner of sale and notice conditions of Rule&nbsp;144. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule&nbsp;701 generally
provides that, once we have been subject to the public company reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90&nbsp;days, a stockholder who purchased shares of our common stock pursuant to a
written compensatory benefit plan or contract and who is not deemed to have been one of our affiliates at any time during the preceding 90&nbsp;days may sell such shares in reliance upon Rule&nbsp;144 without complying with the current public
information or holding period conditions of Rule&nbsp;144. Rule&nbsp;701 also provides that a stockholder who purchased shares of our common stock pursuant to a written compensatory benefit plan or contract and who is deemed to have been one of our
affiliates during the preceding 90 days may sell such shares under Rule&nbsp;144 without complying with the holding period condition of Rule&nbsp;144. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our executive officers and directors have adopted written plans, known as &#147;Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT>
trading plans,&#148; under which they will contract with a broker to buy or sell shares of our common stock on a periodic basis to diversify their assets and investments. Under these <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, a
broker may execute trades pursuant to parameters established by the executive officer or director when entering into the plan, without further direction from such officer or director. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion
of this offering, the holders of up to 59,809,220 shares of our common stock will be entitled to certain rights with respect to the registration of such shares under the Securities Act. The registration of these shares of our common stock under the
Securities Act would result in these shares becoming eligible for sale in the public market without restriction under the Securities Act immediately upon the effectiveness of such registration, subject to the Rule&nbsp;144 limitations applicable to
affiliates. See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for a description of these registration rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We filed a
registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register all of the shares of our common stock subject to equity awards outstanding or reserved for issuance under our equity compensation
plans. The shares of our common stock covered by such registration statement will be eligible for sale in the public market without restriction under the Securities Act immediately upon the effectiveness of such registration statement, subject to
vesting restrictions, the conditions of Rule&nbsp;144 applicable to affiliates, and any applicable market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_16"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material U.S. federal income tax consequences of
the ownership and disposition of our common stock acquired in this offering by a <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; (as defined below), but does not purport to be a complete analysis of all the potential tax
considerations relating thereto. This summary is based upon the provisions of the Code, Treasury Regulations promulgated thereunder, administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed, possibly
retroactively, so as to result in U.S. federal income tax consequences different from those set forth below. We have not sought, and do not intend to seek, any ruling from the Internal Revenue Service (IRS), with respect to the statements made and
the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary also does not address the tax considerations arising under the laws of any <FONT STYLE="white-space:nowrap">non-U.S.,</FONT>
state, or local jurisdiction or under U.S. federal gift and estate tax rules, except to the limited extent set forth below. In addition, this discussion does not address tax considerations applicable to an investor&#146;s particular circumstances or
to investors that may be subject to special tax rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies, regulated investment companies, real estate investment trusts, or other financial
institutions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax or the tax on net investment income; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension plans and <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlled foreign corporations, passive foreign investment companies and corporations that accumulate earnings
to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in securities or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities that elect to use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or are deemed to own, more than five percent of our capital stock (except to the extent
specifically set forth below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold our common stock as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion
transaction,&#148; or other risk reduction transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any option or otherwise as compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code
(generally, property held for investment); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if a partnership (including an entity or arrangement classified as a partnership or flow-through entity
for U.S. federal income tax purposes) holds our common stock, the tax treatment of a partner in such partnership generally will depend on the status of the partner and upon the activities of the partnership. Partnerships holding our common stock and
partners in such partnerships should consult their own tax advisors regarding the tax consequences of the ownership and disposition of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You are urged to consult your tax advisor with respect to the application of the U.S. federal income tax laws to your particular situation,
as well as any tax consequences of the purchase, ownership and disposition of our common stock arising under the U.S. federal gift or estate tax rules or under the laws of any state, local, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other
taxing jurisdiction or under any applicable tax treaty. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder Defined </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, you are a <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; if you are a beneficial owner of
our common stock that, for U.S. federal income tax purposes, is not a partnership or: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or other entity taxable as a corporation created or organized in the United States or under the
laws of the United States or any political subdivision thereof, or otherwise treated as such for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate whose income is includible in gross income for U.S. federal income tax purposes regardless of its
source; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (x)&nbsp;whose administration is subject to the primary supervision of a U.S. court and that has one or
more U.S. persons who have the authority to control all substantial decisions of the trust or (y)&nbsp;that has made a valid election under applicable Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the
section titled &#147;Dividend Policy,&#148; we have never declared or paid cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. However, if we do make distributions on
our common stock, those payments will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those
distributions exceed our current or accumulated earnings and profits, the excess will constitute a return of capital and will first reduce your basis in our common stock, but not below zero, and then will be treated as gain from the sale or other
disposition of our common stock as described under &#147;&#151;Gain on Disposition of Our Common Stock.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions
below on effectively connected income, backup withholding and Foreign Account Tax Compliance Act (FATCA), any dividend paid to you generally will be subject to U.S. federal withholding tax either at a rate of 30% of the gross amount of the dividend
or such lower rate as may be specified by an applicable income tax treaty between the United States and your country of residence. In order to receive a reduced treaty rate, you must provide us with an IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other appropriate version of IRS Form <FONT STYLE="white-space:nowrap">W-8</FONT> certifying qualification
for the reduced rate, and you will be required to update such forms and certifications from time to time as required by law. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of shares of our common stock eligible for a reduced rate of U.S.
federal withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by filing an appropriate claim for refund with the IRS. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock
through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide appropriate documentation to
the agent, which then will be required to provide certification to us or our paying agent, either directly or through other intermediaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends received by you that are treated as effectively connected with a U.S. trade or business conducted by you (and, if required by an
applicable income tax treaty, that are attributable to a permanent establishment or fixed base maintained by you in the United States) are generally exempt from the 30% U.S. federal withholding tax, subject to the discussion below on backup
withholding and FATCA withholding. In order to obtain this exemption, you must provide us with a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> or other applicable IRS Form <FONT STYLE="white-space:nowrap">W-8</FONT>
properly certifying such exemption. Such effectively connected dividends, although not subject to U.S. federal withholding tax, are taxed at the same graduated rates applicable to U.S. persons, net of certain deductions and credits. In addition, if
you are a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, you may also be subject to a branch profits tax at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty between the United States and
your country of residence) on our earnings and profits for the taxable year that are effectively connected with a U.S. trade or business conducted by you, as adjusted for certain items. You should consult your tax advisor regarding the tax
consequences of the ownership and disposition of our common stock, including any applicable tax treaties that may provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below regarding backup withholding and FATCA withholding, you generally will not be required to pay U.S. federal
income tax on any gain realized upon the sale or other disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with a U.S. trade or business conducted by you (and, if an applicable income
tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by you in the United States); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you are an individual who is present in the United States for a period or periods aggregating 183 days or more
during the calendar year in which the sale or disposition occurs and certain other conditions are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a United States real property interest by reason of our status as a &#147;United
States real property holding corporation,&#148; or USRPHC, for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding your disposition of, or your holding period for, our common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we are not currently and will not become a USRPHC for U.S. federal income tax purposes, and the
remainder of this discussion so assumes. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our worldwide real property interests
plus our other assets used or held for use in a trade or business, there can be no assurance that we will not become a USRPHC in the future. Even if we become a USRPHC, however, as long as our common stock is regularly traded on an established
securities market, your common stock will be treated as U.S. real property interests only if you actually (directly or indirectly) or constructively hold more than five percent of such regularly traded common stock at any time during the shorter of
the five-year period preceding your disposition of, or your holding period for, our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the first bullet above, you will be required to pay tax on the gain derived from the sale (net of certain deductions and credits) under regular graduated U.S. federal income tax rates
applicable to U.S. persons, and a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the first bullet above also may be subject to the branch profits tax at a 30% rate, or such lower rate as may be specified by an
applicable income tax treaty. If you are an individual <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the second bullet above, you will be subject to tax at 30% (or such lower rate specified by an applicable income tax treaty)
on the gain derived from the sale, which gain may be offset by U.S. source capital losses for the year, provided you have timely filed U.S. federal income tax returns with respect to such losses. You should consult your tax advisor regarding any
applicable income tax or other treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Estate Tax </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock beneficially owned by an individual who is not a citizen or resident of the United&nbsp;States (as defined for U.S. federal
estate tax purposes) at the time of their death will generally be includable in the decedent&#146;s gross estate for U.S. federal estate tax purposes. Such stock, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax
treaty provides otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, we must report annually to the IRS the amount of dividends paid to you, your name and address and the amount of tax withheld, if
any. A similar report will be sent to you. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports available to tax authorities in your country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends on or of proceeds from the disposition of our common stock made to you may be subject to information reporting and
backup withholding at the statutory rate (currently, 24%) unless you establish an exemption, for example, by properly certifying your <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status on a properly completed IRS
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or another appropriate version of IRS Form <FONT
STYLE="white-space:nowrap">W-8.</FONT> Notwithstanding the foregoing, backup withholding and information reporting may apply if either we or our paying agent has actual knowledge, or reason to know, that you are a U.S. person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax; rather, the U.S. federal income tax liability of persons subject to backup withholding will be
reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Account Tax Compliance Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of the Code commonly referred to as FATCA, Treasury Regulations issued thereunder and official IRS guidance generally impose a U.S.
federal withholding tax of 30% on dividends on, and the gross proceeds from a sale or other disposition of our common stock, paid to a &#147;foreign financial institution&#148; (as specially defined under these rules), unless such institution enters
into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding the U.S. account holders of such institution (which includes
certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally imposes a U.S. federal withholding tax of 30% on
dividends on and the gross proceeds from a sale or other disposition of our common stock paid to a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (as specially defined under these rules) unless such entity provides
the withholding agent with a certification identifying the direct and indirect substantial U.S. owners of the entity and information with respect to such substantial U.S. owners, certifies that it does not have any such substantial U.S. owners, or
otherwise establishes an exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The withholding obligations under FATCA generally apply to dividends on our common stock and to the
payment of gross proceeds of a sale or other disposition of our common stock. The withholding tax will apply regardless of whether the payment otherwise would be exempt from U.S. nonresident and backup withholding tax, including under the other
exemptions described above. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. An intergovernmental agreement between the United States and an applicable
foreign country may modify the requirements described in this section. The U.S. Treasury Department recently released proposed regulations under FATCA which, if finalized in their present form, would eliminate the federal withholding tax of 30%
applicable to gross proceeds of a sale or other disposition of our common stock, and has provided that such proposed regulations may be relied upon by taxpayers until final regulations are issued. Prospective investors should consult with their own
tax advisors regarding the application of FATCA withholding to their investment in, and ownership and disposition of, our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The preceding discussion of U.S. federal tax considerations is for general information only. It is not tax advice to investors in their
particular circumstances. Each prospective investor should consult its own tax advisor regarding the particular U.S. federal, state and local, and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of purchasing, holding, and
disposing of our common stock, including the consequences of any proposed change in applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_17"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below,
for whom Morgan Stanley&nbsp;&amp; Co. LLC and Goldman Sachs&nbsp;&amp; Co. LLC are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares indicated below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and the representatives are collectively referred to as the &#147;underwriters&#148; and the
&#147;representatives,&#148; respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several
underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and
pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#146; option to purchase additional shares
described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters initially propose to offer part of the shares of common stock directly to the public at the offering
price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share under the public offering price. After the initial
offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the
underwriters&#146; right to reject any order in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days
from the date of this prospectus, to purchase up to additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. To the extent the option is exercised, each
underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to the total
number of shares of common stock listed next to the names of all underwriters in the preceding table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per
share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full<BR>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions to be paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are
approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have agreed to reimburse the underwriters for expenses of up to $40,000 relating to clearance of this offering with the Financial Industry Regulatory Authority, Inc. and compliance
with state securities or &#147;blue sky&#148; laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on NASDAQ under the trading symbol&nbsp;&#147;ALEC.&#148;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our directors and executive officers, as well as certain of our other stockholders
affiliated with certain of our directors, have agreed that, without the prior written consent of the representatives on behalf of the underwriters, we and they will not, during the period ending on and including the 90th day after the date of this
prospectus (the restricted period): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">file any registration statement with the SEC relating to the offering of any shares of common stock or any
securities convertible into or exercisable or exchangeable for common stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the common stock </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whether any such transaction described above is to be settled by delivery of common stock
or such other securities, in cash or otherwise. In addition, we and each such person agrees that, without the prior written consent of the representatives on behalf of the underwriters, we or such other person will not, during the restricted period,
make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described in the immediately preceding paragraph do not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sale of shares to the underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transactions by any person other than us relating to shares of common stock or other securities acquired in
this offering or in open market transactions after the completion of this offering; provided that no filing under Section&nbsp;16(a) of the Exchange Act is required or voluntarily made during the restricted period in connection with subsequent sales
of the common stock or other securities acquired in such open market transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of shares of common stock or any security convertible into common stock (i)&nbsp;to an immediate
family member of the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory, or to a trust or other entity formed for estate planning for the benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory or immediate family member,
(ii)&nbsp;by bona fide gift, will or intestacy, (iii)&nbsp;if the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust, or (iv)&nbsp;by bona
fide gift to a charitable organization, provided that no filing under Section&nbsp;16(a) of the Exchange Act or other public filing, report, or announcement reporting a reduction in beneficial ownership of shares of common stock or any security
convertible into common stock shall be required or voluntarily made during the restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory is a corporation, partnership, limited
liability company, trust, or other business entity, transfers of common stock or any security convertible into common stock (i)&nbsp;to another corporation, partnership, limited liability company, trust, or other business entity that controls, is
controlled by, manages, is managed by, or is under common control with the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory or its affiliates or (ii)&nbsp;as part of a disposition, transfer, or distribution by the <FONT
STYLE="white-space:nowrap">lock-up</FONT> signatory to its stockholders, partners, members, or other equity holders; provided that no filing under Section&nbsp;16(a) of the Exchange Act or other public filing, report, or announcement reporting a
reduction in beneficial ownership of shares of common stock or securities convertible into common stock shall be required or voluntarily made during the restricted period (other than any required Form 5 filing); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(i)&nbsp;the receipt by the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory from us of shares of our
common stock upon the exercise of options or the settlement of restricted stock units granted under a stock incentive plan or other equity award plan, as described in this prospectus, insofar as such option or restricted stock unit is outstanding as
of the date of this prospectus, or (ii)&nbsp;the transfer of shares of common stock or other securities convertible into common stock to us upon a vesting event of our securities, the settlement of restricted
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
stock units, or the exercise of options to purchase our securities on a &#147;cashless&#148; or &#147;net exercise&#148; basis to the extent permitted by the instruments representing such options
or restricted stock units (and any transfer to us necessary to generate cash needed for the payment of taxes due as a result of such vesting, settlement, or exercise) so long as such &#147;cashless exercise&#148; or &#147;net exercise&#148; is
effected solely by the surrender of outstanding options or restricted stock units to us and our cancellation of all or a portion thereof. In the case of either (i)&nbsp;or (ii), no filing under Section&nbsp;16(a) of the Exchange Act or other public
announcement or filing shall be required or voluntarily made during the restricted period, and the underlying shares issued to the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory shall continue to be subject to the terms of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement. For the purpose of (ii), filings under Section&nbsp;16(a) of the Exchange Act shall be permissible if such filings relate solely to &#147;net&#148; or &#147;cashless&#148; exercises or settlements
of stock options, restricted stock units, or other equity awards that would otherwise expire during the restricted period and any such filing includes a statement to the effect that such transfer is being made in connection with a &#147;net&#148; or
&#147;cashless&#148; exercise or settlement of stock options, restricted stock units, or other equity awards, and the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory provides written notice to the representatives no later than two business
days prior to making any such filings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the
Exchange Act for the transfer of shares of common stock, provided that (i)&nbsp;such plan does not provide for the transfer of common stock during the restricted period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange
Act, if any, is required or voluntarily made regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common stock may be made under such plan during the restricted period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of shares of common stock or securities convertible into common stock to us pursuant to agreements
under which we or any of our equityholders have the option to repurchase such shares of common stock or other securities convertible into common stock upon termination of service of the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of shares of common stock or other securities convertible into common stock pursuant to a bona
fide third party tender offer, merger, consolidation, or other similar transaction made to all holders of our capital stock involving a &#147;change of control&#148;, after the completion of this offering, that has been approved by our board of
directors, provided that in the event that such transaction is not completed, the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory&#146;s shares of common stock or securities convertible into common stock will remain subject to the terms of
the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of shares of common stock or securities convertible into common stock pursuant to a domestic order
or in connection with a divorce settlement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">j.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sale of shares of common stock under a trading plan pursuant to Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act established prior to the execution of the relevant <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement and has been disclosed to the representatives, provided that any
filing required by Section&nbsp;16 of the Exchange Act that is made in connection with any such sales during the restricted period shall state that such sales have been executed pursuant to such trading plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any transfer pursuant to (c), (d) and (i)&nbsp;above, the donee, transferee, or distributee must agree in writing to be bound
by <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;restrictions.</FONT> In the case of (c)&nbsp;and (d) above, such transfer or distribution shall not involve a disposition for value. In the case of (g)&nbsp;and (i) above, no filing under
Section&nbsp;16(a) of the Exchange Act or other public filing, report, or announcement reporting a reduction in beneficial ownership of shares of common stock or securities convertible into common stock shall be voluntarily made during the
restricted period. In the case of (g)&nbsp;and (i) above, if <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> is required to file a report under Section&nbsp;16(a) of the Exchange Act during the restricted period, <FONT
STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> shall include a statement to the effect that such transfer is to us in connection with the repurchase of shares of common stock or other securities convertible into common stock or
pursuant to a qualified domestic order or in connection with a divorce settlement, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representatives, in their sole discretion, may release the common stock and other
securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time with or without notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain or otherwise
affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater
than the number of shares available for purchase by the underwriters under the option to purchase additional shares described above. The underwriters can close out a covered short sale by exercising such option or purchasing shares in the open
market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under such option. The underwriters may also sell
shares in excess of such option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned
that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid
for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels or prevent or retard a decline in
the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any,
participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long
and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or
express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of our common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited
investors, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT>
Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of our common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities
laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or
damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the
purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of
<FONT STYLE="white-space:nowrap">a&nbsp;non-Canadian&nbsp;jurisdiction,</FONT> section 3A.4) of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts
<FONT STYLE="white-space:nowrap">(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in
connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a Relevant Member State)
an offer to the public of any shares of our common stock may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any shares of our common stock may be made at any time under the following
exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined in the Prospectus Directive;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD
Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives for any such offer;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer
of shares of our common stock shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article 3 of the Prospectus Directive. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares of our common stock in any
Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an investor to decide to purchase any shares of our
common stock, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (and amendments thereto, including the
2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State, and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
underwriter has represented and agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000 (FSMA) received by it in connection with the issue or sale of the shares of our common stock in
circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it
in relation to the shares of our common stock in, from or otherwise involving the United Kingdom. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than
(a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation, or
document relating to the shares of common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issuance, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are
likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong&nbsp;Kong) other than with respect to shares of common stock which are or are intended to be disposed of only to persons
outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No registration pursuant to
Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as amended) (FIEL) has been made or will be made with respect to the solicitation of the application for the acquisition of the shares of common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the shares of common stock have not been, directly or indirectly, offered or sold and will not be, directly or
indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">for&nbsp;re-offering&nbsp;or&nbsp;re-sale,&nbsp;directly</FONT></FONT> or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the
registration requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For Qualified
Institutional Investors (QII) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in
Paragraph 2, Article 4 of the FIEL) in relation to the shares of common stock constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph 1, <FONT
STYLE="white-space:nowrap">Article&nbsp;23-13&nbsp;of</FONT> the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock. The
shares of common stock may only be transferred to QIIs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">For&nbsp;Non-QII&nbsp;Investors</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in
relation to the shares of common stock constitutes either a &#147;small number private placement&#148; or a &#147;small number private secondary distribution&#148; (each as is described in Paragraph 4,
<FONT STYLE="white-space:nowrap">Article&nbsp;23-13&nbsp;of</FONT> the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock.
The shares of common stock may only be transferred en bloc without subdivision to a single investor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
invitation for subscription or purchase, of the shares of our common stock may not be circulated or distributed, nor may the shares of our common stock be offered or sold, or be made the subject
of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (SFA), (ii) to
a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the
conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares of our common stock are subscribed or purchased under
Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trust (where the trustee is not an accredited investor) the sole purpose of which is to hold investments and
each beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA)
of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares of our common stock pursuant to an offer
made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any
person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)&nbsp;(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures)
Regulations 2005 of Singapore. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_18"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the issuance of our common stock offered in this prospectus will be passed upon for us by Wilson Sonsini Goodrich&nbsp;&amp;
Rosati, Professional Corporation, Palo Alto, California. Davis Polk&nbsp;&amp; Wardwell LLP, Menlo Park, California, is acting as counsel for the underwriters. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_19"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our
consolidated financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_20"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> under the Securities Act with
respect to the shares of our common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, as permitted by the rules
and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained or incorporated by
reference in this prospectus concerning the contents of any contract or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or
document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC also maintains an Internet website that contains the registration
statement of which this prospectus forms a part, as well as the exhibits thereto. These documents, along with future reports, proxy statements, and other information about us, are available at the SEC&#146;s website, www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended, and, in accordance with this
law, will file periodic reports, proxy statements, and other information with the SEC. These periodic reports, proxy statements, and other information are available for inspection and copying at the SEC&#146;s public reference facilities and the
website of the SEC referred to above. We also maintain a website at www.alector.com where these materials are available. You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or
furnished to, the SEC. Information contained on, or that can be accessible through, our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_21"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we
filed with the SEC prior to the date of this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC <FONT
STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;001-38792):</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000156459019009358/alec-10k_20181231.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT></A>&nbsp;for the year ended December&nbsp;31, 2018, filed with the SEC on March&nbsp;26, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000156459019018837/alec-10q_20190331.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT></A>&nbsp;for the quarter ended March&nbsp;31, 2019, filed with the SEC on May&nbsp;13, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000156459019031488/alec-10q_20190630.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the quarter ended June&nbsp;30, 2019, filed with the SEC on August&nbsp;12, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000156459019042920/alec-10q_20190930.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT></A>&nbsp;for the quarter ended September&nbsp;30, 2019, filed with the SEC on November&nbsp;12, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information contained in our <A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519088558/d714966ddef14a.htm">Definitive
 Proxy Statement</A> on Schedule 14A, filed with the SEC on March&nbsp;27, 2019, to the extent incorporated by reference in Part III of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on (i)&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519033930/d702882d8k.htm">February&nbsp;11, 2019</A>, (ii) <A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000156459019019627/alec-8k_20190510.htm">May&nbsp;
16, 2019</A>, (iii) <A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519172525/d748620d8k.htm">June&nbsp;
13, 2019</A>, and (iv) <A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000156459019031472/alec-8k_20190809.htm">August&nbsp;12, 2019</A><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000156459019042915/alec-8k_20191112.htm"></A>; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our Common Stock set forth in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519024072/d708505d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;011-38792),</FONT> filed with the SEC on February&nbsp;1, 2019, including any amendments or reports filed for the purpose of updating such description.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated by reference into this prospectus shall be deemed to be modified or
superseded for the purposes of this prospectus to the extent that a statement contained herein or in any subsequently filed document that is also incorporated by reference in this prospectus modifies or supersedes such statement. Any statement so
modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding
the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information that we have &#147;furnished&#148; to the SEC pursuant to the Exchange Act shall be incorporated by reference
into this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish without charge to you, on written or oral request, a copy of any or all of the documents
incorporated by reference in this prospectus, including exhibits to these documents. You should direct any requests for documents to Alector, Inc., Attn: Vice President, Legal, 131 Oyster Point Boulevard, Suite 600, South San Francisco, California
94080. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You also may access these filings on our website at<I>&nbsp;www.alector.com</I>. We do not incorporate the information on our
website into this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or any supplement to this prospectus (other than those filings
with the SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN THE PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the expenses to be incurred in connection with the offering described in this Registration Statement, other than
underwriting discounts and commissions, all of which will be paid by us. All amounts are estimates except the Securities and Exchange Commission&#146;s registration fee, the Financial Industry Regulatory Authority, Inc.&#146;s filing fee, and the
NASDAQ listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;to<BR>be&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC Registration Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be provided by amendment.<B> </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law empowers a corporation to indemnify its directors and officers and to purchase
insurance with respect to liability arising out of their capacity or status as directors and officers, provided that the person acted in good faith and in a manner the person reasonably believed to be in our best interests, and, with respect to any
criminal action, had no reasonable cause to believe the person&#146;s actions were unlawful. The Delaware General Corporation Law further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to
which the directors and officers may be entitled under the corporation&#146;s bylaws, any agreement, a vote of stockholders or otherwise. The certificate of incorporation of the registrant provides for the indemnification of the registrant&#146;s
directors and officers to the fullest extent permitted under the Delaware General Corporation Law. In addition, the bylaws of the registrant require the registrant to fully indemnify any person who was or is a party or is threatened to be made a
party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative) by reason of the fact that such person is or was a director or officer of the registrant, or is or was a director or
officer of the registrant serving at the registrant&#146;s request as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against expenses (including attorney&#146;s fees),
judgments, fines, and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit, or proceeding, to the fullest extent permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a
director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except (1)&nbsp;for any breach of the director&#146;s duty of loyalty to the
corporation or its stockholders, (2)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3)&nbsp;for payments of unlawful dividends or unlawful stock repurchases or redemptions or
(4)&nbsp;for any transaction from which the director derived an improper personal benefit. The registrant&#146;s certificate of incorporation provides that the registrant&#146;s directors shall not be personally liable to it or its stockholders for
monetary damages for breach of fiduciary duty as a director and that if the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the personal liability of directors, then the liability of the registrant&#146;s directors shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law,
as so amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or
negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid
liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the
unlawful acts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by the Delaware General Corporation Law, the registrant has entered into separate indemnification agreements
with each of the registrant&#146;s directors and certain of the registrant&#146;s officers which require the registrant, among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors,
officers, or certain other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registrant expects to obtain and maintain insurance policies under which its directors and
officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits, or proceedings to
which they are parties by reason of being or having been directors or officers. The coverage provided by these policies may apply whether or not the registrant would have the power to indemnify such person against such liability under the provisions
of the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These indemnification provisions and the indemnification agreements intended to be entered into
between the registrant and the registrant&#146;s officers and directors may be sufficiently broad to permit indemnification of the registrant&#146;s officers and directors for liabilities (including reimbursement of expenses incurred) arising under
the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement between the registrant and the underwriters to be filed as
Exhibit&nbsp;1.1 to this registration statement provides for the indemnification by the underwriters of the registrant&#146;s directors and officers and certain controlling persons against specified liabilities, including liabilities under the
Securities Act with respect to information provided by the underwriters specifically for inclusion in the registration statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent
Sales of Unregistered Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following list sets forth information regarding all unregistered securities sold by us since
October&nbsp;13, 2017. No underwriters were involved in the sales and the certificates representing the securities sold and issued contain legends restricting transfer of the securities without registration under the Securities Act or an applicable
exemption from registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) In April 2018, July 2018, and October 2018, we issued 9,373,633 shares of our Series E preferred stock
at $14.2154 per share, for aggregate proceeds of $133.2&nbsp;million to a total of 32 accredited investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) From October&nbsp;13,
2017 through the filing of our registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> on December&nbsp;2, 2019, we granted stock options to purchase an aggregate of 8,824,155 shares of common stock upon the exercise of options
under our 2017 Plan and 2019 Plan at exercise prices per share ranging from $6.95 to $21.00, for an aggregate exercise price of approximately $111.8 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) On October&nbsp;13, 2017, we completed a reorganization whereby we converted from a Delaware limited liability company, under the name
Alector LLC, to a Delaware corporation under the name Alector, Inc. (the Conversion). In conjunction with the Conversion, (i)&nbsp;all of our outstanding common units converted on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-1</FONT></FONT> basis into 9,421,460 shares of common stock; (ii)&nbsp;all of our outstanding preferred units converted on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-for-1</FONT></FONT> basis into 36,001,203 shares of convertible preferred stock; and (iii)&nbsp;our unvested restricted units </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
converted on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-1</FONT></FONT> basis into 202,924 shares of unvested restricted common stock. Prior to the Conversion, we
had issued profit interest units to employees. Our vested profit interest units converted on a net issuance basis into 1,035,653 shares of common stock and our unvested profit interest units converted on a net issuance basis into 3,165,350 shares of
restricted common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offers, sales, and issuances of the securities described in Item 15(1) were exempt from registration under
the Securities Act under Section&nbsp;4(a)(2) of the Securities Act or Regulation D promulgated thereunder as transactions by an issuer not involving a public offering. The recipients of securities in each of these transactions acquired the
securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these
transactions was an accredited person and had adequate access, through employment, business, or other relationships, to information about the registrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offers, sales, and issuances of the securities described in Items 15(2), 15(3), and 15(4) were exempt from registration under the
Securities Act under either (1)&nbsp;Rule 701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule 701 or (2)&nbsp;Section&nbsp;4(a)(2) of the Securities Act as transactions by
an issuer not involving any public offering. The recipients of such securities were the registrant&#146;s employees, consultants, or directors and received the securities under the registrant&#146;s 2017 Plan. The recipients of securities in each of
these transactions represented their intention to acquire the securities for investment only and not with view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these
transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibit&nbsp;and Financial Statement Schedules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the
Exhibit Index immediately preceding the signature page hereto for a list of exhibits filed as part of this registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1,</FONT> which Exhibit Index is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements
or notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements,
certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and
is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the
successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby undertakes that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of
this registration statement in reliance upon Rule&nbsp;430A and contained in a form </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act of 1933 shall be deemed to be part of this registration statement as of the
time it was declared effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment
that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incorporated by Reference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Form</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>File No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filed</B><br><B>Herewith</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex11.htm">Form of Underwriting Agreement, including Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519003772/d550248dex32.htm">Amended and Restated Certificate of Incorporation of the Registrant. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">001-38792</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">2/11/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519003772/d550248dex34.htm">Amended and Restated Bylaws of the Registrant. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">001-38792</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">2/11/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex41.htm">Amended and Restated Registration Rights Agreement among the Registrant and certain of its stockholders, dated April&nbsp;26, 2018.
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">4.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519003772/d550248dex42.htm">Specimen common stock certificate of the Registrant. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519003772/d550248dex42.htm">Opinion of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1<SUP STYLE="font-size:85%; vertical-align:top">+</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex101.htm">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2<SUP STYLE="font-size:85%; vertical-align:top">+</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex102.htm">2017 Stock Option and Grant Plan, as amended, and forms of agreement thereunder. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3<SUP STYLE="font-size:85%; vertical-align:top">+</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex103.htm">2019 Equity Incentive Plan and forms of agreements thereunder. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4<SUP STYLE="font-size:85%; vertical-align:top">+</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex104.htm">2019 Employee Stock Purchase Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5<SUP STYLE="font-size:85%; vertical-align:top">+</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex105.htm">Confirmatory Offer Letter between the Registrant and Arnon Rosenthal, Ph.D. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/29/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6<SUP STYLE="font-size:85%; vertical-align:top">+</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex106.htm">Confirmatory Offer Letter between the Registrant and Robert Paul, M.D., Ph.D. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/29/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7<SUP STYLE="font-size:85%; vertical-align:top">+</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex107.htm">Confirmatory Offer Letter between the Registrant and Robert King, Ph.D. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/29/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex108.htm">Confirmatory Offer Letter between the Registrant and Sabah Oney, Ph.D. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/29/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9<SUP STYLE="font-size:85%; vertical-align:top">+</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex109.htm">Confirmatory Offer Letter between the Registrant and Calvin Yu. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/29/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10<SUP STYLE="font-size:85%; vertical-align:top">+</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1010.htm">Executive Incentive Compensation Plan. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11<SUP STYLE="font-size:85%; vertical-align:top">+</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1011.htm">Outside Director Compensation Policy. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12<SUP STYLE="font-size:85%; vertical-align:top">+</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1012.htm">Form of Change in Control and Severance Agreement between the Registrant and certain of its executive officers. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1014.htm">Lease between the Registrant and HCP Oyster Point III, LLC, dated June&nbsp;27, 2018. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incorporated by Reference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Form</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>File No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filed</B><br><B>Herewith</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14<SUP STYLE="font-size:85%; vertical-align:top">#</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1015.htm">Third Amended and Restated Collaboration Agreement between the Registrant and Adimab, dated September&nbsp;19, 2016, as amended.
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15<SUP STYLE="font-size:85%; vertical-align:top">#</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1016.htm"><FONT STYLE="white-space:nowrap">Co-Development&nbsp;
and</FONT> Option Agreement between the Registrant and AbbVie Biotechnology, Ltd., dated October&nbsp;16, 2017. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-229152</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">1/7/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16<SUP STYLE="font-size:85%; vertical-align:top">#</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000156459019042920/alec-ex1017_159.htm">2019 Collaboration Agreement between the Registrant and Adimab, LLC, dated August&nbsp;16, 2019. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">001-38792</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">10.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">11/12/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519003772/d550248dex211.htm">List of subsidiaries of Registrant.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">333-229152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">21.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">01/07/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Independent Registered Public Accounting Firm.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex51.htm">Consent of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation (included in Exhibit&nbsp;5.1). </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (see page <FONT STYLE="white-space:nowrap">II-6</FONT> to this Form <FONT STYLE="white-space:nowrap">S-1).</FONT> </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicated management contract or compensatory plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential
treatment and this exhibit has been filed separately with the SEC. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on the day of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ALECTOR, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Arnon Rosenthal, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Arnon Rosenthal, Ph.D., Sabah
Oney, Ph.D., and Calvin Yu as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and substitution, for him or her and in his or her
name, place, and stead, in any and all capacities (including his capacity as a director and/or officer of Alector,&nbsp;Inc. ) to sign any or all amendments (including post-effective amendments) to this registration statement and any and all
additional registration statements pursuant to Rule&nbsp;462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be
done in and about the premises, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agents or any of them, or their, his, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons
in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Arnon Rosenthal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and Director <BR><I>(Principal Executive Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Calvin Yu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Finance</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(<I>Principal&nbsp;Financial&nbsp;and&nbsp;Accounting&nbsp;Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Tillman Gerngross, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairperson of the Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Louis J. Lavigne, Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Terry McGuire</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Richard Scheller, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David Wehner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kristine Yaffe, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g838337g02g68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g02g68.jpg
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MFW;FWL;Q5/SG=]GY/[7\%V'[W[?_ ,H:=^E+5^9XX@]WZF3A/WOK=/>_;_\
ME#3OTI:OS/'$'N_4R<)^]];I[W[?_P H:=^E+5^9XX@]WZF3A/WOK=/>_;_^
M4-._2EJ_,\<0>[]3)PG[WUNGO?M__*&G?I2U?F>.(/=^IDX3][ZW3WOV_P#Y
M0T[]*6K\SQQ![OU,G"?O?6Z>]^W_ /*&G?I2U?F>.(/=^IDX3][ZW3WOV_\
MY0T[]*6K\SQQ![OU,G"?O?6Z>]^W_P#*&G?I2U?F>.(/=^IDX3][ZW3WOV__
M )0T[]*6K\SQQ![OU,G"?O?6Z>]^W_\ *&G?I2U?F>.(/=^IDX3][ZW3WOV_
M_E#3OTI:OS/'$'N_4R<)^]];I[W[?_RAIWZ4M7YGCB#W?J9.$_>^MT][]O\
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M$PBA;RIG+DSM.HZ_4K;-U4]I?2<4X6B9-_'I**NI&N,FJ[Q-BN@+@K07JIB
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MQ&9QC-T[';%$R1WZ,N@<R^L8%T(%4CXZMKI7 Z)"KRME:D?N:TQS7IW0%*B
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M(F$3")A$PBP[8.PJ1JBDV?9&R;3"TJB4N'=SUIM5A>I1\/"Q+(G?7=O'2P@
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M1YCF+N^5X\ZFL:I.+^D;&[BT31;LWF&W-DPZB\?-7M^H@?R$C6X1UYY"Z_1
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M]75HTV%OF8IX9Y=F^>1_GW6+5CMZ^U9K#U-T'*5S/MRG RT;9]6:9F&3HH"
MBDHJ?7J4F@0W3H(L)!FKTZ@"@=1RK+H;2\K.WY,:-_445JX#M\[-Y0XO_P 0
MNWS*C#TEZTA)G_++RLW,)J6/,2^9W\E8V_X3%_G5H_&GV4YMJ$?1\1RST#4;
MY7Q420>732KE[2[@R; ("J_7J%IE)VL6=\/ZP S93M!9CU*(*D$A@5MG(]&-
M0Q(\7?F@DVW&&XPS0D_LZV((Y(Q^=PG?GV/OV7EB>F6[&0!F\9!8BY%8Q[E!
M.+>\\$QRQ2E_LC)7;Y_;M4<0^=W%WG+35+CQSV?%VU2.1;J6>F/BG@]A4M5Q
M^J1&U4Z0%.58(F7!1LUF6Q'M<E5D%_:::DDTC*!C#+83)X69HLA6.'B=VCF;
MSZ\VWKBF'<"?;M<'=I!9VXP%9GP>I,/J*N\^*N!/PLSS5R]':KN_JF@+8Q;?
M=FD9BB-V?JY#9MU+[/)7N)A%J3^RN[\]C]5\.-6I+'".MVP-LWYZW P^3,]U
MW7*=78M90G[!.FAM"7(B8?2 *+@7]ILRIT70,5K+V?YT5>K S[=NUB2:0MG[
MZH[MW+"/359(:6!IL[\$]J[9)M^QRJQ01 [M[6:X;,_SO[5I3YF1:^IA%M"\
MB>R$XQ5VO\G8"AZRY?:MD^/_ !A@-_4_D[L><@9;C)M^WOZM1YT^F(YP[UU6
ME!MD]*6US4X!*NV^3=-IZ)>*2* @T]J'V-,?JS)228PY[.)LC?R1T9L;7"0,
ME4A&2</+29K$GH@&)I9'DA%G F87[>,<Q970N'BBS$5:GG*1XS#Q9.OF+<L1
MXB_8*&"3\GBYU8?3RG,\,;0SF[21DY-YO <6^77 GB;I.!Y.Z=U_0N:4[N3B
M/7Z8:R<FF=75O_'"^[$=5VJVO8%-M,15:"G^A>#CX2QK.:E/3UU=&2*Q(>R*
MN&YD'4GZ>*SN5N28VW8GPX4\M)-U>-*5J^0@KM))%!-$<L[^6&1QLTL<<+;[
M^CV?=A\?.:9PE"+,4:E74$E_!Q5^NR[0/:Q5FT\4,]JO.$%9FQ\8QRN\$LMA
M]F!GE<F=B.5/,#L@.,.J*%RP>UC77*C3[#CKH2O[AH')O9U\HT[Q_P!XW"1@
M:1*J:;AX52D5NQ%M4Q*6F3J4$K"SSTB%A@'9Y'KWF4/)^7B=6Y*U/BQDL8NV
M60O25)\;6@G"_2A&28?+#/KI(^K$8AE-C!MXY&X?YQ#[6=T+AZ5;-E#4S- <
M5C8KU7+V[5>3&9&<XJYO0CC>O%+UQG,4$;QR$S2Q/Q?S8SX;<78F:AUYM24F
MJ[/WFU<>7'"W;VS#NVECBE[-K/E!K30</M]CKR\2+:!%L2'M,#.P5^KT>Y8L
M).6KS^68HKD1A22;V=36=NQ6 )(X(L@V8J5F9XS:.SC+-XZA6(!>3?CB.,X)
M"8B$)& G;<^%H7NCRA5O')%)9FQ18"];=QF!YJ>8J8V.\-6P8Q[,$T4D=F("
M$3.(C%GVC8RUCLR2L/)A%O>>Q9K\\F^&N\M>NUU%TZ%R&=R\8"AA-YG&7>A5
M$XL40Z]"-PEJW+OP*!0_SB1<G$1[X 7"'2; (9BE.S;//CV$G]XH9Y>U_GX)
M 'N%ELCT-62DP&1JD^[5LH1A\P6*T#\+?-QQ&7>3K9TS&RR^F$4:N4'+_CEP
MUH)]C\C-HU_7< J*Z,*R>J+/[1;)!NF4YXJGU.,2=V"RR!042%P2+CUT(Y)4
MKR5<,&!5'2?HXW$Y#+S^3X^K)8D;9S<688XA?D4TI.T<8]C[.9,Y.VPL1=B\
MG,9W%8"L]O*W(JL3[M&).Y33DW\R" &*68NUMV 78&?B-Q'<FU5^3WLI^VNG
M\A"</N/D'#PZ9U$6FP=]NG<S-/TA$2 Z;:ZI4S%QL&L0 \HV._O-F24[Y1=1
MJ7<.@?)^-Z,8F$3RU\S-V9WKT68 %_8]B82*1O4_#!$[>HG6%\QTS3D1Q8'%
MQQ@SNPV\D122$W:W$-2N8!&_K%SLS-[P>I5-6_M]NU7MCU5PGR9+5&9SB=&(
MJ&J=/1;)J!O^8D[=4.0G5B!Z  'LP[$.GH-U$PC=46A=+Q-M^3>M?;9SEM6R
M=_@TX@S_ #B#*RI^DS6DY.[9=H!]004J "W<15CD?_B-U]](]D!=JI37J*[O
MD3'7E@D<IU(6[ZGU.^9.>@]1(M(0E-@+(4A@_5,5M.M^@#U()3=#!&;0>EYF
M=FQY0$_\^&U:%V[A.8X_WQNI5^D[6=<F<LJ%D6_Z.Q2I$+]Y1P12]O+LD;]^
MSJX3BM[*<2=OXVO<R] M8MHX420=;.T(Y>JMV/?$J0.9+6-QE'SU1H01!R_>
M1%]=.TTBJA'UMXJ*38;2RG1B["4F'O.;LSNU:\PLY>O8;,(B.[\A8X&'?;BD
M%MW5]X7IE8B"+/XQ@9]F>YC7)Q'DVYTYS(N%OSB*.R1,W8,1/LRVH>/_ "0T
M;RFUY';4X_[+K.SZ/(F!'VUKSLQG,6^\D192'L<*\3:SE7G4$E4E7,'88V,E
MFZ2J*JK,J2R1SXQOXZ[C+!5;]:2M,/\ -D;L)O?C-MPE!_4<9$#\F?=G69L9
MEL=F:H7<9;AN5C[..(NT"V9WCEC)FDAE9G9RBE )&9V=QV=EW=G27H)A%CMO
M^"=H\.S?V:YSEN;=[?:N'Y/W/]BC7PP]4;[QI,_9L'DCY_#Q=1#E\?!ECO'O
MU]<B?$4G]ZYG!<A[O!D'F7?XNIL9!33")A$PB81,(F$3")A%J$^RPJ@]=5/A
M+?44C#'0=BWM4)!<"]2%>VF-U9,PZ1C?L*8Z%.G#D+_SP3.(?T!S+'1;,+2Y
MF!W\XXZ,PM_LQ%: W_?-'^]8,Z:X"*#3UIF\R.7(P&_^U.%.2-M^ZO)W]OL6
MF+F8%@),(N^-Z\C=C\B2:8)L4\&<NA]#T#CE0_:2+&+$FN-;+3B]:),=7+GV
MQG"J6&1\^E \W!V HAYLEY+];HT<?7Q_EGD_'_GUZ?(3\9<7^<66!I.#L;A#
MT8\(]NW;VKT\EEK>5_)_E?5_][<95Q-;JPX/\TI]8\/6><_')Z4N(^SB[/-;
M92D:=J9RG::1;:7)^B=5ZPTRXXYQ>\W&J:LMR,B- ND562NGHS;ID/;IK2RQ
M:Z\2W0*@,JT8+'!I*HN0(Y)YCZ8QCW7N?YUPE<;(E2:U*V/*^S\7E95-^!YN
M-F-WWX')NT';L7L#K/-#CVQ_^9.0X]\2&1>E ^5CQCLXO0"]MU@U^!W!FVXV
M%^PV)F)L>A^TEY)0]UHUU36HCX](X?1?!4]8DJH+JH7+CI%03Z!1JEZAO;-,
MTZ]71>D?NI--VQ.K*1\<[*BF5N9)6H>G<<<,\+M.S3Y8LWU@R[2PY I!D>6
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M8"JU>G&SR$P^46C9NOLFS<S+^:#/OU<0OP1L[[;DY&6IFI=4935%TK5^5QA
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M\>F?TK:=+@+O75E/)@Z18ST>B]]KY%-,ZA6TM%+**Q<NS$XG8RC-VS5Z*('
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MFN0DBW[HC>K,Q3:G:N6[JL1%G(===A86I-=4,4,E;'E'?R/:/F%QU:Q<MYI
M?:0Q?_H(RW9V=I#CV9BRAI'HSR><.*YE0EQF)\T_2#P7;@<^&O";;PQFW_WB
M86;A<2ACF9W<=]S46HM;Z&UO4=1:BJ$11-=46(1A*Q6(1$R3*/9I&.JHHHJJ
M=5T_D7[I5>0EY>1<.I29E'3R4E'CN0=N7*N#+=NQ>L2V[<ISV)S<Y)#?=R=_
M4WJ$1;80 680%F$6869FV5HT:F-J04:, 5JM8&CAAC;81%NU^U]R(B)W(S)W
M,S<C,B(G=X(=H-M)(C.N:CC'(&<+K)6NT%2-Z46Z(+-X&/6[HB'5PL=W)+('
M[ITRM8M< $BY!SYW_+?Z1HPJX'HQQ\[%--+'J7431G_%01-+!A:,O"[L[SRE
M:R$T)\)1M6QTS,XS"[;+]!.FB>7(:ILQ[1@!8S&N3?G2$X27K ;]OHQ:*L!M
MNQ=99#F#LI4<2)A2:X\:U<K&$RK6-DX<>OI$J<)/RT2U+_U S9M^[_L+T#^&
M;'_)CRDF6Z#- 6)2<I*]#(XM]WW<8\1F\GC*X]S5:L&S>H=F6,^E.J-/7NH8
MP;89+%:UV>LKE&K:E?XRRR;^U]U([,\K'Z81,(F$3")A$PB810GYA_O6G/%C
M[ZR"RI'Z_AXJG)ZOCX*;&4U43")A%"7E#ZT>._BH_P!XJADQY%W>#J!<Q[_%
ME-K(*:H_]D2O7C7LK=U(-1."$E=-+,I$"B(%,S3VG6)$@*=/VD]L&# P /H\
MH!!_: 9>G1^POJ>F[\QAN./]+R64?^4B6.^E,B'1F09N1V,>)_.+783;?_B$
M5YQ^;"+5-,(MD#@5M:FZ:[(>RW6]<B>2_&J$:]I]"(A<.*K=%SL:T.DN,S:4
M"@297=TI,:2HS;6,=R;]26=3<5[=05?(_K<D@<RK3'>=JS7-61PP8_&Y$WTT
M;]3E'=J\;/DB'KQVAF+K0<F$>%HRX#DX9!?L++&FKM>AH:6Q9RN6Q$8ZQC;R
MC#-Q6IG;$"?DQ[V*XM!(P$9N92!QQQL41L^XS;K>Z;YSCUJ]W5PD+OW0;;;'
M:K2]BWX?C+7"6_=E3JA-#U.'TY:=G52MS\"UDJ%9+/"+3MW)8+".L(^Q3-I>
MRDA+KL%UW?CR4X,)9&EF?(+[U=+C'1_*4G4TY97ORG;BK2R1FXSQQ&P0N$?E
M)1A$PL#%LUQ0Y"QJ*H60T_\ E/&-=UH<V2_)$77Y"&!L9#'1FN0121B=>:>/
MK+#22O3&628C(W%W+/-=S% UUK+<M1V5S$W[1$K?V\DOK1YR+XHC3],&N&QY
MO0=)&<#9,="2*58@]425G:3:MQ0AF=A9%GHZ*F',.Y8)OEV_7L!/8LU):V(H
MS]5H<++8_*=;<ZFN%Z?@\F(QZP[0Q.#0\;QEU9$#&Q;,_8JR5:M7(0V\[DJP
MS])!5"RN$ZBAY1;DQE?K/*QC-H8Z1S#*]AHQE;K0 WC<>)QXF]7_ %19-4]H
M/KGF%K.+TU1>4/:]ON.5EDDU47A]"VJ0XVJ3.LM_1[_S:):R8>[C7%/N%IE^
MC&.F:E<;5(JJ/(UXHW?3@@M1VL#8Q%DK<^,TD.0B%V<6O1#D>"S1(=R<?06)
MHHA[2&6&(6X2;<8V;-*:CJ>IGJ@4*V9UT>*E-G8GQDQ8AI*>3$G8&/\ SBI!
M/,?F@<%B8G=P?8J-NW4A5ZWVF&ZJZY70<N8&B\;H5PY:B<S9PO%\:]3,55VY
ME"D4%!51 RB(G(0XIF*)BE-U +UT0;2:<J2,SLTEC(FS/S9CR%HF9_G;?M6.
M>D>-XM6WHG=B>*KB8W<?S7<,53%W;?9]G=MV[.2J'R[%8JW /8G+UX6?YS1Q
M1.,>M#\=WJP>D2$>-GNZ$&P@'["G40=N@'IT$X)%Z]0(7IB;I2$>KPA?SF/(
M"W]%QIN_ULW[UG7H3(NLU&'\QPQ1/[&)BR#-^]G?OV^9;F&8@6>U$SFCPPTG
MSMT?/:-W="G=13T_MI5;5&%;I6S7MN;H+(QENJ<@NBL5K),RKJMW;59-6.F8
MMP\AY5LY8/%DA]7#YBYA+L=VD>Q#YLL1;O%8B=V<HI19VW%]MV=G8@)F,'8F
M9UXF?P&/U)CI<=D8^("\^&8=FFJSLSL$\!.S[&.[L0ON,@.0&SB3LO.A[07L
MO.3/9XW9U'[,KKBU:FD9)1M1-ZU:.=K42TMU#'.Q9RJ@"X/2[>=N4WGE1GUR
M.17;O%8%[8H9!.9<; X'4V-S\+%6D:*T([STI29IXG;\YQY--#O^;+&VVSLT
M@QF[@VJVJ-'9?2UAQMQ//1,W:MDH1)ZTS/OPC)S>O/LWG02OONQ/$4H-UCUP
M9<2M-,(F$3"*U;LW^R1Y(]H?:X^1@HA]K;CZQDBHW+>UEBW!8(J+9?N2$-0&
M*QFI[[;0*15'S*,6)#0R_DQLTS#@NS2>VOJ'56.P$1#(8V+Y#O#1C)NLW=O-
M.=VWZB+U\1-QFV_5@>S[7II/1&6U3,)Q 53&">UC)3 _5[,_G1UA?9[,_-N$
M'ZN-]NNDCW%B]%/BSQ;TWPXTK5-#Z,K1*[2JNB959PX,FYG[58'9$0F;A;I4
MB+<TS9IQ5%-1^],DBW002:1<6TCH6.C8UGK_ )/)W,O<EO7I.LFD[&9NR.*-
MG?@AB'=^",-W86W=W=W(G(R(GVHPV&H8''P8W'0]57A;=W?9Y9I2VZR><]FZ
MR:1VW(MF9F9@ 1C$1&0^>>O46J-[*S>O$]!\3HXAC^U[K;]Y>NB@(^3%XPIC
M1!@8P?L$Y4)*1!,1#J!3J=.@"/7*/1>(^7Y4OYS5(1;^B4SN7UB/U+"W321-
MC,(#?FE?L$_](:[,/U&:TB,S.M>%,+L](:(L7/3A; 6"*C9V"F^5.@HJ9A9E
MBUDXF7BY#:57:OXV3C7J2[-^P>M556SMFZ15;N4%%$5DSIG,4?)SQE'@\R8$
M0&&+OF!@[B0$-65Q(29V<2%V9V=G9V=F=GW7NZ7C"74NGXI0"2.3-8P)(Y!8
MP,"N0B0&!,XD)"[L0DSL[.[.VRV9K?6.'.X.1M-XQ<BIOA%MC:4[VBT/%Z;J
M_%?63:G6?7VA:M.W UJU7R+ML%K[7D-*#*!'0-(?T\[B>DU)]PX?,Y>7\F=_
M#XWBDR]/'S9+'QYJK5#3YE<ER=IY8Y[TL</56L?"=BP8\'%),,S, L#,+@'Y
MIY?FAP%[*P8C+2:=NW9-5 &/@PU1H)JV-ADGZZGE9HZU6,^/@BKE [RD\I.X
MG)VE'TE3:U;.1UJXH;AVGJK@8-%KG:N4'2;*'UC2FU!WAK6 5V'9JV7C9M+6
MT'JZ'UW:*6O"5-*[QY;+:;#;6<*YB7BYS(3DLQ2[DTD6/BRE2K9SG72Z6GN.
M=F9YZ5F1J\4CY&K8.T=B*;CFZDNKBCB<V,6[0!UY]>*?+3X6_=I::\FAUG7Q
MXA3KM6R-2)[,T+8F[4CIA5FKO'"U@.NFDF&-P)_XPQ7?V[Z)I)_9>*TG>(WC
M!NZ:N_;*ZEU#J&UZ XXP6M([6>OZ1MZ-C]G:'WW+MZM56EP>N8M_'L&U9G8.
M11G?-7UDCG\Y$)JNVW1I3W!CR@P%DJ4<&D+=NW%?R!V2LSS5"*M>H@\LKPLQ
M"1/)&8N&XQD($^S^ED:V.*;#'8'#Y&2QKZC1H38S%1U IUJ]X!N8W)2-#"-@
MG @%HI(S:1V*4#DC9W'H3FUQ2XZ5?B3VLG*/C]7J:;66Q-D\?:E 01H:""R\
M>]]ZLY33]&Y%Z[@$$T57E1K=@&3K%QKH1)HIE)4VY1\4A'HPD9')J=["Y3(2
MY72V,OR3-9KUK\LA\9]7?HVL9'/C[$C[LTLD?!+#)Q<;C-"1.3F1;>;J+"8J
M#!ZVS&,CKO5MW,7!'%U<?78O)4LS-6RM6)F;B@AEXX9XN#@8X)Q!AZL!WU0<
MRDL)IA%O\>Q?'KUUV=]]0="<4(WE9L=E' 81[I62FM=,R)P3Z^@">V#]^80#
MH'E#*#^T1$<$])8BVH(';F6+KD7]+RFX/;_PB*V:Z'B(M+66??8,U;$?Z+U*
M!]GS<1%\=UL+6_X)VCP[-_9KG,?-S;O;[5E5^3]S_8HU\,/5&^\:3/V;!Y(^
M?P\740Y?'P98[Q[]?7(GQ%)_>N9P7(>[P9!YEW^+J;&04TPB81,(F$3")A$P
MBJ![1%HH3:-*?" ^1<T%-H0?3T%1E89Q94 _AU K]$1Z>GH)>O\ #/EU\NBM
M('2+I*X[/U4^BHZP/V[/)4SN8ED9O5NPW8M_7VMOZEM9T"2B^F\Q"VW%'G"E
M=O7PS4*8#\'> ]NYU$G46T9_3]YB;K CY4S0PMI6,.H9-M-0S@Q ?Q;D2@8"
ME6(0JK982*>:/D6KPJ9S(%(.LG1ATBYKHMUCC-785^L.J15\C0,W"#+8FP0-
M=QMAV8N$9A 9()7"3R:Y#6MC&9P"+Y2U5IJCJS"VL/>\UI6:2M986*2G<C9^
MHLQL[MNX.3C('$/6PG+$Y"QN[7^:ZV)5]HU2-N%2?E>QD@F *I&$I7L8^(4H
MNHN3;E,86K]H<P%53$1(H04W+=19JN@NI]L-":ZT[TC::H:ITQ=&WC[H;21$
MXC;Q]P!%[&.R$ D3UKM4B9I(W=P,"CL0'-6FAFDT:S^!R6F\G8Q.4@>&S 7F
MDV[PV(7=^KLUI'9FE@E9MQ)F9Q=BCD$)0,!SC+P7C*KWDWV-G9W\K'\A8;]H
M"$J=YDSJKN[_ *B=N=8V1T\7$3.)&4;5L4*K9)-<P@961M-:G'AQ !%;^EUN
M;&ZOU!BV$(+YS0CLS06V:S&S-R$7DWEC%O4,4@-\RL[+Z"TMFB*6SBXH+![N
M]FB[TYG)^US-H=H9C?UG-%(7SJJ*W>Q5.,3YXJI1.3F]JRQ,83)-+5"4"Z.$
MBB/4""\BHJBD4 H>@!%H4PAT[PB/41NB+I/R8LW7XVC(7K>(YX6?X&<^W[U9
M4_0OAR=WK9C)0CZFFCK6';X@%;?U^KV=[_92O8K'%6->)+; Y([\MK-,X'.R
MJ\?0*.*_='KY-5S(P-Y4*D?T%5!$B*PD[P)+HG$JA.)ND_*$+M!CJ,1>](4\
MVWS["</;[-W=O:S^N5?H8PH$SVLMDYV9]^&$:M;?MY.Y167V]3[;/['96Z<7
MNR5X \1'T?8-3<?:R\O489)=IL?8JKS9%W:/DN@$DH:2MJTBRJ;_ +H=T5Z9
M&5P!*8X=SHJKW[3R>JL[EA*.U?D: NQZU=FKP.//A,8F%Y1^:8I.3>Q7SAM$
M:9P9#+2QD)60V=K=IRMV&)N1QG.Y#"7SUPB5C^6\KK75&Y-NUK3%+?6NP*D5
M<=U1M PI%2D>STN9,1;L6P#WC$1*/15^\[AR,FA3K&*HIY%!;&O2KTGZ?Z)]
M)W-2YN49)^$Z^%Q R"%O-91P=X*<#.Q$$0OM+=M<!!3JL<KC)(\4,MSZ2TKD
M=79>'&4 <8]QDO7'%RAHU6+8YI'[&<W;<8(MV*:5Q!G$>,PU_+G;IN^6F<N%
MC="[F9]^J_>J^D$R"?H1%LW((F\DT9-R(LV: "((-4$4BCT(&?$G56I\OK/4
M67U1GK+VLMFKLMVW+YS1B1[#%7@ B)XJM2 8JM2'B)H:T,43.[ RWHQ&*IX3
M&TL3CX^JIT8!@A'L<G9MW.20F9N*6:1SEF/9G.4S)^UU=MPP:*-..5!%4!*9
MTI:792C^T$U;=.%2'_J43(54O3_FG ?VB.?73Y)]8ZW0-HIY&<7L2:CLL+\V
M"35&9&-^XXP&1O:QLZTZZ791EZ0,YP]K1CC8G?VD.*I.7T2=Q?YV=2DS8Q8U
M3")A$PB81,(F$3"*$_,/]ZTYXL??6065(_7\/%4Y/5\?!38RFJB81,(H2\H?
M6CQW\5'^\50R8\B[O!U N8]_BRFUD%-5B=LQJ1[NGLR.751BVQW4I$:Y;[+8
MII$%1R(Z@L\#M)^1J0H"=1PYB*C(LB))E,JN#DR"11.H4,N71]H:>I,3*;["
M=AZQ.[[-_G<4E4=_F8YA?M[&VW?DK0U[1+(:0SD -Q&%1K8LW/\ S&:*X6WM
M=P@(=N;[[-VNO,*S9-:?)A%RX6">"!-5@FY<*P:6+/FK@23P($TZ1F:.)-&B
M/+>UXRQ(\YV)9(6_GA69S-@6!$PD&'5Q]9UO '6\'5]9PMUG5[\7!Q[<7!Q>
M=P[[;]NVZJ=;+U74]9)U+GUO5<9=5UG#P]9U>_!Q\/F\>W%P]F^RY2J7R\T1
M:0<4>YVNFKRS(T;*KU2Q2]>6DX\XB)V$@I$/&9WK(PB(F:N3*(&$1$2#UR,L
M$$["TT,4S 7$+2QA(PE[PL;/L7SMLZG#9LUG-Z]B>N\@\$CPRR1.8>Z?5D/$
M/^R^[?,N-]T5@"""KA.S(5H)GW1!7?;-[[1!8/,_:_V]")\OY@$SY@ ,?;/S
M?SWS,/-O+^1_4R75Q\?6]6'6<'5]9PCQ]7OQ=7Q[<7!Q>=P[\._;MNH=;+U?
M4];)U/6=;U7&75];P\'6\&_#UG#YO'MQ</9OMV+E9[8%\M2+UM:+M;K(WDI9
MK/R*$]9)F81?SK&++!LIIZE(/7!'4LSA"$AVLBN51XWBRECTEB-"@B$(Z\$3
MB\4,,;B#QB\<8 XQD7&0"XBVP.?GN+=CEYSMOVJ<MJS.Q--9GF8S&4FEFDD8
MI!#JQD)C)V<QC]&)OYS!YK/P]BX::G9NR2"DM8IF5GI55%HW5DYJ0=RD@JW8
M-46#%!1X^67<G19,6S=FT2,H)&[5!%NB4B*1"%J  1CP1@,8L[NP@+"+.3N1
M/L+,VY$[D[[=KN[OVNJ<DLDQN<LARF["SG(9&;L+,(LY$[OL(LPBV_8S,S=C
M+BLDH+>&]BK:D>U_CQR=W6[;'00V=MBH4*+55()1=LM2UB0EEW;;O  G:#([
M4=LO+$$4SNX]TCU\HU.!<+=)]MI,AC:3/N]:K+.6WJ*W((LS_/PU1+;V$S^M
M;$]#%$HL5F,@0[-<O05@=V_.&E"1N3>T>.Z0[MV.0$W,5M59C!9G3"+@;15:
MQ=Z]+U*Z5R"MU5L#)6-G:S9XB/GJ_-1RX "["6AI5NZCI%FL  "K9XW614Z!
MWB#TR<<LD,@2PR'%*#\021F4<@$W(@,78A=O:SLZIS0PV(C@L11SPRBX20S
M,L4@OS$XS8@,7];$SL_L5 _)WV-IP1W:_D;'J)Y>>,-G?G57,SHCM"U:V,[7
M$3JN#T*UG6>,$P.(>0C:K;JO#-4^\DWC4R"GY*^\;TB9RD(QVF@R48[-Q3L\
M=C9O5U\6S%\Y2Q2F_K)8RS'1-IO(D4M$K&'F+=^&L[35')^;O6G=R'Y@AGAC
M;U JG;?[%,W\R>*DH/+#3]DCP.((.;?2;I27AR=?U1590KC8""1Q#]I22"P
M/[#CETP]*%!V;K\7;C+UM#-#,V_S.;0._P"YE94_0MDQ)_)LW1E#?L>>O8KE
MM\XQO:;?_B^*^ND^Q2MWO7B)=C<MM55F/[Y?+JTF@6Z\/ 3 ?U@1;SLGKU 3
MB'H*8[D *(]1*< [H\3=*%(6?R?%6I"]333Q0-O\[@-A_J4J_0MD")O*LY3B
M'U^3U9[!;?,TAU6^OY^WD]O7%OV.?P#T _CK-L>.MG)VX1YTG*9ML.F;;7K=
MZETZ*MM;5Q!C&234X=X%8R\2=V8'$PF% #%3$EIY/I!SM\2CKE%C8B;9_)6)
M[#L_MLR.Y"_L*$82^=7SANBK3.,()K03YB<'9V>\0M58F]8U(F$#'VA9.P/S
M<MKX8>'B*]%1T% 14;!PD.S;QT3#0[%M&147'LTBH-&$='LDD&C)FU1(1%NU
M;(I(()$*FD0I"@ 6.9G(1'(1&9DY&9DY$1.^[D1.[N1._:[N[N[\UDB.,(@"
M.( CCC%@".,6  $6V$0$681%F[&9F9F;L9ER614TPBUS/9.6I7MY[/\ K&QH
MQJ9972F]J;89MP!.\#2IW*(L5 =F,(!U("MLL%)2[XF GI[IBB8Q!+D'HVM#
M!GI*Y/LURC-&#>V6(XYV_P#VHYEBKI?HE9TQ#:!G=\?DJ\LC[;[0SA+5+?V>
MFEK]O+U>M: 69W6LBS#7M^MVJ;[2]GZ_F5:[>M=VJ NU-L"+5B]6A+15Y1K-
M0,LDSE&KZ-=*1\HR:NB-Y!F[9+&2!-RV61,=,U&Q!%:@FK3AUD%B*2&:-W(6
M.*4'"0'<7$FXA)VW%V=M^QV=5ZMJ>E9KW*LCQ6:LT5BO*PB3QS0F,D1L)B0$
MXF+%L0D+[;.SMV+[G^T=@R.T'VZ5K9+-MJR%\=;/6O,2L2"G4+^\L"EJ5M4:
MO"IQZ<1*DL2II9HK$I,DV#L$S,4VY4DBDX&M7&L-/J@>J,#5F@-N,'@:/JFB
M)CXN,>K;A=B=^)OSM]W4BN6CN%D'G-KI62N/9!^KD:T4KS/,#QL+ ?6OQBX,
M+"6W"S;,I7[([3/G/MRSZHN&P.0,].3NDKTQV=K51&LT"#C838T<J@LRO<A
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M+O"L'9P@Q-YO$39U+DRLJC?VK ("2+8U ?N5*J,&1^1!FP?IN8UBR9H56Q=
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M+N\'4"YCW^+*;604U\,G&1\U&R$/+,V\C%2S%W&2<>\2(NT?Q[]!1J]9ND%
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MC[ZR"RI'Z_AXJG)ZOCX*;&4U43")A%"7E#ZT>._BH_WBJ&3'D7=X.H%S'O\
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MN*6E,[O"3OMQ'&[>=!*[=G6!V%V=8$C"S-:&J-%8?546]N-Z]X X8,C786L
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MDE%]EG32?1EB\ <5[(&.5R@.QQD0;4JIMVL]> MWDE!^T;$W:SL)Q10FV[[
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M7]MC*2PN&QVZ[---F)1=.6]SZHZ+Z/2'K[7$DF=?'9#'5<%'3IQQ1RNY38:
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M ##_ /%Y^AKRF?\ 6/\ N'[E\XNHB]QOK^]/T64#^6VO_F'_ .+QY3/^L?\
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M$6$5&M2*.Y!^X;M&R9UE2%'U<-ALEJ#)T\/B:QV[]Z5HH(0]O:YR2$_FQ0Q
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M8T_E[M;9WW[0J7CR.-CVW[&"D+=C;L[=BOK'=,&NJ'"QY*#(QCRCR-*"3?\
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M 1 BDNG;*LM!.+0A9(%>M-&RSQS8$)=@O"H-&Z?E5W*LHDX.R(@DE_E%%3+
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M4BN?I5H9W:G56XQY#)LK578:PM4C& QT$9B/;OR-U!  ZJH OY%7T!T4(8!
M!#IA%D^$4)^8?[UISQ8^^L@LJ1^OX>*IR>KX^"FQE-5$PB810EY0^M'COXJ/
M]XJADQY%W>#J!<Q[_%E-K(*:81,(F$42-S3$NQNBB#*5DF:'M8P/Y%J^=-TN
M\8%>\;R:2I"=XW0.H].H] ZCGJ5  H6<A%WXB[7%G?ZV70L$32=CNWFMR=V]
MJZH]TEB^/YKZ4??X^=GJX_U8?1'[E0XS]XOI/]Z>Z2Q?'\U]*/O\?'5Q_JP^
MB/W)QG[Q?2?[T]TEB^/YKZ4??X^.KC_5A]$?N3C/WB^D_P!Z>Z2Q?'\U]*/O
M\?'5Q_JP^B/W)QG[Q?2?[T]TEB^/YKZ4??X^.KC_ %8?1'[DXS]XOI/]Z>Z2
MQ?'\U]*/O\?'5Q_JP^B/W)QG[Q?2?[T]TEB^/YKZ4??X^.KC_5A]$?N3C/WB
M^D_WI[I+%\?S7TH^_P ?'5Q_JP^B/W)QG[Q?2?[U@.TYZ<<:ZN2#B9EET58%
M\15%:1>*I*$%/TE43.L8ARC_ !*8! ?XAF'OE @#="G2:[ +.VD,ML["S/\
MQ/<KTZ.B+^'6E?.+_75/UO\ K%67GPC7T"3")A$PBG)QCEI5A1YE%C)R#)(U
MK=J&2:/7+9,R@Q$*45#$14(43B4A"B80[PE*4.O0H=/K'\@X!+HEU*Y"+O\
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M?'/_ "0]+/\ YK^D3_U*U+_\L6Z/\,M(?^56F_\ TYC/_BD_0ANG_HAVA_Z
MM?Y3C_)#TL_^:_I$_P#4K4O_ ,L3^&6D/_*K3?\ Z<QG_P 4GZ$-T_\ 1#M#
M_P! 6O\ *<?Y(>EG_P U_2)_ZE:E_P#EB?PRTA_Y5:;_ /3F,_\ BD_0ANG_
M *(=H?\ H"U_E./\D/2S_P":_I$_]2M2_P#RQ/X9:0_\JM-_^G,9_P#%*UK@
MI5;14-466.ME;GJO(+["DWJ#"Q0\C"O%F:E;JJ!':362;MEU&IUV[A$BY""D
M95!9,#B=(X%^D_R-]-ZBTOT:Y^AJ7 YK3MZ;7.0MPT\[B[V)MRU#P&FX0M1U
M[\%>8ZYS03Q#,(/&4D,H,3E&;-K%TU9/&Y75&/L8O(4<E & K0G/0MP7(0F'
M(Y0RB*2O)( R"$D9N#DQ,)@3ML0N\ULVU6($PB81,(F$3")A$PB81,(F$3"+
M';?\$[1X=F_LUSG+<V[V^U</R?N?[%&OAAZHWWC29^S8/)'S^'BZB'+X^#+'
M>/?KZY$^(I/[US."Y#W>#(/,N_Q=38R"FF$3")A$PB81,(F$3"+C9*:AX4&(
MS$M&Q(2DDUAXT9)^U8A(R[[O@RBF(NE4O.Y)YY-3S5BW\HY<>3/Y)(_=-TD(
M&?%P 1\(N9<(N7" _G$6S/L+>LG[&];J!R1Q\/6& <9, <9,/$9?F@/$[<1%
ML^PMN[^IER614TPB81,(N-B)F'GV*<G!2T;-QJQUDDI"(?-9)BJHV6.W<)IN
MV:JS<YV[A)1!8A5!,DLF=)0"G(8H2,#C+AD @)MGX3%Q+9VW9]G9G[6[6]K=
MJA')'*+'$82 ^[,<9"8OL^S[$+NS[.SL_;V.VR^MTZ;,6SEZ]<H,V;-!9T[=
MNEDV[9JV;IF57<N5U3$20002(=5994Y4TTRF.<Q2E$0X9G)V$6=W=V9F9MW=
MW[&9F;M=W?L9FYJ1$PLY$["(LY$1.S,+,V[N[OV,S-VN[]C,ORCI&/EV+63B
M7[.4C7R)'#*0CG2#UB\;J!U37:NVQU4'")P])%4E#D,'I PYR0D!.)B0D+[$
M),XDSMZG9]G9_F=<"8F+&!"8$VXD+L0DS\G8F=V=OG9U]F14DPB81,(F$3")
MA$PB81,(F$4)^8?[UISQ8^^L@LJ1^OX>*IR>KX^"FQE-5$PB810EY0^M'COX
MJ/\ >*H9,>1=W@Z@7,>_Q93:R"FF$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(L=M_P3M'AV;^S7.<MS;O;[5P_)^Y
M_L4:^&'JC?>-)G[-@\D?/X>+J(<OCX,L=X]^OKD3XBD_O7,X+D/=X,@\R[_%
MU-C(*:81,(F$3")A$PB81,(M0;>G(KE;RQ;<'.2FQKCJZ.XWO>VPTMKG6^B:
MU1'S;851<:PV#=Z_7++-[%<V!R%A>3$/&6I.RP9X1DW)(N(.5AEF3)=Q$,\L
M4<?B\46:QU>&T61'1MRS8NR3B]>5K,$,DD05VC;@$#*+JY&,G<6,#8B9C+!F
M2RF9S8Z<RUJ>F&*+I!Q]2IC8JI-:@>G:LQ132VBE?K2DC"9IHNK$6,HSC<1=
MP;.- =L/V@UOAAY06+1T[L'C58M9<L]BSL' \9MF5/7NE&>CZ;?[+K/VLY-J
M/I*K;*2MDU1_<A>'#QO')5^4=.F;(@2J9636C?TC@83_ ";'="#)1V<57 SR
M566Q=*[-!%9XL:S#-6ZH)^N@9N)Y!9G?S.U^SC-=ZGGC_+$N.EM8B6GF[<D<
M6'N0UL>./KVIJ?!E^(X+;3R5_)[+DP-$9$(^>W"W+6/M&.TEU#6]17C8FT]!
MW2)Y'=GGO;FI3(:JZ=7K[C75@K&H$]BU"ER+MY:Y<;+#0IY2"%604!H[E%C3
M4:\,NDS:2+F$>GM.VY+<%>K?A+'Y^EAICEN-(UB.2V]>686:(.K,V$]A[6%N
M FV=W%IS:KU91BH6;5S&6(\MI?):@KQPT"B>I+#0\K@KD13GUT<;G%N3\)&_
M6 6[,)E(^?Y0<\-<\:=%[3W'S.T/5[;RW1U+8M/5+6O!O9VZ=GM$++K1]>;A
M2:71J=L9=2YOXP']947FIN&39)-4I<_G\6Z?P44X\X,;@[&1NU:>'O2Q8I[4
M=N6SFZM.L_5V1AAGFFFKMU(GPR-P ;ONX>:3"9MZTF8U)4Q&.NW\_C89\WY%
M+0@IZ<N9"V(RU"L3P5ZT%MWG(&*(BDDCX6%I/.!RC!^E^.?:9<\^8DQQXXWZ
MYM6G]3;BL<SRG6V7NJZ:8L+QK.P?'V9B8RJ,(_3<I:8EU3IZT#+E0OD:_DAD
M(-1$7,8C%K,W40Z[F0TY@\0%_(6(KEJI&&,:O3AN1LX'?C,I"*X,1#-''P.\
M!"/">[,3DQ,3>?BM7:DSTF+Q-2:A1ORR9E[>0L4)2&2/%R $(#0.:,H)9NL9
MK($;G%L[@P.+@\..*O-3<_'SL[] T[2?(*LT[8T30^6^\+#J.O<1ME<EK=8F
M5?Y$;*8QUDL%DK$VA7=5Z<DY5C(U]U;YR.3>P3YJK(J*S#!91*%]C*8:G?S]
M^6Y0EEKE/BJ4=L\K6QT4;R8^NY1QQ2@\EJX(N,C0@7"8NP[ 3>?X6%U!D,7I
M?&08_)PP6PKYS(S48L'<R\\HQ96X(RRRPR-%2H'()Q//(+%&0N6YB[M'W;4>
M1W,'D-R'VAM"Q[7J:>K+MV+[;DG<./#VM6>6U<\A+)2IB,FJC%0+J[@QC["^
MV.#Z7<WPS=Q,NM>.4Z$Y%4Z9IM3I2X[$T,?6JQU97LPZQ?&Q9!I(@M,<4PD$
MI&T/$48U]A:#=@:PSSM^K7I097.Y3*7+DMV!J5G0 9:?%%#-)4>.:O*$D 1E
M8X1E*UQ2%9<7,JKM5)GVZQ<]J7G1S+D=!!!<7I'CWHRD\*.S2U/RQO-8GM72
MUJ9[6EIZD3%]=Z^K");?&C0Z:UKD&XCV3QDJ]EV\X?R2[\[2206A*=K"8@;W
M'DAR%V;,ZCM8J"2.R$95@CG"!K$KO"77S/(;.XEP@X,[LS.+L4Z.H\\>,ZO#
MEB\;7T]I&CF[,,E*28+LDE:2R]2%FL!Y-7:*)P$A<I&D[')Q)G#D9[M1^T'V
M/5^8?(C3MIT70=3\4-+\(M^CJ>Y:OD[9/W)IR9T73MFV&A'NK2SPRD;&PKR2
ML*I)DD<>7?=V'CV3F+0,[?%B&FL!7DQ&/N1W9[>4N9JAY5#9&*.$L=>FJQ3]
M2\1L1&PQMP<7 /GD3%YHJ4NL=3VH<[E:,V-K4<+C].Y/R*Q3.>6PV7QM>Y+5
M\H&:-P",CEVD8',O1B+@W$:V@Z%: N]&I=T*T&/+;ZG7+05@*H+BR"?AV<J#
M05@(F"PM@=^1%4"$!02=_N%Z] QK/'U,\T._%U4LD?%RWX#<=]O5OMNLPUIO
M**\$_#P]?#%-P[[\/6 )\._KVXMM_6LLRDJR81,(F$3")A$PB81,(H3\P_WK
M3GBQ]]9!94C]?P\53D]7Q\%-C*:J)A$PBA+RA]:/'?Q4?[Q5#)CR+N\'4"YC
MW^+*;604TPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A%CMO^"=H\.S?V:YSEN;=[?:N'Y/W/\ 8HU\,/5&^\:3/V;!
MY(^?P\740Y?'P98[Q[]?7(GQ%)_>N9P7(>[P9!YEW^+J;&04TPB81,(F$3")
MA$PB815D..R%X/*[DCMWMJ+=XNS0N[XKD;!5N*VSL9CK.#W+&SC6R.+K$:U3
ML/N/8/IN88LW$T@C%@R<(-DXYJW9QG?9GN1M69IJ94GGA*,Z18\Y2J5RLG3(
M'C:$K'5]:0@!.P.Y;L[N3N1=JM!]#:=>^&1:M8":/(AEHX@O6QJ1WQD:5[ 5
M&EZ@2DD$7D9@V=F8680W%^;IW9;<2]56^XW_ %A2;%'OK#![1CX[5LWM;:#W
MCY'N-N1+Z-O;1/4!;*I46L!;RO549R&2B',6V;G35A8M@ZC8@[&$VILK:AAK
MV9HR&,ZKE9"K6&^35"$H'\KZMI7DBX6<#<V)W;SR)B/BJP:.PE*>Q:I5Y0.6
M.Z(4Y+MPL6)7@(;(^0]<\ Q3[[21M&X,VSQ@+A'PU3\6NQ/V,WWHG8^2-0U7
M0=(0?'O:^A7&O]5\A.0&W7%R8;5CW%>>Q]0<[61;/]1:U@X24GG4#"14NZL+
M:4D.L@ZEE'!I"-NC)ZRKO1ZO'36I[IWZMYI[./H5&A*J32,4S5=QMV)#$&D,
MA:-Q'S6#;A*RL-T?6FR+2Y:O3JXZ+%W<:]6EE<G>>P-T'B(8'NL)4:D<9R/%
M&!E*QEYY&[\0W3;>X#\<=UZMTEJ>W0=OC8CCBA7D-)6BD;#N5&V+KTM;K#:F
MLS0E\K$O'6'O/*VT0C9;SMVY)(^20>KD&0:M';>SJF<R%*U<M1'$1Y!Y'N13
M5X9Z]CK)'F?C@D H^R1W(=F;A[6;S7=GR!>TUBLA3Q]*>.<(\4T38^:O:L5K
M=7JH6KCU=F&0)?.A9@/B)V/9B=N,1)NA5.QQX)DHU-HD71;_ %QMK^[W^]U*
MU5G<NT(+8D3([3:QK'8D4&P&%H2M3VO6UE$,&LK%2,F[**::RC99NX>O5G'>
M_A=F^OFG*>"1YX:\$L4M.J=<QJN15R\G*)XFDB(B<3$6YMONS"S>9_ /3;5H
M*P5K4+5K%JS!-#?N1VHSNB V@\J&9IRBG&,&,#,N3NSLY$[\4?L6. Q*K2*?
M$T38M7BJ-2KGK)LM4-V;4J\M9=8WVX3E]L>N+S+0MI9OKA2G5MLDS+DA)I9P
MB0[U5J8RC$?-LG_#'.];/,<]>4YYH;+M+2JRC'9@B"".Q !Q.,,S11@'&#,_
MFL[;%VJ#]'^F>IKP!5M0A6KV*8O!D+L)RT[-B2U+4L21S"4]=YYI#:.1W9N)
MV[1[%V<Z[+/AFX>ZNE$J#9HV7U%H1]QDJ\K$;)OL4Z?:2?05@KXTFVIL9]%C
M;FK5I9YERR?3K-Y)-Y%=N^!V9:.C?-.JVILNS61Z^,@MWFR4HG7@)ANL<<G7
MQ.0.43N\0,0@3"XLX\.Q%OW7T=@7*F;5I@DHXPL/"86[(.6.**6+R>=AE89Q
M89C(2D$B8W8N+<1VQ"\]CYP5V!$ZZA9G7]TC6.N=4P&C$@J>VMDT]:[Z?K#@
MKN&U]LU>N62-4O4&T< *@*3)E)4X>32-)"BU9IMJT.K<W 5@PL0D5BU)=]+4
MK3-#;E;8[%9I8R: W;U!YO\ L]K[]>QH73ED*L<E6P(U*46-9H;UN![%&%]X
MZMMX9@>S&S]OI-S?EQ;,+-VX^[.GB>]@^2U93U^\C*[RSJVJZ5N*$A;-/148
M]J^EJFC2-<PU7:,WJ25.9P%9;H1I$Z\5B#E-%,[CRAR@;.HV?RC'CI'G8I,5
M+9FJ&<8$32W)GGL'*[CO,YRNY>DXMM^Q=X]+84X\O#Y,0Q9N&E7OQQS21@4.
M/@:M4CA$29H!BA$09HN'?9M]U,BMP$94Z[ U:%2.WAJU"Q<!$H*K*.%$8R&8
MH1S!)1PL8RJYTVK9(AUE3&45,43G,)C".>1(92R'*;[G(9&3LVVY&3D3[-V-
MVN_8W)>]%$$,4<,;;1Q1A$#.[N[!&+"+.[]K[,S=K]KKFL@JB81,(F$3")A$
MPB81,(H3\P_WK3GBQ]]9!94C]?P\53D]7Q\%-C*:J)A$PBA+RA]:/'?Q4?[Q
M5#)CR+N\'4"YCW^+*;604TPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A%CMO\ @G:/#LW]FN<Y;FW>WVKA^3]S_8HU
M\,/5&^\:3/V;!Y(^?P\740Y?'P98[Q[]?7(GQ%)_>N9P7(>[P9!YEW^+J;&0
M4TPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MH3\P_P!ZTYXL??6065(_7\/%4Y/5\?!38RFJB81,(H2\H?6CQW\5'^\50R8\
MB[O!U N8]_BRFUD%-,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB818[;_@G:/#LW]FN<Y;FW>WVKA^3]S_8HU\,/5&^
M\:3/V;!Y(^?P\740Y?'P9=>GU9R-J>QMC6O77M R:W&QS#TJSQW#.E%XU>8>
MOV/>;R""_FRG<<@8Y2@4X"/<,(]W.=P=FW]3?.N-C9WV];_,N?\ ->;/QE5/
MFZI^ QZ/\<2>D_'"GFO-GXRJGS=4_ 8]'^.)/2?CA3S7FS\953YNJ?@,>C_'
M$GI/QPIYKS9^,JI\W5/P&/1_CB3TGXX4\UYL_&54^;JGX#'H_P <2>D_'"GF
MO-GXRJGS=4_ 8]'^.)/2?CA3S7FS\953YNJ?@,>C_'$GI/QPIYKS9^,JI\W5
M/P&/1_CB3TGXX4\UYL_&54^;JGX#'H_QQ)Z3\<*>:\V?C*J?-U3\!CT?XXD]
M)^.%/->;/QE5/FZI^ QZ/\<2>D_'"GFO-GXRJGS=4_ 8]'^.)/2?CA3S7FS\
M953YNJ?@,>C_ !Q)Z3\<*>:\V?C*J?-U3\!CT?XXD])^.%/->;/QE5/FZI^
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-).SOV>Q2!G9NWVK_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g838337g14g22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g14g22.jpg
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M_*F2GBTYQ;CQXY<=></'Z4-H6H_8#KJXQF+2%+=IZUIM$%;CB'T(2DD25*4
M  .9-L<Q5TJPG36,J4M*M+3:FU*L(CKN1$"_TPTZAXI#K%Z4S6\;C0%M=R_:
MF!*14,QEM<NY;2EODE],9M3?/EPW"@%!?'^]MU'\Z>#F5UR>]2OPM0.\"C(?
M9FTDF/I]CC0)BH844$*4%$DIO!;=TR8MX8^'E.-D^JWQ(\#OJKI-F&I6I&G5
MI$S.9B&#875VTFYCTT[(8M[D5]-R[ +RN;A.U&1TE=6(@5>%6M).G7=7E34V
MCS>^JHE; <D.S^C!B@8&@FNV(V6/7-'>RK?%ZN#(R?)]*F]2,LKI66YGD-GJ
MYD,RC@9],LI$RBI,-M9VC-70_N3#FT&+SXCJ&HK*ZZW,9M]QZ>?K]]HY1:&Z
MYU&;XWE%Q>93#PG%\,NW[ZKN,\L[.-*59X[KI:V](Q#1FF4RYJ8V;:HXW J*
MJ^>OH#.":;XD_,S.?DE+#B/&,@@&?,;>1!GRY_L&*-[4J^:-&^VY7MG./[,=
M)%!91N.(Q?'3ON?&P!.WGP!N!YVZA:@Y[6HI"PHU30\,@D=ZJ0(N1ITDCF#T
MV])+?8.1.(E C*&DA(@"31B2!L+GQ<SS)QLK(251WTI&ZE,NI 'DDE"@ /ZG
MJ:8\VHC6B=M29G:)$SB UL*?'FQGY+#K3#;@6ZXXA:$-H )*EJ4$H2E/R2H[
M#HP_5+U.XRXVVI*UJ&E"4E*E*5J&D) N23$  F=L/>2W=+#H;.3,N*N)&;C*
M+DF3/B,L-I*T("ENNO(;0.:DIW4H?4H >2!ULAM;ZPRRE3KJY2AMK4IQ1TDP
M@(!7J !/A!( D;8;:9MQBH9>>;6RTVXE2W'$J;;0!S6M0"4CS) OBCH>38Y<
MJ564^2X];6+S*UM0*JXKILQQ+)#CJD1XTEQY8:;2M;A"#Q0%+5LD$]+J3+JZ
MB?0_64513,) 2I;[+R&YDZ2MUQ"4R5*@ G<VWC#EF]72U5"^U1U#;SYTZ4,O
M(=<5<$Z4(65$1)) -I],3;#(<F+=H>E,J9:3%D)]1Y'!(4KAL I0 !.Q\ C?
MR=C\]+:^H9<I2EMP*)6@Z0L';5N)O$\Y_68C3TE0E\+<94-(6 HMF1J"00#I
MM,7 L8'08N!#K3AV;=;60-R$+2H[?GL"?'\^F+#@4J3[R5)]01]N/3HQKB(Y
M;$D2V828S#KRDNN%7I-J<*4D(_BX@D [?Z=NE] MM"G"XI*;)C40+R=IZ?KP
MCJPLA(2E2A"@=()WC>-]MN>/#&!^%QI*+)28)>?"V1,6F,7$I0$J*$O*22$_
M3R(\ J&_YG-8 ZM'<CO $^+NAK )//3-SC-.LA![TE,&$A9(A(&PU'8&;".L
M"<.TY29WI+A+1*0DJ0M<9:7D)5])"5J;*D@@$'8D$ [[;'I"I*DF%)4DD2 H
M$&-IORD$?##K2.M@+)4GE!!'Q \_2XL?+%-9S07<RU0N+4S);8@M-%;$5YQ'
MTNN_NRI""D\0KPD_"3L!MTU5R'W'6RV%$)2#,$I2H$D$<M0M!%Q\,3KA[,<O
MIZ127JMEE2JA;FEQ:$DDH'C(*@9)2)5<D@7VP*FHBF:;)%PK1V+5RQ"B.KBS
MY+$.2&W YZ:RQ(<0[P4 >"N(20/!.QV0*R/.ZM*%TF75C[*=8!9IWRT'%**W
M "VDHU$JU*(\1)E4G$^RGB'A]FEA_-LN;<+BB0M^G0N+7(4J;G40><S><0[1
M.WJT6FMI-K7(2O5>M6@F?%"5I&B>CB"M!]8!:>;:T%2=QS0I)/)) 8LN;?H*
MWB"EK0NDJ$9LR7&72IMQ,Y#DBP5(<*570I*@2-B(M&)EQC_A'*>SJKR]*JRD
M<X,K W44J"\RHI[0N/$J"7&@I!(4"" 9D7O@,M:KFC_:KFF]S1C_ ++#<*M:
M])/^!1!N4JD!7P"-MM^.WV/41SNI9_"5>KVAN5/M2KOD23I2+G4#MM/GRQ<_
M!-!7?Q8R0^PUA!IGIBD?,DJ=YAO?PJWOX3^CC372[5;2R%IM@<&5J+@T65'P
M['&'XSN78^RMEYNKC)=:<:58I4VXA:>*T$ @CB0".K'H<RR\4%*E684/Y%"5
MI554\@A(D+!<.Q$G4+'TMY?XGX4XG<XDSQQGAW.5,*SC,%-*;RBN*"T:ESNU
M-J33D%LI,H*3&DB)!$LF@6;8:UH[I\'<RQ1M2,>8/IN9#4I4G]^^I/TJF;CQ
M\ @>#OMMTOX8RK-7\CR=]J@JGF7*9M;;K#+\*;.HH4A:$:5I4E0*2"H:=K''
M'M0KJ%CC[BNG?J:=AYO-7FWVG7FVW6U)0A#B'&EJ2I"DK24J"A(4"%"9 T&>
M4E=>ZM!"TKA+4E22%)6E3!(*2-PH*!!!&X(/CIZ2"%I!D$+ (-B"#]",44J(
M5TOZ1CY58.+Y FSAJ50V'%,Z.HJ,5S;BF0@DD\#X('GYW^_7K)533]VK\>W)
M0?Z0;E)\\5R4$$D((N=DGZ0,,FI^)Y+-TVU!APJ&RF2Y6%91'C1XT5V1*E2'
MJ2:AEAAAH..OO..J2AIIM"ENK*4I22H#I3EM72HS&A6M]I"4U;!4I2TI 2'4
MDE2E0$I&Y)($"9PBKFG'**J0E"U*4PL!'=E6H'<!.F\B0-_C@#.PC1O5BK[Q
M^W>PLM,\Y@0(FHT!Z9+FXG=Q8L=E,:;R=D2'H*&FFT[CDMQ:4I\;G8]3CCS.
M,I7PAQ$A&8T*UJRUU*0BK86M1\,!*4N23.VD$SYX@7#67YF,XRY;E/5)"794
M7:5Y* "M/O%: !:V\1:P,8^LKN#J;2-BVG[\FOF,M([E>T;FX\PZEM!/=-H^
M@;K4G8<E$ ;GR3UXKJGF%TKR6W6R>[3"4K!)_&MDRD$F?4>L7Q?M.EWOP76R
M"%J 5I($!M82 8B(Z6_6??4=PYXYY$N+$]#W4F/&]S(;B1O</-L^XE/<BU&8
M]12?5D.A"BVRWR<7Q5Q2=CL8,9K7':9E4JSU#F)U/Q 2=3LDU+"U+L(U)+AR
M=1:ON7J9F+N2,:QBGL<S?PMW57323BDG,)]WD5.<8OJVIDT$),!JR,;2.8Z?
M2.?*0#M]>4JI.W?4;'+>KR/+\JQ7+8N)7V?7]=F#UW;S<VML>;T<R/1G$\9E
M0K3'GV574_#:7 <RU$R.FRNHCY!G=?E:I&-3JDT#U0"]L8^_WZ?"/MF#]J>#
MY;^PGMLF?@,[VW[)=(I'K<$</05A^.NAW?G_  !OZR?L/GSXZ8/8JGVM+G=^
M /!<ZD^[*;[^6V_EBY%<09/^"EM>W,]Z<O;:#<G67 QI*=,3.JWKC3_I_P 4
MUCALVG'ZZ<RTDK==B2&VTC;=2UM*2E(WV'DD#R=NL'8^AQWI5I;J:=Q9A*'V
MEJ/1*7$DFW0 X%?5G!,MNM.<GJ:JCESK*97(9BPV"R7GW$SH;I0V%.I23Z;:
MU>5 ; ^>EW#;B*+/,NJ:I:6F&JA:W'%&0E)9<3)B3NH#;GB09]6TM9E=?3T[
MR''7FP&T725$*28E0 F!UP,?;SHQJCB6J%3>9)A=O3U,>OO&GITL1DL-N2JV
M0S'0HID*4"XZM*$_3MR(W(ZL?BK.\JK<FJ*>EK67GE/,J2VC5J(2\VI1$I L
M 2;^DXK_ ".DJ*:N9<>;*$!-S(/]&I.P)._ESD6QHA[=XI&R1_"/[[?R$@?X
MWY]59!_O(!^1OB;EQ&HR3&J_A5U],/5$VM$ETJ  ]NE/\23Y"T_XJC^7S\=8
MY??X?KPCK5)+: #)UD[$6T^8'RWQ*.C#;A=&#%=YW7S)RJTQ62Z&TRTKV4A/
M$K+''^-2=]^*OC?XZ=,M?:9[WO5A$ELB9O&J=@>N$M0PZ] :05P#,1:XZD8<
ML)@R:^MDMRFO14N:IU(4I"MT%AA'+=*E ?4A0\G[?EUPS!YMUY*T*U)2V$DP
M1<+6>8Z$8Z,-.-)4EQ,**RH"09!  V)C8V^E\1O-=<]'=-[9NASW4K#L1N78
M;-@W67]W#KIJX,AQYIF4EB0XA98=<C/H0X!Q4II8!^GI30Y%G.9M%_+\LK*Q
ME*RVIQAA;B M(!*20(D!221T(ZXU>JZ:G4$OOMM*4) 6H)) M(G&0W=KKIHW
MD6KTBSI-3\(LX"L=I&$2HF15KC*G6!*#K:5>N.2D*4 K;<;G;?<$"XN$,CSB
MFR9+-1EM8RZ*I]10XPXE02K1I,$<XQ&,RJZ==25H>;<2I"(4A:5"P@[&QGD;
MXJG17+\5EC4B;%R*E?B2L_C.1I+5E$4S(;3IIIO&4ME?J\7$)D19#*E()"7&
M7$J(*3MY<X_(INT#C5A\]T\WF>6ZVW)0H=]PCPX6Y"@#X@A7TZC'O7@6FJ*K
MLG[)W*=EQU"N%LZA:$*4G\3VF=H*G!*0;I202-[VG AZQ8M?7>IF7VM3!$ZN
MG6C+\26Q,@*:?:$&,GFV3*!*2H%(.WD@[>//5)YM2O/UU6XTD*0ZXA2#K0)$
M0294(CSBV/6'!F;T-)PUD]/4.K;=80XEQ)9=\)4:TB^B#^6;VZGH8_5?B>0(
M@PD+@!"T1(Z%)5,@ I6AM.X(]U_C#;^O@?(ZV13/!LC2F5 @2M($Q-SJ 'NG
MGZXU?S6A%0ZKO5$**8AITW*T)$C1-U0/C@K=&-*=1;'2; IT'$[.5#EXU#?B
MR&A'4V\T[R<0X@E\?2M*DE.^W@I_/KW#V;9IE[7 7";3E6TAQO)Z!"TDF4E+
M"018&84%7$@\B<?+'MZ9=5VS]IJTMJ*5\4YRM)'-*J]Y8MN"4J!@P>7(X^AJ
M)^YHHK3A2AQNI9:6DJ3NEQ$-*5I\'8E)!!V)^.JY6H&H6H&07E*!\M>_UQ&$
MI.@"#[HFQZ1CY_HK),Z.E+L4DRF0 )L0DDO)   ?))_D!N?Z]>AU3W:B0KW#
M^:K]'TQ!Y$QYQNG]N.F)0VKC[;+<9*W''/30A,J(I2EK'%*0 _ON20-MM_(Z
M%/-@%15 WG2O_LX DD"WNB3Y "/M.+FT/HK6@U;P.YN8OX=5UMXB3.G27XR(
M\5A$>2E3KJP\=D D>0#_ ,AZ9,]=;J,GS!AE7>O.L%+;: HJ6=0L!&]\*Z,Z
M:EE:O"D*$DV N#/I -]MNHP=7<UG6'6^"8/75>24]A.D]RO:$&(L2:R\\[Z?
M=1HZZYP0A1)X-H6M6WPE)_+JG5Y=7,-NNO4C[3:$>):T%*1*T)$D]20/CB3)
MJJ=Q:4(=2I9)A(-[))/TDX,#IOPHQ0.L6D=UJ/D^F%_1VU+02\%NC/=NK&N-
M].CUCN08A=V]778[9MS,6L%Y)#Q44AMY\2%D6'OR8V28G>19<2;5W!@P$0[9
M-.,;<J6\VUTT=QN3IR]BD#4+&8LC'*6EDU$P=NM.J'F O+55W5V^<8QHI>V$
M2^5)I<B>O<]BPS;WM)BZOUA,;=8&_P"PR+>O[N6"&QS HJL!T2H,CRG3&XRK
M1#',MM:25BEDB[L\K@5.D%CI7?9!"7.;C65<F5,U#:L\O,-%A'8G6&.19=F\
M[9(4[LGWD_VA]N-5;*\P?4?']>+.[5IL9';#VXI6\D%.@VD ( .PVT\QW?<@
M'<CR#]M^M<= RZ0"$$@[;7G:,77.R2DK8<NPFV#3$2#&>ERGBEU?I1V&E/.N
M%#;:EJ"&T*5Q0E2CML 20.M%K0V"5J"0D$F>02))/H+X4M9=6ONM,M4ZUNO+
M2VVD%'B6M00E()4 )40)) OO&*SK>X71VWGQ*ROS2+(G3Y#<6(P*ZZ077W5!
M#: MVM0VGDH@;K6E(^Y'2%O-LM>6EMNK:6M9A*1JDGI[N)+5=GO&5%3NU55D
M-4S3L)UNNJ<I2E"9 DZ7U$W(%@=\6@QD%/)<#3,]IQ9) 2$NC?8$GRIL#X!.
M^^W2\*23 ()B8\CB,N9?6-)*W*=:4C<RDQ>-@HG?RQZS)+#L9UMMU"UJ2-D[
M^3]0/P1^0/SXZV G[\^6.32%!:5*2H)FYC80<,C#"WCZ:$)*T@DI*DC;8C[G
MY^?M_P#8PM=4E)U%:@E1M8GEZX=JV$_&<<6Z$I"DD !05YY _;^0Z/KA+4.H
M< ""3!FXCEZG#D_(9C)2I]P-I4>*2=_)V)V\ _8$]&."&UN$A"2H@20.FWZ\
M?QB2Q)Y%AP.!&W+8$;;[[?('SL>C&5M.-0'$E,S$Q>(G;U&(-G&68[C)K4WM
MDS7JF^Y5%]5N2YZH8] .[".R[L$>JWOSX[\O&^QV54U!65NOV5@O!$=Y"DIT
MZIT^\1,PKF(C&S553TH6I]Y+0($28F"9Y$VD?/#CAN0TN25LB71ST6$9F6J,
MZ\AM]"4/AEEU3>S[32CLAU"MP"D\OG?<#%525%&M+=2V6EJ3K"24DZ22)\)(
MW!^6-'*AFI5K96E:0 DE&TB3]A!^.,;?TBV@FJ6IFNU5D.'8VW;53.GU)6JD
MN6U1!"9<>UOGG6_3G3XKQX(D-$*""V>2@E1(5M=G9MGV5Y9D#[%94EIY68O.
M! ;<5X%-,)!U(0H;@VF1:<0KB*D?J*Q@H:"VPR02?& =6P0-C_6(V/SSPM?T
M<_=YF#S-SCFEK,ZN7'$82!F>#107H[[X<1Z4S)&GOH*P.10$DGQOL=K ':)P
MC2%3-3FQ:="M6DT=:[ 4E,'4W3*2 >DX9/P%7K2E3=)K209(6EF"%&VE2M1C
MK$\KXMS0_MAUJPVOSC#,CQ$0,BQ?-F(%W 3>X_+$27.T_P $R&,W[F)9O1'O
M5J;NNE<X\AQ"/7]%12\VZVCPSVF=WQ'VD\<9ME#GM='4YGD_=.Z5L$^R<(\/
M,K)0ZE#@"G"I,J0GW#$A0./I3V8\293P[V/=DV6YL^Y2U;?"W$#O=):4^.[J
M.TKM ;2=:!$I+9)$R?+#ID6(W=3<3*V>U'BS8+C;4F.N9&4IIU+#*N!4VZXV
M?I*5 H6H;'Y.VW5;5-(\TZ4+2$J$:@57B-Q8SZ\_+%LY=G-#6T-,]3+=73N(
M*VU)94+@Q<$@S<[@$1YXX/PUU(2 Y&"@$)4"^@C=.V_P3\J'CS]Q]^L-H(5'
MXNZ'O>&H>%AU0 V@G3&J;23M;'8U+$R$NSJ8NM!&U0SYD7Z3Z3&#E[=^Y/17
M%]#M+<?O,XBPK:GP^HKK&(:R]=5&FQ&/2?9+D>L=97P<04\T.%"OE*E) 4KT
M]P'PQG55P9PT\U1*6VYE-*XA0=82%)*+0"Z% ;[B0 +"<?/3MSKV&NV+M'U*
MB>*,S;4="U:3WQ/E/P)VWF,&2OO*[:76?;(U-@E]:7$I;_!\H*BZ6U-I;\TB
M4@E1"=U'@/@GYZ4?Q)XH"Y_!3D @SW]+%S,_E^0OS)&TF1B$C-:  DU2(TI'
MN':02=,<NG*.6,OX^GV4P9C$^3"91%AR6YDASWT-7!B.Z'GE\4O%2N+:%*XI
M!4=M@"?'5Q&NI5MEM+A4M:"A*=+D%2DZ0+I@23%[#$$4A8<4HBP6522!;5,Q
M)BU\>%1J3@[%I D+R**E#4MAQ?[B<2E"'$E7CVP/T@'QMOX^!\=:NY;6E"T]
MPHDI4F"IO\X&/Z3SOZ[X4AYN""0! A0U7,CEI!Y&?M'*\</U!PS-\GI\2QG(
M(MG?W\ER!50 Q,C^YE.1GEI:]>3&9CM^$+)6\ZV@;>3N0"S5M#64%*]653"F
MZ>G2''G-2%:4!0DZ4*4I6]@D$G&["VW7$M-JEQP0E,*$D&-U   SS@#;GB<:
ML:1Y[C4/3&[N:=J)6P>Y;M.,EY%C6R"GW'<UI+&:V:8EN.JW>=0D\$* WY*V
M )ZA6:YUEM5EM6PP^5NN-H"$]TZCW7VE&ZD) L#SO],.]+253=8TXX@AM)4"
M2I!_HG #X5$W4H6Y3C3?,LSQO3_'+++<OLOP?':=A<JUM%0Y\UFOB-)4X_,E
MMUL68^S"BM(6_+F+:$:'';<D276F6UN)@6'[$$G=PFB-6B^<M-4<-JV<8C3Y
ME_)L[F/71:N+4U.47EQ(DRYA8C!FEK<(S)VZ6AU::>1BF10+(Q;"FL(L<P0>
MGW^Y'SP+,W&M()^JKD;(^X&+"CS=9C;4^ 89<ZD8'6(SJ:=9, >QJ%DD;4ZQ
M:J]2KS(\SE2\EA:?R,*5DUIA=G:VF#._B%A95QC:3T^?00?I]AQ)<#I=!\6A
M8T-/M3,)MF7,+UWH-/:?'W:Q2+BDU:R']ML2JJI,2QFN3H>$8IB"(M4RQS3^
M )_&'Q#:L:^.O*?>'J/MQJ38S?:?@#]N+'[6ZN0OMA[="E37[S0C2-2.1)4
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M)2=]U*'TJ^G@//TG[\SUMS$"\B)/GZ8Y1Z?,?MQ_0$CR5*_A7M] \ H5OO\
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MEK5WB+E +8,%)L8F-P+3:2J:[)4NJ8J_PL$:PEXH33K%G2'0 >^W2%1.Q-X
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MVE]H:@M+CA2I1EP@BT:8WG TZF=S&27&>9/9NXY1M.39C;JT-O3BAM0AQT^
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M+359D=92.+0Y4*6&WJ-UE92' @!6E9*2>8'A(WU+R:G;RVAN<:E+>AQ+F$]
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M(TV%-9D19"7K J9?;.[;@#LI;9*5;'9:5 _<=(*O-ZYZF?:75*6AQM25)*4
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M^.:_RTXYNC\4Y?\ HU_81M^KZXRD[=LFO6-(]"DLV;S8:TZTR#0"&?H",;I
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M)W 2 !ZP,8^ZW6]M#U]UK:B6$R,V<KQ1:FV7UMI4X=(=-$J64A0^HI0D?&Y
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M54[2&$-)<*U/+<(;2V$E:ED)"23MTMH67A64:BTXE'M-.HK*%A(3WJ"5:H
M O,P!><<G7$AMWQ)*@A?AD23I,")FYM&, \6TOU+A9)CLR7@&9PXT.[J94J4
M]C-JS'CQ8TUIV0\\ZJ($MLMM@N+=6I*$("G%J"02/4E5FN6.4]0TFNHUK6TX
ME"14MJ45%)"4@!9)43  %YL).*[11U"%I<"' E*0%#0$IV )3(LD7W^E\:$Z
M7(DJU"PQ(0Z2K(JQ'@G<E4A \#D1N=_RWZK_ #0C\'ULJ3 IW3M%@DF=K>L_
M'#LRI)=;"0K5((F"/CN;\K<QC5*BB3F[6,IQB2E')XE3C;@2G9IQ(W)'P3Y\
M@ ]5-4K:4RLI6F8 W!)@C:\$]!O\L2!I*TJ;21(%QI!B2"9/I;X_/%:]V[$A
MS0O)DM)<<<]_CA"6DJ*QM?U^Y^D;[ ;_ &Z<.#5)3GU+JL.ZJKDC_P G<L-O
MMY8,Q2KV57(!:#<&/?2/K,3ZX +MDCS&-4X2WF9#;?X'; K<2M"02J( G=8
MW^2!OO\ ;;J:\>*2KAZIA2?YPS%P?Z!\3:=KR?*)QC@X1F[*8\1R_,+@;0\W
M: )GT&-4<-6%6$G8_P#D8^X\GU$;G8?UVWZIMK\Z_/[,3K.TZ:=G_'JZ[:+"
M_H?KB':_.!N@HR5!/_9ASR5A'Q!?W\DC?^G4HX;3-14;_D4["=W$],0C,S#;
M?]LVF/S3UQ1F(6];!$_\0M(,,.&*6_<S8[(7P]P2$EYQ/,@\20G< ;$D;CJ1
MU;+KG=]VVM8&L&$*,%6G?2"!86GSPUH4B#JT@F /$-K_ &>1V.'ZTY9"&7:
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M.)6E>Q0I).R@L CB0KR-NO+%7J5F58I*TJ"*RI6DA06' NLT-A"D$I,I=2H
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M>9V?\$9E8_S1_P 1&PT&;GEOZ##?3#4^T--RH1MZ@ SS^N-JX[+J'FE*04I
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MD -$=(M3Z/5C!;:YP;(ZZMK[M,B9/E5[S4:.S[=])=><*4I0D$@;J)\J V^
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MER5H4%J#$5M;SI2VD%2R&T'9(.ZOX?&_B(H>0\MMELDK<6A" 4Z05*(2)5,
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MIUMO9I(<5R4&ED;I&PV2=]_RW(L)^J;905J"BE)'NZ29-A GD3][8CP22GI
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MH),?DXU#5!Y2-[XJJH[2LB:IW*-QBN#K#"Z=9"&2@K0R[3:I#TE)64JVG3N
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MUS):(<B2[)4R&'4$,MN08[:U%2QL%.H\;GE^;Q69Y25U.]2,H?#E0D-MEQ*
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MU&JQ)Z#\9MTL$VCI)Z8B*<L4DA7?)D$&.[ V(,3)Z;\M\-3!2'$[<M_J._\
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M'I(=<D)<<"0V/J4 22? \=,?%7:G69;Q#FU"C)Z-Q-/5=WWBJAT%<-H,D!!
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MUW3?N)=<6ZK7O @IPDJXZ"2 /)W\?[KY/\OG?;[[DGIO]ESW_=BA_P"AE_\
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1Z F,M0<,)3KJ4.*)68,?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g838337g14o83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g14o83.jpg
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M(30V.516M+6VM]+5&358E]'6UQHB,54D05.3F=0C)3)'47&2F++3V"A"_\0
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MS7Y1.EV:64F+/*Q3D\N,FRE1V[2L95%1'4J,^\;BG>%<A(W5(+5&=Q'9PQ3
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M6NUE@M;BKTR(S2UUS71):/(V7C5Y'<&[">?EN/FE&CSA/._,ME>R+.:>$8[
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M,:BXY/;/EM]73_A[JU5;\:IZ#TM^.5.>%,RBRG4JZ%Y,4H*\@EY(:D-+2_\
M*$R.F,\DG#=4GR8FTEN-\'OI5QFZHN(9*NPBFK,D;RF,N<=DUB<##4I=?;5%
M^2:Z6N;'6;26$+.8;RS)Q[A2;4C1),I/[X9WS7!N 8 :T.\'X<0[XJ*_K=[E
MU')V]Q"TOE[.\Q073?W'N?C6;^I'9%?+V=YB2.3M[B%6Y 3# !@ P 8 , &
M# "?^U<UXKGKA=$[Y=RIAQ$Z_/G.7D'+C $O;\,&NRW*L=-&0<E%#"FOB_\
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MDF0%N6+3L8H;RR3*D-PY3T1*4)C/S8"(LQ]A+;26G7UH2TTDB;33F:B.P P
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MRQC0K!ZL15+A/5EBU(A6$4HZ5.-KD-I=;?-*T*)*5(<H#JWUN']8:_DD$'S
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M[S%!=-_<>Y^-9OZD=D5\O9WF)(Y.WN(5;D!,, & # !@ P 8 , & # !@ P
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M1V17R]G>8DCD[>XA5N0$PP 8 , (^E%S7HCV"L2F(O!*S;#&'78O9E3R.6S
MZFI+IVR-@@?.LS0#@U](7 1I YJP6Y9^R.2F-QY(AHF"9:#M2H5T+37I+O\
M;R= DW?NQV%?"9 UB6E(2G:/PWM/<T2N/F$3P+5_8"I.L4?ZZ^>;5]%MK1*F
MH@G,K)O8[7PJT5IQ9$2W%U00L>.QF7QZ=1QFR"NA=/HXN8SU]O)T<NGH%E5-
MW)I6X[!95-'=+8 6.0@\DL1@ L?K]?56BC<3AAF%1V7F(9/+'K6*UY88Z/G+
M$A3-P0@$JDK)ZWD@DP+7?!7J)'8*&DRX^(RYR,C^!\7;H*IP*!@ P 8 , &
M$,]7Z4[3UK;W8R67GV ^VO7E@3C4O4T+]96 WV"!_8?7@]/7A^T;Z.".J'(=
M_%/-W.@W392,J3K9DX/63)5&H5,RXM"TY^G[?^/0+FP*!@ P 8 , & # !@
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M$1E(-SJ\#R&/&6J;X47&.]/4U<,7[-9)PV6UX]11)37;C_C@4'+, & # !@
MP 8 2C+O?<U5Z/SGU$QR9?0/K\! _IEU>(J[("8E'JE_55J>E:0?HS')KY>S
MO,6V_3V=XJ[("X& # !@ P PU4W8SKY?BTH;47>M.W.XA"PUO,T*HLR%V&M$
M5S.Y1,.C)THB:+[@5BNX,UH-3*ZM=WVX@IJVU5Y8.N$@:&7*6@S+@ P 8 1[
M:7A".BM(3L[5]Q=ONN-7V/%^1O$C@L[M^#Q>5@N3(<?(!/!4$8--"+'DD#*C
M"[+SANGYR.?M'B7C(.$M]@D25'QDE1ESD1F,?_TKW@R?[?O4/^_^M/\ ,6 W
M%_ZJO]T_ 1Y>M_>!9[#772%]V%WNZN.)Y0A=J6A+AAV6@#)EILPY./&:#Q@W
MDZ;)\FF<+,S6_)-L1]14(S:L]&2#LMZX!4B<(C(DJT/E^]/P"OK^\"S6G:2S
M>W<8[W=7$+9M:.M8_*'+CLM '(M73@T=,%';<8M)]Q[18KP_C[!3@>S8\I-H
MB-6V4</R<@=E ;J]"+=5H6OY)^GL^W&+#_I7O!D_V_>H?]_]:?YBP*;B_P#5
M5_NGX#^S?PJW@T'CA!HU[[]1W#ITLDW;-T;\K919==??5-%%)/60\[;J*J;:
MZ:::\<[;;;<:\<<\\X#<5_JJ]A^ OS B& # !@ P 8 , -:'>#\.(=\5%?UN
M]RZCD[>XA:7R]G>8H+IO[CW/QK-_4CLBOE[.\Q)')V]Q"K<@)A@!KH[2W/.M
M;$UZ]5J9%^O\U;0[?S)D_P!X9/!;_5\^EBR4>+#;9ATQF;:91B$%8NLS "ZY
M"@TWQ!V4["Q!PR5;"@J7.?VU[#T[>P5Y18DZ$JN*#I.1DQ20))%-RKB8LW[.
M1-W"YLDOJ(?:E9A89-TC'FZB,?%$R%@3MX7#BQY1>9RE1WR<?!095Y<-]5]6
MVRZ.KG=%1QHWY5TX7V;H[IIJKZI<[>4V12461T45XUYTTW53UVVXVWUXY /F
M:2./*,6!/0Z&W&E'2+$80T*,=F)%ZY6W;MV;!WPORW=NEW">Z"+=NHHJJMIN
MEIIMOKSKP 1]._QC?5KY%??+]^'@YLIZ2ZC^)"OH/K+X&+:RHH& &([/Z_T/
M=RH9:YZ3J.W5HXF^2CRMGUO#9\J"2*;-=R28925ABVPM,CLQ8[/M&/*&KO9F
MUY<<*<MT>= :F7(>@USN.D_33CO^(C''4CK'Q&E.G<C/;Q[BA:KX![G$KJBP
M](SN)]BGF&Q9-@LLQ3(\M^7FC-55MJMPBIMIR$]3W>4_I<_0-BM8]?*#I)P7
M=TS2%05&[D"+1L>=5C6L,@+@VW8;KJL$"ZT5"B5"2+)1TY4:)/-EM&V[A?='
M73953G8(:F?*>HR_@ P 8 , & # !@ P 8 , & $HWU[KO6CXX&OTF)Y-/(K
MJ[C$%<J>OO(5=D!,2AU5^\[:]*I[ZIODE?D_JD()Y5=?>8J_(B88 , & $2V
MC[_WIW\G?NW^U73K KZ#ZR^!BVL"@8 , /\ FVNNW'.NW'&VO/\ QXVXXYXY
M]3[OW>.?N?\ '[N '\_((?\ 8I?]WI_A@ \@A_V*7_=Z?X8 /((?]BE_W>G^
M& #R"'_8I?\ =Z?X8 ?)/E!,9!&I&62<<"X^)(FR7(T.2.$>!XIFL_><L @-
MB1-F'O#=!3S44''ORA!?R;0>S=.UD4-P","?A%>I04<0,&#5O"1 ED[)E2I/
MJ7VP8#AHY@@HZ?$"#YU1Z39FR9MDE7+MVY530;H)J++*:)Z;;<4U+I]A^ KH
M?1[2\1^IIX1+JP]:-GC Q=#MB[;HNF;IIU*[;+M'+5PGJJW<-ET:.W16;K);
MZ*(JI;;)J)[:[Z;;:[<<\M2Z?8?@&A]'M+Q%I"R+4P,'%V/G'F11BT(L_/&+
MT8[\U?-TW+?SH:2;M"(]QY)73R[$@T:O6BOC(.FZ*Z:B>M10?NP 8 , & #
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M/:!>Y)?%6V*8!1SAR7]8\=QIS?:X/=^^4^X6[]\>I;O'Q<9#MAYU:.ZPP 8
M, & # !@ P 8 , )1OKW7>M'QP-?I,3R:>175W&(*Y4]?>0J[("8E#JK]YVU
MZ53WU3?)*_)_5(03RJZ^\Q5^1$PP U)]L&HJX)G+FS8EV6X;-(>[BXBO@O33
ML@=9NKDA0&](W7T\AME$6\0J9JB*.W#Q+AAEX['B7$SKFIITUMF+!XIP\W"I
M:]'M+X?^-?0-MF!01+:/O_>G?R=^[?[5=.L"OH/K+X&+:P*!@ P 8 , & #
M!@ P G3N#[TGM'\G2[?W:2; J7*767Q'/:3]QFH_1C OV5$X%!D[ !@ P 8
M, & $HR[WW-5>C\Y]1,<F7T#Z_ 0/Z9=7B*NR F)1ZI?U5:GI6D'Z,QR:^7L
M[S%MOT]G>*NR N!@ P 8 , (EK_\8OVO^1GT%_?3X1S KZ"ZS^!"VL"@8 ,
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MR?\ \8O#_DMUK^WUMYWOLU\WWO6<G^!$'S)MA\ZH_J:)]:G#KFYV".J@P 8
M=@;[&C_&7LO0/:_UD7S1-HOFXO\ OL7XN#L[9)YW)]6S?BR/0RSH(?408 ,
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M;B;9^$C^Q<73S$7O+7C&V; B(EK_ /&+]K_D9]!?WT^$<P*^@NL_@0MK H&
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MTP:1]QBHO1A ?V4$YYTW/XXM?64[ZTZ/6''_ ,0TGJBM^ILC)^8T9<, & #
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M 8 , /,]NSW9K<])T]_:HMGHM3?B>J]6P?JK0\G\A_']YZXL_KKXQCF2&'#
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M@XP;C38Z9! 61/ GQZ:Z'Q:>@N3V<1%S\?8.Q[@0$2VC[_WIW\G?NW^U73K
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MGX> 7$1<4%OCT+37C4?&?ITT+F(AD/\ VDGPGGYWU!_=$#_\UCYN\:_V4O\
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M%T?]^CU%^4Y0W[THKFMYEYH95^S=Y_+)0V_9]Y^X3^UN.?SB&/1NSS['J2&
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MZB8Y,OH'U^ @?TRZO$5=D!,2CU2_JJU/2M(/T9CDU\O9WF+;?I[.\5=D!<#
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M&1TDV6^J56J2Q%BV<9]]U2435K4EMI"UF2$J49%HE)GH0[OG](9U<_YU<?\
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MKLB,%L&C<*#G> # !@!%5Q]J&HN71^NZ5G%&&Y9S*"$3FSV6RM8S'X1.?O.
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M7T#Z_ 0/Z9=7B*NR F)1ZI?U5:GI6D'Z,QR:^7L[S%MOT]G>*NR N!@ P 8
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M\'X<0[XJ*_K=[EU')V]Q"TOE[.\Q073?W'N?C6;^I'9%?+V=YB2.3M[B%6Y
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..VYY_Z\KIIR"FNO*/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g838337g15f12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g15f12.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5[":'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^5%@@,3 V/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,3@M,3 M,3)4,3(Z,C@Z-3$K,#4Z,S \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR
M,#$X+3$P+3$R5#$R.C(X.C4Q*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,3@M,3 M,3)4,3(Z,C@Z-3 K,#4Z
M,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L
M/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R
M5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \
M<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H
M/C$R.#PO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=)
M;6<Z:&5I9VAT/C(U-CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @
M(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @
M(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!
M0D%G14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!
M04%!04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL
M04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$
M06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'
M>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C
M>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T)!04-!07=%4B8C>$$[04%)4D%1
M35)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K
M2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O
M3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I
M8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY
M63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+
M0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2
M,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C
M>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1
M645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-
M2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G
M2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2
M;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S
M3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A
M86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y2C98<&5N4V%D8E-3
M5S!B3S!A;"8C>$$[;4MI<$Y-5E)8-D@P<B]L;&DO-$59<3<Y1#96+WEY>&8X
M0TU69"MH.4LO-5I9=CA!9U)I<G8P4'!8+TQ,1B]W27A6,S9(,'(O04I:628C
M>$$[=BM"1TMU+U$K;&8X<W-8+T%!27A6,S9(,'(O;&QI+S1%67$Q*VED234X
M4'$P4$]L95!%5G T,'AT3F)7,2MI.4<T<S,Q94AI<$E9,"8C>$$[5V=)-C%W
M8U%8:$LW.40V5B]W07-S6"]!:D-H,S9(,'(O;&QI+W=#0D=+=2]1*VQF.'-S
M6"]!:D989F]F4W8X06QL:2\T15EQ-SE$-B8C>$$[5B]Y>7AF.$%!:D953G%'
M;39F1&)#4TLS4DI&;&@T<W%G159L55EQ:61(+S0U5G(O04U9;"]6:7%->%8R
M2W5X5C)+=7A6:E U:'HS;B8C>$$[*TAZ65=53'HS5W!33&%H22]T8T<K2U$Q
M3W<K1F5/+VIM1#)H22M(=W@S371N83EJ=VHT,TA-9U)G3TQF=C9F<EER<$]P
M>E=-+VQK-B8C>$$[=$10061(3V]79'=41DI)44]%66@R:E8V+T-W1E)T=&U"
M:7DX2G@X9&IG-&=F<W R*V]W1$E-,VAK2'A01&M.=T]P=FY35S-K370S<B8C
M>$$[.3%06C(Q,C)R,T8S8U1W,T-P2V].:$IA+W5H=E-L4V5H1F4S=&Q%=UI:
M0UEI6$=35"]M,7,U5T]1:&AI2D=0:&E-45)9*W-3,U5T328C>$$[:3!Y1%,W
M,E4V6F145U,R,6US,6]236E486MG8FY7:')W1S5B+V%Y3TU215-E13A.4C(S
M,VMZ>GEY4WE22$A%5#1P,&1T<V8V*S4V6"8C>$$[-4EG:70O2W5N47A43D]I
M4FM'4C%D1'DU;FM!<V=6=W%T5E9Q3VUB>E)207A204YV2SEQ5$UT4DUK5G8U
M9F\R.2]M;FU:5&=/>%8R2R8C>$$[=7A60C9T+W9&+WHQ:"\U4$II<G1(+S0U
M5G(O>&E8.5=+;WI&6%EQ-T9867$W1EA9<7!88S1T-U=A-$DU0T9':TLY2SA1
M5%0X36I/6"8C>$$[1$5N=5HT-&-5:$AV3$1M+TU:,#AP5T=V1WE"93AU>&%T
M04@R6&0V<T=P+TQ(;75084)'15I+-7EP,UDW1T(Q37-01CE-94LV.3,V,B8C
M>$$[8EIS,U%U>%8R2W5X5C)+=7A60C9T+W9&+W=!.5EF.$%K.&U+=3!F+T%)
M-59R+WAI6#E72V]Z1EA9<3=&6%EQ-T9867%H3E@O04]/5"8C>$$[92\X04=#
M6"]!26=C<7IF4DPS1G4P,SDU2"MS4'9E43-(+VMQ=$4O-V%V.$$Q5WIN-68T
M<D@K=BMT-U-(+T=H:R]W0T9F.%,Y<'IP6"8C>$$[:%A9<3=&6%EQ-T9867%G
M.5<O,VDO=T-E<U X07EE5$9885 O04UC<3$O-'A,*W)&55II<G-69&ER<U9D
M:7)S5EDW-6@X,#928C-%;28C>$$[:$8R:S%'-70U:4DT>'E#05)-=SE1,2M'
M;T<R65=P,55"95 K26<O8S=04C9$3$M)>E9527E(>#,V4$QP8DER*UA/:UAF
M,6U:9RMP8R8C>$$[4'%P665I=CDW.%-R4W9,8GAZ4T=(*T1X;%HK<FPP-G97
M4GDS<F-K84@Y,WHV+W=V5SE0.#%A4F9A>F5A4$5Z<&8R4DEK:6M8:GE!-B8C
M>$$[<VTK-'IF-#E60U5Z06952&IC,F=Y63A58W K:5AD*VQ/37E80V1I<G-6
M9&ER<U9197)F-WAF.$%05T@O04I02FER=$@O=T-/5F$O."8C>$$[66PO5FEQ
M37A6,DMU>%8R2W5X5FDO;F)Z:4Y%9VIS<D9F<D]U6&Q%=$Q:9FE+.'1H27<K
M9E%D>CE/64]T,69H:FAJ=DTX;F)D;#EM*R8C>$$[3U1/9G!X4C5N.41Z>4]Y
M,7DP,6%F4F10;FIV=DU7<E)!87)D-W,Q<E9I6D4Y5W!'-FMC>E0R1V%C46Y'
M6FA%.%=36#%(=3<Y+W9E;"8C>$$[;&QX5'AJ3$U'1TA'9E%0-3-C82LU;C O
M-60V8R]K-5!,<7ET>6E0<E)84C8O5TM(-'EV.'9X154X4&9F3G1,<RM09RM(
M9FYF;3@W1"8C>$$[=&U9,5AJ,7HR<BMJ,TU#1G!R9"]R1#)T.61',#@T855I
M3'!R54-I-E-,:WAR2C%D,E5J:51S4C$W-7%E0V-P,4DQ;&IY.#8X*R]U928C
M>$$[:#A41FIX0U5).%=M>5AX9C!B<G P2&8U=E)V2F9N0TQ8-U(T<#$K<C9V
M869$9E=P0E5G9S U2T1V46YT,D\R8FY2-G-:4E(R;4]9928C>$$[6C=4-T]/
M;FQ9,WAY*VLO:CA&:VU:<G$S67$W1EA9<6<Y5R\S:2\U-G<O.$%*-4U69&\O
M+T%">7)8+VI%=C9S5E)M2W5X5C)+=7A63"8C>$$[9DUE<5A7;#9.8UAT<F%V
M93--64%H=#1W5TQ--T)254QV459Q85I2<4UP:$%Y07-U5F]S16-U55%L3&AI
M95IE6%8Q5%1B>7!R9F5F9"8C>$$[6C)55D1F56]N2'9S<VY(-D98,C8V4#%1
M;#,U-2]W0W@O8CEW97,O9#59+WID2FHO04YM9C%F969S-D@U3CAO,C-L-G=+
M;'98,4<T*R8C>$$[3SEU>G578S<X451V>$(K+W)M,S!E:T='4&9).'DX,S)L
M,FI,57HW;U(K:V9J<7E$37@Q<D<O3VYL0TQ8-TY*64<K<C9V869(63-92B8C
M>$$[56AG83A723-P6' T2&9-3%=A45I263)M3U)D<#):,FED4$MJ=FIL.5$O
M2#1,045K,4Q53'<S,6]V,4QZ>F\Y4F4R=$-0<G-C64%,0B8C>$$[4G-8<#EP
M4CEO9$\R86M'57IX1&).1&U0-3,W92]V96E-65DT.$5V5G!-;C!N*UE4*VIU
M4%(V<F]7;WIA;'!&<F945S=7<S!Y5FQT,R8C>$$[0D1)=TI$0V@S<%5B93)B
M-T)K331#4D9%=DDV=D--5U=5065)1'%J<W1C9#)+=7A60C9T+W9&+WHQ:"\U
M4$II<G1(+S0U5G(O04U9;"8C>$$[+U9I<4UX5C)+=7A66E!01D)#.#!Z0DEO
M=U=D>C!!1U%Y6DEW:5I33D%-;WA-:E$U<TDQ6'HQ95-336UN2TE9:'-*6$%:
M>C<P4'=J3R8C>$$[3S%V=$AK:V%W*VU0965F-FYC-$]Z66=84&-O,WE.8E<X
M.&PY<3@P879Q53!G:FMU:5!J2VA&,CEU;F).;#=0-41L:DQ*4&5F1E8O028C
M>$$[3EAA5U-116-94&](4FQU9$4V;#)+=$\V4F]Z=5%Q24-Z365G03-*=U-K
M26EZ>4-13$Y"-7!R*W-7.35R2S9H6E%I0S1H57A2,W$Q5R8C>$$[5FLS2%5(
M655/,V9/1#=3-UE/5$IE3# Q='AD5"MR-S-O.4QH;$1&=U-.>$\Y9$5X.&E4
M5%-A>D]:2%IY8F1I4WA*+V)4>'DO,F-Y4R8C>$$[;'%*5U-F469V:30O8551
M35ER=B]!149N961S-DXR2W5X5D(V="]V1B]W03E99CA!:SAM2W4P9B]!2356
M<B]X:5@Y5TMO>D9867$W1B8C>$$[5TAE9CE28V5H<#9':7-05VQ(:G924BM"
M>FLO86)616-/261D>BMH,B]:;4EB>BM$1$TU1C-$3R]Y+SA!*T]D8R]W1$=B
M+VI56C)V<R8C>$$[>"]C>2]R9F]$;RLQ4')(=5I4;E-U<V1I<DA04%8X.$=L
M3$%H;S%Y+T9V.$%55590-#!Z;B]A3%5'1T%22#A:*W@R4%IU4&EY5V5J>B8C
M>$$[-T]&9#AY8GE"+W@R6G8X06U(8B]!26UM9$8W32]W0TU3+W%(-S1U=#=4
M+W5X+U<O45=F6C-$;VY9<3=&54AQ,RLX6"]!1#%H+W=#5"8C>$$[>5EQ-U(O
M.$%J;%=V+T=*9C%9<6I-5F1I<G-6968K9EDR6%=9,U R6&A8:69K>D$U=S-T
M3$5J54$Y.%(Y-60Y,EEF,V9X63-N4$]X5"8C>$$[2%1D93%05%EM:71*06E/
M,TIG5E9T-E4W:DTO4V1P-71017AX;6=F2G@X,FUH:TYY0TPO>&XU9R\S*W8O
M04-,5"MM6F8X=C9R*V-0:R8C>$$[1W(K5#A89#ER2V9+1W%A:G%.=F-46&IH
M=VIH27E&0SEQ=#!!.%)N4V1H-GI,<4E3;&M.,&%$<DYF:&AJ24552"M934QT
M6E=S=TAW>"8C>$$[>4UR9C=-5D@O16-X4&%F1U1J:$QO2F9F+UDR.6QY.5)(
M:W=B3TUD,G)7=#5D5W-H:W1P5VAK231L:TI";U17;3-Y>3-$;FYI3G=*:28C
M>$$[9DIH4$A'47%1=$9F<"]7+RM7-F(O9S)Z2B]L4%4O-G!,-718-5A(+T%$
M47E$>5AF-G!E86Q,.5EU6DI9631I4W)S5TA)<T%/=C U=B8C>$$[97=.5&YY
M-6IX>4UO:5!6=T\P355)449!03)Z5$]V9$]G.5<O,VDO-39W+SAN:WA6,FHO
M.&-Q,2\T>$PK<D956FER<U9D:7%2*V).128C>$$[8E4W15!!2S-6=E9O>"]-
M1#EP9G<R>E1D=&1N;E59<FHY8V58;C-H>F1$<69$;'8Y2F5C37))>%9G5EI4
M4FQ/>$)(:FYN-4)";S@S;R8C>$$[46)A=TI6<E,P=4QU-%,S=#!-:W)M:7%0
M,6XR>3-"9VYL;4E11GE,0V-X15=E5#%(4G1-5%1D3VET5DE:;$9:2$@W5&YC
M;E!39$)P0B8C>$$[<#A19T]N4#-V339J36-K>DIF<65N=S9H67DR:W5Y>41:
M=39S3G=2.&IK.5AP;S4X6GAY-F]W-51J:TI"-69Q3VTS96XS3%<Y>6A6:"8C
M>$$[.6QU>D1X52M'96(V<E-:344K0UDO83E,:7EX>5)U2T9Z1V)6.$U-<SAQ
M>%%O6DI(3D924E5K-5!(:FQ/46I%5U-X;$E!5V54,')Y>B8C>$$[;VXV2W-/
M16Q$8WI(;D]2,E!:9CEJ;F]F6E!:+S5B1E(K=5<U+U8X2&YD6G%01FYT>4A*
M3C@R:FE)4%9V.31V*V5S4"]!0V541EAA4"8C>$$[+W=!8W$Q+S1X3"MR1E5:
M:7)S5F1I<G-6678U-# K>B]!16-B,%)+3&]/<2MQ3FE19D=N6#9C-7HR:3!U
M4'=F17(Q,DXS6CEN6EIC9B8C>$$[1&9P67(U93 V1%5D5FET6GEW:6--5S1%
M02]#<%!C2'=Z;4]Y.4Q(4&Y%2EA7+THR97%Y;DAJ36AZ96IA9'!';C9C:%<P
M:$-%+V%F<28C>$$[>"MB2&9/+S!U:'A90E=/3F9E."]L>GIY2#%&1UIL=$QS
M5E,O>D)B=U1A4&5'5TY836--:GAL9T-66E5*0DAG8W=/,#A56C9E9D5!828C
M>$$[:DEJ,S U1VQM4FMJ4C9H-6I:4DI,95%24'5K:VE+=SEM64$U-3%P-$-7
M4TU4>4UG4'1E:WE';VMJ=65P869O*VTV94-,4T)9>65R-R8C>$$[;&HO<VI5
M-394<'1$:'=$.3-%1#<O;3AZ;'IZ>69555IM5S!U>%9"-G0O=D8O=T$Y668X
M06LX;4MU,&8O04DU5G(O>&E8.5=+;WI&6"8C>$$[67$W1EA9<6M(;FHO04DT
M5&8X6D4O:FUJ.6]F.%90.$%71&XY;F8S=G=95&]G,6LS=T=I=&)R<69"=G%Z
M6&=D;T%A9D9Z15I6+W,Q<"8C>$$[43EC-7HR97(X,T<K-"]C-TAT1R]"3F53
M5D@X,E!Z06<X:F%:-6YV5&]D=6UR-F]M;C(W=$9D:4M#3E1D2E!*4"LK2BLQ
M8G%6-&YP5R8C>$$[;S95.4LX1U!%44PR1'E8:GI%451W-VUV=C@P0B]W07(T
M.#!09%=T=DQ.;VUL=W9"4$HK:S=Y1RME,G5M:'540W(R;VI94T)*1D96-28C
M>$$[:CEK-SES;"M82&U6+TUN8F-$;6Y(;5@X.&(S>3%R,VUJ4DY3=')E4S@P
M>3!T6#!:;VQL0WHS8S!-5%-2=E9M<6]E9FU!3THT2V4K*R8C>$$[46AP*TE!
M:G%M97 T6E-"-F-K5'$S-6AE8V8P9#5C;&%Z<TAS+TUT;&$X-V5->6TV9')M
M,4TQ,U!%=DER2$1B06EV4&Q8>'I#-U%X4B8C>$$[+TPU9DM%+W5,;&%B3$QX
M35HO;D=0-"M#>E10*T]J82\X6F\O*TI$4$U.2"]!2#!0-G<K.39Z3CE".7AE
M=#4V:SAQ-T9867%G.5<O,R8C>$$[:2\U-G<O.$%*-4U643)L-FQ9>#9D8E)V
M2T9D63%"1D0T9DQ$4E)A2R]3,FYF-RM(,TXO5$AH2S)(9G!B5'8X069W*S5V
M-EDX2E=W-R8C>$$[.4QA9"]V-&9C,SE-945R65%.-S5Y.'1753-O,U8V<V-L
M03-(:$ED:CAL3UEU8E=9<U5U1UIO="M00D]9=4ES2D8U;3@R95AT5#!W,B8C
M>$$[=&IE0V$T3'%W44DV-T1R=7EG6F]U,TY::7EA8VE-<DYH>CE$<#5W>5=1
M;%AL1V%+2%A96DI7-&]&97 K84AW>E,K>C0O=T%+:C=J.28C>$$[>FUD;V8S
M2BM#6E<S:VYY9D)O5VEA2W0W8TYA841Q2#95=$=C;UAE8C%*6D]%=C=R:7E6
M=4<R04(V8C4V36-K<DHW=SAW36-104\T,B8C>$$[;$5(-55E5DQ/-FIU3DTX
M>#9Z<')1>'DR.75T<%!%9VET-7!J3S!#13(W3C99:TY10U1K:FUK95E$1'=!
M3U))+TAU4F5R959V>3-I=28C>$$[=%)V9%IU-4HW=E=5:E$S3G="23A4=U=N
M,5 Q25-S6'=U,&)667158W0V6FI:.61(0T)X;F@O1G52:3!P>44X278X56MK
M,F@K45ER;28C>$$[,79T4#AZ86ET-7 K;E$V6%HR-$ME;3A&=D=%5TIU5G15
M0U5R*S@T<W1393)A-UAD<EE:-$UK45%42TUU+VU16$DP+UHR4T]3370O5"8C
M>$$[6&1Y0W!P>D)D471M63!!;%%K*W=96C4O;R\W-D@Y85 S=E(U=F]0=4PQ
M2#E,860O=C1F8S,Y33E4-%,X<%ED*VQT3R\S.%!U8BMM4"8C>$$[0U9S3R]3
M,FYF-RM(,TXO5$AH2S)%3G%/;S)5,7-)-#51>G1,1%%54&%65#19,%9T:G-8
M.3%(+W%R*V]:64="6%E69&ER<U992#4R+R8C>$$[-#=)+S1W<"MS-7@O8FXY
M+R]M:CE,=F5Z=C=V-'!B<$@K.7$O22]Q>E$U+V]0-#9U>&IZ6EIO,RLY-F9*
M=C%::RMZ,RM.>#EX*S5X928C>$$[,&8W:R]":U=E:79.=7A6:69N+RLV<W8Y
M850Y4S5Z=G1">6@X9C!/,3=,-7DK1$5R8B]E:4PO6%@Y96-V4&M88T)L,7(O
M=E1&+W)R*R8C>$$[=DU,4F8S,% V,&9V5&TK:5AU3$LX.5AE4F1I<G-68E0K
M.6DO-'EX+SA41U)L>5-&:U@Y,4@O<7(K;UE19W)S2W5X5C)+<T0X-V8X028C
M>$$[2%I(+T%":%0Y6GIJ*S-0-R]W1'I2*VPS=EHS.3,X570P:B]E,69K9C%:
M;V,O=T)"+TA6,DUE8DQ.1R\S=E0U3BMR36XR92]X=5!U4"8C>$$[,T],,FHO
M8VXT36EZ,%8U=#)+<U0X+SA!.3%:9C8P;C9L>FYF841L1#0O;V1R,EAZ;#A'
M2E<S*SE%6"MU=C8X-65F274T1$QR6"]E;28C>$$[3"]86#EE65=I+W9O9C%O
M+V5N3CE%=F-75C4V=3AI-T9867$R;CDW1B]W05I9+SA!:5EY375346E,6%,W
M*U<R:6MJ:7%J27!5.&Q(8B8C>$$[,T]):T9)5E P3G%8*RMF*T=8*W50149O
M=2]1,G!F-S4O=T-'6"MU4$5&;W4O43)P9C<U+S1:9C8T.%%7:3@V."LR.#%V
M<F]J;5AI+R8C>$$[;V]A5D(R2F)W>FM/,T0K+R]W03!/.3=/2#=V-'!4<$@K
M.7$O22]Q>E):+V]0-#9U=VIZ6F8U9F=L;C%33T]*951K3E%6039+5#-Z2B8C
M>$$[.6YJ+T%)6$@S2#=N1S=2+W54.$=79F]B578X0690.$%W>2\Q>C!0:41Z
M9$8S-D<Q3"]F4"]$3"]!1G@T9W1&:'8U:C)6>F)1,D)M5"8C>$$[:'EA5&IU
M1#!#*T)/8SDR*V1O9D@Y1'1E>7AV3#1-37,P6C=U0D5"6FUK54MO-FMK:6=Z
M;51%:U5/8G0W<&YL=&]/=$,U:4IS<&=!-B8C>$$[,4I19V1C1VPW3S%%8W-#
M65-O4TA4>F%S=7!X;4)!:T]26E0K:'13+S-Z+W=Y+S%Z,&II1'I&1C,V1S%,
M+V90+T%!>2\Q>#1G=$8S-B8C>$$[1S%,+T%(>B]!34UV.6-E24Q25W9P;#=#
M635:62M+3$Q&53AL4%=24C)/06M+06YU:B\X04A+=&8K35,O<7E$3D=9<3=&
M57$Q1'I6-28C>$$[9C K8S(Y,65O:S0K,4=O85)L+S%G9V)J.4]9;6)8-&-2
M<55G0S,T.4YK;4Q!95<O;4QQ1FQQ1W9P8S)5>7IW3F)O039N=4=A;U!C2"8C
M>$$[-35Z6&%U5T]43'A23FEG-V)244U955)2=$,K4C<V>7-F361V9%AR8TQ:
M1FM$<U9:-F-K24=Y:&HQ3U4Y;C5963AO;$TQ2&1S,55*4R8C>$$[9U)(;3EK
M,'I53DHQ0TPV>' X<U5Y1%ES;$MQ9D)H<WEN-34Q*T1*:7E$:6A29$9K:$]*
M<59O,TPR=$-A;G$R;C988B]!1FDK;45-9"8C>$$[94LQ<5=:=D)61E-X*U=5
M-3E21$9(:6UA1%IJ>%-M86E,95IF;5 U:7-.6FAS4EIR2U!1851M6DEY9RM-
M3%-L9CE83UHW5#=1>%IX128C>$$[44XQ8G0Y2'!P-#<T=7)%3DML4TA5-U-A
M43!J:FUJ9'I1;6EQ-$HR1V$S1DE2;4-E44EC=DE,:5%/-3=.82MF4$QS.#9W
M=$Q*8CAZ4B8C>$$[2DHT,E)#5#!(23=$+UI5>G%S6&)';FY,:$5N4U0P3U=)
M=6U1-71(161I<G-6465R9C=X9C@Y668K5'E9<3=2+RM/5F$O=T1'2F8Q628C
M>$$[<6I-5E-R>E9F>C)(;"LY=7)C,&Y207-B9GET27=13B]S959C>$YF;4]0
M1$M1-6=.*VUG2C5!0W=8>3-P;&AC0S5.,51J145D;F54,"8C>$$[=U,W:%=:
M,TYD.2]P3V-2,F1H:&Y--5IE;&,U8U!-.3=V3E1K;$%!4C8K5CE'4#A!;6UZ
M<U5U2EAT1S5X2DE6:FLW<VYB-3528UDU6B8C>$$[4F=B:&5Z9$=Z14=83D\O
M2V5J,D5Q>DI/0GAH:$5H678V44QC;$),3U%A9&-V-T]W47IZ;C1N2TEV;G=J
M;C-T3W!Y4V="=SE4,U=R,B8C>$$[33!';2MC24<P,E%V8E14<F)-83=02$QT
M=C0X5S-">DHW4'EX=S9Z9WA'.%I.3F5E0FYG=5EQ5E<Y3GIU6%%0379/9'A,
M8V5A3&U/428C>$$[,5-Z4T]/0F5W1&]*1U!Z2F(X3318,FEZ4T]F:#9$*S$S
M+UHP04UD.39T-6TP;E)R4T5X44U0<DAQ;$=H.5%35FDT+V%952M!,3=:1"8C
M>$$[=%A364U!+V1N,6E83&EV8G908V9*3VMZ6DHO5CE.9#%B+W!96G!&=D=,
M:61V=$=).%90,S<O:&UU,45Z43@S36E'6C8Y<%=J,C%G;R8C>$$[:EE#-EEX
M+W5F541L:V5-37AD2V9"=61T.#)(84=K=UEC64U45U1B83<R36(S2%1Y8U14
M-7-K-6(O5'8P."]T6E U174U<FIY-4-*;28C>$$[3'1B=DI!<G0Q6DDR25@W
M;#(K:D]R-TEZ4WEA94IL>F14<EE#3U4P>41.;31J<U9197)F-WAF.$%05T@O
M04I02FER=$@O=T-/5F$O."8C>$$[66PO5FEQ37A61&%N<#A';S9F8U=-.693
M=45+35(Q1F5J1#-",WER3FE'4T)I95):-#5M36=2,&5B6$]H95ID3V%3,6$Q
M;75),V]$3B8C>$$[87%84U963E%756)Q86IO4FY$86IS9E4T:5EX0DU:9#-6
M,S)05UEP9T5M:4\Y2&%*-45U9%)F,71A:&$S<VQ".4\R-55L9&IS1V)J.28C
M>$$[:T1W-C5S97I/=VE$>%IV:S0K<3=12$M#0C%$471E,$U4<#9C:SEI14E.
M,T1U<E),.%@W,5%A<E%$974R665P-T<Q1TM21T\U4FQT="8C>$$[,6)S971X
M5$%-<4)(97=/6#AZ3$Q49%1I;G1,6#8V.7%X84E/,T=)>6)G35-T4W=8<4%0
M=GIP3W=F6DQ,0U%Y-7IW.3!E=G@W;FXK,28C>$$[4&%814%966AX9694.7$K
M8B]N24AZ=SAH84]'>&E4<V=I8S K;'!#8S=19&U9+TXU;SES6F4V4#0K2T%U
M=GIA,4158CE,>E5B1T53."8C>$$[0DA/.71Y5&U&<GA9<35F-&A8>'I1.7(K
M>6-.5C9O4S1:*V9*,FUG.7 U67943TYX.&UC*U=H965C=61Z<#AQ8T]63'$T
M;6M5>5)K+R8C>$$[>E)!;5-P+UIQ040T-7AU5#)A,5EY+W9U=CA6,V(Q3TAT
M9E1Z>#-J3BM88WEZ5B]Y.70T-U=&.4552F11<G=L4U)J4V-E3$XR9C,V6B8C
M>$$[<V1F,D9$2D%$2'1)9F$Q869T06E2-"M2*WA+4C55.#-8='="4&)I,TQ5
M1#-5,'-B:%%O049&4FY:<4%B1$Y02'-(535*,VLK9'599"8C>$$[9FEJ2#!V
M44Y),'E$5$Y/9W-92VU/0F%C:C%::6%S>#DR66LU,E=N=U)X445).&<V6$QK
M335'4C9O=DQM=#)+;U!6=CDT=CA!;G)$+R8C>$$[04UN:WA6,FHO=T1(2W1F
M*TU3+W%X5D=9<3=&6%EQ-T989R\U-V5F3&EF540U5W-:4VQP8D)7,49L4#A!
M95-K8VQJ2D@W2T%G:V50>28C>$$[>F0Y;39906-:-3E(;BLQ=%=B.$]03'(K
M<#5";3%D1S=&6%EQ;79L:GI,<69L>E=)3E4P*U%R3$5F,VM:4'=3269T230W
M9VHW=7982R8C>$$[<S)'3U-00U<O5#9I5TM1;$8Y839*<3ER<D=K5VUQ5VAR
M8C-K4WEO1#%(26)Q9F14<V,U9DI!=VM9;F\Y;&IY0V-226-I:F-G>F1I<B8C
M>$$[<U9D:7%$,6(O94PO04HV=R]W1$HU359D;R\X07AY<E@O:D5V-G-64FU+
M=7A6,DMU>%8X9BMC2EIP=DYM=%-45CE6<C8U-3$R;V96628C>$$[52MJ3W)W
M0W-C83=G.%AQ:51L;&8X-'!2;')J=EAT47-V>2\Q=50V-%)B:4\P<TI,,C1T
M.4]8:D9#3%8P06AA4EDW9&TK<TMX0RMO=B8C>$$[3E-09DY41U=71S(K-7)F
M>BMF2C9#8TU'5&9B84XK;G!85'!Z66@K63!8;&<S,71C-D)*1$I&37)'-TU4
M-VE9169$-EDK1EEW=$]*6"8C>$$[<G98,GDY25HP4DIW3S!":C1G659V>EEH
M;5<V-3E,+VM83DY**UAT<7-H2E=+961)<2]Y."M8+T5M3V,W,FE0,W!E<S=,
M4#=G9D@W,R8C>$$[;T=93'-(67$W1EA9<6<Y5R]W0C1V*V5S4"]*-4U69&\O
M=T1X>7)8+T%)>$PK<D956FER<U9D:7)S5F9.;C4R*U5P.4@X,E,V;D=H3R8C
M>$$[;C9U5$]K;EI:+SA!9'%%*TYF:4AS9EDU,%!:*V-4:'<Y679,.7$V8W=Y
M8U@X379V960U;G5R8T-10T%D:C%(:FEM,UEO5G)+>75R-B8C>$$[-VAS-U-*
M<')M-&-2=WA)2W-Z36%!1$)+46E,4$IN0T)K44)Z3#8T.&TK6&LX=F573E P
M9T5-.71&*RMC9$=L8VPU0U!B;7AP-UIY,B8C>$$[9DPT:WI,=F5Z,"M(=SA9
M:C-*>FQ,8S=&6%EQ-T952'$S*SA8+U!72"]K.&U+=3!F+VIL5W8O1TIF,5EQ
M:DU69&ER<U9D:7%8-CEO3R8C>$$[;&$W<&MU;39P04HW5UAQ<#)+<T]J27<S
M5F@T:DQ-95-51&-E8EAL>%)Y4C1:0W<X2C@Q9FM,-6MS2EAM,$IL,5-Y,TMX
M:W)(8TM0028C>$$[<7A#="]S5'8T6G5S4&%52F96<UAN.5(R4D]*=4AQ2#)S
M3&LX:"MD-#-+3F]';VMR,4LR<WI$-D=64T1M64Y4:B]N1#5U061(;4)R:"8C
M>$$[;#AK,#!8.&\O4'5Q>7%Q-EI*6GA';DMA."]C2V]0:7)F=D0Y0S56:S$R
M2U!7+V,S675Z8S K;&4Y-UHK6'8U56%2-51!=DI71CER3"8C>$$[0VAU;49&
M:D)&0W-3;G!8=7@S4'0P>E0V<E=Y>3=C;W4K,&5G:&@S-7DW,F1::$]E-T98
M67$W1EA9<6<Y5R\S:2]W0V5S4#A!>6541B8C>$$[6&%0+T%-8W$Q+S1X3"MR
M1E5::7)S5F1I<G-69&ER<U9E2"M99D]8;6DS,2]5-V5(57!O-%EB=65/2D%2
M4E974F=O1S-96DI$3%!Y<"8C>$$[,2]79%5U9%)854QU4S572DEJ1TA.849I
M,6%F9&=+:#9*9U,W1EA9<3=&6%EQ-T952'$S*SA8+U!72"]K.&U+=3!F.$$T
M-59R+W=!628C>$$[;"]6:7%->%8R2W5X5C)+=7A6,DMV;EAZ5"]Y:RMR+SAX
M='@O>61B2DE:="M3,RLY97$O.%DT9C%V9TMH-G!G4S=&6%EQ-T9867$W1B8C
M>$$[54AQ,RLX6"]!1#%H+W=#5'E9<3=2+SA!:FQ7=B]'2F8Q67%J359D:7)S
M5F1I<G-64TQZ8C53<V9-5F@V371)-W5)13)T>4)U:%!9*R8C>$$[2VYU359E
M1F%T<$XO<$XO2EDS,%II;FE/-#=-3WI+931/4U%N+VMF>5!C*UEB;C$U*U5/
M;%%T*RMM-D9Y4#)%.2]%.7-693-7;'!B5R8C>$$[9'1(83(P87A7.$MH630Q
M,D%!>4M66$9867$W1EA9<3=&54AQ,RLX6"]05T@O:SAM2W4P9B]J;%=V+T=*
M9C%9<6I-5F1I<G-69&ER<R8C>$$[5F1I<50K62]+;6ME64E9:W9K265&9UDU
M;WE&8T-V>$Q7:#)B1E5Z=$Q3,G,W84\Q=%DQ:'0T5D-X>'%+04%9<7$T<3=&
M6%EQ-T98628C>$$[<3=&54AQ,RLX6"]05T@O:SAM2W4P9CA!-#56<B]W05EL
M+U9I<4UX5C)+<%@U<#%X3D(X=C,R<G1(-G8Q4TEU<U9A8VU*0W%#97=,128C
M>$$[67%X85 X>7)J4W)Q-3 O>E1::$PK23(O;TQP<79-2E!R2T\T5&<Q1T1,
M-EI(=FAP5W)V.#%B5UAM3DMG3%)"3$]A3SEU1FLY1FQU<"8C>$$[4D=Y,%%C
M9WDW9V1U45!H:E-O;38O3C-Y;F)4>G=Y3&5&-V0S4FET=3=+9E)9<DM68F]2
M2%-R2$=L6&HX>')+,7,W=2LQ1D=K<S!V-28C>$$[8E,Q;7-O<$I"=U%2.$),
M>7!34GI*=%19.7-A5F)Q,S5P-DYP-V%L04Q/-V4Y,#9)>D=#4TEX0U)69%59
M<7@U8D%T,4DV63!Q,2]Z328C>$$[<V)&3#)45DEP0C9D,39&<&%W47E'-31E
M9W,W97%J,$%:1F%R54Y":E-O=3,O37IY=F-A=&)A8D,X-WE84FA73S1%5&5J
M>759:$Y#<B8C>$$[4#):,6)P5$%Q+U9F>D8X=C9B<DUU:GEI-&MV25%!>&II
M6F\O5F%)>7AW.'@O=7@Q2'=I;4MO=GE2<CDW<B]L=3$Q83AG5S-L=5,W0R8C
M>$$[2D]814E(25AD='I51')I<64T<3=&54AQ,RLX6"]05T@O:SAM2W4P9B]J
M;%=V+T=*9C%9<6I-5F1I<44Q9E-R4%9T375D3G963#)T,"8C>$$[:&IL04Y$
M43EW9D5D4FER0TY5+TM:6G!B3C=85DQX<&AD47DS="]03U!R46AG:65/3EE'
M4TQI0T]F8V94:'15=U U5BM84DA$1D9C6"8C>$$[:TU-345&=5EK:U1I-'1P
M=EA2,T1),5@U:S%)<'-4=&IA<3%X*U=U:%1X;$AN=6='4SEJ3DAJ-F%G+T]8
M+V1F-THK>BM.8T-Q52\U6"8C>$$[-E!*1&)X2G%&+T%,5S=K=C1J1DI#1#8X
M:6]O63AO;4AW0U T3G%I<'<R<6EV-5)E5U9U=%)U5%!E32MP>'I2,T-M4T]G
M1G=W9&U7:R8C>$$[9&%H;#)Q5&IA<3$Q*U8R:3--0E=3+S%$-C!:9E<K=G)-
M9W5/4G0Q=&Y(4# V56M20GDR-C1,5D97;C5E-D9A96U)2DQH5FEU3$\V4B8C
M>$$[3U-%8S='15%21&1+.%=55F)V6'5-5F%V=GDX,%,X.'=.<F-K,3!S<GE2
M>GE7:5-!5WI44E)M2DI3:%5N;7%N>'A63W1#,&$Q,%A33"8C>$$[6%,W5FYE
M,W1%.4].<%-#-49A+T560VIV-%EQ:G-69&EQ1#%B+V5,+T%*-G<O=T1*-4U6
M9&\O.$%X>7)8+VI%=C9S5E)M2W5X5C0W8R8C>$$[*V$O>DA7,FYV271345)R
M8EA..4A#8E--;FIA6#,Q6#!A,"\S67 U5C8K2&IH46DW<EA.6#!Y*VQH=&)G
M-E1:6#)U86HY9#%#3S!.,B8C>$$[87AP1C9+*VY2=C<P,4<R*S(R2W(Y53AY
M961O9$YU.51'<D=#>D]S>6%D5F)&2D=T<E-.,T@Q:FI4:W@K14Q2:#,X8U93
M;%!Z1C@X:28C>$$[.#!:3#(U*W O5W9Q4VDS3G%T3'!*-5=%<W9.;"]D:TMO
M,DAJ=&EQ<G!U<#-';39865A514UQ6'1J<&UQ4G5Y=SAP;S56=3!+9TDO=R8C
M>$$[,$AQ8VI8=&EQ*V)79DU0;50X<TPW.4E81'1-3E=I<WI+26Q2-4QC=D52
M>59&461:3V]!<E1&5S(O34QZ5W1R4%IW4TUL+UEX6%%N1"8C>$$[,G=#<7E8
M:U552%9A1VM41W1-5E)-;FUV>FYA,SA/;6%J<7AG:&@Q0S=T6G18:G-"3C9V
M<%)1>5%X;49&64QY37)$-&0O9D95=5A6+R8C>$$[3550;48V5%1A;G%M;E,V
M.3E7:G5)5S52.%EG,$)J,C-75'%%2&A167%V,'IZ;C4O,4<R4S-G,4TO=DI*
M3T=Q4%I)<%!P,DQ836M8<"8C>$$[;%%V=U-*=T)P=EAV:7(Q2'EP<48S<5AL
M<E1,*SA!1C%C,C!C:SE">$A.;$A,8G1V9U-M=4MO4%9V.31V*V5S4"]*-4U6
M475L-G!P,"8C>$$[96Y7,&-L>D=R<D=O6E-W<4141E56*VU.2R\U86]V.$%G
M:&ER=C!X<%@O3%9&+W=1>%8S-EDP<B]!2F%O=BM#1TMU+U1';&8X=%58+R8C
M>$$[04%1>%8S-EDP<B]L<6DO-$E9<6Q6+W S:W$O,4\S,5,X:G1P<BLR2W1$
M3WIB9V]A;U-!84YX2C)Q3G-65%@Y36%6+WDQ4F8X14U69"8C>$$[*VU.2R]W
M0U=Q3"]G:&ER=C!X<%@O3%9&+W=!14U69"MM3DLO-6%O=BM#1TMU+U1';&8X
M04Q61B]W47A6,S99,'(O;'%I+S1)67$W.28C>$$[36%6+WDQ4F8X14U69"MM
M3DLO-6%O=CA!9VAI<4<Q1%5T4&UT:$A&8TDX:E-W.%969U-A4W%C5F8O.6L]
M/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM
M;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*
M(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HR1C)$,T,T.$4W
M0T1%.#$Q.3,V1D5"144U,C<X,41&03PO>&UP34TZ26YS=&%N8V5)1#X*(" @
M(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HR1C)$,T,T.$4W0T1%
M.#$Q.3,V1D5"144U,C<X,41&03PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @
M(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"
M1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X
M;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&
M<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T
M4F5F.FEN<W1A;F-E240^>&UP+FEI9#HR13)$,T,T.$4W0T1%.#$Q.3,V1D5"
M144U,C<X,41&03PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T
M4F5F.F1O8W5M96YT240^>&UP+F1I9#HR13)$,T,T.$4W0T1%.#$Q.3,V1D5"
M144U,C<X,41&03PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y
M,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E
M9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O
M;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C5E,6,V,&1E+65D.#,M-# U,RTX9#%B+64R-&(Q
M930P86(P-#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C Q."TQ,"TP-50Q-3HP,CHQ-"TP-#HP,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@0T,@,C(N,2 H36%C:6YT;W-H*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z83!E-#9F9C$M.&9C8RTT96)E+6$U,V4M-F$P,S=E-S4W
M9&8P/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#$X+3$P+3 U5#$U.C V.C,T+3 T.C P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B!#0R R,BXQ("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T
M97)S/F9R;VT@87!P;&EC871I;VXO<&]S='-C<FEP="!T;R!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N:6QL=7-T<F%T;W(\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F9D8F9B.&0V+65D
M,3<M-#@P8BUA-&-B+64V96(P.#8U-C8W-CPO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q."TQ,"TP-U0R,#HU
M-#HQ-2TP-#HP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0T,@,C(N,2 H
M36%C:6YT;W-H*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-64S-F(W-#0M.6(R-RTT
M,#EA+3@Y-S(M939D-V-E-3$R9#0X/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$X+3$P+3 W5#(P.C4W.C(T
M+3 T.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#0R R,BXQ("A-86-I
M;G1O<V@I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO<&]S='-C
M<FEP="!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N:6QL=7-T<F%T;W(\+W-T
M179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C@W,&4S-&8T+6,S9#4M-#DT,2UB-S=B+6-F8S(T83)F861C9#PO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C Q."TQ,"TQ,50Q-SHU.#HS."TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL
M=7-T<F%T;W(@0T,@,C(N,2 H36%C:6YT;W-H*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z93)C86%D-#,M9&1C-"UA8S0V+6(P.&$M,S%E9F9F-&$Q9F,W/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#$X+3$P+3$R5#$P.C,Y.C S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R
M871O<B!#0R R,#$U("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P
M<&QI8V%T:6]N+W!O<W1S8W)I<'0@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E
M+FEL;'5S=')A=&]R/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HY0C,T03,T,D4W0T1%.#$Q.3!".#DS
M,3!%,C0P-$4S-#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C Q."TQ,"TQ,E0Q,3HU,CHU-RLP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z,D8R1#-#-#A%-T-$13@Q,3DS-D9%0D5%-3(W.#%$1D$\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,3@M,3 M,3)4,3(Z,C@Z-3$K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S
M=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N
M861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@(" @(" @(" \:6QL=7-T
M<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T87)T
M=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @
M(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T
M1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B
M"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L94]V97)P
M<FEN=#Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @
M(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP
M5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z
M3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z36%X
M4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" \<W1$:6TZ=SXV,3(N,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \
M<W1$:6TZ:#XW.3(N,# P,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$
M:6TZ=6YI=#Y0;VEN=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G
M.DUA>%!A9V53:7IE/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @
M(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT3F%M93Y$24XM0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D1)3CPO<W1&;G0Z9F]N=$9A;6EL
M>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T
M1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y
M<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.G9E<G-I;VY3=')I;F<^-"XT-C \+W-T1FYT.G9E<G-I;VY3=')I
M;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\
M+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&:6QE3F%M93Y$24Y"9%]?7S N4$9".R!$24Y"9%]?7S N4$9-/"]S=$9N
M=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@
M(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP
M5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T
M8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \
M>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS
M+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@
M,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 6L M0,!$0 "$0$#
M$0'_Q  ?  $  P # 0$! 0$         !P@)!08*! ," 0O_Q !9$   !@(!
M 0(("04*"0H'   ! @,$!08 !P@1$A,)%!4A-W:UMA<8(E57<I66U#%6=;35
M"A8C,C4V09.STC,T.#E187%S=QDD)5-TD9*RM]$F0E2$E+C3_\0 '@$!  $$
M P$!              (#!P@) 00&!0K_Q !=$0 ! P(#! 4'! X&! L) 0 !
M @,$  4&$1('$R$Q%#)!48$(89&AL<'1(E)Q=14C,S8W0G)TDK*SM+7P-7-V
MHM+A%B0T. D7&"5#5F*#E-/Q1$555X23E;:WQO_:  P# 0 "$0,1 #\ ]GFE
M-,ZTM6L:Q/S]72D)=^67%V\-)32!EA;3THS0ZI-9%!N3L-FZ*0=VD3J!.T;J
M<3&&HI1!(!]G=5-*00"1[>^I3^+QIO\ ,M#[8L7[7R.M7?ZA\*EH3W>L_&GQ
M>--_F6A]L6+]KXUJ[_4/A30GN]9^-/B\:;_,M#[8L7[7QK5W^H?"FA/=ZS\:
M?%XTW^9:'VQ8OVOC6KO]0^%-">[UGXT^+QIO\RT/MBQ?M?&M7?ZA\*:$]WK/
MQI\7C3?YEH?;%B_:^-:N_P!0^%-">[UGXT^+QIO\RT/MBQ?M?&M7?ZA\*:$]
MWK/QI\7C3?YEH?;%B_:^-:N_U#X4T)[O6?C3XO&F_P RT/MBQ?M?&M7?ZA\*
M:$]WK/QI\7C3?YEH?;%B_:^-:N_U#X4T)[O6?C3XO&F_S+0^V+%^U\:U=_J'
MPIH3W>L_&GQ>--_F6A]L6+]KXUJ[_4/A30GN]9^-/B\:;_,M#[8L7[7QK5W^
MH?"FA/=ZS\:?%XTW^9:'VQ8OVOC6KO\ 4/A30GN]9^-/B\:;_,M#[8L7[7QK
M5W^H?"FA/=ZS\:?%XTW^9:'VQ8OVOC6KO]0^%-">[UGXT^+QIO\ ,M#[8L7[
M7QK5W^H?"FA/=ZS\:?%XTW^9:'VQ8OVOC6KO]0^%-">[UGXT^+QIO\RT/MBQ
M?M?&M7?ZA\*:$]WK/QI\7C3?YEH?;%B_:^-:N_U#X4T)[O6?C3XO&F_S+0^V
M+%^U\:U=_J'PIH3W>L_&J7<C*96:-=HJ*JL62)CW-692"S<CEZZ [Q66FVRB
MW>/G+I4HF1:MR=@JA4P[L# 0#&.)JB"2./?5-8 /#NJYO'/T,TSZD][SS64U
M]8^'L%5$=4>/M-3;D:E3%*8I3%*8I3%*8I3%*K)RXWZ^XYZ=>7F @F]JNTK8
MZS2Z#4W)79R62UV63(BA&@DP.1\NH2+0EGZ3=H8%W*K(C<@E%7M%\1M!Q8[@
M[#KETB143KF_,A6VTP%APB;/F/!*60EDAU:A'1(>2ALA3BF@@$:LQ=?8QLYC
M[3\;L8?N-P<L]AAVNZWW$=Y:+*56JS6J(IQR65R0J.VE4MR'&6X\-VTB0IU0
M(1D8:NO,]_'<.-=\GZ; P4I(W)Y0HR1@I)5^:*C):<G"5JW,$E6KA!XH:"FF
M\FS9J**!WOBR:BY! XESSESVDNL[.;1CBVQ8K[UQ<M;#T5Y3ICLR),KH5Q:2
MIM:'#T64A]ILJ5\K0%+'$BO<V+87'D[<,3;)KY<;A$BV-G$<N+<8J(XF2X=O
MMRKK99"T/-.,)%P@.1'GTH2=&]4EM7R0:F3E;OB;T#0*S+U.LL+9=MA;*J&I
MJ1%3#]:,@BVBY&D#,7DZ[;$.Z+%MD8MT95-MW:JJQD$^_;IF.LGZ/'N*I.$[
M3!D0(3,^YWB]6^P6QB2ZIF*)UQWQ:<E.(!6&$(CN:@C2I2BD:D))4/#['=G<
M#:/B2ZPKS=9-FL.&L*WO&5_F08R)=P-IL8C"0Q;V75)9,MUR6R$*=U(0@.*W
M;B@E"JDS'/+:^O8+>%/V/K"D.]\ZFO&I:+%L:989@=;VA]NAHY?U:0\=FFQ)
MU@TC6+-9S(H+]A9V==FT*>,.=RLU\!)VJWZT1<3VZ\V2V.8JL%TL%J8;MLR1
M]AISN)&G'H+V\DH$MEMAEI3CR5Y*<*VFP6"7%-WF@^3O@_$MQP!>\+XMOS.S
MK&5@QEB&7(OMLA#%%HCX$?:C7B-N(#JK?)>E2'VVHKC>:&4H?>*982TV[(M1
MY0\B#2/(#5-ITQ3[9R T]"T>=KL%J^TO$:7=F5]% K107]R*Q?Q"=;3<IR$P
M=RIWL@U1>MV#9!=%LH]^Q;\<XO+V+;#.PW;[ABW#L:V2H<6QSEHMMS:NNC=G
M>W+=.QQ"#B79)6K4\A#J&4(4E!=\Q>MDFS,1=F^,;1CJ]V;9OC>??[?<[ABV
MT,.7ZPOX=WA>3T:Q*D1IJKHII4:$&DZ(SKD=V0XXVMU+$B<==^[0N^T=P:-W
M/5:+$["U(QILT\F]72\S+TM_'76//(,HY4+ W0EHV;CT@2[Y-P(D?@=RHW00
M09D6??7P=BR^7.^XAPOB2!:X]WP^U;I+LFQR),BV.LW)G?-LGI:$2&9+22G4
M%\'05E"4);"G?,;3=G&$[!A'!.T# MWQ!,PUC.1?(#$#%L*#"OT:589*8S\I
M/V-=<ARK?)65Z%M *C%+2'7'''U(8N3EQZL?3%*8I3%*8I3%*8I6=O+CTCP?
MJ3'>W;'E5'+Q]PJDOGX>\U:7CGZ&:9]2>]YYK(+ZQ\/8*FCJCQ]IJ;<C4J8I
M3%*8I3%*8I3%*8I6?W*C1.\]];PT6E2K$EK+7FIF\SL;X3%(RK7(Z>T3.46=
M;8(T*;DT3R#B%8LS/6DH]8C%M/+#LQ%E7J"2);2XZPKBC%>)\+)MLQ-DM%@1
M)O'V:+$&XJ%\*TMPVD6J4\"ZN,VUO6WW6BPCI+A"E.H2D9(;(=H6S_9W@#:$
MN_6Q>*\38R<@X8_T43+N]C2K"(;6_=)+F(H$58C-3Y#Z8[T2/($M[H+(4A##
MBG#4^5X@\G:_QPW5QYCH9GL5NQWO2MF:FLA9>FT]O;H5](-9JZ,RPAYP6U,)
M$RL>+HD:Z*@W4<S+WR.#MLDF4/!/[/,;1,&XEP@S':O"&\4VV]6";TBW6Y$^
M,ZZB1<6^C&3HMPCOM:PRL);4Y(=,<+0 *O%$VU;)[EM0P'M+DSI&&'7]GE^P
MIC*UF%?+VY9I\>*];[$^9Z8&]OJIL.2&E2FE..I9@L=-++JU$SSNZN\L.1]!
M@5)'CI!ZMMNE]RZLW12Z_(;KJEQ;;.6JBED1EZP$G#1$<VJCA!"09N$'TL<6
MCP53(E40,B<X^JQ/#Q]C*U1%/8.B6.X8:Q'8\2VV([B:#<47M4#IJ)$'?QXK
M"("TI>;6AV02VYJ*0I!3F;>8!NFQS9?B.XIB[3KABZS8[P-B_ M]N4; 5WL;
MN$T7A%K7"NW1)TZ4[>&W'(SS3D>$D/,! <*7 L 0W;N)W)7;B'(K<\S2:QK_
M &9L396@;U2=0O+Q%V(IF>BXQW$JL)FZ0Z802+RR-7A%V!TCD01=M54'QV+=
MPFZ2\W<, 8TQ C&&))-L@VB]WB]83NMLP\Y=&)@W>%X[D934FY1T]%2Y-;<"
MV=)"4N-J0\II"TK3[FR;9-E>"W-F.!8-^NV),*89PMM'P]?\:L6"7:R'MH4M
MF8F3!L4U9N"V;4ZPIN0E:5..,NI<CID.-J:7*U=I7,!C9N4G)ACIVMU3;VS*
MGKRCZNU*[V)5[,,<-=20BI.V3]I05CJNNDQ2.,W'Q(.6ZLB9LK%N2-^B+A]]
M^%;-H;4W'.-FL.PK?B&]P+1;+'A]V\09VY,-*([\^7/06H*TM)_UIF/K0I\H
M4PX&\DK=\=<[]L3D6G9'LID8WNEXP7A2\XFO^+L9L89NUI$H71;DN+9[;9W$
MR;LVN0M(@29FZ<1%#J);*G<W&X\E<$M>[8UC7[9![8THM2+78'I+?<]M2NUZ
MML:Q;=O$HY=#*NY%E ,45J\PBTSAY'CEGSYJU;N52$5<2"TE(/?L[++/?['$
MGQ;_ (:-MGRW!<+CB!Z_PKS,Q!<WEKWRWFHK*%PVF$G_ %9E3SR$(6H:EO*>
M>=\MY0N)<'8LN5FN&#L>HO\ 9[:PJRV+!D3!UWPO;,%6"(TR(;,5^XR7$7.1
M+6D].E(CQWGG6D*4AN,W%C1[^9=FL<:8I3%*8I3%*8I3%*SMY<>D>#]28[V[
M8\JHY>/N%4E\_#WFK2\<_0S3/J3WO/-9!?6/A[!4T=4>/M-3;D:E3%*8I3%*
M8I3%*8I3%*8I3%*H?;.:*E:YLTKB46BINXZSP:+IY=1F3)/64L^@IBP,DFT,
M#$Z#B/3;Q:+1R=1^DY,L]472*4C$J+ZU<_:286TRVX %K2XS-BI6Y<NDE+K4
MAV+(EMI1&W10MD(82VLEU*RITK  :"7LA[/L*3==@E^VS'$*F9-IN"V6;"((
M6Q(A1[C!MKZW9W2$N-R5.S%O-)3'6T&V$MK)5(+D<7FBH;G4?AU^\5/Q(D #
MG]^_EHWC8S0Z_+L?L>1_$>Y\F>23A%_X[XUY0#QGKXO_  .!M)/_ !I'9U]B
MQNA%U?9/I)WG2?L0+UET?=:0QT<[C[H5[[Y>>CY('82D>3VG;?\ Z0JWYN6Z
M^P'01N>@?Z2'"^KIO2-?2^FCI?W L]&^U9;W[95\,NI6/%,4IBE,4IBE,4IB
ME,4IBE9V\N/2/!^I,=[=L>54<O'W"J2^?A[S5I>.?H9IGU)[WGFL@OK'P]@J
M:.J/'VFIMR-2IBE,4IBE,4IBE,4IBE,4IBE82;5_SS.J/T57O_3BS9BU??\
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M2Z&664$14=2,BY$ 4?2LDY,H\D7Z_59V[645.(=0*7+*QV.V8<M<2S6B,F+
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M5*3U4Y9J) '.NG$V@V2<ZVW%C7IY+L@1DOHM,E48.%P-$J?2"VE"%GY:B<D
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MJN1,&IT2"F+5>=,83]Z(=0-WX=GL_D[(]?Z,SH\@AHNW':< 0,H6%.?G?O\
M5@?*%=#47"I()S?N_+S-VZKX$VOKA.)?0">NFJ<%)K.'$E"DC((L3(+NSE5=
M+/HXJ(,W:SE4A5'"BZ*AUCE*=0QC  ALF+4@K#A?45IR"5E:]:0.0"N8R[,C
MPK%[>1M"FNCHW:R2MO=MZ%%1S45(RTJ)/$D@YGB:_5QM[7[M6%6=T!)TM6S
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M,>&UNF%.J"UEL*41FL)0%99Y9Z0<@-69S)X"H4:2MJBBB1RLHY X)KOE2&4
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ME32TZLBK>#0D K40E)(Z\J[,6*+(O$F;]C8]M9<EOS@ZMDQFF4E2W XV0X%
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MXI]^O-GV34R0.L&2KZ]>2)AE8)6OD24%#Q9Y!PJSZ7+(K. %LVC2LQ?.G/\
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MO2T_.V-R1[8)F4FWB2!&J3J6?NI!PFV(HJJ1N19VJJH5$JJRRA4BF @'54,
-=HYA'G++E7&>?.O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g838337g17w57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g17w57.jpg
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MT?$^8H'G!F;,-1'22PXZJ",?SW)RA4BMD6)'7$:YQ48P8Y@A>;E$"O+:@D2
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M[,&F)IM"+P8KQEMJK2"SU*(E$2B)1$HB41*(E$2B*\>! $<HQ\0 1"TAZ$>
M.HJ^W6.\&L0#VQ *VOR)L[\HV$V,[[ 99W]YNI-UMK]QMKLWWW9O;6'Z\^YF
M]_I*?SL/:[JE)]AB1-[PM6QI!<[,RM0:H()2W%]-H.C7C>*0Q-??:8:45<(V
MD'$ ;K*"WHP%F?A9!KWD8U%0R]N[IJC++8>X<E@(:TA\[Q[FF\Y525ISA,HA
MRD\0% Q=HHQXS#FWKK7IS7>+L4@ RMAJ5X X"(0L9<"SN,T6- L6E&$I,S.2
M!-S9-WW'E'M6_P"QM//!1Y]Z7<]:_P"C;7G@IF?%)>=9)UU:<[\T?QS>9.QM
M//!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+
MSIUU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*/
M/O2[GIT;:\\%,SXI+SIUU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK
M3G?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+SIUU:<[\T?QS>9.QM//!1Y]Z7<
M].C;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+SIUU:<[\T
M?QS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:
M\\%,SXI+SIUU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S
M)V-IYX*//O2[GIT;:\\%,SXI+SIUU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF
M?%)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+SIUU:<[\T?QS>9.QM/
M/!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+S
MIUU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*//
MO2[GIT;:\\%,SXI+SIUU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK3
MG?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+SIUU:<[\T?QS>9.QM//!1Y]Z7<]
M.C;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+SIUU:<[\T?
MQS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:\
M\%,SXI+SIUU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S)
MV-IYX*//O2[GIT;:\\%,SXI+SIUU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF?
M%)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+SIUU:<[\T?QS>9.QM//
M!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+SI
MUU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*//O
M2[GIT;:\\%,SXI+SIUU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK3G
M?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+SIUU:<[\T?QS>9.QM//!1Y]Z7<].
MC;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+SIUU:<[\T?Q
MS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:\\
M%,SXI+SIUU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S)V
M-IYX*//O2[GIT;:\\%,SXI+SIUU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF?%
M)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+SIUU:<[\T?QS>9.QM//!
M1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S)V-IYX*//O2[GIT;:\\%,SXI+SIU
MU:<[\T?QS>9.QM//!1Y]Z7<].C;7G@IF?%)>=.NK3G?FC^.;S*XV/,-2!4\H
MG.3(KFII;U!2JY,IN+Z<<#"+P,*3@19??<2GN,MMZ8,/Z'=<5M%DVW77]$+V
M/R><C6H+.9I934U*6*Q6/L"MO6L3&]S(%!-B"KM7'.<@5W)&/."'X<Y#VP#"
M3S<@\7U/KG&"H6*F)L-<N613"Q1-)@UH$9XS(Y)19ID:+OPXCWF:6R4Y,T=V
M6>!?XLO\RW]$*["6EU2;%TGURSCH'4+IKJBR]/=314=5^B=;S?T#KC W[R"K
MI?8ZG=*_>Q:^ENB??^B4[GZ>V_:_3M[5YW?O_P!C=M?M,F5%(F%8R.%MUR1Q
ML$@T;! #"QV1O*.*$0&T#2#K"SRANMNM PNW:MNMU@-ISN%I:BQ&0PN1C*5/
M(UY +N.S$&^UIB,)W:46+7- 9Q/*,HL0<7E&3,[/64;Y\9<KWZSLQZI(DAO;
M7C)OM9PDS.SO D)2A-F=G>,GV.RPB=L$3=$K,*;2D3PDVAZ"J*6ID=]Q?[GH
MR=::2)1NK\.PLP^P!_!-N#NUR!E>0?6].V06-'1R]/>EP+0[@*<Y#V^MX]>X
M03B+L^V@(AQL_P!J63=E;HI\HNGSAA.U.Q2/NMQ S 4\6E[?#(")&G#;]J\H
MCD[=N#/V%%]A3(_Y#)\K-'GM6SH2Y1N\U?RMB_I:J^O[2_N\GB5ST"=A3(_Y
M#)\K-'GM.A+E&[S5_*V+^EIU_:7]WD\2N>@3L*9'_(9/E9H\]IT)<HW>:OY6
MQ?TM.O[2_N\GB5ST"=A3(_Y#)\K-'GM.A+E&[S5_*V+^EIU_:7]WD\2N>@3L
M*9'_ "&3Y6://:="7*-WFK^5L7]+3K^TO[O)XE<] G84R/\ D,GRLT>>TZ$N
M4;O-7\K8OZ6G7]I?W>3Q*YZ!.PID?\AD^5FCSVG0ERC=YJ_E;%_2TZ_M+^[R
M>)7/0)V%,C_D,GRLT>>TZ$N4;O-7\K8OZ6G7]I?W>3Q*YZ!.PID?\AD^5FCS
MVG0ERC=YJ_E;%_2TZ_M+^[R>)7/0)V%,C_D,GRLT>>TZ$N4;O-7\K8OZ6G7]
MI?W>3Q*YZ!.PID?\AD^5FCSVG0ERC=YJ_E;%_2TZ_M+^[R>)7/0)V%,C_D,G
MRLT>>TZ$N4;O-7\K8OZ6G7]I?W>3Q*YZ!.PID?\ (9/E9H\]IT)<HW>:OY6Q
M?TM.O[2_N\GB5ST"=A3(_P"0R?*S1Y[3H2Y1N\U?RMB_I:=?VE_=Y/$KGH$[
M"F1_R&3Y6://:="7*-WFK^5L7]+3K^TO[O)XE<] G84R/^0R?*S1Y[3H2Y1N
M\U?RMB_I:=?VE_=Y/$KGH$["F1_R&3Y6://:="7*-WFK^5L7]+3K^TO[O)XE
M<] G84R/^0R?*S1Y[3H2Y1N\U?RMB_I:=?VE_=Y/$KGH$["F1_R&3Y6://:=
M"7*-WFK^5L7]+3K^TO[O)XE<] G84R/^0R?*S1Y[3H2Y1N\U?RMB_I:=?VE_
M=Y/$KGH$["F1_P AD^5FCSVG0ERC=YJ_E;%_2TZ_M+^[R>)7/0)V%,C_ )#)
M\K-'GM.A+E&[S5_*V+^EIU_:7]WD\2N>@7T,)Y&$0 64BT!_="[-6H.$=E9<
M/$ CP5ZW(ERBN[-U'K-M?MOEL9L;WWV6G?8WO,[]QG1]?:79O\.(_O-2N;7_
M )PLW\[K(O#6*C(6N,>7D\A2]J$QJ8DE,-QB9O3&;-YH ;?;8)RHX;++;S+;
M+;";+;RB[C;3;[QWWR5\E4]%D/F<R<%G-V /6"*J\IUL?6)*,RLQ9Q@YK1GA
M",R1A& H1F,<BQ+.;ZYU=K&.>85&B,@J B<6<R[(ELEBTF@[PB\F@*&UY1B\
MGE*3M*31>+,KOCWQ]L?GK=BU^OE$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB415:7^++_,M_1"BJ% M1BJYZE%AQCM<G*6M@)+%S:E2-Q5ES.BO.!E
M7$V6J'5/<>-]ZP]9>9>E7B>B)&T@BRVG<_3VW7GMOYO>]KNKW.GX@O\ G0_0
MOHO)_:O^#\K*"HI*41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*RVD'G6(:-
MV)Y+EZ<)'QS8XX:RI+66+HB7.3OSI(7QNC[0SQ]L/5(['!S6.#F0%B?IDO4G
ML4*+K@+(O$+S@,';U'E:V(I3 (]AC3<UF;CK %7 2P8U@L8S<8X#%+;+=?US
MQCVW96#4VHJ.E<+;SF0A8-7JO7@U>F.)KEDUJP*L %8,IC8I9E+'9'?;9%I2
M=]D75FYOILP.%3RV+]8V0I1#TD>PC*)+ER+!"5<%B3)I#2QZA>+W)U1N,R:Y
MNXH'9[8U +E<6B,@L:41R9<N L@P1"\4M%WKE'G//L?5N3L9JK6Q-KGL+ULV
MGZH;F3&*8Z9:0YA":.Y"U;KN:;2&/;)E8\AK_&X_(M4ZGY.Y1A6T];MYNGU/
MGCJ5?5%ZQC\.4PRWPY$HS6*\N).G1M, <H$(S1=9FUARSM*(E$2B)1%[F[]E
M6?FW_HC110^V;\/Y'7B'OC[8_/10KY1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$56E_BR_S+?T0HJA4TS6V _P PNM))LNO7M(F&EOQSF:>(,2"V
MVX]GO^]1NZRT +L2D=QR*"UU,^[5#3N>;]-J\]M_/_9[2E73\07_ #H?H7T7
MD_M7_!^5E!44E*(E$2B)1$HB41*(E$2B)1$HB41*(E$7A4NC8B5($*QQ0I%K
MH8:4V(U*M.0J<34Y?1CRT"<TRPU6825]]-L3V&7%E_=W@%O=J9$19Q). R3@
M)F<LXPE*(VD^R+DDS.T&=^PSR=F=^PW94N9A#F,<RC@0SR8,)SC&97@V])AQ
M=VE-XQ]=)HL[LW9?8RBD<PB3C>86WRF.+C"EB9O-+1O;8JO+7K;C[$:$RTA5
M?=8L5W)E-J9-< ''W)SP*LN$HP+9DZ=L;,Y*MB#/"1&>8"Q9X0W=^;/*+;81
MWH[TNU'>CM=MK*2.]2*[L*Y5(\9P%)AV!3>)"/)H#=HS?9.;PFT(/ZZ3QEL9
M]U]ED\^X2Q[I HXFBGLTD31%<53,R;N[;$)JLA!A\A319V:V6Z0RJ.KVR3,1
M+ GDALA2IV]Y:!4*^IRA?<H0V 0;>L#FLA@)VIT*=<MK*4VI");I0NM$$K0B
MFYO5L#+6/(\JS E(@2[L>)&#1F^\U@U)I[&:FA1'DKUH-/#9!\B8-&_/'O.U
M"D<0'M7*I W*\:T+;VH1%8!O3X,RO,3-&6-T6T <?F)8T2R9XR2]XS0Q?#4(
M>8D@48^<VB=171TR%*)[B1@>I7?%G*3)D,672&UB7];#XR+'MF9TB1T57GW*
M#KLCM:]OM.Q(^"QP<G.SF+H+<VOB+1M:AQ]6CEK :C61UIDM0KN>'.@'@$QI
MS%!F:+-BE3DTQCPIQKZCRUC$"J8''GHCGC# R-/2V4N9/"5K%UZ1;D!TRV6K
M$YG9K3L !"!9[SR=;%C5R(A2D1'JTI*Q?T?I%(:H*+4K.E2P-4]*$7W@:HZ7
M*NM,/Z#9?T$NX+S-FT0&M>-"<HRG&$GA#=WY-%WC#>?9'>DS;([S]B.UVVOV
M&6T7(.,X#E.$9DWN'!Y,TR;C;9[D7?;+=;LRW6?=;LOL9>JH5&E$2B)1%[F[
M]E6?FW_HC110^V;\/Y'7B'OC[8_/10KY1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$56E_BR_S+?T0HJA4RS7%#()C;8:DO,L7M '%D,)[:H)N%B0
M#9:M>#/O,C,O+&V\E4G^Y;B+BVHT>B)1U>^TWG_L]I>-VW\WO=WVU+.GX@O^
M=#]"^O%Y/[5_P?E905%)2B)1$HB41*(E$2B)1$HB41*(E$2B*W.76Z7.^-)F
MV0(QS)FBUE4$1@]GDR"&N*=YNN+Z24D2=TC,T;F>U,<%IZA2MB,F3BF+.),8
MG2TWI(ZXXDE062IDOL-Z4#1E9B:M.X.069]^,JPK-,AMZ/K8QA;K2WG:3'$[
M;\;5FQ7CXF^+&N6-\E>4:<@6QT"1L.[<.<;AJF0$!H2V2E,E&Y'<:47K&9^'
M+77E;!&D;,4NC0CG^/XGF#-,2GF)Y)+-(R)6P.-L4?883FEFFDBACJWR58P3
ME@;U<70IGCKVPTT)WB8REA)CKM#X[$758V+-A8K.:=ISU).AD+>(PUNCE:U3
M3MOG]D]@]W#&IU[@B5H6*)R0LDD'F>8-(5.K8E8#<L6Q0+#5^9TYJJ]#24,E
MC:6<S]')82W=U52CC*E>M6Q^H*^0M4#"MDK9&J,E,4#]4, "%B]<K1JFHU*)
MIB)C)=H.Z1#G$W?&T3B$@Q8QILV8-EL>F3VXX!639EE4)D&:G-_R:T23&:"/
M.<NQPP6/6+G..M>1$U^2#7*^4D%M"<%"P\_)6UMIX5H.1MVZ^4/+"YRI8I@'
MGH4C5;M?#"KXPU;)3L#J9&PX<F*P7'SZFL-JLG++=@S8D_)YJ<U(^)HTK6&K
M0U!IR]5O6"Z8GD*]W'VL^:UEP6\0*J:]BZS'PYJH<K!\M(KW8Q##>)*5\&+1
M-TAV'1:W1/&TF+MR#E72 >9)*HT\I71C0MF0)5-\'8\2R88]8YNR>V,Q=!DD
MF51:+-\J,95"*/,K9<:46AN3*3;(?5>GSZHY/LC6?F&+P :U6R&0CS)0JTLU
MD)5FL.(4N<VIXUZMFT2JQXSL&)L=R;T6R&OHK5%;1W*ABK;-E,SJ8]N[4/$U
M88<E<R.G<5"VU9BF@U2F++1NTJ8KKUYCJUPO)N&\)R\&7M%W2>P5C98TZ)1\
M@DDYGTSE.29*ZXVLQUAF*Q68-,%AD5@3(WXJ+G6/87;$GZR/J5<L<E*V:F'/
MZ>]P>(?) ?K19YF)U/IG.9*!=5QKUJ-&G5QM861ZH9BU9IEO7+5\\\H]'(7>
M=@>Q&%0<84VB"3##;K\!^+*SFC]7:=Q1 :)G9M9#)9"[EK9\2V*P-.G>#CJ%
M+&@%AFR.,Q_,K$:LYW2SGD'E9@Y3T;?.6X$H\X*TO8PYY:OQ&AD#<_N63M,.
M;0^5/\L@SFRF#DZ!M)V)ET<*7OBIT9C[9"*QH-3.[2V$-S^B+6.I!T< ER/E
M!SFDK(L4V6F E<>,TA2N505;PC[<;?(V6'8<8("-%Z^Z9I!*5R F\12C9VBC
M./IW7%0N;?"CLBLFR^N\C1NV;N-,!WS&/#+"$J1)8D:O)K.^%X' *(;,&(:,
MJFZ64=?BW3^5Q&,J$<QS4G=XW#\P2)D;'*3X[B[Q=-NREA11BV%SPM-E[+:&
M;-(PTC+JHA>\S5RMN9SB661*D*ZUN2KYG5304+=F,ZF%D*S;Q%<Q!5<A9"U+
MJ7F8Y2Y1>6(Q,Z1>>2Q,)0%2&[%:1J\9PXDQRVP_*7.E3E"_GHGJ4<Y9KB+;
MQ5,[Y#JQ@)8>ADFCG,X/(A>A#-SB6QD"LX)-7M3&7AP+^ZC$6F) ') CQNT9
M97(K-+?2#GCVT&3N"$069P;(.4HM+H1(7:5),TQ2=QEC;X@JDR94P]9,YZ=D
MITPM><>F&'0U[5PMEM(7Q$GD"XF$WTG@* 3-1O2O4[V/Q=JI=KBJ3PUJC9.2
MY"M*-CGM'<K1J.'(,S7012PFN<88,,2#-$&VM]49.P!\CC8XV_C\IF:=['VC
MW8:@HY*I6%1);C.KU.R7$N2O\?&.[T+!-Q5:A6]$HB]S=^RK/S;_ -$:**'V
MS?A_(Z\0]\?;'YZ*%?*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
MJTO\67^9;^B%%4*!:K%5KU*+SBWBU.8L;11WKUR-2V&66LZ.TX6)(1<*IN3V
MGA?:N*76VF*'$%"HC:3FV#3N?I_.G=_3^9>YT_$%_P Z'Z%]%#/[5_P?E905
M%)2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBMUF"2.D-Q)E*7L9A13U%,=3>2
M-!IY-B@@MT8HRYNC>8<09K+/*L5I2KC";PV#; &R[N7#5QQ%85S+8NH=G<-K
M(TJQFB[QDXCV1"(S2;LQ=X2=F=NRS]EE:\Y:-0PN8O5WC&Q3Q>0M E*+2BQJ
M]0QA/*+]B46G"+O%^P[=AUI]G>GMG; [] XW(R#Y^P(\>Z.FD;/).='4'5FS
M1G?8:WX^S,[&&,J)N;E,I:\T*44L Q*C1F$LSD:W)4(HK"K;-N4="8/.@O6:
MSQH'GD-0Z=HUFL$X/7("X3(8<3<8A"1JEPT9U=DY29S#B29-]W=]'9'E(U'I
MRSC:EJ+Y.L/%Z5U5DKDJHN<-I*Q0%B\_8?F\!"E=#GY#NL\!#V ,X8#X;1:,
M?(M/C2APHOQXTY69F^1*W"#X#TH,G&M$2*2A$M&^2-"V,9W;$):.VVU1(<?9
M'4Q]6E-47@N,:5EY'WZPTN^V.MH33&9'?+BS3!&%W.Z9QK%MO+G6HJY86<$4
MF_V8U\ACHV(2:/ZFQH,_K79]LJURDZOT^3%AS(!VIEQ^FM7YB0:,8<QTI;KS
MIZD#!A_;6L7EIUB0>7ZI(!'AZYG9UFUHI95S9,<A)F++[V4K6O\ HA:.>;G"
M-DM#6V)(C-,DS+-J9^:FX4*-,LO)(9F&,-*TMS4N-PKV,Q6E-3VJSRK\,U3B
M\+3Q\CX@+Q@#5VHL(.RY2DE;I8VGA)@*3B3E!I2-8LE@XXC;AF:,FENQ=M@:
M,S.?O9.-;.6&F2SH?2NH258@"*%&_EK^H860"X8X3>,05J82,697XE=YP>+3
MDSY^U@2V4E$2B)1%[F[]E6?FW_HC110^V;\/Y'7E&P=8][OC_P"N]10KYL#P
M<O-1$V!X.7FHB; \'+S41-@>#EYJ(FP/!R\U$38'@Y>:B)L#P<O-1$V!X.7F
MHB; \'+S41-@>#EYJ(FP/!R\U$38'@Y>:B)L#P<O-1$V!X.7FHB; \'+S41-
M@>#EYJ(FP/!R\U$38'@Y>:B)L#P<O-1$V!X.7FHB; \'+S41-@>#EYJ(FP/!
MR\U$38'@Y>:B)L#P<O-1$V!X.7FHB; \'+S41-@>#EYJ(FP/!R\U$38'@Y>:
MB)L#P<O-1$V!X.7FHB; \'+S41-@>#EYJ(FP/!R\U$38'@Y>:B)L#P<O-1$V
M!X.7FHB; \'+S41-@>#EYJ(FP/!R\U$38'@Y>:B)L#P<O-1$V!X.7FHB; \'
M+S41-@>#EYJ(FP/!R\U$55%]RRP/^I;\P450J48@1A)9P)'4+ID7%EZ>ZFWJ
M;G?HG6\W 1UQ6'!T$M5TOL=3@2")=S7TM<9]_$P*][GZ>W_ZKSVW_![?]GM?
MVJ<<PUDE@'_2A^A=7B\G]K]__P#JA-@>#EYJ*2FP/!R\U$38'@Y>:B)L#P<O
M-1$V!X.7FHB; \'+S41-@>#EYJ(FP/!R\U$38'@Y>:B)L#P<O-1$V!X.7FHB
M; \'+S41-@>#EYJ(J3=YS!X^K%O?YI$F1?;9:9<B=Y&T-JL++PUV7BF6JR3@
MLO 0&VX;-5P#K 1"KC6P^6NCXU/%Y&V%W=F+6I63C=V[#MOB%..UG[#MMVLK
M5;SN#QYGKW\SBJ1V9I."WD:=8S1DVV+N,QH39G;LL^[L=NRRB^RKBWQF8^^&
M<=^L:J.MS4/>+,^2[WH%2]=>EO"3 >6,=])3LJXM\9F/OAG'?K&G6YJ'O%F?
M)=[T"==>EO"3 >6,=])7E79'Q Z(5C8Y9!QJO;G%*H0KT"R61E2C6HE9-Z=4
MD5)CE]Y*A,I(,,)/(-LN+-*ON+OMNMN$!CA@-2"G @\)FQD'*,QDAC;\9PG!
MVE&<)1"SQE&3,\9,[.SLSL^U0$U/I,HYB+J'3I!%A(9!DRV-G @YQ>,X3A*P
M\90G%WC*,F=I,[L[.SJATY6BZG9$<;!5@U0R((*3C!.WKW&$N9/8Y3E$$EP8
M^YQ4*C5D5NL2I^C,:LP]N4WDV&J"#30VZK94M:2/.R]'4L3DO/DY$'3R0GZH
MR>3O=BPQ0:%K;*6P\&B2+.[1DS=A6^.0Y/XUX5.J.D95AXV.'B(M[$&CU*C&
M,6QTN*:;SI;L([U:;R%-XL\HN_94P\/FCM(;UIC^]X4?#'&,KH6X&/#E!G.]
M?#G0PHYSB:VY::?<JC+B<22:N83QO:U9A15ZA*9<7:(20XK5U=H,#&ZC P[,
M+@V#3R8VA<$SL.W!H#CNV1L[M \=A8,[M&3,[J>?-:&M.1[.6TI9<U0N/*Y[
M^(,Y:!G9S4B.0LM^H5XQ<M:6T)'9GE!W9E_;=(< M$E>9BV2O%*&4R%GC\?>
MWU-*(R4XN+'%#'<V-M*@^UP 10,QC\\WH$UH6E$W.*FX+==_<\)B=5EK!IEQ
M.>G5KFL6  ECKSC&>TP6LEC'@?\ :&8 6))]KR8<.XO19S10;9[PLWIH=RT"
MK6L6(97&Q*6O2<\JH9R:QV1UWLV''#L-%RS[JJ?LJXM\9F/OAG'?K&J;K<U#
MWBS/DN]Z!5?77I;PDP'EC'?24[*N+?&9C[X9QWZQIUN:A[Q9GR7>] G77I;P
MDP'EC'?24[*N+?&9C[X9QWZQIUN:A[Q9GR7>] G77I;PDP'EC'?256J%8B=$
MA"]L6HW% JLZ(F6H5)2M(H+UB'1"%*>XPDZS6 AM%WW6ZP$->L*M1@FKDF$X
MB ,-]V8C0D,D'[DX3:,HO[SLSJ] ."R*!ZQA6 %CO", D"B)'M;T"#>4)QVL
M[;8N[=A3#?:(*K!'5^#?^B-2U/A]M][_ /B_ >^/MC\]%"OE$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB415-9^!;^;;\P450J?:C%-SW*;#C72\@M
M:V D+6M:9$WE67,R*XT&=P)+M/>"+SAOO6'J[S+TBX3T!0VDD66@[GZ?SI^G
MZ?\ [4DX_BK/YS_=NHH)]K\/]CJ'HI241*(E$2B)1$HB41*(E$2B)1%8_24G
M+UC; ^49M'3+2'YCBJN]H576VW])."XTAL2K[;+PN+,,0&K;5I19EMY5YI%E
MAMEY8W6CE>AL35SFKL!BKK/.I;R HV1L[MQ0BC(Y N[;':)HB<4GB[2:,W>+
ML[,ZPCE(SES3>A=3YK'2:%ZCBRO4*[-+@6#RA6%8:,F>,I5YF8T(R9X2D-FE
M%XN[/RIN#@O=ERMT=5JMR<G!0<L7."]0<K6K5:B\3#U*I4?>8<H/.,NNO---
MOO,OO$;KKA$1&OH0$ :P1UZXA@ &$1A"&$1B$.#-&$!C@S1A"+,S1C%F9F;8
MS+Y:6+![9S6;1BV;-@DS'L'),QC%))Y$*4I'E,A)R=Y3G.3RE)W=W=W7CJ:I
M*41*(E$2B)1$HB41*(MG6Y@Y*E#7F)RQD#BJ40^4QIX=3&8XZ^]&A?F;I120
M[HB;KAL3*#T8*D"WH 6 M+,2W*>B7(4HE:&Y>\%C[&F09YP#AD\?>K5XVHPB
MQ35+7$'.L6;-O$' O#,+>=^%)B,/=8Q-[IC[&74F3JZOLZ::P0F(RN-N6I4Y
MSE((+]-A$';!!]K#(0+% ?<W6/&0G+O/7#N[^4/[)L]J_P#0&N0%WG#M_@_M
M9>4>^/MC\]% OE$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB415-9^!
M;^;;\P450J:9K;0?Y?<!)98W+FD;C;7\USO/$&-#:%QK->'0HU=8  7:E)U@
MY66VNIGW:H:=SS?IM7C=M_P?D92[C^*L_G/]VZBAGVOP_P!CJ'HI241*(E$2
MB)1$HB41*(E$2B)1%BWIK>I9S+[F4_TXTUG_ "6^R!IC^7S^:V%J_EH]B[6/
MQ:/Y]47+W7?*^8Z41*(E$2B)1$HB41*(E$6?.YK^JA9?<A,/H\NM/\N7W VO
MC+&_USK?'V.'LGT?BG+_ #9ET=(?V39[5_Z UQ.OHG#M_@_M9>4>^/MC\]%
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MSC:>\.I)LWO/LGS!GGLV-O(;NJ2XJ6FXM'%3>.3RDJB!=(=6G+J&.DIZ)8S
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MI.O-N0JQ-;;1M+366@[GZ>VZ\;MO^GM?SO\ HRJ"_O?U_P!@T7JQHTM,UN&
ML&RO(+*E3K)$68W,<;+66":B*>7M5:D)7+"@NM$XAM3]-./2^L+59J4I)?=8
M6?<99FW)YI<.K]58_#VB3'2>)K=Z0GW2RK51N20AR=GW9'GPP[_9<<22(S.\
M&B^N>5;69]!Z)RF?I"&7(M*O1QT31W@PN72L*!S19VWX5A\6PP^T68H"D\8S
M>3<XKKI3Z2;RX*7)7G7*I*A6;<<:6USB0,:"RZ\1$;4K4RKF]L1% (_<$(TA
M!-@=RRRT U5VI7T#HBL$8!Z3T_* XM&,K&*IVC.S-LVDL6@F.67=F0DY._9=
MW=?.^URG<HMRP6R;7&J8D+)Y2C6S>0I 9W=WV"JTCUZH(]GL0"$<&;L-%F9E
M'>B4TBO'SF7XSII]=5.ZR-&>".F?(6+^BJGZ1>4'PYUA_P 2YGZ:GHE-(KQ\
MYE^,Z:?75.LC1G@CIGR%B_HJ=(O*#X<ZP_XES/TU/1*:17CYS+\9TT^NJ=9&
MC/!'3/D+%_14Z1>4'PYUA_Q+F?IJ>B4TBO'SF7XSII]=4ZR-&>".F?(6+^BI
MTB\H/ASK#_B7,_34]$II%>/G,OQG33ZZIUD:,\$=,^0L7]%3I%Y0?#G6'_$N
M9^FIZ)32*\?.9?C.FGUU3K(T9X(Z9\A8OZ*G2+R@^'.L/^)<S]-3T2FD5X^<
MR_&=-/KJG61HSP1TSY"Q?T5.D7E!\.=8?\2YGZ:GHE-(KQ\YE^,Z:?75.LC1
MG@CIGR%B_HJ=(O*#X<ZP_P")<S]-7T-)72*M$!#/.9-8" AKR9,[@UAO@+T(
M#[0@(4ZQ]%^".F?(6,^BHW*-R@L[/U\ZP[#L_P!TN9]KL^[>S]Y^P_MK<UN<
M>E'/,T(9ACW);B9(GZ&H6YZ990H++M<G%D5J#$"I"\F$V%%JE3<J!'>E<+[+
MEBTE8=:M,--2VG'<S\M.@L3I@N-S.#"U*IDRFJVJ$'DX VA08HS5FE*3C&<?
M$8@6=ABD*+B:,2/&/8GV/'*=G=8AR^G]26)9"]AP5[E+)DC!K-BD4D@%!<E"
M,&*6N7@N*Q)G*:!IL:4I":<\F--[U*>:O<NG^G&FL&Y+?9 TQ_+Y_-;"V1RU
M^Q9K+XM%\_J+EAKOE?,%*(E$2B)1$HB41*(E$2B+8'N9?JIV3W'3+Z/+K3_+
ME]P-KXRQO]<ZWU]C=[*%'XIS'S5=(]GX0?U_,-<3KZ++^:(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%BUIBXXR9F/"3GB
M7&)<>M59%D46C<V<)0K4IV9OQ@+N2Z3XI8F0'$.3J1)6)L.A"EM;#BEQB.4*
M5)1Q%J6\\K)M)9#&XC,CRN2>QNX^O9L4QUH1D8F2X3BHO"4VD,3US$:[$A&>
M#3K1B[2WFB^'ZYQ66SNGS87$<U:>4M5*N0+<G*(!8CC1-DHD@-XE-&W7%+'S
M$&42/"Y.<91W'DV'N#\.Z6F"IMB)S=L7QS*2/'.#)3HW&.K'DQHC901%NS C
M?L;R9,EDQ:YU4$)<:MC.U+6M6<8[6N: X3U9PFVFF9=FLOI7-T\J(62LXR60
MS=;43"/C2V7>V3$2!D:\I5G@*,I9$ABP+%F$XR1V1;8[-@NGL%K73E_"%-AZ
MF8AB].W-*.:OEP5(M1%G(6<3;A"W$AI1AB1  0,W<S%%+>F^\SO=K1"P;F/#
MF2)^0Y,%D&P8>RN!,:A3O.89DUV)F3A.W:1WN,-EK%C6$S%)CX&QU<KKV3)#
MU(GNUX<B;T):$I*M.76G5F:Q&7Q]"0S\]S<3#E9N"I7,:*52%(5=AW*I\C<J
M3O\ $$/]6QX:X7%!VFY'E!H7O1&GL[@LKDXEK-CM.R 6-2@?(T,N:-XN1-:<
MM"[7Q./OCQC",5WKY4]JQS@S.-AQA.1=AM8"MGI1$HB41*(E$2B+!V[2KDR7
M/R[%*F*L2B/GZ4S/HX-#D0L7I7E$29H?VZ3CK*W+HG3:)R,-<ST\3;VE,0U6
MI4-ASFI7K%%UB6W-.M>M+!#RD;1XG;3!M0E'* Y!F[:LZW!51[-R8V832M$+
M*17D1V'&$([9+7O7E;AJ4F%G3KSK2U@#2P"QF2!QQ?0[:N-<+MWQF>191I"#
M"(6@/>+,A);(*GU^EN^H]%B':3$;Q"W*I#D>5H(Z^H@4RA5'H>W%2=_BHS>=
M/D)@4NF2F,L21C* XUOAS@<G5.B!#?>A;A4.::HAI0$M3V].6,L2-?'526 S
MW:T;%N;U@6FI4@7+U6I&R>9WV,2V-I1&0C-,FZ*5*76U@>CJ.K*F#%.UE;HZ
MM@>_<G5HC:W9I=4,E8Q^-NWY4Z\*\6E(5 LH3,,;N,6\:.6&-,E()WB*+93.
M<H4<A>XB3)E[C#989(H,2):2\]T%IE[RS1,Y6U(3B%))K@[L3">E%.=:Y(4)
MJ<\NS%LECIT<M:QC#N-,-MZT!VZK5[K[9LPN+4":VT"SC*,F&$]B,MYN&0C2
MB[YIB<L+(X2GF)&Q\AV*4;9#4;KVL='9!Y&<-XX*;S".49Q<IZ]:4-V3%&-X
MR9L:=!S3.3:7L,?7MUCD;@$K:W@P$T*;9L7*7<V,=2(XLO>UZ%4SQUZ;+6R0
MO;C#5"E2S@S/JU@ND<5<W>,/C.N.R+6FD):4N "*Q8OU2A;>N$IO6%&SQK,.
M! D2V E<E< [D8Q-Q@0L-7M"%9"6#8GR>:]AKC'V+!JM3&W0F?=QX<@UTTJG
M JSYP0<P5; F%9L%H2G,# LDK/:IF/4L )+YH1:5\LTL8RZS%YC6/8PU)VMB
M7)FJ*R3(C[(FU2]*'BPM#)0EF+8-&AN AI-OL40^1R],!H7EJ3D]ER8Q3[K/
M2]72U@-4-B_9+(AX2+:KX\%<D0Q"[SK<UR=VSLWBLV[;KU);NQXM)]YH^<GV
MM+NM*9KYZF,I@B&N2 :=O*6;0IV)'9AV^>X?'5'=H@D[2HVKT-YG:;P]:\I/
M1TTM'#.KAA)$JA".-AES1:*TBE!B=].<Q8UADMCD:ZU2;3&M%T^F"Q]O5]5K
MQ2FC<FM)Z0 #!,LEZ@TJ/"0S4XW9V.I.IGT_%I 87'@U6Q9YT^PL^'+:!H<)
MMYMDG?B=C8\_2^M":B+@!SQ\*O5K2#:HD\;$B\WF]VK4YG%G"/B0V6')QG>#
M[8M'A]G:UWM'K*3[EB(S!UDJ!I0N\0S5G+%1HL=BPEM<$>+,JRN#M#L6F7JE
MRI(I<F=E0*G%/<M4E6N5ZN]-<6EO)3DVG/XL&*M4Q5R%F*WAL)E&XSP<@YY3
M%U;I1/*$81E$933B.30B_#:#2VR9Y/>],9BQFJ5XUH81GHY_46&?F[3B(L,-
MF;N."9H$F2<)%!7',L7)-F*\WB[0>,8WXJQK(THB41?N'>#V@^:B*FF>P;7Z
M77"498%ZYJ&TRY^O<[#@M9$-HW%,XCLQL+! 2[DM@!U1OM%UNUBJIW/T]M_Y
M_P!&]I>=W[_]C*H[^]_7_8-%ZM=^Z=>I<7^[F(?ZY;6Y.0K[O!?%.1_(%<__
M &2WL9&^/,3_ $CKG"KM1?.]*(E$2B)1$HB41*(E$2B+;'N2G[:N4_Z/D7^T
M:&N>_LA_V P'QP7YD5=4_8I?=3J?X@#_ ,Q MG>F]ZE/-7N73_3C36BN2WV0
M-,?R^?S6PNE>6OV+-9?%HOG]1<L-=\KY@I1$HB41*(E$2B)1$HB41; ]S+]5
M.R>XZ9?1Y=:?Y<ON!M?&6-_KG6^OL;O90H_%.8^:KI'L_"#^OYAKB=?19?KJ
M#>#B"B)J#>#B"B)J#>#B"B)J#>#B"B+ W2STFLB87RG@W&D!;HO<.5HWEA^<
M7F08TS1E0UO.Q\Y8N;FU$EC>$&YWD*1*Y#D!6:X/SJAM8FWJ>E+5+DABPFT_
M.-*Z;Q^8QF;R5XEENI=C% &&OD</C&(U\>3(2<[.:(&O*0VH188!3<Y.))X0
MDT'W=<ZTU;E,#F-.XG&BJ/U9JYJP4]G%9[,2%+&%PXA#A5T^(]J$"]4YN6R8
M;5Q<*#3)!YQWK4Y#TJ]*#'3KI8EN#'@-R:]'=DQJXLP(T&0B5[\IR\Z"3%+'
M.\]_N3V$,C>2HZX>E;"#%BVXFYMN)(MOL&Z8_2^FLB/2SC-G!EU ;(P-OSH2
M&".)%O6N&T0-)Y&(\>;[SR:$-O$:4MBLN4UEJ_%FUFQ*^FRBTO7Q)0;@\G$E
MF>;-NTV,\K+QC&N-I<YW&9YS=G%NQ9V>^F(=*]&L<9?CS/B^ PO*T3SDY8.;
M"(HL>SHWD=Y*AF,ITVKHFF>DUSJWGFMN5HXTKVAR5*Q3.Y1UQ+BH2J"1+L>5
MTM. ZM_!CO7,7:PH\T25J 6L8\+W,C2)"W(,N$2+$Q=@L"CC'>"[;1QE%]N1
M836@YEO8S4A<;0S-+4)M/!C2)8E5RIXT,1D1$IP/#C"DXLS5 4!9SW#QENEG
M"4=F(ENZ0SV["+CD@]KQ2AFLI9='S(.-L>IXYFQ^6L&-,X99BF/#7*9JD4=1
MH)\Z1]OFK JM38I<ECFMD5SE'NMLL]"1<X97T>T6S(\>Q,I.G5-GJ&1ORL88
M$#Y'"XNU?8=.,[$B416)TSQ>64% <*_#L<Y>,WW,);E5R76^;*S%AQY"W7TS
MD\5C(U-0625L1J#-4L6YK\QU8#R1JP[]>>YABD-.TY:O-&D.+EB5FZFRJ+1O
M$TNF&,F$R$9!AVDB]+\B,9<L1QM(3BJ=1;'F+,E SR9,V2A@QGD>6RMBCSNB
MDZ%*_P :6R!O<%*RQJ1*CU$Z')E5LV,K4J9$[7:%S3P1X\W-9V9/DZ5G(9/'
M.6M(E8^1QU6L>P*=8D@685R0C#BSC&%.3EBNTZF%O7L17?'Y.CJHY,I7:["K
M".'R-3%X;+<WM0%<JXG*WKE:L<=L<+-2=H19D80YO+;#B&8J\BXGQ?D%Q1I$
M#A.\=PJ9+T*+HHHD2V3QIL>U21()]YAXI4QZZ\E.)QEYHE66"9?=?KN'5V6I
MPQ^5R= <Y$'1R%RG"<]F_.%:R0,9SW6:.]*,&>6QF;:[[&9ENC!WR93"XC)E
MA 9<CB\??(,>]PQDMU!6)PAO.\MR,B/&.\[RW6;:[NKB:@W@X@JWJZ)J#>#B
M"B)J#>#B"B)J#>#B"B)J#>#B"B+ C.FDUDF"Z4&/< PIOB13=+8 SS)6]/F,
M\UY&5W+73(1T+!K$W$K>Y-T,;;2+"U=\KG8-D80FC?<X.I!%EVSG.$TWCKVF
MLAG;A+3DJ7C5(!!D<-CXM 5!KG%V94@R7";SO!JM'B69ML88I2=:WU%JW+8[
M5^,TU0%385W& OSL6,3G\I/B&R<J'!=\*(HJ MUFF]S(\&H-]KE-&+/LM$YZ
M5FE:PE9K(<V31Y4N&.-)3!^C&P7H&[)!:-=*,SNN#;T\I>+%$AO/Z@LS!F,+
M#D"*\EQ/>&?HEAO21W0KKJ/3&ECOAY#-GXCR&G<UJ0[3)CGG"MAQ9II5A/&N
MT>.8^(VM.;.-A&V.V^VU64VLM95FST35],2+B]5Z>TE6<0\JT"6\\;3SQN':
M5G>YL"MG=DAC>)9'!M9^'+8KR0739C=F/9@HR]=$X_F"!R'/L55P:+NCBI;Y
MTX8"<I&E>7*$*'9 6N(;GQ"P@L(2/%@JVI0><B/-6]*@I/M%W1MA[]2.):U8
MQ-T&"LQNV1#B2D/.CKS".[$1'A(@9GW)3$^X6,6FS0WMV-\QW*!4;&7I9MZ=
M;.8ZUJ2G/'4S%F+(ETT6U Y<?,PV)$5@=;?C [;X92D.3DW-Z5E\KZ8^DWA[
M1TQ[G&1XSQ:[]D)(,N)-B+?ER41V-L+GCQ#*H-CV0]0V5P>$<WR#,5Q6.6.<
MJ"4D"1.9[>O=$9)[HC9;KSB](Z:RVH+^%KY+)BYA/FCM;)B:UBR<>0G5NWZ_
M&,,,Z="I!\@>E&4KTQ1) 4Y1%,RL.:UUJ[!:6QFH;6)PY^J<.>QE2%F[=6I6
M-C!W,?C+7-P%/#(9.\2.*K9"3#QL"R$4T8R+"N]X)!NAF)XJMFS<^X^R\4JA
M9$B*+.0L,26-\VD4&F>-L>Y&BD%4&S5&J6O$"F&5HBTO!LE011J<P/6JHNX/
MR= HNMM%?0.4M0ID!?Q+QN2KN\9GM1)3KW:>1OX^U=BU.<(!O5,7;*%JQ+11
M[L(6A@E.+/?+/*=AJ9,@*QC,XT\?&U%I#KTICR%K'7\3C,I2QTI9"$R'QU[,
MT@&>V.F$V\2=,MF Y.J F^F!G_KIS8DBN)(WBZ(8'QQC?)$]>L\FMBQ>QL4H
MCTVE<I4K$^,<GO*12O8VZ-)6UL8&M0M+<' I\5'R-,40U(W*OI:3P/-L-*UE
M;&3MYO(9''T18-B0&8U8].K5C"62Q@9Q&<EF1"'+&#C&X8QKR>1)CMN0UQJ;
MGFH(4L)5Q%'3F+Q64R-C4<A3("O<JY"Y<G..)RQX2)7%4@(-84B<4C6)RM0C
M$ S5GCO2-TBG3)FC=!I_CO%S>HS!C!!.9_$XJ[2Q;D#&208*Y2![FLC3KD8,
M$<AK9/1C6)&YG<7!P>I-(7E<Z,[L80P.C831W]/:>'CM17:.0R1&Q.2G2H6K
M0JL*&2GSX8 TJ[PEQ[%LE'G&5(8<!AK # 11,YQ$>NQ>J=4&RVE<=DL9B!2S
MF)'D,E2IFNDR>)AU.+:/D+420YM4HBR7-,((!2%/;M'(8!WC6,&.P34&\'$%
M8&MF)J#>#B"B)J#>#B"B*T&5\INV,+&0]NPQES+*1S%P%R48J;84[&Q@I$".
MU.8\-LFG$3>%HNJA;80WDQAOD!]EJ9>K<2V]$DN4W7;%XP62<T29?%8N0]SA
MQR9+@FLO/?>3")6I6A0X<8.\Y625XN\H0&\YS:*L>9S)\1S>0L#F\U W%XLL
M,*@9Z;#X;0<XK>0I')QY$:(HU!V9,T"S,PAP>;ZNLX:?,M9)AI9Q=@=YGCR1
MPO'%R'"[ ]8[;"&@AP@4A@[;E/)CU+)&TKV,E<ZO64DT1AJY:K?<6QYJQL[S
M:66W(WAO3/.RL+H:H>KI:R<-3(5[F1WLQ8!D"2+*%ZO=+C,:&K7+ SP$'&2M
MVXPB#)')D14ZK[X9R#J#4/*1?KWM:U*I[^+M8_%<+ 5CXP,01+C;..'F,O8N
MVPDK1(>QF(T:!"3LX>J'$GOW6W#B@>HF'2RF;EH<QAU>,Y,[%DURT@&O'<IR
M%U0Q&Z2V)806Z7]V$EV3[EJ)ANQ&^6-<0V&@S+;;!^Q<LD0&N29L TNX@*<V
MEJ0]761"PA3XT>!+D*U#AY456UFH:2ZM#QK0F=LL'BV]I6Q1+O5.%?8.1=U]
MY5=?6M\NAJASZA!6RQ=3!Q=S).7"EN4M/DUP^GB9?B0K=1;,0T=@>K8L?U')
M:VD@+>9XJP$4TV](UQ=L9JSLKIG1^-CV-DK#C.V*0$$^=F"6->E ?(,LG-R*
M.E3%Q/2V8H@+LD<,:O$=A#;8>X@H93T3Z263?K6C-/#'DH1Q<A :QD9'R+V;
MSRP9ZA=-Q!BXDG8>I",GRMX4QY$-BZ1XCV&:8)/+&J7*!JHI\3.6:B:R];%0
MKXGF6.:.HJMP.KY6<U(8ZS72RCU&QIH$Q)ZM 6TC2!(=F,8W6@>E1F9QT(],
MG)C?FH<D2C%F*XE,H%E6QEQL><RS.6Z.L'R7+(Q85$HNV09Q)@TX?W%(@:W-
MA6NS.A/3,LF5NJA):?=:[NF,/#6>D<:3#=3JV3R=JG>QG&R,6/4JY^[C:MG;
M:LENCE=I '(A1G@(Q(R-7B*,]UKSCM8Y\O)_KK+#S[Y2WA\/1O8W,,#$RE7O
MW=+X[*W:>RE3#CC-CLC9+ 8C5IG .<:]N9I0:3^V9:8VD5H<XZ%TSXU!*W&3
M324/F.(UF&18Y;,PKL0PN-8X+E1+R^Z/\6'"1TEZ]94X!&$Q!I#L:PJVDM4A
M>E9;H<SP5-(Z?U;D.%@R\U'6IU@Y"QB:^0)B896Y8R+U7"#/6NK+5^9U1O9E
M)I"8\2O&8(N*)8[VNM4:&Q?&U(+GI;=^Y9Q5/.VL6'.$P="IBVN1/9TU3ZWY
M6WR%PG,X1>)WK3"TAV)Q/*O(O>G9E/'JS(KW,&YHEP8XR%IP-R6'0Y\;F\M3
M&\&HXNX0=#.[%<*6.[7>4B> 7@^-RY)<7'S#Y"Y(W^R],B(EAT3C+\,>&I,U
M7JA0T825NV A)1L9J=F%V='<NP"7;,7#X!(3VG:(!SKOO3>:?E%S.,)EK%X8
M;S8G)\H0X4:%@0FG4T["B3'BR33H$.%V'8XO.!$ALK/*T4=EG@.$E?NC>4@8
MXR^DX=QNK1D1V>S*<JDF4C7! OBD$S/BK%!B['BU@87],J=':S*!+@+-)SFF
M]D<F)T:ERL\+4RE3+;D]QG'L@EE\A";GI5*<9XMASA:NX?*91H7X'."41"?&
M.-C5F+QAG$6$8OO1C-?E3S'-Z=F.#Q1!QJY._D9PS$B#+2QN>PV%D3%DK5[,
M)F,V78C@MR"]<U8P23ELC*?Y-^Z"9'A9["WY(;<3N1+OI5Z1V(I ]HYF!+Q#
M8KCC.[)CB&,H8\;&D9H\OZ]HD]BE,[M[&YH@:&^*.DB%(KGQ%S:GH3'7(G)C
MR903BTQI[*@!.GM%;LY#"&R-PW/R%YF$ RUMV0B&'/BDM"K[T*,N)X+E-RE"
M5865'A2Q/K+5.#LV!W]AZ%/%ZCKXJA7ZF! ]\]D@;>_$XZY1L 5(MK<GDHN+
M<!J#>#B"M4+>":@W@X@HB:@W@X@HB:@W@X@HBQGEFB5B";.4]=7\F8=/3[(\
M7RX:N8)Q)(8\Q+)$3QTV8H12R!2>%KX]*XJXKX(TI&%YM1/MR5R1W+2#4]I#
MBX$J<CJZIRU,=$0'J;E''V<4T#TJUP-K'6L@3*3JWJUR!ZMH<+Q9'#O@WAS:
M#M)W&-XXG=T7@\@7)&LQO<3)92GFI$K9"W0/2RM+%BPP[N.MT"5KM,I,<&%8
M[#LO H^)%X-$I8S^F:)6'BHNVPU@[)<'CK&P1&.1]!CS-67H$+"AA1\C4-*A
ML512:M2LMV77RIYZZ7@\]0Y3,;T)DL4O![2U&HS:JRSV27#]3KM@Q[=@\[^'
MQ-[CSN1KQ+$L;5,L7%!JP>:A9HCI[)M5B%BE:9]%X.-0-&L^6Q]6M6I5*P\7
MG\YC>;BH2M2!(4Z>0#-C$>X?GAY2D6^[C>[,\@A>%5PG1WQ/CV.N4.C#$Y$0
MUV@S?CM;$'.5RN01HR,H;Y(:HMM:7YZ<DUCU(#9:]G2Z3!;UQR\X].=)'1S-
M0HKR*6[G\I?L#N63CE<%=)D(6QU:H+#69\W:+\4 1R<(&JA:K6_P>I&,HUQ"
M:<VE68_3&&QE4M&G7-&@;'BQ9*1;MVS5>H-[<I,P;-@L6L697;$KMMOUU=E*
M,K9C2&-XTGA+1%PAH]2B33+&+1+$4DF3$P1J4.LFR1D*>J7IDB)-B.'H5=\X
MDLA$+(BU6 QQV\@23&YFNO;[;[RK[M=5F=5YG/UJU/)%JSKU#GLUA5\=0HQ"
M:V[SMSCS*L#LVROQK&]M8AF:>QG94>G]$Z?TQ;MWL0"Z.U?KUJEPUO*Y3)3/
M7HQ8=$<WR-NUL:D!N;57CNN*O^I,[Q7EQKH@8DQ(W-;)"7;,B*/,3O&GABC+
MCGS,S]&60R*+U+BUMK/'GJ;KF=LCYQZLVQXCB)&0R/R2TE$\H5J1.239%D=5
MY7*D(:X+$3.85D)K \%AP63-:A$92&L I#,4[1@SBL$G(P)/*89PG*3O!B=$
M87"!#7QYLZ.K6-4/6J%U)GK%2N](DBA$"J?($ *M*4Y,>J,<:]B&P9QDA&+-
M^$0T+\ P&Y[OAS%,& QY+8$!!J+*>3KC8K'(Y-2,A-\(Q_>IEIXX^@)TL(%P
M=83#>HL;>DIY[,ZMRQD$MN+BMZPSMY@M;/4.P7/.33QF-V6K%BF^/G=OM&JW
M/[T:K\,-VWQK 918PB0-M(\-'0>F\8]AZ%>]6<\:PHR'F,OO4JE6_')BQV,>
M5V3XS&RNQXAL?1YO4L0DX#")7W11O'C#%T;Q*P.L>C1KHK(?9QD#(CPO>U92
MUR7R?)<S>YS)51IJ=*B3%)^K#ZJ(;TJ9(04D;B4B80-,*,4'6C)Y.QE3BL66
M%&0*5#'A@&#P&.MCJ8:5:#-*4Y/+@@C(DI3D\R2G+L,[1:^XC$5<+6-5J2-.
M-C(9/*')8G&926\M?L9&W-WA <&CQ[,XBA"$6@*,(OO2:4Y7&U!O!Q!5O5T3
M4&\'$%$34&\'$%$7VB*E&2Y.,AF=I5S6)]K@S@JM1LRA X67BP-XE [NAOWE
M]/$D;+DBA*&P@0B0W&B)I%VIW/T]MUXW;?M>U]_M>W_8JKU:^_1>K7ANGH &
MBVOU '^74/\ ]:NK<?(7]WH?BK)?T1+G_P"R6]C(WQYB?Z1US?5VJOG>E$2B
M)1$HB41*(E$2B)1%MFW)$ '*N5-8:_\ !\A_VC0USW]D/^P& ^."_,BKJC[%
M/[JM3_ZOB_YC76SW3@ /0HYJ[@?Y+I_6_EUHK17);[(&F/Y?/YK872W+7[%F
MLOBT7S^HN5RN^5\P4HB41*(E$2B)1$HB41*(M@NYD^JI9/<=,OHXNM/\N7W
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M329:TN;;E"3J7#(<>-EC2R/<MF!SG,6HEZ0W+GE,6?#:PFL\L>IF+-:U8LY
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M_P 5-C=QOYF3?G^^E_O/YTZ:4_P@_P#TIG_%38W<;^9DWY_OI?[S^=.FE/\
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MJ.*5UF&7\PJE;C%2\>Y+%&JQZC+R]C9!D5VR7'X-,0MQ]>8TMT==WE:SH76
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MQ:H3FA;>%MP 8299> 76A< #J$ '6%8%R11>/*-I^,FV2B^7B[=QVP>39V_
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MXRQO]<ZWW]C;[*%+XHS'S>*Z2ZXG7T55$Y+&6!CB?C @ 9R$)E0PP!Z&(#+
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M41*(E$2B)1%OF_4]<7?''3$R%*TC>H,CT8P/(D#RZ@7=TFC<9),80#&W&'
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M--;X_!9.J=5867= 26+P1-B.PPS5L <I5*K0)*$>B&6%*#++1L(-&W2_+O:
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MH^A5O]3GR5]Y[_EK)_2$[6KHF^!LA^&\F\_ITV\H7?*GY+H^A3U.?)7WGO\
MEK)_2$[6KHF^!LA^&\F\_ITV\H7?*GY+H^A3U.?)7WGO^6LG](3M:NB;X&R'
MX;R;S^G3;RA=\J?DNCZ%/4Y\E?>>_P"6LG](3M:NB;X&R'X;R;S^G3;RA=\J
M?DNCZ%/4Y\E?>>_Y:R?TA.UJZ)O@;(?AO)O/Z=-O*%WRI^2Z/H4]3GR5]Y[_
M ):R?TA.UJZ)O@;(?AO)O/Z=-O*%WRI^2Z/H4]3GR5]Y[_EK)_2$[6KHF^!L
MA^&\F\_ITV\H7?*GY+H^A3U.?)7WGO\ EK)_2$[6MHF^!LA^&\F\_ITV\H7?
M*GY+H^A3U.?)7WGO^6LG](64&)L)8NP<QGQ_&$101A"M.+4.1Q1BM<Z.J@JV
MZPHYT>'-0L<UPDA>:"8H]5>G1@<=:C)(L-OM'!-0ZHSVJK4+F=R);Q11> (R
MB,0*\).SRB"L" P"WG:._* VF1XQ<DIO%G;9>E=%Z9T52)0TSB08T)I1)9G&
M13VK1(,[0G:MV2&LGW-Z?"A,KC"TYL& XR=GNK5@64+23N_^9\M8'W/Y9/,+
M9(FF*YK9F3&K/;*X%(G.+O\ :U.-L@%>W6NC0H2K 1K!3D=,IP-Z&=T(O;M'
M9#5F>A*=2]GF!<KAM!YG8GPCCB0>_%Q[LMV3.VUMK['V>VZU]RF9&]B],RM8
MZV>G8Y_4'QJ\W&3<GQ=Z.]'L[LMC;6]O8N'LK=.]T4&[NZ;NE /MYHG8^L/\
MM5NGK:T_WEQOB8'_ "P7.TM:ZM9G=M0Y7QLG=^^O=9NG&Z):O5MZ3P^MW<S3
MH?\ ^YJ9#3&G7;LX7&]OW('N?YJE3UMJUF[&HLK]KM_PLG;[/OKV%[IONB W
M7:]-G2<'V\R3C>#^6.&I\=+:<?MX3&=KW&'NO_!]Y4\]<:O;;LU'EF[+_MPO
M<?W_ 'E)$;IGNA@W  Z:NDT(:P[^8YN._P#RQ476KIOO'C/% _FJ"&N-8/MV
MZDR_CA??]]2Z?=+MT(N"T;M-+27'7J[^89L/KC_*]>-I;3?9_N'C.W[D#W&_
M@J:VMM7/_E'E^W%O\--VNS_"4J3NE&Z!W:M>F=I*#W0[^7YKOC_*]>]:VF^\
M>,\3#^:ICZUU:S?=%ENVW[<-[;M_"4D5NDFG_=KUZ9>DD/?_ 'WIKP?RO4;:
M6TV^W^X>+[$7?_ @?F*FGKC6#;-FI,O[?[<+[W\)21>Z/Z??<UZ9&DB/W7KY
M=FH[V^[U[/2NFVV;,'B_;_:8/>_@*!M<ZP=VVZDR_;;]NE;V_>DI(G='-/@1
M#7IBZ1P^WEN9_P#._P#BU'TMIMHL[8+%[>Q^T@=QW_>*'KYUAMV=<F8V;9_M
MTWM2V-_C*43[HOIZ7#JNTPM(L0[O?RS,A]8/Y5J/K4TUWBQ?B0/S%[U\:P\)
M,QXZ;\Y2UFZ):=^H/\;[2(_"U=W*\Q']SPNM.M337>+%^)@_,3KXUAX29CQX
M[?DDI(G=#M.RZX->EWI##KN]?*TPWO\ XI7O6KIKO%BO$@?F*2^N=8^$N9[3
M?MX_<;^$I$O="M.@1[NEQI"#W0[^59?]:5-?2>F=L6Z@XKL[=OZR!W/\Q0MK
MK6.QO[YLSVF_;Y^Y_G*5(W073DN -K2UT@A[H]_*<N^M*1TGIEV[.!Q7M?M(
M'<9_WBA?76LM[[ILU[3_ .'G_?,W[]3!&G_IOC: CI8Y_$=0=_*4M'?_ )3J
M8VDM,/+9U Q6S:_[2![[_O/T[7:7CZ[UEO;.N;,[-K?MX_YRDD^GWIMW#;M:
M5V?1U]_7E"6#^ZN_E/@"IG6CI?O!B?$0?F*1/7FM&?L:GS7:]WG_ #E*EZ>V
MFOJ#_&KST/<N[^3I6/> =]RJ.&D=+N_9T_B>U[AK_F*3+7NM>S_?1F_*%C^!
M_#]]U*$:>6FG==9M:4^>!U]_7DR5;UO\I5'UH:6VO_>_B.TW[1K^_P#P%+EK
M_6WK_P"^G.=AWV?W0L=QOX:FB-.O3-N -K2CSJ/='OY+E/#_ "E7O6AI;P?Q
M'B-?\Q4Y>4'6[/L;56<9OC"QW&_AJ9(TY=,BX0VM)_.0]P>_DF4_6->MI#2V
MUO[WL1VV_:%?N_YBIY<H>N6[6K,[[7[HV/X7\/WE*DZ<&F&.K7I-YP'\'OY(
ME ]_O]]QJ:VCM*[/N>P_;?\ :%?NO_ 4OI$UT_\ E9GO*-AOR34B1IN:8 W6
M@.DSFT0$+._D:3CW[>[_ /B-3VT;I/P<PW;?]SZW=?\ \-2)<HNNV_RMS_\
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MM7N[/^[4M^4OE!V?=EJ+MM^ZMKNM_P"(IA+I<Z45XCM:0&7+M0AWYU(.#_\
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M6 (P;<BM"-@9W$$M(9(?=-C%D6+E\FSQ,S&DR1K(QJ:LF/ZY0"]"Z29D/.L
M;B$RI%:[0]_0WG(E*DQ->E2'K"4R1W9E#A<L)4Y+L_?ECJ.DL=&Q&D.]^N,)
M5%#A%!1M1@[L\YC*]?)5#-$L(1G&9(CE,E:S -IU%D>6C3&,CELEKC+O5ED3
M8S];:AN&)S@%K)4ISBS[@RA:WB+X'F$A)#<0B&@,-NF2Q87T56DKX]LJ?#5]
M\\K+NC[0_@I@?)M;T:P7I3Y2/#?4WE>WZ1;4=S!RUD[)CUF(G(4^EDT*9VN%
M&M9<E?'!XL;S%JN2VJ[TEJT\X"+E-J9/:=<6%HF 26%VO8#5H/EVT[@<%5TW
M+#8C'XR5FQDXV)4JHJ[FB(=)QL1QQCO-!YS>+/VMY]G;74/V-&K-3:EMZOAJ
M#.Y3,QIU\+*K'(W#6FKR,7)L5Q,64MQR,(;3W=F]N1V]IECM^J6/\VBO_IVQ
M1^A)JU?R<_=&W\AM?E$MQ\K?W(R^,J7Y#+DJP'EK":?1'9,5O&;('AI>.1LM
MFY^ATGP3(\K27.4/FR+#2#&"N,.3-&;FY';CD8]/U J%^4,;26"'J5,AQ[U6
MD,C-MK:UZK=?*DM0I'N1YM4:@85X=0=(P97)6F)&9-YWL,0#;&JV1'9F'8W!
MCVK1^.O8Z."A2)D:V/=[5[JI7-C37C9&O9CCX4Y!F,.Y%JCBLRVRNU#5I.Y:
MK$(5V62>0&_<=5"Z4N,,D,&)Z@PR7+4[&WI],EL9)U,G+#,N982S0)4]Q:2N
M["6S9=0Q.3R!5.3TC:G*=S+42^5,J=:Q$4566L&B)C#/^J'#%YN^'E, 870S
M-,[#**!'G3D44& SR=X-O1$1XD5PNPT!)SS :LW"JV)Q%%M0#%9L3Q]@=8=6
M4PF()AWH@,5[+L-F(^[,XHR%&XS,][CG"\BS7(#3(L<W)F24XEEN,HO&87IC
M+E487Q=YASZ[ML9D4]7+F?(C:O)0R)OE5^2X%!2E1H@+*@ML7([4,N0]:'K
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MO/V7OD!]M:=,OP;^6/JM/4\_"_Y ^NT[7G[+WR ^VM.F7X-_+'U6GJ>?A?\
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MO/V7OD!]M:=,OP;^6/JM/4\_"_Y ^NT[7G[+WR ^VM.F7X-_+'U6GJ>?A?\
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I[VJ+9LV^8+F8X^19/CFH.,@37RSF^R[;8CFE9=]C1$T-WL;S2V1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g838337g21u52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g21u52.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!@P)# P$1  (1 0,1 ?_$ .H  0 " P$! 0$! 0
M       ("08'"@4$ P(+ 0$!  $% 0$!              0#!08'" (!"1
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M2F*5JG9.B-'[E9K1VX--:IVM'N$#-7#'9.O*C>6:[8Y2D.W6;6B'E$%4#D*
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M>U;E-DR84<,ARX59G2WI*$^$2#W>_I:]Q4&7>MJ@Q(L^7(C&%.R+&][JS/\
M! ([_P  L2;6-;9RWU<Z8I3%*8I3%*8I3%*I'_$3^^X_N/9>O[;^2_A58O\
M+_SW\>IN>/W\!%]_3<\F/]1_E;D+/_3K^QA_<I4_;O\ #M^WG_?25-S(53J8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I51/FEY/,=
M <.;-2&1VRUXY%)RFJ8!DL":@MZL]8 .QY\S=3H*J+&NNRL"&*/<B]E6RGQ
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M^0^C'_W5V=(HHMT4F[=)-!N@F1%!!$A4D444B@1)))(@%(FFF0H 4H    =
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MS)G.D+0RG2_,\-U8>9B"#Y*Y'W7(GZ9ZCW7&QQK,DT0UMRI/9E/G52"/**I
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MY_I+:N\=$RASF1J&QY-&/1+Z@(-)6(E5F8*MR' 02 T0Z514$.T3&3(!A$2
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M6XTS?(!X]1D;1(L'KJ39-5(9XB@[#[9*D*3M5B]2;QLN9@2OFMAY;3 ^!+"
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MJLCS$:S.F*5S<_Y%UKCT=3:.IQT.^3=W5],H*].@),_HI\@NIW"00$Y%61"
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MMB+A[,]DP]VWEY\U0\>,@<(=06)LI/>%U-NTVOI<'M[*4I2@4H 4I0 I2E
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M#'C8C*_JT'([#7TRQ8K?@>46OW,2#J"!32\>-V#59XZ4!)NW()U#]!'H'4
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MV(>(>-VEMV>+'3=/,X=H,"_2>P?7CI=P1XX4339JQU02DW2:PB4$E4"F$Q
M3%RSHK;1N/4,/B G'@O,^E](]1IVW?E%NV]81[0]V;:>EIS$0,K)M ER!K+<
M,;GA9.<@]A'9QJ"'";:[KC5I?GIH"M76J[#F^+-5O>[]1VM@\:6&J66NRFNW
M=F:IH+0TB+:0CH6T1B!I B2J1@<R:B?<0X&(EE/4V N];EM6[3120Q9TB0RH
M0596$@4\1<%E)Y;WT4'SX7T?N;=/;1O>QX\T4\VVQ29$#@AD=3$7%N4V(5P.
M:Q&KD:'09WK;EQS7)*<49'9KS0TE6>:%<LS*AM*O5[4RD]<6=O4TY2GS4Z+R
M<42F(UX^DF2LFV(J<02]8B!DS%3$\7-Z?Z9Y,],(9:S[:ZERS*1(O/9U6RZ$
M $*>^Q-]:F[?U1U>)-LDW$X38^[QN(PB.#$X3F1FNWI DJ7%^%P+:7C97+OO
M-OP9VK>]OR.M-T56*Y)M8*NU^]0MPGI)E;DMTQD!-2;B0>6M,3UYDU?J#"M$
MS$%B(%[Q4 .T;U-C;6W5$&+MZS8T[819F1D4%/!+*+!?A$CTS\;R5C\&9O*]
M&9.;NK8^9C+N 55D5V(?U@*Q)+_! )\-1\'MO6QFMPY8ZWVSY+-JZ%?:C0H^
MI-FJ[$O,%L&'FI.8NQ:]2!E9F%B7<7)L21+2,J\6JX[NJ*SARH1,BG03=D)L
M?8,W V7 W49!RLB#PT:,@!.9[ D$&Y+$#M  N1WSUR^I]OW/J'<]D;%&'BY'
MBR+*K%I.6/F95((Y0$!/822 #W;J?<S^4.]['<&W&9MJ.APFH^.6I-\W5+:,
M98;'+6.7VSK-CM2,I<8XAW;)DRC64!(D04<@0%?=$$?4 A^TEM3IO8]JAC;>
MSD2RY&9+ GA%5"B*0Q%S<$DEA>W=V=]W?JWJ3>LB5>G1BP0XN!!DR>,&=G:>
M$3",%2  %-B>-^VQT_BF<T^4G*NPZEI7&V-U)KB7E..C3?>Q9W93&?L,4M,A
M=I.A&H]<:1;Q)ZVAGLU$F4,Z4(=P5LJ;HH0Z)/=?<GIK8MAAR,G>6R)HUS#!
M&L953R\@?G8D6) / :7'"Q]'YB=7]2=2SXN'T^N+CRM@#)E:4,R\WB&/PT -
MPI9;W-S8\00.;3?"'D#L;1NI>%K*P-:TGIC=FY=Z:KV _49N22=4VI*WNT.Z
M(+&9&1.R+$SLF"K<R2J9Q(DT44]7+CU/M&'NF?N30E_O+&QH)8Q?1X@BA[BU
M[J+&X[2!:K3T=OF?LVU[0DXC^Z,S+R8938W28R.8[->W*QN+$<%)O5EO"C>U
M]Y)4*_[;LS>":467V]?8722<1'.FCM[JVKRAH6+FIUVY>N22$L_DVSI)0R2:
M*91;#T#YW0N%=3;5B;-EP[? 7.4N/&TUR"!*PYB%%M  0=;G6MA](;UF]084
M^Z9 083Y4BX_*""84;E#,23=B00; #2JYO/+)1JVH./],3C6KNW6/;$K)0"X
M(@>6+&PM86BIF-8*=.I6LE)VN+,N3J'>J@@/_9^'0?\ M9AF7J'=MR+LNWPX
M"K(+^CS/*&1F\JK%+RGL#-WUSQ_NSG@;IS9]L5%;<9MP=HS;T^5(BCJI[F:6
M+F':57NK3D/OSR#^,%['57D55W'(/CF@JDPB;NPD7LN,.R$Y&[5"'OKAG])P
MRJ*1 !*)L3<"' OIM%$TP]3,BR.E?9+[;8WS^D)QM'6!!9X654YSQ)> 'E<$
M\9<=KCC(&.E8WC=7>V'V$R)M_6<!WCHL$*DZLS\B\ $R"O,A X19"V-K1E5]
M*KI.-7,;0/*Z!"5U)=6KR9;-4W,Y1)KTHB]5SO'L-]*5]59119J13YH/&AW3
M$YO@581Z@'-_6?L[ZKZ#RO W_&9<=FLDZ7>"3^K(!H?F.%<=JUTWT1[2>D/:
M#B>L=.Y2MDJMW@>R3Q_UHR=1\]"R'@&)J468/6>52AY,-S[VVAN#47CLXHSL
ME6-A;:9)W7<^PX-TX:N]>:J3?J,TP=2D<JD]A6#@K1R^D125;/'"*+-D@93Z
M1,DIGW2>!MV)@S]3[RH?&A/)$AU#R6OH#H3J NA )9C;EN-<]8[CN>;GP=);
M&Q3+G'/-(IL8XKVU(U T);4$@*HOSV-G-UW?I;CVGJJD[7VO!UF;O;^'H-")
M;90YIZZSJ*;"+!<P%*NX-ZCIR@#Q^OZ;1%=TF"RQ#*D V)8^WY^YF;(PX6>.
M,%WY1H@U/_.P&I -AI69Y&Y;=M0@QLZ=4DE(1.8^D[:#\=KL= 2+G45O;+=5
MSKGEYZ<NN:OCXYAQFTW<C([3X9;1/!$;T61BH@L57WS"%9QUFJD3:FL0E)UB
MW%48.):-%58S5^FX,"R3D6ZQD]G].[)L'4VQG$4"'?8;W<$W-R2K%;V9=0K:
M7%M"+B^INI]^ZCZ3Z@&:S-/T]-;T"!92  RAK75M"RW-C?4&QM;_ %[8>C>9
M_&-_;*X\8W?3^UJ3.QDDTD4"HK)HN&CF.G*W8(Y0QSQLW$NP.W<(B(]JI.Y,
MYR&34-A8Q=QV+>T@E!CS895X>?0@]H(U![N.NE9V<O;.H=A?(A(DP)HFX]FF
MJL.Q@="._AI8UPZ[,Y(0%KXQU?C?-+RTE;N-&WK$ZT)LI@1(4);5,[)22DM6
M9=P1XD[CY%E.&1DX]RD11,[8 ;_:?03%;H/%VQX-RDW!+"'*B7Q4/9(!;F'D
M*^B1WB^M].;<S=$GVN+;)+F?$E;PI!VQDD\IUN"&])3W&VEA?N;XF\@JQRBX
M]ZPW56'[5V6VUF//8F;=1$RL!<V3=-I;JZ^01,;VKJ)G$UB 4P%[T135*'IJ
M$$>==YVR7:-SFP)@1R.>4]ZGX+#O!%O=N.(KIK8MUAWK:H=QA(/B(.8?)<:.
MI[B&O[ECP-2*RUU=JX]_\A;:+*Q[[U=K5@Z*LI2*A(24HFF<ID^Z9>))1P&
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M L6NQ-RUK@&U2.X2<I;AP+Y)53<;.,&>A#L7=9OE;;.")#::#-KLE)N-9NU
M K>58O&#9ZT$_0@/6:/J=4A,!M1==]$94F$=HW'E69@'B=3S*&'E\ERK"U[&
MXX@UN7V?=>8L.>N];9S/"I,<L;#E8HWX>-@R&]KBQX$5W,Z"YW\3>2M>C9W5
MN[J,\>/TD!<4V?G8VKW^'=+=I#,):FS;II-)+)N!%(%DDUF:YRB*"RI.AQYB
MW#IG?=LF,63C2V'!E4NA\H901Y;:$=H%=7[;U5T_NL(FQ<J&YXJ[!''D*,0?
M)<7![":WE:]R:CHC%>3NNT=>5)@V("BSNQW.NPR!"F XD^?(2+<#&4],P$*'
M4QQ 0* CD?$V'?,]N3"P\J5C\B)V_$IM:^I/#MJ5F=0;#MZE\[-Q(5'RY8U_
M&PO>V@''LK@4\HFQ-8[1YM[BONG9V/L%/FY1DY;3T.97V4A+H-BH2[]JJ<"G
M.1S((F5*</@8IP$.G7H'5&TX^5@;!MF'F$#<8,)5D 8$HPDD**2MQS)&8P;$
M\I%CJ#7(>]9.)N?46ZYN""=MGSF:,E2H=3'&'8!@#RO*)"+@<P-P+$5EWB7X
MB.N6G+JE,)>,4=:PU:Y:[*V:Y5;>K'+Q4"\15AJLY,H06RI[A/%19G0$P*F8
MBZ5( ^@;IC'6V^#9=DD,9MF3#PX^^Y&K?]HN;]]AVUDW0/3[;]O\8E6^% 1)
M)W64Z+_W-86[N8CA72WRQ\D_+'@UOJ[26\N!=ZV1P%(A%.*ER4XV2)-B7NCM
MFT&Q&T26Y=<KN&J<3#EL*BXIO%%X9HT8@D4BL@Y.9,F@<7;L7-@403JN?VH^
M@.NG*?-Y]>X5TCF;GF8&0QGQV;;^QTU(TUYE[K]NEAWFI[<4>=7$OF]51MG&
M+>%*V@BU9MWLY7(Y^:-OE33<B0B86^@32<=<*T4RYA2(J[9)H+G*/HJ* '7(
M.5@Y>$W)DHR]Q[#YCP-7#$S\//3GQ9%?O':/.#J/P5+3(E3*8I3%*8I3%*8I
M3%*8I3%*8I3%*@!7^(7'3C;:MR\IKY=[7*7"P$L\I+[>VI:T7\AK*O3HJ-CL
M*7("R;_0QV31RFR:.3%<2 ) 1LB<$SBB?+INHMYWK'QMAQ(HUQDY0(8DL)67
M6[B_I7(YB-%OZ1%Q>L(@Z6V'I_)R^I,V:5LJ3G+3S/<PJVEHS8<M@0JG5K64
M&QL:_7/D/XH<,:%84.,M!VYO63V#;9:S6+<%]"QPL)>KO*^X5<R=BV-;X5*?
MLTFU*F82-FD6F@JDFH<%RJ**+'RY>CNH.I<M#ODV/B)#&%6&/E9D06L%C1N5
M0>\M<&PM8 #!VZ[Z9Z2PI!T]!E9LD\K.T\G.JR2->Y:5UYG([E0 @$WN23$Z
MI>/#F%Y"=BV7DGO1U!:+C=CNV,H#V:KCWZ:=1;:,CHJ$3JNN$WK)\C!1\"P0
M206EI!FX=D3(MWN15.N.09'6/3G1^&FR[4'RGA!%E8<H))+<\EB.8L22$4@<
M++8"L8Q>A.JNN<^3J#>2F%'D$&[*>8@ !>2*X/*%  +LI:P-VN6K>-H\!,@F
MR]6E\F6;V1(DF7V%HU>O&,EUP]055OI:*NTLNT2,/8!4O9+B'Q$5!^ 9:X/:
MVA:V3@D)WK+<_@*"_GYAYJO.3[$G"7Q-Q!DMP>&P)_K+(Q'FY3YZJ_Y(>.?E
M/QA9O)^[4=.RT5EWF<["UXZ7M%69HDZ=SF8+[-C/UQH'<4/7D6+1 QC 4IS&
M^&9ULO66P[ZPAQ9>3*/".0<K'R#4JQ\BL3Y*USO_ $%U)TZAGS(?$PQQEB)=
M!Y6T#*/*R@>6JZK'4FUB>1+Q9ZZ:FBU14*1#M$%2BHDKT 3" HJ =(/GAU'I
M]CY!#*@2KAU-F4WK$0X$;1D JPL:Q Z\E99X[0Y1239KKD2;F 03:)I',FHN
MKU !,N?I\H_9-VAT <OF-E-DY3[CG-S2]I/8 +  >:P'X*M&1BQXF*FWX2VC
M/8.TDW-SY[D_AK\9ZS.8LQH*%7$/;',1V]*4HK*.!'YZ#<H]X)%2'X&'XF$W
MP 0Z?&'NVX+N.2KPH5"H%\K6)-S;SVMKPXU+V?;#@8S>.W,68MY%! [_ #7O
MIYJ\)D^M95"KHR3[KU W:Z>'63,/P^!T%SJD'X!]DOR9YQ]HW#(U10!Y2![W
M'\-5<G==LQ_1D-SY%/X_^5;68JJV*),C()>S>I')ZOI"51,3%^*:Z/0YNJ:A
M>H"41[BCU#Y.@C<L>+,V23Q<Z)Q W:MB+]FM[:]Q(-6?)EP]W3P\"5#* =&N
M#;MT(OIW@$5Y#"D'C+,E.LI(46QT52OV2: ) Z5.10@=>PWIBD)C%./<!C=Y
M>H#\0[;-F3+E9CY**$5S>P_XXGB?+>KSB X^ F'(2[H+<Q_X[. \E;2AXE]/
M2\5!QB7N)*:DF,3'H=P%]9](NDF;1+N'X%]1PL4.H_)UR))(D4;2OHBJ2?,!
M<U6BB>>588Q>1V"@>4FP]^N^3C9HJL<;=)T'3E630,UJ4*@C+2:2((JV*SNP
M]W9;&ZZ_;#+S$PLJJ4IA-Z*(D1+T(F0 Y,WK=9]ZW.;<I[\TC:#Y*C15'F%A
MY3<\37;'3^S8_3^T0;5C6Y8D',?E.=7<_P!9KGR"PX 5O/+55YIBE,4IBE,4
MIBE,4IBE,4IBE4C_ (B?WW']Q[+U_;?R7\*K%_E_Y[^/4W/'[^ B^_IN>3'^
MH_RMR%G_ *=?V,/[E*G[=_AV_;S_ +Z2IN9"J=3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*YE+G>33?D_P":6\$UE"M.+?'?;4K7USE!5%G8*CJF+U<S8)F6
M^U%<R%NM3PR*8"43*',/^DIS9VIMNV#&]B/3?3) \3?-WQ5D' F.7*;)+::V
M6*) 3W =I KAK<]U.5[=NI^J5)\/8=FRWC/$"2'$7%"ZZ7::5RHTU)[ 35LG
MBQHH4+@IHIJHD5-[9HF=O3]0I"E%P-PL\S,Q:I^T $QB5]PS2ZB(B()A]CH
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M^F)61(!'LB\<D* =$U5U#)_#X=13[@()O]_3KD?*WG=LY/"S,F:2+Y)<\O\
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M1S-'&S6[RJDV]VU9:_>^X4!-/[6S;AZ+-N4>B:2)/FE$"_\ PS@'4P_*(_\
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MFYX#I\Y"&!]Q>?\ #6I/;%@+D=-Q9P'YW'R5U^;("K#W6Y/P6[:Y./D^(_
M^4<Z!KF6H5[1VI4J/.ND8TRUD!1<ZBY88R1VD:L8PBNU</CF] RA%!'H5+U
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M^H= RG>)?1%01$0 H"/40$1#X9-7.G&+ZF"!#?W==;>:]6H['@-NWWPX)R[
M"Y'*"!8-:U^:VG&W:!?6LPT?7Z];-T:CJUN6*WJMEV918"RN#."M"H0$Q9XR
M/EUC.CB!6P)1[A0WJ#\"=.OV,M&XRRP;?/-!K,D3E?.%)'OUD^VPQ3[CCPSZ
M0/,BMV>B6 .OFK_3-:M6K%JV8L6S=FR9MT6K-FU13;M6K5NF5%NV;-T2D20;
MH)$ I"% "E*     9R826)9B2Q.IKL=555"J % L . %?1GROM,4IBE,4IBE
M,4IBE48:=_R"N".S>0]NX_69]=-3(M-T6_2>K-XW*'(IQ\W39*A(,(QPG6-G
M1JJ\= /GR\@DLDE+)M&@,W3-47?>\22Q50Q,!>IX<Q?''PRYY0'T1R9T=5KM
M+M6IVL'L)@1>K[1K)>TWHA!["KJL=94F*"W:J,>NNXBUU"%]=LL4.W)N)N.9
M@M?&<J.T<5/G!T]WCY:MF;MF%N"VRHPS=AX,/,1K[G#R55,'$GS ^-HJ3K@_
MR#9^0SC7"I."I<5N6TDVC-SU:%;@J9G%ZUW.#F/0F#,&*)44$G#N+CV_4B:$
M.M\I;IZWM&XZ9L?J^2?CQ_!/G7L]\^6K3ZGO.V:X$GK.*/[.3X0'S6_Z#YIJ
M27&GSF<3MKW-/2')2)N_ /D\U(U1F=*\KX\^OV2TDY54;D1J&R9MM#5J>8O'
M!2IL32"<(]DSG#VK14/CD?)V3*B3Q\8K/C?*37\(%R/+:X'::DXN_8<S^!E!
ML?*[5DT_ QL#Y+V)[!5T:2J2Z2:R*A%D5B$5252.51)5)0H'3434((E.0Y1
M0$!$! <LU7RO[Q2F*4Q2F*4Q2F*4Q2M8[DU@QW'KBR:^>SUBJ:DRBS<1-MJ,
MFYA[-5+%#2#2:KEDA)!HL@JF^A)N/0<%()O36!,4U $AS ,[;<Y]MS4S%1)
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MJ8)MRK(06&@O<C3C>W'2UR:W#M2;I'@1IO+Q2;B+\[1 A#J;6#:_!M?A<WL
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MAQ1J@MLQE78[8BM;A3WAC47KZ1J[6UFCT!GDJ\\DFS.07ARR7J>W%9,% 2Z
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M<DCHN4N]9F(:(5?E*_2*FO/2#AL].LY,;U%>QK938Z7-7BU;SZVRMNX^<O\
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MUNG'"T1&H_+SQ/OW"RX2<J:#A>05,C)/9W$B]/ +ZB;F*N$&O8)>M*.DU4S
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MCZ=M$S&M9.0H]J.U(FC9*I*%$5&JJZ)4E/F',BJ=%!42B=%$Y% 2-!5%^L_
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M]@\;O$_+?7E+HQ4$DA2 23K4A<Q&LRIBE,4IBE,4IBE,4IBE,4IBE,4JD?\
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M=^@VW+YACR<]^4V/HQNPL2#VJ.SA6+=:;QE[!TUD[O@A#E1>'R\P)7TI40W
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MKC);GGKF;H/95G C/6"AJR"1"J$9$=2LJ<ZH"I&LD^H%^ML^/F R;1,)#_\
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ME48\:D=K/,4++Y8EE)[ ;&T\(CQ3[*DXZ-^N&TZ!'NQ(<7\?"U^P3S9@H'H
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M:WG[+(LF#V9]/PY8MD+LN$"+6(MCQV4@\&46#>4&M\,X])FLNHF  "Q2 /\
MM^:)A#_\;+Y6>5Z.*5JO=D/1)C5UR#8]/A[U58J#D9UY6YN/;2+5ZM$,UW;8
M$4W*9P;/?4)VI+D[5$C&[@,'RY?^E\C=<??L8;+DR8F?)*L8D1BI4.0#>W%;
M<5-P;6M6*=<8^Q3]*YLG4>'#G;5!CO,T,B!PQC4LM@0;-?16%BI-P17"GOFZ
MV/1G)JC\@=2KFU*Y?NWL&L% </H-O"-%@.T4:(+@Z4>K(+0D@9,?77545!H
MG,)OG9V[O.SX2Y.!+O8]>P9"L4YG"OSD:<[ @+?E8L+  %18"OSJZ+ZGW+.V
M[=<78F^[MSAYI\9<8M'X8;7PT(8ORAE"L69F82'F+7KL'\<?)N?Y0\>4;/<U
MVKB\TZR/J19W3<A$%)11A'Q<E'S;AJE]K06?LY,"'$H%(HJ@<X%+W=H<M>V3
MHG$Z&ZP;!VT,-KR(5FB!UY0S,K("=2%*W%]0& N;7KMKV%=?9OM!Z&3<=V96
MW?&F,$K 6+E51ED(&@+*UC:P+*2 +VK^_)W3K=?N#F[ZE1*M8[K:I;[VOT56
M:E!R=CL$G[#;U DWWT?"P[5Y)//9QK-9PKZ:9O302.H;H4IA#$^B,G'Q.J,7
M(RI$B@7Q+L[!5%XI +DD 7) &O$@5F'M%Q,K.Z-S,7"BDFR6\+E1%+L;3Q$V
M502; $FPT )X"JD=N<#-FT+9'"K:VIZ'>'=/O<WQHG-YT& K<Z\6H6T:0S@2
M2UQL\ QCSN(*.=Q\A(J.W+HA2L9$7OKG3]RD3-@;=U5A9>%N6!GRQ#(B7)6"
M1F4>)$Y:R*Q/I$$+8#X2\MKV-:OW3HK<<+<-GW/;()CBS/B-D1*C'PYHPO-(
MZ@74$%RQ/P7Y^8CF K"]C<3MDLMR<E-=;-U;S:M]:VOR%7O]9?\ 'Z"KLUJB
MXU^PVN2E6-GO-CL4>\C8VVUR+F5%4B+N0(1PHLW74:%$[D\G#W_";;L+,PI]
MLCFQ\/PV$[,LJ,J@%452"48BV@X6(#:*(>?TQN";MN&!N.-O$N/E9YE0XRHT
M,BLY8/([ @.@8D7/$E24%V.U=Y4[>NHK;Y(-<,.->_-I-.5D?K$FL[YKFC2U
MSJB3*KMYP'[JSR\*V=F:/C(3AP%L1,[GW3<2F3*FJFL,#:\G:MPQ]FS'S<2!
ML!I?$CD<(UV*V"AB+CT>/"QXW!%7/><3>MJRNH,!-OSLE-S6'P9(HVD2R!KE
MV4&Q]+A:]Q:P!!J07#C2-YC^7-%FMAZBMC*GM/&9I.A/):YT&8;5IM>6$-IV
M.G:6Y?SD22+1MC-HV?H.XXQP>)IIN"*)@4J@!:.H]SQ7Z?EBP\B,Y!WN:0!)
M 6*$S%7 4WY"2I#<.!!X5?>D]GS8^J8)L_%E&(.G<>,M)$P02!8 T9++;G #
M!D^$ &!'&M2;\I.X]<;"\B5$0XI[7VX;E^A3":BV)K^D+6ZH0Z*;9ZS63MTZ
MV!0M3"">R15TBG IR.F)3J%*W%)R6X;3D[=F8>SY1S\?'^[B_BQR/R.=0?04
M_#Y@+>9K#6XJU;WA[MM^?OV$NV9.5]ZB/P)8H^=%T(]-A\#E)N/*MS9;-65\
M?>,FSZ-O3=L7?]96.6;Q_CHU_JAC9W50E)6IS5R8:NUU S]+JMB5CE8>PNV[
MF,68^W:J**JI-Q**8!W%"AN^]X.5M>,^).BD[Q)*5#@.$,LC*[+>Z@W#7.@)
MXU*V+IW<</>LR/.QY&5=@BA#E"R-((8E:-&MRL005L"20.'94_?&-4;C1.#N
MD*I?JQ9:;;(@NQR2E:N$+*5ZQ1A'6V[Z_C2/X::;,Y)D5S%.D%D 43*!VZB9
MR]2&*(XGUOD8V5U1E9&(Z28[>'9D8,IM%&#8J2#8@@Z\;]M9O[.L7+PNC</%
MSHY(LI/%NCJ587GD(NK $74@BXX$$:5/3,4K-J8I5(_XB?WW']Q[+U_;?R7\
M*K%_E_Y[^/4W/'[^ B^_IN>3'^H_RMR%G_IU_8P_N4J?MW^';]O/^^DJ;F0J
MG4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2OG=M6[YJY9/$2.&CQNLU=-U0[D
MUV[A,R*Z*A?^T15(XE$/L@.?59D8,ILP-QYZ\LJNI1Q=2+$=X-0DU?XY.(FG
M]@06RZ1K1TVLM4=/WU2+,7*Y62&J[V0.H<[R%A)Z=D(Y!TV]8WH*'(H=$X@J
M406*10N3YW674.XXCX65.##( 'LB*6 [&95!L>WOX<-*P_;N@>EMJSDW##QR
M,B(DIS22.J$]JJS$ CL-C;CQL:G'F+UF5,4KXW$C'M$47+I\S;-W!TDFZ[AT
M@BBNHN'5!-%50Y2*G6 .I *(B;[&>@CL2J@DCR5X:1% 9F 4\"3QO7V9YKW6
MA.4]$/L[C7OBA(%*9[9]3WN.BP.1-0A9H:Z_7@U#D434 2I2Z*!AZ !P .I3
M%-T,%VV'+&#O>)EGX,>1&3_5YAS>]>K)U)A'<>G\W"'PY,60#^MRGE_\K?T5
MP(YUM7$M?\,FZ*43BEVIF$ 2.8/FFZ_'_;\IB@(AF;OLNQX>W8&Y9K2F&;],
M$(O=E+)86T"D6:VI'#6L&BW[=<[<\_:L$0C)AUBY@;65PKWUU)O=;Z Z'2A>
MO3YWRY8=SCV=3?;78KY;_P!(%9%MK[LPMN*J&\EOZ":D]QTYB<A>*\@Y<:=O
M[V&B)%R5U,TZ400G:7-+@5(AG#RO21%FK9^JB@1,SUH+9]Z1 ("P$^&83O/3
MFS[\@&Y0AI%%E<>BZ^9AJ1\TW6^MJSG8>J]]Z;<MM4Y2)C=HR T;>4J= =+<
MRV:VE[58+,^<7EK.5Q2 AZ5IN LC]+V)+1#5NUOI%NJL!TB.8>'E[A*Q1),5
M#$[/<)/$>[J'HCW%[<0B]EO3T4WC22Y+PC7E+(!YB0@-O,0?+6<R^V+J>;'\
M"*'$3(86YU1R1Y55G(OYPP\G=8+XCN"=]T>>R\BMVQ2D!?[]7@@ZC3Y)(I)V
MN5F6>LIR9F+*T42 \-89UTQ;)IL_F.6;<BI%P*=8R2>(>T+JK$W0)LVUMSXD
M+\SN/@LP!4!3VJH)UX$VMH+G.?9?T9F[.9-^WA>3.GCY40_"1&(9F<?%9B .
M7BHN&U-A>%FKJW#3%*8I3%*8I3%*8I3%*8I3%*8I3%*\J<@H2SP\G7;)#Q5A
MK\VQ<QDS!SD>TEH>7C7B1D'<?)QC]%PR?L72)Q(HDJ0Z9RB(& 0'/JLRD,I(
M8=HKXRJZE6 *GB#P-4:[E\$^HX:ZRF]_'+N797C>Y#.$O4.ZTH_7=:)N*B*R
MCQ**OFE7CI&'5@E5^TA&<>NVAVP"*IHQTH %&]P[Y*4$&XHN1C_.^$/,W?Y]
M?**L,VP0K(<C;7;&R?F_ /D*\+>0:>0UJPODN\BGCU,K"^5GB2KM/3<29HV+
MSGX5QZ]II:##J5N:=VSK)Z:.?50IC]57;[TZ^@0P BSC7(G(8U7[MV_/]+:Y
M>68_V4FA\RGM\VOE(JC]Z;EMWH[O#SP#^UBU'G9>SSZ>0&KG>,G,7C#S)I@W
MWC)NJC;>KZ!6_P!*IUJ3[+#6EG9!4;L[?3Y-)A;:?(+D*)B(2;)HJ<H=Q2B7
MXY9\G#R<-_#R49&\O ^8\#[AJ]XN;BYJ>)BNKKY.(\XXCW14E<C5*IBE,4KY
M)!ZE&L'LBN58Z#!HY>K$;I&77.DU1.NH5!$G4ZRQB)B!2A\3&Z &4,K(3$QI
M,J4,8XHV<A1=B%!)L!J38:#M.E>78(A<WL 3^"HD#S>TV#\L4,7LX)0[7WQ8
MT=>38/S,@4,C[PK,0]P+7UBB3U.WL[@$.O7-''_<5T",H8)AWCUTISB/U&;G
MY+VYN2W-RWTYK6OI>L>_U1MO/X?+/XEKV\-KV[[<;5+&(DV\W$Q<RT(X3:R\
M<RDVR;Q [5VFW?MDG2)'393HHW<$35 #IF^<0W4!^(9NW S(MQP8=P@#B&>)
M)%# JP5U# ,IU5@#J#J#H:R".02QK*M^5E!%]#J+ZCL->CDNO=>-8+#!U2'?
M6"RRS"#@XU--60E9-RFT8LTU5DVZ9W#A4Q4TBG76(0!$?B8P!]G(&Z;KMNR8
M$FZ;O/%C;=" 7DD8*B D*"S'07) \Y%4YIHL>,S3L$B7B2; =FIK[T56<FR2
M71.@^CY!J15)0O8NU>,W:0'(<.O<FL@X04 ?L@8H_P"S)44L.5 LT15\>1 R
MD:JRL+@CL((-_**^^A*G8T;#S@@_C!%0!V)XQN*6PK-]9?J[8J29RZ]U,P5!
MFT(2M3HF.)ET'42[BY4L4U<E'M.2*/'ATZB'0PB(ZYW'V2=$[CN*[F<=X9@_
M,5B<K&Q&NJ$$#S)RCW:TUOWL%]G^^Y39/AY.''(?SL>-(L<4H/PE96C<HK#0
MB$Q:<+$DUD/)O@K0>0;ME9HJ8/KN]L(YM$A-LHHDQ$2L8Q)Z;!I,P0/XDRJS
M%,/31<(N45")#VG!4I$RDLGM%]BO3W7TXW$2R8.\! ID10RNJBR^)&2MRHT#
M*RFVAY@%MDO5OL^PNHV3*PY%Q-RC0*&Y.=&5?@JR!TX< P8$#0A@ !$5OX]=
M>Z1C'.U.1>S'-YU]37T,_>TBITP\4QFE7$W&QL6WL[IY.S4A-PIY1\B*[%LF
MQ*L4O:LJJ@91$^KH/8IT)[)<63V@=9Y<^=B8#1MRK%95:21(D/(&8OZ<@N"=
M!K?2L$/LH\-/6.L=P7(V")U9L7'@,:S69>5,B1Y9&DBYK%HHUB#@<LC/&60W
M/D(1,A4TRE(F0I2$(0H%(0A0 I2E*4  I2@'0 #X &=;@ "PX5OT * JBRBO
MZQ7VF*5YTQ%,9V)DX231!Q'3$>\BWZ B(>LS?MU&KE+N#XE[T53!U#XAE?&R
M)<3(CRH#RSQ.KJ>YE((/X147.P\?<<*;;\M>;%GB:-QWJZE6'N@FN&_R,ZC=
MT]7:5+=D]5]KJWNEF:OI]@.&4=(*()OR%ZG%-)W77IERAU'H4P /V1SO]<R/
MJ?H*'=X1J\$<P''E( $@O\V[@^45^5.T[?/T+[6LGIS)-A'DSXI/#F4DM$P'
M<Y6)@+Z!O)4^O GR,*PO<YIN8<&4;[BJ;:;@A$!.9.\ZV:2HS"( 4P>D2:K7
MNUU3F[OG1Z)0Z=XB.NO;ILS=0] ;9UI#KD8/YJ8]Z2,L=SY5F1;#NE8]U=#?
M[>=[7IGVB;MT'-IBYY\: =SQJTH4>1H':YUUB4:7-=4^<?5VU3%*8I3%*8I3
M%*8I3%*8I3%*I'_$3^^X_N/9>O[;^2_A58O\O_/?QZFYX_?P$7W]-SR8_P!1
M_E;D+/\ TZ_L8?W*5/V[_#M^WG_?25-S(53J8I3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*UY:'^O[L6UZ;DK=$?3MAJDK&3=6B;2R87AI7[#&.&#B1
M;,6CPL]%B9F[,9!V5,OIFZ'*;J #DR!,S%\/<DC;PDD!5BI*%E-[$D<IU&H]
MRH&2^#F>+M,DJ>-)$0R*X$@5@02 #S#0Z-;3B*YQ^0NC;)P@I-AXY[KF;#M/
M@MN64.IK;8K9O[RZ\?=KLTWLM ODX0'3=HKWF15/(L6QF[6:9"Y7; @Y]TU5
MW-L^Z0]492;SMBI!U5C+^<C.B9$1L&'-:_=RL;E&Y0UUY6&A-]V;(Z/PY-AW
M=Y,GHW+;\U*!>3&F%V4\MP._F46$B\Q7E;F4RX\>7E%U)/:T@-.\B=CQ5.V/
M0FZ59B;_ &YVXC:GL:LQHE904R[M$P"*,/8F[ B:3X)4[87785R50QU%TD,>
MZQZ$W"+-?<MFA:3"E/,8T%WC8ZLH4<5OJO)>WP;6 )RCH7VC;7-MZ;5OV0L6
M? .197)"2H-%8NWP6 L&Y[7^%>Y(6P'=G-[C/JK5]PNJNZM5V-[&UZ57@:Q7
M;Q5[-.6B;!@L,3"Q<-$2$B[=FD7IDTSJ"D+= AQ46,1(IC!B6U=+;[N.X18B
M8N0H9U!9HW4*+ZDD@<!P'$G07-9OO/6/3NU[;-FOF8SE(V*JLB,S-8V4*"2;
MGB;6 U) N:X4RJ=R@E /F@'P'X_$0'X_8^3.TMRZ7GVO9(MSR6(RGE :.WP%
M()4D_*N-1V7 X@UP;MW4T.Y[U)MN.M\9(R5DO\-@0" /DV.A[;$\"*]5>147
M8MF1B$ C8PF]0.O<<  0(!OL!Z93"'_1EBFSYIL2/#?]'&=-?.!^ $BKAB[+
MC8FZ3[I$3XTXL186' M8\?2(!\_O>$219J@4R2Y52G_TG3ZF3,'7IW%4 .PQ
M!Z? 0$0$/B'PR\8'2.^;CCC+AB"P,+J78+S#O XV[B0 >R]1-PZKV7;L@XL\
MA:==&"J6Y3W$\+]XO<=MJ^\2F+VB(" & #%'[!@'[(#\@AEFSMOS-MG]7S4*
M2>X01W@BX(\QJZ[?N>#ND/K&!()(P;'B"#W,#8@^<>4:5U<^+'QXT;5^O*+R
M/VE ?3NY[E%MK556$ZW25CM90$D!W-><14:JGU+<)6(51=N':_VYCZI6Z!$3
MIKJ+\Z]>=8Y6=F2[+@/R;9&Q1RO&5AHP)^0#< #1K7)(( ZF]F_0F'MV!#O^
MY)S[M*H= PTA4ZJ5'RV6S%CJM^4 $$FZ[-8UMVF*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2OX522724163(LBL0Z2J2I"J)*I*%$BB:B9P$IR'*(@(" @(
M#BE4R<G?!SQ+W)<U-Y<?)"Z\$>4K9RK)1.]^+$JYH@KRBARJJ*6S7<4]BZG.
M,WKCN5?"P"&D9%0W_$O5"]2#>,;>\J%/ R.6?%^2^OX#Q'DO<#L%63*V'#G?
MQ\<MCY?RX]/PC@?+:Q/::C5_S4^8;QM_\%S1T*U\CG&N+?>B;E'Q/AVT1OJL
MUTOQ+)[&T8V9L6,R=HU* J':-V+)J!%#NYIP8Q#&D^J[1N.N')ZODGXC_!)\
MC=GO^05%];WK;-,Z/UG%']I&+.!\Y/\ E8=[&K2^''DEX8<\8-&1XX;NJ]GL
MA&9W<UJV:<%JNWJP#<" ^"=US.&:V(&;!<_I&D&B3J*54 ?1=*E^=ELS-NS,
M%K9"$+\H:J?,1I[G'R5=L+<\'<%OC2 MVJ=&'G4Z^Z-/+4Z,@U/IBE0OFETF
MO/"&<KG]-!MQ<=KK'[3&[$D=@SBBA^T@&.;M(41Z  B/V,Y\W"5(?]RV/-*;
M1IT8S$]P&;,2=->'=6-2$+U8K'@, _O&J'4'<99'8&B=CTE#;T77ME[MC*[]
M<+]MZ*LPWJO2-F5A)F(>4*/6(ZBTVA#"FF=9(R*((I]#&.9,XZ%V[?\ .CZH
MZ:ZLZ=7?8=KW?J*.#UK-W2/(]<@DR##+$V$A#1A0>52RE5"I8EBC'&XLF09F
M)FXHR%AGR@O/),&YU+<K QC46[+BPL.VQK/7NQI@G%"ZN!O,J2U-^0CF 0<C
M8WI)]%+Z_P >Y+$(KB\"0(A]"%4,"!1[/; ;X=H#F39/5>>OL2W"7[RF&])U
M4T(;QW$P'KJ,(@>;G"^#<\@-O#!TY0:EMFR#I^5O%;U@9A6_,>;](#;C?X/9
MW>2I4\VX8DQQLV$H921(I#(Q,RBG'NEVY7!V\NR;*)R": ]'L<1L\45.D?JF
M!TRJ#\2 (;J_W$[>N?[(]U8F4-CK'* C,O,5E12' ^'&%9F*GT;JK'X(J_=4
M1>)LDQ]*ZV;0^4#7O%C>WDOV5'*Z,*Z,-H[5%:3W%L:7=:[?WI*%@=T1E.AG
M$<\!LN[DI>RSRXA(N(9PW7(R; H5-JU[@#J'P#4W4.-M/J'3G1.T#?\ =LY]
MJ?,$4.[1XL31OREI)<B8_G&B97$4?,!''<"XTJS920^'B[?!ZS/(83)RK,$4
M@\26;CRF_*+Z"M?T5>U[:B>&U+LFPM@M8^UR_(^,L;V*N$@A-S$/4",Y&,BI
M.9:+A]*HD;LA: J?U.ULJ<$Q* ATQ?IJ3>^N,'H#I_=]UW1,7-GWZ.=X\IQ-
M+%BA)(XY)5/YP!4,7,>:T;,$L+5#Q#D;A'MN-/-,$D;)#$.>9@EB 6''A:_<
M=*^IS,V>+@7>G'.RKFQI).9:6IG%C<V)R2S,]>J19'):]]:%3 HT;'43Z]P]
M" /=U+Z0F3&O+N&\X6VOT#-N^X1].CK\;:T[3L,A,$QAO ]8.JJ2./#C<<G,
MA]-).D)VUIY1B_>?A<Q;TA':_+S=@_XX:5C&V8P*C6>:VO8N[6FVU6I16A"0
MK:RV1_8S0+B0NM?>2<6BNZ741*9H[4%,W80AR%*5-3J=,PC9NN,,;%L_M#Z6
MP]QS<[9<&'91$N1D/.86?+@:2,,S$>BQ*FP!  1KLI-4-P3U>#=,..623'C7
M'Y0S%N6[J2->XZ>\=16Q-].=B;'WWL.MUEU.2\53];P$S3PA=R,M6P]9/*1B
M;]>^']PW<-;4FU?+]%C%50 J)2D,J =@DROVF3=5=6>TW==HV=\F?"P-H@EQ
M?"W5-NBQS)&';,/,K+DA7/I$,@" *S@<I69NS9N;NTT$!=HXX59.681!;B_B
M:Z/8\=1IV\+>?M&!W6X)2['L%S/WB(A-)QCJP0VN=T0=/L%4FF!W(OMDG9)J
M.VUN))MT 6*Z03525,(D,8I42%/%ZSVSVARKM^[=4OE;C@X_3L;3Q8&[0XL^
M-,A;GSR@++E"15YA(BLK&ZD@1J&\9T6Z$139A>6-<4%ECF5&1A>\MM0]QK<7
MOP[-;(=1V.)MNL:'8H-Y/2$5*5>(6:/;2N5U97!4VB;=12P.TP])W,^LB8'*
MQ.J:JP&.41*("/6G0V[86^=';9NNW29,N%-A1%7R2&R&LH4F=AHTMP?$8>BS
M787!%9KMTT>1@Q31%S&T8L7U8Z?&/:W>>TUL3,KJ95'_ ).> E\W0]LVT]6D
M@I()ZKK1]X@IB;AZR=I[*'-'?3K>4L#R-@S,ACD2^X!9PBH0Y.X.\#"!>EO9
M%[3MGVW9FZ.ZB\5%;G6&18WE!$M_0*1J\E^9CR\JL"#;2VO&OMZ]BW4&Y]4)
M[2>DO!D>/PY,F)Y8X"I@ M*LDK)%R\B#G#.I!%Q<'2D_P=6_1NN]]2EMWEL=
MO0IJ@*O(R@1TBPE!BWLY>XF5J\FO-S[1NO$0T9%,".B=71DTC.'93F5(5,.[
M*NJEZLWOV?Y72O3N&V5'ZPLLY#+SI&I5PJ1DAG8R1@GD!(%Q8\PM:>DLWH?I
MKVE875O5.X+AO)C/#C71S')*P9"TDJ@I&HBEL#(54FQYARF_;:FHFJF15(Y%
M4E2%4343,4Z:B9R@8AR'*(E.0Y1 0$!Z"&<@$%258$,#J*[?5E90RD%2+@C@
M17]Y\K[3%*8I3%*8I3%*8I3%*8I5(_XB?WW']Q[+U_;?R7\*K%_E_P">_CU-
MSQ^_@(OOZ;GDQ_J/\K<A9_Z=?V,/[E*G[=_AV_;S_OI*FYD*IU,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE5]<M_'=J_E%8XS9\;:+/IG>D"DR2A]
MKT4XE?*A&"(19I^+3=Q:LFXBDS"5LZ;/8]^F4I""X,BF1(,OZ>ZQSMBA;!>-
M,G:GO>*3AKQY38VOV@JRG4VN2:P;JCH3;NH\A=QCDDQ-Y0#EFCXZ<.87%R.P
MAE8:#FL *A;R.X;>2G>NHH/CQ<=G<<]F4V&ML-9F>TY@UTJ6QWHP["4BF;2U
MM64%+0B[=%*7.JHJV;N7RPI@*BRAQ,!\FV7J3HG:MQ?>,:#-@R6C*F(<CQBY
M!)0E@W9:Q(47T K$M_Z3]H&\[6FQ9>1@9&(DJN)F\1)3R@J X"LMO2O< L;:
MDGC6+:O$%R2CH.R2FN[IH[>,K2'R\+=Z=JJ^N).UUJPLT0<OX)VPG(.!;%E6
MC<Y#"S660D#]X 5L(B'7-,3VE]/Y$PBR%R,=6^"TB#E(["2K,1Y[$#OK ,[V
M2]38N.TV,^+E.GPDB=N<'M #J@/FN&/8M5@N(V2KTV_AI]@^@Y:(=NXV6B9>
M-7:R4=)L7 MWD;)1KU))VQ>-7"1DU4U"%434*)3  @.;WZ#R]E3.$V5(/%E4
M+"PL5]*UF#V-B> 8$"QXD'3G'VDX&_2[6V-A0DB%^:9"Q1[+<,I6ZW"\64@D
MV.@(U^!PU2ZJ+,R&*D ^H4A@ #%((?;"&Z"8>J9O^GJ7H/4<V%F;=DR;))@Y
MS&:$%K,26<+>XYB>+(>&I%@._77FV;W!%OD61&HARF"@@ "-GM:Z6^)*O'0$
M,6%A;3"KFLHE7G1B&,1(Z\>D\.7J E8+/VR3WJ(?$I#-SF*<?L%$?^G-+ICI
MC[DF/F6\)9E#]W+S"Y\Q77S5O@3M/@O/B7,QA<H.WGY38><-IYZ_9HB!C%$
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M/]D^QY&0W/*,3DOQTBD>)1[BH![E36S6E;6IBE,4IBE,4IBE,4IBE,4JD?\
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MHT,H8!342$OI>_:K[")MW!W_ *0USHH0'@8ZS<OQE<D!9.73E(Y6L+%2+%[
MO]S\^%*>F>OHR=LEF9X\M!88W/\ V;Q*I9HBVH93SH2Q*N#=>F&%FH>QQ3"=
M@)-A-0THW([CI2,=(O6#ULIU[%FSIN=1%9,1 0ZE$>@@(#\0SC?)Q<G"R'Q<
MN-XLF-K,K JRGN(.HK]#</-Q-QQ8\[ ECFPY5#(Z,&5@>T,+@BO3RA4FF*4Q
M2F*4Q2F*4Q2F*52/^(G]]Q_<>R]?VW\E_"JQ?Y?^>_CU-SQ^_@(OOZ;GDQ_J
M/\K<A9_Z=?V,/[E*G[=_AV_;S_OI*FYD*IU,4IBE,4IBE,4IBE8NZDV]ACK
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M4< SNE-V[25RF[7#M6!@9^);&*!2JE45BK'],B9-3J'0K 1$ Z_ 1[0AY?\
MMNZV1?$V[)V_)7L =XV/=8-'R</G_P#.KQMW^Z7H+(;P]RQ=RQ'OJ3''(@[[
ME)>?_P#A_P#*K0]9;,HVXZ)7-F:UL#6TTBV,U7T#.LTG3=)XBW>.8YV0[5\W
M:OF;IC(LUFZZ*R2:J*Z1R'*!BB&:.WK9=TZ=W2;9=YA:#<\=@KH2"02 PU4E
M2&4AE()!4@@D&N@=BWS:NI=I@WS9)ER-KR%+1R $ @$J=& 8%64JRL 58$$
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MV^&2#8+<#G5=*)9\HG)R(W.(#H+V ':Q'$]__,5M@FD=5OZC<ZFK H2M5V3
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M<BR(H-S;^H;[V[O?E\LW(JC#K'0?,)[=[GK:R,A29S6NYZM24J2)LD*_,AT
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MNF6,7&('PB*_-3IS;7W#.#L+HI_":M9X7?2;9Y(-RF5".$BJ"A1[A3, (>Y
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M7.[=9T;:]$EBF]]5;_68BTPIUA150(]09R[5TFRDVR:YO0=H>FY;G'N24(8
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M[":R<5$B9?M!>H%  'J;K_K/W3DWC=(_@SR>Z>;\=ZM\FR;3+\+'C'F'+_\
M3:HA6K_&?\1%A'K$:(O-%#N1'I5=Z[>>  )%.4Y?_IO;;B/:X$P&/\>H"4.P
M2AU 9:]2;LO&16\ZK_0!4-^E]F;A&R^9V_I)J/T[_B=>,V7[?H^]\N:OVKJJ
MC]!;1UJX[TU.O:U-]9M*V+H@CU^:(=%1Z?..;)"]4[D.*Q'SJ?Z&%1FZ1VL\
M&F'F9?Z5-:SDO\1/@LJ]64B.1G+)C'&]/V[62E]/2KU+HDF"OK/VNIH9!?O7
M QB]K9/M((%'N$!,:H.K,VVL<5_^[\HU2/1V!?26:WG7\D5\/_\ R(<*/_\
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M;F@ 46 L*_1\^8QC1=_)/&L>Q:D%5R]?.$6C1NF @ J+N5SIHHD 1#XF, 8
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M<)+)&([]YVS;7 EA(4=)$!NZDE6(#'EX@K>_F'#NI8&][MD/S&+GC>-RMD8
M,JL5'-P8-:W'B>/?.'PN>2KDMS V[LK57*G;NFQV%!ZL9WY7CPEQ[V]I#>VO
M)HEDBHF>]P[M@?4*S:Z@BRZ34QT5WDTJ]<(J*%:H)F%U"WG;<;$B67%1_#+6
MY^=64BVG#4$^X//V3]DW3*S9FARW3Q E^3D97!O8\="![IOW=O1OF/5DM,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE4C_B)_?<?W'LO7]M_)?PJL7^7_GOX]3<\?OX"+[^FYY,?ZC_*W(6?
M^G7]C#^Y2I^W?X=OV\_[Z2IN9"J=3%*8I6$;+UQ2MPZ[O.J-D0+6TZ_V34K!
M1KI7'IETVLW6+1%NH:;C55FJK=VV]W'O%"%514362,('3.4Y2F#W'(\,BRQF
MTBD$'N(X53EB2:)H91>-@01W@Z&JI-.^"7@+J)AL^/<0NW-MH[.TK)\<_4W1
MMJPW9?7FD)9T9\XUUJI5$D-]28=L^!-9HLB"CYBHEU;KI>JX!:Z3;YGRE3=$
MY7Y_14"[=[=_]/;5IAV#;X0X(=^>/D])B;+\E>%AW=H[*_>_^'_CK ::OD5J
M:B.]F;%;\"+=P3US6M[[7NIZ'+:P>;'DMTU6 M\] -E+7'KPNRG"!VLHP.D]
M8L6J#=N9$$B*$1[MD-,IE;EC\<2DJHOS6Y20#IJ.PZ$TDV;&6!A"O-+ZN8E#
ML;<O-S $C71NT:@<*JF\=O@IVJTWKNV[<Y=>-X'15QXEO.*D9J*8Y(RW(.XV
M)%_8ZLY3L#&_-H2OGI-*J,-34PKL<V,W>Q2AV1B"51LN92Z[AOD1@1,)KSB7
MGYN3D T.EKFY-]3VZU:=MV"89$DF>ML=H?#Y2_.3J-;V%@ /1'$:=U6K:V\%
M/ C7]'WA1YF'V[N%'?FL(+2]LLVZ-LV"[7" U75)N#M%2I%#FDTXD*I"56T5
M6(D6!$DCF2<Q#0!,9)$$QM4F^9\CHX*)X;%@%4 %B""2.TD$CW35VBV#;XXY
M(V#OXB!268DA000 =+ $ CS"ODUMX(N"-!@=U0$X7>.Y4^0&HH_26RI7=>X9
MR[SDC1H"QUBU5!&,DDVD0I"2-&F:7$GAUFP)@R+'(E*00*/7[)OF=(R,.1/#
M?F'*H N00?/>YOWWKY%L&WQJZMXC^(G*W,Q)L"".ZUB!;NM7JUWPB\0(G4%V
MTG8[GRBVA4KY=-47>4<[3Y VJWR\<^TJ=Z.O8RNBN@UAH2'B$WYTCE19 X7;
MD2146%)%(A/C;UEM,LRK$KJK#T4 ^%QOVG\->EV+"6%H&:5T9E/I.3\'A;L
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MF_EL_G78^M?-^ST^I_K/M58#^;=]YO\ %E]&_7[_ /VN_5[ZO?\ /E_];/\
MFY^MG_\ %'UH_P#W<SW]8\;X]^7]1>_A?@\.W_;R_.JG]5\#XMN;_P#N+6\7
+\/B7_P"[F^;7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g838337g28j20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g28j20.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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M-;=OD/I30O9YGZT^@GIW]'.6_AL?]>-;=OD/I30O9YGZT^@GIW]'.6_AL?\
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M?#Y"N@G17V/=<_JK6?RN5O[Q\/D*L3W1X_,U+'(U*G%*<4IQ2HUDZ=ZLF&V
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MHJJW9V"[[ HJ^EL;@C7Y//:&IN [RMBN+J_KP8$*JS"&L#G^[H.SKJJU-L*
M@EO;IX6D!I;XJ_#;7O1M;"0#'O\ 6&'LN,8Y@;-U@XQGK%0.L X]KLZF'7N-
M@W5MMMD==6CZ>[&9O\Z]II()&DHOAA;F:ND8^ON!B8WR4^LJ%C1(W4^E%AD(
MB2!9AZZV&NL^A11%&3,Z:/K7.,'D1V$<ZDIU 'D>L=AZQ^.JO%W7TM3]Q4E6
MK;6PQG8.+LONDZN[/S[(ETW7VKBC6.,\-DRM&N:*SA\ZO7XZV]W/["@G*I[@
M9S)("!KXY#&3MJ5MG0\G7L/8>M6&ZG<5AT#@;Z67=6'-3VCM!Y$'8C8U!'A<
M\5^D[.H^UJ_Q"]>S^'O>]+;*KQVB;L4.S&8V579U0R4G9N/+U4->UN0VF@#U
M F=%2QN)!H:F,4BU+.=*C8WSVMC$;J:Z@AM A=YYYHXHH0#@B65V5$P"N2Q7
M<\A4;=I)LIT;=(K:=(4DMMLRC!."0=AG&.=1LX\#94EL*_<D:MIVOK*#=!2Z
MA=91E36&N#BJ-7G0#3;6E'< 3.!I<K74L$-+IJZ!,5;518Q4@%=^3^'>G_IE
MZ._NMR^COI!>S\6]'O2GCA@X/'T<4MNEAQ*?1P;B'!KJ%,&VM]45O?1)))"F
MBY:4"XBUUZZ7A]E<<)$\$8BGMH,S<U8R1KF9)D)R'.[HV =UT^R15DZ@+Q+Y
MJO9G17=>Z6&M:@U7H- 1=3$SU\'X OS&>$X*P+,]EK&)&6(09"QK$L]3I[#X
MFY+_ %6.D&WLG'62<GX@#[Z\J,CGOW\B?#<?'<? 5J])-N.PNX^K[/655'4_
M1X#V.:KZDN6=UD2K?N*OQ;&K>I\%$\&ZDIB*>*+07[+4<<L^$X>00D&# RSC
M(P4SG&X);&,>&>?[:P#DD8W'[>6#\.?QJWW+*E3BE.*4XI4(=_;<S&X98ZDD
M@.XTARTHAH:>9H <0!UQ=E@K]:PVDM/5F5.<(<R6*/66N>CEBD;-[;X.VE=N
M9P!\3L/K_=46) ..?(?$[#[N9[JSG3_7C>N,BE9/\+\ZNCY-)IO@47X!M\<$
M &3""][6D$CB#5P87S(Y9+.XE'EN+.1]@>2O,JND 9R>LGK/760, #)..L\S
M7OLNV.O:JZ9GB=*-+:_,1J@J"M$LKF"IM#)H8!0-#84X1U=FRB)21VQ0WY5:
M]Z3PO:BLD8Y1900"0">0SO3(SC(SU#M^';4B<E6:Y1^,C[8?V5I/YMARY/='
MC\S5+^\?#Y"N@G17V/=<_JK6?RN5O[Q\/D*L3W1X_,U+'(U*G%*<4J%-_JNZ
MPM*/0=:=5TE[4+50V!V[UFV"I*6 Z4DF%:$+/@#6&B/,B@@C+(/F975\+"8(
MH7F2NE2":A#[[E>Y4U'XG+(/N)^6=::2Z4@6]O%+L"6FN3;KS/LKH@N7+ ;G
M**NXP2<@:5D>K^S=-VK5=M=VEXM)\136=3UOD,4EN17TQ6A:QEYI+<^X5LI%
MW* WY,R$5KZV05D)R0BFCQ<D64(4CU'4079@%)QR4*"V #N?:.2 =L 53%!<
M23K<W@A1HD=(+>!WFCC,FGI)GFDB@+RLJB-,0H(D:0 OTA(M!RJM^JZ]Z48U
M6N?[' ';#9 6U7E]#) V..2WSFB-;5U\1JI&KBI:32&UAM;-,_U5P1>@@%5B
M6Q*2;=E(R3!1R<$$=X!*G';G;X$\^5</C\"O8/<X'2VN)%;D=!95D0GK!!U8
M_648Q41V25.];/E_H\F[3F ;$0?3PU>?-#J/>8CX'G6NJ/I\]7&S1*DPP#[>
M*X)&<A(H4HR/E;U'N5M_>?VN8502WD0H Y<^T &O'IP:+T@@,=SP^UOK56'^
MF0Q20A\'=>E#'4.LQC*DC.,U](*\KKNJ<-%TYH,#0-625TM/29BTK$>QGKEG
M.AZZN-.4#''$U7S65P&$$UC%1QGJ1&\K6]BD."Q7.WM C.>_<#?X? ULIZ-R
M<)MC'P_AMK#",L8K".*/)_6,<:QEV[\.W?67Z<W5=!V4X5+,8BG[(HAAJ6<>
M:.<"31Y9;6RBB&(@<^&0B\SUA9S+*YWH=%E((62>Z^..37OXMHYEP5QI)&_,
MDJ>\9)&?"M_T7X@#-=</ERDF>GC1\ALJ DJX."& 5#IP#@-V'%R^<RO:4XI7
MQG)'%:UY,\(['RPP,?/*R)KYR)&PP0M=(YJ.EFE>R*&-%5\DCFL8CG.1%4K[
M<4JO/B([4R^$S$64.[8KNH-MV&.?68#56E5-95X%J'+7,E,LI7 &5555LFL0
M*\RTN)0APTLV3P3H3'&K=*^N8H(NC>\CL9KD/#:S2!&"SE3H8+)]FY4D'0Y"
MM[N=Z[O >&W5Y<27R<&GXYP[@HBXCQJTADEA!X;%(#<"6> ]/;QR('1IX@S0
MC,N,(:YZ9ON"^ZW\6_7EKW57H'I--FJOIVT[1H]'';=6]KC6?RQ];K,_,S.9
M\'/6]1H/D(FASZ'F5I IMGH*ZLHR*BY&7CQS20\2MYKL,)GMXK%YHY=5E>)+
M*#%=01Y]B2.Y*0RQ:2\8NR=3PQK*^]?<3AFX++PKAZ01<.;CMWQ>VM)X%EXK
MP\&#U>.W?BJHGK5M+;:-:E(R;FT#]&FH:NP5HMG\KL5I&@/N?@"UJ&VCR&5C
M[/X>10&V,@C)"F .*]I"WC1O(:.LBPL=(C47TPQD9SC.^.>.O'?7E*_R;=G7
M/B$%[R[!%"@T/W%K8=L,A?TM:=RW'0 P]G%E'^+=:;3V-:W0Q8^#;.L5[:FK
M8V+D[SXX;//%)!K95^J<)A]#&]%KM^(OCT@ DZ 3F5+\LJ$<(%G"C]&Z/%ZN
M20K(6+"9B@C:O/W+<5'$85MP/4B5Z3&DQ8)'K'2L1J# ZP.1 P5&=0K_ % =
M&IH6]4XQFC@Z^'ECJ61T475MG?7.'3%1R2,PBTUIIA0K@[U8Y*1QI)([(YCU
M)D%\Q70KSY=+CI&QK.<%ND 5^D*CI<@$@ 2:PO7IP6 .0.\O+JQ^C@Y&G]'R
MY]783SJIG^D:ZW[4[/Z<@R/65C?GG:RR QPF%I^N<WK K+36UU36=/L-)M+I
MT)W5=!DJNBT(IFSK)XWU[]!!/$PBT@JQ9^IP*YL[/B5G<W]NMS:VUU!<7$99
M<R6\3_:0K#(RQSLY9&Z)SAA&5.$9R*;E)9(94BD,<CQNB-@X5V'LN64%ET[^
MT.6<[D &B7^BOZL[:S>I6^*%/Z_R^IH8[<2SI,=A=_D-U2]<[+:8C98FP[3K
M;*VFQ-V[6V-?= 4E83&Z_ JC+89Q""V#1O4>G?%^#<7O89^$VAA6&V2&=Y(U
MLY9)9/M87%LI#2+#"&CZ9UVZ14/LK"6Y_![6[M862ZE$A:1F0!FD"* %92Y&
M 6?VM*G!P3S+8[RW5+4Z*IM*&]K@[:FNZP^EMZP^!A(5E4VHT@5E7&02(YDP
M9PDL@Y4#T5DT3W,>BHO/ *S*P92592&5@<%6!R""-P0=P1R-=@C.QW!V(/77
MD'&S>)SD4 T-5F<KE*.$:)C$'K:>BSM  D4$2+_A#@U=36C(QB*K(!!8?J]$
M;%\L$DDLQR3DLQ.22=R23]Y)H 20 ,DX  &22=@ !Y"M0J>R<'LS(LZU+)9+
M6.9U>)J<=I:$#01C12%3-J9M-2UX%Q)$+!*>HHDDY/P,,E@V!0XI)V5B1'.D
M'//8@C4!S*Y ##O&1X8K9EL[F!!))$57(!8,C:2>0<(S&-CC8.%)QL*RN^ V
MQ>9D&ZYLZRFT,9(+H);%(H19 (9F_%A1%RTFD'K998?+VRI,Y<L]#'BL&&D)
MCL@9G.#C8]6=ZUCGJV/>,^61\ZAS'=U7--I9>O\ N0,>@NVRP15FB;$@E8>A
M4K1JY;)8I2:Z(:XF5(Z33@%1TUA8J_.W-;C-6@.=LHACG2X ;?!'NM\,[\L<
M^NHANIMCOCL/PZ\]H/Q&1O5DRS! !IC3BAPPQXUEG++GB'&@B3\<DT\SF11Q
MI^5[W-:GY5Y.I533 :#+N\2.B/R]M7/RNE@TM; =4E12YZYTT]/U=>PAA%#?
M\WE&RE";VV@B'EF7YC+K3F.^*N+!9J@1TK $'**=CG<$@[=PQ401K/:0/(D'
M]F?"KI\MJ51?VUCR]9FH2*A7?=)D3Y=7F(?9C(A/MQ::XJGU)$$IE?&Z.XJ[
MBRJXIWFCH 68/9>MZ"+#+Y#TZ]$+/TY]&;_T=O)YK5+HPS074(#O;W5K*L]O
M*8F9$GC$B!987=!)&S!9(GT2IN6%TUG=1SJ%.DE6#YTZ'&ELE0S# .<JK';W
M6Y'E!>=^Q-)L=!282MZU\1[ 0>OZ["=CTH\.S&V.SO:.BQVNKVW>>2H/I\>2
M?8W NL0N9L391Z6QI4!TLD]?\6_<N]"O2;T!N.,KQ#B_#KBUGBM[?A?!A!=K
M-;<6N[R*T@XLT=[!'#:1"*4QW7Y.GNXKH,B/.Q@BU_5_WK+?\0X?+=K%>^CL
M2<0XGQ#CG!KV&ZM;OA?!.&W'&>(\/AEB87%MQ2>SLY8[:TXE;6=[#(PF>V$0
M=AV3!=-0YL-^FO(3B*:C'=H-(7")5#F35P#%MKPF"%(@:V$A\)!\T,21B!L>
MYD:,AC3R_2X!  )U$  L0!D]9P-AGG@;#JKX\Y5G=D3HU9F*QABP1220@9O:
M;2,+J;<XR=ZA_JQ'MU5K965?)5G;3'UVLJQB8GPDLJ[#>]B7TU<3%(JK#<T@
M6MS,6E@C5T,%B>/''--$D+^8 W)QSWZ_@/+\#85&I\Y*E.*4XI7\541%551$
M1%555?)$1/K555?J1$3\:\4JG7S%>^.YJ*6JBE(ZYZ[]H^6P=$K!+B>&S$O0
MCA3&*]DS;K39['F9X=4\R,GGM+;%)'5;'+$'UYUOM[J=?:QZO =AY[&H>\W<
MO7_&Y;? 9SV$CLK-=[=M&1-L>O<(8GW0/')%N319+=IJF25LIHV-ST^?KK:Z
MAO[ ?V2M!<4U<=88C-SI;0P16QU24'B1R/94$L=]AG ^6>P>)K#L1[*[D\]L
MZ0>O'(]V_/[JP'0E=TM=-I1488=N*%%)#J]5+"/7,,IYF+-<XK*5EK88@=*@
MJ6)$DJV$ZW-/>+%JB1[R668E&(^H>T.98>T/OY>&U94+U#<<R?>\<[[_ '=E
M7+Y;4ZY1^,C[8?V5I/YMARY/='C\S5+^\?#Y"N@G17V/=<_JK6?RN5O[Q\/D
M*L3W1X_,U+'(U*G%*<4IQ2G%*PMUI,[FXH9]%?TM! 3+[ \UU:@U44\WI5_L
MPR'3P,EE]+7.]MBN?Z45?+R15XQGE6"0-R0!RW./G54_$'V34ZX?$]2]<:7/
MWNLWFWH89YZJP$OA<W6T-B%<RVES!5&/E:@YD(%@E7+*'-;TU;H%%*'^!F)@
MV( R$SZ?9B&K<;,Q]E%[\DY..H'E7&XM)%<)'PI9!T_$9!%A"&>."/[:XE8;
MZ0(D**6&#)(@WSBK-8C&T^"S=?F:5LCAPVR2EG%>TZPN;4MZD6EW:RPQ0Q36
M=J:^4PQ\4,([))?8$'&#B'&BI9F=BS'+,<DUU8((K:&."% D42A$4=0 Q\23
MS).[$DG))-;9R-6U5#O3H2>\&.W'5?\ S#V$&5!H9:\!8!0M7;54L)X%A'#/
M)%6@[40P,2>NNB$8%=^PRCUOQ-;*)84FS#/H!BDRT#[.O,KG]-.Q@=^_X[UP
MN*\'%V\=_9%+?BUJ1);SXPDNG.;>Y W>*124+#VT#;'3E3*?2_:@';&!"U"M
MCKKD&8JDV=,^(L*7/:FG5(;@ D*SC'LJ^/U>@\0>RAA-BKRQ4-CB)2:-E,B%
M&*YR.:L.3*=U89ZB-^[D=P:Z=G<B[MTFT&)]TFA8Y>"=#IEA?8>U&X(SC###
MKE6!,JC%#&P1%!D0%C3L22$@:6.>"9B_B?%-$YT<C%_(YCE1?R+R%;5<OO%1
MVQ+V0'>9X;)W-9C^OKWL<&#9&6 <8=YO,;1&4APU;6#N4^"2B9:VQ(EC+)[:
MN1D\*0FP*P;HV,::I&<J3ZN[:?:RH;8DG 'NYY$[$=><>&]+K^Z$%G%:Q3QJ
M.,V<9N-482:2)FD$2H)#*5$JJ<LBJ7CV)&DMT\KG$/KP7EHK2WABN*:J>2M(
M= Q9D5$\D14D5R*GY/Q<YU>YJ%^_,5V)M\U0 =:+UG'=AZD,ZP)[/SC=+6CT
M25UG 6^G$?7V38K=39JU7JL([B:EMF#!95A1,!L.I>)=21*+-[9)1*A9KJ%Y
MX^BW#A422)M9!]DZP,9!QG(ZW!YN$0W$YXU#Q*>U>RN8XX^%W<%G.;M@OJYF
MEN+>Y1K4,"9HQ&78Z"I(4JU)"_\ 19]=V=<=$5V!?U1;IDL:2OR@153CZ*WB
M'EA$GASUEH+XJ0(=9I'*&)<UCI?4G^.QS4=SB3^C%M<0M$UQ);ZBSE;***"!
MI22RR21.L[R:"?95IO97*H4SFJ)N(33R]-*(W<JB$B..,E44)R@2)-;*H,DF
MC7(^7D+NS$R'X6^KO&#U!VB?A>P];1;'P[5.*-EH[XJP;8WY&LFM:J*AIZ 6
M9S+NEJZZICOB+P:S22F$6:AKLU\4SXV:NV."V/%K SPW]^M[;*$%HQ#&7&^H
MNSYD7 "J$>6<;@JZ@%3KS/$^DHA1_P!,;!>[&,#/6< ?"KO6."QMOJLQN+/.
M59NMQE?JJK+7TXZ..HZ[;K3KK1 7^:,CCT"Y^F^9>;'.G^7PIZD3U^OT =PK
M(&8(Y5F4$Z69-00L.1*ZVTD\M1QSJC SG&XR >O!QD9[\#/P'947]D>)7J'J
MLLREO-#";H:?3=192[RM%+7$:"@F[MUD.,P%K:5QI];\/0FV;B)R38I)GCUM
M;8E1C3J*L3K$@D< A2%99F5V!"MT$9DD53@@L%&,?K,H. <U$L!U[^SL.?M'
M ..S/74IX[<X_L&K*N\1HZK45 -Y?9HJRIBF&!Q7V8M2J._K%GC\XW$U5L$4
M"4C%<QL\+T:]S?)RULC(0&4J2JN 1C*NH96'<RD$'K!J0(/+O'B#@_<1BL^X
M-L0,P==[5:KH2&C/''B2,6>?W'_$-'1&Q/<V>12'M<B)+(KE?YJ]RK&E47KK
MW8]=SBL+N=D+N03H([C*:J\T^JJ.Q$9/' ;!DOGA%E"3\]C<A=#98M!C:8\F
MM$T-<R(:US$GY2X;QC]V?T.]/X>%\:AXWZ6\"XIQ=;<W"6#77#CP^\N%1.(6
ME[;0$<+EL8G$D]G<R10)'%*CQA&CNAZF2'@UW8-+"T-K/'"6"F31)TBKDQM&
M[?:ASL'4%B3D$X*U<K;T)6FREU2 SCCGF"M?7RF)(X!3PYX3@8K)D/\ C2U9
M!0T,%G%#_BS 2D11_AO3GZK==:,H."RD9YXR,;CK':.L;5YRWEZ&>&;&KHI8
MY-(."=#!L!L'23C9L'!P<;5&4(&[V%UDH;W%IC*S*70]_:VA%]36LMH;7"EQ
M! Y)*8@HKY>69,Q;*RT N?+DI$(KF4[I[.62N@ [%-2JH0EMFU G2R^R-(P,
M'.^_5N,UO2W%LL,ZPO+*UR%!#IH$2B1)3J.MM;ZDTC3E0"S:LX%3ORVN76D[
MGKW,=AUC*W1A.D<,I#ZVS%<V"TJ9RAWBSR@DNCEC6,@=[H#JXV RHM1E<%;U
MYX3Y!GX*AAAAD5@@$8(S^/QO59[+I#JO*U;K[=]PFQ8/(6, L3;_ $M17Y_/
M&I/"+%6I-9S$T&2.DG('$'9A*O#68\LT =8\6*1@KL1VSS.L48FF=CA(D#.S
M$;X"H"6Y9P!L >K-1(55R[D*-R6;"CJW)QM\2=ZDZRZ!ZIUN=@6C4X*&R$$/
M U%%I;"WDM(95A/K[,DFV-NJ[3(Y$@*K;2SBL# O5&?16%<:P8Z+#1*/9*Z"
MIQL-+*1YY!'(UG2O4 .PJ ",CF,5JX6D[AZC-"H]M&)V3ES91P*+5CS?)K9U
M@04Z(6B-+LRB@X[,N-T -!!K;$4>U.]H<SLFPO[4*H=@LR>][2_K#8CXC]H^
MZF2HWW'61U#M(^',C[@*F$?M"A>UK3:?=U1B,8X@ GKW9FN&D?Y_X'S.BI+>
M@.D9Y*CY*BXL1O/R])#D5%Y(,K<CG\9\*R"#R/X_97*W_2:!S=E9BFV&.S^S
M?/TS5MN-#8V&5L<J$-3=A7/R2MG+74"TFFDDK+W)P&A3T%99C0,F*F.4<9SS
M!?.^DUJ)K);D>P]I(-4P!+0V\Y$<LVW5:2=!Q ]ALU/+.?J7[E/&&LN/3<*<
M&:'C-O\ 961]R^XGP\/<V?#R,@:N-6YXAZ-[Y^SXY* "<5>7P[:RS\2?4'7W
M9>QM!9:RP!@^.Q=.-*$)-JLT<ZKN)M:9+(I-PQM_4SV-?1"CU-%&.3''9C:1
MK BX>OPZ[]>LK>Y(T/(F)H_X.>,F.>(]\4R.A^%>+])N#_D'CO$N%*YF@MKC
M597!&/6^'7*+=<-O!R]F[L)K>Y7NE%6"UV?/M$J[F@(@#U.;*D+IY2WRLKSQ
MBFLAN,]<.@CEF2INQ&,8^:.$A];:BU%Y&(;-41"3[M<*OUFMG7:"6:LG@)H=
M2!"R6VREPD<%P"QRHQ#!D8]XUU22S>N$30TLQU,5-%.*PQIXAH8JE;AQ2HQU
M7;^%R<Q@!%G)=7@**A.?S(TEY:B3+"L\$-NHGG79GXN-%44O5V%%72^3E^-1
MK7.;%G5>; 'LZ_N&]19E7F0/G]W.JB]J=[6VVS9(=+-G1:2P>RO+RM7N<@3H
M[04R5\,LNJM9-)2UP-$&.JK;Y/*6EA8Z,A(J=NLAIB[2*6AI6;V45@#S;22>
M>^ .76-R.8Y#>JV<G90PSGVM+9V_5V//J/5W&MBRESV49F@,%U-A+C+"S3OF
MO]O?0D VATMA&V4_0$7%IGPLP&4=/]2RXZ+LB4$7X2IIJ*DK1P[:HL!; 5$T
MCM;J':!UGX[5,9P JZ1CFW5X DDCOQOV]=BNJ>HJ3K&N<]CF6VH/@;'=:*2&
M6-\R.(F.E!K8RB3B@ZMU@46?*TH^PM;:R**NM':W5X6593350N<<R<L>LGM/
MTY"I 8[R>9ZR?QR'(#85Y>QNC\EV%,ZU5Q6<TZO%F704GIAG,GKVN2LEM8$]
MOXHFL>YKJRZ#GK-73-:Z*AT=3'.0DQD#8SD$<B-C]]8*@[[@]1!P1^.^MDZZ
MQ^@QU;8":+:';,HVP0N$DN*TBAKAVAC"H&(V[T&IM?3)) \J=9[N:!T\SG#B
MB^<JS9 (&"2W><?LK(VZR>\X_8 *YR^,C[8?V5I/YMAR]/='C\S53^\?#Y"N
M@G17V/=<_JK6?RN5O[Q\/D*L3W1X_,U+'(U*G%*<4IQ2J4V?BS.ZVM-OG>XL
M'85]UG'$SYV7'PE68NL$).(%S#(A"%D*"CTC61,K+ULYE*\]MA2VTE!HP4HB
M-D6S/&)8V#*,"3)"F(XW+#/N<RK#F.K-<%^.Q6MY)87\$EO.S$V#(K31\1C)
M 18&51IN 2%D@?&DC6',9#5F.O?#\!IQ[#M+Q)TE-L.RM7$\LJJT#(;'-];9
MICI"*S'40!!!=4(VI@>Z>SL8EEE?8S&.^.+>I=I9P,I7V8F**-LK[+.1^DQ&
MYSU*=E&!C.2=I.'QW"]-Q*&&YG?VNCF59H;52-H(%<%1H&TDH4-,^ISA-")%
MVDK?#\%VQX<7>'N+KYV[9V*6ED_JR3/'>GK::@L(]L_2E43B(F"*V.L8 EG.
MR9[&6252/DA)]N2ERDO2%RN@#VR3[992H&3S.#RZ@>K<4R0V<-QP\6,5M'+Z
MR[D6T<2_8"&5+AWZ,#V 9%74>4KH!N:Z'\UZ[5.*4XI58]]X5L/NM1<:%FBV
MN0"V; X.S<MC[F.ISO9 X$KIAVZ,7X2:5L\JN>,>6!,+.6$2?&CH3+ L^2U9
M64 84Z<Z"PR4SST[X[QJ! .X K2FL(IG=^DFB$NGUB.)PL=R%  Z8%6;.D!&
M:)HW>,".1FC 45I[AZNN?#]M,GH^M^RMGU)T5J[<FEV(>;5MY2X76:):\2IO
M%S]U,77K171@S!7D,&C.I+,N9D)YHYM!GA+$?I 0R*\@]I2VK4XZURK*68<U
M!SD97GIQSKBV]0E6:&ZGL[!U$4T</1&WM'!.B=8YHI8X89,Z)R@14?HY6PAF
M:M]ZXF\/EX3CNCJW-[_LMBZ#0=CNW6J"E@0S3L:;8WNKU+R3L_HIP[L@UU*9
M*1EGYJ\FM@*NR^8,M5D(E)'<1+TKCHM8Z,+D*Q7&"H0;Z0!OJP>6>8S&RON"
MW\OY/MG_ "BUI(+N29HVFBCN!(9%E:Y9!$9C(Q:/HC@;A JK@7UYJ5Z"J*4O
M^D3\-UEN-WA;6UT^3*PG86LZU)N]#FRHZ&ZOL1:&T6BGI9ZV2R/?5!WE9:5T
M=B?7 CDH#(? ]]<]A2\.?TCX1:WDMC<W0@FAT:V=',(UA6 ,R*R(5U -TICP
M3U[5>MO,R!U34#OMS^[8G.,C&:_E]X[.N-,0[(^'4NB[C[&L9W@4(7W39W+Y
MPHZ&9D9K!SM1=Y\O2% QH1(RIS<1+SB8&@R656TAIL>Q+Q,%,6$)O)G#= "R
MVT$K*NK*3SE!,F.;6HGQUZ0"1T.$\.AN[N+\HS7%CPF.6'\I\1M[.6_:PMI'
MT=*\$.,,S82-9'CU.0!J/LFW77E[<Z7#Y:]T8U(%HK&E"GT &<MX+ZEK[SVD
MCMZ\"V%DF',B L&$".?"03&R6&2%I121_$2=&,NT<;2*J2%%,B(VM%<J-:J^
M%UJK9 ;2NH#.D9Q7/ND@CNKA+626:U2>9;:::(032VXD802RP!Y1#))%H=XQ
M)($8E0[ :CN7)U17^>+_ $DGAL[OUW<.?VX)^IWV.I--G<34F]MNZ_K<S77'
MB-[)KZ+.X[JAF)RD&CL<KBR9ZX'>G=A)-;5U/'3%5ECJ)4N/9^C>@OI/PST>
M;B!OK$S->6RB-[50\\8LXIGE247$J($N@VHF*3&N/#1A= '$XOP^>^6%8IM
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M#_QV[CNY_:5/F*M-EUCUKU XH7.=>XRGTU'FII;/9&YS']B::PC AHMPW1B
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M+Q#8V,BLJJP&.IK6%C(;2N,BC8QMD<CQ-K1M)Y'K!'6&!V(/8?G6G?6%KQ&
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M830Z7'Z<$A<P2^RRCI$1TU%-1:,YRC@,NXJF>!+A"K94D8#K@2)D@G2Q!QG
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MHO,;;$D9][/E@<Q5+'.^=OV=OC]_E6A7O7T$(:N6%$_!^I?)/\O]WE_3Z_\
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M1SO@+"S*<U& JK2V*/0': E]?//%+51:G2TV>E)?42#'K;[,K 8TPQ+N=LZ
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MC(&3I4&V<.@W*'J/6=!ZB3D'(Z@3JPSO'-ZI<-J?!:"8@*)XQU$C"].G)U4
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M M_W-/2^Z@AN8>'PM#<11SQ,;^R4M'*@="5,X(RK X(R.NO+]\?U,OXKXO\
M@MK_ &O(_EWAG\.?ZJ3^S5W^2WTT_P!G0?\ ,+'_ +]?W[X[J;_KTS^"VW]K
MQ^7>&?PY_JI/[-/\EOII_LZ#_F%C_P!^GWQW4W_7IG\%MO[7C\N\,_AS_52?
MV:?Y+?33_9T'_,+'_OT^^/ZF_P"O3/X+:_VO'Y=X9_#G^JD_LT_R6^FG^SH/
M^86/_?I]\?U-_P!>F?P6U_M>/R[PS^'/]5)_9I_DM]-/]G0?\PL?^_3[X[J;
M_KTS^"VW]IQ^7>&?PY_JI?[%/\EOII_LZ#_F%C_WZE^DN:_15%?>54KIZZT&
MC+#F?%)"Z2"5/-CG12M9)&J^7UM>UKD_*G.G%*D\231G5'(H9#@C*GD<$ CQ
M&:\1?V-SPR]N>'WB".ZM)6AG0.L@61/> ="R,.PJ2#VURX\9'VP_LK2?S;#F
MTGNCQ^9KFO[Q\/D*Z"=%?8]US^JM9_*Y6_O'P^0JQ/='C\S4L<C4J<4IQ2M#
M[(ZYS?:66-RFF'5PQ'G*$? P9Q]/8)#+!%8USBX"1TF;#/.,0.2.0#8UY)E7
M9BEUII8LTE8H0PYCQ!!V((ZP1L1V55-#'<1M%(,JV#L2K*RD%71ANKHP#*P(
M*L 14)C=,]X2,AI[7Q&6T^8'9(-\,%E1*^YG!]#HPXH]&'9#:H4T!GMI\SLM
M-HYK-\3I;2(F2=ZMLZ2,;B$9[&=BG@HP>_!<UK"WN\!&OW*#;4D$2S,/XTAU
MIG'-DB0D[C%?0GPIX0.BLH\\181[$\2: S77TL-F1I&2+'+-7:T(4:O -K[*
M6 ?YB;5B56A1\,1P5R/81,(7*W$BG]$J=F30@5EZU.%^OC49.&V\@S]J)E]I
M)S-*\B..3@LY&QZL8[ -L9'K'M.PKRG=?=FODK=#6&#4P5O9$LF4HHEGG74]
MY8L@&&?:&L1$S6@6(8'=B+"\=@NI9;T(N9(AIZ6++1'GUF,_JOCOV#<C\:G;
MW#:O5KG"W"#9N23KU/'WD;LG,'.V 0,UW^+4ZC+ ];DN818[*[I7H!',K"F9
MZANJZVU%I(D?JE'!BK('U'QCFH.ZUNJJM?(V6QA:[-I&9)U&,J,E^P+@C<]^
M<=^:<0D6.UD)/M'2(QUZ\@J1WK@MGNK<.M]I'HJB"IMR8X-Q0BPA:JHGEB:<
MI8S4&6_%A:D;BL_?NC^8U%G#"V"2$A0B&B6P5C7!5S1-"Y1@>9TGJ9>HC]O8
M=CO5]O.EQ$LB$;@:AUJW6I'5@\NT;C:JN[?.S]O]PP1T5V>+1RG&9LR6G2!P
M5G0Y9N3M[S5+9^XJM7/:N"3*4[!6NECV[:*\5T]?GBA2]A?LK99&'M&1S$#R
MW51K_FX; ZR5-<Z4&YOW@0_9"&(7)!/M*LCOT61^OK"MUZ0X[15W*NKKJ2MK
MZ:H"&K:JJ#&KJVO#B; ($"'"P<44:%B(R*&"&-D4;&HB-8U$3FE77 QL-@-@
M!U5[^*4XI3BE.*4XI3BE.*50>]ZH[6BW.VO*;*?&"W=WH)0R'7E<-$17V1QS
MVM)#6SB:4(3$1%-(&;#Y^Y# J^VK9&/\9-PWB0O+R:*VU+--.4;ID4%'=\:E
MZ0!E8$$HXY@<MP?T9P_TQ]#I/1[T?X??<9$$W#^'\,CGB_)]U*\5U:6]NI:*
M;U1S#-$\3HD\$F"LDGO91E_!G77=$DDL8^+BD#D@;'/&1:5$7QL\U+8UMD45
M#!?.;ZSS;BRM7(DKUC(EC:QS8V>CA[+BQ) M04*X(:2)=9:&6.5F"S$9D>:2
M4[G#$;X%2@])O0-41I>/.LZ2:HVBM+U_5XH[ZUNK2")Y.'!M-O!8VMH"4&J)
M&)&IM5>PW!]QEU[(F8-D!T<QJ,=%=TK T%*KT!19(66K$(*B;).L+WQL; YH
M\\:^ZQR+-[/BKQ@"R57#/RFB":6C";@2C4PRQ&<!3I(&15$'I#Z#PW+.WI&T
MMNT<)8/87YG,\5T;G".UD>BA9ECUJK,9098V 1AC G]5]SV$!P\N*:QALDDR
MNBT%6R9LLA5V3Y23);(XB#SOBXW#RIZ'MB&]:N1DJ34OP[BKJZFS&');:= 0
M2\S;D2Y9?MW&D\\+GD=72M_2[T$MI+:5./$M;HL>'X;=M&R+#P^$%$-D1%)_
M].@82H=2EY=.,H8_4;UCW(\-00,;)!'+1TU3/--?5#I4=75U,+.X1C+CVA82
M):M[9&,14+@G526>ML;8Y/8<5*:$M" 888F)GCSF-(E;0!+A0QC.0,:@WM#(
M&*+?TK]!EG]9N>.I(Z<0OKV*-.&W@C(NKF^FC$Q-CKFDB6\4HS'[&2/[(Z2Q
M;[E]?=VE1SQ,PPHT9+BWD,CNZQR2O-77.G]7JN4:K/<V)[XHU:K8_A0D_"5D
MSILM9\78$"S50VO5B:/VM9NBW_W<<[MR!R&E.>#JA!Z2>@$+QR-Z0S2O%T C
M+6%V-"V_Y%$6G%CD-HX);J[9]KIIR H*!/M'U[W23))#88V.($ET_O*):5$I
M [9W:R9_P39- .D+WRZTICY&S,<D0HWJ29&S1$9%GQ8Y5[0!&SDK)&S+GUHG
M0#,,$FZ89U>ZBYU;AJV])/0.)5DM>.L]Q$(M GM+U(I#&.#(.G*\,DUJJ<&A
M*HT;#5++C0>C>*8>DL3KLYKNP[W1T3Z432$,*KHY#J\Q_E)8V!3H7_ ED^E\
M,9$2.<]4:YRKZ'.\EYU.$VES!<WTT\)B6X8-&"Z.=WD8@Z&;& P^IKQ'I]Q_
M@O%.#>C/#^%\06_FX5"T-TRV]S OLVMK"''K$,61(T3D!<D#F!5E>=ZOE=.*
M4XI3BE.*56CN!R/[)P[?RBX?=K_M1+"_Z_\ +S\_QH[Y8OEZ?]56KZO]9O-2
MZ]U/B?V?C?YU5)G*]F3\C]:R_0:^?TMI_EV@,G^[_P $W5:__P \LM_S8^/T
M^_\  ZJE'[OBWS-48MC:86_[!BM*5]J2:?=CTY++"8-*BP^;D.0YT,2*PUJ,
M\VK!+^ J(K?J]?K9\]F>%;CB EA,K/),L+!RG12=*WMD#WQC]$[=6-\C]G6-
MOQ";A?HP]E?K9PP6O#Y;^$VT<YO;;U&,>KJ[D& EL'I$]K?/Z.EOLY,S8"-,
M()B]5=EZUJCQ,+&);;5_M#J%*CHX!B(;9\SD=.)*25 V!"%;%&V=>9Q;2('9
ME)CMD]D!U;I8R%T'8*RRZL%E+.N-6PSF /%[6<P10N!=<7NCTCM#+$;*Y#R>
ML)I:26*2S$8(CG2&&0R=$"[F.ONZ3KMLLDB0*Z%Q$+T@;/?L1(_*I5HXAKXG
M/>*BI;MMRBP&F?X@JU B^A461_)^2<;:E(7,_+[/V5<KG2#THE=H]?N]$FQS
M6!Z4%%7I-+]$Z]*8^'-[?^>9DFMUD $V#8FRAAN6@VE%[.,YKY3R]?0M>Z")
MQ3F?,W11.^>1.E)]J]4".=%*8U*CU+0,@6*:*U=,TQYSHX%1O,,;  E1JP9<
M#$PR<3=&#EQ]E^8"X(EU:RY"[5.-?29V59'Z$'U0.X]0<)%KX>+EDQ$3Z[@<
M2:0,CV80P"W#2 FO6,5URT\TKV98((/>^6#L2XD>Z4<RWFKRFNEG)CDEE@CI
M(3AC$C&=',1- Z":)T4DE;AXD=L:57/1@=,22KRF-P6+;E1"'5\+[3%0",&F
M:+TI:VMX0ZRR2A!=R,;%5"RV]BES%A(XF5(Y'X@]O+"7E#1Q))TD;JZZ!9R0
MS6=E,,YKQYK V4=[6OC:^"0B1\3VLD:Q[&N8K5:Q\;'M3R1S&KYISGR$&20J
M<J78@C(R"QP<$ C([0#VBO36221V=I'*I65+:!)%)5BLBQ(KJ64LK$,""59E
M/,$C>O%R%;-=5NG?LNPWZOA?\'<^D\+_ -76?^X3Y5^.?3C_ ,7>D'_$I_F*
MYV^,C[8?V5I/YMASJI[H\?F:\>_O'P^0KH)T5]CW7/ZJUG\KE;^\?#Y"K$]T
M>/S-;1N\@NYS9><33Z['_%SA3K>X>Z6@T4"!%PE^P-:-')? .7[/PQS&1H^<
M22:!)(_<5R84Z3G ;N;<>1%0GBZ>)HNEEAU8^T@8)*N"#[+%6 SC!]D[$U5Z
MOV6_\.>LKLOVSI3-OU%I9OA\WV=:0D26V5M',DE6GU9CR;$XD%$B?/-8VI!4
MD,$I%U!8P9^NM:C)W:5E!*#3(-S&,X8=J9).1^DN3VCK%<Y99^'R)%=S-<6D
MI"17LH1)8)#LL-V8U2-EDY17(2,:_LY1J9':Y/KC-$]P0I%B+']8QHKXIF^B
M>/SA*'>J2P2IZ7-EA>K9(GIZ55'L7R6BNM54Y.O_ !!]:LCM\5V/-VO#%&WY
MMC]LV2,RV<SVO676V]M=&H/83-26.,(.UR=(&LLATH=R^ :K==JB889.C.,!
MT+$;?K(Q.<]9# Y.=^5:!BO(27BN#=#))@N5C0G.3B*>)$Z,[["2.1=@,IDM
M4K=7]R9[LIIE8@Y&;VE/[S+_ !ELYT=K7O%EC'*G&2> ,@T"*:8='R3 @60+
M3:]MW4TY)XPLD'0I@[%3[K*<@C]A[0<$=8K8AG28$8:.1-I(I!I=#W]3*<'2
MZ%D;]%C4O<A5]0IW5F:R;/&;>802:?)59I-^,9 T@'1X..-Y&JSUL$]DD%DQ
ME:TNUHHR(G.&O!H862Q5UI=0';%M*8I!UHV%=>HJ=MQW9SY<C6G>VXGA;JDC
M!>-AL58;\]O>QCGC.#S48TXJ/KSJZJLM"2/GL?6^@6.RLHQ!@E)0='Q5XCW#
MP_%'/A222&M!C2>1B/="' GJ5O.^D:CV8T5<\PJ@9[S^-LG&,UY#B/$K3AUK
M)>\3O%@MH1[<US(2!G.%4'+.['9(XU9W.RJ343N[F\/?89H=/=/J+15(]%8_
M99*9:QQ$O^&BCEWE8\0)TR+Z&O*<)[GG[?FJN1JVM 2/;16'/!TMC/8#G?X;
M_"O,6?I]Z,7=PL%OQ*2WDD8)%)/;W5K#(2< =-)$B)D[#IC&22 ,Y ,]=<!5
MXG9&P@''9!\#@.O(*Z"*.*(,,">][%:1#6PQM:T=LCP &G,A1L;XQ*I%:B0Q
M>7$XD3TD8Y*(]AU Y(.!R'(<J^E<' $4QYN91D\R5TC3DG<Y.H_#PJ>N<ZNQ
M3BE0)W!VM>Y:SSW7_75.'H^SM@DCZP,]T_RJBK(VD*^]N_8=#_R95#-6"*8Z
MO9*/76Q,,YAH E'<6(@.6<E47F0,DD\E7J+''7L!N:U+FX>,QPP(LES-G0K$
MB.-%QKFF(RPC34HPHU.[*BXR67X8/JOLFNTX6S[#[DT.F/'0YZY6H8M-D&L/
M%(&CK#P!WCU-Z/4(0DH%M%F<Y;$F""F&.\O?$F,Z$:4C"C/O$EG/Q.R_'"BL
M06]PLG2SWDDS:2O1)''#; G&ZH%>4D8]DO.Y )SGJL%RNMRG%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*K!VPJKVEG6JOU-P%TK4_R6315"/7_\
MR1L__2GE^7SU+KDGCX\JKD_1\:V#H1JM3MAR_BD[/'<W_:B=4]6QK_\ NC=_
M_OJY;!^;'CR[MOV5F/W!U9)/WD_LKG[K/_*G3?K#=_\ S(KGS6[_ -*N?_R)
MO_<:OV_P/_4O!_\ A?#_ /\ DAK:ZBRQT-!$)8U\\WQ1(,Y+O0>QK[,&NU$#
M93"XY'1.":39UDD0X$"$-A9/\0R?VU:3M126:P!70MJ9"WYP?:)'<KEW&5*!
MI(R%C75@'4&(]KBWUKQV7B3S6MS&ABAN(X1FV9EM;BZX1(5@@=587!BM+M'E
MN9#&9#'T31!@8OT5=XPRLA&(J"?37!3"U;4)L8XX8R;C3F/:/(KIXY3%833.
M9,5%$R9!2HIW^<7MRY::S>(*T3?9HRQ;R *&EN6PIRV6]J(@L &TN&.VDPAX
M?QV"[DEBO8LW5Q'-=DQ6K/(T5CPF%6E4"-D@U17RM'"[LG30O&OMZT^,1V)1
MS8)ZP-15N9"O=C&N1YG4\M:4/!"R>0DR?W1"VPRSQJQT$Y?DUCG0^],L1)99
M ,:%>F+;"53T1C90-678E&TDCW6;M!8U8UMZ0$-)'>7 F%@(=#2V,J+?)=0R
MR.\:Q01Z)H6D2-@1)'!NP$AC01RJ,1SO1ZO1ZG>A7-]+E9ZE]*N;ZG>3O3Y>
M:>IWE^+U+^/G/.,G'+.V>SJ[?F:]8NK2NK ; U '(U8WP<+D9Z](SV#E3F*S
M3BE=5NG?LNPWZOA?\'<^D\+_ -76?^X3Y5^.?3C_ ,7>D'_$I_F*YV^,C[8?
MV5I/YMASJI[H\?F:\>_O'P^0KH)T5]CW7/ZJUG\KE;^\?#Y"K$]T>/S-2QR-
M2K#WV?I-34&T.CJ@;JFL8DB-KK$>,D6=K7-DC<Z.1%],L,K&3CSQJV<8B.(B
M"2.:-CV@2#D'!'(C8U%D5U*.JNC##*P#*P/,%2"".XBJOQ](]J=6.G=T/V"/
M)G7NC=!UUV.XHZC <U%1ZUUP.,<=&,C&M:VM$&I#; N66QN]2:4LCY;ND1_S
MJ'/ZZ$*W\Y2-+=Y]DGK-<\6=S;8%C< 1 D^K70::,9WTPRAEFB7L4F5%Y*BB
MLH%1>*[4.GDO]OU_UM%&C&B197/NTCB_Q>[\P O)"7C.14]0Y8&L5'M58IZI
MBM25[,*\E=SVLP0#^:NHG^F/A5@3B,C9>:WMU'Z,4;3LW?TDK1@#NZ'/+VCO
M6G:#P_=P7NNH-,=V%3V%K4>IK]8"C,3<OB</)"/%+59[*$S6$59)*^4-7ZX&
MPE%FL:.6TCH+Z_K+.0EB 8=$V&YKTF5R!L?<U @]8.<;$D'%526EV[*_K<0=
M,Z9EM2LH4\T)$Q1U;K#)@'< ,,UG]#H.\>HFBEZ#8XO>TDL+HFL-KP*?6VUG
M'"^2&IS>?CL<['+-.V%6L?\ /]=;%S2+[=-$R-9%PJQ2$*%D1C^J.E']'V6
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M!763[3.]+98V)YC!P07Z/:EBRL8H32V6D4(H0IH\BE-1OW.:&KF2&&P!5Z%
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ML*/>V*-KIIG,9[DTKV0P1(JR3S21PPL?*]C% $G &2>0&YK#,%!9B%4#)).
M!VDU#=UXD^I*6EM+E]^63'6!E%.'2AOJ]9W#1/D]KXZYK:VI!BD<Q(WV5M8
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M9.SHJ.ZC=%<TU5;1/8L3X[.N$/C?&OGYQN85#*US%\U\V*BM7S7S3Z^4UOD
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M2VG3'@:0SX]HL,A2?T0O(D#WBV=S@ $9.@G27FJ7I9(K;4R0K$P5I@I*F=I
M"P1R#T2H5RF)&)UA4V\_PD]2G4U\&4%96M]<A+!!K-'82W5I5EP2-*K#Q17_
M  U2Z>O/CB*]QP"$&,:\0PF8618D":3(.>1!P JJ<'.X4 'Q!QU5/U&WTLI5
MF+*5Z22226501C*22L[)CJTD"MG\-&RM-[TGB-%=/2:R>-954Y/NH0XME!<V
M%(*5*2B-:440& /(:4UD;"3%(F9%$UZ1LC( KD#8;$#.<!@& SW XJVV=I($
M9SEAJ1FQ@,T;%"X'8Y74.S.*G?D*OJGS,W2=O^(CN"LUP,5A5==8K+XX 3XF
M9CQ_NWJGWB70?M2MDJ[X9TN@%AM15B,:)-6202QRB1O2[)2-"IP6<OD$Y&C
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M14U;B%@L,S5YELL5D587("^2V/X=>H4AE;)+6DDPVH4T*K[3;D>ZN-B>UCV
MXVW)Y;"M6Z2>51#"1&D@(FGU>W&FP(B3!S(X)57+*(_?]I@JF1\>9U]0H-U;
MD[W.K88NE"&?D@[RO-T-14BQC#0%VE8PJ6UB;*Z8=TQYT+5))*;++*^8E'/B
M2222<D\S6PBJB*B *B*%51R"J, #X 8K\]GT9FGPE_G =<S#$7T(E/\ =*\:
M,I1(+*Q##*"AB?853VDW8TTM&).+8B'C$V41%;.RPB&7A2 02 P!S@\CW'NK
M$BL\;JKF,LI D4 LF=BRYVU >Z2" <$@XQ68QN2I\)EZ3(T,3HJNB!C#'61(
MO?)D]3IBSS'0Q0Q2'V1DI%@?-'#$V<TF>9(V>OTH8EB6.Y))/Q-(XTBC2*,:
M4C540;G"J, 9.2=AN222=R2:V;F*G7X;'&U[Y&QL:^7T^X]K6H^3T)Z6>MR)
MYO\ 2W\%OJ5?2GU)Y)Q2OWQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*PFDS]=JJ&VSELV5U?<@S@$N'E6 N!)F*D98)+45XE@%+[
M9=>9%Y3!FPP%0JV6)CD$9!!Y'8^-*KO)U?VG7.^%%GQ&J@C;Y1W-C;W./L"$
M3R1B&4P.6U@+9T3_ .T%AV<$!$GJE'J08W-%BU&M<G*M]XSYYWV[A5718P =
MN\;X^(Q\JS^9ZBOB+:MN=W95+1:@P:S!R6:>:8!); 3Q%5I]SH[$6K+M8:\N
M&&P!K1**DAB/@@F.GM(HF0-LC@5#J.[=78.\?CSWK*I@Y)SCN 'QZSYU83E]
M64XI3BE.*4XI3BE.*4XI7*/QD?;#^RM)_-L.7)[H\?F:I?WCX?(5T$Z*^Q[K
MG]5:S^5RM_>/A\A5B>Z/'YFI8Y&I4XI3BE.*4XI5.*?H7M2LI*/!"[L'/8ZD
MU%I?V^CS%K>UF^[&^=]T9CLVS)OSZ^NJ3\Q:66=K=3C]--3ZFVBUL^P,N9TI
MT#" @4K>>M^EM)16>MG['VEGV#6VUS77N9 M+_2VD6<)AN]%=%!01W)A"LKH
M7V% ($)!.@#A\U4/DKH3 G%FNO;\?=6,<L]7TW_!K4>U^G>]MCO;*ZQW;!&.
MQ;,6S/T>;S^GT67(6T0JM/C/M5;3ZBJB*$/ G:E[5@0'G9RPFR\H0KF+?3JS
M\*U@+PZ=V"2%EIW'8P3N)V=Q)75VU[,#I[^XUW8>!V)44\<UR85F*UN6I=OU
MI4N#FT!&0 T\.OSS4O8G"0JQC\?C[_C7P+ZD\2V6QNMFJNS#]=O9K'-6_71\
MVKU9-=EE$O,BY.M;_,618--M<0R"MO/NG[.NSX>QK>DO;*-M4AH5=ZU-_P >
M/]W/:OU1>&;N'-:ND)K>]]O+DZ_LJZUUL/-N[V2ZTU78V/6%F$W0MN:/1UM@
MH@N0UN5/RPWRRCL:S7DW8-A163E!@?@5GR\\]6_XY]U7HXI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI5*/%GTKV]V8;6:?I^Z'J=-D^F
M^\<[4"6%X74TVFO^P%Z] %R=\P5?\*ON\_4:=E?I)(3$QFJ@S6F0"Q97R5IB
ME:]8!>.RJ [#GK[FCT5D3>[8' THU%U]35%'2E9CMV#K6T$O;*\+L[H.MO"^
MF2=M!IZ@"XB/J-.M+!H:0M0Y5*R%O1^-H6>U=3; :RGL;3>'9QA(_5T6<SPD
MN_W#<Y3Z9BY,/1FUD'5;.O'XB6D*.N8NPYM/)V5:6>9^ #@4JR/4-?VE54EZ
M!VM>1Z6R'U!/W-W;H:$>P.RLU/2$0I;PYJHH:9AHE]-H (/A:D5[JD6L>4I)
M;IS"%*E?BE.*4XI3BE.*4XI3BE<H_&1]L/[*TG\VPY<GNCQ^9JE_>/A\A703
MHK['NN?U5K/Y7*W]X^'R%6)[H\?F:ECD:E3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE<H_&1]L/[*TG\VPY<GNCQ^9JE_>/A\A4G]=^+K(
MXS#Y;*F9;1EE4-.)6SDC2UB#SRCL]+I(4E*;(D;E_P!7UM:[R_&B<BR$DG:I
M*X  WK<_OX,1^9NJ_?5']WS&@]WG]*SK'?Y?6GW\&(_,W5?OJC^[XT'N\_I3
M6._R^M/OX,1^9NJ_?5']WQH/=Y_2FL=_E]:??P8C\S=5^^J/[OC0>[S^E-8[
M_+ZT^_@Q'YFZK]]4?W?&@]WG]*:QW^7UI]_!B/S-U7[ZH_N^-![O/Z4UCO\
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*%& !5;'))K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g838337g29t30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g29t30.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ O0)4 P$1  (1 0,1 ?_$ !\
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M2B)1$HB41*(E$2B*G#E-^/$\_KC?\0 5,'U6_']74)_6?\/T96#<4OP(A?\
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MM>&P 121<2A.K,$@MWP<3\AG/D3'MRZFX;LQ;6^<#M/S70W%#4^K=B#QH27
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MI"QD=I[C1.+2<7E*7@)6'9YG@BB@Y]*-@74_>@T!_JE&?U7G^TK*^4;W$/\
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MC,DU7$PXZ]-1P_PRT<D=S.U\I+9.L4+6*V*Q^2>D,H69I2A<N'/([T\8O/\
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M,LSB\IA##&1O'%&(X>)[H?<GP76^"":AWPT;3/!B<@Q2#"Q-$!$4!%PCYFX
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MW&/1\2NEF&J9\-')0.2F[E]IME")+$+%CCVSAXAAKR1Q8>K$"AC)NW;XXNV
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MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%@92
M;RJ,2.+NUUFS62 2X!RY;VPNX;MS ]P.670LICDG=9)-QDHE93'+"^>./G8W
MQ\MJI=282#4VG<_IRU-+7K:@PN5PEBQ P//!!E:,]"6:%I!*-Y8HYR.-C$@Y
MBW(7'=EFXVZ>,R-#(Q ,DF/NU;L<9[\#.K/'. 'Q=BXD4;"7%V?9WV=G4$NS
MLUUW\FOZ(+P^OB_Y!V@_/75W]K#?LE[7\?F?\B8?\UWWZ=G9KKOY-?T07A]/
MD':#\]=7?VL-^R3X_,_Y$P_YKOOT[.S77?R:_H@O#Z?(.T'YZZN_M8;]DGQ^
M9_R)A_S7??IV=FNN_DU_1!>'T^0=H/SUU=_:PW[)/C\S_D3#_FN^_3L[-==_
M)K^B"\/I\@[0?GKJ[^UAOV2?'YG_ ")A_P UWWZ=G9KKOY-?T07A]/D':#\]
M=7?VL-^R3X_,_P"1,/\ FN^_3L[-==_)K^B"\/I\@[0?GKJ[^UAOV2?'YG_(
MF'_-=]^G9V:Z[^37]$%X?3Y!V@_/75W]K#?LD^/S/^1,/^:[[].SLUUW\FOZ
M(+P^GR#M!^>NKO[6&_9)\?F?\B8?\UWWZ=G9KKOY-?T07A]/D':#\]=7?VL-
M^R3X_,_Y$P_YKOOT[.S77?R:_H@O#Z?(.T'YZZN_M8;]DGQ^9_R)A_S7??IV
M=FNN_DU_1!>'T^0=H/SUU=_:PW[)/C\S_D3#_FN^_3L[-==_)K^B"\/I\@[0
M?GKJ[^UAOV2?'YG_ ")A_P UWWZ=G9KKOY-?T07A]/D':#\]=7?VL-^R3X_,
M_P"1,/\ FN^_3L[-==_)K^B"\/I\@[0?GKJ[^UAOV2?'YG_(F'_-=]^G9V:Z
M[^37]$%X?3Y!V@_/75W]K#?LD^/S/^1,/^:[[].SLUUW\FOZ(+P^GR#M!^>N
MKO[6&_9)\?F?\B8?\UWWZ=G9KKOY-?T07A]/D':#\]=7?VL-^R3X_,_Y$P_Y
MKOOT[.S77?R:_H@O#Z?(.T'YZZN_M8;]DGQ^9_R)A_S7??IV=FNN_DU_1!>'
MT^0=H/SUU=_:PW[)/C\S_D3#_FN^_3L[-==_)K^B"\/I\@[0?GKJ[^UAOV2?
M'YG_ ")A_P UWWZ=G9KKOY-?T07A]/D':#\]=7?VL-^R3X_,_P"1,/\ FN^_
M3L[-==_)K^B"\/I\@[0?GKJ[^UAOV2?'YG_(F'_-=]^G9V:Z[^37]$%X?3Y!
MV@_/75W]K#?LD^/S/^1,/^:[[].SLUUW\FOZ(+P^GR#M!^>NKO[6&_9)\?F?
M\B8?\UWWZ=G9KKOY-?T07A]/D':#\]=7?VL-^R3X_,_Y$P_YKOOT[.S77?R:
M_H@O#Z?(.T'YZZN_M8;]DGQ^9_R)A_S7??IV=FNN_DU_1!>'T^0=H/SUU=_:
MPW[)/C\S_D3#_FN^_3L[-==_)K^B"\/I\@[0?GKJ[^UAOV2?'YG_ ")A_P U
MWWZ=G9KKOY-?T07A]/D':#\]=7?VL-^R3X_,_P"1,/\ FN^_3L[-==_)K^B"
M\/I\@[0?GKJ[^UAOV2?'YG_(F'_-=]^G9V:Z[^37]$%X?3Y!V@_/75W]K#?L
MD^/S/^1,/^:[[].SLUUW\FOZ(+P^GR#M!^>NKO[6&_9)\?F?\B8?\UWWZ=G9
MKKOY-?T07A]/D':#\]=7?VL-^R3X_,_Y$P_YKOOT[.S77?R:_H@O#Z?(.T'Y
MZZN_M8;]DGQ^9_R)A_S7??IV=FNN_DU_1!>'T^0=H/SUU=_:PW[)/C\S_D3#
M_FN^_3L[-==_)K^B"\/I\@[0?GKJ[^UAOV2?'YG_ ")A_P UWWZ=G9KKOY-?
MT07A]/D':#\]=7?VL-^R3X_,_P"1,/\ FN^_3L[-==_)K^B"\/I\@[0?GKJ[
M^UAOV2?'YG_(F'_-=]^G9V:Z[^37]$%X?3Y!V@_/75W]K#?LD^/S/^1,/^:[
M[]9R.=/W4P@NT(F#LLD[)MEZ3,*]78,&3W.U[>9@\7&M&[^[>WWWS2;.FN:E
M_-M=;T=LT\[C _P.]S'&92M>RN:U/J&G7+J'B+<U*E3MDVW$+<V/JP77@^ER
MCK6:QF_%GFX<@/#R'=TU1:JRUZE+%XZ:1N+7(0GGFA9_I>(+$LD#2?84D<C#
MV[!OL[3;"@PT<&- H 6P"B&"5D68T8T19,FR=OO\U)NWP33Q\Z][Y9Y6Q\Y3
M.^6>=\L\KY7^P,1A\3@,=5Q&#QM'$8NE&T53'XZM#4J5XV[>,4$ !&/(G<C=
MAY&;D9N1$[OXY<N6\A9EN7K,]RU.7.:Q9E.::0OM*0W(GV;9F;?869F9F9F9
M92K)8R41*(J<.4WX\3S^N-_Q !4P?5;\?U=0G]9_P_1E8-Q2_ B%_P!V3?RP
MY49_6?\ #]&4@?5;\?U=2)KJNR41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB418
MHZ\6'A#!!OYOK#$40>(>?CYV'IFS199+S\?+;SL?/PQ\['RV\MO+;RV_ZUR+
M;D+/]#NS?U=<$^PD[?2S._\ 1E0IQ=ZD7+,KKF'[1VEK QN2%;.B?'09%RK+
M3,@XRMVO('?FS1&O!NL8E*]BGR<<VY!D&IQG(U=GQH:R LD4L$<G[SVDVQ;[
M#;QE,99(8I1A.$[+FW7&T[UJ\92/*81B)0R>*X](GY._\FVW?7*F4N/%'--$
M4\<P51!^@=1FLV9AB:(#E(AFCV)CZP-Q;;Z7W;:6DSZH$?UC(9L-V3HJ?QP%
MKIE.P4MD+"30B19M-Q:RXLM^7,UU@P#,2B3PBT8:U56%C9[BJA'RLN;9#L4F
MPQ5(SEAQXDYAC>*>,RE>-P%Q,?F9;?><<KD[;,[R]KQ]I"';VOXJS9,L,)R#
M+7D 8FD$S8HRVGBI]^G$PL^Y,T/8TG8#GV?1XRT[5?4+WA(-H2G5\CXXN2L\
M/\@Y+KR"Z_#;"@S#.#0F%\;M"[F.O91-7+G(#*7[O+99DD,N+Q:JWP6&@G*3
M=1NY>I238VN,,<PV6:-JPRR2%'(_4D.U8@%@C^L#-TF9]]_H<FW9V91PY.P4
MQPG5=Y"LE''$,D;=...K7G)SD=^)._5=QVV^EA?9V=UF+]5(0Y]*D)X^3I^]
MD\@A(W2S568PEE_BD(FW))UQ;:&':V3M?" .&VQ$6SS(3(;+9*QQ^@^S>MW:
M#\>TZ?!)-VE8C9@&1YWX&_2*.KWVXLS-\YO%NVX[>.VVVW:NWPP/T-6D=S*,
M8&ZD;/*TEMZ;$_\ */YQF?8O^%V=]GW9O6C/59$'(G(CQK0TB@IAO$8G+8.
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M%>8H"E>8:S[1N4$9OV/'$3N(N+"+LV[,S.J_NAUJ=4M*QT'"2N^E,8X60A&
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M^#!B>)F:8>'#K$7/<"[-^#"3?]Y54^J)9\7G,8].,1S>9^&#F:4G*N?4ZG0
M.&T@[]G-R%]O^%3/,];:\\F?*-[M7BJ&ENLN5NJ-$ZUG$ CNZIAKJ1#%^/\
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M6%L$DDDL+8X)I)X8XX)IX8XX888VQQM:UK6KQMW=W=W=W=WW=W[7=W^EW?\
8F[KWUF9F9F9F9FV9F[&9F^AF;^3,O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g838337g33c68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g33c68.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5LZ:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S,S8S8X/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/E1H=2!.
M;W8@,34@,C Q." Q-#HQ,3HU,B!'350M,#<P,"8C>$$[1W)A<&AI8R!T>7!E
M.B!!<G1W;W)K)B-X03LF(WA!.U1H92!D;V-U;65N="!H87,@<&%S<V5D('!R
M969L:6=H="XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z(%M497AT1F]N="!!<FEA;$U472PL6U1E
M>'1&;VYT($1)3BU-961I=6U=+"Q;5&5X=$9O;G0@07)I86Q-5%TL+%M497AT
M1F]N="!$24XM365D:75M72PL6U1E>'1&;VYT($%R:6%L351=)B-X03LF(WA!
M.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @
M(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$871E
M/C(P,3@M,3$M,354,30Z,3$Z-3DM,#<Z,# \+WAM<#I-971A9&%T841A=&4^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$X+3$Q+3$U5#$T.C$Q.C4Y
M+3 W.C P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,3@M,3$M,354,30Z,3$Z-3DM,#<Z,# \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R
M($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM
M<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T
M:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I9VAT/C$S-CPO>&UP
M1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA
M=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14),045S04%$+S=107-5
M1VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04),04%!04%%028C
M>$$[05%%<T%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G
M445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!
M=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%
M2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M+SA!04519T%I045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"
M05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!
M04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"
M04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C
M>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(
M5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I8
M5T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP
M-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53
M355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$
M9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X
M<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD
M;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C
M>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!
M=T1!44%#15%-4D%$.$$Y1U=/;E=(-D5I=6YT1&-3:40Q1"8C>$$[1V@O95--
M1G)X6&MY<GEB=%5J1E5M,#=53#8U=F]O3')Y4F8R5G4W:$I,=#=N5#56:35D
M1V1)8G U2V)I=$9*>%9'95HY53AR95A4628C>$$[3&4R,T]455IX8C(V0U=#
M16-Q5DI,,U4Q=DAT+TM'-4@Y;%1I<6$R=&XU8W5Z24Q8,$QG>$YX;$55;E!I
M,V<S1FI1+U!&5F8Y0V%6+R8C>$$[>7IR.34O<FER=C!*<%@O3$]V,VXK=4MU
M+U%M;&8X<S8O968V-'$W.4-A5B]Y>G(Y-2]R:7)V,$IP6"],3W8S;BMU2W4O
M46UL9CAS-B8C>$$[+V5F-C1Q-SE#858O>7IR.34O<FER=C!*<%@O3$]V,VXK
M=4MU+U%M;&8X<S8O968V-'$W.4-A5B]Y>G(Y-2]R:7%N6C(P1G1Q.#AC0R8C
M>$$[8TEZ8GA-5D9A5DQY0W4O>7A637-69&EQ5UAL<F)83W-14C-%87EO3&56
M9W)#;W)Z:D9F>'A65R]196HO05!,2$8O=TEX5D-A<%DV8B8C>$$[63)-=#%&
M;R\Q.31G1#E7='AB<$EW<G51,7A*0D5/23-02GAI<D@Y23@Q950Y4G5K:6)3
M,W-,85<S*W-1,SDV='9&03E&9UHT=C<Q<"8C>$$[1F10<E-!.&M!2G)X2G!H
M5FQ%3VLV1DY%:S!.=$)*1DEO94]207)+>7-+:&Q),DE)=TMV+T%%2&\O=T1Y
M>'AF.$--5F0K9SE(+W=#5R8C>$$[3TPO9U)I<G8P2&\O+TQ(1B]W04--5F0K
M9SE(+T%/5T],+V=2:7)V,$AO+R]!0WAX9CA#359D*V<Y2"\U631V*T)'2W4O
M465J+W=$3"8C>$$[2$8O=TEX5C,V1#!F+VQJ:2]W0T)'2W4O465J+T%03$A&
M+W=)>%9"-G9P1VQX85AD4U(R<V%/:V)&5T-G145$1E52<&)Z2F]%1'=X*R8C
M>$$[=$UT=41(1GE#.#)#,4,X:G-+;F%U2W9%9GDP+TQR>B]!3UA0>DMK,6PY
M3G9)9$AV1T%U5FUN=$53:&ID0S!I5W0V-G9W2D1+1$,O<R8C>$$[17!Y>%8W
M6G)N;'92=&1I:6DQ3T9P:VE,1D%K<W-*261E3&]X:5I#.&)Q84]J5E9H,4)X
M5G5W+S0W3W%F.#A0*U1:>%9-<U9D:7)S5B8C>$$[9&ER<U99,S4W,3=Z2F]U
M:W<S5V<V5"ML-VQR:4I*<F-E;U=72&M';%E,16IK+W5L64$Q,F%M>FXT0W%K
M*V]E8U!Z06=V.69T<F9Y,"8C>$$[<WEA9F%X>6%:37)Z<VQX8TYX-5)O>&E5
M4U5%:2]W06=Q0T]8,FU25E<P+WIB-3)U3F,P0S%N.'5I1%1T4W-J4'%.>5=U
M2S(P>D%02"8C>$$[1S5A1E%J0EDU07E'=GA&4GE88FUQ>F)&6%EQ9VLO-#=C
M,R]-3D8O>6-K>%9'-'$W1E5%+R](8F@O=T-985@O:S5(:7)Y=CA!34A6+R8C
M>$$[3"ML*UEP3$DS=7)4835C5%%V.$%5,3$K6%1R6F)E66=.2T]%,W!1<DA7
M9U-2134O<S%W<3E/,5AY-7!M<C9**VAT4SEA-'-M5D9L<"8C>$$[4$Y$2R]P
M,$E,>7=.135Q4E4W-S1&561,.&]A1G!E<$YQ5G!(4#ED94PP5VQN=7)Q-$A%
M:4Y74$=E4U)E8FE"3V(P-4Y4-&EC5E)(;"8C>$$[<B]L2$Y++S5G-V8O04I.
M3&EQ631Q-T9867$W1EA9<3=&6%EQ-T9867%G=&,O=T-/4&5F.%EM+U9I<G1$
M+W=#3U!:+SA9;"]6:7)Z1R8C>$$[4%9R:'8K8V=:.5!'<V%I4D=S2EA31T(K
M<&E'5%0U5VM+1#%+1E!6:6E:<%!4,FMO;&9I,U9E=#1Q;'1H+W=!9&Y64"ME
M2"]*<S1Q;28C>$$[5TMU>%8R2W5X5C)+;TLU,7933&0S:6QV<F%/9$]S56MY
M25%A5D%)2G%0=7EQ5V5!3D=1*V)F2%1:6D-X1U)(=4M3>BMC;6AL=#1Y,B8C
M>$$[;$XY66M-65ID4S)7:V)Y5F(Y># O9# K6G@O35DO-3!F;44O;$TS.'E8
M>4M0<R]-=&<T8C8U96%F0U)49TEB>%IQ*TYE4U)5+TA"*R8C>$$[67@O>F\O
M34HO2C5V-6MV.4M5,6AM:&YI5U='4EI9;D95:U%H;$DY:4YS=&I)15=':554
M13!24E@T5TM#5"]J='IF.$%-3D8O>6-K>"8C>$$[5D<T<3=&544O=T1X,C1F
M*UEA6"]!2D]2-'$X-#@R*U5.0C!V>E4K=E@O;E<Y,&$T,5IP;6AS,U<P;&=0
M0T%,3WE25%%3<E514G%P9"8C>$$[9U<T9TQY<%%9<3E2=#1J1$)(15I(;$UA
M2VAL:TE,=GA&3U1%04-P-FUG>%9F:7%895=V*U5C,'(O;41T+W=$:S!U2W!J
M:7)S5F1I<B8C>$$[<U9D:7)S5F1I<G-69&EQ0S%Z+VIJ,VXO04)I8CE72W4P
M4#A!-#0Y;B]W05EL+U9I<GDO5U!/3V\V8BMC4FEE*W9(,&5%<F)Z86)A,B8C
M>$$[;'AE*W)),6HV>7=O<TYJ.$Q,>CEC+S95+W=!25!W:79W<7988U93,G<O
M-#=/<68X.% X06LR8U943$9867$W1EA9<3=&6'HU*UDS+R8C>$$[04-M=7$O
M.$%'4F8K5&$U>5=V.$$W-EAV9E-/>'8X5F@W=C!L:E=9:G,S67$K:5!)2"]+
M1S94+WAG2"]%:FY7840K-6DK8F1R+W=#3B8C>$$[5#DW24UZ2%=O2E K3S-.
M+WI$4F8X;DI-5E)U2W5X5D)0+W@R-&8X06U';"\U3U(T<3AC+S5Y6F%&1#5A
M;&56:VU4.4EF57A&2$A-+R8C>$$[<FU+3VI3>'9(3'ET5E1N.5E!-G)4-%<W
M2W94=$\Q4%=T1SAM1R\X04Y)830Q1WAJ;64W3F]G:V56235'151"27=Q.#-I
M0W,Y0495:R8C>$$[.49'2W),1#AW9DPY-7)L+W!!:T5%;6UX>%-85GA.4&%)
M9TUY4GE+=G K<V)G8E1,.%)I0U9Q3U9D<U944'EY>70U8C!L;$E+;7IT>28C
M>$$[0TYW45EL>%9-<U913C%R5FQA>4]K>3-(-W-69#!T8FU204M6<GI33FM0
M,S1Q-C Q;7EU-4531F)J.31+;S<R,7A':$9+,35V1W%F:B8C>$$[:7%/>%8R
M2W5X5C)+=7A6,DMO3%A0*T]0968X04=*=C%9<3=1+W=$:FHR9B]!0FE8.5=+
M=DIT35A7.50O040P:#AW45=&,4AO.&M29R8C>$$[171X<$TQ;DI(0VQO-%E3
M,T9Z87AL=61X>#1L6C9G9D1X24I+<795=&8X>6%B;U5%16PU>EIR;6%/0T-'
M2F55:DY)=UAL46M55D]65R8C>$$[66YB-6M!<7).274W5S4Q9E9M='!O-3%5
M=TMZ4G-(05E)86<P2C-X5DXX5F1I<G-69&ER<U9F4&XU:F8X<')Q=B]'4F8K
M5&$U>5=V+R8C>$$[04PV6'9F4T]X=CA!1EEE-SE*63%M23=.,DMV;VIY0B]Y
M:'5K+W=$1T%F.$%%:FY7840K-6DK8F1R+S0Q4#-S9WI-9&%G:R\T-V,S+R8C
M>$$[041$4F8X;DI-5E)U2W5X5D)0.$$X9'5(+VU';"]W0U1K94MV4&9Z:V@P
M;'13.'5Y87!A86)F,GER9DPY5C%#-VMS6D-E151S,%5S528C>$$[53=&0DA'
M-&Q1:FEW2416-EEQ.4MU-U=#-W1:<E<T6&YB,T-.1DUL4T]33T-R0V]O4E5(
M=&EQ0W1V3#)L,C)P;E5O;&U.,398;THV;"8C>$$[>&-3>%)X+T154E%Y4TY&
M2%@P,35&1D).3CA68CAT9CAO-7!8+TU(8B]W1$IP8U9E5"\X04]2+VY8>E0U
M62]W.2MG9%%K<U!R9C%Z-B8C>$$[>C9943@O4SE$:%AK1S9C,GI-,&U/37)S
M3T1R8S!O5G=N=F5+>69N4"M:.&MB4G8U9VY:2$)6:'AI,T)&1"MX;5HK6&@S
M3T(K8GED-R8C>$$[;R]Z;B]-*T].63 X=U1Q:4%+;S1X8D%#9R]9>"],=S=L
M+TXU3SDW:"]W030U*V,O32]M83$Q,3ED,4-3+V$Q93)&=5I!9S1">$IY<"8C
M>$$[>$,Y94EZ0S%73TU32V1J;SAS<&<X4F5X-6E/63=&6%EQ-T9867%G=&,O
M-#0Y-2]X:6(Y5TMU,% O:FHR9B]'2F8Q67$X;RMR84AR,R8C>$$[-6TO<'IY
M=C4X,&]A>$TO2S-S4'$U=DIU161N-D5K4$IB=4AL1E)7;31"04$O=T%8559X
M5C9H<C-L6'DS-6=J:&HQ=E1,8E56=#(U,B8C>$$[-75),61O,G%R16]X2$IA
M.$)7:#,V2&)&5C%H+W@R9%4O=T-E2"]*<S1Q;5=+=7A6,DMU>%8R2W9N>CAX
M=BM5,3%8+VI)=CA!>6)83R8C>$$[4S$O.3E,,W9P2%DS*TMW.3,V4WAR35(R
M8G-69E)(:T0O;$1D2B\T=T0O:5)Z<DY"+V-X9DYU,2\X86XW,E%:;4]T45-F
M.&1U8B]M1R8C>$$[:2\U3U-9<6IC5F1I<4-F+T%)-V-0+TU.3"]Y8VIX5C5V
M*V5':V%,<48Y-5EL,4Q5261-*W!Y,T5Q,TTP8SEZ*S90;W)/:E<P4TUJ=R8C
M>$$[=6YW>79+-DMU,6$X<U9E<31Q-T95=3AT9CAO-7!8+TU(8B\X;6QX5C1:
M+WIL<"\P>78X03!F.$$O671M9F]E=G=D6C)J+T0X9C!0;B8C>$$[=DTY,7)S
M5F926"]/2C,K.&9M6"]!27E7;B]%6G,Q*W0U:#)V6B\P;C-V9G-W6%E-8C%$
M.'=F3&5N*UDU4$PY,#EW=6]25W)8,&=3,B8C>$$[;FQ544QU6"]!2&%-4W8X
M06QG8V58=SAU9G<T<6=B2#@R9DM6-4(U9FUJ*W1O4$UH-#9E<C)S=&5817-6
M66=-<F-33TQ'375",7)X*R8C>$$[3$95,3AR*V1.1#AZ4'%+85<P>&)3-V<R
M=#)*;UI)94UQ.58K340T:%0T:TY(6#EP4E565E0S1E5&<FXO04)X-WHO:D4S
M-G-69&]F+R8C>$$[04)X-U O:D5V-G-6965W*U=T5% U,U0V,6-1,U,R0VQ7
M<WI&8U=F,4IJ*VIX0S P.7,X<'5F5W%7:D1P1U!H-&HW3E-66' K2W!B628C
M>$$[9CAD;E90.$%N:"]Y8D]+<&QI<G-69&ER<U9D:7(U."]-8B]L3F16+S1Y
M3"]!36TQ>FMT9B]F4SDW-E(R3B]I<U!D*VMS87I%9&TW1B8C>$$[6#!2-4$O
M-5$S4V8K34$O-&MC-GI19C--6'IB=&8O1W K.6M'6FIR545N+TAB;2\U:&]V
M*U1K;4MO,T9867%G;B]W0T\S1"]Z1%,O."8C>$$[;DDX5F5F.$$U,658-U16
M23E*:W5T83 W4C0T>&-W2RMP6$%T47I806E)6D0O=3=H-EAX44XX1#%(3&]-
M5F5G-GIQ<T=K-E9D86YC4B8C>$$[>7EW,FMB4WE2=TE:2D=#:71&569X,DA5
M:T1F1E5N=&9096U4871*<#<R=#%B>')',&MD+TES4F=K35EH36E)16ME8FMN
M,7!+.&]W1"8C>$$[=E%M;4MP;#5:26)Y,W!,1&]B3S-)+S5&3&ER=S,O;DQ4
M+W!L9BMJ+T%0-T9S>CE$,2M$<D\P9C1F:BMH.#DU;G5T9&ER-DLO-7A/+R8C
M>$$[,VHX>2]W1$=3,"\T:DYM=C%V34\Q-U K:RLY-SEM0S="0GHV3G!&>&-0
M8U0R3G9.8U-X;4=385-*1V1O;4)5;WI%5DMK35)4<&EQ,28C>$$[9$(P3E1!
M5C V,54R<D\Y<5)$1U!385)X2S=2-V9#5VM!8S V='8Q>%97<SE.,#9Y36AS
M-U=',DUZ8S5J1$=S9DYI4V548U%+;F9V:28C>$$[<4EX5D)A-2]X>#=Z+VI%
M,S9S5F1O9CA!>'@W4"]J178V<U9E6DI:5TYZ+WIK0DID3'!S.'1X6DE!.3AI
M>$Q(13<R04%K:V5/,%9M428C>$$[>'8V65-7-TQC>GE%9D1I=U9E=%EQ;'1H
M+W=!9&Y64"ME2"]*<S1Q;5=+<48U9E$R:7$P<7ES1TY"-DU-<W@K:U)+-4@P
M-'%G62]-,B8C>$$[;'E02VE*9',P3&-*44Q+."M&:6]E:"]D9GEU1&EQ84MW
M6E%W<E)H559"0C,X461X:7)E2W9N>CAX=CA!;$YD5B]W0TUI+SA!2G1C-28C
M>$$[3%@O,S!V92MK9&IF-')$,V9P3$=S>$A:=7A6.45E45 K54XP;B]J05 K
M2DA/<S!(.7I&.#(W6"]!36%N-S)16FU/=%%39CA!2&)M+R8C>$$[-6AO=BM4
M:VU+;S-&6%EQ9VXO-#=C4#A!>D13+SAN23A695=F;G1P,$8O<75H4EAI5VM-
M2W<S;W,W-C0Q0C=2=SAI<CE:6#!69VXU>"8C>$$[:3-1.&E#1S,K1FMA:%EQ
M.6)U-U=#-W1:<E<T6&YB,T-.1DUL4T]33T-R0V]O4E5(=&=63')(>7!O5FAQ
M,'5R5W-$<&5Y>&U*:5HU,R8C>$$[:D-K4FAU14QU,%--=V=4:WEQ0S-%5DIX
M5E8X=&8X;S5P6"]-2&(O.&UL>%8T6B]Z;' O,'EV.$$P9CA!+UET;69O979W
M9%HR:B]$."8C>$$[9C!0;G9-.3%R<U9F4E@O3THS*SAF;5@O04EY5VXO15IS
M,2MT-6@R=EHO,&XS=F1T4W5Z6C9D9%A96&UB94=354E44W9"4S%++U)M=28C
M>$$[>7HT66U88TAA-&-F2$]-9C5X02MB>64W+T]3839J16-U;&Q60C5!=S-C
M,$Q604DK,45%86TO4W5A4#A!;&U8.#!05V8V1F\O>GHX=B8C>$$[,G!E;C5M
M=4IP6&%Y=4=J9FHV8V8V4W9"=V]..7<Y5%A$+TQ-=C5O4B]O5VHO<6@K6#=5
M+S!,.#-B:3<Q2%0Y34=M2VE813!.=#9J5"8C>$$[=DEW1'5%-45U<$Q%5C=N
M2C1U,7!4;4DX4$UG3E=O.6Y)-#AC<#A:4$1%;FPS1#-V56,S8GEI0S%Z+VIJ
M,VXO1TIV,5EQ-U$O*T]06B8C>$$[+W=$1TIF,5EQ."]4>3DU=&HO3S)45C P
M=U)E6%IL5G!.45,U;DEL2S)2:4Q34697;&E$<DQW4E8K<DY645=Q0TXQ5V-E
M671E+U%D:28C>$$[3#$W1S5V8F17075'=&91<D5H+V):6G!95UE6,C1X.&Y*
M-DMC5E=A4F0R.7IQ*W).0R].5F%"5TY#3G=H<C%!>%9,9GI5;&MI+TQN>B8C
M>$$[1DI%-U)Y3%EY;%A5:T5';EEJ3&-0,6AQ>FUO2#-0:3<Y3C8Q+W=!=#EZ
M+WE/:R]R;3,T4C-/:3A76&57:')/<T%K:2MU05=.5U!Q=B8C>$$[=6%5.&9B
M2&=(8W9I>3=Y>E@X;617,5-B.'IT06IL=DHU23)N64UJ>4]Y:V5K+U5%-51Q
M26IG3&MA6$I)-4):3#=(>E5U-F90;C5J9B8C>$$[.'!R<78O1U)F*U1A-7E7
M=B]V<&4Y.4DW1R]X5TAU+U-73EII3WID:7(V23AG9CA!2T<V5"]W05E"+WA)
M-3%M9R]U679M,V$O*TY4.28C>$$[-TE->DA7;TI0*T\S3B]Z1%)F.$%*>51&
M56)I<G-6450O=T1(8F@O-6AP9BM4:V5+=DLO>G$X=2M:4$U'=&%$0D9A5TU6
M=$)C>5)A4"8C>$$[9%185$-3-'5P;U!5354P6#%36E)"-F-%;VMJ3#!L1E!I
M6&]66'-/2W5X5DQV3%@O04-J;6QF.$%-2&(O05!*<&-694=F.#5A9CE-<B8C
M>$$[+W="2"]W1#),6FXV2'(X2%=D;R]W+T@Y1#4W>E!D83=&6#!6+W=!-&YF
M-W@K6F8K36QP+WA'8DYF<F599'(R9CE*.3<R-WI$+W=!8R8C>$$[1%4O*UE3
M9B]!2DYT;7(Q2#DS3"MQ9G5D>F\O-S9(.6%0,W9M9D].9E5N67%M=FQ0+VQ+
M9$<O-6IR8B]K.'58-E@K.6HO5T@S=4HR:"8C>$$[+VDK5"MP3#=I*VLX-T8X
M=E%7=68X8V4X+W=#351F<7A6,F@O.&-E>B]W0TU3+W%X5C0Q-68X,%<R=F9N
M9F%8,6YQ.3%.85AC5E4P>28C>$$[3S5T<FDR9TUD9S1K:EI,83AK;W9Q16QM
M84$O=D%V1F=0=$98<C)V95=D23$Q8E5A:7,U*W!3:31T;70W;35T5U=50V=B
M;&)34D4P<B8C>$$[=%A!<39W+S0W3W%F.#A0*U1:>%9*9GI:+W=$2F$K6E K
M64=B.5=7-%!R2'9A<R\P4SEZ-&IZ8W90=7A6;2\U2V8K5%,X=F8X>$1F."8C
M>$$[;6YY;E5F45A),&XY-$@R:FUN9#8K9E!Z1R\U5%A69BM-:2\X;3%Z:W1F
M.$$S,'9E*VMD:F8T<D0S9G!,1W-X2%IU>%8Y16514"M53B8C>$$[,&XO:D%0
M.$%I4GIR3D(O8WAF3G4Q+SA!1W K.6M'6FIR545N+TAB;2]W0UEA3"]K-4II
M<4YX5C)+;THO*T\S1"]W07<P=CA!>6-J>"8C>$$[5C56*V(R=&5C=$XQ;3)L
M,$A59%)L:5HU23%S;V1-:759<E<W5T=%=WER2SEL3S5I6DIN.5)L9&UQ94LY
M1T%697A9<7AQ3'IK=S@P828C>$$[:F\Y-5IM>G,W3D$Q=F93:39"=51X:4QM
M24<R5T)K4G!U0DM4<S%2=6]'*TMP;C5:26)Y,W!,1&]B3S-)+W=#4E,T<3A.
M+S5Y,"\V6B8C>$$[6"]O+R]W0WAB32]1.69G-GIT2"M(-"]O9E!E6C=R6%EQ
M*VEV*V-4=CDT+TUV+T=3,"\T:DYM=C%V34\Q-U X07!0=F4S95EF*T]"<28C
M>$$[9B]-2E O>6)B3EAQ4#=U6#E5+V,W;E(O,S!0-C!F=F9-*V-A*W!/>%9.
M9DMF+TM5-DXO>DA7,R]!0V583#E,+T%(<V8V=RLY>$\P4"8C>$$[.%AY9C%*
M9F-8,&YN679L-D,Q>B]!230Y-2]X:6(Y5TMU,% O04DT.6XO>&E8.5=+=DQ0
M3D8O-31U=GI.;C!B469-+S%+<%(W5S)D0R8C>$$[,7-S:V1K2FI:>4$R5'$P
M<V@O9FUL,5@P<6II3FUX5C=":7%7,D@O2%HQ5"]!2C1F.&UZ:7%3+VUZ+S5,
M6'I*+WI!>F9Q>3-".5DY-R8C>$$[5FXK:5AU9D5E8FPU.3)+<S,O2E0O=T%M
M;#5E+S5I1R\U3E!L3V\K9W52<% W=U!T2$Y/-S$X*V9M3B]Y;75Q+SA:1B\U
M3G)N2F$O*R8C>$$[*VPW,S!J<V(O1EEE-SE*63%M23=.,DMV;VIY0B]W06]B
M<% O04)G2"]%:FY7840K-6DK8F1R+S0Q4#-S9WI-9&%G:R\T-V,S+TU.1B8C
M>$$[+W=!;DI-5E)U2W5X5D)0+T%-9'5(+VU';"\U3U(T<3AL+U!3,#$W5716
M,&UZ1#9:<&1N>6QJ,"]5=%%V2D56<$I6:#530TU10DEB:28C>$$[1F@K-6(Q
M<6UP;TXY:7(R84]33U-.6DDR1'AU07E/<'%#1'5#0T\R0E5*1&\R:G=A;%!Q
M:TYJ8GAA;F-Q23=M*U-*1FYK4F%55C513R8C>$$[8D%51WA/2W%8;'(O04I2
M>E-V.$%M1'0O*U13-'$X32\U>3 O-EI8+T%+4"]!4'-7>E P4%@T3W,W4B]H
M*U V2'HS;64V,3)+=F]R+R8C>$$[04IX3R]W0C0O378O04)K=% K27I:<CEB
M>D1T97HO<%!V93-E668X06IG86XO=T%W:R\X07EB8DY8<5 W=5@Y52]C-VY2
M+S,P4#8P9B8C>$$[=F9-*V-A*W!/>%9.9DMF+T%#;$]J9CA!361B9CAN;'DO
M4R\S<V8V=RLY>$\P4#A!1CAN.5-8,T8Y2C4R3#5E9W1C+S0T.34O>&EB.28C
M>$$[5TMU,% O:FHR9CA!>&E8.5=+=D]B851425!Z>G4V5'=Y86YD;%EJ8E-7
M0W1D4G=*<'EY8S1R>C9X>E,S3$I1=#9(2#%#57)89D98<28C>$$[94MP8EEF
M.$%(6C%4+VYH+WEB3TMP3"MB4"]K=&9-;B]!1$%Z9G%Y,T(Y63DW5FXK:5AU
M9D5E8FPU.3)+<S,O2E0O>6%8;#<O04II1R8C>$$[+W=#5%0U5'%0;TQK850K
M.$0W4GI4=3EF4&XU:F8X<')Q=CA!>&M8+T%*3G)N2F$O*RML-S,P:G-B+T99
M93<Y2EDQ;4DW3C)+=F]J>28C>$$[0B]Y:'5K+SA90B]X234Q;6<O=5EV;3-A
M+W=$:E4O97E$37@Q<4-4+T%)-V,S+TU.1B]Y8VMX5D<T<3=&544O+T%",C1F
M*UEA6"]K-28C>$$[2&ER>E X.611:'0W>GDS8E-X,E5I>G1D4T9D4F%)=T52
M1T$P34XQ9#9F87E'<D0W8G-W+UI89'-696YA5G!/;F%467@R1VTR-E=T;"8C
M>$$[0U=-5G9(<VEC,TQS1DA98VU.04YH,C)X5D8T<6PS;'(O;$A.2R\U9S=F
M.$$U3DQI<G=Z+T%*>3 O=T-M5B\V4"]W1'-7>E P4%@T3R8C>$$[<S=2+V@K
M4#9(>C-M938Q,DMV;W(O;D4W+V50>DPO>&MT4#A!:4TR82]7.'<W6',O-E0W
M,W0S;4@O:F=A;B]Z0U0O.$%*=',Q96\O=28C>$$[-68Q5#EZ=61(+V91+W)2
M*SDX>C5X<C9K-T95,3AP+SAP5&\S+TUD8F8X;FQY+U,O,W-F-G<K.7A/,% X
M6'EF,4IF8U@P;FY9=FPV0R8C>$$[,7HO:FHS;B]!0FEB.5=+=3!0.$$T-#EN
M+W=!66PO5FER=W8X<G1D:C%0.$%.<5,S8GI"86%G;&A#,%9N3F)Z6#E,;U)W
M;5 P;&AU<B8C>$$[-6=7:E%C,F-1>4MA13@K5RM&6'(S;E!Z6&0K6#=E3V$R
M<V\W,"MN8UA.=W-S-70K349P2#9K<&IP1E!Z:W Y;%!H0B]M1T)64S$Q928C
M>$$[,VDQ9E5894,X0T]946II>75Y<F-626%H159$=FEQ569M5'%#-FHU0S$R
M>'-B4RMU3'4T<S59-$E%<V)W<S=%8D%$,'-S>$=P06QQ>B8C>$$[06U"03=N
M>58O9TQZ-R\Q2RMS+SEW,C@O-G!:=&9(:#-H,'8U8DHS1EEN:V9Z>3=/<657
M9%E:;VTT>4%A9&1K<7A53E$O=71J>%E(2"8C>$$[>#1D-%@X=&LW:7I$.' O
M2W9M-U,O=T%X3D5V.5$X=F%T83)6=DUZ5%1Y861E0E9(<'-+:RML-&Y+<RM7
M2F=10S,V8D)/3U%%:#E7+R8C>$$[<"MX+S,Q968Y258U+W="57,Q8G5(:5AN
M<7@Q93DX,F%J9%=M:V%N3F)Y=7!J;%14-W=Q44558F9U=F)/83%U;'E3>7E)
M:5-(=2MY=28C>$$[,&-%3DY#37!G140Y3$AN,&Y855I&9E)T5%9P5S129S9F
M94%S=U5T469U='IX56Y-6#AN;2]M;#)(.'$V8B]627(O,$HU:"\V<VUQ9B8C
M>$$[.7<K."]W0W%74#503B].2R]W07$V8B]6279C4$IE<5)79FQB5&)A-G1R
M,D<T:6E#>5)T63-G6E15-T@Y,6Y3-DM":FEI1'-89W4P."8C>$$[:UHV:6-O
M;7=3>4<Q,5<R=7!F4VE3-%9Q5G),8EA%2S!(*U9+:4PK3UI49W)5+S0W8S,O
M34Y&+WEC:WA61S1Q-T9512\O2&)H+W=#628C>$$[85@O:S5(:7)Z-SAZ4$QN
M-6XV;G%5575K,U-82&PQ2EE';#!U>F1,3R]W1%-6;$YW1G5*03-*<$9$:$]%
M<U!%:U9R5$98<#)+<UAH."8C>$$[-7IN>DYC-EA064)B0TE4:4,X:&MK=4HS
M:W1V<2]Q0C=73T@T1B\P<V-716ID3G=-5E)'9S9Z8E%A1G P13!&-FMS5G)#
M:VE'>'9+<28C>$$[>7AQ0T0K-C=(1EAK4"]/4VQH<2]M2"]$;C9%,&Y5=%$K
M<2]89G)(;U=&-#-$,5!1-&-V,UAF9V9U>DXP:WA'-TQG83=(2U953#5V128C
M>$$[2#AI*V4P574O;&I71E914WI(5')W04%D4V8S5UIN:G<W=S8O.'1K-VDU
M4$EV;G0Q1' U63%H;%E!<7<P-CA)25!1:CDQ:C0X3SA,*R8C>$$[5WED>&4V
M9C@T,C)7<F58<EA8,3%V4V13,#ER;5,R34%N<TQX95E14SAQ9G5U,TE::&%U
M66M24F1L;W-C;V<R2V5T835R5G).;W5O428C>$$[>%%8<GEY5S!Y4F],1SAQ
M5V%-9T%F=74U>EA:-&LT-4%D>&1P<%I#3U=*4$E32#-V078P2C5H+S9S;7%F
M.7<K."]W0W%78W(K5'IF>B8C>$$[4RMI9GER<'8Y56ES6%-T9&%2-#$P8E5Y
M.&1/86I4-WEQ.'1X565L,W@O2C5V-7!8*U9D3B]Q:U4P.'0V6G)D=C5I,'4T
M;C!B530T628C>$$[8GE#4U=2=%!V04966E9,12]U=7=Y-U0V5$M-:U-9;75)
M9F4T,G0W4S X<T5W2GA*34IF8SDV+U0Y:B]V<3@O-E%R>B]!2W!:,4PU-B8C
M>$$[<S%'-VEU=$1V2DEL:U9F5&-5;&EK:&%O2#AS<6\S,#!X5E@P4"]J:C)F
M.$%X:5@Y5TMO,T951G%E:6%.<7%W<G%L:&)8-C(X9VUT,28C>$$[=6]K;45C
M:3E(5&U'-'-016(T<6IC5F1I<G-655<K<#)G;&YD:VA%,&EM5U)I1D13349I
M4W!08S!64FER>FIZ6#5N=3=V>E!,6C949"8C>$$[6'IF55E!3%9D4&AM;%58
M<V,U:G5$3D=H:E<T4E5P1W9);4I*05)*5&)#<C!04U<Q2G1,<S(Q4E5856I"
M1V(Q678W<U1L0C9G5&,O0R8C>$$[1W)49D%Q2WA66DI"1DDX5'5O6F]73'A%
M+W-S5DM62"MX8VI&5U V,RM94&Q,4C-33S8Q0THU1VY.=$I(0S933D9);W%W
M:U5.54UO+R8C>$$[62LR97EM:'A6:T5%.$TX36,X3&E31U91.&-I;7%S<D-O
M25!G4FEQ+T9516XO2&)M+W=#66%,+VLU2FEQ3GA6,DMO2B\K3S-$+W=!=R8C
M>$$[,'8X07EC:GA61S1Q-T952$1O=6I186Y0<7-.:&)X87!C<4DW;2]32D9U
M2D57;$9E541M=TA%8D4Y<U92;4MU>%9Q4D5K4F\S2$I(0B8C>$$[5FQ08TA9
M:D952&5A<'!/;#(W1S5U231)-V5.5TUD875%3$-.2TE+=6549D-T0G5D:'9I
M<GIZ>6YR2&UJ54YC=')Q,6UU<FE/-75*=B8C>$$[,'5:-'!466DS5U-4,&IB
M=7I,2$-Y2GA2;VQ4,65F.$%E.4-C2W9534-U>%9",SDQ<'5L450V:F1(,&]Y
M544P:7%Z<WI%:4].46E";28C>$$[6FEZ0E9#:7!*>%9*3D4O36IY:G)7<G1P
M5VXS9VMU:%0P=U)X1'-9>DMY0E0X87-I2U-Y=7%N63!R43!66E!I<4,Q>B]!
M230Y-2]X:28C>$$[8CE72W4P4"]!230Y;B]X:5@Y5TMO,T9867$W1EA9<3=&
M6&TR<F5F5C%$>D=M:W=78T=T95=R>B]!14<X=%594&10>FE-,S%U1T1I1"8C
M>$$[3&)G0F\R25DW<65/-C!9<6TK:F9L:G R;6%X6C9K3#8V=4194UA%='1&
M3$EZ04YC,3563$TS54XX6E5!>45+>E9027-&6FQI<G-6628C>$$[6C4Y.#54
M85I&4' K;G!D2F5O;'1,8U@X1555:3(X33@O<#$O96MJ,4A73U0P>7E&3U%O
M>$9C5E-,>7 U4'5.579N=7)K3$AO16--9"8C>$$[:DI!,79.0DIF+U9P6C5K
M;&5/-"M/2D-B=V@Q-FPP3DM*<U-R,#E%5D9#24%Q<4%&54-G04A105E&8GA6
M0DHO>#(U=BM984PO04I/4R8C>$$[67%J8U9D:7%#9CA!-#=C4"]-3DPO=T%N
M23A64G5+=7A6,DMU>%8R2V]45F16<SE,<S)U-W1I14)615)25C5*2%!&23!8
M=7I-84%9<28C>$$[.#,P,E9F>D-&>G R<C(T4V4P<&1A8G)T:$E*66QI;EE3
M9E9*6D4Y36E61C1H,$MQ9&=Y,%I1,D978BM6=DMD<#5D4RM%1GA.8U!F,R8C
M>$$[1%A-,&MZ8VTU3C1K-W,S.'I.=69K04%&5'I&6%EQ.&PQ6%@O041(<G5S
M=WDR9&Y/:D9*1&\Y:VQZ13A*=3=#-#5..6)H;$UA8W5F0B8C>$$[6E9.6&EO
M<GA&=FI+1E=:*U4O265N84,U=7!*2'9D4U!.575*0V5%351U>FE/1TUF06Q/
M6C5/0GEC,7%A54%#<VYX5D)A-2]X>#=Z+R8C>$$[04EX3BMR1EAA2"]X>#=0
M+T%)>$PK<D958FER<U9D:7)S5F5:*V1.6#%8>DQF439";S<S9&AB4$IC4B]P
M0TI6<3EZ851R1GE$2UAC428C>$$[=WI$:DPY;"]I5F=(:D0T5EIB-4XX=3-'
M:F%5<U8V64=V5UHS65=Q<W1V14I#0S!D=7)K<VMB379-<CEN:U11055!0W O
M:7)S5EDW-28C>$$[*S%Z5DY$.'90<65N,CAD>4E*148T:VAK5VM$;F=Z2S!8
M>$M66FQ*64$P5W!P:7)(9$@X=2M9.61E3T1Z6'!G=')7>5(T1&13,U!+."8C
M>$$[=3=E44M28E-M,&19-4DQ4#DT,&UZ,$@W=%159W$Y17=+-T9867%G:R]W
M0T\S3B]Z1%)F.&Y*3592=4MU>%9"4"]W061U2"]M1VPO-28C>$$[3U(T<6IC
M5F1I<G-69&EQ13%F5DQ84W1.=4Y1=758;U<V.&U#:7)%,6]&1E-"5FE13GE"
M-&Y&6&QJ84PU<#@V95EB,CAK;&5Y:7-P,B8C>$$[=%ID3W9K26AJ:55L-V53
M1G):;$IU;U-E9DPQ4&A*1$DO0G%-5F5S,C%T2&)W:4Y.>C%E46A1>G0S9'5)
M549M-FLP=TMQ-'$W1EAN6"8C>$$[;F%(>GIC*V$W9E0Y2G591FAL9TXO<&)4
M+W541&-7=C=U5E5M:D1S5UE42E98:F174FY&0G@S2W-O.'9E6$=S<#4Y53%-
M5S%X<CDV>"8C>$$[3GIE5SA#=VA525921$=D-4-G15DS9&E39F%G05908U9D
M:7%#,7HO:FHS;B]!0FEB.5=+;U13=%1T64Y.=&]:4DMS:V-A<38K:DUA128C
M>$$[1'A#67%I+S!Z62\X5R\X04EI8B]!2F]X5C,V6G-F.$%I,R]K4DXO>E)I
M<G8P>EDO.%<O.&E*=BMA35911W5Z5U=Q-E!E86-*-3=9,R8C>$$[5512:5IB
M95IU3F9&4V\U2V5J3%AC5D=+<%HU5#!R4TY&.64V;&EI+U-L,&%3>E=L:DQ"
M1VM3:%931TIE3$U%54E/<#,K9T%&5U)F<"8C>$$[;7@O-'0O-4549CA!3D="
M6&9P;7@O=T-,9BM213,O3D=+=2]43FHO>&(O>4EM+S5O>%94;C%,4W)I0U,S
M=4DS;6=M57AY>%-7.'))-B8C>$$[34M-<DM5;U%2<U%C5EAJ5TQ!0V<Y54%F
M.%549C@P67$S*VUB2"]I,R]K4DXO=T$P67$W.4TR4"]!0F(O04UI2G8K84U6
M9"MM8D@O:28C>$$[,R]K4DXO>E)I<6Y:>G!C87)03D5(.5 P23 U3VIP.%%D
M>5(X65AX1TMP:FER<U93-CAL34=Q47IT1DLX9F]3251&1S!L1TQO4EAI1"8C
M>$$[+TMC5E90,'9$+W9I-2\V4C5F.$%M;D989G!E2"]F1GHO=T)).'8X07I4
M:7)V,'9$+W9I-2]W0VME6"]M;D989G!E2"]!2'AC+W=$4R8C>$$[4$PO>E1I
M<D=V3U=K+W X5WAH-7A.1$AC449B;7=L=5EW=#!Q;S!Q265!13!96#1'3E)U
M=TDS=W%N3VQ(4TY+<UDW2%0W1V$S=&\V;"8C>$$[630W85)256UR36%+3GEE
M=4)56BML-&8Y.%A0+T%%:GDO=T1.3TMU+U,X4"LK3&XO04M2-68K86-69"ML
M-&8X069&>B]!3DDX=B].3R8C>$$[2W4O4SA0.$%V:34O-E(U9BMA8U9D*VPT
M9CDX6% O4U!,+WI4:7)V,'9$+W9I-2\V4C5F*V%C5F0K;#1F.3A84"]34$PO
M=T$P-'%H9"8C>$$[578Q=4Y/=5E)<F4U36MK8DMG.4-58FMF-G5+=B\Y:ST\
M+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL
M;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@
M(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C%!,T-&-T$R,3E%
M.44X,3$X-#)"0C4P.# U,C0S.#E!/"]X;7!-33I);G-T86YC94E$/@H@(" @
M(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C%!,T-&-T$R,3E%.44X
M,3$X-#)"0C4P.# U,C0S.#E!/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&
M1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)
M1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM
M<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R
M;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12
M968Z:6YS=&%N8V5)1#YX;7 N:6ED.C$Y,T-&-T$R,3E%.44X,3$X-#)"0C4P
M.# U,C0S.#E!/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12
M968Z9&]C=6UE;G1)1#YX;7 N9&ED.C$Y,T-&-T$R,3E%.44X,3$X-#)"0C4P
M.# U,C0S.#E!/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ
M-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @
M(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F
M.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M
M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z-#$X.#8T.3(M,S,W8BTT8C P+3EA8C0M,6(X,S0W
M,&)D93DW/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#$X+3$P+3$P5#$U.C$T.C4V+3 W.C P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!);&QU<W1R871O<B!#0R R,BXQ("A-86-I;G1O<V@I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E
M9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#IC.&,S868V92UC,#9B+3@P-#$M.38S8BTS-S@S,V(Q8V%C
M.#,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,3@M,3 M,3)4,3 Z,SDZ,C<K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M($EL;'5S=')A=&]R($-#(#(P,34@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F9R;VT@87!P;&EC871I;VXO<&]S='-C<FEP="!T;R!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N:6QL=7-T<F%T;W(\+W-T179T.G!A<F%M971E<G,^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C8S.48Y,#4Q0T%#1$4X
M,3$Y.3A&0C-!.4$Q1$9$1D$T/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$X+3$P+3$R5#$P.C4X.C(S*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HQ03-#1C=!,C$Y13E%.#$Q.#0R0D(U,#@P-3(T
M,S@Y03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C Q."TQ,2TQ-50Q-#HQ,3HU.2TP-SHP,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT
M=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @(" @
M(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T
M;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T
M+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @
M>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6:7-I
M8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L
M<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \
M>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP
M5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T1&EM.G<^-C$R+C P,# P,#PO<W1$:6TZ=SX*(" @(" @
M(" @(" @/'-T1&EM.F@^-SDR+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @
M(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \
M+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*
M(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF
M;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^
M4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#4N
M,C \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;"YT=&8\+W-T
M1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^1$E.+4UE9&EU
M;3PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%M:6QY/D1)3B!-961I=6T\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y-961I=6T\+W-T1FYT.F9O
M;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP
M92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.G9E<G-I;VY3=')I;F<^-"XT-C \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT
M.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE
M3F%M93YD:6XM;65D:75M+G!F8CL@1$E.+4U%1$E532Y01DT\+W-T1FYT.F9O
M;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @
M(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'
M<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*
M(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP
M,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ Z0&Y P$1  (1 0,1 ?_$
M !\  0 # 0 # 0$! 0         '" D*! 8+!0$# O_$ %80   %!  ! PT,
M"0(#! L   ,$!08'  $"" D8-[81$A,4-597='=XEM35%187-CES=I2RL[6X
M"ADA.%AUE[36,;<:(I4C)%%9)4%"0U-QDIC1U]G_Q  > 0$  @(" P$
M         0(#" 4&! <)"O_$ %@1  (  @0)!P8+!04& PD    ! A$#! 4Q
M!A(A05%Q@:&Q,C9A=9&TT0<U0G)TLP@5(E56=I2UP=/P%A<TE=03-W>6MA12
M5-7A\4-78R,D)3-38H7"\O_:  P# 0 "$0,1 #\ [$H-B$C(L:(3M7WQ)P:J
MI#+ 9C%.>9LN4MB16#Q$#L8(H!G/&]P"X=\^J-EUV?796MC:]L;9(HVFUD,<
M,":3RDM\FIL=_<M^G0_J-1COHW^).(NG=X#DU-CO[EOTZ']1ICOHW^(Q%T[O
M <FIL=_<M^G0_J-,=]&_Q&(NG=X'_.>MK4#M:^;^EG"U\L<+7S?8N-KYYY6P
MPQM>Y&UKY9Y7MCCC_KEE>UK6O>]K4QWT;_$8BZ=W@?\ 7)J;'?W+?IT/ZC3'
M?1O\1B+IW> Y-38[^Y;].A_4:8[Z-_B,1=.[P')J;'?W+?IT/ZC3'?1O\1B+
MIW> Y-38[^Y;].A_4:8[Z-_B,1=.[P')J;'?W+?IT/ZC3'?1O\1B+IW> Y-3
M8[^Y;].A_4:8[Z-_B,1=.[P')J;'?W+?IT/ZC3'?1O\ $8BZ=W@.34V._N6_
M3H?U&F.^C?XC$73N\!R:FQW]RWZ=#^HTQWT;_$8BZ=W@.34V._N6_3H?U&F.
M^C?XC$73N\!R:FQW]RWZ=#^HTQWT;_$8BZ=W@.34V._N6_3H?U&F.^C?XC$7
M3N\!R:FQW]RWZ=#^HTQWT;_$8BZ=W@.34V._N6_3H?U&F.^C?XC$73N\!R:F
MQW]RWZ=#^HTQWT;_ !&(NG=X#DU-CO[EOTZ']1ICOHW^(Q%T[O <FIL=_<M^
MG0_J-,=]&_Q&(NG=X#DU-CO[EOTZ']1ICOHW^(Q%T[O <FIL=_<M^G0_J-,=
M]&_Q&(NG=X$6S3#:='\9.=W(3XD_-51\$K(IB?>9HP4O<ZN)B<-V8$(N7$SZ
MA<X+?#K1L.M$MAE?KK6OC>88VVED(B@23>4NBG7ODGD<LKWRRR)EKY97O>][
MWN#A>][WO^V][W_;>]_VWO6,NKEJ1YE"10"@% 4=BR%8]DD>4EQW)1Q04BLP
MOE* &!65<ACB1 &)&@@NPD3@ .5\1CIC+LE\+B7MG;&^5\<,+6NXFL63]%%%
M"GC-_P"\R5^2I"?>VH^D[C]IU&/%IW+P)Q(=&]^(Y*D)][:CZ3N/VG3'BT[E
MX#$AT;WXCDJ0GWMJ/I.X_:=,>+3N7@,2'1O?B?\ &.J\(999X8MX]EF'>UA,
M<72XKY87RQMEC;/&RIU<;Y8WME:V5K=7&]KV_9>F/%IW+P&)#HWOQ/[CJO"&
M?5O@WC^=L<LL,KXNAQ9=;GA?K<L;]14OU,L;VO;+&_[;7MU+VM>F/%IW+P&)
M#HWOQ/\ KDJ0GWMJ/I.X_:=,>+3N7@,2'1O?B.2I"?>VH^D[C]ITQXM.Y> Q
M(=&]^(Y*D)][:CZ3N/VG3'BT[EX#$AT;WXCDJ0GWMJ/I.X_:=,>+3N7@,2'1
MO?B.2I"?>VH^D[C]ITQXM.Y> Q(=&]^(Y*D)][:CZ3N/VG3'BT[EX#$AT;WX
MCDJ0GWMJ/I.X_:=,>+3N7@,2'1O?B.2I"?>VH^D[C]ITQXM.Y> Q(=&]^(Y*
MD)][:CZ3N/VG3'BT[EX#$AT;WXCDJ0GWMJ/I.X_:=,>+3N7@,2'1O?B.2I"?
M>VH^D[C]ITQXM.Y> Q(=&]^(Y*D)][:CZ3N/VG3'BT[EX#$AT;WXCDJ0GWMJ
M/I.X_:=,>+3N7@,2'1O?B.2I"?>VH^D[C]ITQXM.Y> Q(=&]^(Y*D)][:CZ3
MN/VG3'BT[EX#$AT;WXCDJ0GWMJ/I.X_:=,>+3N7@,2'1O?B.2I"?>VH^D[C]
MITQXM.Y> Q(=&]^(Y*D)][:CZ3N/VG3'BT[EX#$AT;WXGI<CZV1&W8_>R\E(
M)\NIHS57E1/'S<2\/B"=(IADR6%R!&4<P1;8#!X97#%PS#SM;K<\<L;WM4J*
M*:RYUF1#AAD\F;I,NNS"_P#Q1/\ Z\O_ ,UE,1KQJCS&-+QIR=)56L,?*>S@
MC-!R5MXL]MG\%Q#0I*'O5E0[!ZV79BV?+RXFLLA(JG'Q9,*9J*HYDQD*9<Z0
M<BFGI)4]FG)ID@IAB';@"62E3(/%/,U++MZ-/9E.=AA['Z5R*]+L%$_2!=X"
MSH'D%&C5**N%UZM-/W?<2S'XTB642!%=U#)J*2STXB4/MQ9=SG)H+:1WZ5#8
M1M4Q<JFA$%49?E?_ $H;I\F+Q_2.B#7UL/!G1&TD!\3@>V/62H*@.5F940&@
MW55YMM053R@T3"H580!1H**DG-<RDI!UR(2>EDW49("..R6G"*8A,$8GJET?
M]S*#?)@/&>=U242*#6UI=\>,S19ZRZVTG;)'<CLC#!TC2>8;$E*J$TT%=:^"
M<]R+8+Q\FAS;FKG%6#4%?4C"*WE?-^G :%ED4YM.>;-^.R:G+H+(1IM%+Z5K
M9JG,"' #3P@22V/IBG$S;VV4?A^>&P2V&,1&PBF+B;"Q "V1=ZXRUN0RUE55
M6)@+J;S)I)I>/&TM75,TT &LK4\N6Y*62>A\$::T*B@% * 4 H!0"@% * 4
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M$)M7.6HB3<X $M!K>+%@0BY<OL?I*    '@$" "%N5 080((0=L< P@\,<<
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M0"@% * 4 H!0"@% * 4 H!0"@% 1O,7--)?T%=/X*<J5>M:XD.YZGP,/ZSF
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M@C<?2W)>IFY&J\/MJ4W0A0RY8NS<@L<2TMJ4AI3\;T7OIW0_=Q,U):#F74/
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M)C/V* 4!4W67X\[G^=D;_+KKI0EW+5^++94(% * 4 H!0"@% * 4 H!0"@%
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MH)GS^!LH!@CA$F*\G"J@&12Y@P=P-&202?B$1&"$-8&12H0XC;/M_%(FR@%
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MVPQ*7$&Z@&(E[0['M:%3BLNT84KVZE64EFO=$6AMZPHFDK8LESS*T:JWT_\
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M:]&G3J6*][^37F_3=9UGW%4-8_+!SJH>IZIWBNG.A7L$]5B@% * [P?T5O\
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M^FM8VQ9"57HK*"4J*2^&:P,H I^XNUD<U*4DOE3[5ES7M8JG+)F.INAC% *
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MMT:4ZX?"'S!;G4]I]RISLV!7/+!+ZS6#]ZU4X9*^7Y^@H4 H!0'[;:^,;?\
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MA:)IP\JYO(\CDY222FI*3SK4CH/H4/0)7DQIPM%TD3$_3HJ<QHI8;NDAY'P
M+F3!)K,A 4',OF2Y:V6%S)@%*3#0@!;'/'(P+C@#CE;+.UZ!9<FDK_ >T+DD
M^05B)95A-=@:2@8P:4V-EN*SP;KX+N2,G<K*K?N.(JMT,N$C/9F+Z8$D2"TA
M@#A%&,+K='0'0ZR*@.;)"6M#G^OU^,CS=9?CSN?YV1O\NNNE [EJ_%ELJ$&7
MO&E^2XW(\F9'IJU:[+@?SFLCVE^YI3IWE YG6][)!WF@/F$ULF:@"@% * OU
MPK_E(-(_.4BGI20K@L)^;UL]75KW41V; SG9@]UM4_?0GU/JUD-RA0',KQG_
M -YYA>0EM]/I+K2?X1_/FR_JK4?O:VSZN_ 5_NFPB_Q#M7_3F"AD36OYNF*
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ME''"U%!'!$E%!'"U%#$DTTT1K^JLX?/\,#%^ON[_ ".N$_9?!GZ.V%_*+/\
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MPE@%3/,5?4@FY( +:(.00W#>T,&O-M* ^>:8,II:<O--^-%2]V([?Z:;9SK
M27(DF4XV+989-95NZ4T_T[T4*!UAW;(+FS[84GM))MTN&,6\V7C)##:\,*3/
MWHC[%'4V"TW($G28KH"!KSNTT6*4O'TF+^62G#;L04]CO$%H'@\$MO-=^OUF
M)FLC7_\ +T9YPSRK/>NEZ+:%P0Z-<M>DV-'$GA-1/ >3\<#"B@J[#K\(0;&K
MC<AQ39,.$'F?QQ&7P&8D#!AB]J6R;Z$>.FVJSQC3.04 T.*N^^?3IZ?UESES
M:$"@% * K5.VR9:&'$Q6$@1+*D[RC(:*^7<WXSB'&.@7'9AQB.SB<@/<^IRO
M(D7,PHD-U2D)BH@:?=TYN-<7':CD4%$40[*AI,$RV?KH,2EL]J2PFIK5N0YW
M4R%!X.[B [#-'9&<7HP5!H2Q\&[YC;;%SK^J6Q[9<8:@]#1ED,5'CR*R\(K9
M,R@B.-GQ]>-6AB7,LZQD6RY5HA4L^6:RK7E<\TWGOT1U)U CDB=CB=$&/W)
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MYQ#Q(K]P'525<M2X'FT)% * 4!7/7'N?+?ER?WV4>K1>CZJ*P^EZS+&54L*
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M5^3*UENREAM:Y-VIW/;;,:#M&@5WZWM=0$O)^U3/#8\D,;>5J)1P0FC,U@1
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M!JKA.*+W.]LJ1$QBJ@"I+;';[:#3T<LVDU'20;OD\FCHS+9Q-"*$"@% * 4
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+!0"@% * 4 H#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g838337g39b98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g39b98.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ L )@ P$1  (1 0,1 ?_$ !\  0$
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MI;SRI>LK6_\ ZJ'_ .581_WA-/?_ .+5RR\*?YU__C3?W@JQQ=_FA_[3!_\
M[6L<CI7[-^\U+I2Z<"(\;K?J'WGT]]*FSF-@ZP&[PL.Q09.R:F)[(W=9-H/[
M'VXYT^FJ_91P[Y&F5'7M/K=C$6.5#3-+C@[,YA^SO;R<96[+.\E>"Q;BY<O(
M&,A&9HH!B:*%K#$+OX9R&0D+/W.6BJO4\7(%.L[-'9L5JDO,A:P4HN4+RSG,
M\LSUB$A;P B 2$G;4F9G7&NM>R1T7MJGZGOP#=FVZI2]I*HUDK-RMU)HJZ9?
M8]_M>Q@T7ILUE:(]O@CK#U:5,;2Q7K55G5-!8QXY/AOPQ@D8"+W'+)EYX3F
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M@/U7L#5%AC:CI9G2(.T&K;T[Z\WI>*'=;#9]T6NCG[(*U?L/9G45NFIQNE\
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M[I\K5]W5;R&@Q>XSA65J#6VAQ]R+4&\SNHO;UDHUCVI:K]/@^K-DU6,K54!
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MB:2)XY'(IR,GA&28V$Z\40B00@92;MX.O4CS;K3IPBR<ZM_^52J?[L?1/_\
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M[_4ZU?EXO^SXYD?U@>T/Q38?HE[+_!<\=+%)N;/4[TY.NU&SM--;XU"XXXX
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MH="W2+@ILOV!TH='>%[5L =J6CQ;>I7SCK3S300/=@P8W((F.5SL5H+(06)
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MGA16I+L>X2BM;XR.&,2E%HB<!)YH]RW22;5.TIL#)6QO5#N/+/>-K<0#'?\
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M3G..]..[65,+AJ%@[='$XRE;EC>&2U4H5:UB2(B RB.:&()#C(XXS<")Q<@
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MY@G_ +?C^/C5;PB<(G")PB<(G")PBC+/AC)W76747-3B;>0S&56'2+8)M[-
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M(G")PB<(G")PB<(G"*.C"T(V 8->I@6,Y)IU;%YV$V_"583*()JUR\4R9&3
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M\;?A6KZ$J^41X<YQGQI[O%@BB]>QHL*@T>'! 6*J0HE0K4:'5K>2],6RM16
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MD8,Y5RT<#\.9F8C&"EA<?3HU>Q\;%8EJM(T9GCGH3>&OZM7A>S[[N[?<WK9
MT;J/N'4)J5!_8=^J8,K1P=M+S!6UM&/SG %$H=,7 %L:I]3&M<3;+)R%'B[,
M3C&)GF++Q#@<C;LS8K'X'AX.!;%_ABGPYF.K8W'W+$-^>G%'+A\^,;6,AD+S
M23%E^O/DXZH-/)+5B.$-M-X3XGQ%"I!G,KQ/Q9)TF5<7QGD>+\ UO,9;'U9\
M95OV98,_PN4I5,5B<845<, ^-;#2W#>M!!>F"S+O\MJ+KRZFMPVVOZLK=LTP
M@G8=D6BNQ-FKH4.QPLU>#TQIW?!?36M?[XM=2?+QK/$+59<D7LTP/8::4P28
M6;"E1TC%F>C[A;"T[.6M4\YRJV+J6CQ;9 ZTG6Y.*GP,@O:R7#].X,)53AML
M$N*@D)W9XBY$\4HY^'NE;C?B/(5,#3R'#8SW,W>I1YLL3'<BZC'P/^=$9=1Q
M/%=_'G8CO1ST7D@S=F$1'9.#VJUB$^.K#UW;JW(%TY&,W:AZ>E'K+V<]FCZ]
M!C+0-V!MV#N"[4(_LVU4FQXNT5V%KD$87,H)@,NOV@>N V9"68WB<:#I5LJW
M1_@\+-FR@HY#-#7J])=4LA/+4EQ^&DPM'(5\74OU>H&TF3L0L&1@G:Q4D:3D
MSU8.77G=:BYTJ<3<1UN'0LY3$\.G:N=#EX,15@O09;B*+B/)XFWFLAB[O:@%
M'AJMEY<19K/4O0O$-FK=M<ZS69X>Q]9.XRG3^*I7^(E9U#\C1.G^T585+?V*
M6VQO*7=>ID^"O3VN-A'=F2+)#&:V"5(>Q:&'HUX?6-,EHYR2' RAS@_85>"<
M+%Q'->;&VLUKD.(ZEN8!QL.'P 4.%J]C'CD\;7Q0U3ER<]R0JA"= 6EAA* 9
MK 2M+JKG21Q)/PC6QCYBCPZXXKA&]1KR'F;'$/%,F3XVMU<H6&R]O-G=C@PM
M7'PA= @RIE!9L!:DK59('AHMI]H9OBZQ]N@Z;M>C4VL 'J;<8MUCTB'7[-1@
M(/K*UQI6U!++"'[RLQ4,):J=MCG+@[?HFO;>L)")9<K53#VL45%Q<5T;</T2
MPUB[B+]ZW8:]1.@5\[-7(6)^",GG:MBK))@*L4\SVZ95Z;8X\E3&<XM+5N:G
M+#+-SO3!Q5DPXAJXW/XO'4:I8[(QY0,7'3NXJK5Z1\+PU?J78X>*;T]>!J&1
MCM9$LJ&(R+UHYM:6/KWX)X.3/:-]2DV1O5 F-I%A^CP]F9CBK/D*$7K6+1]R
MU#7U5LUG>@[B.GY8K85*,E;+%);"J&HJ>P>E5::)M!;7BCEAC:K^3/A<!P'.
M//.-^3%;IJO/G;*%?P=S(VZM09,)7KC-CKT$-8XL;<S-TJPVPFJ0Y)J]8]W_
M "R<:RGQ2U<.&!/&1YK9!>ZM6?"AC.),=B*%V\47$EFW)!F,;9GNA-E\=P[C
MQM249:]ZQAWLW ]E_19O,WU"Z,@7ZQOLS#L>V72IDB$*OAP(@@]5[!+&MR@K
MM8V)M6HV0=Y9#$?ULI]Z,UH[-8F21R!N$NBX7EW'& @X;S\F.JBX5RIT;D49
MV9[$T8VZP2N$[6L;B+M67>Y%U.[CX+5<" )7E[I3]KZ-.*;/&'"T.6N&,EH,
MAD\?/-%4K5:\QT+<D#'5*CF,]C[L.QA#M#'92S2MRA(<#0MK!'ECRH*_IPB^
M?#TL3NFJK;=VGL#J>R,-5"N.R @.@2P$BT3;66N=L]$G2$4.S.&)0FK:_9N4
MT<;<FIS7+Q-HYAN+.5&\JY]&>+8^)[>'Q6.X5YL%VSMGGR(6!JA3AI5'FKQG
M,4<KOUK(O1"6!HWZS0"_"YQL6YOD7P'+P70X@SF7XWY%K'4W*K6Q,E0[TE^Q
MDK_5[4H5@E@TZCB!R4L-IY/YEE),78:.5PV/FE16NB"EF=/5:^VOIFO>K*P[
MK@*2/#ZG!=V+9MAB>L[#EBN5N*1*TR9E:R-=+K4YZQB[H5E 5#I,$<.")M2&
M,LTC(/QU>AS5O'T^*,?EK8Y*>*O)<-L;5QLO!&E:E4B.T\ 96'BMXQK3480L
M<T9)99^JN6[TK%MT8XVSPY1RM_@G*X*@^&K3VXL?$68NYFOTDL]W)9":.BUF
M3!VN!AF*Y!DYY*G).*&&LU]@<8FJ[7Z#=AURZ$+5KZATCT56I-?MKI>I5@!>
MMAX8HNYYE,MFKZYKT%!JU%/L[3,ZH VF%1_1\TC5:M#,GY<X<1M36)MO#](&
M-M48Z>2R%_FVAL4VAN6[&/QN[(8,+U/*VLE8DN9"N6(@S%BG)?YH1V[9PUPC
MEBINM90SW15F*>2FOXG%8SD4CJ9 K&/I5,KF-N+XDDQN0P=+#U(J&)MCGK.
MJWXL6T,LM"A'9M2R0S7Q:QV06Z#GJ?O%H0]H%5RG:VM+0^74JY#A"81N-(ZF
M9FIW*'$<KF),LJ1K\CIM '44.93; 'N#4BR[3(VP'"NM=(0\7#T@#<P+S#Q!
MU*/)U7D"Y:,YS@(.%0R[9 VM; BCL!Q19KOD O5IJ3A4Q$5.Q)0LQ['-6.BL
ML=Q0-<N$WR,F%O-">/IQQ5X[0%QM)@'Q0%2YDD\U0^"ZEML7)C;E;(B=[/3Y
M"K'E*<WKPZ%Q^UB75UH&/I5?R6PV]BA98V0XEY8^*(AJ<D6Z0<3'4EY=<;J+
M9SUB9:4EZ0%S.C,9R\\VG/H?2%+AH>"N)"S[:XM\78"86=FD.:1F"D%=RU%K
M3W7K]5)_!&QRS+P1=UY+T40\03](W!X<+OMS+9JK) 9,3PQUHG(\D=I@=B>D
M.-&WUT1=C.KS@#PR%GW^.?-E?7Y.$3A%,52;/G0RKA _6K$XQ9[1"CR:O$=B
M1!T"$<FQH  HETX=R]90$5IH399:'Q[4DU%F/-@PJ%8'L$5/PB<(G")PB<(G
M")PBC+..:FG==2G*F]8EB+>0(,&6B4."W0W':!=Q2K1)BR9T1\RS.9).TE(X
M?&)RFI%O9+N0FH(N61@$\_XU[V_YJSX1.$3A$X1.$3A$X1.$4PQ.GJN90:L_
M671C%8 SF*LS%=Q<8$^45L;$L^2FY-N,N5DO'APAP.*FMPW62@2PO+-DD/MP
M!1/)^-%3\(G")PB<(G")PB<(G"*8A3I[EPL(YT_698V( JLN%6845UNW!)<^
M;;&B!BP3%&Y+,D%86H ^+5V&Z\'7%F5VTJ=)G<2FHX,GX_N_'W*GX1.$3A$X
M1.$3A$X1=*\YPA><*2C.$JSA:\=Z$9QC/<I>/$CO2GZ58\:._&,X\2?IP12M
M-FSB50JI F=KEH)3ZV#FD+-3HSD*HV*=*&17Y9VK0WC-B>B5PO(6X0"1G; =
M<8&2(K2S)-2,S7RD-XF5)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(OEB]DN>J(?J#V%"M;U?PJP:(M<()$,Q[7'(R) *Z:\O5FG5>VT^P5
MHI1RU4US4;O=RI9T@N+8:96;5KQ$?!*Z#ID/UO+B;UHW#=X-@')V<-&8@E =
MXF),;%*<<;-IJ)F$NND;L_CN&(!LR,>WPZYL+.QZZB<4A.!QD#@01QR2.[OH
M0 <7CD9VV,/Z2F2,F;][2N6%*-G \I.H9(DTS#*#F3 Q^Z;I=@%&AYR5.-06
MR$534MN&7FS"D5+V&"$J1+0Z\NN<7:M7QC$VTFYVHZB^U]D&K:BS"^C]VHLP
M^9M%9N#G9[&4<7W,_(=BT=M6<Y]'T)W)M6[]'=W;RN[K:ZUWUEZONS4%;XP]
M7)9H4#.CQ[<!=L+%F+)'&K$1H(BD-'S,\SA$U+9,>T.4X/;B2)*790^'-EP\
M62X)RU I&&6O9&":Q7DE>1JD,+U2E:8Y)K[UX(X-8W>*1Y&:1S$78)#C X^'
MZ1\'DQB<X+=.2U7JVH8FA*_/8"Z,+UPBKXP;=B6S]*PS0M"Y1#&9L1Q1RG'<
M0^J314]WY0?:"DQN1 40:*0]>;&?$SH+$(Q/2Y$.LU%0DAXV@A5B&S$G/O2R
M32!$)MXK,B0I$ ^%,_&VDE6$'&3EO">2Q@S1R%)#&['7*ZTT6CSQ%(1QB(1.
M\YN,,9R#M(N.N%978H;T\@G$\PSQX?,E7EB"*S*Q1VQQSUY=1K6!B$)2*286
MKQ"4\D<9^+']7.AR1.I" 5GED&+68D5L408JMKA"T'(T@E!0";>G@H:99?S8
M8HF0(&IE3Q(X=-/%XT"OQ7B:,TG!O$$45R:>H$95(1M31E;IG+U<QBD>P[1V
M#<(=L\.V:79'-++'7A.2R8Q/@AZ0N%9Y\?7JWI)AR%@J5>8:%^*!K0%/$U1B
MEJQM)8WUIV.O"TDM>&&2U8"*G&<X]O&ZS>FB>,<L _8:B@N.N/%?)BJ1L$HS
M#=(Y"*'Q9;P^IR<PWC&#X-P1%D_)/&$S6'!K<O#;F6^Q<$<41RM6DQK13$QF
M,4U_'0D8Q=8:4P:2X.\8>K6&F,=6@>,FE<-6UZ!TD\%2P%;AS#SP!L YH,9E
MYAC*;JKPQR/%0-XSL];JE6 ]I66E$H6D9G=N136[M<UZ[0*,<)38=D)9#-"F
MFJY92;;F+"8K5?AJG3A869!K\5\_;:H(S*.S!T54\S#:4ZG*'LM:R#!9*S1D
MOUXXSK1<XIG>U5B=NK06K!\N.6<)+!#6IVYMM<)3:.$W9N\=VXL\3X:GDXL7
M:GDCNS=6:N(TKL[.URQ2J1O++!6DBJ =O(4*^^U)#&\MB,7+N+;RWEEG*'&\
MM-Y0[XLNHRA.4.Y7CN7EQ/=W+\>/F5XL9\6/I[^:?<^K/J^K::/J^K:>+1_)
MIY-/$K!M'1VVCH6NYM&T+7QZMY=?+KXT^2:[W%?)M^)U*4NJ\">]Q*<92E+F
M>[O6E.%9PG"N_&,9SC'S9SQJ_=WOW=[=_B_=YOX+G:VKOHVI=Q/HVKZ>+7SZ
M?:NI"$-H2VVA+;:$X2A"$X2A"4X[DI2E.,82G&/FQC&,8QCYL<.[N[N[N[N^
MKN_>[N_C=W\KNC,S,S,S,S-HS-W,S-XF9O(S+JYPN4X1:9ISK;[+AHZ9C2>S
MJ<F362I)N5(3.!YS(D,RG\29'=Z2\7<XM#CN>_&.Y.<YSW=V>?M"#@'I?>"$
M@Z4! "BC<!>&?P1<!VCKR>_1G9OM7SIL]*?0(-FP$G0N\D@S3-(;2U/#,3+>
M?Z_RNSE]C+QO^6WV6G<VKV;\CPO*\+2O-A.YU7?W>%O/I+N6KO\ F[D]^>_Y
MN9?S Z8>_P#ZT@[N]_H9^[]_T/<L7\J?0%X+_P B9Z$^@OS:OA/KIH/T_>^O
M=W>5?BNMWLLD96E79P/IRUW9<PJ8#QEOOSC&/'C)+&4=^5)QCQ=W?G.,?3G'
M'Y@=,/=_UI!W^+Z&?O\ W?0KA^E3H"9W9^A,F=O&SRU&=O%XVY_=XV\?G9?F
M>M[LL<>+O[.%['@PE2^^:#QX4K[LHRKO)?VX7A2<ISGNPKOQW=_?CG/Y@=,/
M_P 4A\O_ &,_D\?_ &/D\J?RJ= /_P %"[F9W^EJ>)]-'_7^)]6T?[6\ZS<[
M/?J^[/V[=1PFDZ9Z5X^@-D6NM6$97+C+6'DI*.1VHQB;5&'V)C[L&45'BY4M
MAY*4>:6,]%I4IV>TR[Y]TF\$])=#A::_G>,"XEQ5*W6FM48QFCY+$YP1W"$H
MP:4(9)@ A?78TO.T9HW(?4^ASI(Z'LIQK7Q?#/  <'YO(4;D%+)R/6D:P0"%
MF7'@82F4,EB&"20"9FYCP=79W*81+8"Y^:E^P4X1.$4S5H9*%$*-DPM:!.O6
M:S3(K%7DOR8DX;,-S9(TT45(#A5,V4U#=9)66,VS.8CFI$QM@P7:2F>^14W"
M)PB<(G")PB<(G"*,L[$=T[KIQX7;Y[D:W$'HDRMEI8\(#?50;M'42V!"C'13
M!VJO17I(: -GCK-%8O)6FF6PT6<*AV($16?")PB<(G")PB<(G")PBF6(9)-Q
M)D%A:TT(?K(*'&L3$E_-PFDHI2Q/S0I.'D.W&16AD66/G Y*+!+?=*%["TZ'
M'-LLS2A/Q^/Q_P"U-PB<(G")PB<(G")PB<(IF'#)-VZP3W@M:C"90&K18%@A
MR7UVTO.A3;4X3%V"*H/&C1P0-F<+D5=YDZ5=DS3EI3(&A4QX[YDG]ZIN$3A$
MX1.$3A$X1.$72O&<H7A*4KSE*L80O/<A6<XSW)7G"5YPE6?F5G"%=V,YSX5?
M1DBEZ?#(#ZE5X!<-7*Z6@UT)#)U^GR'I=2!$(PR,S-#5:5)$@)$FN#)*'802
M1(!!7GAC$5QT2.6I4-DL[>)OW>547"Y3A$X1.$3A$X1=M,ELP8SLJ1G.&F<8
MRKNQC.<Y4I*$(3WYPGQ+<4E"<J4E&,JQE:DIQE6(=^]7QM.>[:)Q@@$7+:S.
M1$9C%& ZN(L4DIA&+F01BY,4A@#$;9J\$EF8((F9S-WTU?1F81<B)]&=]!$2
M)V%G)V;01(G9GFXMK;>FIAR(#\1*Y"(;<A2\.-NR74LN,X9Q\FCS,=;<B/XI
M,53Z&G'F\NI3%6B4NGT>.8K&2&A;Q=F@$EJ.A%:DE&2.:[.%>:N-8>7&]RK+
M#;J;KE(K,<$EB(IA"C)%>DW,^!..J]B&U%8(82L'"(N)A!&\@R/)X1<F83AF
MTAG:(C&,V!RF$H![.-LNA3")X3$M0B22J]V&ZXL$-B1EUX1>C%; V\;6)J4)
MSAHI+K5H &&V>_*<12D?QK2Y\HVCT!XI&82<"9CC>47T\<8F0.;?8Q@0_O95
MQI8W<A8Q=PD:(V9_T9" 38'\SN!B7[B9>"*;KUT%/62O$R1R*_36I#UP-YHU
M[<H]4;B56+=Y>;+L9FM.4 $J+59T$U(04LL5QF+.@I<2E^9&9=[#7E(0)F%^
M9^K'F1\P]3>-MD;ES"U-G%M!?5V?S+J5B(2,7<FY>N\N7(\8: TC[Y6#E#H#
ML3[C;1G;SLI]SJ1U.B0)AIG7:1/,G'ZO%&P=0[?(%(MFCAEV5RMFQD&B2)];
M/YJJ/6YH+88PLD_3ULVUB,Y7'V2;G;JLW>^D;,([W=YH69PW;-PN\C,0[_ W
M"[MO\#7=W+KUJ'P6UD=R)P9F@G=V-AW["%HW<"V>&PDS.\?ALVSO7=9ZB-0Y
MBD)<>SSB28$L-$;CAJA=CA(YBQ3IXT$1IX@/7)Q2\@2\X44CC[)3(9ZORE"R
M66B:D0):F759]6;8S:L3ZE)&+#L9G)C=S9HR9G9W$W$M';N[V3K4&CNQN^CB
MV@QR$1;W=A<!$'*02=B9CC8@\$O"\%].3ZU9@5P"0K%6R+)0.0\QB/*:0\RI
M+\*6^/(09D24VQ-'%!9*++&%Q1"/%)"2D.8,)18L^)(CMX3 @)Q)M";35NY_
M&S.SL[:L[.SL[.SNSL[.SNSK,!C(+$#ZB^O?]K.[.SL^CLXNSL3.S.+L[.S.
MSLO.\ZKLG")PB<(G")PB<(OEU]C?7RMBZC=F1@00A8C,+0A@B/$U^C2[E;YB
MD;7U!"DQ:K-AW_7*J<]/ASI RTFI!R1%L&O)URUNX.6[>F9L'UC-$(UHG(F$
M7L"SN1[ ;Z&9VWMRY-[,[:@+,VV5HY==(]'\?P@.=J5A%R)JY.PC&YF_TT#.
MP.TD7+<A=Q,MS[HGDBTUDU;84_I.<*:ZBNTY2\.@AEMR-58=$C1,>O#!*D7G
M=F%CH *-,(10<&#G&8T43'(3HXV.TW#:F26V4OKK_%O?7Q>CN6O.T=W<W+P(
M-'<G9G)W\[LSN_>[,_<K+P?W6<MJS#H\.K,S"PZ26.YAU=A9O%IJ[,W=JZV7
MQ-UZ'(2I$9Q10$X#<$URLG#:]NI/^KPJKT2]5ARCG94B1;*S366KL&'T"/"E
M !Q(O),0*+#G(*R<DMC-0X]D8#9HK#3C-9M5X&PW5^L36\CC[;7ZX"-.U=(J
M,\F1(PL2Q0C#)D#C>$.56J^3Z+XGDC)YZA52@I4K-I^(6M]4@HXK*T2Q=HS.
M_1QPCDZ\.(&(ZD,]D[,.*CE:P?/H;7=>B(&/DZ]FM5.1!8FCZ3,KXY@K $#F
M"ETEU$A&086H< BHKDPX?.$8,$NDM"KL(H<%PGH<6,YF-3H<=SR!D0>X,A!)
M?CL2E#)-*4-$+D9O W-L&]D(*]>.22%X3LR15Y3&0S92[^2Z,:L)X>4<><0R
MPXR2I$-B&O"$V3DQ\P-9=X:L8TI+=NU+%%8:>*G'/9@C**,'7ED6/HX#Q28V
M3#>B>K\N5?3Z#]/VUDP!.2D6"^MG+').A5&A-O+XKQJVUULR]&LYYUB*8KC$
MYZ>*?E87J\:S'%*)B?6 ''5GKW</R;%<7K8YZ]8:\[034X>LP4[+PB56NQ'#
M9*,8YA"0UWHYKQSP21E'U20\K;:WCL_UBK:-K>6:S=.U6>S7R-CJ=G(5!LD%
MZVX1V*82E+7(^S3<.B^-#S37R<H'Z=<BUKT89C[AK1Q$$>9D4Y$%$DQ'&G@=
M1!& \NCSWVY(^IUU<"32R3X]AMT3S(]'C@CZZ,06.0QVN; >%M5WDD@&Z\CC
M"<M>>Y8@G"_&+C)<LM(-Z(9"=IEB;(]&H1OC3GDJ];*.ER+(<1TK310V3QPQ
M,=D(;=;'U;%:3%S&QPX^GRI,;.<(,5=<@T>S=.FV+E#;IH&07,PJB"-Q#+U/
MMM;&P0(4IK>VU:$VLZ/"H9>^48US; 4-$/P31$8<1C+>@97AS6WZO$F'I&]V
MP,,,ERQ < W:=J62>>')T[<CM7DG<AT+)4[!N>L<QRQ$PR::;?%WN#L_DHVQ
MM4[%F+'U;,=DL=D*4,52K/ALA1B9[4-9A+4<-D*L;1Z2UPAF!RBUUREY4U>T
MX1.$3A$X1?/@Z6>H?6_2]MS:>UK=2[%L"X-O/5BB5P04 UX:F =MN'MC33)\
M_6+NPS'*TH9.UY)#-U.:LY7-@6=MHK7YL2$23]&>+>&\GQ7A\5B*=ZMCJ3LU
MK(69H;%F5SKU';&A!7KVZ!$4-Z6/)!,]R-H+..JN\5D#DB?Y%\"<7X;@?B#.
M9[(8VYE\BSE1Q=.O/4J0M%:R#%F9+-NW1R@"%C&02X>2LV/E>U2RUX1GJ2A%
M.V9M&Z\.FS5QO44>OVC?EHU3K%S7%?!Z>/U,0W6Z^S1.LU._HVXH[KNS)P]S
M9D35+&:%&CC:Y!FSR14C#F7!FMY?8GTF_P  <3Y6',E8J\/5,OE1R=BQFJ]R
M=[-A[_!'YNEA29L5'*V+DR[MD3*2S($<4,9A2*UM*/TC%]*O!F#L\/!4N\6W
ML#@WPM.KP[;H5QI5!Q720W%@<1@19R6(LW'@!?$@$-.*66:Q-')D6I;PFBZG
MVE57/5NX-;AJ9EV8S6952$58,_8;O"V[6'Z+ND "";BO>S+\>N)5^B7[;$78
M-=FF';1"AQ:^/" Q@)8 $M<ZWT86J]JD^%N0C&5H;DUN8:U"3#6AOX.Q//A<
M?BL?7I0CD,?ASQMF.$:AF5F2>>:PUBPS:S']--*U2R(\14+)2-2DQ\%&L=S)
MQ<0T3Q?$M2K5XCRF;R]O(SGBLMQ!'EZ4M@KT44=.*M4@J/3J.5?L;M#])6:M
M[G!MN;'MN;CJK8-2@2+)4&A12_V>_P OJ'<JLV^$H&TYH]P+I ;MO7HRGBS@
M"X8@O:S;)4Z36GO126X>,Z.,[5LX.=^S*?4LOCKD@5KA30XZIC@X;:W'CHI,
M2$C3YZ7#9&6[+7LTN8.5>*Z-MN<[[',=+_#-ZEQ+5US60[2P.7Q\1W<<,%C+
M7<M)Q@5"7+3Q9^6(JW#$/$&'@QT%JID6A/!M/C3I'U;;@=T!:9OF\NK33=5U
M\2(UXD#M@J^F+>,3CS--K=*(1#96P-K6AUA$M&6(PP0B4VN)+.DQ4&2G+,I>
M.7KI)SN-X>X+SMS)Q16HK%*;&P49?T+]J_$=>&J[,[$X/N*6=P=C"M%-(/>#
M+S#H@X9R_%?2)PSC\-/-3GJ9&OE[.2@9M^,HXN>*U8NB[L0-(S@$%9I&>.2W
M/7A-MLCK?@Y\X%]=4X1.$492!C N ;98IK-)3*N=T)N06)8^8DV^3LI*:]<G
M'!KKK;3UR<>58WHDG*2$-P@J,0::E-.(P16?")PB<(G")PB<(G"*,L[C"#NN
MDNR[E'<=MY!$5FLP"$L%/>Q0+NXJ+L23#&SHHJHMQFWYH^:6EAH+M^B4D:T0
M>)SQPDD3S_C[E9\(G")PB<(G")PB<(G"*,C#&$;#-&<4UF-)DTRL#%[!Q+'J
MD&6()RW2FZ:N"AW)5EFM.$73;<M]E(^4Y:W68CJY,2:ELGDT_P#HK/A$X1.$
M3A$X1.$3A$X11@X8PS?[883361T@A5J/ >OJ98]<BUM"B5Y?8K#T%EU1.,U2
M5%7R+$J<RW$F*N[[0Y;KD$AAHGD^_N^[\?P5GPB<(G")PB<(G")PBZ',84VX
MG*,.X4A6,MY[NYS&4YQE&?%_;W+_ -'^[YOG^?YN$47KT:R&H-'#QJBSK^.*
MJ%:&L4*/+@3V*0S!"PHK518G"W'ADUFM(:2&;ECGG8$E$)+T1QR.MM62D-XF
M\OVJOX1.$3A$X1.$3A%X.Q15RQ,E+2%.NL_)R4-)\.5.^7<2XXVE*T.(4MQG
M#B&L*1G*7LMN-J;=0VZBM\6TI+V!N!#$4\T')N1P#L<I^J2A-+"(R1S1G)+
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M97F]6AM)&Y29"*S3%N@)P27'I0EEPC=<,%*T:578D4G8CBVY$:W#V;.<?$0
M=/>DAZXV7BRK&7/D;^/^"K_*R?=W_P )SX>%PGE9/N[_ .$Y\/")Y63[N_\
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M?=W_ ,)SX>$3RLGW=_\ "<^'A$\K)]W?_"<^'A$\K)]W?_"<^'A$\K)]W?\
EPG/AX1/*R?=W_P )SX>$3RLGW=_\)SX>$3RLGW=_\)SX>$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g838337g47g23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g47g23.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X6-\:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S0W9S(S/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!&:6=U<F4@6S$R75]0:&%S92 Q8B!#4T8@
M4$=23B!B>2!6:7-I="YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!$
M96QT828C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C<M3F]V+3(P,3D@
M,3<Z-#@Z,S<F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C<M3F]V+3(P
M,3D@,#@Z,3@Z,S<F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C
M>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC
M('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[XH"B(#,P($--64L@
M8FQA8VL@;V)J96-T<R!C:&%N9V5D('1O(&=R87ES8V%L92XF(WA!.R8C>$$[
MXH"B(#(Q,B!#35E+(&)L86-K(&-H87)A8W1E<G,@8VAA;F=E9"!T;R!G<F%Y
M<V-A;&4N)B-X03LF(WA!.^* HB S,"!B;&%C:R!R=6QE<R!C:&%N9V5D('1O
M(&]V97)P<FEN="XF(WA!.R8C>$$[XH"B(#(Q."!B;&%C:R!T97AT(&-H87)A
M8W1E<G,@8VAA;F=E9"!T;R!O=F5R<')I;G0N)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M)B-X03M->7)I8610<F\M4F5G=6QA<B8C>$$[07)I86Q-5"8C>$$[07)I86PM
M0F]L9$U4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @
M(" @(&<T-V<R,RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C(Y
M-#$V-28C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C@M3F]V+3(P,3D@
M,3 Z,S4Z,S@F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C@M3F]V+3(P
M,3D@,#$Z,#4Z,S@F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C
M>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC
M('1Y<&4Z(" @(" @(" @($)A<B!#:&%R="8C>$$[)B-X03LJ*BI4:&4@<')E
M9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A
M;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C
M>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03LF(WA!.U1I;65S3F5W4F]M86Y04R8C>$$[5&EM97-.97=2
M;VUA;E!3+4)O;&0F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @
M(" @(" @(" @9S0W9S(S+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @
M(')R,CDT,38U)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" R."U.;W8M
M,C Q.2 Q,#HT-#HT-R8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" R."U.
M;W8M,C Q.2 P,3HQ-#HT-R8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @
M,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R
M87!H:6,@='EP93H@(" @(" @(" @0F%R($-H87)T)B-X03LF(WA!.RHJ*E1H
M92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@
M;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H
M92!D;V-U;65N=#HF(WA!.R8C>$$[5&EM97-.97=2;VUA;E!3)B-X03M4:6UE
M<TYE=U)O;6%N4%,M0F]L9"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@
M(" @(" @(" @(" @("!G-#=G,C,N86DF(WA!.U5S97)N86UE.B @(" @(" @
M(" @(" @<G(V,#,W,C@F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(X
M+4YO=BTR,#$Y(#$X.C(R.C P)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @
M(#(X+4YO=BTR,#$Y(# X.C4R.C P)B-X03M38W)I<'0@5F5R<VEO;CH@(" @
M(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$Y+C N,"8C
M>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!"87(@0VAA<G0F(WA!.R8C>$$[
M*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N
M<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N
M*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M4:6UE<TYE=U)O;6%N4%,F(WA!
M.U1I;65S3F5W4F]M86Y04RU";VQD)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.
M86UE.B @(" @(" @(" @(" @(&<T-V<R,RYA:28C>$$[57-E<FYA;64Z(" @
M(" @(" @(" @("!R<C(S,#<R."8C>$$[3&]C86P@5&EM93H@(" @(" @(" @
M(" @,#(M1&5C+3(P,3D@,C,Z,#0Z-#$F(WA!.T535"!4:6UE.B @(" @(" @
M(" @(" @,#(M1&5C+3(P,3D@,3,Z,S0Z-#$F(WA!.U-C<FEP="!697)S:6]N
M.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N
M,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($)A<B!#:&%R="8C>$$[
M)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A
M<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O
M8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.U1I;65S3F5W4F]M86Y0
M4R8C>$$[5&EM97-.97=2;VUA;E!3+4)O;&0F(WA!.R8C>$$[+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C
M.F1E<V-R:7!T:6]N/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @
M(" @("!X;6QN<SIX;7!'26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O9R]I;6<O(CX*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C Q.2TQ
M,BTP,E0R,SHP-#HT.2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @
M(" @/'AM<#I-;V1I9GE$871E/C(P,3DM,3(M,#)4,C,Z,#0Z-#DK,#4Z,S \
M+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q
M.2TQ,BTP,E0R,SHP-#HT."LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @
M(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7
M:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.E1H=6UB
M;F%I;',^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @
M(" @(" @(" @(" @(" \>&UP1TEM9SIH96EG:'0^,3@X/"]X;7!'26UG.FAE
M:6=H=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z9F]R;6%T/DI014<\
M+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SII
M;6%G93XO.6HO-$%!45-K6DI29T%"06=%05-!0DE!040O-U%!<U5':'9D1SEZ
M84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!05-!04%!045!)B-X03M!44))
M04%!04%104(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"
M9U5&0F=K1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$
M031014$X3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!
M,%E%0D%91VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G
M079!14%!=T52)B-X03M!04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!
M04%!04%!05%&07=)1T%104A#06M+0W=%04%G241!445"05%%04%!04%!04%!
M)B-X03M!44%#07=11D)G8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"
M06=-4D)!049)4DEX459%1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH
M37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*
M;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X
M9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+
M:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S
M<F$V=F]204%)0T%1241"455%0E%914-!341B445!06A%1$)#15--545&55).
M:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7
M:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P
M)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)'
M,75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*
M5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%
M44U2040X03E5-'$W1EA9<3=&6&QA-FI.9&%0)B-X03MQ,35Q979896HK83=/
M5%9M;71)6DI:1F=T-&MU171N*V]G;$=I5T0P-6QK-&9%.5!I<6%95EDY3')/
M=EA+851:,G1Z2S)O>C9X93)Y)B-X03MW:E=B<U=&,%8P8W5G='(Q1SED-%!8
M5D=#='5K<$M61TMS:"]-9&1::C$O>2]O1V@V:F4O<%,U,&I5;S=13&9T05=U
M;U!Q;W1B;355)B-X03MY27-V06U2;2M":7<U9D-E=U92<R]W03!V3FDV4F(S
M13!D:F4S17(V:DA&.5AI:U0V>$YP;#!T<71O9SE:*TYX9$M7;51S04M58711
M)B-X03M654Y'+T]N5F1:3FI&6FY456MU=%)H<UIN8C%*0D5:-$QQ67=M3EI6
M6G!)5&%Q:&-(:DIZ2$5#;$-Q;$5N-2\K66%88DEM;4M,5S!U)B-X03M,.59D
M6F%Y>'=15VLV4DEF5T9'8S--:V133U%+9D5I='E12V]Z5F9Z4C$V-C%V5#E)
M:W5B83-%3W-#2S=K=%!6:&LT5S)U,G1R1TI+)B-X03MY=5!4=6)+-#5L5T<T
M*TE(:FEQ2SAP9FTQ<DYZ-6MT9$AU4'%C;'!C86I*6FUH;$YX*SEN,5%",653
M850T52]2<69$>#9/04M51TMO)B-X03ML+TTO;BLP.'EE6DY,,%$R*V]4=&8S
M3%=6:F9#95-3,VIJ,#8S=4DU2VE685<P,#-/1E%&1DI'<4-10W5"560U:#AY
M87AF951.23%V)B-X03LV,T9P>39H9DY,8E=K,&LR;7)C,E125'E147I884]8
M=#5(:%%3:#9H95E64TM(1E=+1#@Q+T]/:F%D8T]Z<$IB,C!%4S)S97$R,&=U
M)B-X03ML<F]"=C=C>GE*2VY/4V4V:4U48F9%,TQJ5&]#<4DQ=CAZ9DTO=T1I
M3S$Q4%1P<F1,97AG,44V:&]R:5HR83%S-6)6;FY+3$U&3'E7)B-X03MZ>7I7
M>F-0<S=(;"MY<7I(>E1C95EJ-4TP=GI3-U1286IP16M7<3,R;C)C:SA#5%=D
M954Y=DI%<G8V:DI!,TMJ5BM.9'1I8T-S4C%()B-X03MZ>C5N.'%4,U538V)M
M.75,3S Q1U=#.6QU<FPW63,X=#8U9U-&<#9.-E!P4G!X47%3=E1K,T972W Y
M-5 X-C8Q<5!M*S%S2DQM26%8)B-X03M-*W9)>3A*2&%A97@Q0DDT=4UK:VIM
M4#EY>%E*,$,Q1E!S.%%Q46%:*UEF;4LQ:S$K."MU43,P.&1Z96EZ5UEY3D1D
M:3%V<&)E3WIS)B-X03MO>$])-#5L:5982D%02EA3;S),:W%Y4T@X>6182#59
M-E@U<'50<5@V4C%L-V1B4T].6$9V1UIT,E(K8V]"9$%K9TA+4D%7;W95,$E6
M)B-X03M)4$DQ+W%N;F)7-S(K3C-D45="=4Q#-G9)24Y6=DEN=&MU3DAI;6MT
M,'0V:&933C W07-#1T<O141Q0W%#,&I53$0P+TLQ.68K6G(P)B-X03M75V\V
M>G).<'%$4V%X9$I$.5AS+S!I8F8T+UA5<G0V1R],96EE3S16;2]K<GI"8U@S
M;$16;V12=FUK=6)$-C)9<#57358Q*VIM9557)B-X03M.>$U2=UI7:VAJ-4(Y
M:6%C=F9&5T112G%39FQF<&YM<E5T8G8W5S5U0F]C14QX-C%E4$9.1E!.6B]7
M<#5E5'!W;F)L3VIQ1'A64B]S)B-X03MS5E1$>D1D:E-D83@R,DYJ<C)O2%9B
M1%1B0V9Y>EI.<49X4$DY+TTY,C1I5S-E4FA/1S1W<7=D1RM#:% X,DMP:"M:
M4#5S-C4U4FUH)B-X03MT,&=S,G5&<U!R3C)K-&M.2C)T-W%647!%:V15.5<Q
M5U T43(W+T554$1M<6MF;6XX,3EE=2],1W8R14XQ8E=L-V)*96E$5TQ4,553
M)B-X03M2;TQE,'5)65E/37A:3&@O<F(P*TUG*VLS=VUP0VQ5=R]-9GI"97=A
M,35V+T%%6G%D26]F2V-D-494534W65%43DIC.%HW84],;6I3)B-X03MT=V@O
M;'(X27(X931634ER8E=L.'I7,FI1,V5O6$=K95I)8DQ624PX6'0P+S%:3$91
M8GE*2D]D5E-E<U$R8F8Q1SA"47$Y4W=+-T98)B-X03M9<3=&54XK:SE.+S5A
M-&8K4FEF,7A6,S94,#,O04IA-&8K4FDO=T)C5F0K:SE.+S5A-&8K4FDO,7A6
M,S94,#,O04IA-&8K4FDO=T)C)B-X03M69"MK.4XO-6$T9BM2:2\Q>%9X,4Q4
M1T)"=6]#1'-16D5P5#<X5E-Z4DY0.'$V2$,P3VUY>'A2;%510C=L-75-8V1F
M5&E1>74U4TY/)B-X03M2-$ET1E=P;TU65% Y2C9B+W=!=&-0.$%Y35@K=4MU
M+U-E;2\X=&-0+TEX9C8T<3<Y2C9B+W=!=&-0.$%Y35@K=4MO8E5M,$Q5<DM3
M)B-X03MY=3=M3G)E6&IZ5DIZ13-W<T=&2&ID2$<T-TA&5F5+*S!M2TI);W)I
M0DEO,4-O:75G0W%O;T%"6'1I<3<Y2C9B+W=!=&-0.$%Y35@K)B-X03MU2V],
M5F]F3&5R,F]T3E)L:&YT9S9Y1TPQ=4-S54Y11S1-=DIF1E1S931X5D<O<%!4
M9CA!;')H+S5'3"]!1GA6,S94,#,O;')H+S5')B-X03M,+UA&6&9P4%1F.$%L
M<F@O-4=,+T%&>%8S-E0P,R]L<F@O-4=,+UA&6&9P4%1F.$%L<F@O-4=,+T%&
M>%8S-E0P,R]L<F@O-4=,+UA&)B-X03M89G!05&8X06QR:"\U1TPO049X5E13
M-S!62G!*:VUT;&UL0VE754Y'1V-*6&IY87144W4Q8U964#!N<'8O3%A$+W=!
M:D8O<FER=C!N)B-X03MP=CA!>3%W+SAJ1B]R:7)V,&YP=B],6$0O=T%J1B]R
M:7)V,&YP=CA!>3%W+SAJ1B]R:7)V,&YP=B],6$0O=T%J1B]R:7)V,&YP=CA!
M)B-X03MY,7<O.&I&+W)I<G8P;G!V+TQ81"]W06I&+W)I<G8P;G!V.$%Y,7<O
M.&I&+W)I<4IX5DLW=E-,*UA7:S%+2%5:24EK=$I,55=91$Y%)B-X03M:2DI5
M:SE:;$PX0WER2'A(=U8S3R]B1E5$-4LP-U0R.&TV0WI7,$Q-9$]T0WI'3F%K
M;4).*VU+<'HK:DY.+S5:268X06M7=CE-5F0K)B-X03MJ3DXO-5I)9BM282\P
M>%8S-DTP,R]L:V@O=T-282\P>%8S-DTP,R]L:V@O-49R+U1&6&9O>E1F*U=3
M2"]!2D9R+U1&6&9O>E1F*U=3)B-X03M(+VM7=CE-5F0K:DY.+S5:268X06M7
M=CE-5F0K:DY.+S5:268K4F$O,'A6,S9-,#,O;&MH+W=#4F$O,'A6,S9-,#,O
M;&MH+S5&<B]4)B-X03M&6&9O>E1F*U=32"]!2D9R+U1&6&9O>E1F*U=32"]K
M5W8Y359D*VI.3B\U6DEF.$%K5W8Y359D*VI.3B\U6DEF*U)A+S!X5C,V33 S
M)B-X03LO;&MH+W=#4F$O,'A6,S9-,#,O;&MH+S5&<B]41EAF;WI49BM74T@O
M04I&<B]41EAF;WI49BM74T@O:U=V.4U69"MJ3DXO-5I)9CA!)B-X03MK5W8Y
M359D*VI.3B\U6DEF*U)A+S!X5C,V33 S+VQK:"]W0U)A+S!X5C,V33 S+VQK
M:"\U1G(O5$989F]Z5&8K5U-(+T%*1G(O5$98)B-X03MF;WI49BM74T@O:U=V
M.4U69"MJ3DXO-5I)9CA!:U=V.4U69"MJ3DXO-5I)9BM282\P>%8S-DTP,R]L
M:V@O=T-282\P>%8S-DTP,R]L)B-X03MK:"\U1G(O5$95=3AX-F)P>2M8=%5)
M=%E14F%4:T52<E=V<$XW67%N5TMU>%9*9DI0+TM'84(O,GIR5"]!2DU*:7%D
M67%H-WDU;F=6)B-X03M41F%3,UI9,$MW;4E&9F,K<DI%4'5W1D)+1'-D8FYV
M0T-M;#-A4F5O.$Q3=3%T>%9O<$1'.5%S-TY137 V031G;T5R-DIP:%I/>%8R
M)B-X03M+=7A6,DMU>%8R2W5X5C)+=7A603-U=%=.:WII-$4V:4]N2C%T-VE2
M4&EP5#0P4FQ06'-C:TE%<S1W2C5+,7)F=UA265),379':%!Q)B-X03MW>E$Y
M9D0Q5E-V,%E$1VM'3DEJ07AD:7)S5F1I<G-69&ER<U9D:7)S5F1I<DAT4G9V
M3FQT93)C36$R1%(S='<X15)B,753:%E:6F=7)B-X03MP-U$P>7=#3F165&EW
M+U-0;T@Y265J-B]),"MR.'5(2'0Y=F5U44YD1E)/0E5U.'DO=T1+3V%R+T%-
M=V1X+WEA8D95>'A6<5)!-DUJ)B-X03M605E%17%3<&]D=&U7:$AZ1TMP3C5)
M1E!*96=$+W17,FXO2FA-5E1R1EA9<6QV;"\O94-8+VU-=G8K;WE804=-95-:
M65=4<U9D:7)S)B-X03M69&ER<U9D:7)S5F1I<D1V>DPX.%AN;$Q48D\V=$Q7
M3S9K=7!Z0U9L6FQ505)S.69H+S%C>4Y0:$5Y8F-V4C996G!%13%S.#)V=GHQ
M)B-X03LQ*S=T6'0R,'4Q5EAP5FA*2EA99RM(=&U82%-20C5L,E5E>6]G+U5I
M4"MH9U!-4"]!1F%B5"]K6DPO5$DO:V\Y-5(O2DUF-7AE<V54)B-X03M.9FPX
M=V573$172F]69VQU,%IN:5%L;$)6,E19;F8X05IZ0WEW-%I%3W!Z-'9$;5DY
M>61:5S!U>%8R2W5X5C)+=7A6,DMU>%8R2W!4)B-X03MR6"](4S!$+T%*:C,O
M=T-O1S9Y8V52.3,V47%B6D)867%L,VU8+VQ(3E8O-6<W:B]!2DY.:7%9-'%G
M<$YB,&U05D1P8VPQ1VUO3&(O)B-X03M!1GAR9&I1:41N-EEK2C9!1CEH53<T
M<6=V2E O04-H;6=F.$%B3W10*U1#67%N5TMU>%9,9DPO*SA%=B]!1$=8,R]5
M6DQG1$=02DUS)B-X03M,2C)+=7A6,DMU>%8R2W5X5C)+=7A6-58O=T$U0F8X
M04A$,&HO;4YB+VMY*UIU:35N,T\Q-THK<RLU-&IM=V0X-T98,' K568O:W4Y
M)B-X03M'+S1X>68X04HU.#%/<2]V0SAT<G8W-E1,.&]C5C)+=7A6,DMU>%8R
M2W5X5C)+=FTO=T0U>5$K3'HQ6DDS>$MU;'=L5D\T0DYX8U9))B-X03M(=E%:
M=75Z041!*SEQ>48U5#956#AI-V1.:&UY-%(S3F1L6E!'9V=K255!:%=)24AT
M9TU26$I14RLV8S52>55U.'DO.&\U<78O34AC)B-X03MF.&UM>%9:;VUU='%J
M,V-C;6XS5VY45V-G:FQI=7I!4U-W-4%Q8F579&%&84AR,WA61E!P5VQV94YE
M=EIW3F5V2#9$,TIJ47EM3&M')B-X03LY3752>4LX9T1X<E-U2W!F-4HO-5%Z
M45 K,F1A9CAM17A63W-69&EQ5RM8+T%094-8+VU-=G8X07%-;'=":DAK;5=&
M:S=&6%EQ-T98)B-X03M9<3=&6%EQ-T9867$X<2\U>41.3D,P9R\X=G)D3B\X
M061,-6TV3&UF8S=8<VXV>C=N:'I426]Q83 O,50O5$YJ5'9M+U58,R]!3T)0
M)B-X03LY349+*VQV>6HS+TQR4G8K36-V+T%#9F9.5'%V-W=V3#8W*RMK>2]+
M2$5D:7)S5F1I<G-69&ER<U9D:7(U="\U>5%25S@K5U939'1+)B-X03MH-D5J
M+VHT=5!!-75U>E!O4'9A<VIY950P63)137HQ8SA6*TYV-C5S:E17,6-1;TE*
M1%9V<TXK,#-H.#A33FQ$-W)Z:S-*4S=Z3"]Y)B-X03MJ;7$O.'=D>"]W06UM
M>%8U9B]Z:E9"-6$P-WDW<3)J85!Q>F%P4&(S9W5,=C%,9C9S>4-:0D=N=VE3
M64UR1S-B:65686(P04MK<799)B-X03M*2$-)>G15:%%346],1V<S,E9A:R])
M67%K,VMG,3AL-D%F.$%T5S)N+TIH3594:5-33T].<$I'0U)O0WIU>$%52T)5
M:VLY04U64S,O)B-X03M!0E0U62\V=3EL+S!K>&8X,5E/24U016HS:$PY0SAZ
M95<P<W!1*W$R86LS9#1W0G5)9V%.9'EK2&1U-$YC:4I":DA*1W595'5Y,514
M)B-X03MB.$]B1S=H=6A(45-'0U)*3TYE;&5*3DLP>5%.=&=K1'E23T9,<U9D
M:7)S5F1I<G-69&ER<U9E5F8X-4)F.&-04U X06U.8B]!2DUV)B-X03MM8F]U
M6CEZ=&5Y9G)0=65)-7-(9D]X5CE+9FQ(+W=#4S<P8B]!27AY9CAN;GI5-G(K
M.$QY,G4O=G!-=GEH>%A9<3=&6%EQ-T9867$W)B-X03M&6%EQ*V)V*V-J,E5E
M9DQ/<$$O,T9W.68K66DT>F1D;6919F4Q6DAL4F5),'%64&AU33)B57-U2D4K
M<GDO15!S3C,Y<T)/>5$K-F,U)B-X03M.>55U.'DO.&\U<78O34AC9CAM;7A6
M9R\U1C9B6C)0;'DY5WDP=38P:3%K=6EY,G0W6C-&:DDW8T9R349U8G4O9&<V
M.%)53T)T<V]X)B-X03M6-E1I<5,K4V8K54TP1"]T;E=N+T%#651&5EAZ8B]Y
M:75S+SAW3GHO04UM5WE-=5)A.'8P2#-&.#0U:E!N5'-696\O:V@Y<E<O;&$O
M)B-X03LX>G-T>&18<79:+RLW;#<S<5=83R]D:7)S5F1I<G-69&ER<U9D:7)%
M4'I).&I84&TW5')/,70W=$Q.-U=C>D8U14UG649'4VQ!>2]Z)B-X03M:9G X
M=V=466-V4V%N=UI%,65Z>FTO.$%Y23%A>G1*3&<V>D$T4VYW:4)X5W)!9C<X
M.3AY-#9Y2DY5-T=086]*<F@K,45F.$%1=FUR)B-X03LO=T16-W0O*VMD+RMQ
M;40X-TAU4B]+-"]M+V$Y53AN84)*-64X=%=/:GE40S1E,%9L85I62T)I>G,K
M>6MM;C)V2$U,3%!I:U,V<E!L)B-X03LX4UIL,W!Z;&)3-T9867$W1EA9<3=&
M6%EQ-T952F4V4'!&.#9V9E=.=F1/9S1O,#!34T5$<E%&9V-):U)Y5FDR<#9(
M67E8,6<P2&LV)B-X03MS3G!D4$I/>7@V86]K:BMR>E)#9TTT2BM/4E=O=T@S
M-6%*1VHV=G963V),>2]W0UAR:45Y5&588F5Z97!(<%1W5W!A;C@S-VMY<E0V
M)B-X03MC9UIN=E9/.&=Q6&5:9CA!;$A.5B]W0UE/-"\U3DYI<GIJ+VY'-GEU
M<E!Y5G%%5GAC5W1Y2#%/5V5&-T]E,W5%0U11=W51>'0U6C%2)B-X03MG-5E&
M0V%I;FAV:7(P3S5U9DUI83198F4P9VTP9S):9&)H-41'-'5X2T(V8D5E;V5$
M4D=O26HR238W-TMQ6&MI=BM#.4%R,2]2=' O)B-X03MY651&5EAZ8E@O0VUT
M538O54QN+T%*371K6F-I,35F;U!U3#5R-5AN*RMO+RM2:F8X,%IJ4&YE>6A:
M=U@Q=D5565)Y16M'=DYH,%5$)B-X03MU<F5&8U=5:4,Y8B]!0TU-<$]T*V]Q
M<68Y1G!X670O=C=X0S5B:39V5#EG9C-C=F4Y5GDU,S=S5F1I<G-69&ER<U9D
M:7)S5F1I<5AE)B-X03M99CA!:FHS2"MW+S1M=51X.#)E4&UM3U%93WA6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A63'9-=CA!>6IM<2]W1$U(8V8X
M)B-X03MM;7A6-3<O>FIV-59V=DQ8:S8O<W(R0U<S;6LQ1U-92DUK<U1&6&=H
M<#A%<U5"<78R0U9Q<$LO0V%9<3E4>%9*9DI0+T%#:&UG9CA!)B-X03MB3W10
M*U1#67%Q*V)F*U56,6XO;4)U9BM43%I'6$ET95@V1#=I*V-C>&YZ<#)+=E5F
M>5$K,7)F>71F.$%M9&QU3'$Y5C=0.$$Y,TPS)B-X03MV57-U9"LW1EA9<3=&
M6%EQ-T9867$W1EA9<6LS;4LK:BMP6$9Q<U9X2DXX1D)(8E1Y2V9I5G1N4D=5
M-V4K5UEX=F)::FIV9C95>'1B)B-X03LK0S9,0TI:;#0P2CE71V%(<C1E<7%6
M*VI)1TY-5$=K4F=9=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+<&0U
M;"]W0U5C,5@O)B-X03M!2F<W:B]K,#)+<TLO27IY:$(U5SAR,S)N=U-83GA$
M2F9Y5%)85C-A6$9H3$ER4E)D64QK3$E/3$)L-6-11W!81EAO<V=C;W=J259Y
M)B-X03M$=UIH>4%066M!<E@W.%938GE26"]"96=6-B]O,C O-4U*:7%B,T9V
M1&,R.'1V3V=K9VU2;S59,C-$27=O>6ME0D)X45)A42\X<3DX)B-X03MK+SA!
M5FUT=BM"+W1Y4$%(2"]*668U:V9K14)O;FM,>61.6GE03'!.=3=#-G4P0DLO
M<W!D4TEO-CEL541!26AJ2%(T9C5K9FM'46%2)B-X03LU93!44GA+3DQS-')4
M,2M0<F5K2V-U1F5.9FQY3U-!06(X94M%4'!!2'541$,R3WA6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+)B-X03MU>%8R2W!6<4=R-FI:,6(Y2$=317EX
M=V\T;5%%;5=266M.1# K2GAI<4YS-7)U5E=.>F)F5FU"*T9E879595!W-'%I
M359D:7)S5F1I)B-X03MR<U9D:7)S5E,W>DPO=T%O-7%V+T%$0C-(+TIP<U9E
M968X-#8S;6\S9FLO54I.43AW;GI*8TIQ56M:=FI*95-C85%X3C9F.$%P,%5%
M)B-X03MQ.&585&I4,WA5=E9-5E-8>50O>6AM9V8Y<S8P+W=#5$-9<6Y72V]E
M.'5:-$95>%=K=#)73D-S2FE"6#-0<7E21#=S0E%3;&UI5#9J)B-X03M"16)E
M9E-R;4PQ3&TT:SE5=F%L5E-A-&524V5->DYS<FET06-!67A*-VLW>51.,DMU
M>%9J,VYB>D)F-DQ95V,Q:TEZ2F,S46=9>7A3)B-X03M49TPV37-L46M427A.
M67@S>%9G*V]E8F1D=E$O2V8P6DA1;TAG='14:30Q0F]W5DQG2E56-VI#:&9A
M*V-T8W1P1$I(27)-4GA);'1T)B-X03M4;5=L469S>5A,:74S6$978RM43F)V
M9&$P6#8W94--5&EE84DK;$<X4VM2=59"-%---T$P1SE49U-N=4MU>%8R2W5X
M5C)+=7A6,DMU)B-X03MX5C5(*V97<F%V63-0;#E.4#%#-G-6;5,Y85E7;'A,
M8CAY:'1W=DPP;51L>#5M;&9(0T9E55-E65!-<W%H6DYC,5(Q1$LT1%@Y,E)Y
M)B-X03M29WEN951Q1T%)=V]8+S1L.# O.5@W5F8K-&AD+W=$5EA&6#!R-4AU
M8FDV.&QE6#=Q-6MA831N,#)Z;&UM:TI:,V0T15IM6FIU4U-A)B-X03MK-49+
M9#1Q-T9867$W1EA9<3=&574X>2\X;S5Q=B]-2&-F.$%*<'-695AF.#0P>BM7
M;W9,=7(V6G!&>E!,4$1E3&188T9Z16M,>&5V)B-X03M%<UE!.4]E-E9K6C=E
M4FQ*9FQ4<4MC4U98<&PU-6)S<G986719:VQM4V5+,&MS:$A%56I":FQK4U9I
M6E555&=H;VA3:V=8<G1V:7%N)B-X03LU24902F5G1"]T5S)N+TIH3594<D98
M67$W1EA9<3=&6%EQ>$PX>&8Y-4Y*+S5J+RMX4S1W:%=,66]D:7),=GDV+W=#
M3T)*+WI'6%@O)B-X03M!0V1/2E-Y:D%R<U9D:7)S5F1I<G-69&ER<U9E3&8X
M04]257-59#4U8DUJ<6=-9"]1<U%0,G)8>'=H6&IS*W R34MH;6U5:&IX2$9L
M)B-X03M/-39D.$M&6#8S868W*VHO04]#2#EC5F95+S5E+W=$2T$K5W8K,E99
M+W=$54UM4E-N*TMU>%8R2W5X5C)+=7A63'9-=B]+3V%R+WI")B-X03LS2"]*
M<'-666PK4S)H83%O=FQ+4WHQ:E)O.41V;75P2G!B3T)I.%IA4E9*:U9Z9#,S
M3&Q49F1+2%E*,TMR4'-64UAY5"]W06]:;T@O)B-X03M!1WIR5"]K=VU+<#%I
M<G-69&ER<U9D:7)S5EEL*UEV*SAM:R\X>"\O04=+6$=%2WA#-W19-W$S94-1
M:TDY2VM5<G-196A"0C9D0TM()B-X03MV:6AU,70P=')A2S-1:W!%;U)3,4MK
M2TMD<40W<U9:;BM86"]!0G=*4"M9>38O-4]N17!:4F=6,DMU>%8R2W5X5C)+
M=7A6,DMS63@V)B-X03MF;#=O;FTU<DHY4VUU65=S0DM)5&)/<59%+T1N>35)
M.68W<&%9<7A:+W=$;DAN>5DU2D]O87 X=EAH<'8O=T$X8TYQ=E0O;D@W>6-O
M)B-X03M0*VXV;S%F-7 T:B]!37EC8E8V2'!/;3(R;#986C9:83AV<3%J0DAB
M46-Z5G94:%%)=%0S3D9W2VES5F1I<G-69&ER<U9D:7%895IF)B-X03LK56,Q
M6"]M1'50.$%K,#)+<U4O2C)/1TAY+V4R.71,6GI7348V5G,S,#(X=6(K,45B
M45%Y36E46$US-7%K:G5R8U-!4TLX5G)41E=D)B-X03MY4G!):E)Y2TA2=U9D
M1T91461I0T1I<51E4T%"-4PP041P*VIB5"]K=VU+<#%I<G-69&ER<U9D:7)S
M5EEL*UEV*SAM:R]W1$UF+S)+)B-X03M81T5+>&)&1'-66F0K6%@O04)W2E K
M67DV+S5/;D5P6E)G5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R)B-X03M+<&0U;"\U4GI69BM93S0O-4Y.:7%9-'%L=#$U9W-,
M6%8P,'%54T<V93%K=E973F952FEI:U-*-DEN2U5K3DUV4DME*TMO9GE182M3
M)B-X03LY05 O04=R8E0O:W=M2W Q:7)S5F1I<G-69&ER<U99;"M9=BLX;6LO
M.'@O+T%'2UA'14MX8D9$<U9:9"M86"](06LO-6I,<B]!2D]N)B-X03M%<%I2
M9U8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMP
M9#5L+W=#56,Q6"]!2F<W:B]K,#)+<&II<G-6)B-X03M36'E4+W=!;UIO2"]!
M1WIR5"]K=VU+<#%I<G-69&ER<U9D:7)S5E-0>F)O5C-R1G!A>#)K<V-C,7)C
M0S1(<6AU3$0P<$EI4&@S2#DW)B-X03M81E=,>2M34$](3#DQ3G O2"]+33EA
M+U%U1S!.>&534$XO3#DW3G O1VTS17HQ<CE+-#)R2R]+96DS3VHV5#E5=5I%
M;&UA85=:;6ER)B-X03MX2'%U5T%(3&9A=4)+8UEQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&574X>2\X;S5Q=B]-2&-F.&UM
M)B-X03MX5DUC5F%K3$MJ1D8U=4%3<3%P53EH6$95;3AK9CAO6&](+V).=% K
M5$-9<6Y72W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R)B-X03M+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9,=DUV+T%#:FUQ
M+SA!34AC9CAM;7A636-69&EQ4RM39BM533!$)B-X03LO=&Y7;B]*:$U65')&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ)B-X03LW1EA9<6PS;5@O;$A.5B\U9S=J+T%*
M3DYI<5DT<6Q&>&)E6C(X=TY08C-K165I;7DY3DQE4D]B0S@Y5W9Q1E%),DLK
M;#A0.$%E.68R)B-X03ME*TMP5#57.'<R;&HU63!I>74W6%59-W$Q<W)E1S1J
M+T%%6G%"-'E2>$MR:7%W14=H2%DT<6UF*TQT2R\S>'%0+V-,,4@O<VYX5C,K
M)B-X03M,=$LO,WAQ4"]C3#%(+W-N>%9B1C5Z,%=64S!C5V]/;UIK2EA43E))
M-4EX5F@O=E Q1$%G-'%U+WAD<%@K*TY2+W=#-%AQ4"]!1U0T)B-X03MQ-R]&
M,FQF-S0Q2"]!3&AE;R\X05I0:7)V.%AA5B]V:E5F.$%U1C9J+W=":RM+=2]X
M9'!8*RM.4B]W0S18<5 O04=4-'$W+T8R;&8W)B-X03LT,4@O04QH96\O.$%:
M4&EQ,DAZ;F]S,%-44E)A9SA5:6@T,UA43E))6E=&45%F<2]1:D96,RM,=$LO
M,WAQ4#A!,T,Y4B]W0WEF1EAF)B-X03LT=3!R+V9';R]W1&-,,4@O04Q*.%9D
M+VDW4W8Y.&%J+T%.=W959CA!<VYX5C,K3'1++S-X<5 X03-#.5(O=T-Y9D97
M;C@T-D]I33=W)B-X03LV:7%+0U=9-EIQ3D%"=50O04QZ-'$U4$]/:G5I=6M/
M;W-J04971VUA:E%G-V<O-WHT<3,O04EU,'(O9D=O+SA!8TPQ2"]S;GA6,RM,
M)B-X03MT2R\S>'%0+T%(0SE2+S=*.%9D+VDW4W8Y.&%J+W="=W959BMY9D98
M9C1U,'(O9D=O+SA!8TPQ2"]S;GA68DXU>C!71THU<%ET45-+)B-X03M.4SAJ
M='!M;V=+<6EP2E Q9F]":7$W+T8R;&8W-#%(+T%,:&5O+SA!6E!I<G8X6&%6
M+W9J568X075&-FHO=T)K*TMU+WAD<%@K*TY2)B-X03LO=T,T6'%0+T%'5#1Q
M-R]&,FQF-S0Q2"]!3&AE;R\X05I0:7)V.%AA5B]V:E5F.$%U1C9J+W=":RM+
M<EIF3V5I>$M':VDQ0D9,2V=,)B-X03MA6G%)2$HR0W%0.$%E9G%724%X5F0O
M:3=3=CA!9D=O+SEW=E5F*WEF1EAF-'4P<B]!2'AQ4"]C3#%(+W-N>%9"834U
M;7-,;E).470T)B-X03M,8E5N;6UT<&\T:R]2;6]#<E!'46]Q64MD5&ER2CA6
M9&EQ5RM:.5HO469L=E9T83E(-G@K:3=/-'9F<2],:#9N,65*<&5(3VIC95A'
M)B-X03ML84=M2W9+6G8K8V]F2S%V<&5O6$4R;5A46#%L3DIB2D1"5F](:TAR
M*VE(;6M31C0O549T5G8S4DMH:'-A3GA65%!Y>BMF;&PU:G8W)B-X03MJ4W1.
M,$,X:S%54G)*6E)I4T9R9#)L=%!R56-C.#9S9E%F-%I&66-'-#AE-R]":7%!
M2"]/4T]G5U13<&8V1&57:5<Q<"MK3'HP=4)))B-X03MJ=5IB9C9S,%-Y96@V
M:&Q7.$1Y9EI++S5686A656DO-7EF.$%)<GE4039D<5E32TM+6F5-9'9)>F5R
M8GE83DM2>D]O;VM91S=6-4=H)B-X03M!;U1I<DXO2E U:6%6-75-:3)6;F0R
M:&IT3%<K<&1I06-O8C!Y*VE6.4=78F-I06MJ='-$=E5"5DU03DAM=E103%9T
M6EA';TQ),&0O)B-X03MF5RMN4D=)265-=# O0D=B;7EF0796<59.3WAX5C5V
M2"MF,39D23!N535T070W84A6-V(V>D-S,F]T1U5!=C1,16PK5F]0,V8K;$)W
M)B-X03LO9FDR,4%'2W%-.'=F;GAA85AA5T9W=6MT2#EB=#=/-&QH,4XU-T-:
M0F543D-W:FI.=$TX=W1Y;%I7555O5C1C<31Q<#(O-3141'DO)B-X03ME86EV
M;'HP64Q/,3!Y-'11='EZ=U-*<50R.%%25VAT-4=$44YC34A663)B-%)19D5+
M2V\R,B]09E%:3DYL=5HY2#%/,G59<EE81%<X)B-X03MK56)*>4YZ3%IL2&Y2
M,VIH5F)I,F142E V86=B,3-P:7%%.'4O=T1/4C-L1%=(,%,S8E1T4G1R>E<U
M,',T5DU58GA,8VXP438X*V%S)B-X03MY2V)G9DAW,T%*<#)X5C9V:7)%+U O
M-6EA6C5.=%EM=7)E4S5U8G5#*VUS-&M+26I.65=R,U1*23=(:V=C2GA"5D<S
M4%1&5T@V:BME)B-X03MT,UI.0D9E95AO:CEA=#=/-$5#,W)'67!E,G0Q8V5N
M-DPR>45Y+S9%55)$.79M;&5*3D%Q,S5X+U R>3AT,V-L=D)P4WEW=W0V65,W
M)B-X03MM;G-,:R\V14QT1T9Q.7$W<D<Y9E)6;C0O1T150E)Y>%9M=FMV>FIC
M95DU3E=J;C P-F5D3757=&QF,6974V1A='AM:5E)9TM-9U4K)B-X03MX<7 S
M6$975%EQ-T973BMD+TXX+VQQ4%)J0G U,4=85TY59S!T66A),%I4,6\U2E!5
M*T=/6&QX.4QP441U5T%'2W-0,&(X-E@Q2%@T)B-X03M.1#%04DE5:G9';&A*
M<V)Q6%5P0T5N=DQ6;BMR2F%2=3!0<5=$8S,V2TI)>3)Z2&EQ9W!0*V-G>6)N
M5#=A,#!70S9N,4M'-VUH:%A5)B-X03M/3'A.8E=A6&%16$A+,T-X>E V;G!S
M=DDX1S=N1EAP=FQF5S(Q,U%,3%8R=%AS:F52*W Y5FQR-FM9<5%&96]7:F)B
M:6UX>%9.359D)B-X03MI<D=V3V9M>2]W0D-N,%<Q,"]4-'11=3E:=3)T23!M
M=5=T5FI#45-4=$MZ3$1C17%Q>$=V=S=9<7=J>3<K9D5E<G=8<VUO84%55WIS
M)B-X03M2<5-W5T4P;7!Z8E$R,7I#<VM59'1'675F,711:FXT47E35DE#5GA6
M5&TO-7E!2V%G3$-(4TQ3.'5(:$1W9E9T4T1X>7I%,T$Y2T]2)B-X03LW94Y'
M*TLQ-$4Q<GE9555Q1UE&6' O;'I6,C%N46)$5FUT,G1$9E%*8V96;DI,>&E1
M8V=R5D,O14%D>%1R9U9-8U9D:7)S5F1I<G-6)B-X03ME540X=G9Z6&<X>&%J
M<3EP-6IT:#8Y>&-V<#9806$V84-#9E59<&A%<EA-53=2<3%M2%(T-$1';DI9
M*W1#*TMT6&9L4#@O.$$Y4&%H)B-X03ME,F9M=E0T-U,U:&1);VEJ96US<4Q,
M.5AA2S-K9W5"8G%'9%!52'%333%#4W@K1E%Q>B]Y9F)E86)B>3=A42MA<G5#
M.3$U9E5.-6,R)B-X03MI.%E7<DEX:D-$:D@Y;4UQ=C)2,'A63V-69&ER<U99
M1#4K.'%F;4)R1W)W>2M8.5DO4C%M<5)#;C%M940P-45J=3!E47AX2WEZ5F4T
M)B-X03MG9F<U-'0V6$4P<G5Q;&M8;'8X04]I.3!(6$Q,53EF5U!5;75B5G1*
M=4E04VA266MU;&YM-%-14GAY<W9O2TEG2D97<CAW,55+=&ER)B-X03LP3%%,
M6%5R5%%T3W1D5'5"9#9L8C)S358W9$-P17,V4FA:2DMK2V9I644Y0FEQ4'A6
M,DMP8C5N<V13=B]!0S-Q,6IP9'@Y53%/-W,W)B-X03MI0WAU=6)X*VQ02D5Y
M>%-C,$)D94QK2&MO<4\R2W9+=$8P>C@S2EIK,'93+U!M:C,V5TUK8VQZ1C9P
M=34T,$YX1$]O9C17=51(-E!/)B-X03M-3$I/5UE'<&LK365M<70Q2S,O3C-3
M.5@Q0G!F4"MI,DU5*W)E=&(R=#-*1TM7,#=!45=P:FYH:V%-=D9%>%)9,T<V
M='4U8W5I<C%Z)B-X03M1;V17:#!45#1D66Y3-C%A3S)H5%5,;4E"56MU1E%#
M5C%!5DM";G%2.$DK47A61S1Q-T95=#AZ,D]P6"]!2F(Q87@P=30K<6%N9#)D
M)B-X03MX0EDS6$XT+U-N:VE:67!/84%U=D9Y1'E55DAB1EAL+VQE>"].5U!6
M3#=3<E!Z+V\R<$-Z9VQ#,D0O-F1C5SAJ<D=9>DM+<F155U%Y)B-X03M+<E-Z
M=6%C4V5:,GA60E=M:R]N,W!T-4QO>#@W-DMB<61*2F1/<S=Y650S9T5T>GHU
M='ET16ML0WAH,%5G0F5W54%#:7(R.%9P=C%X)B-X03M6,DMU>%9I+S5L84YR
M3W-E5DHW3%-.62]11C P,$1V<31M:V=-14M3<3!Z07AL4W@Y345"0WEQ935(
M6$971V56-U0X-#E50S9L0C4S)B-X03LP6%9R35=5,75K,6]Q6$9T.65-<$EC
M<D)(1'E#>$)6+W90:&)F:7=Q<G%P1'!++VY20F98,FE7;C5H95AR;3AI36EW
M,E4Y,4AD,W-%)B-X03MK;#)V.3DO;W%Y3596>D=0:$-G:TM&030P5F4X:71.
M*W5+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5.
M)B-X03M+1W94,B]S>%8X;F5A=CA!;%4S-DYG+S0W;C$W.3,K9R]R2#%4-FPO
M>'DW6&@Y63E(.3<Y6"MQ+U9F<D@W6%AH*S-H4WHS>E8O=T%Q)B-X03LX*V]4
M*W8X07!N.4(O;V)34%<Y1#9N.5@K;V5H9"]5<6-V.$%33V9$,7$O<SAU4$PT
M8U509$)39W P.2\W8T-U>%8R2W5X5CAY83DO)B-X03MY<2\Q>C9N-F$Y8C9X
M0BMI=E<K;V959E8Y1W<T8R\X060O<&5N.5,Y9FXX6%AH=GIW<7EN>3DO>7)F
M.$%49FMR-G8X05A0<B]!3V=D)B-X03M,.40P4%,K<65J.6-8,'5F*S=F5RMU
M.&95<#)R6'9I<C-,07)S5F1I<5,K8W9Q4"M(<"]R=G%E;#9T=#9F<&-E6'(O
M5TDO42LQ.$Y0)B-X03M7-%8U8E4V-'$K9$Q$+VQ62#9:,$0P9C!P.5DU-F(V
M,S9B*V\K;CE4.5-W.4-V,6(Y=C!F<78X06LK;'HU+TAY=W$Y36HO=U K;3<O
M)B-X03M!2F989E@O5%DY86XQ3#!V<E V57-E6&]F5F1Q9E=V<6YQ."\S;$LX
M+W="-WIW2SE:>%8R2W8X02\Y:ST\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @
M(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @
M('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)
M1#YX;7 N:6ED.D5",S$Y-C Y,D$Q-45!,3%!,#0W1#1%-4(U03)$13%%/"]X
M;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX
M;7 N9&ED.D5",S$Y-C Y,D$Q-45!,3%!,#0W1#1%-4(U03)$13%%/"]X;7!-
M33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I
M=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @
M(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.D5!
M,S$Y-C Y,D$Q-45!,3%!,#0W1#1%-4(U03)$13%%/"]S=%)E9CII;G-T86YC
M94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.D5!
M,S$Y-C Y,D$Q-45!,3%!,#0W1#1%-4(U03)$13%%/"]S=%)E9CID;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO
M;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @
M(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R
M>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1#A"1C-%0S0P
M13$Q14$Q,3E$13A$,S-!03 P-$0P,S0\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM,3$M,C=4,3<Z,SDZ
M,S K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D5",S$Y-C Y,D$Q-45!,3%!,#0W1#1%
M-4(U03)$13%%/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#$Y+3$R+3 R5#(S.C T.C0Y*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R871O
M<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @
M(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU
M<W1R871O<CI3=&%R='5P4')O9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @
M(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \>&UP5%!G.DAA
M<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R
M<')I;G0^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @
M(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @
M(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W1$:6TZ=SXV,3(N,# P,# P/"]S=$1I;3IW/@H@
M(" @(" @(" @(" \<W1$:6TZ:#XQ,# X+C P,# P,#PO<W1$:6TZ:#X*(" @
M(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @
M(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&
M;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$YA;64^5&EM97-.97=2;VUA;E!3+4)O;&0\+W-T
M1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A
M;6EL>3Y4:6UE<R!.97<@4F]M86X@4%,\+W-T1FYT.F9O;G1&86UI;'D^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF
M;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y
M<&4@,3PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IV97)S:6]N4W1R:6YG/C P,2XP,#$\+W-T1FYT.G9E<G-I;VY3=')I;F<^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T
M1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M:6QE3F%M93Y-5$)?7U]?+E!&0CL@351"7U]?7RY01DT\+W-T1FYT.F9O;G1&
M:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^5&EM97-.97=2;VUA;E!3/"]S
M=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86UI;'D^5&EM97,@3F5W(%)O;6%N(%!3/"]S=$9N=#IF;VYT1F%M:6QY/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F]M86X\+W-T1FYT
M.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^
M5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P,3PO<W1&;G0Z=F5R<VEO;E-T<FEN
M9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO
M<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9I;&5.86UE/DU44E]?7U\N4$9".R!-5%)?7U]?+E!&33PO<W1&;G0Z9F]N
M=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @
M(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3
M=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R
M;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z
M9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM
M<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@
M(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$U+C P
M/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \
M+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $G 9$# 1$  A$! Q$!_\0
M'P !  $% 0$! 0$           @&!PD*"P4$ @$#_\0 51   00" @ !!0H'
M"!$#!0$ !0,$!@<  @$($0D2$Q46%!@A55=XEYC6V H7(C<XMK@95G1V=Y6T
MMR,Q-#4V05%88764EK73U-772)&A)#(YD]+!_\0 '0$! 0 " @,!
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M=^2BXDB7V"# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X
M]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_
MIAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]
MZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_I
MAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]Z
ME27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IA
MN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE
M27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN
M3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X ]ZE27Q+,_IAN3[?X!H]_C
MVO\ _P XCL3]/EP?;3)1</.^TM7P<R[#H'Y2# /YQKQQSMSQQQQSMSYVW/''
M''.W/AQKX[?Y>?-UUU\>?A\->./[7'& 1KZH?FNE/SE>Y_[8=ZX*\^1=2)*X
M(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@$70'Z:EM?-=Z\_P!;'9[.<G?%J[_QY?'ZA<9V:?\
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M/TU+:^:[UY_K8[/9SD[XM7?^/+X_4+C.S3_B;=?Y37_^RMS9*+.#.LC & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8!SG\ W7I'Q)&_?&'[;.K!YCSAB
M#V9AF3&VGT-7W=U==J)N0%'0F;M*9CXP:Y#1H7HXED3)2HW)B3-D.8-_< 0]
MR+J]*ZL^5=ID"P08!&KJA^:Z4_.5[G_MAWK@KSY%U(DK@@P#13NK](+L]\[#
MM7^T39F=)MOPRT^.F>4S\>O#)_Q4W??E/>GU\1;O/%/6@P!@&Y-Y.S] OIO\
MVFF?U"!YWBR?!;/XF7Y*/V>\'?Q"W&_DS<O[/D$RL\@[D, 8 P!@# & , 8
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MJO2S3[[O*UWC,L\FP6:*5(BM,V*8I4$44]11J6FH=-I.*FEHPUHJ1_<*#?\
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MU%%%3+2;=.<PBCCCIIQQ1TRTHG%3BJV?5F)B, 8 P!@# & , 8 P!@# & ,
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M1/?CC;3?3;C?3;7G^USKMKSSKMQS_BYXYYXP#]8 P!@# & , 8 P!@# & ,
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M>(V7,84S?A11>0RLBQ;$!T=:/MT',C+\ZN'"W*3O9'E/774\V;$2OP!@# &
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MYN21U5XVYY]&MN&/%A^V_'/+=\XT\-^17GR+J1*S!!@# & , 8 P!@# & ,
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M[N 9"_)?_H1U1_&6]/V@[4S0\WQOK-ZR7$NHG[D*, 8 P!@# & , 8 P!@#
M& 8/?P@U[J.\GXB^V;O'>K7L=U\6Y;#VRCQ\OQI-T^?1M6J7'*KA;;^UHEIQ
MSMMS\'&90^ZA^DNL9U7_ $Q9_19IX?C+:_O-LG_<<S_R\\S2_P"F+F-6@_E0
M?G(M-/\ L"4C#_9L&AQ]REM'ER3[DS%)&R6BB23]-MS+S>B&BO#Z)()*JZN6
MR' XC[K8\Z-W:S5P^=@L(ICA>6%-:>&.+=-5.+(SAE)JKB6=,(D]+#W*X=?$
M751LYKNDEO[(V*KYZ>FWI48,9X25\[7CGTB7'@KX)[^/G:<>D4\->>/R]_\
M[N<U%@L(GPI8/BQ?68:#^5!^>B=_DJ9<C(/*E]%6B8&6"MDIO?+CE<_'7X=J
MIQKTZ[&I^B2<.M-4U''/*O&^J.O/G\IZ*[\<>:GMX:9SJH<&L=:-LN&BF8PO
MVJR:?W\.PWYL\<# & , 8 P!@# & , 8 P#G/X!NAKZ#+:[PNE@C4?/XI62
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M & , 8 P!@# & , 8 P!@# & , 8 P!@'.?P#HP8 P!@$:NJ'YKI3\Y7N?\
MMAWK@KSY%U(DK@@P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# .<_@'1@P!@# (J=,@K..4J6
M CUBSAB)[$]R&+5<\?.RHRJBAW O333<G(Y.2,2$T\VXX\5B!@H_(.=O'=PY
M5WYYVP5Y\BZD2KP08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'.?P#HP8 P!@$:NJ'YKI3\
MY7N?^V'>N"O/D74B2N"# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , YS^ =&# & 6T&V_716
M2RZ)MI,R3+P?CSI#[NX5'#V^J:C9N^V:%GR: TEJ'>O&8TYNP=.-0Q1TW&D>
M6[U75'D"UG41XT(5+(GK!TW>LG79#N8LV=M%TG+5PCOW"O7G15!PCMNDLGOQ
M\.JB>^VNW'P\<\X*\^1=2)/8(, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M0 I%0#&$R=2'JAG,?&!F X&V^_%RO)9D[L$& 0*[8])Z7ON3)W3;5D69"&,
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M6K%FV9ZN7JW+AXXU;(Z(\+NU^>..5W*W&GI%UN>..5%=M]^>./.\,&)]F ,
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M3!A!&,OY9+6.DA-B";-L/$;K3EZ74FS@@P!@# & 02[-=-JMO.QN+>M:9\
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M_/BZ6%*;577WKG6NNE#,W@Q& , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g838337g53l12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g53l12.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2\ 4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "$< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 %4')I;G0R.$))300E
M       0^*S$H2T?_KQ""!DS".HC_CA"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !  $#
MP     $  3A"24T$)@      #@             _@   .$))30/R       *
M  #_______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      1T   $U          !                          $
M    !-0   1T                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   1T     %)G:'1L;VYG   $U     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $=     !2
M9VAT;&]N9P  !-0    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     PX0DE-! P     )*4    !    H    )0   '@  $5@
M)(D &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( )0
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M_C)FL#GNK;4USZXWM%[B6SJW</S=REZ#_P#0?^#.55GU=H8VMK;[ &%I( 8
M=KO4<UK?3VU5N]FUE7\RRO\ 1*!^JN!Z7I,>]C3LW[0T;M@:T;]K6[OHO?\
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MQ,AY.58"6AK<^AK=NCI+*]PMV;=_M/Z-UO\ 4_T:GUQF.W'Q?3:QI&;B#V@
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MWU+^L=<LQ;J*FD%K7-OO ;/TG>F6.^E^?^^N]7GX_P :EI_[R(U(UO=V,?\
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M)'Z+\[>__A%"FSK&ZLVUL+-S18W0. </>]KFV/9^A_PG[_Z3TO\ !I*:.-T
M8N9C758>,TL(<^UKK9:8BSTVO=_6V?\ 4+8ROYIO_&5?^?&*L,CJHT.*UT=P
M]HGC\V?ZW^OZ1%<;3B5&X1;OJW\<[ZY^B7)*?__0](9ZGO\ 2]?9O?QZ,3N=
MOV[_ '_33_K/_=C_ , 7S"DDI^GOUK_NQ_X E^L_]V/_  !?,*22GZ>_6?\
MNQ_X E^L_P#=C_P!?,*22GZ>_6?^['_@"7ZS_P!V/_ %\PI)*?I[]9_[L?\
M@"7ZS_W8_P# %\PI)*?I[]9_[L?^ )?K/_=C_P  7S"DDI^GOUG_ +L?^ )?
MK/\ W8_\ 7S"DDI^GOUG_NQ_X E^L_\ =C_P!?,*22GZ>_6?^['_ ( E^L_]
MV/\ P!?,*22GZ>_6?^['_@"9_J>SUO7V;V<^C$[F[-WI^_Z:^8DDE/\ _]D
M.$))300A      !=     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P    %P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $,
M0P @ #( ,  Q #4    ! #A"24T$(@     !,DU- "H    (  <!$@ #
M 0 !   !&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "
M    (@   '(!,@ "    %    )2':0 $     0   *@   #4 "W&P   )Q
M+<;    G$$%D;V)E(%!H;W1O<VAO<"!#0R R,#$U("A7:6YD;W=S*0 R,#$Y
M.C Q.C(W(# V.C$P.C R   #H $  P    '__P  H ( !     $   34H ,
M!     $   1T          8! P #     0 &   !&@ %     0   2(!&P %
M     0   2H!*  #     0 "   " 0 $     0   3(" @ $     0
M        2     $   !(     3A"24T#_0      "           _^$!-$U-
M "H    (  <!$@ #     0     !&@ %     0   &(!&P %     0   &H!
M*  #     0 "   !,0 "    (@   '(!,@ "    %    )2':0 $     0
M *@   #4   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#0R R,#$U
M("A7:6YD;W=S*0 R,#$Y.C Q.C(W(# V.C$P.C R   #H $  P    '__P
MH ( !     $   34H , !     $   1T          8! P #     0 &   !
M&@ %     0   2(!&P %     0   2H!*  #     0 "   " 0 $     0
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %M 8P# 1$  A$! Q$!_\0 'P
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M8MA)J:5*)>RG'M\EMD[)7?:#;1@[.R,KU$66@&I]*&E]I>T :E2]T4A#]=&
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M]_R932('(> ^4,SMF^0O'O\ -LA^O975U/C-QB"?"';YC'"JGV1N6?Q,H/\
M0>Z#\ <?6(#XQX>D2#U2+P:0@TA%57;;D(IV7NZ@BA2G(,1C7DIR@8H\9HQP
M(<E$! >! !#D/C#G5B_$'.J('YAYA'G1^#9_\$;?F$OV=9HF#P;/_@C;\PE^
MSI"#P;/_ ((V_,)?LZ0@\&S_ ."-OS"7[.D(^BL&QS%(1D@<YS 4A"MTS&,8
MP\%*4H$$3&,(@   "(B/ >>D(D"\V?[EXZTQ5'?[:\R,KG.QLM,PM3=XIMK>
MQRT3 K,F\W)QT*K"$D7C&(7DH]&2=-VZB+)5ZU(Y.F9=,#14,ZA2(O!M#G\H
M:^^XMN>++&XI^3,?V'']L:-6+UU6KG67]:GF[.3:IOHUVM%3#-F^2;OV2R+M
MFL= $W+95-=$QTSE,,Q,(SP;/_@C;\PE^SI"'1P>S:!FO#H@U;@(95QV("""
M0" A;X?@0'I\A#4#EVAYA$#D/ 8]6#6")CRPMSS=N.Y;<4/<(\CGC, C]:)Y
MB.0[&(C_  ?MZS%^$.=<0&0< ACO#M_]X1_-$_9U:)@\.W_WA'\T3]G2$'AV
M_P#O"/YHG[.D(/#M_P#>$?S1/V=(0Z+#!&793'3[+T;B._/\4QAW*4CDEG29
MQQ16*C-T@Q=D=6I*.-"(&;/7+=HN51Z447*Z2"G2JH4HQ4-H0J&5<=D<2YX7
MR?CF(KT_?\772E0EL3,K6I:U5"8@8Z<*1HRD#%C'<FP;(.E0CI*,DA02.9;T
M;)QLCW?@I!FNM-0'(80W/AV_^\(_FB?LZ0@\.W_WA'\T3]G2$=^#ZG?(0G9Q
M012%*0/?BRJ/!2@4.?2$9Y\  !K"?XA[/*(#,>/R"*A?JG#[)C;I^0N2_K_/
M:LGK[/G$QUG]9(0:0CYZR=(GZR] <\FZ@Z0X\AY-SQY#Y#YZ0@$Y  !$Q0 3
M=(")@ !,(\ 4//\ A<^7'Q\Z0AQ<<8KO&69*9BJ-&QCY>N0"EIGW<Y:ZA282
M%KZ4Q"UX9.5LEYGJW76""D[8H*(;D<RJ:[N0E635JDLLL!=0(TYYY[80K(C;
MCF.?BK)-0E592L;5Y&X1+IPQN=$<&GI#'T2G/WEOCYLG9Q=95]R-?6;V"Q+8
MQ0MZ$3 NV4V]51BWS-VNJ >'#'#G\X5AD-3"#2$=G_ZF%^6_=/\ DJHG];I+
M6,_]W_XHC6' ?,([!7:\?[&SNX_)HE_6FO:H&8<0\XF/-VUGA!I"/GJ+U"7J
M+U '(EY#J !^V(?'Q_'\6D( .01$ ,41#D! # (@)>.H! !\N.0Y^YR'/QZ0
MC[3 5A(5(!5,H8")E3^&)S&'I I +R)C";X( '(B/D <Z0A\5]MN:&ET;8[>
MT]&/NRD%*6:4KDE:Z5&OZ9 P;1=_.263P?6-NCB5&$8MUGLP3)ZU17BV92NG
MR2""J*BD5 ?R'GGA"&XO%'MF-K3+4J[PKBOV>$,T"0C'"K5STI2#!K*QCYF^
MCW#N-E(J7B7S"7A9F+>/8F:B'S&5BGKR.>-G*L@(#E"$II"'EVY?9"X%_+3B
MO^O4#J!R'@/E"/5#U@A!I"#2$8^6_O5)_P WO?\ )E-(@<AX#Y0S.V;Y"\>_
MS;(?KV5U=3XS<8@GPAV^8QPJI]D;EG\3*#_0>Z#\ <?6(#XQX>D2#U2+P:0@
MTA%5G;:?[%_NG_FC&O\ ]L^.=6)\0=OD,0.7:'F$>=5K-$P:0BTK&\?MKC-J
MDBPR-9L<VE>;Q3&7-L9I*X(@,E5#)K7<]5XV;QW!5UG32;BYRV%PJSL]A"WV
MF^-L?2-:L05R$KTF2 B'S&N-=@5[\->K.E-?=A&O?EKV=U-VW8.<BD([ KJ+
MD[EEUOM5F,4,M\M!KN-9S$D!C*-CHW$,CA_<K+4. NLM3*D[FV-%=6ICC=W;
MX#*C&:R"T9Q$H_R5770*QXRL8ZJB.-<LZ@&_8-,\L(</GQK2H=^=1B .X^=K
MTODW$+>K4W&M5M$1&1S6=L$7E3;G<*A<WZUXEGM?E[G+;=(>CXAJBT2Q71@)
M<RC:(E1JD9#2UA<$*9*4=6I@("([/#;K@'. AW /RA<94KF%<FY(PF_R)*X7
MQ/=KU9LEVO=*_P ,9&3R)C]E364DRM$7:(Z:6OF2ZZ?--S8IY$8(46I7:2BY
M&33QNU2AX.QV658*5QH-,>. UKC7;QKG#RPU<^04\H>9BR2]R]DNVY#>1K2#
M2GGZ"<)6X[J]&5*HPD>SKU)ID2!Q,<(>F4^)@ZM$ H8R@1L0U!0YS]1AL 4"
MD3E#::F$.AA#Y:L/?E4QY_6^'U Y=H>81 Y#P'RCU6-8(F/+(W._9+;B?R[Y
M?_\ M#L6LQ/A#M\QB R#@'E#':M$Q-K9:E0&$Y<[==)_'I7%=4H;5E1<A+X+
MB(^VU^:L:ONTF4[!GNB9&@B,J;'1C(9JJ4JL/<EW)A8@95D@Q["?$M35U5[.
M _3;P&D1SVQ-O%$/@F4R!4*ABH-L\SC!I.[PU,R0MXB<8VR_S,A6I7,L[AZ:
MI;RTQ4QD>4Q^PQ!&XP?5*9Q<]]R</.Q5TE<AN6+"1DG<G7&F8@- S$ #+'/7
M77LQ =0N-?'GL'/+&(]YGG]OS?;<QB<=4>B3C"5Q1A%M!V8F2]O$=D2C9A9(
MT=[EV;E\?,Z/%[GYI]+3C/)%6D6]EMUAQPI!V2&LL&9.)KE*:P=@SSH-<0VX
M;-U<PSI6&-?S'#OICJV;X05<?4FR;87,1FUC@]FRQ]C:8:;?+E5<BHO]PR5Z
MF\RDLRM6L&,(#(\L(U9RUM.0)&;D+SBZL@T@FL,O"W+TIZ!C;# AC4 QRRKL
M\\JY!VUAKPXCPRSIGEK\(>O?-D#&MJH&14JS.XX2F+%NG87>(=XUR7"Y$>;C
M*N>AW:(?9ZRS L'\FIA^]QS\8E=M3&<?C&+>/<OW5@7&+9>F&DD(* @(8:L_
M&F>_9GD&8Q/.7/.X0BJ#62$&D([[GU/#_L<<%^6+*OZPC-83_$/9Y!$!F/'Y
M!%0?U3A]DQMT_(7)?U_GM63U]GSB8ZS^LD(<C#@4PV7,7!D:S35*Q^.1*7[N
M+C7&GCK!5*E[HXT;%8X1F#&3%S+0D3XN2CT2Q<H<[ILD!(R1-PS7#S6 Y#%M
M5@SMCNRR,8M5LTU^*W#-MM-SH<9N'BUL\9%6H=M:;BX>W1+N<RE.8^=984FI
MS"RL_0H[)U?JRJ577L*%3BPKU86*O%X\:Y884R 0$ [-^[73;%//OS#$ X]P
M!7<X-OR_0L69)O4(XOM0J6=TZCLEFY>]V)?)&*X>]U^'VOUE3(=2D%:/C*R6
M1J29O,LPLUYQM=JO7H^_IN?_ $NCUK)648 R@B&=<\<_'.E,!&H[-41V#KV;
M=^&\,*]\5BX5N:J&2LK2\#>]N6'ZS=%'+6=JN7\?S60\7SE(>7V.N1*C!5Y;
M$V4'YHNN2-=KSY@*C.NV[PL9'^@Y$98BZ:5M08#EJ^HYAM'+;$TRW<[HE?CW
M<W@6BV:QWF,A,>GQU@?+N>+;M$H=@)EQ7,:+/(1"NZC75F4$]1QPO0FDNC 2
MDA+9*LS^QP"#>U,4&-\57BXI2! 1[:5K35PIV]P;F/:-*[ X5].[.*E@#@
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MHX 8P@7JX#D  INKS'D X,'D)0-Y"''(:B]A4=8TSPSSKAQX=M$/3MM1<O\
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MSLC=XU6;)MW@(:L< R[A"H8[HN U#=EGZ>NR-[;&@;UE=OICG.4ZF;,6@MT
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M+RF,@+\Z9U3@=02GZ0F%T #$PXB.O#7GW;8=6-W7[)<H1*##.NR#%\6V=OC
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M^V$PB)A^,1Y$?/4#_1^[\Q@&8\?D$4[?52P<YLVI" <B7%&0A^W\7NMB>K@
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ME: %1IJSY\O&(#8JC)?(V3*;3SI*R\I;+[6H])%1$SAV\?S<_&(&.Z./<-3
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M+-TE9<ANCU:/@VQ@._*X;N 9V)PV\"<07Z&[=)@FNETB\D)&/4XY?"B0.S5
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MAD[,;)JE(XTQI",RG2\9+*RL='VV^JI)G19,(_P[\!*Z3X=_?SV4RPBX5
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M)-$T&2":)T7*40Q$<1IQPXXXZPAO=J1C>L]MQ O ].>L.E!3J( J$]\.O%
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M% ( %*<>OI(!BE$ $.!-TB(#YG$QS'$ Y^((QIES\O"O9"/0N^IY^ [,O'
M;K ,BY:^%\75S;W0\\<!Q\?W-2.JFSYCO'SB S'C\@BFSZJ;4Z,Y[3 'CI-B
MC(8&Z@Y 0]U\-R7GX@,;GX(B(>8:@ KJKPB8ZK)G *G @B4$Q. @ B!..DHE
M#^#\$#<?[;@1'@//[B@AM[L!U_6$?23D2%*8%.@0ZRB7H1+\$W'("/0!OB#@
M!YZA*(CSR(CJ1"E<-U0'"N=/H..&<(WDG9T%2.6[A1LN03&*HB)4O(3!S\,
M\@$Q>G@H@;S$0,7R$(J(<Y<Y0A_*?NVW+X\9'CZ/G+)U=8FX$S6*N,ZT:'.!
M0 IQ(@_*F!R@ @4Q2 /PCE'XP$MP,.&(!QKNQ\]<5NEV<\CS0(6EXW\;RLE1
M[6'N^Y++$[&-4$T$F3BW2J#;N"))I@FH@V<)I.A[M,$Q4<E45'D1,H(G/U+P
MU&Z'=M$<!'G/NA=#9WU'SB+$G.2LP\4>R\B^?/CB8RKMZX,X4.)@$1$AU.H
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M\X7B_N]X^L _4RW9P"/(YEW4<_=]]O$W\GS,:BAM@]PPO%_=[Q]8T'ZF5[.
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M/FFEL)UZXU&_R,/#Q5E<.7P0G,U)0:,<6!CY9V"[@S]@SC@BFSE59)@B#4B
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M5B*-J%CV;<] B=KY>I-49=+5'$Z),G"*LW62(BBDB]T*7\Y;-S=11NG%%+1
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MR\NL3+I+9X6Z1[1+.YQ-)D_OF.J$K!\NPD;<@%4%(J;ALW.]4**9504.0#"
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MK^#:1#UC(L/#0%XAH]J];-+/$U^2/+Q#65!-Z"BYF<F<STKGO"NUEAZG"ZH
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M<(%5\*[.S:BZ06\.CT:$LGTXDR;]&5S%TR1FC4S.8)(*42>-CE.44ETQ 2'
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M\6]A6BJZZB$9(KO&9%%US]SU+JB?=:6_MFP4?K,[231LI-'2CU^*+BX#AXJ
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M\.8O!U#%$2C!YW-CRU*4&?+C+47YYHDT 2@FG,%""F=V42E X+"01+6]0 R
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MV%S_ (4+Y/M%_$'K&X;M(+(J!1:Q&Q1 3?&68[2O&C42!SY=7HK$TX ^7Q]
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M7S4665(F0/,Q@#2$5X97[0JK1+:20PW"H7<6JQ&2=WFSNV-)4=J&(F!H9DU
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MAVEPK$2H*IC%)*UMTL )F(BJ['I,;L%M?-&:9%)NP>D;& #!,Y0Y/-9:9,0
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MJGI""L=N82-IA<(<""[9KH&,C,&I3&)_/&QEBH"JD1SU5T?0E]02TEI94T2
MSUI:ZS)!*F1&:)'F+1$I\0:*"J9*<R%4P@("FT>,06$AA;KN42Z0>>;$V_3
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M3P[6[O<W$9TL$G9&L,A#N';U1&/9MP B3"(8D*T8H)  %X,=-(7*I^/A+N%
M+\$ Y\9T1=&KJPDN;2P[P[I-% IUE3"(F<NUC"JX4,(B8* 8VC*%0]PA:B(U
MI[&P+!:PLAF2LP74.]F*RZB6GJ!P3]XB12ZPJ4"B;"E3:\XVL#YE?8OI=&D)
M<BR]2&:M3&19$>.4&KDD@OXDII J"B8*HBHQ<("101*)#&,<O %$OZ[L\ %E
M:)2A0 .J !_VQ'Q&HT&/Q9TT*JKV^F*ZX?K5&<M,-,0$!9IW:"(!6A;H9TO
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MS#J;"3$>-U"F 7*Z:9U')KY#)D*W$2H*&OJD.8A2#7]=,39(QW%-W=UA'$?
MD$Q&;)5RBJV5?E ?$N^X34,0_!NI)-82CP0G)>GO#=7E)-:NS=H7:B,D>)K/
MC%*==8J)RJ B8:)HB8Y ,4:!42E&E<ZYQ]5LQ-&S0DPGMIW#5ZV264]DL=,B
MZ21I2^NDB)@(4QC&.4B@@-TGN@%1I$<WMA(Y.<#+E(=$H]"*QN .B3^"4O\
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MA'J[)R@F9R-EY454HN).L:8MO>$R%PJ<T:E*6^;K3$AU#&3(4#&ZVT,X:W
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M#E_8G*$2T>R8$,1U+$1-X9:1$QA4(V5;(H) DHD='3?NNIM3K@03B42%#$
MHJ& A3&$1#W0,8+U*CNI40]-9&SWZ43UK*!<E; H1PN<P@85%4VB!W*J*!2E
M$!7432.4E^ZF4:G,(T IJV-MW:"5/!V"+G3%H))[<I_QC]A-B5,APG%N3(OC
M*=(% @.3BX.B4"AR4"E @ 4 _"'2?T"3SI"Z1)9:9:8G&6I*E*\;&J8%6HF
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MFZ"VMR$>/9R@U9F9Y/OF8F;QS%\Y=,VC K3D[8):4/WBB3"*;KD76.=1PF!
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M   3#F(@ !7( CCN%NL+K+@DB@"RJBN@;D%-!&^83:)$@F.)$B5NIE$QA*4
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M+/;5%S+MX8"F>+.!*400B?12E(4I"%*0A"@4I2@!2E*4."E*4. *4H
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MU6$&D(-(0A\F_)OD#\2;5^HWVI#,.(><(Q6%_DCQI^)%:_5374G^,WWC>8Q
M9!P#RA%Q/V35O_))6_ZQOM3^S#[X_P (14/C'AZ1('5(O!I"#2$&D(-(0:0C
M3I >>0 >0X'R#S#XN!^Z''W=(0R-UVS[=,D.A?7_  1B"YOS&,<TA9<<U&8D
M#',8#F,9\^B5G9A,<I3F$5AZC !AY$.=(1FL;8+PMAQ)REB?$^.L;E>\B]-2
M:;7ZTL]Y$!$'CB)8-7#H.0#@'"J@!P' !QI".IEOPG)5?M"=P\9>IP\58(R:
MKR4$A)G439O\<N*;77=90A2..E$[0K!8#+E9B""DZ:8$_+\7@Z1&->[M#'#O
MUQ6N^S+$Q#QU'4&$D9.>B9B:,_C(Q)XX55;'<^&;N>]3(<C$ZK!NB"BBQDRN
M [M0IS 4Y3(@*^05$?/:-<!QX4K&S78+.FXV44;NV4_4*!&&%5^,^W<-I"4Z
M5DTW#!!VH"7<M"JG3(Y=)?#$I^Z0%18RPH(GQV;,,J\>%,M8!6Q3'-:Q=@J:
MKU,JM#<9<R'<P"$KF.:A!A,STK*+D*=SX2-;E.1N5N#9R]>.W)TD&K0KE^]=
M-VR"YTT "E->JO/(<(MWQ?LEW@9,9)JY)L].VJ5!1J9%&I4IG$Y'RD*2O0!R
M.)9)V./ZLN5/S2<M'-\,=0.%V+;NRB=#PV4Y\/&)64/LM-J-4DXN>MT1=<V6
M"+5(Z3?9BN3ZQQ3EZ0P'\4_I42E7Z%(?7 ZRMY"KNVQ#=(E2ZB%,")YVQ8JD
MDD@DD@@DFB@BF1)%%(A4TDDDR@1-)),@ 1--,@ 4A"@!2E "E    TA&YI"#
M2$&D(-(0:0@TA!I"#2$5BY*R-D9KO>K>/*G:\JT)G:U@A(ERG48ZTXAN,_7,
M;H7N596QE=LJN7ON=8Q3N-:2+S!F-,<V0)UXT"9RA)M(ZRL(YSSSJASSS\HL
MZTA&G(?=#RX$?^?XO^G@>/Y-(1KR'W=(155V+_V!54_+GN[_ /%=F72$6JZ0
MBK_<]6YEQFW(<Y!;&Z!DB3';DJQC]RTU7U['8'3P)\#%Q8M#U1@CD:8BXA,3
M6M"+JTXVEWKQJFW@@;RZC5P3G^UIW[2]B=4<>P!;]?%YUL>J^T;VBT74[U-,
M*( .GNWKM"Y!&[U=GU#K0N@ZZ#C0@TT8WM!<O:;2UI2_[MSMW1!NW)1C)[BH
M9/LL%(=$*KCII;[(C5[/6R0-N6N./$:I4:NB5)6H,X11$%7DO69>ZD1]+2K>
M+&Q.[]#RT+8.A&E$C<'0C">L<17V'9J16WN(FJA?XB9LUNKEDL[%B24Q[:V"
M;1_6F53JK"Q0ES*H-6G(V:M$'/3S1B$186<&D.+).R(19+MHKTW5\"XKA[-4
MJI0[$6I,)&=IE*AI* KU:EYTRL[(Q"$9,S=DE4Y)F[DE4[ ZD)V4=2=A"4DU
MG:AW@\(0^6D(-(0:0@TA!I"#2$&D(-(1BIN#AK+%/X*PQ4?-PLHV59R,5*M$
M'\>^:K%$BK=TT<D4072.41 Q%"& ?N<\:P.6S=X@JV=H).6ZQ!3507(55)0A
MLRG3. E,'$,!Q#&,S=PNT63<MEE6[A$X*)+(G,FJF<HU Q#D$#%$-H#%=<IM
M7S#MCD7]UV-65J-37=/):R[3\C23MQB^>6<&%P\5QQ.J=_*XQL3Q7O3IG9+*
M0+EZZ5?SD;- @VCQH1U,&)$T7)'%H92D!2$*JX ;3RM A1*4DLF;P^BG;5,*
M7)3:!8J^!4F5HI8V(#4_5%67341%V"4HF)J_S]LW$)8]5,8!$\S8-RB+10V-
MY_*D1J-XSB5O%E!<$?# N\C&V:9MUCF:CYO#N=X8BWN@PADQ)*'MY/"%3%W)
M51P)@C;S7BE52<%DZ^LL\9-'+,]BB(!TZ39ZWTBMWC5282IVG,F"*A$7*J2:
MJ#J6N% $Q&<YES@I'LH>F !$B+Q(B;D"F58K.VUU<W->,G;!4B3Q$4M*4RC9
M8ATUVCU$IA**[%X@91N[1 P4,*2@G2-^K<)HJ@9,)<ZQ1K0:0A#Y-^3?('XD
MVK]1OM2&8<0\X1BL+_)'C3\2*U^JFNI/\9OO&\QB R#@'E"+B?LFK?\ DDK?
M]8WVI_9A]\?X0BH?&/#TB0.J1>#2$&D(-(0:0@TA!I"#2$&D(@3O/[-S;%OI
M)#2&88*?B+S7(]6(K^3*!,IUVZQ\0HLJZ]#N5W+&5A9R)1>+K.VC*?A9,L:X
M<O5(H[ T@_%RA'7GM_U.9N:H=]<2& <_XXM58\<+N&F<E3-RHEFCT#&.H,=.
MURJ4ZXUJ;*F3I:C*-7[ SXPF<GAX\1 A$!"L*FC=F3VI[^65QW+16(\=5$ZR
M:+S)3_(4=8X<C%XJ"T@XKU>KZ3FVO73,2"=DSEXFN(.7 I-E7K=L*CQ%$4\>
M/S$>Z.P=M V(88V>P9U:NB^N^5)IGW%VS/<@2>76R&44*NX8L +U,JE5P7(D
M+6L5XC9F8K9JXF%YJ735EET3$U](0:0@TA!I"#2$&D(-(0:0@TA!I"#2$5CY
M4J>YR#W5S%^P[1UWT:[/$2YT%Y?(;?']Y@Z_B>58NO=.JTW.TO'<=?I&WMXC
M'<&E,X$M*D1#KP5]<2%C;P:S*MM5*=NN([1X<X^,6<:1,1@RIMDBLJN;:I)W
M&:C6UMKT77'!6L?&.W[-@PM*EN723?OR+DD&SN2)&)-F4PSD&\$TBD4J^6-,
M^ECR$UW<\[.VN%*TQK7PQRVZ^T(^)?:K5I6?NTNUR%F*ILKZ^0F)J+H.3+71
ME2SB"J"II-I8*Y),;"@#DY7@NX\LEZ-6!^JF#5-!!JBC-X: &&&7/.^) *#4
M/7SKO[\*1"_L08)M!; :TDU?S<@D\SMNO<=Y.3<G.+)^$W+91A4RMEI1RY6;
MHKHQ23YVDF8I'<P[E)=<IW\F\65K$Q;EI"*>=V;_ !I)[CLJT^;WLWK'EE>[
M7G0/]O+&G90GZG#U]W(>&'*9CU2<A(:1>G5<)M'D0B[:OE&@*'E5SP@/D#Y/
M8,UT0VDJ[]BB<)33W.I>T  SFH>]I.L"B./NB6X&=<([@S^7_HZ%FO8LL]IA
M-!F_M\ 'VN+,6X-@EHB):=1!0HK  & VE,(B%,0C'/.Q;R&%$XGM2XUXE&XK
MK2%7B9#'-DB&,Q2/=MCUI9++99XU@LM8934G(Q*<36X^VUEV=RFQ)!1RC293
MD+2ECCAP_>!W/NTL5>B67:4+[E9&3K&2H2%B4:#>V\<^DWF.;0@Y++.<<WR#
M;F-32N&5K;,W3N-O:R+U- MH2>2F.9&#0BQ[:3#L8+;5AB/B[JYR-&#18I_'
M7AY"6.LN+(PF 4EV<B:L6R1E)^L%,V?)I)5I\Z(6OHI)P[)A%,&36+9H1(G2
M$&D(-(0:0@TA!I"#2$&D(-(0:0B/>>]L&(-QT*A'Y$KO,S%'*ZJ]W@UU(6[U
M"30,*C*4KMC9"F_8NV+CARU^N'20<E*Z233=)I+IZ2C,0=)S)BZ<RJ<((J(-
MYLP,0CHJ"O\ I&K@BI%6LQ8*CBM+9DW=R]?]HW,-!#HLYDLU3.V431>R]<Q3
M.)<\**K58Q<E"@4Q%FKDH8)O6:K=XB CHER5&KOTV!=56HU>LOIV4M#RO5^'
MA'5DFUU74S8'$5'MV*TU+.5UG"SB3DU$#/7RZJZRBKI94YU3F,)AW ,J8+RY
MDCK&]Y4Z*!6R)E#8G%)N03$03$PB)$2&$J1:$*(@ 1HJ"F*AQ2(9)(3F%-,R
M@JF33$1N$,J8"F4$I:%%0P )Q"\( (PI=3%(0^3?DWR!^)-J_4;[4AF'$/.$
M8K"_R1XT_$BM?JIKJ3_&;[QO,8@,@X!Y0BXG[)JW_DDK?]8WVI_9A]\?X0BH
M?&/#TB0.J1>#2$&D(-(0:0@TA'7?[?O?;NPV51&T1MM6R;$XODLPW;+4/<Y:
M4QY3LB"[CJ;3H*=B$&["XL'K=F8KMV[!59F=NJH58O>F4*D1/6E,7I9<R6>F
M3,L".C_5E."8FTBA4_C$IP"EZOPC6E,,X]?82R@VVM3+;- ^]FC, >#USJW6
M]%U1BY>_[WT[:_?ZOH_],2Y>O^]=NCUW/W;+M>?+_7BU?[OV+N#?_A'\NO*#
M;9'^C+5-]79<_P"S;(_11?Y+%X:?IS00Q'_<W7#=_G[;SACD6W;1=KRXX_UY
M58)SQY^JS@XP?;__ #6'Q>7\NL![>HD"OLM4=6#P@!KU]5'NSSBP_P E:@86
MYJ./_-N@;?Z^$84[+M@.UY=EY]=:L)^?2(#M1P<;S^Z ^"#R\AX_YN1#7.6Z
M3$4@$?8JHT_ZP)CP_F4:RG\EX2!4+; -!I_\G:5U?UWN'#'9"G:=JYVO+H2!
MZ\=73ZQ$/L2<'&X$!_\ JY>=<E;I@11Q_1]4VK_A,@8ZO_$!SWT'<,:9_P"3
M08O_ #S*- J-9 (;\/\ /(UPX0M6':6]KP]Z1'?G5T@-\?\ K/\ !QQ#[G'F
M7G__ %KD+].J*%?]RZIJ5K_G@@99_P#)@QH*_P G8R5:VN*-  ?^ QUX!_RM
MSOA;,-_G:\/N!_=!*REU?%_K,\&GX\OM_OLOG_T!_'KBK?RC$$JTL@J:F.,]
M(7"E=4G-OC04Z S)C3]*0,.Z2C__ &G/A"\CMXW:\/\ I_\ PBM82ZAX#_64
MX-/]KX_[YE_^_GYZ\^Y_E4HMSW?T%5/F(#^DI2UH.L/8(T[QC04Z$3)C3])"
MFSRE(ZO_ $CK#LWPO(_<?VO3\ $.TGJR7/'Q['\'&XYXX_\ QV7[O_9KA.OY
M8B#8PA_D]4/2M!_2HA0&@;1LZ-,?"L<Y;H@,E7_/Y3!J_P V"6O_ .>&OAE"
MYC,M=KY(B0/W3FJH]0 (CZBF$#]("'(>7NC)S\8!]K^+[7/GGO\ +C;LRF$>
MC-8]VHT_3 A:TV#^C Z@'@.$<P_1D)!, 3H!$O\ U?0!IG3^>&[/IBX\9,=L
M!)< ':G5)(1'CSV$81.' @ _:MA1^[\0#]K7FE__  @C5#_Z*'!@  K_ +MD
MP''8'Z*8ZL1$->> QR5K#:&@>U*B/_U/S_G6&4*4[7M@R@40[5BGCU!R'^L#
MPE\? >0C[L/NC\?_ &:PD_\ "%-3A4.B9P'&VR8:QKA^B@[,,8T364(4:=?,
M.- HT#5_WK7J^<2Y[*+/6[/(F6-]>$MUF=(?<!*;<K?@"-IEWB<2T_#P'CLI
M8H7R!+MG%<J!W2"AF[ITT9)N'LD_5,5B9=(6I71VQ/VMT0](I>E?H^D=O"2@
M\B+.C30H2L[T)B9M[,F[^55%X5JR!73"RTX #9/1@KH_?N7S>:?M.HNE&NDT
MNC!,=)=N7KZ9%/AO'I2]3XAK2N%:1='KZ5&G!I"#2$&D(-(1 >KX@S;8MULK
MEF])2$71*-)O8V@QTC8*NL60@Y$E\;%?UZ4@0G;6XB4B2<=)RU4M+>A#(2%G
M2BWKRQ0N):65^YYYVPB?&D(-(0:0BJ;L6?L :5^6O=O_ .*W,VD(M9TA%8NY
MRLY.>Y6R?+4_9GA?*Y'&#U(:,RC<Z%!6.?M"RB[51QCR:>C86EADJPD85W"E
M>:Q#A8WARNXYO+OBMHE[S/:5H?:_LGJO^Y<&(/0>]>$:SC3"D+?V=?H%&OO]
M:%/7H[VJ.MU63^Q0>=?4]N#,!;C+NK&T82[0B<'?6KMP3"O1/0WZT]ZZ%:A#
M^SM<C-YO'JLGV3^-&R*-*JS>ZWB)KD!69R,O9W=,CJ]%U%S4%Y>0B:['0+0L
M=*5XECE6S@'9*@>PN/0#]G8>G')A\,(O<SI6>JS$?V7^+=O<K%UFY.&-B:>Y
M21EHF88TG)BU-B(R1K\'6!@VMBL#H]<D3KNS'9-)^2(]3:,[+!22Z$6*;9'M
M^?X%QFOD_'T+BR\DKXLYR@UMH6/K]>]'2#V/C4H2-[Y96+BWT0UCY1C%/!3D
M8ML^3CY-JSD6SIH@A#[:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0A#Y-^
M3?('XDVK]1OM2&8<0\X1BL+_ "1XT_$BM?JIKJ3_ !F^\;S&(#(. >4(N)^R
M:M_Y)*W_ %C?:G]F'WQ_A"*A\8\/2) ZI%X-(0:0@TA!I"#2$4[=IIL;Q%OY
MSILHQ#FM?(C"FP[;<M;TY7&=H7IL^QFF%9QJS8E-.HL) $6KI!Z]15;'1*+H
MO44IP I@&BB::I#)JD(JF:EY-0I3D-0:A>*8!*-! !"H8"%8W&$P?RMTF^EK
MUU+WB('!)VR<*MG*8*IF24!-9$Q%" HD<Z9[I@O$,8HU 1"(T?V,GV>'W];Q
M/\8E[]KXO_R7^UK6]G2__4&?]E0_N1Z+]/[<Y?IC:B@_]>S/_P#DQNE^IFNS
MV)_ O^\@O_N[C'X?]U8\O^;5!E4L'.7,!XM&^K_S<1^GUN1_YXVH_P#7LSU_
M]ZB/UE^I\MF,-NLPOB&.R#O$"AWC!NX6_61R.X*9.^1M&-[KMT@ZBDVE"0!4
M&;9>,R5<#.V2B"BD@H@S6242+'*E5QC)),8/>E,M'BQ;#MVI:^=T#;NVPUK:
M^TPCL&>3(<]=!<[@B2A/J;/8<GQW>5-[1./BZ-S4P7C^3BNAK"-G;/F^*1R@
MW&7,Q\T=P=T8QMO;(V=K+1CJ_P"&ICE_:8Y9/J</8XE_<\P[Y4__ '-T4\7_
M +H -8C66LR?XK/2,WWI4Q'S0B@VSM<-:VHM -<ZSA^/FXA@H7L(-KB^[2_X
M</F??(E0*YMUQ!DR(<I;FK2D_/<+EDO.%7L*"LJ$1X==FE"T.KJ-X\B!56BR
MKERHJ<CU,B>$UC;(&#WK+6=-6H8R:7#A0-0MM>V*&M?:HU*VDG@B-:UFKX<K
MM/V^\<<]\273^IY]GJ7]RS[O[3__ %>[*T$_HPH:US6"L.<:FL=9<P[32&5B
M/BU&,0VHM*;$T_G(COF;P?-:.:G]3\[3DN.ZW%]H.GQSQW>[NW$^/X_X,0'_
M -_Y-83]'/1^?X[#V1/]ZSDH-YLQC$-HI\;XIU-!XOW0^:L,35.Q3P;(;I\S
MXE<[D^T(1HM%P7MRO]:<H;M;T@^5M.3+QN:@+BDXD_ "@\;(1>+*29FR3134
MCE%WBZJBI9)(J6N;HNZ-3A0_1]8HP#]JRTD-7M%B,8QGDY-6]-IB.(A07KC*
M@:M)O&)(D[![;@EQW>ZKM($^...C>??"<<?%_!C@UKFZ).BL_P 71K8,W&R,
M@'/_ +A&,9M-!SF+X>+M<=O_ )3?')_<*]O@?%NT[2@/_P"=6_\ L&J?Y'^B
M<,NC*P ;@LA9\ [0]GT'MB@S*8CF_>#_ -Y6_OPX?9T;0Z/L[W#;[*11+/EZ
M[L+$\VU6&0N.;+Y*9*NLU(ACNSLQ(YMTNW;NWS>,:)M8]H@;O/ LT&K0# FD
MF4/:2F32F02]"52.5R^32MMI>K2Z5LV[!BAIECKK:!JU3202TJZJBREPA;ZJ
MASFJ8PB.JHHHL<5%5#JJ&I>.H8QSC0 *%3&$1&@  !4<@ (MOUT8I!I"#2$&
MD(-(0:0@TA!I"#2$==;83NWR!L\VZLL 9([/CM'[):ZKE;<+-.9['6V-6?ID
MI&WO/>1[W7W4)+R=P@'KY%:!L<:HHJ>*;I=^*I4#N$"IN%4.VG.Z)F_NJ:G_
M ";O:J?XI37_ $DZ1- VAX^D:!VJBH_^K<[54/,0\]I33[0\ /RD_$(>8?R^
M?GR&D*!M#Q](![514/\ U;G:JCY@'EM*:?;'@1^4GX@#S'^3R\^ TAVAX^D:
M_NJ:G_)N]JI_BE-?]).D*;P\?2-/W517GC]S<[53CCGGU2VGQ_<X]\GG^/XN
M-(=H<<?2L:_NJ:G_ ";O:J?XI37_ $DZ0H&T/'TC0.U45$.?W-SM50\Q#@=I
M33G@!$ 'Y2?MAYA]O@?, 'D-(4WAX^D ]JHJ'_JW.U5'S . VE-/MB "/GDG
MX@#S'^(/+D> TAV@/?\ ,(U_=4U/^3=[53_%*:_Z2=(4#:'CZ1I^ZJ*\\?N;
MG:J\<<\^J6TXY^Y\I//\?W/^W2([>WG&-?W5-3_DW>U4_P 4IK_I)TB:!M#Q
M](T#M5%1#G]S<[54/XAVE-.0_P"C)(A_T#I"F\/'T@'M5%0#_8W.U5'S /+:
M4T\@$?,?E)^( \Q^WY>0"/ :1';7O^8!&O[JFI_R;O:J?XI37_23I$T#:'CZ
M1I^ZJ*\B'[FYVJO  'GZI;3@1'GD _MD\^7 <^7'F' B(#PAVAQQ]*QK^ZIJ
M?\F[VJG^*4U_TDZ0H&T/'TB5FV'=8?<R-T VVS=9M[&FA #_ *YK$B.+@M?I
M\9D.*8*5EL(38POH?_5[GPOH\)2'X[[QOUI$1+#2$(?)OR;Y _$FU?J-]J0S
M#B'G",5A?Y(\:?B16OU4UU)_C-]XWF,0&0< \H1<3]DU;_R25O\ K&^U/[,/
MOC_"$5#XQX>D2!U2+P:0@TA!I"#2$&D(K:S]E/(U=W15^HPEZGH)Z9QM']ZC
M&K 6(1&5XB]9WN]9W72#Z.6C%W=I''F&H^)L<D+9V XS;-(BUF.P+9!.^GZ^
M6'.N'U^GC%DNHA!I"(%Y4R/8:QO/PY6&=T:V>OW.+KM96PU5LCNHF^4I\FSS
M#89S,UGQHRK4@WM^,9)JRIU7D9>>LM::5J1BD%HD\G*OTX65<UASY<^43TTA
M!I"*;KWEC*E0Q&S;WG.^2*K%LLE[^(-OEP[2MM+I8+YC#(%WB]M5"6)%TYK7
MGWIN-:R4E 5.)K3%#($M1ZY4",9B/FGM=G4-8[,/X0KXUBVREO)^1IU3D+6Q
M3C+0^K4$\LD:B @C'S[F+:K3#%(!$P@FTD3N4" )C#TIAR(CYZ0A0+IG6062
M375:J*I*)IN4"HF6;G.02E71*Y1<-S*HF$%$RN$%T1.4 514)U$,A%0$_E[*
M-0Q1@:<L&69&V3[#*>X"L2F-7V06N.,\Y_0@-R*U"I*E CZW3%&5ZG:M4&J_
MB*2VAJI6[">8AUI&>K$8@>3;NSZ98\[8C/7W:\..&,7":1,-QE^TU.D8NOUN
MO=Q?8^IU>JTQ*62ZQ:@IRM;B6S10[N3BA+'RRQI1)/X,:BTC)!\N^.@@P:+O
M5$$S(13=";B\M/XRC.XG.$S)#,HQ%AVVP#&SU&X/LIS]HW9O(F7PQDVQP#>5
MC;M;L6;>W6/8*Y1;*7=.:Q'7JZ762DYJ9H;/(L5-.<L.<MM0PB,? =GEAG\J
M!G%[&HB8-(0:0@TA!I"#2$&D(-(0:0BCJE[V<SU/)V2 N]]0L<3)36Z:NXZI
MMA+CV0BUK10M]%=VY8GB8YGCZL5F]4--&"M4761]]"?F(/(DP[;3IKA0V=<M
M$R]FGE7P#?\ 6'#/#7NKV;O*HPX*/:?V4]%K]]>8=AHUM=<+T6Z4B%1NJ=B5
MGKY9<FTS%]Q8NK%!-%X*N4S%\G=X2>F)&QFC'MIJ+U"Q5<[EHUF2140\]W.'
M.ZJ2LF^W.%7N 6JW5*2JJ2%$ILJ[Q&A8:JM".'\'3>U"LTE++37N;M<DG"Y-
M9[9L93 1<=*1-BK(IQ+)S,J>C+/#6A$:QQYH \_E"XMW:+9GJKY_0D]OM7LF
M6FT\95A'5_(3DE&EJXMA.CYIBX$EGLT#67#&^29+J-6(1:/6C$HRLV3(I&[I
ME&N*BDB>>?"+;V3A1VS:.E6JS%5RU0<*LG(HF<,U%DB*':N#-U5D!6;F,*2H
MH+*HBH0PIJJ$Z3"A'*TA!I"#2$&D(-(0:0@TA$8-Z-KN5'VL9NM6/I5Y!W6&
MI3I>MRT>NBU>L9-5XS:HK-G;B/E46BO"YB%=GC'_ (7J\0#1<R8)F0B+SO<[
ME##^0*WA2>9U8DU'3&"HIS4;O>IF_P"7,M-L^Y2M-3F;+BBV(QE)0E(#"$!'
M)6RSG=8]EQ781EFA91Q28ZN1]ML:$1"P=OES13Z*N:X7>KJ.)/&V-KTWR1N!
MD9D:0E,5;8)M%RA)XHCW49)0SI#(6:[MD>YVZ,<$<R:S1M7<C3S6HVY^S3A3
MS3;AMW:JPV<*[\S!PU;8E"7?]ED]YCZ XPFSA9M_9Z;C9RG++3'?P.3<]*PM
MXP1"2;1$2@K'P&$D;M8,TN@=-%HNU0\-'0B:+656(UB'/.//F[&5][$ABVVD
MJ=IHS7'$W/Q>'5\?53)UBJ*=MO$E=]P+;$=X;U]&C72W0LXG4ZQ*U^W>%AY9
MU+19)EDO9F4<R7(32$<#:7O(M6X*]Q]:DR8LF(^=QUDB[R"6,9"7D)7#,OCO
M+49C*-I65EG\C((GG,IL)*1MM0*$?4EX_P!P5^A$V-J9Q3>TK.>><(<\\]T6
M)Z0A#Y-^3?('XDVK]1OM2&8<0\X1BL+_ "1XT_$BM?JIKJ3_ !F^\;S&(#(.
M >4(N)^R:M_Y)*W_ %C?:G]F'WQ_A"*A\8\/2) ZI%X-(0:0@TA!I"#2$&D(
M-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA"
M6-1J4=*=0/3ZL=&T*]]9D35^),E8EN\%7O9U,6@DEU>]$5.\D <'[P1/SU>>
MD(^R4NG)K/7"=3K*;B2BQ@Y!<D%%D6?PIC*'-#O52M0.ZBS'55.,>N8[03**
M&%'DYA%"/MK3JBQ9MH]E5JXS8,VY&;1BU@XQNS:M$TI%!-JV;)-2(H-R(S$N
MB1!(A4BI2DBF4H$?.050C64J%3G&RK.:J]=F&:[ED\6:2D)&R#99W&IE1CG2
MJ#MLLDHY8)$(DR7.456J9"D0,F4H "$*+2$&D(-(0:0@TA!I"#2$&D(^3%*<
MHE.4IBCY"4P 8H_R@/(#_P ^D(^#(HG537.DD99$#E16,F0RJ15>D%"IJ" G
M("@%*!P*( ?I+U<\!I"/@S1H8I2&:MS$*HBJ4ID4Q*55N!004*42\ HB!" B
M< ZDP(4""7I#A"-WNDQ-U"F03=0'ZN@O5UE+T%/SQSU%)\$#?&!?@@/'EI"/
ME1!!4Z:BJ*2BB/4*1U$R'.EU\=?=F, B3JZ2]72(=72'// :0A+4>B5+&];8
M5*DPK>!KT8"X,H]!5RX[L'+MP^6ZW3Y=T]<"9RZ74*+ARJ*93]TF)$B$(5"%
M=I"$/DWY-\@?B3:OU&^U(9AQ#SA&*PO\D>-/Q(K7ZJ:ZD_QF^\;S&(#(. >4
M(N)^R:M_Y)*W_6-]J?V8??'^$(J'QCP](<^^9!IN,:ZK:KU.MX"$(_BXE)=5
M%X]=R$S./V\5!P<-$QK=[+SL]-RCIM'0T'#,7\M*OG"+1@S<+J%3&D7CZHM^
MJ&2ZXWM='FV\]!.'DG&BY21=LW+*6A)%S$3<++Q<BW9RL).PDLS=Q<U!S#%C
M+1,BU<,9!FV<HJ)%0A8:0@TA!I",8ZFH9D^0C'LM&-))S&R<RVCW3]JW?.(B
M%5CD)F50:*JD<*QL2M+Q*,F^33,U8*RD<FZ52.]; JA')8OF4HR9R<8\:R,=
M(M6[Z/D&+A%VR?,G:)'#1XS=MSJ(.6KE!1-=NX04.BLB<BB9S$,4PH0/GK6,
M9/))\L5LQCVKAZ\<'ZA(W:M$3KN%C](&-TI(IG.;I*8W!1X 1\M(1Q(*<B;/
M!PUD@7J4E!V&*CIR&D4 4!"0B99FB_CGJ(*D35!)TS<(KI@HF10"* !R%-R
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M0DF7E0RP])"EY5-SU*CP <J&Y'J/_"'D>1TA&YI"#2$:&*!@$I@ Q3 )3%,
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,J(B.8C7OBX881__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g838337g55e46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g55e46.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5-*:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^5%@W-#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @
M(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE($YA
M;64Z(" @(" @(" @(" @(" @56YT:71L960M-B8C>$$[57-E<FYA;64Z(" @
M(" @(" @(" @("!R<C$Y,C$P-"8C>$$[3&]C86P@5&EM93H@(" @(" @(" @
M(" @,#(M1&5C+3(P,3D@,30Z,#0Z,3<F(WA!.T535"!4:6UE.B @(" @(" @
M(" @(" @,#(M1&5C+3(P,3D@,3<Z,#0Z,3<F(WA!.U-C<FEP="!697)S:6]N
M.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N
M,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C
M>$$[(" @(" @(.* HB U('!A=&@@;V)J96-T<R!H879E('1O=&%L(&EN:R!C
M;W9E<F%G92!O=F5R(#(X,"XF(WA!.RHJ*D9)6"!!3D0@4D5254X@4%)%1DQ)
M1TA4(%-#4DE05"HJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R
M92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[07)I86PM0F]L
M9$U4)B-X03M!<FEA;$U4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @
M(" @(" @(" @(" @(%5N=&ET;&5D+38F(WA!.U5S97)N86UE.B @(" @(" @
M(" @(" @<G(Q.3(Q,#0F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(# R
M+41E8RTR,#$Y(#$T.C T.C,T)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @
M(# R+41E8RTR,#$Y(#$W.C T.C,T)B-X03M38W)I<'0@5F5R<VEO;CH@(" @
M(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C
M>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.RHJ
M*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U
M<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ
M*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN
M('1H92!D;V-U;65N=#HF(WA!.R8C>$$[07)I86PM0F]L9$U4)B-X03M!<FEA
M;$U4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z365T861A=&%$871E/C(P,3DM,3(M,#)4,30Z,#<Z,S8M,#<Z,# \+WAM
M<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$Y
M+3$R+3 R5#$T.C W.C,V+3 W.C P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @
M(" @/'AM<#I#<F5A=&5$871E/C(P,3DM,3(M,#)4,30Z,#<Z,S8M,#<Z,# \
M+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D
M;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O
M;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C@P/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G055!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X039H+WIK<&%F6&9*96M72G9%
M,#E,)B-X03MZ6$Q/,V4Y;&)H2$-S<5-O6DI'<4M);&548CE-<WAC,G9,>65!
M860K53DU<6M.,61A8C4Q,&5A>7,Q95<T;6MU8FE*,&A8:59K94YO)B-X03MU
M4VAX279Y2C1N-'%G6&UF:S!I0E!62G9/6&MU-SAS,DYT9&IZ4G!E<VDU8W@K
M:G!D-# X<UDT.&<P:45+5E4T67EV;WAL16IQ>$@V)B-X03LW968W+VLO-$YV
M-C5+;49L;5@U3S-D,#,U;RM71F%:,E4S.%%)3$5G-R]027I'>%HT>65)35HP
M6F)J5619<V10:S%$-FQ(95A%5G4Y)B-X03LU4$E6:6A75G=H;&M*26]Q5C5(
M,GE264%K;FTY06TO2T,U-&U3,3@O95A:;VUQ,$EF52]3:UI0:31K;W=O<%E,
M.6YL=#-Y=FHX;3-G)B-X03M096Q'=2M1<'1),&DK=GHU=C!M*VQS;FI28D]Z
M=DAL;&PU:W$S<&II=&5&2RM"2&9P56E6.45'2D$U<U%3.790<6-V-RM4*SAJ
M+V)B)B-X03LK5B]F2C!W<S!Z1%)V27%A=EDR:S!(;E13<E,V;FDY5S5T3"LT
M;'1M:$HU,%5U5EI'3D5R<V$W.4UG6E8P6FE..55D9"]L6DY$1D$P)B-X03M8
M;FI1-VEA9$90;W!F.&5$3D9*2GAD,S1O=CA!8SA+:R]A27)3=&-E4'E4=V5B
M169.3VTS96=A,5!P63%A2%5V44,Q=DQ'9C%R9"M3)B-X03MH=F=D4V$Y9FXT
M9TA*1&1R;%E03DPW>3AV0F549U1Y53E2+S(R+VU0=FA!56LR>FEW+TQP3E%H
M<S)T9D\K:WAY>C(X53DS1F0S5%<O)B-X03LQ9'!90D]9>51Y.5)K-4MJ0D%4
M>4Y0,E<T=TUV2FU),S%38GI&-5EU9$1T,VMF>DA9-FA+=F]L26)#-4TO25-V
M36IF14M#<UIT-G-0)B-X03M",4]%1RMI2D%J<6M&<F58:&QA<SAN.3-**S(S
M*RLR.3AK47A"2TDP3D@Q2%8W5WAU9%0O045F8GIY0DIB,E9M36-3.3-903%)
M2'1G)B-X03M+>#-03FUP+TLK4U-Y9W9B8GHQ;V-K3G=946MC;#8X539I859)
M:5I);5@T0D@V;DIQ;C=)<FME4'EB3T$Y-T4O365M,T=J4U=C839T)B-X03M(
M9G1D5WDS16AT6F5A>'-Z<W9P;&=X,V]L93-82D1D:$MX,5,U<GDX*W!X2#$U
M2RMP2BLR,SAQ92M':U=A5&YY<F\X5W0O5W9R=FU+)B-X03M(4G9235-W;39:
M>4I7;%EG9V-4<T564WI(*W5!;75I66DK<DIB;CAQ-S(R4C5:9D]U:%!&2$Q&
M17=G,4I:2D=74F]63'AO95!*54TU)B-X03LU5DDK>69B23AF:WDT1#-S1C%-
M,T9L<58S6G@S-74T-V%A4T9,<4HR36-Q>'5616E'=C)7<%5:34Y:2C<P.3!$
M>3E0<C,Q:&IR,7)P)B-X03MB=TQB2W$S,7@V2W8V:V13,5-A,%AJ*WE$=5(P
M-C5%;6U91CE74WHO04I06'-38V@U+SA!3%5H3&]G5DY62E!X:T-V,F5G<G9K
M95!Y)B-X03M:8T(W,$]V-5EG5W-D>$PU-S!53$ID=S)N<'@S:DTT13!I2C9P
M5F=L15)83$U7<%1I8U!(-4QW96%0;B]!0UEU67)1,S0X.6%-9$YL)B-X03MD
M;S='-V$V:U9:,E=,,5=58D5",7%&2S%Q0V%E1T1J.&LK1V4Y-3=R360U<'1Z
M4' O=T)F5S=.<&1814@Q<3)L36M-=G!L5C5X=CA!)B-X03MT23%+<69$2FAQ
M3FA/4'DV6%5,>EAY:3903C5K4DDQ8514,&Q:1%%Z>$ER8W0O:$UJ<6IE>DAC
M9&-%=51,1U1F93E(9E0W87DQ1S=L)B-X03MN+THO5THW1E9547AV95@X9D=K
M<F=Y8VM6=U-Y>4E/24I!<#%Y2'AB4&=K;C5H3' V*U=,;35H+TPO5F9+5B\Y
M8FE%5C=.2F1Y5S-O)B-X03ML5'E2;6U+2W)L=V%"539D>'@S365F3S!43S-+
M;FY':#-L-2MM=% O04@X;BLY35 W8F8W.$AV;&A$5D5M,S%4869M2BM6+S4Q
M,T-E)B-X03M46CE/,5%+;&(Y5$U);T4U44%R.75'95)U:W R<&U.=VU'-VMI
M8UHW2FHO,$Q&*U5V+TQ$8R\X05-63"]!1G=E3$I09WAD+S!,1BM5)B-X03MV
M+TQ$8R\X05-63"]!1G@X5U,K1$8S+U%S6#53+W=$3$1C+SE*578Y8V9&:W9G
M>%(K9R\X-"LO;'!O5W,R97-A9EIZ<&9736EZ5S=T)B-X03MC4TUO9&5H2VLP
M3TIY17%-8U)U.&)0;"\X;&I%<S!0:V9Z6&,R-W%J3%!B24HP<$MA4CAM:G57
M-&PO,E9A:%!H;&QY-W<Q;4UE-'%P)B-X03LX<"]L34-W+S56,34P2E)I<CAB
M85$P2S!"<E-F,WAU6&5&-%DY>%<O-%DO2TAK>70K6'9N2D]&4%5A4S-D1E=P
M-#%D;6Y!56-T=#AB)B-X03ML,VAE1U!C5R]W1$1F-5(P:U-,>40U=FYI4C%7
M5C1)5$]G:TMH;%@Q27)H,35C6E!S,7)V:F-U.$Q5931O82\P;CAK9$]T<$QQ
M+SA!)B-X03M*2&UU,&=H67)-,#AF<#A#=D-V34YC9W%0,S!E-2]M6'A'1S5D
M-%%22'5+3VDX;B]!2E!Y-EI,<6M8:V9Z3DI947AT3DY/:VM$0D56)B-X03M"
M27A90SAQ3TM/0S%2=#-W8U5U.$HT23EX67HK;78X06Y'6"]!2W-'=B\X04)X
M+SEL5U-Q8D,T9'EU,VU4+VY'3C),>6579&),<V%U)B-X03MF54<U4%@O:CAX
M<69E;FEH,TYF-&@O-7AG+S9L:E<O*U)N+UHU:E4K.49W-VYF-&@O=T-C65 X
M07%73F(O=T-2;B]:-6I5*SE.=S=M)B-X03LP.'EF.#1Y23-*4$Q'=&I9:'8S
M;EIG5E O2#4W-#%0=EAI:#-.9C1H+W=#8UE0.$%Q5TYB+W=#4FXO6C5J52LY
M8F@S2FXU96XO=T-C)B-X03M83EHQ3U!4,S!R54Y,86)A3S4Q0V533T1K96ET
M2DAC>3AF;3%"-S1$>&A-94%V5%(K45@U2VM":%EG:&=#<$8Y4%%G:6])+V4U
M6#1K)B-X03MM>G=O=&XX:&9Y6DE74#9I3T$U3B]V8E Q4$5F-SDY<V9%:VYW
M;W5(-4%F:W5304Q#<%!19EA:+RMQ=5!I4U(T55AF.'%"+TIB+VQH)B-X03M(
M+U-B4"\Q5G@X4U,K1D9:3BM1,S5*45%V4$YA3$9"1W!A4U8W-F155E9&5TI9
M>3!!038T*TI*9D-I<40O;DA4.'%,:T-:8DM9<7=O)B-X03MH4S9L2SA6*T9A
M2&ME=W@X5U-F0VDW+V]7=CA!2VXO;&AU4"MK<5@K=5!I>5AW;W4O=T-H82]Y
M<"]W0U='-"\V4W!F-C0K3$IF0VDW)B-X03LO;U=V.'%F*U='-"\V4W!F-C0K
M3$IF0VEU4#A!>FIF*U9:44HY4G5/2VMS0CE:;#9M9U!F,G@X5U,K1D9&-E8K
M43-K2%-,:')J4VAF)B-X03LR1G<V*VTX='1F6$54;$]3=GA,27=.3U-+865)
M1T$U0U9'341K;D5V-6)A8DU+4S9X<FIJ+TLQ5SA0978K+TU(17DT54AQ4#50
M959T)B-X03M3<W!,2%5B=E9B>7IL:SEA5S)N,4<V:VIA5')Z6E=C9W0W-&E:
M45E!<%9B9C@T-69L8F(S354X9&IC0U-&,6M1;35L235+86IV:#A7)B-X03M3
M0FEI."LO2U!4,7,Y6CAT6%56=F)A3%!D95=T4FM/;W)6:$E6:T%7-VYQ<UE(
M1&]6-4A:83$K25IB3#4W=&-2.$YK.#%+6DQA,E13)B-X03MB-WHY8S)!26IV
M8E=E94<X5UIR96I24B]9;$Y1.%5A;G)7:D5K5C9:35)E-&IF>6-76F]C2FY8
M6'(K=&TO:U1Z>#5.,#9*=$QF>E4R)B-X03MT6&0Q4&)I0C)J=5A03U,R:F=7
M2E-W:RLS2F)U-$9F,G9P3U!M>%-/+T149FAY=T<S1F9,-W8R4%,X>%A,9&ER
M-3-7>2]*>E-F9VDO)B-X03M-1%<Y3U-C2DEK85AK<TM-<UI!:EI!24%#<4=/
M:6MD2V):9#9J,&%V4T]Q=616+TLQ0E$O;6XU:55!;&%F<$MC54LY4B]C.7$Y
M36%L)B-X03LS3&-E.75F5E!Y<G8U,D0O04IN-CE.2D]31$5L.4QX4$E&4W%X
M<D%&,T1%54%X<5AC='A05D-81G@K52ML=6)B+VQ:9FU/>$UN-WEA)B-X03M+
M3S=N57-3:4MP9%)B2')'<3!R,G@Y6&-G.%!E;UAD,RM53C-P-6AU+W=!>B]-
M,"MN=594:$IC,T121F]Y<G%.-U1J5E-O23A-4'$W)B-X03MG=G W,C=I>"]+
M4S,P>4,R=5!Z0CAZ=S9:8W=M0S)I:VMU16=K:&-,>5--1WI#<W!!5W108D<U
M9'=7:#-L2G13+TQB+T%*>#$P=68P)B-X03M.5#AX-C%9>C=J,')M2U-&+VA.
M1#A,,DMN63123U1%-#1"0FIY9"]Z:D)15C@S-FM$,S8O.6M72&EN,TDT260W
M9BM$9BMC6"]!4'%C)B-X03M.4R](+W-I>#1P.7DX14\Y1DHU2"]W0V-90V=0
M*TQ,<S%(57EG2#92.5='1&EN,THT260W:C5(+T%/8UEQ:6YM=39O978W,&10
M*VMB)B-X03M(:6XS3'=W-S(O.$%!,R]/35 X03%.9#,O=T%J4B\R5%DX52LU
M94-(97E8>4(U0B\U>#-K.'=X1%-.5$=T-FEO-3(Y;&93:&M*53$U)B-X03M,
M15DT4DEW+VQ03'AP:UI3;%1+35E8<SDQ5E9647%G0E%+0419041+;35A9C<Q
M4B]K="MS67%U>%8R2W)*-$E:-%I)2C0Q;&=L57!,)B-X03M%-$1+>7-+37)+
M9&E#3V]X5C!)5EDK2V="5DI!039!06M5>%9J,VU(55!.9'9(94A2<E589#!I
M<6)70F=O43%:451Y6F]W84M39G1:)B-X03MQ8U=B3V1765-(-W(S8F9.>DIW
M>"M#2D0V,&QT.5@O364X=2M"=%AS66UH0C5.8DDT5V1,94YI=%=L5VEV3C9Q
M9R]&*WIT=EA.>%%C)B-X03M(9$UV2E8Y-3AU6C5X-6QS-#=A14E04EI65E=-
M9TDU0VEY4S!!0C).5'DO>6%53$MU:5)A865A279.56QL05!,53ET8C-Q5&@U
M:F5+)B-X03MZ>'9#<4]42%)D+VIF9W!)26]+;D%+-G%B638P6#5Y4V%/2U1A
M4D1Q>'5&6GAX;&%)445.>E944W9W='@T,49A9%=W*VQ'-D=U269Z)B-X03MT
M+U-,+U8W:E10<5IU27I%2$A304\O<4)Q2U=026-A155.3G5V>%EF4W4W,%!)
M36UX,4=+=D%F>6%V235V32]K;48T6DDQ='9,;#9J)B-X03MY>D-%239T37(O
M0C9B=65!-69T9T=T9F]U;GE0=F%99%!C.7EB>E(U3FMT1&9T<59I.7-E2T<T
M36M:53%J37ER>4HO:W%W2'IY2&AZ)B-X03MU<4Q,>$DQ9&A'85IF-DAQ8U)U
M3DYM=#=U2TIW1$Q!56-+-TES9S-7=$1W:T(K4GE-9U)Z6E)K1'E2*U):3WA6
M-'AP;C51*V9D3'0S)B-X03MT9% X*TQ&84]9:C9$-E)B>6=F5BM0<&8S:WIF
M6C1$-3DX=#1X,TYF064Y3E8X;&9M,F]02#AX27AY3E=0-D-S<70X+S-M*T1I
M:C-,)B-X03MW>3<Q=#DU1"].1SAA9FXU.6=33S1Q2DE5,%,R0SA453!Q6E-X
M;U=*1E=*<G8Q>#1H,TQW>3<P3%DO;'@K6G5N>%-7,7 U+VIJ:&YF)B-X03LQ
M-58O471Q,5I&4DEG9FEL86YW;T]M4$5/-65'6&5O87HK53-N+U=R0V%W,5!Z
M>F(S3G9C53EF;&]6;GIE:E)0.%1I5&MA;3-J-59/)B-X03LO159R5$-*9V1%
M1T)06#=&=6UF;$8K64]L=T-(5'90=W165T=704Y(<$5#=GAN15EK8FU*=5A.
M=E%4-#8X='1J:5IJ=51W4S<P:#$S)B-X03LO;D=R5W1D*W)(5E!/66YA,%%X
M>% K:D96=4HO;4LS035'9T%Q9#9!1'1K:&QR;WAL:4HU;$M6+S5X135+1"]I
M>6Q11%0Y2"]!4%IZ)B-X03MH.&)Y62M"-70O.$%1;V8O04@Y;B]C=B]!3WIN
M2'AV2F9!.#-F.4-H+W=$9C)F.$%C=CA!*WIN2'AV2F9!.#)M+W=#8U)+1E(O
M:7IQ)B-X03MA9CA!2% X05EN+VQP>#AB>5AW4$YV.$$V1D0O04\O<R]W0S5F
M+S)C-"M.-4PT2&UM6&PO+VY&2%-B2%998G964$U%,2]B47-(*W)7)B-X03LX
M2#%.;5I4559L17-R068V;T(X0TU">DIJ:')Q.7A7>&A646]A5VEG059M;$IO
M0E1C;'%N2U<Y86)/3#%&2$M3:$(O,V)*6'%0.')&)B-X03M6-',T9U%E56TS
M+T9S:"\T,GA6<C9L1"]!1%,O.&I:9BMA<U958C-33$\Y<W W2V-Z1T,U:F5+
M6&I.2W)C6D8T=%)G=TDR3TYO4E5#)B-X03M"26=G<E)344MK<V%!:V)K-VLO
M4$9++T9867$W1EA9<3=&6%EQ-T97>#%'2W9M;CAN.6,X=C8Q-6TP4%1B3T,X
M;%A4=DQ&-UHV;$-X)B-X03M8,4AL8VAP171I:%0T5S5(:#!.5#0W;DEK0U!M
M-#A31'0U4%%B;GEL9#)*:W1,9GE08UAM;EA52S-$=U$V;U533V%1>41H4U9H
M4C!J)B-X03M925-T9BM";V-T1U%(*TQF,TY29U)S23)097E$>7)D*UI.25E7
M3FPU1VTP*WEU<&]"3$Q,<45-;D5I1F)D<%=!.5$X56ET-#8P,UDY)B-X03M!
M93EE45)L=5I8.$=E37EJ<TE54&8K3S4V2FU+-51S5F9-=&HK6%!M0D523E<O
M3$(Y4V5+2TM0,31T9&ET1$DV335L;5E2>F1:95-#)B-X03MH-D%B8FY,*TED
M-U12-W9T4E9V*U=B6$-W4C,O04]71C=A3$)B;4YP8E1865I7;&U,<3-*9SEZ
M1G@K17E52DQF<VEH07@T=DYE2'DK)B-X03LQ-79**U)(-3%--TUU:75I:VMH
M0F97:$%"-V(S0D]794I&<3A/83,O04I54"MD9&%F;V53=B]-9%HO.$%69DAX
M27(T8S(O.$%L43,U)B-X03LR9CA!5FYK+S94<E O<79J-&M6.$]B=BM61&9N
M6B\Q6C50.$%P3W,O*W$K4&E26'<U<VHO04,O+T%#9"]05%-V36QV9%%Y2%%%
M52]V)B-X03MR>5<U:'5)>6=/-DY"1DI,-FQF-5=!2'5-:DMC85I1:$\S,#-B
M>#9K3&5)4U1W=$E%6&UW:5E!;6TU03E1,'I(8VQ62UAU,4I9+V8Y)B-X03LR
M,R].94MU0UAU.5I9+V(Y,C,O3F5+<DA3*S5**SEI*S$O=G1V02\X5UEQ=DM8
M=%135T]N8CDR,R].94MU-%AT4#<R3W8O1TYV*V$X)B-X03M68T5V93AS9B])
M='8K83A65T9,-S%&+V5X9EI0*S8R.%(O>%II<3AP93EP62]W1&M7,R].94MU
M-%AT4#<R3W8O04)J8B]M=D960SEG)B-X03LQ95=Y=4ER4SAI=#=P-#-70S1-
M0F-2>4931F-O6DM.>$\Y3RM+151B0U512TI71'E#;V0Q2$5%,3-)1E13=FA8
M1DM183EP6&UE-E<W)B-X03M44V(T5V,X;U516%1N:W%$:W!98T)V6&I7;6%N
M1G X-#%:;5-4:3DO,E4U:SAU3312140Q<%-V;%AZ<DYC23$U<68W;W=I3U0P
M3#(W)B-X03MJ26M3,VE26&]Q<7!R3D<W141J.79C;6='8FEW-$Y)+WE:;UAM
M,U1*<#(Q>E5H9E)U9U=*0DQ,2U%W4#)I6E98<B]K9U4V2&M/4$9K)B-X03M1
M:TE,.#(O3'5R-CEO3FQA85IA9EA*67)W>7I2:6(P1U=0-G!C4C@P8SE*03!I
M*VY516,V1F=60GAG85))5SAX+W=!165F.$$Y05)8)B-X03M%;6M8,$8Y<#!R
M4E=&;4QM3S5K:VEU,V0U5VMN5C1P3T513E%L84UD:5!I2GEZ:49S2TY*=C5"
M+TMJ5F)Z57)Y*SAY0SDP-E,Q=6]P)B-X03LW1EEM:6EJ;'!,-FI(,#0K455!
M>'%Q.4M,,#=517!D>5)&-V1L5%DR3V]X5CAU9C@T,C9D9C)0-6DR5C%D;3-%
M1CEP;#%.0UEJ0U=#)B-X03MR-EI034IU;C)U:EIK6F54:C1G45@P=2]N:GED
M2&%P9'9R5FMT=$E65DIJ4$=&3$UG:U56<C-1,7ER=W!85D9S.%=&6%E2;6MA
M.6]M)B-X03MS>%-3-E1F45@P8U1C2EAT-49K0W-25V@T:SES:DM":GI$2TUX
M3&MB4BM26D]X5DPX2W5X5C)+<E-F,W%J+TIB.5EX5F1I<G-69&EQ)B-X03LR
M3&5*1"]K:CE72W)S5F1I<3%Z.%5F.$%R9CA!1W!X5F1I<G-69&EQ,&XY-F\O
M>5<O5TU66%EQ-T9867%T:5!W;B]78B]I4GA61'HV)B-X03MP<#!$4T-E-6IH
M15%R23!J0D952'A:<4PS.&-X-#9N1V-H>&<K<V1'=S1P0U!&6'!1:S-M>GET
M03139E=B1TIY<75&935H53A854]P)B-X03MO5S9-:D)H-T=U6DY&<718,#=8
M9$4Q3FU85'11='(Q:TA*:&)Z4GEK0W1+;F=7-S1+5&%/>%8R2W5X5C)+=&IQ
M359F4$@U6'1B6$]T)B-X03ME5C=+63-.,'%E5G(U2C=213E-<DA,=V(P<F1X
M2&(X;6--5W)Z8F1V=#5E9C!T039E-6QE;RM2,VEF-G9&-45U8GI4<&\P=7I$
M1'%H)B-X03MJ5T]:;6,K;5))>6YK:6A+.&%J:T(K>E$U9DA,+U,S.7IJ>7AD
M3T5K93E0+T%#5VUV*U@U6',Y4#AK6%9L85@P.%!R5%A/<'A4.$YM)B-X03M6
M;D\X:D)),59E;35R<TUR>3A-='I,-T=Z1GA2,D530C<S<&U9:FQU>%8X,5=V
M:U1Z:DA:<D1E9FPO9#-T,4A!.$@Q:V$Y8E)*23=H)B-X03MV.4E:5EE0>D1/
M94DU,$-G1'%+-69X1'9A85!C=75F279M2C=/9$EF>7IU,'9'2DYT8W0U:U5R
M1T%F9U5X3$UG8T)D:5-A=#%R:GA$)B-X03MV*WAA4&0Y<7E(>5(U,49P9#(X
M,S5D5%-F5U=D,&M86%E594IN=&]O+W=",G=L-4%,8U)V2T8V569J4V=X-&@S
M<E(W=G11*W0O;#4U)B-X03MT=3='5TA44'DX=3E.=FYI;%=#-4AM251+:FU2
M1$9)56MN8FM5:D)5:71'3%9O2T%94DED+W=":41%.3,R<TLO-55R*V90.$$Q
M8C=N)B-X03LO=4DR=B]:4FMU3TQ8=U1D+W=!<58O4&XO<3,S4"]C4G1F.$%S
M;W@T-')W5&0O>7!8."MF*W)F8R]W1&-2=&8K>6I(:FEV0DYW+TIB)B-X03LX
M*T-+:E0W;6@S2"LU1S%',R]34FIX>%AG;3<O04I5<BMF4"]!1F(W;B]U23)V
M.$$R55DX8U8T2G9F.$$X;B],;C5M-DPU9BMR*V)D)B-X03M5:6Y.1D9N6E-$
M-GA.8G%+:FDY=W)Q1R\Q9FEP,F)T;$UY0V1N26=#0G5Z>&QV43AD6EEI0S,K
M*S)(62\U95%:=#A,-R]F,%@O27!V)B-X03LK<6U+=&Q,,V%K<V9V*S=B+VUV
M1EA"3#-E<W-F="LW8B]M=D96:%<K.5)2-G-843<K;3-I4"M,3598;$PR<'!,
M2%1T*S=B+VUV1EAC)B-X03M,,FXY-TA8+T%)>'0O=T$Q-'%O6'-'<GDR9'A(
M83-C5G9D4$4V,CEW64,T:FM+:TDU47E58FDQ1%1V:6A&46,O4TA-9W5#47A5
M1E%3)B-X03M#86M!:S!R.#A5<T4O34\Y.'5726UT.5=S3'4K:74T;&Q-1G-&
M5E=+>4-G-4)L:W%7558T9S V=%%::5E/>6\O;41M0F\Y,VXS=#@Y)B-X03M8
M3'<O1%!*3&1/=B]!0VIB,VMJ9E4Y5FI30E1B>5-Q16M6-V8P26]/5&DS2FMK
M:'!&1W%U;UIA<E5(9',R4GA(=D1I,FUN-69F-%AH)B-X03LQ:E5,3%1,0SES
M.5%G5F\W;S-P<E9),T%25DI9:S!"03)&4&,P0GE/4T)!0E-&8C@R=DUU<RM8
M+T%#.6$S=6LS071R:#=X635*1V@K)B-X03MS07AI0V%69UEW0S-'<U%,.&9I
M-#$T-S!Y14):5U)O4$QB9C@W9D]S-E133'%M;7E33$UQ4E%15SAO46AP,RLP
M,#9X;$)W0W)Y63!O)B-X03M6<CA23$-Z9T1!5$Q*65!Z:C%(4CE1=')8>E9,
M1$I&1$$Q=SAU;4MJ1S9787!T*V%43D<P5DEV:DMJ-&UA9V]"5&Y(9W9K>31U
M.39V)B-X03MO=7)7=7(V5F$V;F%H:&(S8UEL:D1G0F='-TAI5T@S16IW>7-H
M;6I2,4=+=FPW+VY'>E)P<D0X>#='-6Q10F(O045Y-&MG2WI*2U%O)B-X03LY
M23!D5E5&1S1U<&]E>'I)>6Y:>#A584PV<RMS,B]%4#9Q8T0P8FM+1V\U9&8Y
M6&9-96Y)=&1(3$9)0UDS5G=P;WA59S!.06%';G-C)B-X03M&2W5X5C)+<&9H
M5C)+=7A6850K.555+UIB9C92:7$W1EA9<3=&5G-:<D=P<%-O1S,P92M+<G-6
M9&EQ,7I2:S(V="]X<6-66%EQ-T98)B-X03M9<71*+V5Q2V9S='8Y27A69&ER
M<U9D:7$R33%5-U4K2G8K2DA&5DXW,C!J9&ME6D5:0E9W>D%52'982VAN9UHX
M04DT=35N-&-U2&ER)B-X03M:0WHK679,.74O0V95-U-&=T99<DI01W!O-#5+
M849U-C=J3&%,6&%V6C9R<&PV>DQ:,VM&>7EG37=H:U-19T5K06YI5'1515DP
M;$5S)B-X03MQ<TM-05(W+T%(67%P3F%7:E)M3F]9>D=1055+9V=G8FIA;G1I
M<3$W0W=D>3<R,%1/,4%Z1D9*4$=L2VMJ='A'2W%Y26E)<4EO5D9!)B-X03M#
M<4)1041O04U66$1Q359F3U U5%=3<'$O;'=Z5$Y#3')Y,W%,971B3&-026M8
M-W1!-DQ).#1:,5I7,FE10V\K>6-Y2F9P84%.=F=N)B-X03ME<655=DPY=$=.
M2W4W2'I+8D)K:G9O1G0W5TLT2T%L;&E1<TDO:%E24G!65# S5W1A,7E9-4I(
M8T=.=4I02$@V4TI6>C5-<2],>E5.)B-X03M".'1Y5%=/;F%0-6AL3W!4,C9'
M93=S1FA14'=-86<X4D5O0T-/<G52,S-.8354;6E:8FMX,C@R,T)+361G2F(K
M5#%J34YZ6%EQ*V%R)B-X03M84W9.6G,Q+U-%;FXP6'EW3VMQ,G-S;G!V8W-'
M2WE+-UA*<$=R348T*VYU1G)896U8,E!*<'(S<G)N4G1C*W!Z=&)Z+T%*:TYE
M<50Y)B-X03M7:DYW<7=S;TY&.5)V5F0K5$QU>%550C9#;4YJ>5AH.39Y2%1V
M3DIT3'5/9%!0-GIY33=7:S!D,4E42%<R:4MQ45IU3$MT,39O-E9+)B-X03MC
M9#8T,E!*85!M:'1B,%1Z8CE3;&)28FHX>% P:4EP=G%Y6&QY1VE-9VM14D8R
M:F170W1(>5IG0G-A0W!P56M%95-$12MB0R\P4B]Z)B-X03MK;"]V>GI.+S!L
M6%@O5E1*6$1Y82M'9FTW.45F.#5*9C<X.'IF.4I6,2\Q57AU2&MV1%!Z9"MI
M4"MC:W8Y*V5:=BMK<38O-G%9,T1Y)B-X03M8:&XU=5A34"MC:V5)-'8U;#0P
M,G!D6%A4+VM::F-02F5'9FTW.45F.#5*9C<X.'IF.4I6,2\Q57AU2&MV1%!Z
M92]F:R]A+VUZ1&]()B-X03M(>G)C46UO53)3>F=Y,WER-%A$<7EQ9F%T6"]M
M4&)+6CA.-T]21&ER9&YR<F56:B]!2&M683EF5&)R43<O8CA-9WI80DPS97-S
M9G0K)B-X03LW8B]M=D97=48Y+W8V3"]K53,O5E1&5WEL-S)L:B\U1G0O>EAI
M<3!R965O4#-K6$MH;V948G!55B]B>%9C179A:7-S9$\O-W1V*V$X)B-X03M6
M8318,RLO;W8K4E1F.59-5E5R-4Y:3FQ/3$=A,U<Y.4XO<35M:6-X*W)1.$,O
M1BM81W1+,'A615<O4#!6.51J-FTO37%#1DQ6,TE")B-X03M*3S5X5F=(-6PS
M,VQI>%-A,#%L3'532RMI17!J=$M)>#1/1%%38V<S>$UU+T944W9X1E)V;4AP
M*WE2*UE/64@T3U)K,5I/3'=Y16\P)B-X03MU.#AN=S-R<DIC87-98EI7=#-A
M5F)35TE2*VI$8FU1:4)':S15:6I54W X2DLO84Y4;3!/2UAK-&QH3G9Y,TAL
M84A78BLP,'E(55ET)B-X03M1=#!A3S9&*TEW07%-9T-J9T)1:F)O3BLU86=/
M4GE1249L25I4-75T=DYT>' P4RM6-W5#>G8Q;41Y4UA38S0R:5=.>G=P>&(W
M56Y!)B-X03M';$1X<E$Q>6]6,5-B-DU6*W(O;F<K;5AH;G5D35152&QI3FM,
M33A5:FHU4W1.-FYR>%-C=FAA3D9P+TQY2E!X0G!E;&HV:S,X:E<S)B-X03LU
M:U$S1C1F3C$Q8C-%0D-I,$5(06M-0V52*T-+2%DY9FER=%%D45-22W5I4F96
M;#)26DYJ<4U6668U32]*;E%V2VUS5W5Q5W5R-G1F)B-X03MY5TYT2EHR9'9F
M,T55,$5-37!$37-A3$9'5C-8<V%:2U5Y5T5957HO04-$3C)+=7A6,DMQ9C%E
M3"M8.%1I<G9Q.%@X=C1N1EAF5C1V)B-X03LU9GA/2W4K<E%C9S-(8T-G3E0S
M+T%.<D989E8T=C5F>$]+=2MR>&9Y+VEC5F0Y6&DO;"]%-'$T5S!#9T%,4419
M0W!X5C,Q94PK6#A4)B-X03MI<G9Q.%@X=C1N1EA',F=*0DLW9S%'-3A+67$W
M-G9&+TPK2GA6,S%E3"M8.%1I<G9Q.%@X=C1N1E9+-E=#0S-L=692855W>'4T
M:FIQ)B-X03M886<U8U9&9'EA8EEQ>&)44%!T=F98-S),95A.871:66]5;6QK
M;7,R15%:-4DT+U1%:7-Y<WEM5W!P*WER3C!'-G%K;C5J5V9Q=W=4)B-X03LK
M5SED:&YM2R]$.5)K:U968F9K6&I,1#=/+T@W6&%L46-+<51F;69P<3-344AY
M-7(U5U-(,7A-3E!L35EQ2VA#.65)86QE.5!(9D95)B-X03M01BMB5VM'07EF
M-%<X>6]60TTX4C!Q-#5"<$-+<B]+4W!F-'%(-59W2WE45F9-54=N,F1N969O
M<2]U;V)Q2C4U1G0T5V570D5I.50Y)B-X03LW1U-'1$UA248O;2MN1E5(2C5Y
M:E,Q<S4Q.'8V=$MB;VIL16QU9553<TI45U-R0E%6.40T:%AB:W9J:%9#5S,U
M:S9:8T5C4$PK=7%P)B-X03ME2U!K*VYZ<B]E.'E7<#%)45(Q86QE;W!7=4MR
M3&HX>F1,=%E43&-E6#EC0W%616YP,DUK9UAK<718-%-A,$1B,#DX5E1#6'IH
M0B]H)B-X03M74'I&8C9(<61Y:VIU;S Q64-,,$I'-W%Z*VEZ03 T>&QL1F%S
M0TMD8T-Q579N94M05#1R,"M8=%A+=2]'5T57<D=33DM4179X57-8)B-X03LO
M=T(U-E57<'$V9GI95E%K4#5L5V-S0FM(;&I8,&)G2%=.-T)W>$IN34%86FE+
M-V5P,6]%*TEN07%P6F9M4G!.,V92,FME9S8V:GE3)B-X03M*1TI:9$YU16I(
M3VYX33=#9U9A+T8T9D]M2W8O,E$]/3PO>&UP1TEM9SII;6%G93X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @
M(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @
M(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC
M94E$/GAM<"YI:60Z-3 R,SDV0S(T-S$U14$Q,3E#-SA%-$0V-S9#.4%%.$,\
M+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$
M/GAM<"YD:60Z-3 R,SDV0S(T-S$U14$Q,3E#-SA%-$0V-S9#.4%%.$,\+WAM
M<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N
M9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @
M(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z
M-$8R,SDV0S(T-S$U14$Q,3E#-SA%-$0V-S9#.4%%.$,\+W-T4F5F.FEN<W1A
M;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z
M-$8R,SDV0S(T-S$U14$Q,3E#-SA%-$0V-S9#.4%%.$,\+W-T4F5F.F1O8W5M
M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET
M:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @
M(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY0D)".3$Q
M03,U,35%03$Q.4,W.$4T1#8W-D,Y044X0SPO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TQ,BTP,E0Q-#HP
M-#HT,RTP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-3 R,SDV0S(T-S$U14$Q,3E#-SA%
M-$0V-S9#.4%%.$,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,3DM,3(M,#)4,30Z,#<Z,S8M,#<Z,# \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A
M=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@
M(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL
M;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @
M(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z
M2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V
M97)P<FEN=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E
M;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @
M(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @
M(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8S,"XP,# P,# \+W-T1&EM.G<^
M"B @(" @(" @(" @(#QS=$1I;3IH/C@Q,"XP,# P,# \+W-T1&EM.F@^"B @
M(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @
M(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z
M1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1.86UE/D%R:6%L350\+W-T1FYT.F9O;G1.86UE
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO
M<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R
M<VEO;B W+C P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86PN
M='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D%R
M:6%L+4)O;&1-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z
M9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/
M<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#<N,# \+W-T1FYT.G9E<G-I
M;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^
M1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&:6QE3F%M93YA<FEA;&)D+G1T9CPO<W1&;G0Z9F]N=$9I;&5.
M86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM
M<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L
M86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'
M<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X
M;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4
M>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3
M=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @
M(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z
M4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI2
M1$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A
M8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_P  1" "^ ET# 1$  A$! Q$!_\0 'P !  $#
M!0$!              4&!P@#! D*"P(!_\0 81   00" 0$% 0L&"04)#P,%
M!0(#! 8!!P ("1$2$Q05%A<9&B%45UB8U=8*(I26E](C)#%6<9*QT=<E-4%9
MV!@F,C-188&AMR<T-CA"0U)38G1V=WBSM3>1MCIRE<'P_\0 &P$!  $% 0
M              ,! @0%!@?_Q !7$0 " 0," @(-!P<)!@8" 04! @, !!$%
M$A,A(C$&%!4605%35)&3E-'2(S)256%QDC-"@:'3U/ D-&)RI+'!XN1D97-T
MHK-#1&.RX?$')38U18.$E?_:  P# 0 "$0,1 #\ [_'%*ZNWY4IU'=0'3?TU
M],M@Z?=V;5TB=L6\3H<\9U3?;/029H2Q0B<UD84G5@F,DSH#4QMN4W$DN.,(
MD(0\E&'$X5CH^QNW@N+BX6>&*8+"I42HK@'>!D!@0#CEFN3[+;JYM;6U:VGF
M@9KAE9H9&C++PR<$J02,\\'PUTD_A3.TM^O]UC_:/VW^+.=AW-T_S&T]GB^"
MN$[KZK]8WOM,WQT^%,[2WZ_W6/\ :/VW^+..YNG^8VGL\7P4[KZK]8WOM,WQ
MT^%,[2WZ_P!UC_:/VW^+..YNG^8VGL\7P4[KZK]8WOM,WQT^%,[2WZ_W6/\
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MA]&]]_4^P_=W'$C\HGXE]].!/Y&7U;^ZGO5;0^C>^_J?8?N[CB1^43\2^^G
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MSVBBW:FU#5"]WU5M1=?KM^J-[O76!%U%0S1FM1133[];LFK8%^#V*NQ'?:%
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MJ*[QC?N56<("25"'I,H(#D\\C(#$2)<*[*H1PKNR)(=FQF52Y  <R#*JQ!9
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M@=6XM(Y(.4.0"FU$"PBSB7J,@)&UF$A#-'MC3AEA@X"1(%88D&"P<.\C-?\
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M+A+"_O&5-K5NL]A17#@XZ6%4,NV_:6IT9DU6-7VQO+)R 9E&"5DNR1M#[0I
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M#]'61X:?+_S?]?R_]/\ H_H[L_T\57H<^;9\'(=7V\Z?G?\ -_\ MG^SO_\
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MFS)<>+$B9SE"<8E27W$,L9\3K:>YU:/E<1C^5:>_. )( !)/4 "2?N'AK')
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M]\@K(IQ2G%*<4IQ2JUJ'\A#^F+_9(XJ5.K]/^ KR7O?Y[-G_ %>6YOM[2_\
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M=N\\$<L4#S1)-<<0P0O(BRS<)0TO"C)#R<)2&DV!MBD%L BOJ#80!1@G*&'
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MS0W%O,D<]O,JLK-%-&CA&1\;'5CBW-M-:2F*=0K8RI5E>.122 \4B%HY$)!
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MVGG;A.$0QLEU0&()C-RM>BMGF9LPF^53#D1@=4,,N8]AO&GB1"'/CQVFXCP
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M\>.E=WASCZIFH+#TK'1-F+@;+H>PTTYM8BQT[6D/*VB5K<VU2Q^XCRK;.NA
M=-GV4=*<E,W*X2.5 ! PY3+<JRAEG5UB';"GA!MF85VA 0%J-:0"3%I)F26&
M0L9PQS"UHP8J]N\;3'M9P9BA<B9N(7():T?4QVF]6WWHW=.G0/2X3U]+VS;
M5F<M<C:A.]J?(CXNBL%+7<(-NI) O8=@2I^FS+8&U#;37Y]4JNRSE%%R,U9F
MPC[U);:<\$T,K7'$X2LNWA!!@F?"H4<!8P)AE"K!FC5STMNR*[U9;FWG@6T:
M,S.K;^*9,D"WW/('C+-*3 VUPZE$E,8RN[B</'H)WS*7^C/?N<VM:/!\1]!I
MZ"=\RE_HSW[G%,'Q'T&GH)WS*7^C/?N<4P?$?0:>@G?,I?Z,]^YQ3!\1]!IZ
M"=\RE_HSW[G%,'Q'T&GH)WS*7^C/?N<4P?$?0:>@G?,I?Z,]^YQ3!\1]!K5S
M G>2C^)2_P#C7?\ S*L_^0S_ .;PWYJ?_P"]><MJ^7#>,*0[WV_GG^JO@;QM
M^=\W] Z0ZVY%:O(;A@8/SV/6OT4_-QO'WD[3U*,AJTO03OF4O]&>_<Y=5F#X
MCZ#3T$[YE+_1GOW.*8/B/H-/03OF4O\ 1GOW.*8/B/H-/03OF4O]&>_<XJH#
M#P>E<_W@URX]G;V+'5_VA$X;9@5?7IW02I6$%-Z;%%SHP:=&:>RU+:UU6LJA
M%]CDV\MOM)6,<@56-,CO0#-M#R_+9<U.H:O:6 *LW&G\$$;=('P<1N8B7JZ\
MM@Y5&%;K3-$OM2(<*L%MGG<21K@CP\), RGEUC" \BX/(^A=T;]#M"Z--%4O
M1E7V1O#88ZH07(K1_8.V;Q+=RJ1A*GX8.N"S@^JU&N17L.>Q*\!$L,BHZ\X<
ME3YRY)"3P-Y>O>3O.T<,9?\ -CC0?I9B"S,?SF)R?LZJ](LK)+*W2W22:0(,
M;I)"3S\"JN$11^:J@ #QG).3GO=@/3)B^T+UY27O/PKWT-F>IRONRGPJF>ZW
MUBV>[/\ WNM]4?O[E>5XL8SC&XC9SA/5QX]&W%96T?TOQ-[ZU\T,'F0[)]=<
M_,>9RPM.-C[#Q'PC*,-Y4U$Q:/2L/>'&,XDL,MR$K[W,.X<4I66\^)/5I_?M
MR?N--H_I?B;WU3P'7P)8UZ.J=>$H8L-A=;RF];?#O*S@U.1CSLEK>HB0;4E.
M%YFX>6#,+4HL&92,FQ>]O/B3U<?PU4J/Z7@_/;Q?8?X^_-5!FA \O2G\SKIX
MY;66G4XV1L-+*$*PG&<Q8V+3B/"=_-QW/0VH[R<^+*7,94KO;SXD]6G]^W)^
MXU3:/Z7XF]]:?O>@?+BM>OO'AAN9<:S[YNR?,6K*_'G$I[W6>;.;[_DPU-7(
M:2C^#2C#?YO&]N?).?\ Z<?ZNCR^\4VC^E^)O?S_ $U]YH(+*IB_7W7OG(\#
MV,;)V+A*,?\ +#1BU80/7\G_ !D!,9?_ +7RYXWMXD]7'\//]--H_I?B;WU^
M>]^"QZ/'K[M_$<]['_=+V/GQ]Z_,_CF<VOO(X\6.[N(>IQA'\'C'EYRGC>>?
M).?_ *<?ZNCR_13:/Z7XF]_/]-/>_!=TO'K[M_'<XR]_W3-CXRC.%95CTF?=
M7WC\=ZL]Z8&8R<I[DYQE*4XPWGER3E_Z<?Z^CS_33:/Z7XF]_+]%?N*""PJ(
MOU]U[X2?"SC.R=BY2O'_ "RT9M7@GJ_]N>F2O_VOESQO//DG/_TX_P!71Y?H
MIM']+\3>^OCWO0/ERF_7WCPS',./9]\W9/F(5A?F8Q%=]UGFP6_%GNRU"7':
M4C^#RC+>,(XWMRY)R_\ 3C_7T>?Z<TVC^E^)O?R_16IBA TO17\3KIXX;>&F
MDYV1L13*TXPK&,RHZK3F/.<_.SWO36I#RL^'*EYRE.<-YYC"<_\ TX_U';D?
MHIM']+\3>^J>KFO0/L-<;,Z\I;?)%7%Y]WFX!$C"FB\["?*;-V]9J*A>,84X
MZS(;'E<YR1@HR.EQ,8<1O$GJX_[MN*J5&?SOQM_@?[NNJCQ1 F)#,KUUR\UA
MG#"$YV-L+,=2,84G"GH>;1F)(>[E9[Y#[#DC.<)5EW*D)SAO/B3U:?W[<C[A
M5-H_I?B;WUM_>[K_ *943VA>O*4]A_*_?1V9ZG"\)\/A3-]UWK$,]W\L=+^(
M^5?G9:RK&,\<1NO">+\G'_=MQ^GKIM']+\3>^MQ[A GJ?5^NN7F^3Y'@]\;8
M/IO!X/!XO1>Z?T?G>'Y?4^1ZCQ_PGF^9^=QO;&,)ZN//IVY_13:/Z7XF]];?
MWNZ_Z9,3VA>O*0]E_"_?1V9B3E>4^'PJF^Z[UBV>[^2.M]4?"OSL-85\O'$;
M.<)ZN/'HVX_33:/Z7XF]]:^:&$S(>E>NN?F/LY86G&QMA8CI1G"<94S$Q:,1
M(SW<G'=(CLM2$YRI27<*6O*F\^)/5I_?MR?N--H_I?B;WUH^]X \AF/[0O/E
ML.Y>0KWS]E>>I><YSW/2O=;ZF2U\OR,2'G6,8[L8;QC&,8<1NO">KC_NVX_3
M3:/&WXV]]:N:$#4[*>S.NGCEM>2[C&R-B):0C.$X[XK";3AB$[W(Q_#PFX[^
M,Y4K#GB6O*J;SXE_ GPTVC^E^)O?6.G3ATD:TZ0JC)I6M#.RCD"W[<L6RCDK
M85OO6PG&[)<)1PR50"@MSFZ]1 R9,YQ"<Q1,$1+4EN3:'3MGF(,/Y%U=R7;J
M\JQJ4C6-1'&J=%  -Q'28X'6Q..I0JX Q[2SBLT=(C(P>1Y6XDC/TY&+-M4]
M%%R3T44?28LV6.7_ #%K*IQ2J-O9FFU>MD;5>IL477P;3;\LE(S*PME4B0S#
MB18C<#"R$X@1GR(H\4*'LR2)4I*B#AL25/E1X[F#=]C]CV0/!;75B+R4,>!M
M>2"5#C<Q6>&2&2-%"\1V,BQHJF1R I89$&I7&FK)+#<&!".GE4=&ST0.&ZNK
M,Q(50%+,2%7)(%8^VCJ_TK0JS+(OHN09(.90D2J[;]7[.U8;Q6+EM"D:NG6\
M(&V12ZN2M(.GEKX&F6=RLPR[T+,H? E89)'!+4OH-+[%)8([;3K""R@M(H;B
M*V2QNK*YMHFMK.YO4MF:SN)DAEN$MI>&9V0RMQ)2S;)6&NNM721I;FXDGDF>
M2)I6GBGBE<2SQ0&4">-&D2(RIOX88(-J8!9 =S<NL73],K9"Q$\W@9D6]5WI
M B[ZPV?JLM+KYV^T^B%[*!@[-I=5E6<=3Y-T$D;(BN,%) ^/(@L2D1GRHW$C
M(M]!O[B984[7?>)@'M[RSO8UEBMKBY2&5K.XF6%YQ;R)#QB@8AB,A'Q%)J%O
M&A=N(N"F5EAF@8HTL<3.HFC0N(S*I?8&*@@'!9<U*GJFTJU)@0S1RVTN04E#
M88M&R=3;=U>DDX5,B:]&='N[$HM8:FP639X$-*$HRW1P22;#I,RH&"D%3\7<
M74"K-''!<! S/VI?6-YLV1O*0XM+F8JQCBE=$8!I!')PPVQL2=NV^0&:2,L5
M"\:">#<694&.-$F0&90Q')2R[B-PS66P=PTO71 $",DXZK+8Y0- H A3V);H
MXS>J?KY1F4\W'?C#1T8_> ,%J04=A,$2,Q@7"><F.^%&/:V%Q=K+)&AX,*RE
MY<#:&CMI[KAC)!9S%;R,0FXJBEV&T5)+/'$R(S#>Y0*O/.&ECBW' . 'E4<\
M L0H.35+#^IS3I4B+A0"]N?@'#PZLA+E[U&VFM7F#)DNS7PD87MQZCMZO(,'
MC\F(# D(EO>&G#$V",$RYDV=$8>G;1[]$=FC@#11/-);]O6)O(XXXS+(7L1<
MF\4QQ!I)$, >.-6=U558B,7EN6"AI,,P19.!<<!F9@J[;CA< AV(5")"KL0J
MDD@&_O-7653BE88[CZ2!V\MVQ;[;SK\"FC==TVN1Q84?2)1TB=K6Q#5U=\\K
M;-?68]5!_@>$(B'=;6NEVY$GUBVR<61"$$(N9#=F"'8BY<R.Q+%PH5HU3D$D
M56/)LB5'7F, Y85AS6@GG$CMA!&BX4(6++(9.MXV9!\W#1.CY\((4C%I_H^Z
MO2)_7>P']HU9K8NJ*<?'5$U8]CW[8C>-F78=K"G;-V<VY8J<RZ$"WBG#MD2!
M.K1K7N4HQ]%7F D,H.FF*_E=N6@62/AMPY74N%BCC^30RO'&=K=(QN8\RGIR
M+N!^:N</M*\+12<5.+"C!&:664<5Q$DLO20;5=!)B$=!&V%>3,$OC5.D"XU:
MH].%)K.P9>MA>CZUN>M.D:)*!$C3@J[$QJZ>'@*V)KVXBY@Y@7 ;18),H9!+
M,RXT;V=.DM+E*=@:[1I+B1HQ*9FA8"0,!E!TV/#D0YS\W!(\8K(2S=%MD20Q
M+ LRYC*EMKL-@'$C=2 !TB0#D<B1FK9UGHJW-4*0'IP:X 1PZGZEK)&G1JQ<
M;!5207J3(:VH^HMBV$#8&*7/<K55:IU0N,T$<@CW;-8K!OK9;\Z#4)D(0?>E
M:\A9R[(Q+2L'+(KJULLCRQJR[UWN7= 5)VJL$8Z8)6HULIT0(KJ D*E-KLC+
M<F*.&1E;AG8FQ'*L 79KB4D(0K5<2]:RZQ[91=!Z&]M:_@:^N%0LU2ZO=I [
M;?\ .T:T)'OU:0&AZ<.6$I./%B&R*PQ===V:U6"8JVU&:?'[$"6%98"B$7C2
M6S5YY]LAD1U>TB9(^$Q.[=QE4 *(VV2(JC8X4QLH#9%\D5Z\=O;[HUC>-DO)
M5>3BJ!LP(&8EB95XD3.QXB;A*K;EPV=M8K%=I5; 4ZH!!=:JM5##:]6ZZ$A,
M#@X,$'ALCQ0D7 BH;C0AX^#'8BQ(K#:&F&&D-H3A*<8Y@LS.S.[%G=BS,QRS
M,3DDD\R2>9-9Z(J*J(H1$4*JJ %55& H Y  #  ZA4[RVKJ<4IQ2G%*K6H?R
M$/Z8O]DCBI4ZOT_X"O'SU%U<W[2FJCFJZE3=*GX-@V# V!-)[<T5IG>ZHTL?
M7)5<9@!@^ZZ#?@M?2XS+7(E$@<,>4F90U%E27HC:&D^KRVJ32+([3 JA0"*>
M:#K8-DF&2-FZN08D#KQFO%H;R2"%H4C@8-()"9K>"XP0I7"B>.15\9*@$]1)
M%=J[\CSDN3+UV@LQU$=#LH%TZR7$1(L:#%0X^8W<ZM$:%#:8APXZ5*SAF+$8
M9C1V\):8:;:0E&.:[*N26(\37'6<^"'PGF?O-=?V%'+ZD>7,6IY# YFXZ@.0
M'V#JKNXAZG5:\2LA@!6:^#+W(I'.6\J'##AA*UFH@N"#BF+).A1F)1TI&"BQ
M@>.0*.RI;(L=!'MO)B1([+?)23S2I%'+-+(D"&.!))'=(8R[2&.)6)$:&1W<
MJ@"EV9B-S$GMXK:WADGEA@ABENI%EN9(HDCDN95C2%99W10TTBQ1QQ*\A9A&
MB(#M50)-8T<[)5-<@0G)BX^8JY:XK"Y*HN<YSF,I]3>751\YSG.6<JRWG.<Y
MRGY>6;FQMW-MSNVY.-WCQU9^WKJ0HA;<44L1M+%1N*_1SC./LZJ_6AP]G&4L
MP8;25.O/J2U%8;PI^0_F4^]G"48QEU^3G,AYS/Y[K^<O+RIS.5<%F/,LQ. .
M9/4!@#[@  !X!RZJ!$'((HYEN2@<R=Q/5UEND3UD\SSK39$BHZG5L#![*GU>
M-]3,.,VIY?YOY[N4-IRXK\U/YR\YS^:GY?DQP7<XR[''(98G \0Y\JH(HQDB
M- 3S.$49^_ YUJ-CA[+ZY3,"&U)7AO"Y#<5AM]>&L2,-86\E&'%8:Q+EX;[U
M9\&)4C">[SG/$+,1@LQ'/D2<<\9Y=7/:N?ZH\0JH1 =P10QQE@H!.,XY@9Y;
MFQXMQ\9K><MJZG%*<4IQ2MF1_P WSO\ W.3_ /97Q5#U'[C_ '5:/BH*<4IQ
M2G%*<4IQ2G%*<4J!K6.X7G'<[C_*M@S_  T8W$<_./D\]_DV%2B7@SW][3V,
M^S936420>$A'AR<*?_%3W%*<4IQ2G%*<4IQ2G%*@6,?[Z"F>YWY0(+'?F,;2
MQGN(V//<B8\KW-O.X\7>Y&')P;C(4TZ:5F!* X2I4]Q2G%*<4IQ2G%*<4IQ2
MG%*@*YCPPIN.YW'>?LF?X:,;BJ_./$<]Z6SZE2W&L]_>S)B9P$EM91)KZ4A'
M8"<*5/\ %*<4IQ2G%*<4IQ2G%*<4J!K6.X2G'<[C_*!K/<]%-PW/E-$,]^6+
M"I13"<]_>VZK/H9#>4R!&,"'8.,*5/<4IQ2G%*<4IQ2G%*<4J!.8[W0'R.Y[
MCT?/\%&-R,8_B1#Y75!E):C-?+W*DF_$$2K*6Y"<RW8/<I4]Q2G%*H#9VO1N
MT:;-IY,F7!X=*U:Q"CP!<!!JO6BC6L)>:=81J2T L(D2P-LK@4NU","B@>?F
M%Z$J.G#Y$F*[E6=T]E<+<(D<N$FB>*4-PY8;F"2VN(GV,D@66"62,M&Z2)NW
M1NK@,(IX5GC,;,R])'5TQN1XI%EC==P924D16PRLIQAE*D@XW7GI%*[6/U.S
M[+WUL(L8H:)N:=[F:_0*F.$3Y!:MVJ"??@)K9C)D\$O%%H%K%>V)$RO(DU1J
M!*KDJ 6,-3-M;:ZEC'/#::;:I'<E>/QI;J9I%"30-$&XT?#BDMKFZ@?AA92)
MRXE5DCVXDM@9WC>:YF+19X>Q8D"MN217QPVW.DL44B[LIF, H0S SUKZ8"&S
MG8LG;.W[5:95?'R<4-VOURGT]%,M3I:OFX&P8S*!1I)FV5\C6!:P+)K,NJ--
M.DV2M8,8FMJBQ0:PEF"+&PAA$K#MGBS3S]L0".6-[5LO'PX)4F<2F/$Q(0I-
M'MZ5SV9F.9[B1RH/"VI''PGW(ZRCHMND1HUV[LQXW!HVSRJ![I]D7$Q#G;MO
MC^W@HNOVVOCZ61I]6KU2?;O(9=:LA _!&QI$T]-D5B03K\6,Z1BA(X\\:6^'
MF3G1LP5$-4%NC+IUL+&1Y8)6N%GFEG!MI.-$L3.0L2B8)*Q"M(6BC D50ZO?
MVKQ&S<2&X4+(@C:.-8\2KL<L ,L=FY!E@NUWRI)4K%U[I5K@>K%PAB\7F[6$
MS;-5')>PK?-'E+DNMZ0O &XZNH*R&(#+;U=KZ0&(LYYUE12P&K#<[N6F/6RV
M%2+DDVM2R31R1VUM;11P7L2VL"LEN)=1MI;>\N0NXD2R\7<HSLBCBM[=%$$*
M(+4LD1"&EEE=I(',LA#2;+:5)((MV!T$V8/YSL\DK$R2,QMYJCH/UGILS3)-
M2A:^DAZ!,A+J_M[2NNYEX'P!B<M"8^-AP(0HJZ5$1<-1(-I=A+L3J8S,PO/*
MEG)I*9E7O9+>7\=PL[70>Y5A+PM0NUMF9_GGM5FD0([99H0PA&2L:)&%18H-
M,@MS'PUAVQ8V;K:$R@#DORP57RHP _S^66+,23G3SFZV5.*5A%NOI*;WIOD7
M?K(2AB:K7]=T\.)(0 %0*W:)9@.Q#5OEKK%ALE?,%]>N/15!V7;-2Y8FQ.H4
MZF&1'SAXTC%S8;O@0%%!+F1V(+.$VM&J=)58"3P]%P5'B()%8,UIQ[A9&("K
M&@!"H7#+(7Z+,K&/P=-"&\1! (QDD]-W6V6LNM=CNV\9G8&I*=8XM?DW*\>Z
M*!-VW>ANKZ7M2[M-CPC33&M[-7V]CV&@T5Z+'3530X,X@'6(QAFN@<H7-D%E
MCV'9*Z[MB;2(4,CQIUG,BMPQ(_YX)YL5W-C&VO6:*3>O%AC8*7?<#-((DF?
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MI(C1-:I<?/6N[%",B^-II"&X2.&-.,V[Y3EM?Y%F29(VCP,95Y!*\@/$^:J
M</IIK:22>1Q$H7Y+I!ES.BR0/*DN>>&2(Q)$0(N;/(QXGR=I4=)&WI<X1'+:
MGJD>'416O'$S@UN!37=CUX;=]=VVYZ4MY0QY)9_7(O6U6E:*HVM<C(.L"Q!!
M#85U<=58H;=5E[;A&<2MEC(.:-\F2DBI,@'(2&1A.\FXRCHQI@*=T/:<Q(#1
M( BQ<U=3Q%62-W@<G!,8B3@1Q8$3',DF2PV<D>A:8=U]J6HU&QMQ(A(4T76@
M,/E>N'5423L!8M7J.-F8:8;DC*'7YXRFCGF&&(KD($PJ(RU%RTVG77#K),[K
MD@XZ1&"Y"@,Y'@,C N1XVK90(T<2(V 1GH@Y"*6)6,'ED1J1&#@ A>0 Y5=_
MD-34XI3BE5K4/Y"'],7^R1Q4J=7Z?\!7DI^Y[LI?I=[0G[.?3A_M2\]2W:EY
M*Q]?<?N]>.;='\MJ7LUK^]UVT/R5\=TEP+3UK9Z9+CU%6J2[7]"8N*-[ZVUI
M0&(3"".W/8:JRYK_ &MLIPH](<45P604:#HB(9'JAKFJDR4Q>8[)3<E;/MA(
M%Z4^S@R2/GE%NW;XH\>#&,^'-=CV(BS#7_:CW+]&VW]L111XYS[=G#FES^=N
MSC'+&>>.X?SE*[6G%*<4IQ2G%*<4IQ2G%*<4K9D?\WSO_<Y/_P!E?%4/4?N/
M]U6CXJ"G%*<4IQ2G%*<4IQ2G%*@*UW^R\]_G?YUL'_?&#N'?\_D_]%C_ ,I^
M7_ZGN_R9EGR\@O\ (?L[BJGK_P#KQ?9RJ?XJE.*4XI3BE.*4XI3BE0#'?[J"
MF?X;N]@ OY<'?3]_M&Q_\7E[_>UE[_UN!N/;N$>3[;_B&0'%5\'Z?L_^_P#
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M>XQ/BM3YXJ.B66@!2<N(P)/SQ,5S$DK!!SB$L8PEUV<S'0R]E%AAD5 Y4[2
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MOH>QB\[GZH.RRUTW13'9+/IUWJW8]H.F:?J,UL;C@VL3WNG7P:9&,ELCI<$
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M<M@<NO)&8U[(-=<$K*N N_G;P#<N]8\H"@,AWNHVIN;F3C )&U7V]';9MS8
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ML38$Z*XS-'SX\:=!D1YD=AYN6">6VE2>"1HI8SE'4X(R""/$592592"K*2K
MJ2#8\2RHR2)O1A@J0<'PC[B" 01S! (((!JR,GHYT@3EM$;)K\_>"D8>3$CR
M^R+QL_99D.+-07AY48",7^V60F!'D&W6I4J$&EP8SI<:#.J:]M5\&0'[$:YJ
M:J4BN$MT+([1VEK:6D;O&P:-Y([6"))63FJM(K$(\D8/#ED5L?M"W)R\3R,
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MMNE6P0![:T"\4L%B:6RH_KS#^TCES,5<0 .G;!M$K<COK!\^=',%V8$*I#K
MS'F!:[-N!,$"DQ#BJ5^?[D*K-4(#KMF\790<3MP)M>42CK"46RRI 8<@?[#&
MG-("M0203,C#++JC,1+QKPYDPI4J:->9A155S_<1Z?X-6BL'9]"%3&O>YV<6
MUD,9*Q'H#@L6<,6^L!A,32D$"S3+J1OB" FT#!^ICH5=O-Q+.\0 [8V$.E"\
MO6.Q3K JN?'SZ_2<\_U_J'.M[6>A2;7V=OS(NYI=7L>UM;B=<-3=74.!2PU-
M$AQ6PH#<&M03UBOEG%UT@8O7N]*APMV"%)&Q(Q>S1;-!18<C1:J9ZN7(>/\
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-:<*JM)S_ !_'W5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g838337g58a33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g58a33.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4SZ:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N-BUC,30U(#<Y+C$V
M,S0Y.2P@,C Q."\P."\Q,RTQ-CHT,#HR,B @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM
M<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+VEM9R\B"B @
M(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @
M(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z:6QL
M=7-T<F%T;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP
M+R(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B
M"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(*(" @(" @(" @(" @
M>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @
M(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF
M;W)M870^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!
M;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L
M="(^5%@X-#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @
M(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SID97-C<FEP=&EO;CX*(" @
M(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL
M.FQA;F<](G@M<F5P86ER(CY&:6QE($YA;64Z(" @(" @(" @(" @(" @5%@X
M-"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C$Y,C$P-"8C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,#(M1&5C+3(P,3D@,3$Z,# Z,C8F
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,#(M1&5C+3(P,3D@,30Z,# Z
M,C8F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,C,N,"XR)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($%R='=O<FLF(WA!.R8C>$$[XH"B(#$T,2!#35E+(&)L86-K(&]B
M:F5C=',@8VAA;F=E9"!T;R!G<F%Y<V-A;&4N)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M)B-X03M!<FEA;"U)=&%L:6--5"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M
M93H@(" @(" @(" @(" @("!G-3AA,S,N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(Q.3(Q,#0F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(# R+41E8RTR,#$Y(#$Q.C V.C R)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(# R+41E8RTR,#$Y(#$T.C V.C R)B-X03M38W)I<'0@5F5R<VEO;CH@
M(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#(S+C N
M,B8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!
M.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E
M;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S
M+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[07)I86PM271A;&EC350F(WA!
M.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT
M/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" \>&UP.DUE
M=&%D871A1&%T93XR,#$Y+3$R+3 R5#$Q.C V.C W+3 W.C P/"]X;7 Z365T
M861A=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C Q.2TQ,BTP
M,E0Q,3HP-CHP-RTP-SHP,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#$Y+3$R+3 R5#$Q.C V.C W+3 W.C P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#0R R,RXP("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^.3(\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @
M(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!
M4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!
M0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!
M04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W
M;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX
M.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9B\X04%%46=!6$%%04%W15(F(WA!.T%!25)!44U2068O
M14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!
M06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#
M05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-
M<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.
M55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O
M4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T
M95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B
M;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-
M1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.
M0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:
M2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6
M<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA
M2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM
M<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.4LV6'!E;5!P;&\W,FM,3S!-
M6EHF(WA!.VI':$I*445K:VI&550K:4Y*+S59;U X06M5;CE-5EE:<FYM2S4P
M<E=R:7I4>5AC86I9>&)1,VQP8D)W-4U55#$R53=";F144W94878F(WA!.WA5
M;4EG:FUX379*3%4X.5@V4FUE-3AG6%551$U69TAO56M02C%%6'%";V=Q1F=X
M0DA)+T50.&]994%D-D]).7HP6#E%850O>7A19C@F(WA!.VEK+W!L8DXS-DDP
M;B]L:6<O=T-24V8P>%8U,UIE6F9.4G9B1TLX.&AJ,&)P66YL14U8>'AI54U3
M0S=Q259:3TE*1'5V5V@T='1L:&DF(WA!.T\Y:'A(=55R+W=!-65:3&5E9$DO
M>3=M:VIJ-4-):4QM>FQB:C O,DEM5&5-1G9T53<Q;U)H14(S<5I(=65I,C)M
M-F),8E)3>6%F0D@F(WA!.TDV2WIX;4I+<5-+;%159'-R6G%N-DDP;B]L:6<O
M=T-24V8P=TLW.45A5"]Y>%%F.&EK+W!I<G8P4G!0+T%#>%%F.&EK+W!I<G8P
M4G F(WA!.U O3$9"+WE+5"MM2W4O4D=K+SA!3$9"+WE+5"MM2W4O4D=K+SAS
M54@O27!0-EEQ-SE%850O=T%S54@O27!0-EEQ-SE%850O>7A19C@F(WA!.VEK
M+W!I<G8P4G!0+T%#>%%F.&EK+W!I<G8P4G!0+TQ&0B]Y2U0K;4MU+U)':R\X
M04Q&0B]Y2U0K;4MU+U)':R\X<U5(+TEP4#99<3<F(WA!.SE%850O=T%S54@O
M27!0-EEQ-SE%850O>7A19CAI:R]P:7)V,%)P4"]!0WA19CAI:R]P:7)V,%)P
M4"],1D(O>4M4*VU+=2]21VLO.$$F(WA!.TQ&0B]Y2U0K;4MU+U)':R\X<U5(
M+TEP4#99<7A8>FQO;FUY6#%F.$%#,7995S5T-V-Y=RMV1D,S,6DT26M!:%E-
M:#1+0TEZ>7%/<$@F(WA!.W5P5D)7;6UF;5A,3%IV4'!M9U<Q=7!"=31M4C5*
M;D)2:5)647%2<W)"4CA*8V)N<TMS<6]F;U X,7I(8T)O4$QW:U(P1G,P8TQG
M4$@F(WA!.S8Y6D=937)58C!!;U@O3$Q6,C0T<7)A:&\S-6Y02F-P6E=N;#9+
M3FY15S!R4E-&;&IO4%5*57%2>7%0:#A+.395>%9-.44P=EA%.',F(WA!.S9H
M2C5N=&)"9%9(<DY%8DM&56I735)$:GAR>6%V34UA:S$K6%%+<2MQ965F3&YL
M6%-.2V)7<FAR9&)Q,T)I64EZ9RMK:UEA=D5';3@F(WA!.VEG6DM'37DU34I4
M165A2S!R>DAO+VTS4SE2:C!I-VQJ35IK<S5:9VIW>7A34$A66%1K1E!2=WES
M35I1365A67E%=5-34F559GI(9VHF(WA!.V<Y3'IF>6MI47$T;'158TU:0D=:
M0U-X3F9J5C)3;RM%2&E.='-01DAU5VHS<FTX<B]M87%Y96HU>55/-7)74W=G
M9F-#2F1V<W%T46HF(WA!.VY:859B2&EJ,TEO.39:5V5V,FUH5'9P4&U06#1R
M:E5N3#-6<S@V2F)T.55A5# T:TI256ED*U<S=V=%;F]-:E8X9VTV-6]Z4U!/
M9FPF(WA!.VY74'$U,'DO4S97-F0T-$=26#1S.%5A>75T4V]!2W!)1'8X07)"
M>$U316=G<$1F9FPY-6AL;'546BMA-W$R=#=U5S=N:W0R:DUI:'(F(WA!.W%1
M<VEO9E91<6M56C1H934K3"]*0D5X,TUE13DW4RM2+U!!8FLO;F4U:V-.1U5*
M=%DQ059A8W=64C%6=69(<5)T=C0T94ED>65%.38F(WA!.V-89C5G*U1,3S1V
M8F$W,5=',VXP*U)9<G%/54UJ2WHX86-15DA-1&U/4E=O6'9423A"6&E#3C!J
M>E)O5W)V1VUN6%!R3DQB4C-S5EDF(WA!.S5%-5<X<D95:T)D5G)6;$DX4C-W
M1TI#46)45$%L,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DLF(WA!.W5X5D-A=CA!.&-M.2]W0TU%=CA!>$$T<6PT.'8V
M2G$K:S9F*VQ,1T<X159Q16I%>4)W1FUJ5EI!2SEM049C:TI%8VM'25!.2&%6
M;V4F(WA!.VMA4D9,1G!L;D9:>'I31V%:659#.#5';T-Z539M9W='4E!.4D5$
M:VIC0UA9<6QM<S90<&PQ0F-812MM=S9H8T-.94U5<7%3+V]-,&LF(WA!.U-C
M;415;S=';G5C5$EG8DU:.&E13$M795-L,'DK,'%(55E.16HP:%)+-S(P24$U
M5C1#1G!+0E4T;&Q8:C=G6D1(;$UX6F%.3&U/5T@F(WA!.T9W.$Q*<VTU3'-6
M66PU,&<P9E0W84LX:SAU439W6G)K0G=65&US<WA10B]I5B]T=$=I;C9-:&MY
M;4$R,V-85EIZ:6E#23A7.4HS<%<F(WA!.V=A4'!Z0S1S-T-'>G58:&IH:SE)
M1%I)>#A-9%)3;U=U,E=C4E!.>5%%>7=*9&ER<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&DF(WA!.W)S5F1I<G-69&ER<U9D:7)S5E%M<B\X04A*=F8K
M345V+T5$:7%195DY6C%(4G9)83,K;GAE<&-X,CA!5G%":$='0V=Y14AQ1B]W
M03DF(WA!.W-Q>GI-66MH=SEF;FQI=VU54EI(-'1H2#5Y*V-033)M-F0U6G5B
M0S1M,'%E+VEN:W4T14Y#1T-W14LS6#=*8S5T*WDX56-G2FM/-SDF(WA!.TQG
M9&\V<DI#34-04UI$8V9*:3%V-6PX>C-6;D%99D\P<5@P:U-3>3(X>$-):%E&
M=4AQ;C1A.%9*.$]X3RM::'A10BMJ6G%J;'E3:4LF(WA!.WDK<6@S3F%J<E!N
M,GIT8G%F+T=S335T56MC>%(S04QV-F1X-D9%1E!I3$0T>#=965DX4DE(0GHX
M=DLP6DUM84E*.%5B93=V<$-A;C4F(WA!.W4X-U<R;&I5<F)Z6DI015I)269Q
M>&M16$%A83%7-%IV5%5T.$--4VA0:BM%;UE-6FQW;4AF.3E.5UA5-6]X-&A/
M*UAD931T:&5V9FTF(WA!.TXU.6ET,G5)+TYD-UIU2VM,-GIC1U!G1C=F-TA)
M86I2-&=,1WED3'(X>$Y(,4EU4'IB-7=U=%!T;7,O>DMU1C%/5T=Y:VYT<FU9
M4E(F(WA!.U)Y6%)B;6YR35%V-W12>6)S=E%M<&].6'=J=60T2D5J-FM,<EAM
M8C@P9$QT8GEF+T%*5U1"95!:27IM0S)V:3=Y.&)T<E=K230O1G,F(WA!.V]L
M-V9!46-126YO>&Q+439R4$U8;FIZ-7 K:%%A<EEF;4)C,W!K;70T;G-J8THV
M-#EB5#=E.$PK;7)0.$UC<S!K3&5$3%1R6$520E F(WA!.TI%<&UR=#=H*U%8
M-6YE9%!/5VU/;FU$4TI04W1K+V1E65554E%81$$P-$9$>'$O:5DO:#A1=F5R
M2D%$:S,T<&U1,V5U6E4R=7A6,DLF(WA!.W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2V]45B]W1&IK,W8O04)G;"]W0TE(
M1E=T2U97,&EZ5F<F(WA!.T-P=#1W461W455'2E9R571$,%A64%0O4V5N,C$Y
M-E!,,&9R34UC,T1L5&QX-6AQ5C1I=$UN1$I+4#!K:')N:6A0-F=$-W=G9CA$
M*U,F(WA!.W8K<&8P,R]P1&<O-6]Y9C5J2B]/;#AY=R]+-'8U:V9K2&8T2#AL
M9CE3+W!V+U-(0B]W03!9+VU-;C@V6'I++VQC6#AY4'E$=CA$*U,F(WA!.W8K
M<&8P,R]P1&<O-6]X+TU:4#4P=FU6+TLT=C5K9FM&1V(X=79Y*VYB;DXU63!M
M5F=+0FYS8EIJ5#5L36A,3$DX>5=C8TU)-T%!9D(F(WA!.U0O-59L*U<S+U5P
M-DXO,T0W6"]Q;F<T>C-S=4-08S<O04I6;"M7,R]!1DME:F8X06-0=&8K<650
M1V4Y94-08W=Z>DI(*U=7:#-6.4<F(WA!.R]W0U@K;GHR*VYY3$1.9')9,E-2
M;5)R53-L1DQO2SA9;$YF1&%V559M3%!69U)%9$4R,40X,R],=6I1,F-1,&Y5
M27)D<F%'9%5&=#8F(WA!.T5C54QN9T9(<49&*T%$.6XT8419-UE":DI:1UE#
M270O>F$P<69464Y36%1B-S9O-C-4>G-%56U'3WIJ:FMD,TA,-TQE<T%P<G8Y
M27@F(WA!.SA.94Y:8F9N3C58;EI5*W$S-GEY5%-1=U)',TI:+U,T8VUQ0U5!
M<2]4;%AX07@X37)X:&LS;&9Z4G!V;5A4;3%$5'A)<TMY96LV>DLF(WA!.T99
M3T56>4M!<TYU63<U0U5A6D$R;2M"3$$W3'I2*UIF1WAH=G9,4V5P3UEP3&TX
M=#-R2$A&2DE635IG9#%94T%5-4@Q0T9R>4DR-#4F(WA!.UIW>#<R1FQN;59S
M,UEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%H3E@O=T-/
M5&4O.%E*9BM)2$9885(O>'EB3"\F(WA!.T%)=U)F.%%'2V]V1EA9<3=&6%EQ
M-T9867$W1EAK,VY4>DQO;'9R=7!W>65F64Y+=E5L4EDY3V$U94I9549O5DMU
M1G(X5%1S<CE.:#@F(WA!.SAU:D4Q>6$U4T%03D)4969T1FQ7,4HO37I4;S59
M8F%#0U-33&MV>'AY;S!S<%9N:U-2<$5$06QL-T%+1C5.:G=(=5)X:G91<F5E
M-U,F(WA!.S1J:&4W+TY$5'IC>$UX2W=/:T5204U,24-)-'=Z5C132S-):U59
M54=(9SAK8UDW,U1E93=55S9M,"].1%1O<FQO64E*:$EY>7 K-V<F(WA!.TM3
M>7)Y4V]K855H9V1V97500C5,>&IV0S0O;4E1:6]V-6TV3452;%I2>%5S479P
M:W$W<W)S86Q8,S(V+U%(9SAI;FI(94=F95<O>DXF(WA!.SAJ-F=T;'!Q95HY
M4'8Y66%*16LY3U9%33!W54)Y:4AJ.7!T=V]Y=55#3VI)5$(V<FIA*V)F*U9M
M3&,X+RMD9"MO;&%54$-V.&YH-G8F(WA!.W%F1E@K5&),3&HT9CE+,U T<V9G
M5B](9C0K2#976%I1-&)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-646UR+S@F(WA!.V-M.2\T=U,O.%%/2W4P:B]!235.;"]X9VDO-&=-
M5E)E2W5X5C)+=7A6,DMU>%8R2W9J6#@U=GDT."\V;BM:+VU#+S W>3EQ1C-:
M5#,F(WA!.T-T0F-W,C!R>'504U%65FQ59S=J33-&3TEI3C-">30U1U))1$A0
M3&XU869M0G O;4A3-R]!1DAY6G%D-W Y<&1W5#-L;3%L231M:&DF(WA!.VQ6
M-4EI<G)X4$Y15F\R,E-L:VE2>EE2>%-",T1+-VYY:F1A:F%1+W!$.'-.5G1R
M-D\P=30R:S K,6QG4G)M831K;70U1U)3<7-S4W4F(WA!.W%F6D<Q4C!#8UEC
M5F9X3C-!1'II:$@X9UA3-C=P=#5:+VPS<G1T63(Y>&136#ET2F)Y6%-Z4DUX
M83%J5T]7;$%Q+T,Y6'(S-59W.&4F(WA!.S--23A08V5L:#<O;% K6G!D:79L
M6%9!<$IO4'%K=S(K-#50>$DY-U-C574U139:*U,S-7%A:&5X,G-8;'$K:&51
M-U,S3517.%,P,W$F(WA!.S!K=D)2.2M*>7@W,&I$3'5F5C,U4&9L+S4S.'!A
M5TE0369M5U161315:3!S1#%)8F,W5314>6HQ;4%(-TDT<5!$351*344W0GIC
M8T,F(WA!.T)U8F5J6E4R3WA6,DMO1%5T9C!,4S-23E,Q1S%S6&M5=6DS33!C
M2EI144-12%IA9T4T44-516AO*UEV3#1S,794<61O3$XR84Y,;C$F(WA!.S0O
M4UHP0DQ+2#5C4U9#1V]R,D].1F)63$17=$@Q1FU85#<K,W9'44)N145Q4VM"
M9T-#94)/>$)'2D)7,%IG4S=&6%EQ-T9867$W1E@F(WA!.UEQ-T9867$W1E5*
M<2]W1'AY8C,O04EW4R]W1$5$:7)T22\T-4YL+WAG:2\T9TU64F5+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W4F(WA!.WA6,DMU>%8R2W5X5C)+<U0X.&%B
M8DY*6E@O-D5K,7$U:TQ7179P3U5E,W1:1F%A85IF:&(T:#9)54%53&-U24\Y
M1$]*67E90T0U9&4F(WA!.S!#5&9L-W)B<$M/8TUQ2DTX>#ED6%9H25-5<'=J
M;U9&5T%.3VA52$Q.*SEH=#--=R],6%-D171:.5-N<W1"=DY$=3$Y3S-U1G5U
M6E,F(WA!.U)13U-E:U<R6E5"-#%P+T1)5$HW,F-11V1:5WED:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<44Q9CA!-#5.-R]W05E*9CA!:4)X5C)K9C@F(WA!.V-M
M>2\T=U)F.%%'2V]V1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98;3)R83-Q
M.&5Q6&MC9#5-<4I027%+2$E!06-G05HU-7)E,&0F(WA!.U)(4$U#8V="3UA8
M>F5J=V%B1V-C4UEJ:T5,*VXY82\U8G!V*T1/63,X<6%N+U9*9DYT+TLT=C5O
M9"MN.6$O-6)P=CA!9WIJ+T%#<'$F(WA!.V8Y56PX,2]+-'8U;V0K;CEA+S5B
M<'8X06=Z:B]!0W!Q9CE5;#@Q+TLT=C5O9"MN.6$O-6)P=CA!9WIJ+T%#<'%F
M.55L.#$O2S1V-6\F(WA!.V0K;CEA+S5B<'8X06=Z:B]!0W!Q9CE5;#@Q+TLT
M=C5O4CEJ<71Z3&)L<FY66C1P5$EQ26]E=G=N-U1%13EV2$TW5&$R8V]84$Y/
M374F(WA!.TMU9E)O>5E)9RMM04EP6$UM;VAG1'(V,$Q"95%L<4XU0VA/>F1+
M1&Q8=WDT>GI8+T%)>5 Y3C4Q,R](.51#;V8V;CEN:V=P3E<Q2DPF(WA!.U Q
M0G%K<E1I57@K;4A.0V=(,GAV6'(T-6E4,3)962M,>%I'6$966# W,C1924=6
M8T%Q=35$9G O5W8X06QU;2\T335J9GEP<68Y56PF(WA!.S@R>CAR:2]M:#,V
M9C%R+VQU;2\T330O>7!Q9CE5;#@Q+TLT=C5O9"MN.6$O-6)P=BM$3U X<6%N
M+U9*9DYF>75,*V%(9G O5W8K5S8F(WA!.V(O9WIJ+TMM<"\Q4UAZ6#AR:2]M
M:#,V9C%R+VQU;2\T330O>7!Q9CE5;#@Q+TLT=C5O8EAZ1')A<T=&-TU31%5!
M<U-0<$)W:G1856<F(WA!.S,T:W9M9S98168T43E",$A53'4O,#E*-VU!=U-(
M64AS-"]M56111&YD.6TV<65F14I4:G=N-R]-3V<Q5TM-2C%%,FU/8D)X,UEQ
M-T8F(WA!.U5*<2\O2$IV9BM-178O141I<D=B=CAZ4$EN;#(R<W),5V199W1B
M>C9V17I7-#5Y=6]+06IM<U-U5G(R-5I:2$9+5S1$6%!.0T]X2T8F(WA!.R]W
M0U8V9FQ4+W="6"M0.$$U13-(+U902F9L-3EZ1#AZ:C=W-R]L96XU52\Y6"M0
M+T%*13-(+U902#AV4'58.'IJ-W<W+VQE;C55+SDF(WA!.U@K4"]!2D4S2"]6
M4$@X=E!U6#AZ:C=W-R]L96XU52\Y6"M0+T%*13-(+U902#AV4'58.'IJ-W<W
M+VQE;C55+SE8*U O04I%,T@O5E F(WA!.T@X=E!U6#AZ:C=W-R]L96XU52\Y
M6"M0+T%*13-(+U902#AV4'58.'IJ-W<W+VQE;C55+SE8*U O04I%,T@O5E!(
M.'90=5@X>FHW=S<F(WA!.R]L96XU52\Y6"M0+T%*13-(+U902#AV4'58.'IJ
M-W<W+VQE;C55+SE8*U O04I%,T@O5E!(.'90=5@X>FHW=S<O;&5N-54O.5@K
M4"\F(WA!.T%*13-(+U902#AV4'58.'IJ-W<W+VQE;C55+SE8*U O04I%,T@O
M5E!(.'90=5@X>FHW=VPP=C5P+VMF3$LX<VUQ5S=34TU79&I$8S$F(WA!.TI*
M<50O9#5G>C=$>%-*:V-92DQK4C=4249#83,O;%HO-48O.5A/,R]!3U).>B\Q
M5'E(.&=99CA!56=N*U94+U!D+WES+W=$278O<34F(WA!.S(O.$%Y2G5F*W%E
M4#AG668Y4T,O>7%F-3=V.$%L6B\U1B\X059Z="\K4DYZ+W="53AF-4%W+S9K
M1B]L52]W03DS+TMZ+W=!:2]W1'$F(WA!.S4R+R]!0TIU9BMQ95 X9UEF.5-#
M+W=!<6XK93<O;%HO-48O.5A/,R]!3U).>B\Q5'@O:T1$+W%16"M65"]09"]Y
M<R\X:2\X07$U,B\F(WA!.R]);34O=T-Q95 X04E'2"]!1DE,+TMP+VYU+S57
M9CA!:U@O,6,W9B]!2D4S4"]64$@K44U0*W!"9C564#@Y,R]!0W,O.&DO*W)N
M8B\F(WA!.T%026TU+S9P-"]Y0F@O,4E,+TMP+VYU+S579BM29CA!,6,W9B]K
M5&,O=T164$@K44U0.$%Q45@K5E0O4&0O>7,O=T1)=B]Q-3(O.$$F(WA!.WE*
M=68K<650.&=99CE30R]Y<68U-W8X06Q:+S5&+SA!5GIT+RM23GHO=T)5.&8U
M07<O-FM&+VQ5+W=!.3,O2WHO=T%I+W=$<34R+R\F(WA!.T%#2G5F*W%E4#AG
M668Y4T,O=T%Q;BME-R]L6B\U1B\Y6$\S+T%/4DYZ+S%4>"]K1$0O<5%8*U94
M+U!B5#@P9GE.4F=Y-FYB,54Q1EDF(WA!.TQK-VHR3653:C)&:$)S67=P-U5*
M+VI42"]L96XU568Y6"M0+T%*13-(+U9032\X04QZ-VY'+TTT*SEV+T%*6' K
M5E O049F-"]W1&LF(WA!.U1C9CE5.&9Y."LU9GI/4'9$=CA!;&5N-54O.$%6
M+VHO04]23G@O,51X+TQZ-VPO330K.$\O=T-6-F9L5"]W0E@K4#A!-44S2"]6
M4$@F(WA!.SAV4'58.'IJ-W=I<E0X>E!);FU+,G9B3%)T66=U<GHV=DMY,C4U
M>$]W0T5N9W-Q;U=P,S0U1U=+561Y1V--,$IB079J5%=*<FUB5G(F(WA!.WE7
M-DIA-65E47EL=79,:V$Y8S-%0E%$;V-P2FMB-S!(:VU#8RM4<E133'IZ4'!T
M<G)$<DAP:W-W5S9E4U%22T5)4%=2;6I#+TUS4&XF(WA!.VM-:$EI835T=452
M37=*8VUD83$U12],=31V<G1.33$K,'-O<F-3>5)O8FU/8T]Q2D<Y1$E:0VY5
M<VEQ;DEL:4MC;%9M1D5C<W=.=S4F(WA!.V,X1TDX:4(X571B>4PU1VYD+W%8
M;6U.23%T<FU8+U,O<3A:.5=&56%.0GAM64@Q0S57;EAB8753.%=F54U$<#AF
M4U@S2FIB9FPW*U<F(WA!.W0S9$-Y5'I61D0V5V]Z,F-L>DI*8FHQ3&1)=55D
M=W1:0D=58591:6-4=GDU2%IC:6-S>'984FXT1TDW8UA8=D-2+S10.&YY*V)B
M1%(F(WA!.TE034M#>&Y2;G4Y5VQA0EE).6E6;S-Q8V$P1S9S=S,R<FLO16QW
M:S Q2$1J-'="3&(T2FI:*U)025-Z23@S;6%#9%DW4C5*-V-V1$@F(WA!.WEU
M5G192C9*2C9T4%0U6%!P:CES=6I+1DY$4TIY>C=M56-'2SDU26)1+THO:UA5
M9$HP*V$K.'=*<'0O8W%S8VM9849L4C)N.5!N3C8F(WA!.VMQ36=#=4=.0CEL
M4V%96EI*9VUH87AW-'I%16UI;4]N9FQ4;TTQ;2MO<')S5B]$83)%3B]E,CEU
M55I94S5B;6LX9V-C04%I:6XR+VDF(WA!.S9556Y);D]E5DTT-E=(3S=$<F8X
M<G9+*V\S3"]!2TPQ-%A3>#)-,3-C45%#2U)O;FEG:&YP>45J1# O.4E+5F(T
M=5--0411,%1N:T\F(WA!.UE585=%:G-5:#!J>3DU4'5R1S!3-#%543,Q,4-K
M:S=33D=Q>$]:;E524FXQ1DA.;&I!2FQO<3AW5%)D.&Y+8V=E5%9$1FI),T\V
M3#$F(WA!.R]W06]E5%8Q1%$T.4PQ<4998GA9<F95,&%70U9O8FAB5T=74G<V
M4W9(>&MK;4M66F=Q=7)#=D56=U)Y4V\R1FYH:%EO*SE&5R]K,WDF(WA!.TAE
M<4E$<F1V<#=L045N965&>C8S2S)T-E-J,65!45-Z4WE-54HK0D-62EA"-&MX
M,&)00GA%8S8K2WEX.&@K54Y5=EEO-"]-5G!P.&,F(WA!.S9Y9WEY>E%R1$,X
M8UE+<2]Q>2MQ,TTO1U=58TM(:41Y0D=*>7E!-4DX1$=4=$ML3WHX=&9L-V0V
M:G)C52MQ+U4W93)-5GAP:GAZ4DTF(WA!.W-L<V)386524C9P2$]5>4Q&2'<U
M8V=Z57!S845Z;4%.:T1(:4I/.60S>5)%9FLO>40K:C5.4V97-V-"<EI9;TY0
M37E#53--;6II-5<F(WA!.U$P:TI(0SE0<'5$.%!,-&9H<%1"-&LW<79X9C9K
M:D1J<3<O1F9R43)N*U1F2FMF;7I5<D,X,3)'8E1,1S!-,710-FM30V56;V51
M5#$F(WA!.T9K36158S=Q:G-39&PU0W!W;DI,:$)!,UEX=S1X36=N6D<S2&M(
M>41A,TTP<TAM94,K<S1Z1TEV565'3#%"3&)34SAU2U1'46-85E(F(WA!.U%Q
M2T4P3SE122M,33E'63 K24@V=&QB6%!Y<SAO84QC5TYT<4AM3C=6-WE',W52
M3$Q&1T%)6DIN:FMK.5 Q4%9!.4]0;D=V2&QV>%DF(WA!.TMA-'AZ>5!)3$Q3
M-#0W1U9)4%8O2C-K1%,Y36YL5%A%,4M5871B,F]-57-):U-Z2'%F5T=616MK
M.5$P-$@Q04-M-$%.95%":FMM5'DF(WA!.W)::DQ$:FE/9#=H06%N-4XX<5=T
M-7 W2G(X56QL9#-6>D1C<DA*0DI*0D9#4U5B:W-N1G%J87)C5EDO6DI'*U-'
M4U)",E),0D%%97(F(WA!.UEP9R]K3#AV0G Y;&1,-7114UA.:S$Y3D,T:#52
M,&]"8CA6:UDK='IK5497<'-R<TMG6DAX6C-Y5#1'2V@V:UI.*UA0-68R5C%Q
M3&XF(WA!.WI483-L=EIV2F(R.$Q446\P.&ML;7I13W)2>4XX2S-,24-F<S!R
M>30P3T1X<&YO>2],-'=F<5-B>34U1CAR87!:86)09&5:<F%Z;78F(WA!.U1X
M;F=M84M,,&EL>$5S=%=K8U5#,GI34T%U1D1-07$X<35/95=12C)A-%E)14$X
M6#0O<U9K.&ME4S=U-'148BM9170W835-2W0V:W0F(WA!.W-Z4DTY<W-H-6AP
M650X57A:3VY&3U!X3E5Q0U!%:T]J3'=-6D\P=G5234@U9F9L.4HK:E5F>FA(
M2$QC96U,=VM1;4Y'84=",D-%4S@F(WA!.W0U3&M)0S9G1&A*>7!X=TA,4&8P
M<$=N>#=E<$)(>4PU5$=V85!91'I,1#E3,4=A-VIU3'-M1#EY:T1U<T1.-F-S
M<4PV+T5C96)$<E@F(WA!.W!K=D9L4DYC;4)W431G3TQN87)D*U-F271H87!F
M4RM:23=Y37E4;W1P03!$5$526&%1>',V<DMX5EI);F%4875Y;6Q2,$%Y5$\Q
M36HF(WA!.V=X1&-Y=CA!=%-J>FPU83!B4C=85#=M>'9V<DUM<$=E45=W;W=I
M:&AK.497-6EV35-32351:EEQ06$W-5!(36TW-DYE9D9'3D5(;7@F(WA!.V),
M6$=2;6IZ6$U/<E=C='%3='EK.%II2SEE6$E5-EI'67-&;FE*16A893E/+T]F
M+T%*5DXO:2LY+U(S,3<Y2V5Q,S95*W%E;#E4.6$F(WA!.W9X.%!5*TQN>7)Z
M<#A.9G!Z1S O:6-/.54U;7 X3&HV,S504"]W1&Y44#A!=%DO.&M-=CEF:S0O
M-W(K;#EJ=BMD32\W5U X07E1>#DF(WA!.V9K=C=R*VPY:G8X06Y44"LQ:B]Y
M47@Y9FMV-W(K;#EJ=BMD32]W0S%J+WE1>#EF:W8W<BML.6IV*V1-+S=74"]!
M0U%X.69K=C=R*VPF(WA!.SEJ=BMD32\W5U X07E1>#EF:W8W<BML.6IV.$%N
M5% K,6HO>5%X.69K=C=R*VPY:G8K9$TO=T,Q:B]Y47@Y9FMV-W(K;#EI<D8O
M:%@F(WA!.VA,-E@V531C9C,S1#!A8V%J-U9/,69(13A8:VME2# T=G-D0B]H
M6&LS;V9P5&QX4% P+U)R=R]A<E1T-#1N:3AL:C1F5&DK>%,O-3 F(WA!.WHO
M=%DO=T1*1$@Q*U-0,U@Y3#=(9C@V6B]W0G)(+VMH:C8O2F8S6#E,-TAF.#9:
M+S)S9BM31U!R.&PO9&8P=G-D+WIP;B]A>"]W0U,F(WA!.T=0<CAL+V1F,'9S
M9"]W039:+S)S9BM31U!R.&PO9&8P=G-D+WIP;B]!1W-F*U-'4'(X;"]D9C!V
M<V0O>G!N+V%X+S5)62MV>5@Y,2\F(WA!.U,K>#,O3VUF.7)(+T%*25DK=GE8
M.3$O4RMX56XO=T%+8V@V+S95-3A6-#@O4G)W<#A.2SEQ9$U2>&536F5(,31V
M<U4O*V1-+S=74"\F(WA!.T%#47@Y9FMJ.3$O4RMX,R]!1'!N+V%X+S5)62MV
M>5@Y,2]3*W@S+T]M9CA!87@O-4E9*W9Y6#DQ+U,K>#,O3VUF.7)(+VMH:C8O
M2F8F(WA!.S-8.4PW2&8X-EHO,G-F.$%K:&HV+TIF,U@Y3#=(9CA!3VUF.7)(
M+VMH:C8O2F8S6#E,-TAF.#9:+W="<D@O:VAJ-B]*9C-8.4PW2&8F(WA!.S@V
M6B\R<V8K4T=0<CAL+V1F,'9S9"]Z<&XO87@O=T-31U!R.&PO9&8P=G-B4"M$
M82]&*VMQ,$A8,$]L3G-F5C5,*S8O<&99,2]W038F(WA!.UHO,G-F*U-'4'(X
M;"]D9C!V<V5G9FMX+WEQ8B]!0F9:9G!(-CDK;%!66#E&+U<O4RMP*W18-$]F
M<"]&>C55-%8K1W8P6E)Q4$4T9'$F(WA!.W!Y3DXT6$@Q=GIF+S)1/3T\+WAM
M<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @
M(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z9C4R,F4P93 M,3-D
M,RTU930W+6$X93<M831D,#9D-3AA9C,S/"]X;7!-33I);G-T86YC94E$/@H@
M(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.F8U,C)E,&4P+3$S
M9#,M-64T-RUA.&4W+6$T9# V9#4X868S,SPO>&UP34TZ1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X
M.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A
M=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E
M<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HQ,S8T93@V82UA-V5D+30Y
M-&4M.#1B-2TV93!F8S)E-C$U9&0\+W-T4F5F.FEN<W1A;F-E240^"B @(" @
M(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,3,V-&4X-F$M83=E
M9"TT.31E+3@T8C4M-F4P9F,R938Q-61D/"]S=%)E9CID;V-U;65N=$E$/@H@
M(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R
M,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM
M<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,3="-C%!-3@R03$U14$Q
M,3E#-SA%-$0V-S9#.4%%.$,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM,3(M,#)4,3 Z-3<Z-#$M,#<Z
M,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.F8U,C)E,&4P+3$S9#,M-64T-RUA.&4W+6$T9# V
M9#4X868S,SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C Q.2TQ,BTP,E0Q,3HP-CHP-RTP-SHP,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@26QL=7-T<F%T;W(@0T,@,C,N," H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R
M>3X*(" @(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT
M/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X*(" @(" @(" @/'AM<%10
M9SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE
M3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A
M<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@
M(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @
M(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-C,P+C P,# P,#PO<W1$:6TZ
M=SX*(" @(" @(" @(" @/'-T1&EM.F@^.#$P+C P,# P,#PO<W1$:6TZ:#X*
M(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@
M(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%10
M9SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86PM271A;&EC350\+W-T1FYT
M.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL
M>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&86-E/DET86QI8SPO<W1&;G0Z9F]N=$9A8V4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT
M.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T
M<FEN9SY697)S:6]N(#<N,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O
M;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M
M93YA<FEA;&DN='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @
M(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA
M;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U
M<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@
M(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U
M<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @
M(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO
M<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R
M9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\
M/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ U )4 P$1  (1 0,1 ?_$ !\
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M6?.')2/PF4(19?$/),&>5(M\;'#/%.>4'ELFW[EEFM7:VEGEB#J 64LIA/0
M,Z%_"345&YRDLUO-;CFLD5\-FCQ07<:W,4$,I5CHK .)QUU98WV>"^E9XUS+
M#.K^DT0+\I9KR(V')(9LO>(23DH#(YO&-R[B)1GECLD1%8JTE G/.916*["0
M&!@[\@(*AD@6N7RV#0V,!-K*6@E19LPJVB6L2R0V[*)%C:"#=9Q,[E&^C>2,
MEF 8-NE'52QJXB=H<*QNWNI6CEN%8Q-(EQ.4O)0B!QX:++H 2&7;&3HP4:UL
M$X'82'#B+H[&5['=;7D7T7>9%IL\=2D@LZ<YR$UGXBQ+S=NUF!]M"D\L(2RD
MLF03-R9E'6Y\EWSHBIGEC<AM[;<;(^2N\;4T0:#:OA;8_ 4R?ZPHO@H6VCH*
MR>.W"RM]\IF;8=TA+G4[F\'=(!(PC_U89QN8*&/4U+FK.KVE*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2M/?);[<9
M]_%!/PN#J9/)'W_B:A?RC]WX"I^\5/L*A?[V3?BLW4;^4?N_ 5(GDC[_ ,34
MAZIJJE*4I2E*4I2E*4I2E*4I2E*5:A:=P>/O,AQV910(0PPP5S8%I"(&O,4U
MK7R35R:O'B*]L%;=W+#.^%L<[=V^-[U"]Q!&VV2:%&\>UY$5M#XCHS ]:QEU
MF\-8S&WO<OC+.<*K&"ZO[6WF"L-58QS2HX5AU4[="/%79!R^)R?-RG&I1'9"
MHRLED\P!FQI;-IBM=3%')SBP<N,D+*Y)*V2NK;"RETU+8]V^&7<JCFAEUY4L
M<FFFO+=7TU\6NTG373IK4EEE<7DC(,=DK"_,(4RBRO+>Z,0?<$,@@DD*!RK;
M2VF[:VFNAJXJDJ_I2E*4I2E*4I2E<+ERW9MUW;M=%JT:HJN73IRK@@W;-T,,
ME5EUUE<L4T444\<E%55,L<$\,<L\\K8VO>O"0 22  "22=  .I))Z  >,U1)
M)'#&\LKI%%$C2222,J1QQHI9W=V(5$1069F(55!)( JQK[7U;:W=OLJ 6M_O
MO,8[:W_Y(U!VNU^TV_[Z/\U8;OGX:'CXAP?\6L/B*O=H[:OVK9\Q<MWC)X@B
MZ:/&BR;AJZ:N$\54'+9PCEFDN@NEG@JBLEGDFHGECGAEECE:]YP0P#*0RL 5
M8$$$$:@@CH01U!'0BLQ%+%/%'-#)'-#-&DL4L3K)%+%(H>.2.1"5>-U(9'4E
M64@@D$&NQ7M24I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2M/?);[<9]_%!/PN#J9/)'W_B:A?RC]WX"I^\5/L*
MA?[V3?BLW4;^4?N_ 5(GDC[_ ,34AZIJJE*4I2E*4I2E*4I2E*4I2E*5I2ZR
M7#Y7;^KF/(.!AU'NQ=1,LFDH9CFV2S^3:R6<YN'.5DTL<U7+N$D'"YMMAC;'
MO0C^2YYW6419)6TCC/#&\M5R-O&6N;1=)54:M+:DDGH.I:!B7'_PVE\>BBOC
MK^ESW)GXLX9@X\PEHTW$'"D)CR4-O&7GR/#CR&24A4!:27#SN]Y& !I9SY%F
M+,D*B5O3>XF)<4..P40<8IH;2V#V2:;.7RQQ[2S*NFMO%$2NK;NW[/#QBMAZ
MB6*JK?(ZX/OVN?@2%L;9;AK$#$XY$D72ZN-)[H_6KD>!#KYH5.W34CF&1AT:
MNG_T>NY8G<NX L[2]@5.)L]RLQQ)(0.;%<RQ#LN*+>/EXFW;D,@9HS?/?3QG
M;<5L K8:[M2E*4I2E*4I2E*X'+9L];.&;QNB[:.T%6SIJY2P7;N6RZ>22[=P
M@KCDFLBLEGDFJDICE@HGEEAGC?&][5X0&!5@"""""-00>A!!Z$$="#XZHDCC
MFCDBEC26*5&CEBD57CDC=2KQR(P*NCJ2K*P*LI(((->6HITHBU^H<VU*V%/\
M.-Y*ZNX?'V%G&+=IK- FG8AK[$C:_P#H'TCZR4+:XV<J$\ ;QE*U$\L++)X\
MK;A)^^(6@1ODQM;SF#706P;PK?=_:"0B #4MRV64_77YGW/]%ZZ^?V/A:.VG
M'<\N-W%O;AO$<?#B7*B? BX!\&^2^9</$.8URME+#E&4C<*]23%BR&,F8T<T
M;L!X]JW8L&+-%-NT9,FB6#=JT:MTL<$D&[=!/!%!%+'%-)+#'##&V.-K6ZHJ
MJJA5 55 55 T"J!H  .@ '0 >(5^ET,,-M#%;V\4<%O!%'#!#$BQQ0PQ($BB
MBC0!4CC151$4!54!0 !7:KVI:4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I6GODM]N,^_B@GX7!U,GDC[_Q-0OY
M1^[\!4_>*GV%0O\ >R;\5FZC?RC]WX"I$\D??^)K/)0F."#")DN];#1(AB[)
ME"+U;!NS'CF#=1V]>NW"E\4T&S5LDJNNLIEC@DDGGGE>V.-[U&S*BL[L%1%+
M,S'1551JS$GH  "23XA4=S<V]G;W%W=S1V]K:PRW-S<3.(X8+>"-I9II78A4
MCBC5G=V("JI).@K#_'KD#KODUK(;M;6+]P\C9$D:$9H/D<6I4:2!D%F3AF59
M644R9.5D,6I5LBKEWZ@LD/=]RV#G"K/'9&VREJMW:L6B9G31AHZM&Q4JZZG:
M2-' /78ZGZZU+@+CO =T?ARWXHX;G>;'7%S>6A2=1'=6]Q97#PR174(9C#(Z
M"*ZC1CN:VN()=-)!4!^J=U#)]P%%Z4?P6!0^<Y[0(3UF33ECHTUP&X1%O$5F
MF;&X=TVOGDZO(G%G%G'?VQLW1\'WM[Y]WL'<RX"L>.9<PE[?7=D,;'8O&;58
M6,ANVNPP?G*VFWLZ[=NGE'7ZJTGNP]T_)=S:+A]\=C;'(G,29-)>VO.@A%BM
MB4Y?(="3(;MMVXG38NGC-:>OUC#D#ZO^G/\ -9M\5KK/[/\ @?3N7_=V?Z5<
M/_:BXF_X:P7[[(?K4_6,.0/J_P"G/\UFWQ6G[/\ @?3N7_=V?Z5/VHN)O^&L
M%^^R'ZU/UC#D#ZO^G/\ -9M\5I^S_@?3N7_=V?Z5/VHN)O\ AK!?OLA^M3]8
MPY ^K_IS_-9M\5I^S_@?3N7_ '=G^E3]J+B;_AK!?OLA^M3]8PY ^K_IS_-9
MM\5I^S_@?3N7_=V?Z5/VHN)O^&L%^^R'ZU/UC#D#ZO\ IS_-9M\5I^S_ ('T
M[E_W=G^E3]J+B;_AK!?OLA^M3]8PY ^K_IS_ #6;?%:?L_X'T[E_W=G^E3]J
M+B;_ (:P7[[(?K4O^D7\@;_5?C]IR]K_ %7M<K-?K_\ VE/V?\#Z=R_[NS_2
MI^U%Q-_PU@OWV0_6K"VU_P!)9YL0UMF:A?%3C_, J"7?O6?C;9&$@8VPQ_\
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M\4D$\<<$L<,;6M5"=W[$("$X9O$#,SL$O+50SN=78@0#5F))9CU8]22:D?\
MHOY^0JTG&&/D951%9[&]<JD8"QHI:<D*B@*BCHH    JHW_1\.0&3BSK+EY&
M<G6)?$_BYO'9K=QB>PQQPP-V6N?\)8OCAAAAB2MEVS''''&RUK8VM:/Y^<&!
MM'"EP%,1@*]IL].0228=.SZ<HDDF/R"2>E2?LS<2EMYXVLRXF%R'[+?[NT
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MOA9BS6L[,Q)9FE0LQ/4DDC4DGJ2>IKK"\ SHJJM_;JJ@*JK X55 T"J P
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M%CU-N/Q"-.I2A#.1^+)';C?0[-BOQZV0B;.[=R<2]D1@,=$9B;/#4DCC^#R
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MM=7%Q+&\@;43+;[%4D=&@DAW1L1Y!"Z $ZPRX'FP&-ID65;2"VBEC0KM,+7
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M4MQ;"U8J1*%1I1V\M'-D8Y+6>VY<S&29Y(VDE1N4'E64]5B1W)VE2KL4U.\
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M^/9U1O\ XE?4"_\ O1Y.?_[-,Z[1B?\ 9>._^AM?_P#@E<!S/^U\I_XA>?\
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MY1T[Q>*O11]<Q_Q=/G+X)].+ZAE/@:>?OZ2_K:M/<OR)^4=.\7BKT4?7,?\
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MV>'R]V_;X6FG6K>J2HJ4I2E*4I2E*R9I[<FS] ;'BVW-.30Y -APPDD4C\E
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MBU4Z96FN+O4(X]<]-,ZCUJ6X@:8G,XX"-)I%RNX'VV2C\E%=AS>2R-K#I?,
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M93;3P,P:XL2Q2*:-R"R(R'10FX>$QZ%+PEPQ!>7-T]DTU@G!5QQ$+*SRLUQ
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MC7B8\:H2'W:/'S:SO-2]9_AR]R5Q<YNSR-U'>/C;V.VBFCMX[<.AB+%FCCU
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MWO:]K9\9^,N6-[V^K+'^RD)CWV-_\+V[['+'NV[MN[:]O\;7K,\$_P"Q7_\
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MHDEN=[[022%W,=H)) (!)\=67$UA'B^$)<= SM!8\>Y6UB:30N8XK-TCWD
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MDE(5U5.=D!V3N#:X'=2"LLWT;"R?:R![6VJI+$91*(VV;M8])L8">A)"$ Y
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M%M?PMT31L?$6(Z5*S:'5=YY;EU;+M.;&W8UD$(V"#BL?V!;^R_40V53EG""
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M[/+%OA!)(1]PU)_WFUGQ_&/$>+[7V3(L.VW37UP9X+:Z+7K:;KM#<PR\NX8
M!I(]I( UUVKMMK+J*\Q\T>3317<2JX[F&H4<<B!+F$:X=!YX^,#'H9^4:BG,
M0580DPJ-(.&N!B -XL30QLUS0=)J,&.;>3O?Q&N-(LP&Q&T8]A-<!X%1@ZJ7
M$H:9 RAMDYE4G74:,P,/?7G],NIOR4SV\Y5#;6C1W+2(T;N$,!6WD*,5WVPA
M<=-""JZ79-.J;SNV!KV+:VE6^'[\/#BVOC@>0H0[7HS969;5!! MK8@6VN+B
MC/9)M[#23=)\(>E90[>7<VNL^7>9Y7O44/#.$@N);F*Q57F2XC=.=<-;[+I2
MMRJVK2FV19E.CA(@-/) J>XXSXDNK6&TFR3-';R6LL<H@M4N^99,'M'>]2%;
MN1H'4,C/,S:]6+55=@]6;GULZ2:JE<MWG@L6TQL)#;D&P#ZUU/&PZ>U&[55C
MAL22QV/P<;'YM+.QKN6MB4Q&'+)(.WR;=)'$@^LXH@X6P5M'=116.B7D!M9]
M]Q=2.;8D-V>.22=I(8MP!VPLFI"ZZ[1I)=<;\37DUE//D07L+H7UMR[2RBC[
M:%*BZFBBMUBN)MI(#3I)H&8 #<VN"5>:/)-:'NX$IL3#**/N4%^9;H7]#X-:
MZO(^X_(5?87;L8U8CAAV'+)#Z(IN\(/]?A?HWX:UE*OAA\<)A/V?Z48SY'#<
MV;_9VX/V?;S-OE#7FZ<[ZN9ITK&=\&7Y!MNU?0-F/E\IR+;KEMNSM6[D[_)Z
M<@-V?Z^5KUK.4"ZL'/76TNVO-HQNY"YK=<[3VEL%N>UGJ:4QQ]LU!LW9MI^$
MB,C@Q2+1"5H-FC)"Q2)!PBBR+ >D[Q<)#V6"%E/PM@KB*UAELO LX.RP%+F[
MBD6V)+&!Y8YTEFB)+';*[@%F(T+'7)6W&W$MI/>W$.1',R%SVRY$EI931->!
M0HNHX);=X8)@JJ-\"1ZA5# A5TI^G.J5SCT'&)!$]6[B8Q\;(I=,)\H[<ZPU
M*>D 6:; [ZTRDD4DI^#$ST4)'L,N\<7 $&#=K:V.0Y!DIC;.U5WPSA;Z2.6Y
MM&D:.*& *+F[2-X;?_4QRQ1SK',L?U<Q6)\3%A5%AQEQ'C(98+._6))9Y[DL
MUG8RRQW%U_VB6&:6V>6%I?KY;*%T&P*:BSIK?VX^/FV 6\M/3XW"]K1U\0(C
M9@TNU(O<UR[=TT,)E6AML2&'F1EJ]=MC TZQ(CRB#E9-^V<8J96K)WEA:9"U
MDLKN!)K6155HCJHT0AD*E"K(R%049&5E(!4BL-892_Q=]'DK&ZDM[V)G=9QM
M=B9 1()%D#I*L@9A(DBNC@D,IJ5RO53YQJ;D8[U2VT&8S@?K,III-F,U/J 9
M!'>JS93(X9@Q?6K&"H0(X$)FLKEG>)B//GER&*3E)VEFW;71Q8X8PO8VL3:.
MT#7*WA+75VTXND78DZ7+3F='5/ &R11MU!!!.N;/&G$9OUR0OHUN$M'L J65
MBELUG(YDDMY+1;<6TD;R'>>9$S;M"&! TI&PNISS:VF\E[^;[A:%%YWH)?B_
M)L6NL=1@VKS1;@\ZDN4$:,0$$&,P[=(P\77:F0R ^1,V]TQ[4NB.00:IUP<-
MX:V6)8;0H(+\9./6YNW(OA&(N>6DG9G)0 %'+1DZL4W$FH[KC#B&\,YN+]7-
MSC6Q$VVSL8PV.:0RFV58K9%C',8D21A95&BK($ 48)@W*#>$ TILOC7'M@DA
MVA=SEP)G9VO/%$:+CS1./D!#]@:&.3@A^2C1U/,&*36)QDB$=%&HYF.++O!R
M6+:U[-C;*>]MLC);JU]9I(EM<;I$9%D5U9&".JR(0[Z+*KA2Q9 K'6L;;9G(
MVN/N\3%=.F,R#QO>6NR*19'C9&61#(C/%(.6FKQ/&7"*KEE %2JZAG-6$<FA
M7&/2VD6FV6''7B+J+#6.L<]X$HV_V?(7K]=GD=DTI2AN:D6&]T2#B<9#"!*S
MM!@)C2&>+G"SSL+/&8##38ULE>7IM6R&6N^TW/8ED6VC"AMD<1F^E;PGEE=W
M +/(>G3<V:XIXAM\PF'Q^.6^7%8.Q%G9G(O"UY,S%>9-.+?6%/ CAAC1"P5(
MM=WA;5UJ5L5:C2E*4I2E*^L<<L\L<,,<L\\\K8XXXVOEEEEE?N8XXXV[M\LL
MKWM:UK6O>][]RU*5_2[Z('$Z6<0NGSK2'["%N@&QMEFC^[)O'7J6:#Z.D)RD
M+:  A%NK;!=H8806/Q),ZP<II.!9RY(8MAX1G?++YRXTRL66SUS-;L)+>V2.
MS@D4ZK(L&XR.I'0HT\DNQ@2&3:P\JOKCN>82?!<,6EO=(8[J[DDR%Q$P(:)[
MD(L<3@]1(EO%")%(!23>A'@U.7E'Q-T)S+U80T_R%@0^<Q!VO8@-4446'R"*
MG4D546DDB,A99)$X^<:)K*I6=,E[(O6BKD65;$!#QZ/<X7&96_P]RMWCYV@E
M VL.C1RQD@F.:-M5D0D Z,-58!T*NJL-CS.$QF?LWL,I;+<P,=RZDK+#( 0L
ML$JZ/%(H)&Y3HRDHX9&93_-EZE7%#77#KDK,-/:P+S,U%P1-\U9.YR2"E#>2
M3=:^"=EW0*/1IDIE;'ZKY8CD^[W.[_CW:^B>'<I<9;'0W=RD*22(K,(%=4U(
M!Z!Y)&^O_>-?)W%V$M,#EI[&SDN)(8W8*UR\;R: ]-6BBA7_ /0*U[UGJU6E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5]IXVS43P
MOW>YEGCC?N?X]S+*UK]S_'Z_K_W4KT=2!_?7N1Z'?2AX?JZW@G,681F1;+VR
MU*W<1ACL J++02%&1>+5TRD<>B@\"(1='FRR_A6+V5.I*F(=H-"85N-+-$'^
M'%>-.*<L+B?$0R1VUJ5*RM;JZ3S(Q*F.25I'(C(&C"(1[U+(Y9&*U]%]SO@K
M!=EML]/#+=WP?6%;ITDMK>1-"LL4*Q(#*"=5:9I>6P5XPC@-7J<KF-=DK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g838337g59z81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g59z81.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X7'#:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^56YK;F]W;E]&:6=.=6U?,C Q.#$P
M,3 \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \
M+V1C.G1I=&QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @
M("!X;6QN<SIX;7!'26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M9R]I;6<O(CX*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C Q."TQ,"TQ
M,E0Q,3HR-3HQ-2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @
M/'AM<#I-;V1I9GE$871E/C(P,3@M,3 M,3)4,3$Z,C4Z,34K,#4Z,S \+WAM
M<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q."TQ
M,"TQ,E0Q,3HR-3HQ-"LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @
M(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD
M;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I
M;',^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SIH96EG:'0^,C4V/"]X;7!'26UG.FAE:6=H
M=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM
M<$=);6<Z9F]R;6%T/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G
M93XO.6HO-$%!45-K6DI29T%"06=%05-!0DE!040O-U%!<U5':'9D1SEZ84<Y
M=TE$375-04$T46ML3D$K,$%!04%!04)!05-!04%!045!)B-X03M!44))04%!
M04%104(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&
M0F=K1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$0310
M14$X3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%
M0D%91VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G0D%!
M14%!=T52)B-X03M!04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!
M04%!05%&07=)1T%104A#06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X
M03M!44%#07=11D)G8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-
M4D)!049)4DEX459%1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A:
M:3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*
M0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL
M.5=:,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y
M3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V
M=F]204%)0T%1241"455%0E%914-!341B445!06A%1$)#15--545&55).:$EG
M6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW
M3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X
M03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B
M,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L
M-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2
M040X03E!95=F3%!L*S0X=C9F4%!P.$5K)B-X03LP:T-.2DEY06MK:F-K-%94
M4"]#6&QJ+W$R5S,O04-,6$%R=CA*95=0*W):8F8X:3%X5C,K179,2"]6<W1V
M*U)A-'$W+T%!;#59+S9T)B-X03ML="]Y3%A&6&8T4SAS9CA!5G-T=BM2831Q
M-R]#6&QJ+T%+=&QT+WE,6$989C13.'-F.5=Y,B\U1G)I<G8X2F574"MR6F)F
M.$%)=&-6)B-X03MD+VA,>7@O,6),8B]!2D9R:7)V.$IE5U K<EIB9CAI,7A6
M,RM%=DQ(+U9S='8K4F$T<3<O04%L-5DO-G1L="]Y3%A&6&8T4SAS9CA!)B-X
M03M6<W1V*U)A-'%L;FU4>3%O1G1O;#%08C9F0D9.1V]+4TMG1$$X:'5$:%9L
M3T)62S8O=T(U6G8X055B.5)X5FHK9V56+TQS,FAA8DY,)B-X03MP,$1Y>5=S
M3'E/>4%L;6%.4U-4-VY#<5 O=T%*95=0*W):8F8X:3%W2S<O0UAL:B]!2W1L
M="]Y3%A&6&8T4SAS9CE7>3(O-49R:7)V)B-X03LX2F574"MR6F)F.$%)=&-6
M9"]H3'EX+S%B3&(O04I&<FER=CA*95=0*W):8F8X:3%X5C,K179,2"]6<W1V
M*U)A-'$W+T%!;#59+S9T)B-X03ML="]Y3%A&6&8T4SAS9CA!5G-T=BM2831Q
M-R]#6&QJ+T%+=&QT+WE,6$989C13.'-F.5=Y,B\U1G)I<G8X2F574"MR6F)F
M.$%)=&-6)B-X03MD+VA,>7@O,6),8B]!2D9R:7%7*UEF3&UG,G5K>5A&=%E1
M47IX=D-5:U)!1T9::T=X=W%M6&Q,+T%*4FI44#A!;4=J+T%/231&5&)&)B-X
M03M63C=M,E)I<GEO<D1Q<%E!+VIH<&)79E@W3"]F-F9E36%+3%<O<$MX+W="
M+TPK3TY&8D12,5=W2"LW:#EZ9C!X-%-T:$DY9C@R>5=-)B-X03LP4U=A>'I)
M-FMS6$1#:$(O,D]A2'1J=%A*<%I215%$>$1Q-T1285-/545K;EI++SAF-FXO
M04US.% O1"]!4$Y7868X03!4-78U<V9T)B-X03LO5S5V.&QW-WDW+T@K<"\X
M<SA0+T%!+R]!1%9J+V]N>F9Z62]B*W1F-4QH,VQK;'(U:70U3%='4U)(16IX
M<7IH44]027%#859/9&AP)B-X03M:;DII:DTO>%)"*UED3&Q!:DUX-VEV.$$P
M.6)F-S=F.% V-69W=&9%,2MN-&8Y.4XY-'@T5C1L<#AW3#)G4#A!=U@Y;4AH
M6&E41S%N)B-X03LY93-36&IX-2]S,7(S<&M31U%3-WI:+WEJ=#<O04MG+S1K
M34%63G-657)R+T%(;&TO=T)2=C%(1E5(-6$O=T-58S!R+T%*9S=F+VLP)B-X
M03MU2W!J:7%&=4Y4=%E*5$A)5'E&2S!&975%0D)+:BMN3$QW9C=H+UA$=VQ(
M13$K;F)0*U-4-VPO<FIW<GA,9C Y8B\W-V8X4#8T.$LX)B-X03M34BM:4$TY
M.40Y6"MO=5E/6% Q2W%J5G!X<#EO2'!V;D]E,$=T>F%F9SA/5F-81F5W4$MU
M.3)F6C)#1UAI-&AD5BML2F8X6"M9=CA!)B-X03ML<B\U2GAF.# U>FXX=39V
M*V8X03='4#9N6F9K35 X04XK,"]R9"]I+W=!>&8X=&8O2D],+VUN2"M89%@O
M4#A!.6I(.5,O:TU0.#,W)B-X03M4*W1K*VYE67)P-T-&<%9%:W!7<GE(87 K
M44%'9#$R9$]75$)#8VIC:4A1-F]#3U%G8V=R;EAP*S!3:C<X>F5&>"M*;S8Y
M9&1K5#=J)B-X03LO6$AH6&E7;EA,=R]S;U!K1"]82&A#.%-B869C4UA&<7-S
M;$]22G)4<'-C:5%Y0E%0;78O04DT52]W1')W+SA!2C5-05,W>6PO=T%O)B-X
M03MX<&XO041$4B]W1$5C5E1B1E=.86]A,S@S9F-F<4=71&LQ;FUH8TM(67$W
M1E5I.'AF,S!0*W%F,35X6'16+V51+W%N-S-F9&MF5$PS)B-X03MP5&Y+=3)D
M:7),8DPO94LS+W=#36%F.$%%4FYQ9EHS*TPT+S9K9G5$>5=P+W9:9C%J.39T
M;5DP3WA6,DMS;#!V+V5#2#5(.5IY<S@R)B-X03MW8VM(-7,O-5(R.2\Q0B]X
M25E!;$YS5E5R<B]E5V(O56(Y4GA60BM7=BM58S!R+VU$="\K5%,T<6U/2W-D
M,6,Q,4-4,C0O.$%%4FQK)B-X03ME5$-83D)95TQS5F1I<51E62\X06HS+S)F
M+T=U8V8W5B]W0U0O=T$W+V5U-C=)+VDK2#95;'IK2&1/>%9L=6Q15'1P.$)7
M3FE#=7A!)B-X03M*1V5M.6M(+T%!6$@O5F57,78X065Y.39-*W S9BLK2E K
M0F(K;6)+,T9P9#E1=F8Y.'8Y>'=71G!V.$%2=#DO=FQS8D,P;FUM47E1)B-X
M03LR87!)=D9W5%5F335!<W=G+TYF+T%"=W O=T18:"\U4$IG0UAE578K55DP
M>B]M1VHO=T-)-'%M,DMO0V)2-V5A6G!89'=83E-"5"MM)B-X03M3-&U00W1'
M:%=9+V%K4#!J*VU0179#=4=I5U$O;5!Z4#EM4$56-%=X;S%G4#)39CEK8V5)
M<#11>$1Z>&%W5SDS8DQ%=D5'36LW:R]T)B-X03ME*V-8-U5(.35$,T@W,V0Y
M;$0P;C-S87IL,V%U>%8V:&\Y;&%.<$YI>E%O5TYV15-306%K;TTY4#=04"M$
M-"\V:V9U1'EU;T@W>5@Y)B-X03M9+V5J4F%79S91>&HO66HK;5IL=$Y.:3-T
M>#!I468W15E,5%,T4E)J;V=(,$1&5G=!06].:&EQ52MB4"M59'9F.5%F.%-'
M259.<U95)B-X03MR<B]E5V(O56(Y4GA60BM7=BM58S!R+VU$="\K5%,T<6U/
M2W%4,G1S-VPS:5)N4%5S068Q-&)7;D,P=%(P:&I(*WA(.4UB4E,T5SA!)B-X
M03LV4G%0:V]W5VUM>$A'3VEG9E%-5EEH*UE102]2.4)4*RLO-#!Z:W9A;B]*
M+S4S*SED>#)6+T8X4#!S3WIK;F)U>%8V9C5A+S0T5FPO)B-X03MX:B]I8SE*
M-THO>%=(.58U;E=F,W-V96UE8D9X;EEQ-T9867%L4&UV+VIH5"]W0W9$+WEE
M5$5+-WEL+WEJ1VUF.'<P9B]%8U948D98)B-X03M9<3=&6%EQ-T97169M0B]V
M8F$O.%EZ+WA,3TTY<"\W>4AU4#-U-S=,*VLK.6EM8W<W4C)+=E9T1B]W0T]0
M62\X=SA8+T%"05HV9C)F)B-X03LO:2M0*W!(-V<X='%0-WE8.5DO96I->3)L
M,DMU>%8R2W!4-7,O=T-59'9F.5%F.$%%:&E&5&)&5DLV+S-L;2\Q1R]58U91
M9FQR+VQ()B-X03M.2R\U9S=F+T%*3DQI<5DT<3=&6%EQ-T9867%W-SAW+RML
M9B]!33EV*TY--4PR<"]Y9CA!;F8W,3-(6E@X6'<O4W<W3U-D=3=&6' O)B-X
M03ML<B]J:%=8+T%":B]!26Y04V5Y9CA6:"]695HQ;CDW3#-P;FUX8UHR2W5X
M5C)+<%0U<B\T-%4O*W9$+WEE5$5+-WEL+WEJ1VUF.'<P)B-X03MF+T5C5E1B
M1EA9<3=&6%EQ-T97169M0B]V8F$O.%EZ+T%-4WIJ4&%F*SAH-VHY-W4K>2]P
M4'99<&Y-3S!D:7(Q8E)F*T]062\X=SA8)B-X03LO14)N<"]:+RM,-"\V:V9U
M1'DR;R]V2F8Q:CDV37I,85A9<3=&6%EQ;%!M>B]L2&(S+U5(+T5H:4948D96
M2S8O,VQM+S%'+U5C5E%F)B-X03ML<B]L2$Y++S5G-V8O:S!U2W!J:7)S5F1I
M<G-69&ER1'9Z1"]!3VQF+W=!.78K3DTU3#)P+W=!;B]N9C<Q,TA:6#A8=R]3
M=S=/4V1U)B-X03LW1EAP+VQR+T%)-%9L+WAJ+VEC.4HW2B]X5T@Y5C5N5V8S
M<W9E;65B1GAN67$W1EA9<6Q0;78X030T52\K=D0O04UN:WA#=3AP9CA!)B-X
M03M+36%:+W=!=S!F.$%X2$95,GA6,DMU>%8R2W5X5F<S;CDP3B]B2T="6EEZ
M>4%/-'%D<35X9G1024A,068P6&0Y;&HP2#-S5WIM6&%/)B-X03MX5C9N;TTP
M575J5UAP=7(X25DP8FE184UQ045';F-:-EHR8D]-=%!#:F12:5!S95@Q55--
M:W(W>6HX>FUH,DMU>%8R2W!4-7,O=T-5)B-X03MD=F8Y468X045H:4948D96
M2S8O,VQM+S%'+U5C5E%F;'(O;$A.2R\U9S=F+T%*3DQI<5DT<3=&6%EQ-T98
M67%W9GHU9E=L>%!A=U%Y)B-X03MI4U-$,5!60S=H4S-'9W(P<CA/8U@W4S9J
M2$]527A.;5!&9GAR.51U*WI-56]G:VIN6#972S5Z3'1(67$Y1SAP86Q:5#98
M0F%X>40V)B-X03MX06Q*26IS,UAQ4$5:-D(R2G$X8SA%64$K<4DS1'HR=7=Y
M:FM-:4YI;FUB<'=867$W1EA9<6Q0;78O:FA4+S8X4"]*-4U1<G9+6"]+)B-X
M03M-85HO>D12+SA2>%9.<U9D:7)S5F1I<5$K82]-1&%B8G)"8FXO5$IH5E<V
M.$8V8W%(.$TP9F)885HP.$]'2#DU3#=",R]Q8R]1-EAX)B-X03M$6BMK4%!8
M9#5(6C-9<S='<DUX<5-4,TIZ9W!336I:3FPS-$%!;TQC0UA9<6ID2C%E-S!Y
M-44P1&9$+W5Y26XT6$AG9C8U;6%,6%I.)B-X03M.4&EJ.%(P3%1N=U)Y4F]V
M5')#.6AV8E-+-FA.6352565)4%%G+TDU-E!P=%)(3FI%-#AI.#%L>&U%:D4Y
M1F9,,G0R2W5X5DMF3FXO)B-X03M!0VIT-R]Q1"]I47A#<'1I<6QD9C=Y>F8V
M:F9Q3TMO4'DQ+WEJ;6QF.'=D=B]W06UL>%9-8U9D:7)S5F1I<D<O3U=U>5=5
M2U=D<S-')B-X03LT;D),=4]Q<# R.3)Z;G4S=3!J:&E-8T15-6994#)U>3=0
M,'=M94M824U(=&)3-'5P1$A!=DIG0WI%:TM!0C-,35%",7II.$]#954Q)B-X
M03M%5V9L.7!D,5!)26EY<4YP96]!06E";D)$3E90:DA&1TM-5'AR46-L3U=(
M4EI2+T-4>C5B.&I2-65966I.1'9C,FQA9W4S;W-4>5)/)B-X03M+,%IU57%E
M;V=!56MM<3<T6F%,2U T96](9GI(14]8:V]Z=S<O=T%$6E-I;'5B4S1%:UIA
M1V5*=&HP6E-/>'EM134T<#),:DM,3U52)B-X03M-561W6'!M9S9S=7%A8VQX
M44Q+1'=M561!-#8P.6HQ>C!F<S-7:E4T4E!R>5!V96$Q5T1W<#$P5$A-.7@S
M67$W1E5P.#$O.$%(0VXO)B-X03M!3F5(+VLX;4E6,VQ,+VQ'3DTO-6AO+RM)
M-'%M,DMU>%8R2W5X5C5L-7!U1VXQ,C9,2&%.=E1594%152]8;FY08D]5>C%5
M-S9'=FLY)B-X03M,;V]C3TE,9$%V66)7-6ME5U)9;&1/4$UH*U$K24@T5U%%
M9S=:2'-V55)X5$IK94=X>C,W*VQC:S9R1UI21D,O>#5P:V(W>2])<D-7)B-X
M03M4;49T,FEJ16MD5W)Z;5EF1G=A:F9%;E%J-3ES,E(Q3VML9D5B.49#>#5Z
M4&-D.30X<3DO4GAV1'EJ:U T<C4O,690,SDV-F963DAL)B-X03ME97-Q35I*
M-7!O1VMJ6FM1>4I(475P53$K>7<V2&9$:S%U;FM:5U%B;DM1=4I)1FE0358U
M14Q(1&M!1S-)04AF=78X05EX;'9T2&]D)B-X03LK;S)'8S-,;3=)33,X9U1U
M,6QD46LQ5T]1378K>D<O+T%"2$]Z.6U-:$]+565G4#,O=T)J<$\Q26II0C=W
M>7)/;617-T9867%L4&UZ)B-X03LO;$AB,R]52"]%:&E&5&)&5DLV+S-L;2\Q
M1R]58U919FQR+VQ(3DLO-6<W9B]K,'5+<&II<G-69&ER<U9E82MB<%=K.'=8
M6$QO;D)6)B-X03M(<T5'960Y=51-=%9/*VQ$-T$Y2F]"5TE)3%1B-S9L8T=5
M<3=!<59)4BM",W Q2D1!:F)O4FU(;SE4-$TK2VED=6AR.4)B<S)0:D9*)B-X
M03MP8BMA66]P:VM.:6A-9DEO1EE#;DM6<$M,5D=O4&IP='9T,7I:-'4R:$=1
M4&AJ82MV9DEY-VHS*R]B;31S=$532S1V>%9D-FM035E!)B-X03M91S(R;$-#
M5VHP2D-W3D%E4'<O1%97<C-P;%DW6#4K;C9Q=F9U9UEB8F)B2'I:+VQ04&PU
M9C!U2DHU1U9P1UI147!*24)026=(>$\Q)B-X03MC,45Y0U-1-5E'>DQV>3EK
M8FQE>%8K0VMB065"*TE:,5AS=DTO=DDY3G8P=7 W5D@P;C-S>7IR;E1U>%8R
M2W!4-7(O-#15+RMV1"]Y)B-X03ME5$5+-WEL+WEJ1VUF.'<P9B]%8U948D98
M67$W1E=#+VUB-3)B>7AD95A'-6-98FDY3%A:1S5.=D=N0U%5-R\S=V(U:DYH
M;V1,-&]N)B-X03LU4C(Y+W=#031/=#%8:$=(;DPW14(U='1$1')-<W$W=S-)
M13!4:F-%34XY>#<U-60R.7!Z:C%-:C!L=BMV-UAS3D)K17-1.&MQ=#1V)B-X
M03M6=4EO='8S:G%U-4-J-&I4<65M86Y&1&EM23DU06-U8W%"2V8S6&QU,70R
M66HQ6E-&:F(P46%&07AC33=L:U%L4C9F.&\V-78X,UI')B-X03M01V8T<&)$
M8G5V:7-N,&IB,#EW-75"1%9Y;#-$;BMJ>C4W=78Y17-)3$153&U/3GDP8G5S
M5&-V9VHT,U!P0E!%='<S,U!F239N<S=&)B-X03M$1FMM06)"3F(W0W-N1%AV
M<G9+-'142U4T9VXY=G!V-S)/6GHW<U=8-D1D4C9&-50Q2%A,<F%+3DAM04\S
M2EEL4$5$,UIT:&YE97DR)B-X03MK:V-D+W=#<5,K>CA7."\R=FY!4&Q%2G0U
M1C%I6%=F2T=K-FQ-954X.75V<DXT>4HX1&XV5U5N3VTQ5U!G>7EI3SDQ3VUY
M1V5/36HQ)B-X03M#935J=#=S5E-N>EHO=T%O-V4O-F<O-&M-47%B67%P6%@K
M.',S*V\S-FII<40X=&8X;S5P6"]-2&(O.$%*<&-65$A&6%EQ-T9867%W)B-X
M03M0>C%P>GAA:70V0E=+-55":C1/9W!4+V=1331J,FLP<&IL1U1P4#=X*W@S
M=EIU54=(1#%$1VA3;W)S3S5Z;D)Z,V1K>4A58G)11W1P)B-X03M&<S)I1G=5
M03E2;V9T2T,O=W%"1V]6>E9D-F94-#E"<7,R:TU#369$>%9Z-&8V,TPP:7!C
M=#8K2C8V+T9$3'AE<38Y+W4X*UA0.5-P)B-X03MQ=7%A4DY:,S1T-44Y831*
M,CE.9S=N,7<T8FU6*WIW2%%N3$YB<F104$AK-$-/2V8Y13)F5T1Z<FQW.4Q9
M-$U/45-J63)(;B]!168Q)B-X03MS6GIM,UI-.3AJ86,Y=G P;#%)2TYD34-G
M4#A!26QA2#935&YC97IM;$]00UIN;E W9S9,=$Q+2E1%4B]#>5A/:61A-T98
M67%L4&UV)B-X03LO:FA4+W=#=D0O>65414LW>6PO>6I';68X=S!F+T5C5E1B
M1EA9<3=&6&E8+T%$:VQ(2GDX=GE62FIP9')X<'-'+V-M=&9F.$%H;2LW)B-X
M03M%4#$O1#E,;V4R>#E".2\V1B\U6F5A-U!Z4&]C6&QB5EIH1G).:71.3'5(
M4#DW14(Y:79D:T%P5"M7:#=(3E(W5&1H4GIX-&AT-3EX)B-X03LO55A99&AD
M<F-0<&QZ*SAF<D-:86AP;#=P.'AI=6]I:F9S=#%6:#1Q92ME5#9R4C5-175'
M67(W:C=N=4U784]16$5O6$U:=&1I<64V)B-X03M"-5=U.5%K5U=D5VAS:%%L
M>4M&>#1*+UA.,S):,DYK>FM3;4](2#DO=2]7-$]Q,7-C66]B>5ED*V1V;C9Z
M;6A4>6QO,&=A,G0R2#92)B-X03MK:E!W8V\O<U%!.2M*1E<Y-F5">C$S<V91
M94="26EG0E52-5!!9'(V-VDY04XO>G8Q4%$O>6)J95 X='1'5FA1;%HR*VAR
M;5)H*T)Z)B-X03M8.7!'.#AV:#EW9&@R8D=S169X,5IN;4,U>G-64VYZ6B]W
M06\W92\V9R\T:TU1<6)9<7!86"LX<S,K;S,V:FEQ1#AT9CAO-7!8+TU()B-X
M03MB+SA!2G!C5E1(1EA9<3=&5D]7-6EJ-6=T>6M21$E9;#-F:4\T6'(R=U=G
M;$E.03AW840U,S!'4V$S5GA&>DU5.$5O5EIO<$8S-T9G)B-X03M014@K,TUB
M3FEX-FI'65-'>&$Y1')H365*1' K3C).-G8U53%/=V1M:E$S3G0K>DI'2VM$
M+TM58FHY5V-0<G5X33)%,T5C8T\X9G!$)B-X03LP*T1846U..6EK:$)";V5U
M861Z5C!C56MR:$DP3'5E:7%#4V9O1U-H0U5J55):45-"=5=4-D8U3'5*6%=F
M56Q-54$S14@W8F8V,5!S)B-X03MJ.&,V5',S,F9N26E78F%0.#-Q9F8S9F4V
M>E4Y;V=#;V)N=EIW<7%Q:%9!5E9&1E5B04%D:&Y:9T%#9S91;3(X2W5X5C)+
M<%0U<B\T)B-X03LT52\K=D0O>65414LW>6PO>6I';68X=S!F+T5C5E1B1EA9
M<3=&6&YV-30K6%I.5SAL=F113'EU3DMK1C!!3W!I;U9L2#!+95(O=T)8)B-X
M03M.;#)6;31-=$AL3%HQ,V%M2&IW:VIN2&0X,7AY4$<V>5)S56M1:&MD5%%G
M:F-%15HQ2D9V2T$Q=4AP,VQV.#DY871,9&),6#=34%=R)B-X03M504M*5TE3
M86<R*TEK37(O045I=G9M;3%F675,2TYT=DDW:#-/;3=A>5$K<F9Z1WA:3D0K
M83,U5#-0>%A';EAD<S4K,'9$-&$K,W!Y)B-X03LO=T%--3=,-T<T:69O:CA$
M269Q9#%J.7!26#%32'9!+V%V9C@T=GEX<T%7<V1-=6)I66992FI3;&8Y85=1
M<U!U>3=4*WEK35IS4F=0)B-X03MT*RLR=DXW4D%J;DDK-V(Y5$503C,U-2M:
M3F%H:W1.36I':U=59TMU63),,T1+9BM,84QX+W=":4%F9D]G,#-:5T]"=5AQ
M4#)/;#%0)B-X03MA,#5I;RMK9F$X-W,W4S5V<GE','1K371Z8WE,1D1'3W)/
M-6]O*VMN3FY+46E#5'E$<DE137!!1&U8,DAO1VMX85)O;&IP8U9#;&Y")B-X
M03M(1'E',TEO;T1.+W-J=FY%-7-H;DUY4%5V8C1O0T52161!:CAR6G5X5DMF
M3FXO2T\S=CA!<40O:5%X0W!T:7%L9&8W>7IF-FIF<4]+)B-X03MO4'DQ+W=!
M;S5P6"]!1$(R+W=$>6%81E5X>%8R2W5X5C5X*V$R;F%L<'0U<#-N<E-A=&1A
M3E-+.6AQ94PR<DUA-V5&6$EB,DYE,EDK)B-X03M914532%(Q4&%52E%-8SA/
M8T]F.59):S%A>CAR96),3'I:<'IF.#9H-7-!1C1O*WI"8TAC;&=/:%9Q=%0O
M6$AB24-81$QI2#!L>"]&)B-X03MJ:'EJ3$@K-GDX+TDO:CE,,E%%34%Y;6]/
M-$DV15IL=2M5<&)3,&U.6EE9-40T=6]B.5EY<65'179Q:40X1V-C:VAY2EA2
M45%X0VM5)B-X03MA>&<Y46]!+U9K;UDT>#5!0D)K5'I++TIS6%EQ-T9867$W
M1E5P.#$O.&-+9B]8:"\U4$II1F0U4R]W0U59,'HO04IH;R]W1&E/2W!T)B-X
M03MI<G-69&ER5&]K:4Y(26]D2$)6,%E60D(R24E/24Y+*UIF>E0O3%<W.')A
M:3DU6GAM5%%B;#8R.&]Q9E)9-RML2C1F-4HW:C-Z<3E")B-X03MR:&QJ4BMS
M9F$X<C)H;U1I;'A2*V<O67=,3F<V>#)+=7A6,DMV9&9Y5B],2V5Y9&9-,G11
M;4\T2VMA8F%Y0VI)1T9$37=046MB2T0X)B-X03LO1$]F-U0Q=VPK-V=D=78V
M;F]U>3E!669V2C@K9V5X-7!(9'5X5C)+<%0U<R]W0U5D=F8Y468X045H:494
M8D962S8O,VQM+S%'+U5C)B-X03M6960K8F9/3B]W0UAV2B]L,DQ42F]99%%U
M8F5+5W,W27%M0S)T>$I+=C=Y;S539D-I.7E4='9L3V%::GED9#)H<6II:4]%
M:FE09C-$)B-X03MC+U!L.%4O<U!-='AQ2&Y/>70W869L;SDU;V@Q1T],:6TX
M:EA#2W)C<6-V<TY3;&%967IU6&Q48DA/6EI1069165@Y;U-#5'IP-6EI)B-X
M03LX>C-66C!F5#%U.5)S67)!>'%&6#9J66DV4U@Q0BLX3$]X;W=R4VY42WIK
M;&9Z*WAX+WI5>&Q0.#-I36$Y,&5+,6UG95E03T]P861F)B-X03M1=G%Q:35J
M=#E/,4)B<&)A3C5H2&5W4%!*0D)#;S1Y3U!4;VY)16Y'37!%2&9U4F=Z-5IX
M231T*T=-<G(K9%IO1#1B37(X;39H8V$O)B-X03LU37-R;E91:S!T-4,X9#!!
M;T-U07I2<T=516=%9V9%=EDQ1U<T>GA2,V-Z5%1/5$5$3'%.,VQ4*U<W<7<Q
M*S4O3&4K=GIA*U@Y56M.)B-X03LS<$TW4FE6:2]73TY88R]".%%O,4)5:U5&
M3U=9+T1234,V5#AU67I/;6MA>'HS:BMR.&9P6#9F-78X,#(R;E)E5W!.9'0Y
M0S$S47 R)B-X03MG65@V:C!B<45#:UE->DDT6&=.=#9";$MN04IY-5A62FAQ
M<V]J-%IM25I)2"M,;$EE.4]T22].4'IZ8C9B0F8V>C5B82LP-F1&95!5)B-X
M03M,0W8R5'9Y9$(V9T<S63AC<T=7435H>4UF84]C4D5P-#=I97-F,4UM,%@X
M,W9);7%L548O.5)N8B]D3C9V;VMF3C9M4"]H<W-J;FE8)B-X03M,=SEQ64UN
M.%9(>C)::$101%!%<S!%:7EX3TMP26A$2U(W16)(3%%B8SA'*U,O1DQS5F1I
M<G-64VYZ6"]!36-+9B]8:"]W0U1Y66A8)B-X03ME578K55DP>B]M1VHO=T-)
M-'%M,DMU>%8R2W5X5E-U<E<R=3=E4S)U;VMN=#562WEX4T%-<DME;TE/>'=X
M:U%B2$Y"04EO=FQJ.#!T)B-X03M",'I1=D]T.7 R;5)M1WI14E!(15=,8U1*
M1W)%0715,'%C-C=16G!:35%L3&TX:C)J:&IJ>6M2-4U4>DUC1C)+=F]V.'-F
M>7$X<S)7)B-X03ML-EIR.7=J6"MO,U9V1&1X;6%N<'=M5TY:0454;U-T9G1.
M6#)P;DTV-U@U2E-L06)20DEE<#!'9WAX:D=F3U)!3# S3E4W4C)+=7A6)B-X
M03LR2W!4-7,O-5(R.2\Q0B]X25EH53)X5E-U=CA!95=B+T%&1R]58U933%)0
M3"MJ6&5N851Q5C%A2F-8839B0F)+.'1855)&1F-G4G-3)B-X03ML4S,W6$=V
M=FM4044R5W,T66U815)V5DMC,S5B951:;S=73C=&=W1L16)E,C183GEH5TEU
M6D-L5FQ"235-5'9K9D)J,TY",$])9V)F)B-X03M32T<U-69.1W=E5&9,34=P
M='%C9&=G=EA1>'1)>D]W24M#3FIW6FEN2FM&1V%L5#-/15DT,V1.9S X0DQI
M<F1$>&9L.350:7-*8D-0)B-X03M4;%<R;6M36F=*2F5994U%255K-2MO;D%%
M:&5,0VQC2&A2<7%9:E(T:$AH03(K2UE+=6HK6&1(5DDQ5S P-C!7:4E/9S5(
M;TMM<$Q-)B-X03ME+U4U3TUA1S-2=$%J:FI1,D%F4'$V;DYR*VPV3F)4,U1Z
M-CEF83@P<TQS>D=30T=126Q%63E&36TK,U1J,GI",TE(95,X=C1H>7=H)B-X
M03M:=6-S=&IY1#-Z5R]+4&QN6$MN5F1.9W5N230K<WDP;$$X0DEV1G@Y*UIK
M;T$X=SE,;3 R4$HY8U%71U0O:W9$6E-T8RM69&)V9$9U)B-X03M$=G<U;5-)
M*WAO56%N*W-7>6\T2S5&,34W2D5D.%4U45!Z0U$V,S5:+TU#3&PK;DY",#=Z
M6F(O=%AC0VE'.'!48CDU1C9-=&8Y:3)6)B-X03MY:$QQ3&-F3G Y4B](0T=5
M9"]+5#!B>4HU8S W43E":FIS<E=E>48R4F-Z,F1X25I8:6MD44=3=E1A;$YH
M.#AY355A1'1D2F=J:6A5)B-X03M163-V4EI&;&IL3DMY<V]:5%971E%2,$E/
M2W0T<3=&57 X,2\X8TMF+UAH+S502FE&9#53+W=#55DP>B]!2FAO+W=$:4]+
M<'1I<G-6)B-X03MD:7)S5F1I<C5K+U!$+WE9,2\X03A9-V8O:WEU9%@R5B]C
M1#0O93AR,G0O9F9!24A19DE6='%D:%E812MR3%IZ-FU:0EIW;4(U1EEX)B-X
M03MY96M6855%2W)!,%IH*WEN>&4R5'IA<W=K44DS=S@Y+W@O87AW8454:4-:
M55IC='9X+UEX1$TQ,7HV.3AJ+SA!2T9E6"]W1'1M,F8O)B-X03M!0UE43TPQ
M6#DW4"MS9G9E,3!N.3%$*W%0=51V2TA)9&ER<U9D:7%5*V)0*U5D=F8Y468X
M4T=)5DYS5E5R<B]E5V(O56(Y4GA60BM7)B-X03MV*U5C,'(O;41T+RM44S1Q
M;4]+=7A6,DMV2W8K8VA.4VUT+TPR;3)55$90<E8P6DA)2D)+=V]D=FQY:T)Z
M2GA%4GA:2D@K8E@K;3)D)B-X03M0,C%K36-1039L:C-K>$Q8579.4&MF5#=:
M>$YA-E1P,&PU3U8V3%!).&IU4&US;D%(3EHT6FI-4E!D9C981#!G17-U1TDU
M46AX9D4O)B-X03MT93=:;%!33WA6,DMU>%9*+TXO;4=$>3DU8W9T5VQ)<F)X
M;C!53E!J;&)A3F9P66HV378P*T4U2FE)-G1/9DU-8T1).45J+THW5EIT)B-X
M03M3.&=A9DQ/-6MN:$US16IK,4HT4TYX+S11:DPK,'-9:FU)1%(R9FM-.$E*
M-7,P>D)C,3)+<%0U<B]W0T]&4#A!-CA0+T%#951%2VLO)B-X03ML=E=:-'1!
M,"M*555H245!2G)8<#@X;G=S3TI-=C Y8R]W0RLP+T@K=5!#=D4W.5!84#A!
M=G10>"]R:G=R>$\O5#%Z+T%,-U0X9C8T)B-X03LX2SA4=C Y8R]W0RLP+T@K
M=5!#=D4W.5!84#A!=G10>"]R:G=R>%!N:C@T8FAR:GHU97ES04=A3T199$YO
M;$=D4C)74#-)*TQY+V%X)B-X03LO9F9!25129DQE:EAL<' Q-4QR34YR8B]!
M3'HY3'AY5'AX>G<O1WEJ,$E7*T]4;$5&4'=G,4\R5S5C.&]K9U)*4%1B8C1L
M:F<P.$I#)B-X03M*338U.%<K+W=9<FU7-CDY4RM4=&%U22]+3VAX:$5)5%0W
M5E%46'1#;SAC-#=64B]E>2]R2#<S<SE,3#DQ2"MQ4'549CE06% K*S O)B-X
M03M(*W558TQF>$\O5#%Z+W9T4'@O<FIW<GA/+U0Q>B]V=%!X+W)J=W)X3R]4
M,7HO=G10>"]R:G=R>$ID-6@Q:65F4G)Q2FM50FQ!2D9A)B-X03LO84AV:G=P
M-&U7-4)K<%A8*SAS,RMO,S9J:7%$.'1F.&\U<%@O34AB+W=$2G!C5E1(1EA9
M<3=&6&M(+T]28UE/;6%,2G966G!L<C(K)B-X03M*1E O04)R:DM223A-9GAY
M1&]U,V@K-VHO5V5D+VQB-7IS=DMN;4U8;"]%6DQ3-6A.=$Y+=3=X2WI++TU,
M,T96,T@K,6UX+TIN55HX)B-X03MP:B]"44AW,B]1-G9S,U92>%I36F-J=#=N
M,#%P,G!71W!78V0U65A%9#%A>6ES8S!40FQ0,V0O15IG5&A+2G%1;W98>&U*
M0W=B0TIY)B-X03M,2C)+;V953E%S9$]T2DQY*VY3,G194GEK;6M92V](>D]3
M:$%Y3D%75TUP0TES-T(X,V9M="M:5"MA-S5B3W@U4C9*6G-40T1S6G!/)B-X
M03MN<7-/=W Y:V8Q>G%/>CE$-$ES+U=F<V58-U(Q,VI(:&HY02LQ-CDK4U9K
M.70K6&QG>FEH=5I*<&=067E&4CDT4W5A6'135C5Z-54W)B-X03MV<WE*1T-.
M+VID;F5A.7HS67%L4&UV.$$T-%4O*W9$+T%-;FMX0W-9,$@O:FI76"]!0FA4
M.5=7:')+3WA1-T9867$W1EA9<3A'+TYJ)B-X03LO;$YR=B]J2$0O>6)83VXW
M32]U4CA8;64Q9C<W-$)09GDK.'I#=6EA86YL.3=U.6E+,G1V<40S3%)10W0X
M8G17249V359P265,144W)B-X03M:5')-2#%3-#9(3W$S*VUU.$]2;V1186I%
M479Z=F)N9F-8;5=B5C!R-E4X<"]W1$M,84XO>D$R,R]*;&,U1%4O,W-V-G@K
M.3=(4R\S)B-X03M59C9O*S5.8V]B,UEQ-T9867%G=%HO-#5L>"]Q:CE9>$M1
M>GI+;7A3=78X06578B]!1D<O56-6469L<B]!2E)Z4W8X06U$="\K5%,T)B-X
M03MQ;4]+=7A6,DMS9C@K95=%.'DK5G(W4W%$-G<V*W!A368R6C0O:51F=%@W
M2CEI8WE.3&TX3$E*3U!Q<T%Y-'I&.&QZ=WI15%-15$E9)B-X03LU;VU+4U)S
M2TUR2V%&4U!%2$]X:EA-9%AI-5))3DAM:CE%.'IE64Y#;4UU:U@X,6UX3EA7
M3G9G8B]743%2=G!'47DT25I"56AB8F@Q)B-X03M'5$@Y2G!M=&XK9G9N>4)1
M2F9Q9#)F-7!O4T0O04UK;FE'64UU>4U*-W@X6%!(8D=99GI4*U!E-C<O4#-Z
M-4]T26A:,F@X65E35"]Y)B-X03M6951'4%I'160U*TMN=&I-9C5V-"M,0SED
M.#!E661E;45U<C,X=#1Y;7%+-6]I:R]Y>')21BMG6FY9<T5-63E)<'=C,G!Y
M6E!Q3G%E)B-X03MG84IE-C5R1G!P5FMV2S1U-4)'<'!52U R;F(R5F%K-&,R
M55DT;5(U0FIG=VY*35)(5CEF859P='1P;6U7=6Y7=W!B,F-347A$=GA2)B-X
M03M1=%0W;6TK8UAK;5IY36IZ3#(P24--4D5C9VES9WED:7%5*V$O=T1J:%0O
M-CA0.$%Y951%2VAV2W5N5U5N;'946&5)1FUT-'E452]Y)B-X03LO4$1:4E-A
M+V]U=R\S>5!V4#EC8DLP2&9O=7<O,WE0=E Y8V)+,$AF;W5W+S-Y4'90.6-B
M2S!(9F]U=R\S>5!V4#EC8DLP2&9O=7<O)B-X03LS>5!V4#EC8DLP2'I8*V15
M56-8-6A8,&-A.%5%8T9".#16>G%U>2\W9V9(-S-L=3%V-S<T0FQ8-617;7!(
M>79B6$U-;7%',$U%.%0R)B-X03LP36PK1DQM-4QE<F%F5B\S25E)<%-J1F9J
M2DIR,'I%,7-O*TE194<W2#@S=38S=BMX>CE"02M%1#9U4C9Y-RMN4C0S;3=E
M9&97;FMN)B-X03M48DHO2G5G=3!13$YP,6]386YQ644Y.#1Z5D4K3$PK<V9V
M93$P;R]D42]Q:C=K-B]29&@O=FMF968V-5):8C9$=C!8668W-4@S;BMU)B-X
M03M.;&%$=C!8668W-4@S;BMU3FQA1'8P6%EF-S5(,VXK=4YL84-696%.4',T
M.4%V2%--2S9O2T=P+VU(=FIA,&XK0DML9&8W>7IF-FIF)B-X03MQ3TMO4'DQ
M+WEJ;6QF.'=D=B]Y85A&57AX5C)+=7A6,DMV2U!Z6B]+3CEB:VLQ,U%556%P
M4W0S6C=+2C9$-V%(;TI01W8R=FXQ,TA:)B-X03LO85!H*VEF,#DO8S9J=$1S
M-WA06$0V=G8O83A$=6)A-71:-4QE-6EE0S1I2E=32U)3<G%W-FAL3D-$;E)2
M:T-,2$HU=55413!24E5S)B-X03M,1C)+;WI39$@Q4%8W-D]X,#(R939U<%0X
M3559<69C;G-!3S5/,E%Y6DEW1GE.0G-X67!:1%526F92+S589FQJ0C53=$=U
M-W=R4')L)B-X03MY=D=A4F0P:51R-E5:+S1K92MC>'(Y8V-X;V912'%D0F]2
M:$9N95I:-VUU9&<W1EA9<6Q0;78X030T52\K=D0O04UN:WA#=3AP9CA!)B-X
M03M+36%:+W=!=S!F.$%X2$95,GA6,DMU>%8R2W5X5CAY9FYH+S5-82\O04]-
M9'8O>5I83W(W2R]U0CAF=F56-U<O=G9G14XU9#$S>4Y:)B-X03MA8EII+W="
M4"MS6'=R0F9H-%5K4F]7;&52<%5D;7%S:%%P1W9W,5=H3F-L;7A:<%-00V%(
M5&8X04AV6%1:.$5905-(<38W9FHS34QZ)B-X03M/9%DK=F9)+R]+1F58+SA!
M=&TR9B]*:$TT=E9F,W,O-G@K.3=84V8S55 V;RLU3SAO8V@R2W5X5C)+<%0U
M<R\U4C(Y+S%"+WA)66A5)B-X03LR>%93=78X06578B]!1D<O56-6469L<B]!
M2E)Z4W8X06U$="\K5%,T<6U/2W5X5C)+=7A6,DMV;D0X+V=0.&5$,W,T82]W
M1$)0;E0Y)B-X03MK9C-0>$QZ2&)0.$%F1"MR*W0U=&TP9%,W1E@P-RM35FYA
M4F9L,W!T>$9#:50S0FY.>$MQ9U!)5G5:1E5U=S-A:6=!5GIL3S%*135Y)B-X
M03M/-G9U1#%V6F-13454-R]V3$\X,3=S2%EQ-T9867%L4&UV.$$T-%4O*W9$
M+T%-;FMX0W4X<&8X04M-85HO=T%W,&8X07A(1E4R>%8R)B-X03M+=7A6,DMU
M>%8X>69N:"\U36$O+T%/361V+WE:6$]R-TLO=4(X9G9E5C=7+W9V9T="6G-(
M5T]X5CEE*U(O=T1L0W9,+T%0,GIB4#A!)B-X03LU34IN1C9R*SEN+U=0,W9A
M-E0K-F@O5D@S2C-L1&M/>%8R2W5X5DMF3FXO2T\S=BMO4#A!:5%X0W!T:7%L
M9&8W>7IF-FIF<4]+;U!Y)B-X03LQ+WEJ;6QF.'=D=B]!36UL>%9-8U9D:7)S
M5F1I<G-69D](-2]F.' T=B]-1D0O>$HX-F9S:BLU*TIE63=:+W9H+U8O5S@R
M>F%/<&1I)B-X03MR-FDO2F8X03AL<&\O=T0P8R\X05563&Y*.7 O,SAV:#EW
M974W3"]X95!X*SAS,GI!8SDR2W5X5C)+<%0U<B\T-%4O*W9$+WEE5$5+)B-X
M03LW>6PO>6I';68X=S!F+T5C5E1B1EA9<3=&6%EQ-T98>DHK94@O:WAR+W=$
M-'@R+R]!0UI83W(W2R]U0CAF=F56-U<O=G9G1T):<TA7)B-X03M/>%8Y92M2
M+RM52SAV+SA!8DYS+RM40UIX97$O=EHO,6HY-S)U:R]U;V8Q4CEY9#51-41S
M5F1I<G-64VYZ6B]Y:G0W+T%+9R\T:TU1)B-X03MQ8EEQ<%A8*SAS,RMO,S9J
M:7)$9$9U2GAO.6="231!=#1G04=0.&=Y,FUU,&(Y6G50.2MV+W=!16-A5S-F
M5V)J+V9R+T%00DA';'0S)B-X03LQ;30O,S8O+T%!4GAP8F0Y6G50.2MV.$$X
M16-A5S-F5V)J+V9R+SA!0DA';'0T6BMC>G4O;3E3-T9J.55I,TIQ9G10;E-D
M;&8S6'AE)B-X03MA-U@O04PP9C%F,7!:-6$X,%=E:F%8-E@V3VEN=7!,;W1*
M8WHR,$YW<&A-655"4%9&5FMH9C0P04Y'<CA7,E@U.4]:>34W5C-K9FDR)B-X
M03MR5&%K631F5%HT=3=P*W-*1G$X.$9X<70W4&)W9E9B96%E5U-',2\S,&I/
M4W-F.$%S4G1M4FI"15%#8DY/2FQ)37E12S-,,V8X<DHU)B-X03ML.&@V5W%Y
M37%J,39!16=F-S!36GI885 Y+TPT9F-(<"MZ9C=I4'@K.'-S*W,S2"LO6"\T
M235G,#4Q=2MS,T@K+U@O-$DT,'1U*W,S)B-X03M(*R]8+W=#0T].3&)V<DYX
M+W8Q+RM#3TY,84,Q:65:<D)L85)M57E25D)*22]V5G=%2T=1*U5V*U59,'HO
M;4=J+W=#2357,DIT:7)S)B-X03M69&ER<U9D:7)Z+WID*U1E:65:=&1M,6DV
M=G)M0V%D559O-'94-&HP,$-#;DI393)B3%0Y<%1X4311038W53EM=WI4-&E4
M851F.4,V)B-X03ME5W8K<G!E+SAK=BMA378O04IA>69Z43!F>4QI-S5F6BMP
M,R]!14QP-6$O-G5L-R]!36MV*V%-9C5A>69Z478X:31U*U@R9G%E;F%2)B-X
M03MP,%=M851:86)%>E!&67=25S!B=%1K>7A)14).3G%K3&UP>50T-4=2-FTS
M830T0T52161"4TQY1$XR2W5X5C)+<%0U<R]W0U5D=F8Y)B-X03M19CA!16AI
M1E1B1E9+-B\S;&TO,4<O56-666)O='9/9$AS0TDS24YV15%1<"]K1U<R,3!J
M9G$Q>"]V<"\K0D].<E1V<3%X+W9P+SA!)B-X03MG5&IA,#<V=&-F-S9F+V=4
M:F$P-S9T8V8W-F8O04E%-#)T3RMR6$@K*VXO-$4T,G101%!Z;5(P.#-Q2%5Q
M9G%K5WA&1#EP.#94<W(K)B-X03LV*TQZ6&$O.390-G8V,%@U0C!J5F(O>3AR
M4F%81'%T<$9E6%4P2WE#-D)G=4QA,FEK<GET;51L-F]+;VET*S!.=75$5UI)
M>&XY6$-A)B-X03M(9'5#5#,Y>F)O35IL:C5C445I975X04AC=WIZ4D9D4F5:
M=%AI=35&;'5O-S(T5S1L4F5+3DE*5T1S<3EG5S9$33=!46-C83552%=A)B-X
M03MG2'A*6'HT:CDW,B\X<DE*;3AH-E=Y>'-Y;C$V14%K9C<P4UIZ;F%0.2],
M-&9C2'!E>F8W:5!X*SAS<RMR6$@K*VXO-$4U9S(U,4\K)B-X03MR6$@K*VXO
M-$4T,G1/*W)82"LK;B]W0T)/3G)4=G$Q>"]V<"\K0D].<E-#,6E#6F)";6%.
M;%534E9*0D$O=E9W17%'42M5=BM563!Z)B-X03LO;4=J+W=#2357,DIT:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%5*V)0*U5D=F8X055(+T5H
M:4948D962S8O,VQM+S%')B-X03LO56-6469L<B]L2$Y++S5G-V8X035.3&EQ
M631Q-T9867$W1EA9<2MC4'HK+S54>&8K64M(+VE4-3 O6D@Y>CA3.'@R>B]F
M1"MR*W1*)B-X03LO23EH1&12;W)797%813=Z>65I,6YD=U=T<S-O>$-6,68Q
M-#)(2E5"62]&,'!L*W%M4C%I3G5O2E R3F5H:%DU5#4Y0T%0=%DO=T-:)B-X
M03M,:')N>D9Q;'DQ=6)2<#=U95)R5G9T4D8U5V(P>E%$9&$P>DIW4G%%4F0W
M0G<Y46)Y4TY6-FHY-S92+TIF+WE7;6HO.4A0.$$Q1E,U)B-X03MY+V%F.2],
M-&9C2'%/>2\X6&HX9G9,3G-W2%!D:7)S5F1I<54K82\K3T90+T%+.% O2C5-
M47)V2U@O2TUA6B]Z1%(O.%)X5DYS5F1I)B-X03MR<U9D:7)S5F1I<GHK.2].
M9C9T950R,S9,-2MJ23AF4#$V5C1-4E=N<&YW>%)A9BM54$YV*TEO-W O<6XQ
M6#9S549053E4;'IR+VMP)B-X03M3;DA&45=1-'!D:7)S5F1I<G-64VYZ6B]Y
M:G0W+W%$+T%):TU1<6)9<7!86"LX<S,K;S,V:FEQ1#AT9CAO-7!8+TU(8B]W
M1$IP8U94)B-X03M(1EA9<3=&6%EQ-T98>F@K9C,O2V5,+WI"42\X4V9/;C=)
M+W5F:5AM3S)F-S1F,68Q<2\U6')!=6AY4UAI1G)1,U4W97))3&531T%X)B-X
M03MW>&-N-%,R;#(V<R]Q2W164'AB0VTR4C$Y.&4S3V@S-S=N*VM'-W-W1'=Y
M5'EV>3(R2&M70659-#5O=DU/<5)Z1C)M4S=N5U)P1T5J)B-X03ML:$MW2EHQ
M5D%Z5C9K2TLK1V),05%94G)U1'%D44MY4W8K8V9V9E-0-4PO*U,P,&8O;S4O
M-FEP8S5F=% K+VPX4'5$,4A:9BM,>"M0)B-X03LS;&TR641N=7A6,DMU>%9+
M9DYF+T%"=W O=T18:"\U4$II1F0U4R\U4FI44"M985 O:4]+<'1I<G-69&ER
M<U9D:7)S5F5!87HO=T%D)B-X03MI*R\U:4IF*TIN07A:-RM54#EX<68K=$0K
M<#A+43E#>%,W1EA9<3=&6%EQ;%!M>B]!2E(R.2\Q0B]W05-'259.<U95<G(O
M95=B+U5B)B-X03LY4GA60BM7=BM58S!R+VU$="\X06LP=4MP:FER<U9D:7)S
M5F1I<C5W+U W+T%*5'AF*UE+2"]I5#4P+UI(.7HX4SAX,GHO9D0K<BMT)B-X
M03LU+V(V;'%.=$)*8C(Y,4Y$8GI-<E-W>'E-:4]Y1W%L;$)!2E4Y2S5S<%%I
M5%I!=#%K8W-O:6=306]34U-3>4Y*27AE4GE79#).4U=*)B-X03MQ4U0W-4E#
M;4I*2G-V<40X;"\X07E7;6HO=T12>B\Q1E,U>69A9CA!9GDK2#-"-C-S=CA!
M>&50>"LX<S)Z06,Y,DMU>%8R2W!4-7(O)B-X03M!3T]&4"]R=R]W1$HU35%R
M=DM8+T%#:D=M9CA!34Y(+T%-4GA63G-69&ER<U9D:7)S5E-F>DYB*UE(<U1,
M;V0S-D8Q1E4K:55J6EI2)B-X03LT5F17;S-H:7)X0S9A-&$U;6$U0D9W>G-:
M9W<T;FU4.%92=%1F07A:4#5!:CAZ>EAC:T=K6$@Q4S%9<3$W8T=.2$%#,7!4
M;7)F1G5A)B-X03M!67%(<C9+5E)63$9Y04%886Q45'5A040W:&A:3C1Q-T98
M67$W1E5P.#)F.&\W92\V9R\T:TU1<6)9<7!86"LX<S,K;S,V:FEQ1#AT)B-X
M03MF.&\U<%@O34AB+SAM;'A636-69&ER<U9D:7)S5F9/2#4O9CAP-'8O041"
M42]W1$5N>G K>5 W;C1L-6IT;BLK2#E8.6)Z8DYO-FPR)B-X03M+=G%,.&PO
M+T%#5VUJ+SA!4GHO,493-7EF868Y+TPT9F-(<G5Y+SA!1C0O2#=Y>F)-0GHS
M67$W1EA9<6Q0;78O04DT52]W1')W+SA!)B-X03M*-4U1<G9+6"]+36%:+WI$
M4B\X045C5E1B1EA9<3=&6%EQ-T9867%X6'I6-4-S.6)U23=U1GAA,UA)0S1C
M0V]D3S5)+VU!-D@W.%55)B-X03MN*VPV6%IA6%I2,F1N2#9C368S<V4W364U
M3TM56&ER<U9D:7)S5F1I<54K8E K561V9CA!54@O16AI1E1B1E9+-B\S;&TO
M,4<O56-6)B-X03M19FQR+VQ(3DLO-6<W9CA!-4Y,:7%9-'$W1EA9<3=&6%EQ
M9W)Z43E%=EIV5W9D4'1R;6%G6#%*;UDU1V]/9W%W2G!L:V-S-&EG4T=%)B-X
M03MO4E!-0E$O=W U6"]!3W)062\X05-.1"]!33 T9GI'5"MC9FU5949$=4AY
M9"]H5'EV+S%:-T@O<$=H+S5P>"]-6E U>"M:6'=O9'<K)B-X03M34'1B4S%T
M249T-U=&3&5"2SA)66Q#24MM<&]Q9T%62G)L8W!%;7IU>D%!,D-R9U,W1EA9
M<3=&57 X,2\X8TMF+UAH+S502FE&9#53)B-X03LO=T-563!Z+T%*:&\O=T1I
M3TMP=&ER<U9D:7)Z,WIR+T%/5&,O3&8O04QF6"]516U8-"\W=5AW8V),+V5W
M+WIV=65D,G9N6'HU9"M6)B-X03M.3FTQ;E=6,4MZ.#$V3C5G.5<P3G)"0UE'
M,"LS:S1S<VM147-8<'9552]8;#5X>$5J42MK:'!J;&M9:7IF140Y:4$Q9EAF
M3D9H*U@P)B-X03LS;"LY,4-05610;#AQ859Q.6EK;')#;C%93F5144Q",%E3
M:%4O869E=FAK:$5'9"\P:4=";DE1<BMG0WE#*SAY871O;C4S-GE,0RMJ)B-X
M03M34%5T6#!,5#=Z4S-21V5E1S1S:4=M5FHX82MH5#EN8C1T*W=.66=$:D8Y
M>"LY<S1Z2$MA-FU0,TE0>6)Q=79P8F9L66QV<DDP=7AV)B-X03LU.5E3-F=#
M2VQV25ER:55H6DDQ84M.>DE#15-O*T9J>494=&MP9V5V82M336-P96IE=#5F
M<%5R5'IZ-6DP5#AR=DM%96PS.$=K;3E8)B-X03M83&EE.6%#16]7<TI*<%EB
M9%593$=P=4<K1%EC<3E.*W%C64UZ92]*07EK449B9E8Y:5IE9'9Z33@Y,F-L
M<'%/;C-Y5TU-6&QN5#ED)B-X03MU.4YA,VEK4U=E-79&9VMJ3'5055%C6F5Z
M9'9P>4]01D4W2"MC47EY6G!J8V9Z46$K3#-434YZ;EEQ-T95<#@R9CAO-V4O
M-F<O=T-*)B-X03M$14MM,DMQ5C$O=DQ.+W%.*V\T<6<O3%@O2T]A5B]Z0C(O
M.$%Y85A&57AX5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5DMF)B-X
M03M.9CA!>'=P+SEE2"]!2E!*:49D-5,O-5)J5% K66%0+T%):FEQ8EEQ-T98
M67%L=7%Y95<W93AS3'I6;7,T8C%*1V@P=31U:D5S<7E4)B-X03MG27E7-WE5
M64Y)2TM1;EA*0RMJ1UA$64I1<RML95(W5U14=$QN<SE-9VM:8FE(4V)&-#=D
M0U5L6"]3:W1O:4)S-G0K.4-$8T@T<TYY)B-X03M.;F1&4D9$8GE1.3%$*U<W
M>G1P.3!M:G10171V<$PR:V]T4S9O-V5P83)::F)C0FU4;$9&5&-I<6IB0T]0
M;G8S<U1W8W1U-SE15%$K)B-X03M8=$%/<69P8S9:84A64U%4<4AO4B]72VA1
M9R]E.&5F,D%&-CE.<VIX1W%V6FYW:3=R9&%03%AL=U=T<F%$4W)-5W1L2C8Q
M;&(O5C1V)B-X03M4:&PU1BMC4V-A23-).'%R=EA(:E!E=D%/5D]B>7@U8F94
M;W1.9E-B3G1/9V8Q24Q),CA29U)Y>&)K:V9(9W)C;4IQ0C%/4$=B=3$T)B-X
M03M"5E5G=%A(:T=:.5%K,6HY1E-35V--3G9Q<C-N,5IJ1D))-&QG:75$2CEI
M3G!+36EV<U1U3CA-94QA<EEY-$XW<GI4+T%#1%DW1EA9)B-X03MQ;%!M>B]L
M2&(S+U5(+T5H:4948D962S8O=T(U6G8X055B.5)X5D(K5W8X06Q(3DLO=T-9
M3S,O-4Y,:7%9-'$W1EA9<3=&6%EQ-T98)B-X03M9<3=&6%EQ-T9867$W1EA9
M<6Q0;78O:FA4+S8X4"]*-4U1<G9+6"]+36%:+WI$4B\X4GA63G-69&ER0G9Z
M:#%(5DQ$>79A>3)L,6-7)B-X03M.;DIQ3G)&<E8O6CAV6'0Y4&1Z-CAQ36]:
M;$DK2&-$3'-!0FPX1VY/4TDW9"]W0FIZ2%))9%$X=V5A=DEZ86AQ5CED-F5U
M<F$P=6DS)B-X03ML>E%Y>E=6;$=S.71->&QJ<7I334-R35)79S)O4EA-:592
M:DMH,$1J0S53:EHV;C5-:R]05%0Y8G8O3B]K5TQ1,D,V>$-D574W14AO)B-X
M03LP='!$1&-R2#1F2#982&9B9F9B26%C9U)L9DQ:;'%G5$]&8SDR0C9(8BM9
M9$PX,EA55W)Z375S6%AM;GEX8V%K15EI:C-Q6$YY.$IO)B-X03ME:2MR>$DV
M8F5'6%-)361U6$1*;VAX0U)V;GA2*S%M3C-R."\V6#@V1%9F34=Q5UAM4WHO
M045Q3D<P5T]35TLP3FI&6G,Q=&-"5E%*)B-X03MY+V%$.#8X9TUP161O,$)7
M>FLX4G56:S-V.&M*<4(Q2%-F2R]K=2LQ2'I0<G-':#8O0VPQ-6@Q55A-<W-S
M17!S4DIB>'=U<7,P85-3)B-X03MU,5)V>3=N8DI#:DM1049J;#@R1FM2:5-4
M4C5N-$I.<EAM-WIA;6EA3$PU:C%R53E(:V9Y,V185FDY<UI)1&,V;6LW<F)R
M3U58-'56)B-X03MU15IU6'IQ2S5+34DR84%0<2MX:E!*3&A&:VHP;C5Q1W%A
M,5!$-64X-VTT=7!5,6)5.44X<UAL=DUX8U-43$9&0VQX2TI/.4AL05DQ)B-X
M03LV;C4T67@S:C-82D4U14-89G=X5#-Z1#4U,4M,.#-,5S!S8G)5<E9H<G1N
M<#EZ87HS<D<R93-K2WAV-F1H-E%2565T5FM-:%!T-%%J)B-X03MJ2$)V6$PX
M8G,X;55J24LW=T]F-E P=F9-=VY/9&EQ52MB4"M59'9F.5%F.%-'259.<U95
M<G(O95=B+U5B.5)X5D(K5W8K56,P<B]M)B-X03M$="\K5%,T<6U/2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W!4-7(O-#15+SA!<G<O.&YK>$-U
M.'!F.&]X<&XO34Y(+WA()B-X03M&53)X5C)+=7A6,DMU>%8R2W5X5C)+<V0X
M,F529$HX,$=)86AC,S!-4TDX571V85A5<T55,%5H0F%/84Y4>%I4>"ME5U%Y
M1U!*<FYJ)B-X03M%=6%E,G1R8C)L<D1A,C!9:70W9$9I:&E86E9204964C=!
M1$E%,C)!2W5"6%EQ-T95<#@R9CAO-V4O-F<O=T-*1$5+;3)+<58Q+W9,)B-X
M03M.+W%.*V\T<6<O3%@O2T]A5B]Z0C(O.$%Y85A&57AX5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5DMF3F8X07AW<"\Y94@O)B-X03M!2E!*:493
M>GEZ-6TX=C(O;"]4-$HY46=J;6IG4EI),F-!9V=B9VI#<5HO-'0X<V8Y6$\R
M+W=#4FDT1F0O:3-Y>"\Q8S=B+VM9=4MU)B-X03LO=T%7*U=0*W)N8F8X:D9X
M5C,K3&9,2"]!1F,W8B]K675+=2]X8C59+W=#<FYB9CAJ1GA6,RM,9DQ(+U9Z
M='8K4FDT<3<O1G9L:B]Q)B-X03LU,C,O04--6$989C1T.'-F.5A/,B]W0U)I
M-'$W+T9V;&HO<34R,R])>&-69"]I,WEX+S%C-V(O:UEU2W4O=T%7*U=0*W)N
M8F8X:D9X)B-X03M6,RM,9DQ(+T%&8S=B+VM9=4MU+WAB-5DO=T-R;F)F.&I&
M>%9,4$UN;5A13&Y23'%#,S%#0U=A4E%%:E9W5THU1%E$0W)+8T-Q5C$O)B-X
M03MV3$XO<4XK;S1Q>"]14$Y(;#)(471.:&PQ1T)*63=71DI%6G=#<DQ';TE)
M.6IH5D@O=T-,9DQ(+T%&8S=B+VM9=4)89C1T.'-F.5A/)B-X03LR+S5'3&ER
M=CA7*U=0*W)N8F8X04EX8U9D+VDS>7@O,6,W8B]!2D=,:7)V.%<K5U K<FYB
M9CAJ1GA6,RM,9DQ(+U9Z='8K4FDT<3<O)B-X03M!0F(U62\V=61T+WE-6$98
M9C1T.'-F.$%6>G1V*U)I-'$W+T9V;&HO04MU9'0O>4U81EAF-'0X<V8Y6$\R
M+S5'3&ER=CA7*U=0*W)N)B-X03MB9CA!27AC5F0O:3-Y>"\Q8S=B+T%*1TQI
M<G8X5RM74"MR;F)F.&I&>%9,9DU0;5!18G)36DQE,G8T2G U2&A#4F\T3$=K
M>4A9659F)B-X03LO.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \
M+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN
M<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#HR,T,U,S V-$4S0T1%.#$Q.3DX1D(S03E!,41&1$9!-#PO>&UP34TZ
M26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I
M9#HR,T,U,S V-$4S0T1%.#$Q.3DX1D(S03E!,41&1$9!-#PO>&UP34TZ1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU
M=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#
M;&%S<SYP<F]O9CIP9&8\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @
M(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C,Q.6$W
M8V%C+3<X,#(M,#,T.2UB8S0R+31E-#5B.3<S-#8U93PO<W12968Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HS
M,3EA-V-A8RTW.# R+3 S-#DM8F,T,BTT930U8CDW,S0V-64\+W-T4F5F.F1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N
M9&ET:6]N0VQA<W,^<')O;V8Z<&1F/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*
M(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.CDQ
M,F,R93-C+64Y,F8M-&(U.2TY-#!D+30U83)C,C(W83-A.3PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q."TQ
M,"TQ,%0Q-3HQ-SHU.2TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@
M0T,@,C(N,2 H36%C:6YT;W-H*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,S$Y83=C
M86,M-S@P,BTP,S0Y+6)C-#(M-&4T-6(Y-S,T-C5E/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$X+3$P+3$R
M5#$P.C0P.C$U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#0R R
M,#$U("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N
M+W!O<W1S8W)I<'0@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+FEL;'5S=')A
M=&]R/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HR,T,U,S V-$4S0T1%.#$Q.3DX1D(S03E!,41&1$9!
M-#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C Q."TQ,"TQ,E0Q,3HR-3HQ-2LP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z
M+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @(" @(#QI
M;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z
M4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G
M+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL
M;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&
M;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE
M3W9E<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*
M(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E
M/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM
M<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%10
M9SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(#QS=$1I;3IW/C8Q,BXP,# P,# \+W-T1&EM.G<^"B @(" @(" @
M(" @(#QS=$1I;3IH/C<Y,BXP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @
M(#QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X
M;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @
M(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1.86UE/D1)3BU";VQD/"]S=$9N=#IF;VYT3F%M93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^1$E./"]S=$9N=#IF;VYT
M1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L
M9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXT+C0V,#PO<W1&;G0Z=F5R<VEO
M;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&
M86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9I;&5.86UE/D1)3D)D7U]?,"Y01D([($1)3D)D7U]?,"Y01DT\
M+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N
M=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @
M(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT
M(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @
M(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D
M9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB
M<F%R>2 Q-2XP,#PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!<0%P P$1
M  (1 0,1 ?_$ !\  0$  @(# 0$!           ("0H$!P(%!@L# ?_$ &40
M   % P$"!P40#0<'"P4   (#! 4&  $'" D1$A,4(3BVMQA7<G=X%187&2(Q
M,C=6<7:3EZ?5U@HC,U-5D92RM='2T]0D.4%1=;&S&C9A8I:AM"4U0E)88W2!
MAI+")T.BP?#_Q  > 0$  00# 0$              @,&!P@$!0D!"O_$ %P1
M  $$ 0("! @("@,," 4%  (  0,$!081$A,'%"'1,3(S45)Q@9$((D%RDJ&Q
MM14C-C=3875VLK0U5G06%QA"8H*4HL'2U.$D-%5CE=/B\"9#5Y.E)45SML+_
MV@ , P$  A$#$0 _ -H?1MHRTUY6TVXWGT^QOYO2U_#+;NSMY\)ZU\KNV3J3
MLR'^0,LI;FPCB&UN1IOY,C)XSB>..XP\PTT=>20Q-V9]F;;Y&\S?J5,19V9W
M;[?.J=]+OT=]Z#YP,H_7:H<V3TOJ'N4N ?-];]Z>EWZ.^]!\X&4?KM3FR>E]
M0]R< ^;ZW[T]+OT=]Z#YP,H_7:G-D]+ZA[DX!\WUOWIZ7?H[[T'S@91^NU.;
M)Z7U#W)P#YOK?O3TN_1WWH/G RC]=J<V3TOJ'N3@'S?6_>GI=^COO0?.!E'Z
M[4YLGI?4/<G /F^M^]/2[]'?>@^<#*/UVIS9/2^H>Y. ?-];]Z>EWZ.^]!\X
M&4?KM3FR>E]0]R< ^;ZW[T]+OT=]Z#YP,H_7:G-D]+ZA[DX!\WUOWIZ7?H[[
MT'S@91^NU.;)Z7U#W)P#YOK?O3TN_1WWH/G RC]=J<V3TOJ'N3@'S?6_>GI=
M^COO0?.!E'Z[4YLGI?4/<G /F^M^]/2[]'?>@^<#*/UVIS9/2^H>Y. ?-];]
MZ>EWZ.^]!\X&4?KM3FR>E]0]R< ^;ZW[T]+OT=]Z#YP,H_7:G-D]+ZA[DX!\
MWUOWIZ7?H[[T'S@91^NU.;)Z7U#W)P#YOK?O3TN_1WWH/G RC]=J<V3TOJ'N
M3@'S?6_>GI=^COO0?.!E'Z[4YLGI?4/<G /F^M^]/2[]'?>@^<#*/UVIS9/2
M^H>Y. ?-];]Z>EWZ.^]!\X&4?KM3FR>E]0]R< ^;ZW[UUY@'$^/\,:R<NPO&
MK!YVXT#"<*= MOFJ]/&Y>OD1_*S^6/[DZ+[\;Q)7VJZJY(.#]K+!PA;_ *9.
M48N[[OQ/_P"^Q19MC=F\W<LB]4E42B+'/GS$V/\ -&LW%$,R6P>>2-7P;,'6
M[;YJO;/_ "]!)RPI#^6,#DU+_M5E!MN*Y5Q(^']L+'P0\&J!.,9.S[/Q-_[[
M53=MS9G\W>NQ/2[]'?>@^<#*/UVKYS9/2^H>Y2X!\WUOWIZ7?H[[T'S@91^N
MU.;)Z7U#W)P#YOK?O3TN_1WWH/G RC]=J<V3TOJ'N3@'S?6_>GI=^COO0?.!
ME'Z[4YLGI?4/<G /F^M^]/2[]'?>@^<#*/UVIS9/2^H>Y. ?-];]Z>EWZ.^]
M!\X&4?KM3FR>E]0]R< ^;ZW[T]+OT=]Z#YP,H_7:G-D]+ZA[DX!\WUOWIZ7?
MH[[T'S@91^NU.;)Z7U#W)P#YOK?O3TN_1WWH/G RC]=J<V3TOJ'N3@'S?6_>
MGI=^COO0?.!E'Z[4YLGI?4/<G /F^M^]/2[]'?>@^<#*/UVIS9/2^H>Y. ?-
M];]Z>EWZ.^]!\X&4?KM3FR>E]0]R< ^;ZW[T]+OT=]Z#YP,H_7:G-D]+ZA[D
MX!\WUOWIZ7?H[[T'S@91^NU.;)Z7U#W)P#YOK?O3TN_1WWH/G RC]=J<V3TO
MJ'N3@'S?6_>GI=^COO0?.!E'Z[4YLGI?4/<G /F^M^]/2[]'?>@^<#*/UVIS
M9/2^H>Y. ?-];]Z>EWZ.^]!\X&4?KM3FR>E]0]R< ^;ZW[T]+OT=]Z#YP,H_
M7:G-D]+ZA[DX!\WUOWIZ7?H[[T'S@91^NU.;)Z7U#W)P#YOK?O4PZR]&>FS%
M&FW)$_@.-_,&6L%HAYDNWGPGKIR3S4GD795W\@>I2XMA_'MKBL3?RE&=Q7'<
M<3Q:@LHT$@D-R%G?L=_,W<HD+,SNS?;YU4.SSZ'N'_ GG:;-*C+Y0O9_"RD'
MBM[?M=6C5-22B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*+8CT\<O
M^(/'W6)951_)C\YU!O'?U=RM*J:FE$462OIZXG\GR=]:$M5&\F7SF4'\=O5W
MJTZIJ:41*(E$2B)1$HB41>M>'ALC[4X/;TM(;6EJ2'+G%>I%P$Z-&F!<P]0<
M.UK\$LHL-Q#ONONM:]ZX&5RF/PF-O9?+6X:&,QM:6Y?NV"X8*M6 '.:>4F9^
M&.,&<B?9]F9<BI4LW[4%*G"=BU:E""O!&V\DLLCL(1@W9N1$[,S>==/=TQ@3
MOJ1+\N%^ZK%G^$%T+?\ U(TS_IA?^4KM_O<ZY_JQE?\ [#?[R=TQ@3OJ1+\N
M%^ZI_A!="W_U(TS_ *87_E)_>YUS_5C*_P#V&_WD[IC G?4B7Y<+]U3_  @N
MA;_ZD:9_TPO_ "D_O<ZY_JQE?_L-_O+ZB(YCQ=/'43)#INQ2%V D.7C0-JD1
MR@*,@PDHY1<%RP_:RS%!(!7W\US \W/5Q:8Z5>CK6>1+$:5U?ALYDPJRW2I4
M+!2SC5A.*.6=Q<!_%@<\0D^_8\@^==9E=(ZEP=9KF7PM['U2E"!I[$7!&\QB
M9!'ON_QB&,W9O,+KLNL@*W4HB41*(OX#4IB_NB@@OPS2P_G"M7W9_,_N7S=O
M.WO7^$JTJ@0@IU*<\0+6N,))Q9H@6O?=:XK $*X;7O:]K;]V^]J.SMX6=O6V
MR,[/X'9_4ZY%?%]46;0[H>9@]Z ]J$*J<?CCZU$_%?V?:R\MGGT/</\ @3SM
M-FE?9?*%[/X60/%;V_:ZM&J:DE$7P;UDJ&Q]Q4M+HZ&$."3BN4)P-[B=P./(
M*4%_;2DHR!<(DXL?J#1<'A<$6X=A!M6"O+(+$([B_@?B%M]G=G[-]_"WRJD4
MT8.XD_:WA;9^SLW\VW@=>C'FJ! ]BN7&> VJK?X@2ZJ=4G]$6_SF_P!FZCUF
M+SO[G7$'G.$!]B%Y,\! 5;_$5EU]ZG-_D-_G=S+YUF/_ "O=_P UQ!YZAP?8
MM\B,_JW(VX-OQB=;7_\ QK[U*7TH_>7^ZOG6H_,?N'_>7&'GZ-6^YLSZ+PPH
M"_S5IE?>HR>F'^MW+YUH/1+ZN]<0>H%HM]SCSD+PU:8O\T)E?>HG^D'W.OG6
MA]!_>RQ::I,HR-YR^[+V9XD,?0#:F, &U&^KR22QE-Y8##; 2FIR;".%;ABW
M%6O>]_5"%?GKR/\ A=9_46(Z;,U2Q^?S-*J&(T\85Z63O5*XE)C(2,AA@G",
M2(G<B=AW)WW?=UN3T,X[%WM"4K%G&T;$I7LD+R6*E>:5V&T3"SR21D3LS=C-
MOLS=C*=_/Y./=G*_]HG?^,K67^[+5_\ 6K4G_CF3_P"*65?P%A/^QL5_X?4_
M\E//Y./=G*_]HG?^,I_=EJ_^M6I/_',G_P 4GX"PG_8V*_\ #ZG_ )*>?R<>
M[.5_[1._\93^[+5_]:M2?^.9/_BD_ 6$_P"QL5_X?4_\E9<H+G67IH-#$UD;
M(H$GB<=($J6%.:A6I$4SHR[J%)WFJ#C5!UP\8<9<.\9@A"O;GKW8Z,8'L]&W
M1]9L3SS3V-#Z3GFFEDYDLLLN!H22222&Q')(9D1&9DY&3N1.[N[KS[U5,\6I
M]1Q1QQ!''GLQ'& !PB !D+ B(B+L(B(LS,(LS,S,S,S+Z(>=IJ+V)#$7X"%3
M?=\8O,_W[ZOGJ4/G/Z3?[JZ#K,G^3[O^:X@\VSL7L5+:7X#<5?=\8(S_ '[Z
M^]3A\Q?27SK,OG;W,N(/,N0!>Q=R"_ :VR_^(E'7WJD'HO\ 2+O7SK$OI;?Y
MH_[67%'EO(8_7D0[> VLX/S&\-Z^]5@_1_ZQO]I)SY?3^H6^QEQA9/GIE[<*
M2K;;[V]@6D+_ *?^[3AJ75X/T8_7WKYSI?3?ZNY7572KLTHBBV(]/'+_ (@\
M?=8EE5'\F/SG4&\=_5W*TJIJ:4119*^GKB?R?)WUH2U4;R9?.90?QV]7>K3J
MFII1%\]*WV\:CSF^63A57;R0&!3B-N2$T1AY1 0W-L RX.<VU]]@"];=NY]]
M5(@YD@AOMQ/X=M]NQW\'9YE"0N "+;?;Y/:I^'J"<[_<XVA#X:]09^:077.Z
MB/RR%]%F_P!KKB];+T&][KB#S_(+_<V-F#X8EH_S5!=.HA\IE[F_YKYUH_1'
MZ^]<4>?);?V#9'06_P!9,Y#O^.SJ"W^ZI=1B^4I/>+?_ .77SK4GF#W%_O+C
M#SM-!>Q3L)?@(5=_\1P'7WJ4/G/Z3?[J^=9D_P GW?\ -<0>;IT+V)S87X#<
M"_\ B&&5]ZG#_E?2_P"2^=9E\[>Y=9Y;RO-7;&<[;ECBG$C71=X2J2BVY$7P
MR3DAH# V,L3<P%[AO>UA '85O7M??6)^G>M"/0STG$PNSCHK/NWQG\+4)OUJ
M\.CZ>1]<:39W;9\]C6?L;P/9C98EJ\(5Z$I1$HBH73.YN+3D12I:UZQN4BC3
MF3=0A4G)3KE#6-@A%\:0, ^ (0 7N'A;KW"&]_6M6XWP'1$NF:XQ,Q-_<1G.
MQV9V_I'!_(ZPAT_$0Z'KN+NS_P!T%!MV?9]NJ9'S>I7H.72LSV<GD(_#>G(7
M]ZF]>NW*B;P1Q_0'N6F'&;^$R?\ SG[UQ1R!^,^Z/;N9O]?AN2T>_P#]QUZ^
M\L&\ !]%NY.(O2+WNN*-R<3/NB]:9X:H\7YQEZEPBW@%O<R^;OYW][KBB,,'
MSC&,=_\ 6$(7]][U]V7Q>%$5#:??^<I)_P"!0?\ $'UP;WB1_.?[%RZGA/U-
M]KJHJZU<U19M#NAYF#WH#VH0JIQ^./K43\5_9]K+RV>?0]P_X$\[39I7V7RA
M>S^%D#Q6]OVNK1JFI)1%#&5#.,G\D%OW[E*4OXIN1E;O_+@;J[FMY"/U/_$Z
MZR?RI^O_ &,NOJKJDE$2B)1$HB@W/?MCN/\ 9[5_P8*\:?AF_GWSO[%TW]U0
MK>'H-_-[0_M^4_FS73-:JK+Z41*(LFD-_P T(K\&V/\ 1B6OT!]%7YK^C?\
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M%_G6,KYUX_0'WNG51]-_<W_O_P!^%<H& 8Q;[H[OPO ,;P?WH#*^=>D] /\
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MJ@L\M=X;9F(.=@A>09.J\H8V;\9+BH^=,VU^ER(ZZ25Q]O:7=,".+>1I%=B
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M2B+6:^R-8FI/8=*DZ**%=&V.^6(FX'<'> *E\1P1X:"KB]8(AE1Y\&$-_96
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M4H6J61X+?90_HGQB6W3+"%;2D*4I.,2%6*M;+1O'B]/4!'\9)$=AVV^,SV2
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M@J3('I<4YN#459P*7N)2QT.26X.D]+YK3VH\D1W\I=PAX>C%+;RV8ER,V:U
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M7>G/E]-_J[D]%7('ND4?DC;_  5.K0?HV]Y=Z<^7TW^KN3T5<@>Z11^2-O\
M!4ZM!^C;WEWISY?3?ZNY:$&1S!G9#GAQHN$8;,Y088*]K6X0QOBX0Q;K6M:V
M\5[WW6M:W]5K6KT_Q#;8G&,W@;'TF;V5HEYDY7^E,E_;[G\Q(J'TT:7UVI2%
M:@/.27(9/F/'$6A4AQMBV+6:S7>;IW6;H&6;.=T2X5E[DWP^/'W6'HF.WFB)
M8YMR@5Q(TRD@^VM5ZMCTK?TWU]ZU3!Y2Y?K97+V^<T&/*''R6*$7,C;EQ27K
M(\ R6/Q7!%*#;&8D-QZ7TI)JBCJ+J#6+6;QE2A9QF)J<IY[XS7XX+\O+/\9+
M'2K%QE'7_&\<L1/N F)>ZS-H]E>G[3O#<B9D9I=C+,,OS!)(DUXPF)#<W*GC
M&C/#V1U#.VYIO>S^D WRE6J8'%2X!L@6\N;+( %F)E1BFA@M;T]2:GO8S!ST
MLM@Z6$JW9<M1*64(,K->L0OCI9O^K&\E0 LQ!%^,CY<KR.[&#!7S>B[FG=-4
MLGFX+F*S5W-6J<.)NC'$<V+AI5YFR$<#_P#20:.V9UI3E;ER<</+9G W.*ZO
MQ6,MZ33/DV=(].&GY(FD!Y2=+A'%*<@JR5O%8LDB",)10+7$D$*]@ "$-KB%
M<5]V^][WYZ\T]85X7U;JEWC;=]1YMW[7\+Y.T[_*O2+1\TC:2TLS&[,VG,(S
M>#P-C*OZEW=Z*N0/=(H_)&W^"JW.K0?HV]Y=ZN/GR^F_U=R>BKD#W2*/R1M_
M@J=6@_1M[R[TY\OIO]7<GHJY ]TBC\D;?X*G5H/T;>\N].?+Z;_5W)Z*N0/=
M(H_)&W^"IU:#]&WO+O3GR^F_U=R>BKD#W2*/R1M_@J=6@_1M[R[TY\OIO]7<
MGHJY ]TBC\D;?X*G5H/T;>\N].?+Z;_5W)Z*N0/=(H_)&W^"IU:#]&WO+O3G
MR^F_U=R^(T\OCK(=8V7G!X6#7+/05A9''C+)+%Q14A-X ."064#<'A"Y^#OO
MOY[WKA6P&/A$&X6\.W:_;V^=W\RY<!.3;D^[]O;[661VN&N0E$462OIZXG\G
MR=]:$M5&\F7SF4'\=O5WJTZIJ:41*(E$2B)1%^9YE-2SK<GY(6QVX[Q]7.YB
MJ8AF6X)EVE3(7 QK$.UM]@C$B,)N(-M]K7WVMS6J_N@[+6)]1=-'2M;?BFP.
MC<_>A+M=HK^4DEM4 C=]G9VAQ,U2)G=OB'LZ\>CG@EU%J[+5G=ZP6<O-4=^Q
MVBGN3'5]3\D&%F_6JVV?NNR>:$\LJI@Q( 2C'TR+:VC*<#,,+3"D+.V'JS6Y
MR:5XP#\SI-'KN3B<RJ3+#1G 7+VY>5=.NN>F[SX/?1%C]==&^J<G;)Z>6LZA
M&IA<GPN;P_@O'Q2F$H=CRT[4V3..<6=C8ZXR ['$S%D+H.UUD.CV]<R<$76L
M=DIH*N6Q[NP/:KU&,XI89'9^7:JE:F> WWC+CEBD;AD<AWBM..J/".JZ!I<@
MX4FK?)FT1:<+TRC&6DE<1<3R[CNSRV/#-$N9G L0#0%B,"8WN("A+&=>XMXR
M5AME:HTCG]'9$\;GJ$E25G+D3LSG3NQ"^W/I669HYXG9Q=]MI(G)@GCBE8@;
MT?TQJW ZOQX9+!7H[46PM/ [L%RE(3._(N5G=Y()&=B9G?>*5A<X))8G$WH.
MK:5R)1$HB413MJ4U4X1TF0%5D'-4R11Y#8M0%B8"!E+)=,7(@NP@L\2CX3BU
M;LN&(90#COM#6V -"L>7!M0!-5EW-I71^?UED@QF!HR69.(>L628@I48B=_Q
M]VSPN$,;,Q.(_&EE<7""*638'MK5&KL#H[''DLY=CK1[%U>L+L=V]*+>1IUN
M)CFD=W%B+XL43$QSRQ1LYMHW:[]<>1M<N6QSB4EF1V#1T*QKQCCLA6)4WQ%B
M4&EC/4*CK!*+<I0^73IE,B>N(*NI,(2($I:=K;&Y*1Z!]'?1_C.C["MCZCM:
MR%K@FRV3(&"2[8%G81 =W>*I7XS"K!Q/PL1R&Y32RF6A'2!KW)Z^S+W[;/6H
M5N9#BL:)N4=*N9,Y$3]C2VK'"!69^%N-Q",&&**,!M_8%P15)=:SQ+N)%YGX
MXP[,'8U5P=Y0'.0N4?BB!'<7_1.5(G9Y4%6ONL(IO4<^^UK7L#X1V1"KH*"E
MQ-S<IG*4+!\KQ5HK-R0_FA)# #_KE%7Y\'C'E:UU-<X7Y>,PEV9SV[&ELRUJ
M<8;_ "$<<TY-YVC);G=:*K>!*(E$2B*+-H=T/,P>] >U"%5./QQ]:B?BO[/M
M91%I1]H& >#)^N4BKN8O)C[?XG76R^4+V?PLJ(JHJ:41*(E$2B)1$HB41:+^
M0_\ /^<?#"3?II;7IQB?Z*QG[/I?RT:\SLK_ $IDO[?<_F)%;FB3'.,<EP74
M*S2C(&&<99*3*,'KL72W+N3&O%@D:%-.W!1DU/%9$N7(U85[A#T]T"T#;8PZ
MY:E*48:E"> ZK$U]E,MBLAIJ>IC<[EL40Y^/+4L+BILOQR%CHPQ)VZT<9ARX
MKI-)&\KL.X&3,;CPJ^="XS$Y3'ZD@N9+!XK*"6!DQ-S,Y2+$\$8Y"0LJ-2S)
M(!-))2%XS:+<MB$7<&+==RZ],68 QYC*6KL=Y.P;DR0R/5U)E^-CL>9J19CF
M\:TWC@ZH$6CDF7G/KW(4:)$_)Q&F <ECB&R]22(QT/4*+VOT/1SE]29/+4H\
MGB=08FM5T55CRHY/ GA*%O5+9 'MVJL8UX*TDDE8F9GB"+\6),T(B"[KI!Q.
MG,;B[LF,RV RMFSK*W)BRQN=#-WZNF'HFU.K:D*Q/9"..P.[M*<OXPF=Y2(N
MW$=6:5AU;M.G#H\8&\3&+NH['7FSJ_\ *S5'[Q9O[RLKT>TA^2>E_P!W<)]V
MUEW/5NJXDHB41*(E$2B)1%Q-,'2ZR]XFH=U@,KKKWA#U?[77.K>+[_M99,ZX
M"Y24119*^GKB?R?)WUH2U4;R9?.90?QV]7>K3JFII1$HB41*(E$6F'MQ-(;-
M@34!'<MX[B;;&L8YP:#CE:%@;B6YC:,FQ\=BY,F*1(BP(FX,A:U3/(R   1Y
MHNALF/))OR10.MP_@Y_W,9+2&I-+28?%-9.Q+^&H>IP,^<Q62CD",K_Q&>X,
M)%<ID)\800' +<+S]NBW3OH''::U &5Q6+JTL/J:$RLPU:X0UARD'Q+@%'&+
M1@UF&2*R(["TDIVR$?BFZPA6M:UMUO\ ^_\ ._/6Q> T[A-+8N#"Z>QE7$XN
ML\A0TZ@.$0G,922R$Y.1R22&3D<DAF9/X2?9ML%05X:T;0P1C%&+N[ +=F[O
MN[]N[N[_ "N[NZ^_QKE3).&Y4BG&*IS)\?2UO]2F?HH\+6=?<D0P#-1J1I#2
MP+FY3<L 5;:M H0+"[<4J3'%7N"_(RN'Q6=IR8_,8^IDJ4O:5>Y $\?$S.S2
M QL[QRCN_!+&XR1OV@8OVKM\7E\IA+<=_$7[>-N1^+8ISR02<.[.X$X.S21E
MLS'%(Q1FW88DW8LT6&-O]JH@Z1(V9;A&.\VHTP  ,>!$J<=3%9P;6"*ZISCI
M*Z*7O<-K7L(B#$&<.XAF#-WV"'!.=^#?I#(&<V%R&3P!F[NT#$.3HAOX."*R
M4=QNWTL@3;;,S-MVYQP?PBM74 "',T,;G@!F9YW8L;>DV\/'+6$Z?@^4<>+[
M]KN2M]C^R+L4*$X!2333D-I57#:YA+'.(W($X1[N<(%*]IC)@PVOZPA)2[WM
M_P!"WK58%CX,.9$G:KJK&3!\A6,?:K$[?K&.:VS>KC?UJ_*_PE\00L]K2V2A
M/Y1KY"K9%O4<D-1W^@WJ7^/OV1=BE.0,49TT9"=E5@WXLE]G4<CQ A[N:PU#
M>T2<P ;W]<04IE[6Y[!OZU*_P8<P1,UO5>,A#Y2KX^U:)O4,D]1G]IMZU\L?
M"7Q B[U-+9&8^W8;&0K5A?S;E'!;=OU[ ZB#,VW^U4SA(K:\2PC'6$T:D P
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MG!9BCGA-X\?<EC<XI1("<) "0-Q?A,!)MB%G;?V  !0 %E@"666$("RP!L
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MV(]/'+_B#Q]UB654?R8_.=0;QW]7<K2JFII1%C*U.=+[$_B4EG66N=2\9_\
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M%ZY="E8R-N"C5$2L6#X(A(F 7)A<NTG[&[!?M=<#)Y*KB*%G)72(*M0&DF(
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MQERXN=PL_"1<6SL\<]5O6]88# 1YW-TJ<N G*U+2O%!9LG6*=FFD(1Y'6)'
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M^B_<F[>=O>R=T?IX[_.&/E1@_P!.4X#]$OHOW)NWG;WLG='Z>._SACY48/\
M3E. _1+Z+]R;MYV][)W1^GCO\X8^5&#_ $Y3@/T2^B_<F[>=O>R=T?IX[_.&
M/E1@_P!.4X#]$OHOW)NWG;WLG='Z>._SACY48/\ 3E. _1+Z+]R;MYV][)W1
M^GCO\X8^5&#_ $Y3@/T2^B_<F[>=O>R=T?IX[_.&/E1@_P!.4X#]$OHOW)NW
MG;WLG='Z>._SACY48/\ 3E. _1+Z+]R;MYV][)W1^GCO\X8^5&#_ $Y3@/T2
M^B_<F[>=O>R=T?IX[_.&/E1@_P!.4X#]$OHOW)NWG;WLG='Z>._SACY48/\
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9HB41*(E$2B)1$HB41*(E$2B)1$HB41?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g838337g65e64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g65e64.jpg
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M020F16%Q,C22H=;_Q  = 0$  @(# 0$              0@#!P(%"00&_\0
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M8OZ5'8[[4. 4O:^NDH)'K9G5EXW;FUB-E:B*2&K/V,W590,JDC]J4V9L^"1
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MV4&&;+(7)DO)FSQ%>$U: ZTPZZMF&ED,$'QU-16V6W7&ER'4K?=<6H"IN .
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MY,-Q>,KC)>KH%W#*D8<"BU^."P.*[J]O3UJ71X X!'337NK]M_EKI7[L^A>
M2+X X X X X!B"\-%[VG7GRY@?\ 0.QN5ZV2.\RC_M/+?157+K[!/OJXF_=]
M4?K'A<UG.4L/5D< GEX,CW\6CO[[87^U%[YM3(GWSL,>^J_T#5"NVRP_1_R@
M>\PS]<L/&W=ST$/%@TD?#T^_XG_)#KC_ ".<N1D/WCLYVJ'W!0#9'=\B+S)2
MNJ8,+O-P&AAP#:]^YPO<Z[2_'76GU%:^5?V0?=##/@=1^6E2Y>Q9[EXP\/I/
MS>=-E/E=RUIY?%N_*NS_ !A-?64GELX'M$'X*'YB'SE/<R@< ]%+P</O#>I7
MR%T'ZF8Y67%&^*L\X3'GJ9TW$Y$ZB:W.A),;!?2NGKG:^Q.U]D;JV%52]"LE
MJ'J5![?=J]5P-.UA02NF):;R!J/8^KU"MUNS*&";^)B5T'1A,FC2:L2?]+(N
M.D&Q-U1+:->XG'K2_$3GU/.CD]6:T)1(9P?%(:_ILZ- LTR<0LD&/+KHV0S#
ML! FVT2G'(S;B62TP@TW.DST2'I;:'UN)P(*/W]=]DZ]HK]JUE7:G;30V2PY
M[4[(4*BYUT?=?8BC*)4) R#+9AVVX3Y+0H(:,8<!AIJF9!B#(&N2I8X"G=?;
MHM)[9>_Z;>J41H\34Z )FKC5!B!VP7"@%UV^' V&+G5:;9 ]C'6J=2C?L%4P
MK+&P@*XOL7;ZH-GD *C G5V\13?6>YAK[?.V5A Q[-%'O;RJ49#5MI%TU\8P
MY&ZU:%;=RY7+Z K5A98RK[[$ET6B-*1_:1G7F_PN""6W ' ' ' ' ,07AHO>
MTZ\^7,#_ *!V-RO6R1WF4?\ :>6^BJN77V"??5Q-^[ZH_6/"YK.<I8>K(X!/
M+P9'OXM'?WVPO]J+WS:F1/OG88]]5_H&J%=MEA^C_E ]YAGZY8>-N[GH(>+!
MI(^'I]_Q/^2'7'^1SER,A^\=G.U0^X* ;([OD1>9*5U3!A=YN T,. ;7OW.%
M[G7:7XZZT^HK7RK^R#[H89\#J/RTJ7+V+/<O&'A])^;SILI\KN6M/+XMWY5V
M?XPFOK*3RV<#VB#\%#\Q#YRGN90. >BEX.'WAO4KY"Z#]3,<K+BC?%6><)CS
MU,Z;B<B=1-;G0DF.3MZ$ZW2;)7-D6SIYJGL1V!H=@##JI*V)IBP6NY5RN-9F
M&&+I6;!0M!]@=D$*J%*X@QXLZFTLZ*K=T/AHMDFTZ>_(FQ!R2^G2J)PV7=XM
MU+WU&08$1>,! Q>2,FA9!04/(OAR:,-D1+TZ(S)=&$&TYRE$V MU466A.<X2
M^TXG&<XQP<2B]CZBU_MI@'&OP64:8KA"25#-Q[!90.(D^7 D"I,A6:Z8$YE*
M>&3)H]:)F9#7H4Z=%PC#,V4AT#NZS1:Q3Y)N8!@/L3;%.>GEILXJ8-S'E/$"
M99$"/+-SR,@<"A$C9F:)K8UR)7PKY<FL0,A>GR_.@6BTU[J_;?Y:Z5^[/H7@
M$B^ . . . . 8@O#1>]IUY\N8'_0.QN5ZV2.\RC_ +3RWT55RZ^P3[ZN)OW?
M5'ZQX7-9SE+#U9' )Y>#(]_%H[^^V%_M1>^;4R)]\[#'OJO] U0KMLL/T?\
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M,5\.+,RK6P=II\?.>D1RH]8;<Q4<JMPV_P!7/W_^";</G8ZP_;QRN?K><?\
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)!P!P!P!P#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g838337g72l82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g72l82.jpg
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M 0$! 0$! ?_  !$( /("8 ,!$0 "$0$#$0'_Q  ?  $  @(" P$!
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M CF-1>WS' [2@0/9/)\)%I%F0P&+:U3>9W&N<&KGKF;\YFEV%<T5\;8]M?\
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MK$VNJX:JJV4_6)X4%VNC1U+C''F*:<3(WUNNIY2I1+5NE&S96E-G;WYF=)9
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M6Z<CSQ$V1/8XGF+0NFD_NYQN9:HD;8W?I8KVOSRG+5+A)5D.0&Y5$HZ\CM+
MUUY*85'4<35[>C:QG%L&;6Y^ 6IK7AJ-)XLL&P!+=DM.(XDEJ]W$VRBHZ@F[
M;=DHE-IG&4;=FD4QIN2E+W$+E2$OZ<8B4,XV'J?5^W!;0)M374'V.(8.[/V
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MN7D)0A#]DA3*FY[J$--)0[))U:2;025%N)T\,=TIIV(^!EXKJK74;OKJT@M
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MWU9!I7-^E$A_'560/("F^9/@<TUHL^<2.6LAY(6\D<C0(,AZBA/OBQ>NF++
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MV1&A^H7;Y@7KGV>0E?4!,* % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M]G@0@GI5V^)@2^&%'_14M[8;H7J'V^0'ZY=GF)7U 3"@!0 H 4 * % "@!0
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M[RP3QNX?D7;I\\6OFX=N5W"BBN04W3ZT_P!-'^(>W_:\<$?EUNS_ ,E_-?\
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ML\3%B%!0* % "@!0 H 4 * (C2W5/+TK)SQ*(\NH?$8N^*O70",.^,862N@
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MB>K/-+:O\OCU=5[9_F!9_I59]O8'=?W/GY4*?]"N?[LDC[GZ\5CZ&A0 H 4
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MAK 4 9%$/\V1?SB"?Q)M4'/Q;GYBOU3'*Q^/9_G6_P!<AW"U>2A[K"@!0 H
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M"*'%+WKVKZ53_L[*IKZ>[Q,01T=_@0 /AA3;T5-/;(C0_4+M\P+US[/(2OJ
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M@3Q16_P@8UN-$M@"2E $).)WEJZ2+Y[<7_T <%:"I]!=GB8FW04"@!0 H 4
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MI]EE@&0U5;6RPYX-R53:)W.9;-:+8X.5E.\N5VN*;D*ET*Z]/$O;X"RF@H%
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MZ#S\8GJSS2VK_+X]75>V?Y@6?Z56?;V!W7]SY^5"G_0KG^[)(^Y^O%8^AH4
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M.Z/GX#7$GYONK/JB+KP'GGSTRKZ^L_M;H^H&S/\ )[A7^[-/]A9$PJU,;P%
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M[8^W2VIJZ$]G@0@GI5V^)@2^&%'_ $5+>V&Z%ZA]OD!^N79YB5]0$PH 4 *
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M * % $4N9'D>MYUA/H2-31T]WB0@OH[_  ,.&_D>OYUF_H1U%]/=XF".CO\
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M?X$ #X84V]%33VR(T/U"[?,"]<^SR$KZ@)A0 H 4 * (2<3O+5TD7SVXO_H
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MW%+14QO(]K3*5PR]H^3OX+0$SFQRC<-OW0\2[%P6*#K&]D.L;V[H_P )7/\
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MYUA/H2-31T]WB0@OH[_ PX;^1Z_G6;^A'47T]WB8(Z._P(2MJ F% "@!0 H
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M66O0FJ8'&M>QU<@[$QEADS0>E<F-R+]==RN_($7B8I@*#-%B!%V[>Y#P0@.
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MR/(];SK"?0D:FCI[O$A!?1W^!APW\CU_.LW]".HOI[O$P1T=_@0E;4!,* %
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M[5]*I_V=E4U]/=XF((Z._P " !\,*;>BII[9$:'ZA=OF!>N?9Y"5]0$PH 4
M* % "@!0!IG<&^-?Z-0C*\^5/-[30NE%HA81'"QE.0SDB\&C8O &KQBWS',I
MA-R11(=#1IEX,;G'C=\BB]3R:*=@ KL/K[.Y3[J# <&I29:@L^E+DB$F6OI;
M!(YI<PB*V9",LGI0,SC!,_*8HBW%1'<?'G;DTEH3?PW<6<@B\8@^I(8WD<^"
M7,7;]!]?MZN?GTZ--.L6=:KUR"U%KJ':SC*CM8#"@3("-6?8L$G*J#3"]KJY
M-!#$6$&IJ*Y*9MP\?$AXX&;Y)"H\&$!6; :U"/2,_H 4 * % $1@?$'7+7><
MRV])Q(>:MG!L5-=1A9&Q[X8:/G)5Q<AM@OKELOVXZ-J[-D8>-S61F1:"$B-2
M-W*$2[]P&=MF-!74^C]C_;JZ!+F@H% "@!0 H 4 * % $4./_E3Y+>?;'VZ6
MU-70GL\"$$]*NWQ,"7PPH_Z*EO;#="]0^WR _7+L\Q*^H"84 * % "@!0 H
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M * % %FW"'R?2OSR4_@@FN)?3W>)CE1T=_@0C%RY\MAO_NB/?PM&IH]4N_\
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EZO#^E #J$/R*7ZO#^E #J$/R*7ZO#^E #J$/R*7ZO#^E '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g838337g74r49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g74r49.jpg
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M"!87(W1VM"1257)S=925LM,8)30U5(6&L[;4\3-%4U>2EM)"5F6"U4>#_]H
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MWQ]OB'O)ROR\VI\];_W;&U[*?<&R?[X^WQ#WDY7Y>;4^>M_[MC:]E/N#9/\
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MW$+(YI=?>8L+E18, & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M!@!#W(#P,V)YO'_KR,LCG%U]QBJ^:?5WD,^AWQ1BWFXR>K$N0?*?2?>)+D+H
M+N$/4Y\?K^]("/U0#+*Y$]'P(53RJZ?B8L)E!<, & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # !@!7I]\9B"^C*2^M Y<N8?3X"A\\NCQ'E^\9:
M!>C64>L@8+F'T^ 'SRZ/$6$R@N& # !@ P 8 , & # !@ P 8 , & # !@ P
M 8 , & # !@ P IWS6\&D:\_$/L[)<NCEZOB0HODZ_@8S_BMX"83^7)O:Y^R
M%\X^KN(2CFEU]YC29RY53!WY9<ZPM\2Y03\VNJPJ-\@JRC[7>(4PU$\JZD4N
M1TEDK0FD2 *]"M<&],Z!(;&5X4F=Q7;>TP3U8!'?4V$H@L85HY-R=A]85I<7
MD>Q1D-*Q82;N.BZ0RF)$?7$=-IQMIU;)J=D1T%PACY>R@R3\,Z2W;63I(TPI
M8K=(5TJCQ_&I=0YB.22JF'C,IW&7'USYT9N<T3S3SS#<@D,1);BN"R?S>VX6
MW.-;<D9%!+$+N"6S=SMUMAW1$5];CR%N='1$S3B9ML^?1N+R4B<DQ $+X^*4
MNFI>^+F-,ZEZV:-<@)V4-O!CMMB<6QK/(4&O9I'I^F^UHXYO,LN2*^ [6Q29
M84XRI1N1XR'-\W';D+9/B)MU6LG3R^ASR=3W:<GL[:1DL>K_  9J/)I1,2)#
M46WM6+B6;\I+,A""9F3'&^#ORWH;<E/RC>91LFPF05_2+W+4T;L45]5-71TQ
M1\=JYY'5>AJZ4R YD=F&T;&9JJ8HC,U4E;@J&Q^:)9(V@QY<FGMIJ/; +S4
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M:BO530K!\K28J(\KAUFI$!LE,I6LU&HBV+V[RTD$4XY4C;$%K\HZP.14GIJ
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M@IEEY:O69LBLREG6IB.RB5(@UKR%N1H$E55&KCEU\B<]+=ERVXZ52P1R)?\
MC/,.1,$8:PCCC:49WP#HN)HA6C:\BAKW/K3@#JS-8'1TGCP\*&Z+1+;:M_\
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MCCA2$S31+6\M]II:,6B?1X<<(W&+#BKLBGECH;)@[16+LMLZP)#,7EDK>.K
M.<9@T/<U:@D^+QZ-NQ*5W94[9V-0C<D+>J[:,&A3=BYDW2AE<N75S&7*VK<J
MK%^W8;J*R+ 8D6LMLVI=C.9;0:)DJ6R:V9"GM:7&G'4;!$XO7UM;H0P2!7W=
M=):N;UF^J(V/R7<@NYUI*B44%TI$"HJY#KB5UT&!)2W)B(C[*VGV67-X9M-[
M.1L?":KFMO@"%YF%S6$;6UMMMSQMTLZSGJ=NH)6SQX^,-B)0I?BU)>HVC:3]
MEELZ$A"$PXLI0>H--!UV^)(T@7#SMFXQ!H:Q-M2/4$MFHJ(]:R<)^4B8\XA$
M8T'PI;Z",WW%.&234E*2(QSH>B;'HS%*S*M,JNE4.2Q\J@2<@R&7<22L8L)=
M>PTMR:3B2@-QEFDHK*&2-1)6I:E$,0+Z.NAF]'&D49?+@@X(3*[#DD'/@MF.
M\470QKM0Q$?.8!&W!H)3K6^OWA0@(4@8NSFJ&U2-6H:W)&<O7#4\X]*.2.KE
MN2X]'8'80ZN+8IL:AB:U/>IB<376<MI\UMNV;"7%).3LI2\DD)>:<2VV2>M3
MH/PYAJ U7R\GJ"J;&\GU"Z>_DUKU5'R-32[BF@/14H=8I92V4.%#VE+CN&ZN
M,^TMYXU^DJZ-KCJ9#JNAC:NM>,I:FC$Q@S&]Q&RGF+R9\@<]?%\BE$)ESNS%
MI!OD:<G)R6",0[)2F:(.,([8V PWLGZ(TK924ZXGNMTLM=U,@6,F/.J8\R)'
MLJV.W%AV$)A\UE'ELM-(U.$:T[225L:R3J_%S0/@ZJO':IA[)*]O&J^TJ(DN
MLOI5=82Z:YEO3;&HLY40FE2Z^0^^[M,[+:MA:D;>I2MKFU_1^T@:RUHUQZ07
M#7SE5U=^]*SS"M[.>X5,7RM>Z!CM[C)<\,H" /C-IT./<"RQ)$YZ=6>:<F4$
MC%U=<=O29D)2+=Z5&H[-JYM/+;\&UJ(]A CVVZ)GA\%B0:CC2-R26C,EJ2M"
M4I6E1$.6]H6Q)42@CP9N3TDC'J3\6HUI0Y!+J;290[Y4CR59RHI(*9%X0M;Z
M2-IMQMU:EM+09B=K7X^US<U7HJEFY,A4Q]H.C2^/O2*4/::;QU_AXR#8U*VB
M:#6'OX)4UG$!/T^JUBQ:M-,4B<QK=*U6CL<I<FM:&X<NZ]45$I],MJ2PY#CK
MKY4:>2DRX3\ D)C'#>2LT\'0A#;9$C=$WL(V<QR3"J/*L>:QNW1-<A1E0'H4
MIJPEMV\&;6&A4"RBVINKFIL8ZT$LICCKKKJE.<(-TG7"5%$=X-4=&H]"F)-N
M<N:N&WXT\F#I;(9BND$TFEO,Z%:VIY#.I$ZE*53Z6:A6[3J4184)(PIR#"^Q
M'"4F*>ZE:0\AERI\E?D]I$_&GL23"BP6XT"!1ON-O*BUT5DT(C&EQO;0X9N*
M(UJ)6T6P2<;@Z(<1@0JF(WY7D.5691L^593K1Z;:VN3Q678Z)UQ.DI<<F)4R
M[L.-$3*3)"%%LJ-Q2YFL.D839TUJ&?2;3OM_I*3.TLA.V]>%(BT[/3,8Q+>Z
MZ82<[:]-VB8+L1(34^RSNH9UXM:ZW.AJ\AL*BOO*V)N.#9##9A6&]:-;FX8D
M%);W"]M.Z7O$EM*,EZT\6HN495=XG4W]MC-S/X3PS$["395.Y>)MKA,J(J$[
MPELT*WS>Y6>RDE(U+U*UGR#";XXJUER%>H))Y<OGT:E5=]WTT>E5:3E[@$CT
MQRQ,F1RF,K7=B.)5J&%_2I"$Z]. 9"L).CRT:U(!8M"H[#',RM\8CV,."W6R
MX5IP9<J';5T>SB\(A+6Y#EML24J0F3&6M2FE&2D&K9-QM9H1L]3F.CF@S:73
MV%F]=0+&CX:W"L:"XF4L[@=DVVU8U[TF&M#BX<UMI"'D$:'23MI:=;)UXG,=
MK3A72U4&U:=% RO0Z?K>=57$.Z3\6L#J+6&_"D<ATZ:TWD[6N/=$6^T5@=D:
M3$?S6R3=_=YRK;/[^Z3<IFG"U7MM77,[=1C;/AE7&X+%W/YQ6[:W7_:(^4:U
M<>T7(.#0:*,4QM6.KK2LM>,45QCM83\PG2*NO)ASIW"-3*#>?-\SW3I&@FT?
M)V%<HPA3T=]"ZBU6QM@=[<@RRHXD[5_')I7UFO<+G+E 7UZ/D+K"Y._L(4>W
MR/*W=2<M[3-2E&)C1F"2'IQ''[-[!.E#)#F7$N2Q1V+=W.8LY=?9U$>PKFK.
M,PF,S/B1I.\X/*0R@F]LEJ):2(EI424DGJ%Z#\-*NQV!"E9-4.XU6R:6#:TF
M03*FWD4TR6N=)J;"9"W7"X+LIQ3VZ4VE2%&9MK1M+VLKF_!^EIX]7(].BNQ4
M0K]@+#7]J-37/'<+'*$T7+8DD?E*QJ<.Z*8<X:FJ/(V5+)C-&JM-JIW ,L:I
MX<52CAU^D._K8]#'915N?BU9R+.F>>K6#DPURU27)4-M]K=+*N?>E.2%Q"U(
MWJ&#2:4,-(1V5MHDQ2XEY3+D.7C1YG2PZ3(HT>XDE#L&Z],-N%8NQG]^V=O&
MC0FHC=@K:<X.Y))25.2GW'.+E_ /CY-K"]\)Y3SLL3@K@CG,H.USQ];*TLIZ
MK-.D2P9[L.$I30-<C<F EO0A3B'I,F4[3:$N3*A'J]J/U@Z2LGKZOR6PNN,F
MV[)F#8/5L9ZVJ8]NI:[&/5V"TF]%:E*=<-1%MJ1MGNE(V4;/'L]#&$VUV5W*
M;N$F\Y3R+2HCW,V/0WTJ@;::J)=W4MK*//D0D,,D@S)#:]V1O-N&MTUY*X\,
M::<VB:,BD,J[2GG(I#RA?NQOI8#MV>W*6)4GVC,[GBTGCW98\W]>T[":,0>S
MZ[<UV76P<1K/;YE^OD(X%O*W%G<0C:XYFGR0\B2A>\+>EMRMF6[J?UD1'L_F
MSV>/GOZ*\6D1K6(X5CNKC.&=(,S9F$2OQ@8<AN(W2MR>Q!VH+&U&U*,RVRWI
M;7%AS1T?M&,5AQ^PFQWM@G41M-SN.)0,RQW=5647G#X>X*WY:QPM66>WH2'E
M:YJ52PL(Q'%#%LE I1(SE291SG])F12*N55O,4JN'4S-%.LBJF$6\RNC):1&
M;D6"#2ZXJ.VRA"#,ME1%M.H<<2A:.KBZ%L1AWD*[CRLD3Y-R*1E-;3*O93F/
MU]O,4^Y->AU3B5L-(E.R'''"UFM!F:&'&6ENMN2K6/%NL*DKJ>5+$5$Y+KB>
MK92I-BJV=R0Y)$4DRTL$_LM?+4ZU([PQI5*W%Q<PE,[B4K)=EZMS+6:6G".S
MIK?,+>[M*ZZG)KCM:UN&A,QNMB)7.7 W91G[-M3:V+!Y"&FF35(:4A3+:&5(
M-M))&1T&CS'\;H[G&ZQ=NFBN7;%Q5<[<3U-5C5H3IS8E(ZAYN551G''WY!)B
MOI=1)><D)=)U6T(\J_@C2M9S)#.U+Q;%JO[%'WV*0[=UV;(;,;8)&Y.AVU2)
MGA[4^&;0-25Z:-]R%^S"%2@YKV8BT<$@]0$WM+C2-D%O <K4L4M-&DR8TV>6
M/U$6H=LI<-S?17YST9)./+8?_/MZE(2E[4YL[24FGH\?T/8G06K-RY)R/(YT
M.%,KJL\LR"=?L4\&Q9X/.BU<>8HV8S<N-^YGC-#BU1S4UMDA;A*]6J.C^X]T
M[/H[/XR583J; Q/HJLB,RL62RR!5(*2A.+>AUS%G94<D8S%I"@X@1R@QP.+T
M9V8DPM4 M0"]UI,R>]K959+56,ILN#^6)L"KB0K*[*)LG'*UF,(2Y)2VI"5$
ME)-),RU*(T&:3_/'-"V$XO<P;F F[DJIN%GCM9:WEA94V-'/)29:J*NDN*:A
MJ>0M:34LWE)VC4DTN$E9<B7P5HQ/7$%K1'J8H&ZM+?47E!9$CD)9,PCD_5/K
ME(5"Q"]=S1 VVG+7564<UGHSDIZ72<L_1IB8@X'Y'I%R)5K8VR^ N.VU$G';
M&*Y%-4&56(C,Q4(<C[W7ODML-J2\E9+2YM&G4E:DG^Z=$&((HJB@:*T98H<G
M7E]1.:FI39P;IR8_-6ZU+W&K<+=D.)7&6TIM;>PE9*4VA134;2$)-OE+R-'I
MW]\5)5"BFB=Z7ATQ>XU3+ 3,S0FOM?KQ.O=DL/6KNV]!TDZI':^][[)G0%D-
M@6-KQ4MQY*7=)OS_ #1\)X>B$=>6I[:U;G@YGK;V->W\K:\PRM6)5*LR;SH^
M$^76\;7BJ3WQ<#\E+LBM3(X^QKX1PLBU/;PBW?R-CSC]EE+PQ==K)?Y^G;W?
M,%<N]7(-@7!"R^Y=Z?T<D6Z/;>U]C,<>Z2$CL*O2H 2R.O*V2+8NOU5N_GMX
M_(QE.Y\F2K5BX=UMZY'#(\9R*WLN[6HFMTZK:1L&9JU'M%JU'=W%:I[+8F:+
MX3Y:A44G'F=3Q%$\GRYK4]W:8V-:G]^RC9=WA$E&M.P>O6/7Y >!FQ/-X_\
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M-NH>9:@RYJX=?'6;[KK:8[*G8[Q-*9=0AM2',$@Z!X[./7.+V.6SK&IGX_\
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M=;(@6$M:4KULMIBI<4M!.*&@[3\(?+U:(:ZMC2)<?2:VXT[<V11V">CXLVQ
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M=CK=TXBN::>NSH/B7 K*@C04>R(TP9F19#6VMBIQ<A%KC=M)S6%N":0G2Z6
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MT@(_5 ,LKD3T? A5/*KI^)BPF4%PP 8 , & # !@ P 8 , & # !@ P 8 ,
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M3GQ^O[T@(_5 ,LKD3T? A5/*KI^)BPF4%PP 8 , & # !@ P 8 , & # !@
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MU>8]?+]_7J&U76^KK6_Z.KK6^I\/_P#NM;_\]:W_ ..M8$#S@ P 8 , & #
M!@ P A[D!X&;$\WC_P!>1ED<XNON,57S3ZN\AGT.^*,6\W&3U8ER#Y3Z3[Q)
M<A=!=PAZG/C]?WI 1^J 997(GH^!"J>573\3%A,H+A@ P 8 , & # !@ P 8
M , & # !@ P 8 , & # !@ P 8 , *]/OC,07T927UH'+ES#Z? 4/GET>(\O
MWC+0+T:RCUD#!<P^GP ^>71XBPF4%PP 8 , & $96;=-04L@;G2W[1@%7MCN
M>I2M3A/Y<Q1%$XJ49(5"LA$J?5R$E2<F3B">>62,8BBA:,'H(-]7 :M?(,^:
MW1M?&QN>F9P1.S.\($CHTNK:I)6M[FVN"<M6A<$"Q.,Q.K1+$IQ2E*I(,&2>
M08 TH8@#"+8![^ # !@ P 8 , & # !@ P 8 , & # !@ P IWS6\&D:\_$/
ML[)<NCEZOB0HODZ_@8S_ (K> F$_ER;VN?LA?./J[B$HYI=?>8L+E18, & %
M39[7"8[EW2]LIX68IV@H;D#!I?.6]E4*5J=K4R*FWJ)15:ZH2#%H K%(9FX,
M3249V56J+=CD9)AY0]A"?,?27<8H#"(Y&U[E5=[G\?[0B,/8KCBZ"1T4GXN7
M"W'5-1<+XS<HZPI-$JKY56Q+E:<V%([-3AL=^KIHFC="S)9&H>:Z+X37*6>N
M@3Z2XN,N767&>LC]/%U\O85AH$;R5X_TGP<9G-_KMLCP(WQ/HNQZND5:/KK8
M32_.<1CT0F)B:U&JXR(X!<U/*<T1!>ZY>$NQ)CB=KEH3RUH <1F?6?+TGZ/
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M 997(GH^!"J>573\3%A,H+A@ P 8 , & %6.%7BTUY_6Y]]94PP M/@ P 8
M, & # !@ P 8 , & # !@ P 8 , *]/OC,07T927UH'+ES#Z? 4/GET>(\OW
MC+0+T:RCUD#!<P^GP ^>71XBPF4%PP 8 , & &#6?X-;#\QI;Z@<, ,+XT>+
MCQ_]"54^PC#@2?*?2?>)MP(# !@!"B[C=Q^<UJQR<*6K%:O<%2A:N6JH6P'J
M5:Q6:,]2J4'&(1&''J#C!FG&C%L9A@Q#%O8M[W@3K/TG[QZO>P<<O(;57T&C
MO[A@-9^D_>8=[!QR\AM5?0:._N& UGZ3]YAWL''+R&U5]!H[^X8#6?I/WF'>
MP<<O(;57T&CO[A@-9^D_>8=[!QR\AM5?0:._N& UGZ3]YB7(_'6&)LR&/1AG
M;8^PM98R6YG9T9#>VH2C#3#QEI4:8!9! !GFFFB"6 .MF&#'O77"WO80.9P
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M/H5W&+L8$!@ P JSRO\ BY3/]Z;C=]:C#@!:; !@ P 8 , & # !@ P 8 ,
M& # "'N0'@9L3S>/_7D99'.+K[C%5\T^KO(9]#OBC%O-QD]6)<@^4^D^\27(
M707<(>ISX_7]Z0$?J@&65R)Z/@0JGE5T_$Q83*"X8 , ."?Y/'HL0A4R-Y;F
M5.YNJ%C;S7%46E L=W$0@HF]/LP6NRJ3^QFF:+!U=@()/4&=800<8  Q6K;;
MKZZ8L"9UK(/=%'AJQ(1*36I[85J=3VHB<B +662-K0^( N#.YM+^T'+6Y.2]
M1QY99&T&+6-Y;'!6 2/@!5CA5XM->?UN??65,, +3X , & # !@!K<A5.\_V
MY'R\*E'(QH<'.PI*T*^-+GM!&SDM6-Q48A"5=M>W>X#L+^04:C=FM<D1%UZB
MDJYJ=7EN8H!(9TIL-N"3U<6HC]?KXS]W7KZ_/B#E1_2/GTMQ#CC3R6;&VU*_
M=#E/)"4'EQU458K;M 8%L;TNCX"KVWJT!>Q-A3RZGV,C:U)H'*6Q2]78":4M
M83K3Q\7+R>KT_?BU^H;4L"H8 , & # !@ P 8 , *]/OC,07T927UH'+ES#Z
M? 4/GET>(\OWC+0+T:RCUD#!<P^GP ^>71XBPF4%PP 8 , & &#6?X-;#\QI
M;Z@<, ,+XT>+CQ_]"54^PC#@2?*?2?>)MP(# !@ P 8 , & # "N4EEO*]&_
MNZ6)451+_&2%Z@IB>G[DW-XN].;:$>])5CG'4/%F5(V9:<7U!'MZ:2/9*8>]
MEEN2H.M&;">+TG[OM$35S??+6SV1W?X_QJH=,B99]9E=*RW;EE-TZD;Y5-A2
M:M9&H( DXC+BQM:I^BKBI9SS#BE2EJ-1J%B- J,.1)P:B])^;S>GC](MU"%T
MW<8RWK+%C<:B,O-$L[J,$1F#C/6!"$M:H+0;12EVA=?+G(2IO E5J@G1-MTB
M5GGH2AKBDP%ZD(&68 , & # !@!3OFMX-(UY^(?9V2Y='+U?$A1?)U_ QG_%
M;P$PG\N3>US]D+YQ]7<0E'-+K[S%A<J+"B-X;X+1VR'<5T\@X[3MCOZ)I?GJ
M.#YI3OCXN=4O:0&)HDB^"Q>Z("@4FJT#$6U%2,UB$I<4[*6D&O4A;0 (CE_Z
MF7<+%K\Q:^HC^ L30S=326O$;I1$F;)Q ),YNKTGG#79;K<14M=B5.X^ZN*B
MRWR3S%UE2MO/8]1PTY9(W(;6!D*82]I26DI$GD5/7YQZM@4]N>67!YLH>=(F
MN,5G=5=N+64FV)>O!;AE;=:X(UHA[(2[9R8*J"(HY*H[9,<B!!V6%,8$X'FU
M='9K\14:.<.;JCCK7-BAL^L7&T:A;:>AD1('!92A@;]"*>JCD55B)5)4H9FL
MD""4R(?)252Y7W*<%+4U;CD>BA ' )[E*C L9\O%Q'\3(S[N+[D/0L3B]650
M0KA26!F:Y%85165Q'J%%9RAM[GO[LTPC33"@*QIBUBHA!IS0HC#3$0#E(4VE
M0R J#M T:(!'K,_62NXS[QLWP*C5=TV4YFM;=&#REFM=3"4P&9,C;5HV66PN
M0.T6DS0-=>%9MBT36_,:M"ZMXEC:M6-ZH2165M0A5J4ANQD'FECR?#6&9&2U
MC,AEI]E:I6VT\VAUM>S"DJ3M-K)25:E$2BUD>I1$9<9$,,T@R9$3#[F1%?>C
M2&T0]V_'=6R\WM6,1"MAUM25IVD*4A6RHM:5&D^(S(=>'W]O-_\ ')Y5_P"8
M:W?XOS?OD.E_@>K_ *OB?W(^7/QDR+^'[K^M)W]^.-<^:G,A[+2%//+3DR[%
M-[DWO* MSOBTUY:)X:5(%K4ZI *I4:%,Y-JPHM4@7$Z I1J2P'IS2S Z%H='
M2'_W/5^G_-\3S?\ _(2639&G7JO[HM9&1_XTG<A\1E_VXY+O[>;_ ..3RK_S
M#6[_ !?CR'2_P/5_U?$_N1'XR9%_#]U_6D[^_&T/H7N6_*VQNDWXK0NPN3?(
M2=PY\D$^*>XG,KHLB3QIX*2U#8+@E*=&)[DBYK<"TR](E6D 5I3@DJTR=27H
M)Q)8PXUF%55Q\;LWH]; 8>0VP:'68<=IQ&N7'2>RM#:5)UI,TGJ,M9&9'Q&8
MS' +RZEY?31Y5Q:26'')1.,2+"6\RX28$I:26TX\I"M2DI46TD]2B(RXR(QV
M)6: 'U*& # !@ P 8 , & # !@ P A[D!X&;$\WC_P!>1ED<XNON,57S3ZN\
MAGT.^*,6\W&3U8ER#Y3Z3[Q)<A=!=PAZG/C]?WI 1^J 997(GH^!"J>573\3
M%A,H+A@ P HSSJ7K4M:"#(H)!)/6):EK4KW5PO*_:FLQ#+A+3D;6@KINX[41
M;5D/BY<WJ%:96&*N*)V6,RM];5K,JCXG0XQQ^;OU? Q)??B(_?K/4,YXCZ1G
MP^>.Q*.NFAP?;#3.3M&ZV?9W)VJ,:+JVL6J+L[C(+#C,%?')=NOVR'NC3M-
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M->V_DX_[9&&;Z./GK1_RLOZOECLSL^<1]<A@ P 8 , & # !@ P 8 , (>Y
M>!FQ/-X_]>1ED<XNON,57S3ZN\AGT.^*,6\W&3U8ER#Y3Z3[Q)<A=!=PAZG/
MC]?WI 1^J 997(GH^!"J>573\3%A,H+A@ P I/S8:";!K\-6&P:S)&:Y*V>6
M-[M&*G;K>@:=TCSGLY"V3Z'N4JBA,C;]G TX%M 79J5I' AHD+2]-KRTH%1
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M?NXR]Q\9!KU<G%RE[^(_>7$88 ; ^BO\?WCCYQRCZO)?FL=,OT9Y5^BPOK6
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M;X[W)[TN2?\ U ,](]%WT>8A_,D3^R8\<M-WTMZ0/UEG_P!I(IKF>C5@8 ,
M/MRZ(?[WGQ^_Q3^NFQ<\]].'TH9-_J;Z@JQZT?@S?0CA7^T7_%=Z-DV:G&^
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M2UDYBN;?->V_DX_[9&&;Z./GK1_RLOZOECLSL^<1]<A@ P 8 , & # !@ P
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M./G'*/J\E^:QTR_1GE7Z+"^M8 W5^#M],^"_IUC]1V@^Y7/.T>NP8 , & #
M"O3[XS$%]&4E]:!RY<P^GP%#YY='B/+]XRT"]&LH]9 P7,/I\ /GET>(L)E!
M<, & %%^3;MQL,D4X'??'NM+=]YKC^ONA.\S>$P*:O/<(#W(4;C$XTGF;,I[
M1//,C>UVQ@=DR-2>H) >07LKM@026OBU'JUGJ]'H\1;*OX'7-;QTJ+U9#(3
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MCL3BHG7M$J;YLBN9N6%N2<+4@=2'8XI$WC0D]S$RYM>T13^@+*4(G(LET)-
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M4PP M/@ P 8 , & # "!^4WBQ<C?0/;WU?2',CP[YW8M^L=)]9Q1AVD3Z/\
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M$.M!SZ,'R0& # #;5T%?WUSB%YR6-]2UDYBN;?->V_DX_P"V1AF^CCYZT?\
M*R_J^6.S.SYQ'UR& # !@ P 8 , & # !@ P A[D!X&;$\WC_P!>1ED<XNON
M,57S3ZN\AGT.^*,6\W&3U8ER#Y3Z3[Q)<A=!=PAZG/C]?WI 1^J 997(GH^!
M"J>573\3%A,H+A@ P J#R\G,#C$$<$MS<8%U_4NE0)Y/,7-]4<6!5=&E#0Y
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M*_O1Z3;R0Y$,[>A:6B^KH:FIL2)T#:V-MI3A"WMZ%(4$A*C0HDKZ4F2)$Q(
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M]'^=?J=DWU).'7OYZ>CQ0# !@!L#Z*_Q_>./G'*/J\E^:QTR_1GE7Z+"^M8
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MM5H\1:'N.4*IC/8[+E3^N!$-+U$;M^XX A7GU^\;D,'<%[)7\^C#&M>(D^[
M[Q][5-QKPU.*=&K1KBCD209 21F7_0A-4(A;'7D7:X?&Q/PV5G[=[2%)Y=+)
MV^;[?<%;HH[>E4Y>Y'*77J*UI^DVW1Y6=I)-$-R+M=N2)$I 0,KW_P#3X=X
M:WT?(_DB9.T],K"J0W.I)8=<UXGL)@C,[?:TK"=2&FKXO>QZI?6A1.V1XM:3
MUG!Z?B(=2EHDE5II![]<5=G"%1(3 X,3L%M1:M?W/C(NK7K]?)YQC$SY/PRV
M8-PV1/3FSL=MSRY>-,Q<H$W]UE9*-0H?0+7?N6Y*4!1)[44:E7'-XU9Q*X:
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M?X_O''SCE'U>2_-8Z9?HSRK]%A?6L ;J_!V^F?!?TZQ^H[0?<KGG:/78, &
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M6+D;Z![>^KZ0YD>'?.[%OUCI/K.*,.TB?1_G7ZG9-]23AU[^>GH\4 P 8 ;
M^BO\?WCCYQRCZO)?FL=,OT9Y5^BPOK6 -U?@[?3/@OZ=8_4=H/N5SSM'KL&
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M[^FH_P"6#\BDC_[A9_JU?_.C/O\ A;.D6\J/#']*%V?[<,?E2C_P,]_34?\
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MO+=FS7&;B8PTN0Z>M:D,H5LMI,RXDIXB\PP+_AYJ'_&BY-?-Z*_[.YV7Y?\
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M$R%S ?$?W]W5R"=\" P 8 , *+/')J1V-(&-UXM+HW8S+"8XZS>R:JE47FL
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M(31 J1L[B\-J9R2IX=;<6+">XK:MM*-K@OL2FL;&:J(2JXY8,06.BED5,"X
MH]7G'&\VJ7U+:\'CYL".%9\J136'N</BS3.0P6?W,&57A">2,].F0V2]*_BB
M0-FJ^.\ZA,*7SF2RF75G*W%R;68-IR.PPL9Z_OYRY-1>;U^;EU>8;B-:ZGP:
M^#6O@UK7_3 J& # #P(6@ZV(6]!"'6Q"$+>M:#K6NKO>][^#6M:^'>]_!K6
M$!6ONWII$J_E_&.PZ_*,1OJ.=*"9 G(D4%N>!'0^1=H0<$J9R719&&N6.SI&
MG=OL>*A<5C!MM1O &J8,FG.&R4)Z?^GW] JS3E%/$E=*CE43<W&N*NJ2=/3V
MP538<(=4MWT2YEM;M%I_QXA\\2R8$?<:!?'$UM6-;<8W3B)$1IG;D]8R!Y@P
MZA<JL!K_ .OIY#^_)Z^/7KV28$!@ P 8 , & # "G?-;P:1KS\0^SLERZ.7J
M^)"B^3K^!C/^*W@)A/Y<F]KG[(7SCZNXA*.:77WF+"Y46# !@ P 8 , & #
M"-+*L/W$Q5<ZL#<W2^4F(P'QN*#DS;'2W8(W1L:5;RY/*HM<-HA46V[)WR=R
M=&T/I\;BZ5Q=$K&]KR4;,O -5D%:9]S"FLVEA)"V+%OL[JMJO*N9BQQV40 %
M-DQZ!R<B,L<QFL 4/UF5-=]5Z/E,1J$R(TM,*PG%S3>=7 C22 %?LR0)Y/7Z
M.77K]/J[>347I&VV"5]"JRCI$4@,;;(NP$*EJ[N>V$[!I0XN2@:MR='!2:(U
M8YNSDJ,&I<75Q4*G%>H&(Y6I.,WL6! S' !@ P IQS@>[&@M/HK?@-ERRMFR
MEY<VV+;!T2BT<FBI[IE$V/+-87=&-R".R,]Y:(*UO0+:<V:,$-TQD;?7JJ+Q
M5Y9WQ\0N:,)+5R:M>ODZ?OQ<?%QZQ!=-<>;YGJAZE%L*4%!1.TU2256[5=-R
M)5W)NY:J.4J$DE=F<T2]?QEGTA;4S4AOF-UA:EP,EC)E!:,%F*'9*\2A\"=>
MK5JX]7(9ER=''QZO-K+J+D&SO J& # !@ P 8 , (>Y >!FQ/-X_]>1ED<XN
MON,57S3ZN\AGT.^*,6\W&3U8ER#Y3Z3[Q)<A=!=PAZG/C]?WI 1^J 997(GH
M^!"J>573\3%A,H+A@ P 8 , & # #7ES7Y%.T":)!6Y3',8Q%)#!WE5*[TC7
M=IS>*[CI"!>IE<_8('%]-4HF$ JU"0T"NV2LEA5A((JCGD/:*L?)':3VWM+0
M%B+7X?;R='+R<8]NC.*YRJ5O%AWFUM\G<(^X0ADJ8P2"+1,(8I6)RASBPET5
MJI8&,.]81R8J#9?QT@UOOMV3^I@[%,5UA)IW)W%FB@09_?UGR^\N7D(_1Q$-
M@6! 8 , & &L;E45R'A?(N *Z>G,@/1<CF)'4\<@\X,8Y-QR9K-@Q4HF3[NS
M8B_&$R@ECGU,#FKV6&GGZ(R5?(:81,SH8\)9D,3<%BU:N/S>CEU=W+JY=?*)
MXX\\6$55B8I%*G!>Y/,6;G!IK2NBY6JEM3<?&AWZ\I^8J2[KQ>,R-,TO0-B)
M;AS+W0O->PX\FHH$[M%;MNVQT"#Y?OKZ_OQ\HN#@0& # !@ P 8 , & %>GW
MQF(+Z,I+ZT#ERYA]/@*'SRZ/$>7[QEH%Z-91ZR!@N8?3X ?/+H\183*"X8 ,
M & # !@ P IG:?(=-,3(]3_'Z:Q ^9WK75QZKBZRY"F<*ZB<MCM?E.,7)9WA
MJ8Y9'YM9 G.3QF:H*P-5-BYPJQCL"PBCG!!#A,CX$EZ_,9<7G$>4'04H<[$<
M;%L6*W36H(DFA22O2)U>@9M92A06H>'BRX*_V+![ E3I;'',<E2P^55RR7.\
MK)BWR9QLU'N/1. O;;$C 'JZ>PO=Z?3YN3SC8?@0& # !@!4/F=8-J5#6T<M
MBNIG%(7'()/F-==3A,X*MG["34;PC=(T[ORYK9Y!$WU V0:1O,7G4J?&F1(3
MV:"1V6N0DKSVJ6SK@DN/B]W3YO,8KA0%;\BI>G<M-[#)>'U,6"XZE\XK$*YK
MD*[MMY<5SLX.O&&2IW..SNA$-L%]8Y6_"[,JF,R6".CVI<ZQ01"S7N82AJ"3
MU=/KY/?Z=7IU^\;2\"H8 , & # !@ P 8 4[YK>#2->?B'V=DN71R]7Q(47R
M=?P,9_Q6\!,)_+DWM<_9"^<?5W$)1S2Z^\Q87*BP8 , & # !@ P 8 :S;.X
M"Z4VL9,J:][Z,,L]?(PZRU9*&QV6S&AW^'2.33DBPN+BYN$ N-+IR^RF4MMB
MUDX*FRNI X31XG2Y.X%K;'@=M!;7Q>_5U\6H_OYM7K+8! ZZKZK(Z1$*R@T/
MKN*)5"E6FC,&C3-$X^G5+3.RK%)#.PHD#>4>J,Z@U!H$X1FBUK8Q"ZFNH%=>
MOE&98 , & # #UEB-&XHU3>X)4RY N3'HUR%804J1K$:HH1"E*J3'A&2H3*"
M1C)/(. ,HTH8BS B +>M@'])4J5"E3(D28A&B1D$I4B1*26G2I4J<L)*=,F3
MDA 40004 !1))0 EE%A"  0A#K6@#]\ & # !@ P 8 , (>Y >!FQ/-X_P#7
MD99'.+K[C%5\T^KO(9]#OBC%O-QD]6)<@^4^D^\27(707<(>ISX_7]Z0$?J@
M&65R)Z/@0JGE5T_$Q83*"X8 , & # !@!"]^4=&N05<ND D#Q*8DM'VPOB-A
M0%Z/C=@UO*QM+FRHYE") GT,;<])&YY=6Q20I)6,[^P.KU%Y(VN\:?'=J6@(
M]0J?QTX7HHR]O#W<52<?F1%'E\1U6< JAF/'6S3+X:YOQLAOR+Q5U:6U'5;U
M=28JK'62U*RZD;+%Y34L<DZF:SF6]CE"=]_OWBQGZSX^77W=7IXM>OD&QC J
M& # !@ P _(P@DT1(S22C1IC=GIQF%@&(@[91I&SB1"UO91NR#SB=F V$>RC
MC2^KUA@]; /UP 8 , & # !@ P 8 , *]/OC,07T927UH'+ES#Z? 4/GET>(
M\OWC+0+T:RCUD#!<P^GP ^>71XBPF4%PP 8 , & # "DW)ODXGAJ9=754R5
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MYBPN5%@P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & $/<@/
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M"8,ELRO9^HA-D,C!&??7M&M83%6A#;1[#)8*BM.NC JFEJC4G;61UAK!8CE
M1/B2/CB,JD+A983KU>C[]G?JZ2XK]8$!@ P 8 , & # !@ P 8 , & # !@
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...R>O7KZA52MKBU:A_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g838337g77n88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g77n88.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MP'S>U_>G90HGX-/[S2GQG',O/[&]R<!\WM?WIV4*)^#3^\TI\9QS+S^QO<G
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MGFC (.]ZRK$6[=OUM]3*CB.S]GU/];K5EDJB6X3BA]Q,/_>)+_5#QD)_G/\
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M,TLP/,D<[<D=8.R" 31 R2-3$STM?O*=2M,=WY7($^D#=&G9(PR%7I0G5A;
MH=FJ2I3Q5J.6"!WA*><A%H1E%Y <A8_RC=C,+"^[DSD+>3??L409:J<4\[-.
M,%<2-YSA)HI&$G#\D7;R)R;81=A)]V?;;=VGOC'RPK/E8QS-S@3;.(N\UU*B
MX=/8)9<9%$9Q$WI4RMLC; NK/I8Y)MHWAB=D+FUKD3BL3J"3#"A#*5IE*<G'
MM4Y:A TCQF,H<XY(BYQF/)Q?8MF?<29V=G9G;]SLZR:ER*X,CQM(!1'TY(Y0
MX2 3BQMR'=^PA)G9V=V^KRL[-"E/\D;UE//GDEQCL>.5HS5Q7%5P2S:L6144
M@7S1R9I;)GR.%JYRZN"XMD M7>P53B2RLC$46TI5*$A0\.*L*O0)YJM<,=6M
M1%*4LLTD4K'Q8&(!8MHV9N6S<F;D1=KL^S,VRQX+5@\E:J2C$,44,<T+AR>1
MQ,B#>1W?CN[B[L(CV,[;D[K8-FN6R3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB810'=U7R.QWRBG...Z=D%6=J2::N;@9_F+$B1[X\7M4K<X-"098TK
M@Z,\FLY@>@(UQB=,-&W+3-'>M%)B32>?_7WL_P#LJD65TW:A3T)%JRI&!PB)
M.]?1<#>A&R,T5KQ=9;ZAJB5TXU/%DS!LA,D4/YR&*V!.EI[?(6"0-DF=7Y6A
M?=IT#DO6A*O)]]__ )Y=_P"'D75PC@78#X8NG=R6LWI[#LF9JI9<S/$HNV.+
M$]M"6[838#+"&)V5%LXV9G?ZQJRL:CM/9C,\N$B:8HW#:7]&I0*7B0DW_P#^
M=OD[//Y?]=M]EG4<Z>D.C4QJ"1HK"E(V>M:_H&&2".#+5$IK =..$JE]@P65
MNJ=&^)HN6O>;'FCE/)IIXB$G<5<F0MCM$WN&.9D@7OY5Y>7^/\-VV_#R;.W\
M5E%M<&8=;ZBP5;Y,GM$HL"Q9':*T2-I:#0)Y*X\=6SC-'DAY:H!H7:,QZOB'
MX"N..'GM\C42^1%KPD$+1A$5-_\ Y_'?\5F=2\8#JYN>8WJ]V 9-)K8[,[DS
M4L47(86<$D=#H*@]IPE$0].)D5800JLZ_AJR/.*F4N+L3"8V^N$H-? /JI_)
MO]7^_P"__P"=FWUJ,ZFX)IJR.@J-5:;A*(W%76K)@^MY\0;VU^FD_IR"!@4,
M=W*4Z=W!0VQDT*='84CB;:@ <[VQ[9DR:0M<;E,CA+D3=_Q]OEV]O_QE_9KP
M=52ZV)3;@+?5H'IRE<6G; SG0E*IC(Y?#)G6,MBCO9<=;I&R,-@K(:WU6PP2
M(2%G:Z^GY<(VD036<3MUBD&>HN3?_P"?C_W_ (]O:RP63=-U+-I*-UFE^3R2
M,I[B<[+V%2SH&Q*\+Y%4:.E[",<&*/N316#>&80X^;EZ,AU8Q)<E567,C'I=
M* B8PLI-]OJ;_P"/NWM]C+F13I_%PAY8D2&?O$IB@+(A\L5GR56['O$:B5<W
M&'D:VQ]E&YO$C OE=B7,TP,=DO: $1B3M#(<?ZK"VV8N:]_>R;^[V;?_ +?[
MJ[]S_='9?\#R;^4*LJWE;][?BK7\C_N?\%H[R=0+<)Q0^XF'_O$E_JAXR$_S
MG_A^#*4/)_'_ &96,RU7IA$PB81,(F$3")A$PB81,(J?S+AM7=A<MV+E5.0,
MLP''^/CC1""MY5#6.11\DU;9#?89,\3KG?:O:5]0"1J&-,22V:$%&X*C@.!>
MQC(,S NRQ4RJ1\@Y6&G>4#(2[(WCZ>P[;B^[$_;Y6;L^M8,E&*6Z-R3B?&L5
M=HC 2'ME:1I&=]]B;9Q\GD=^U1OR%X QZ_I/R-DBNQ72*]H;BU%^+ZQO;XVA
M7D1-IC$QD\O(E3>,QS2>T%:@R2F-^V@TM&F()1EF@5B$;LL$M;(E7"L+1,?>
MUL[3.YNSF1@(<7['V9N.^_:[[J*SC1LE:)Y7#OFH%1V8&?@P&9L;=K;N[GMQ
M[&V;RJ#'?I+QITY7,')\5QFFJ6&ZJRN\EF=JGASS-M/%<1%NAX(2@N10M+F;
M35KBE;27)- DA?L9J=]A7B+<STZ49.0.7(:956@_.@EK\FF-H^,IN?4>#;@\
MS;[/([[DW9XK=B@?# ]P;?7W<9XI^)0QE)O$#!TVG=^H,+LV[1MXK/V^-LRQ
M\KHXPA[?N3SQ85RK'<GDG5LCJYR;ZYIZL:33(2GJP6JR6^<2Y% D2=ALBPXX
M_L+42W21T86CUIMV[DNJ1<I>5*L%WST8C5&.!A>K*,K/)-+.[\8WB>,'D=RB
MC,2+D+$7;L[;,+,K/F.,BMO+.Y-;A*)VB@BKLW*5I6D-HF8991,1V-Q%W;ER
MWY=EXN'W%@KBM"9+&37VO),[R>2%O:YZKGCW4_'1JVD2-*%K;FY3%:H;$:-X
M5)A)UR\U[?5KFXC4.JI.DV@;"DJ G N6^^Y!-AD 1'BPRV);+[N[N[L<K[BS
M]C<19F[-WW?=UL*--J<9ARC,C/DY15H:S;,S,S.$+,S[=K\B=W\9V;9MF601
MWC8W1[EE97*LN5+5+I8].P*H5$-&UD%H&I)!9 _/Q#V2[A6#4*E#B8^C3&HA
MHB2DX$X# 'FB,V$-I6G*G%4X,S1S23,>[[N\@B/%VVV[..^^_P!?D5PU6&Y+
M<YN[RP1P<-NQFC(BY<M]W=^6VVW9LK,YBK+3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%&=S_='9?\#R;^4*LJWE;][?
MBJ/Y'_<_X+1WDZ@6X3BA]Q,/_>)+_5#QD)_G/_#\&4H>3^/^S*QF6J],(F$3
M")A%\3%"<HT@@T\DL]5LP*8DPT #5 B@;--T06(6AF[+*ULPS1>A; #6QB\@
M=;WC;V>7_1-_;Y/]43J$ZLD"A*>2I3FZWLL].: XDS6A;#O8#2Q" /6A!V'>
MPBWY!:WK_GUO#L[=CML_F?L1G9^UGW;SMVK^FGD$>BT><43L\T)!.C3 %^F/
M'H0@$E>?O7I#1Z +82P>48M!%O6MZUOR-O9VIO[>Q!'D!.+3".*"H.+--*3B
M,!HXTH@183C2RM[\\99(CB0FC"'82Q&EZ'O6S ^4F_U?6Z^N$3")A$PB81,(
MF$3")A$PB^(E"<)Y:41Y(5)Q9AQ2<1H-'FE$[+"<:63L7I!EE"-*"8,(=A!L
MPO0MZV,/E;?7]3)NV^V_;YOK7'1N;:X[/"WN"%<),/1:D*-6G5;3F;V+6BS]
M$&#V4/>P"UH)GFB\H1?L_9OR5=G;RL[;^3=MMU1G9_([/MY=GWV7.RBJF$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBC.Y_NCLO^!Y
M-_*%65;RM^]OQ5'\C_N?\%H[R=0+<)Q0^XF'_O$E_JAXR$_SG_A^#*4/)_'_
M &96,RU7IA$PB81,(M<O,NJKML3D;P4>J7>%,)4P>6\@%LDM$R %V-'X$B?:
M4=&= .0,*AW846P2=6,<;;#E3LE]$XKBCB0J#B0D&;*E+!'6OC.//J!788FD
MZ12.,[$_$N)/XK>,^POV-]2UEV&>2S0* GC<#L.<O2ZHQL4#LW(7(6\=_%9W
M?ROV=JUS<9(WU#JL<>!M9$$V=7511^!PS4X8BJO]LQYWD2J^K7472P6B,N,.
MSC"%B^KC8.IA3L^R6)L;.J<@N;.>].!;LC!LK18Z9LA+^2DF*63ID\O$F'O>
M)H"B\=FD9I>?,1 R)F=B86XNM73#)P_-\6TL4(QQ\P:+<7/OB9YQF\0G#>+I
M],B,!9WW;D^Z^]7J^=UIRF//-UUCR&.A==\M^'UHL<?L%D;GB5PU.YD<B8I<
MWLQ\:ZKIY)+6&%*UU7'OHXQ'WJ,LR!4HD$:<U["M.4965L?"!-!+6YRT[L1%
M&1"!NW>QP;B\T[@4C-+QYD)D[<"82;9(GR,Q@4\5KIQ7*,HC*(D<?)K03[$T
M,+2#&[PN7$2$6=R%W'=U@HJ-YO,$7C$CB#YRV3W905;]410S2M]8(I)'2231
M9<%+2RAJ];ESM!79IEE<VPQ,B20HD[<1I>]O**8,# \M,?; QYND>Q0(B$QI
MO!8FQ?(!(Q88^A,%B1V:1B"6$G<7??81<")B=^16=[WQ$3 KG7K0Y;B9"!.<
MCSP'7B9WC(3BF$6)F9MR=C$2%FXML9X^6'R4EW.V\:BE<XV[TU1+6ML,Q4A%
M'C#G9PY%M,#7UM4\D*1H1+6@VD5T2O7U9&8L*>5[&_P!<^;/+TE.6:RS'5"A
M!,$?&:P[1LS\MF:L\C2S#N^S]=C@^KBQ#*P[>1MG6EM'D;$!GO!7%Y7=N+\G
MLC$\4);-N/>[A8[-^1"4;E]6^TW-2MNF$3")A$PB81,(F$3"+1->,7Y=.O4F
MB_*N)TG-W6GN/4VJ7C^VK$SP<E6R6I;%9GI+R&E['5FVDUTG+4FE-JP9X)ER
M!T2)6M/02_9*%T).4JFWH("IMBRJ'/&T]F.:P3.S.PS1$+U@>7EM&7"(QX.S
MN7?#=K=C/SU@+KY0+@02%!6DAK,[.[.4,HDUF08N+O(+'-&7/DS"U9]F=G=V
MPWI[<?YK"[THA[;.-DYI)]@3)S92\J+/D-?IZ[;;D)LJ["'Z@F43SL29SMQ>
MS-!7ME Z*T2PB(M*,+>4YDZ5)D0KLE9C."P+V8YQE*B]2(9'E>#I0.-@N/:,
M+$78[,[.;OOMV.ZLQM8X[%<FJR5RC&_WW,431#/U9^5<>7EF(1\9G=GX#V<F
MW9G]!><ZND3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB811G<_W1V7_  /)OY0JRK>5OWM^*H_D?]S_ (+1WDZ@6X3BA]Q,/_>)+_5#
MQD)_G/\ P_!E*'D_C_LRL9EJO3")A$PBI[S*ON4<9HI5=P$#8"JD:[OK^*<B
MESXB4G#C-26(K4P;[<MS@G6$>RQ0Z>/D*='@T](XD&QK;T'9!9H"C0YM*N%H
MY87Y=8H)#K,+MXTT;-)TW9V[><8F+=K/RXK"O62J!#/N+0M8C"RY,_B0R.\?
M49V?LX2%&1=C^)R\GE:H%;]3-];J^JN57%5$E=%5JQUJO=Y6PE-'65HIKCG=
M5^&5)QS<Y @DTK*?YI('5M<HZ[2LF+H3E25-MW<RF_02D+>KS),6SR2A!*#-
M$3UQ8W(BGM05VFLB+@#B L[$(<W9G=F;?RNV#%E2:*$YH3+K"U@GCX"T%6>S
MT:KDQFQ&;LXE)P9]FY/_ -+/W4/ZER>.4P?-;<AK@^2=LJKE_>+B*#$(&QI/
MA7&GE'JB$K D2O#L<>"2NK8_QE=ZP:H]FGGH7@\PQ'Z=(DU:>+Y3,$,C,#S4
MZ[=3=R:2U4[X<G<69N(D)MMMNS./E[75P95@@<Y@<C&"[9?I[,SQU+?>_%F=
M_P ]V('\SNQ;[=C+^VEU100Q)R&2L''Z<+'.I(SRT5060/DC@Z>'6/)^'PF/
M^]!"(EOD9\JC[,A;Y(VOR5:YLZ94]HD3TV-"<UW(;R7%%BN;UG*S&S3%3:01
M&3G$%WETG[18#)W%Q=A)V%W%R?;?:DV7:-K7&M([P#=Z9$4;!*='CUFV8W,1
M9C8F=Q9R9B9FY<>7;BZIT$8;*6UA/*8M9@<XA5R:>6F_M!<9E+!7[X.@UO(Q
M1%EFV9]4*5B4,#1EH4\J)T%C-ESJS1W9VO7#' BGS3(432QSPDQS=.(7Y@4@
M]\-68_&%F;\H^_#\[@Q%MV;*_P"=XQE>&2"82"'J2D+"8QEWL]EP?B3[_DVV
M8F\7FXCOV[MTM6=2>-S])"S*NXCVH98=UV5*&$N'E*:LB:B0*8O4D<M55.U$
MU>),SQ.2)CH*O(9MJ?;)SDEE,?6Q-5YA2),O,K+BRC<^K<A:.&(2<_RIL/*8
MH6C8! C'\IXWYK,X%S;ZV5(<H,C!TJ<W5GF,6#>$.7"$9GDYD8@3/&^V^[NQ
MBX/Y-U:'CCS(C?(NSKRJ]#!)) 'VDI"J8UR*;/4-2RA\3(I-(XL-^W7Z)^53
M>/,+@JCWM./O3RRE,L@8W=J5M[H-8-6W),6S2*M%7E>09!G'DSQB;@.XB?'J
M.+ 1,Q;$(DY"0NSMML[Y56\%J6Q"T91E7)Q=I"C8R9B(.728GD$7<=P(AXF+
ML[/ON+7(S"6<F$3")A$PB815(YWW9,N.7$B[;LK[V-]LH!&V]T8MR!I6/S.%
M4KDK(T&F+F9N7-JYR++2N*@8$B5<G..."6$ ][_PBS*$ 6;D$$G+A(3L7$F%
M]F$G["=G9NUO*[.RP\A.=6E8GBX]2(.0\A<AWY,W:+.SOY?(SLZH0BZFU@4=
M5$]L'D7!5<_C#'8S\U5E/VJ K.)4EMNLXG6K!.9O+F3CWR-G/]Y*U=$'QP=X
MB5MBVJ;9&>@3*-[8PF .7;!\7'/+''6E:,RB$I8WD:X$,IRE& %9JQ])F,6$
M_&V<6?;QOJUK9:6O#)+:CZ@C(312#&](IX@B"20QK6I.J[@3D#<>P]F?Q6?=
MY9US\F:^;2AK=8)NN83#.<D/XV(988F:)UNQ(8^4$ONA<I,;$<R8W2".X6LU
M@??;0T$C*2M+ZSLA4<<'\$G#'(?FX.F!#)U#DH':<.V/IF-AH&;=P)I!WY#M
MN&[BY<F'CRF^<C>4Q>/I1AD JL>PR=4"K/8?=FD!XRVV+EL;,Q"/!RY\>C@G
M5GC5H0>,2B!<:;L>'R?6=!Z[KZ(KE]?,(Y:FL>I[(M^*R9+*764$1-.G)CM8
M2!)*V<;L:Z1MS,0$>C<=*TVSKI,.<4A!):@$8XI)9#9I"X=*:*$Q<!!S[2F%
MP+;8F9_)LK8\R,L0''4L$4DL<<0;QCS:6&:<"8W-@;Q(2YCON#NS=NZ_C9U3
M!NR.U;":N.]@R"F87QGXM\AHN],3A&U,T=P<E7MU94;+(HR%Y.VPML9,;7E9
M(9&4-:V1YG@$X?7,XQL4Q$Q\/B=GBC>S$,QVK=8Q)B:,>]18G<3V\9RW%A'L
M<BD 6[6/8.7Y=:1JTA0!4IV@<7%Y'[[)Q83%B=A8-B<R[6!HY")^/%RV.T?:
M[/>=20*VV%.G1M4\8$[XF1)9)%9>2B$88:G4HM22$O#_ !AU&C5D'ICCFMU4
MA+.*,3J@)%Q*E&GUL\)5YI(2W=XR<7=P,'?S/PD83'=NWM9O.V[;.MI7F:Q#
M',+;-(/)F8P/;ZG;G&1 6SMY1=_]=GW92KD*F3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A%&=S_='9?\  \F_E"K*MY6_>WXJC^1_W/\
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MJ#2(.>X5J@CO:TS 6PN84*<4=RD[CU)0BRDLQN?39_--U'URTOG?RN !8J
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MSIFAS8)2:3(%C*Z+249:8E<4K>3M&!84[IYNO+?#J_ V\E0QM2*W=GR%*AD
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M">+;B9[@9\>F/-8S4<:9IU8L4B$F>G=G;)$[)6?UMH(+5KMK7 T"1O(*"I-
MG(+-6'$A4*S0GZ3)]&FA3*#- *%SO<MT[B-::^TSI74.6RF*QV?RE;%=]8N&
M.U=>W>D&M2AC:Q(,$ 2VI8FGM2#,U>!I)!KV#8(BV.JLA:PFG\GEL=2J6[./
MJR6^E:-XH>C +RSF3QBYF0Q ;QQ"X/))Q%Y(Q=R:18]1JF7L\Q,8)"E3OS#:
M3? 69'(7M"S(7HIP32'U9,G/4 !ZQ(UJYL0)D",DPHHX)ZH8@!"5Z0OO<#W&
M9]5XK59X3.5H,WA>Z10T1B:F=S%+$T\O%?@SW>]>":P ]\9^Y=QU&O1J121Q
MRC-9(@88^I%S^0UI%B;>(:]CY)*-[3,^<N2X^E-;GIG!)0ZDAA&[]/'PP69Y
M)YC$B!PC9B=RXE7M6!>A5*4*SUA.K1J#DJH@P8M&$*$Y@B3R1Z\[?D&6: 0!
M:\N_((.\\*M1W:5FQ3M=>"U4GEK68)")I(;$$A131&V_8<<@$!-]3LZ[V)Z\
M\4<T+1R131A+%((BXG'(+&!B^W:)"[$S^9UQ_3G_ .N-_P!H/_CD'6E_2R?^
M9>]2=./]&'_B/N3TY_\ KC?]H/\ XXZTOZ63_P R]Z=./]&'_B/N7=1Z526)
MNR5]C3ZZ,CNC%YR=P;5IZ90#6]Z\\L0BQZT:0;K7FGIS=#(/+\I9Q8R][#O;
MX+4NH-,9.MF=/9G)8?*U"Y5[V/MS5YPW=N0$0$S20R,W&:"5CAG#>.:,P=Q?
M#OXO'92K)2R%&K<JS-M)!8A"2,MO(3,3>*8OVA(+L8%L0$),SK8[3?/C7_)&
M*YF[_P"0D,V84O[/^[TSZPD!_P#J(U6Q@W^W80%LNM><;GW]W)OEN-_EL-W6
MZ&WYD0ZPPM;L^INKF<) ._G*6UAA?_E"/$-XTB^?=7=P[;JW=(3[^4WPUV7M
M_P#MI7I'[?,,5TO.Y6_(*V0QV2Q^6M*5]C#PW/K.M#YR9Q:U12M,9O7D\\O9
MA0A>C/*WOS#TYN@'D&>4LXL!@=AU]_X'4.#U1BZV:T[EJ&:Q5L=Z]_&V8K5<
MW;;G&YQ$7":)WXS02,$T)L\<L8&SBWSY?Q][%VI:61J6*5N%]I*]F(HI!\Q<
M29N0%MN!CN!CL0$0NSKN\W"PTPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M1G<_W1V7_ \F_E"K*MY6_>WXJC^1_P!S_@M'>3J!;A.*'W$P_P#>)+_5#QD)
M_G/_  _!E*'D_C_LRE2RZ[BEMP"7UG.&T#M$YNPN$>?$0O-"8)&O)$7ZPE-$
M$>TK@A.]$N;5H ^F0N"9,L(V$X@L6L:U6BN5YJLX\X9XRCD;Z^)-MNS]NQ"^
MQ"7E$F9V[66HU%I_%ZJP66TYFJXVL5F:,]"["^S.\,X./4B)V?I6(3XS5IA;
MG!8CCF!V,!=M0G31Z;3SQDM:V[2M<A(Y2".OSS7],J]!)&6JB1@0&.%DD%!&
M?I$KE#8I2LB%/LPM<U)RY2A5!,+<"AYQ^F--28NW<M6V8I(S.M2?L[8?^:SM
MV\7E%Q 6W9P;JB^_)MOD_P"3G\G>YW-]4:JU-J@(K%_'WKF!TA+L+C+BB82G
MU$ ,Y]&7)UI(J<$;DTU6-LE!*Q#.)+S2=1:"S9PYT<J5J"'2I:C4W/,3DRM)
M'G92F4%"7BV$T@\E(,HTL6OVA&6,0=__  WGZ2Z NTPT5I@#MU@,</38A*>(
M2%VC;=B%S9V=OK9VW7D_=.HW3[H.KS"G:,"SMXA,*\I"3/(^SB3 [.S_ %.S
M[.J7_P!W5@_ DR[L/?\ ['.O[_H^FU/M,/\ .N%^;LAZ#<^S3?R*5Z+=+8H>
MXJUN9@K&0/3U6<P99BUM+Q&9*%K<%K(K K(2+Q(DZ=7I*<,&@F[3G%&^;O?F
M##O]N:O-Q8O.8C(XB?(P0PY&I-4DEBL5WEC"87$B#F1#R9G[.3.V_E9;C3]C
M+:>S>*SE;&3SSXJ]7O0PSUK/1EDKR-((2=,1/@3ML_$F?;R.I!@5P\A(3=3I
M>"N#3*9R-RCUJQD"&6MTW=$2!LM>&RR%N1*(\W>UY)3,BERU6T)]*/5PJDR?
M1Y9I.S0#P+V(P-S#Q88+M2G7BL8NSSJG3B.27%VZMN,C%O$=YCJ@$I<>7$BX
MNSLSML,?F]14<[+GSI7+UJ6KF*G"Y'>E (<Q0NX^48R=^H+01WI#@'FXL8"Q
M,XN3/9*I^=O(VIUC$H;J#,<"F&BJEHQ.),7<$/>36NFI<\3*-.XI1!7^-R(H
MIY<GD])-8N0X@C<K:2$K>XHMDE[T/GLIHC3^4"<9,XT;SYO*9LN7S3;A:7+5
M(:=B)JUZ"Q [PQPB=.RX=\592.2,]W;;J</W0]2X<ZY1:?:1J^G\/I\7'YZH
MV'APEV>_5F[\QUJI:%IY9R"_4&5JMR$0BECXMV]8GYMWRABW*./)>/@RE_*B
M37+()BXFK+T/8VH-VJ3#I 4FK0V8;K%T=HX2:,F$REUB)L@81^8J,6+SP^=N
M\](8$[6FISU /'3%;#UZD;-@QGD?"BS0.61:I\Y116'9GNU8K8P3MXK" ]BC
M#76H@IZMKQZ:?J:PMYRU>FYZA*M$V?)WLL&*>\^)FGJL[MC[DM,K-9^)N<I#
MN\?<DN3]]<G8)$HG-JDDC<\L1D8.?I,U.]YJF^5*(A$@PUG4ZK-[ESI5455G
MMH KGE9%(:UK'![$J7IU#>4Y.J1?FZ>T[@--WK5JGEZLD,S61@K2AA!DJC;M
M=]RC\XPU8LG:$9'Z<(6K<HQP\8R:1XXBCUVJ-4ZCU70I5+^%M1SUN]'L6X9=
M0E'<*E2:C ?S58O38:G(4+=2Q)2H0R2V'.0"A&6:.2%H-,K;@E*7O2""KWA:
MQWVJJE4_O"R.2;3LR"J>1/$C: LX222T8@N:EY.3N/KI"C82"BMIME&;&+>X
MNUL/>S.$S1Y6N$V#'*!!"%JKTIFRM>&O+U=R<V>,81*/@0]KORW;;;28^[F\
M?@=0X"/$6#KZB/#G9G.I;ZT#X:S/:@:#B+!M*4Y#+U!+Q6'AQ??>R_*3F;R
MY550R53*J.41IO:YQ&["/7L8;;="/;D=@2^OBV^-QN5OK]&X#$SVQ;I<&*0M
MN9FA*Z@/6%DC,6J-[YW3.D]/Z8RDV4JYV.R<E*Q0:.<L3&71L7@OO)9LU88+
M%ZTTH.#VKDDTI1.(.[, KJ=6ZWU+J_#08>YI\ZL<.0JY(I*XYJ4>^*N.DQHQ
M5*MRQ9JXVD44G4:E0B@@"5B,1W,M]?']WT]^")?W:>?_ &6=Y\Y8[T^E]J@^
M(O-_FS)?J^]]DL?#5F:EX+7]:'JSBKB+M!8P?YAGMN4L[FF5*"!?M](UL.B
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M'ROZ%S-9"E%J>I?U'M\_7*_='P$5G,.(%&!9&8-4M);..,SCB.8B.*,RCB(
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M@/V$#[TZ-_N!/"]W/OU\7JK,_P!/3L8\C_E^5WNA/ZBQ]$GY0'["!]Z=&_W
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MK8 [%K$>"81(BAE81/ID3QFPB?\ T$[MLQ__ (7[?]%F-/ 1"(S1$1!U!%I
M<B#;?F+,^[ALV_)NS;ZU#\=YN<69,ZV,A1W=6J)IK.01F+O,V=IY"V^ /#]*
M8H.9(VN*S V0;9W]:A9R%FGE(F/"I;5C>X)SB=^IGF F*C;!HW>"5RE$C:-H
MY'D$1/@[F''D+.6W%_([.WG4 WZA/+M8B88B$'D*2-HR(PYLP'RXD[#OR9GW
M9V=OJ=2V=>-*IE<L0*+@JY.N@2)"Y3E$=8$3*5PMN=!IBFU?+$PW8)T=1.)B
MQ&6A5/ $9"L:I,!.88(\K0H>A/L#]&7:1W:-^F>QNWE8'V\9VV?=AW=ME,]B
M!G-GGA9XV9Y&>0-XV?;9S;EXK/NVSEMONWG77,_(GC](4SLL8+TIU\1L,;',
MGQ4SV;"G-,RQ M2)&9*G8]$]GE-T; K -*-\6"); J0"(VJT:'8=5*M8%V8J
M\PN1<!8HI&<CVWX-N/:6W;Q;MV^I4&U6-B<;$!,(\R<98W80WVY$[$^P[]G)
M^S?LW77QSD94DRL>)5I"I4WS1QG%62ZX8S)8@N:I+!G2&PB91.!OQJ65,[BK
M0*7 F13)J3%)4OIRQ@)<=F*"C48B1W%5F"(Y9 >-@F" A-G&1CD Y!W F9]G
M$'?=_P#3SJ@6H))0BC-I'DA.<#!V.-PCD",MC%W9W8C9MF_U\RX2+E5QM7'6
ML1J\*T;]T;-4E=6T<_2QJC2."3->C2K4#(]KY"H:T19JX*D2)&K3J%#>J>4#
MVP$*S'R/OK<W'J66Z/Y"5^^ >2%A!R>0&?9R%AW?L\KMMNS.);<2%WHURJ[S
M-WQ$W>\C13<C$6C,F9V$G)V;MWV9V=V<F(=^0DS2)+[2K*OH\@ET]L6"0B)N
MIR=.V2>7RZ/QJ/.1ZMO5.R4E ]/+@B;5AREJ0KG-.6G4F#.;T:I:6$29.<8"
M,(I9"<(XI)#;M<  B)MG87W$6=VV=V;M;RNS>5U*<T40L<DL<8/LS&9B N[L
M[LS$3LS[LSNVS]K,[^1E@ZWDA3H2V(V.3:.V"6]V?&:B.,KR21:5@CTRE9:@
MYL2242%]T%I" A/L]2G%LUU"0:2:G;%(!^74C5IO&Y 4?&$I_P H)ARC#RN.
MX]OF9_S?+N[*-[4'BN,@R\I@@_)&!\9#WV8]B[/)VMVE_HZBH_GEQO24M4UX
MN$Q UL%WZ@(ZTB3H<RH+*DY5AS:.0)I/;(2I>2W)Q(:GF4-JF2FM@EP&1G L
M<5&Q%I]@'*U"R\\T#!N4'4ZIMN\0]("D+>3;9MQ!V#?;D6S?6H7R-5H(;#GL
M-CI=$'XM*;2R!&+M&Y;NS$8N;MOQ'=W5R,PEG)A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$49W/\ ='9?\#R;^4*LJWE;][?BJ/Y'_<_X+1WDZ@6X3BA]
MQ,/_ 'B2_P!4/&0G^<_\/P92AY/X_P"S*QF6J],(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$76O"#;HT.K8$S1(G%M7( G"#L>BMK$IJ?1FP:V'8] V9YVP
MZ$'8M:\GEUY?+E1?9V?S.S_]G5";=G;SL[?]V6J6"=)RIX!QWJRJFHQD66=&
M77C"?9-K2!-*I;]O8]0-M0RTGJ'-3%+I6^E0N)313&%:<$4CYZ2+H%C@G6JF
M9?I"43O;R9>:2S+,_)HB:UTHAX!TRL0G$QN0 /4,&)GYEN;LVW)MW=:>/#PQ
MU8H6XO*+U.K,7,^H-:>.8@$3,NF$C@[<!V!G?=Q?9?2V^F,.SKMG$Q0V-$X3
M5\Y=SI@-HC]:[(M.+2,/$>2<0T,5BLZ3RA(S-]6$1J0!G9L9U%0JAR=$)O(6
M)T"O:I.ARO2@C!XCDEC'AN4OY(Q[\&XYG&X.[S<AZ?/E^8^_E2?$]:>0VE".
M*0G/B,7Y4"[R*DP!(QLS0L)=3AP_/;9G9G6/TWTPI'$[!@TYM*;4W+4<6M*#
M3ESA4.IU5&H:^,]?<2IIQ?9VXQE?9;*2-/*\R0-,\<W-1M2E"X-ZIO1H20"1
M*DUT^5$XY A"<'.(XVD.9BD$I+@6B?D(!V-Q>-F['V=G=_*RI!BC"2,Y3@-@
MFCE( @< )HZ4E-FXD9^,_(9'=^S=G%F\CKHYKTH7Z92&XS5%LP5)%IJJOU;#
MR4M6*B9<</DER!K"^IFW6S(A3$]'.F6&*:X^R-?H43,R^A:7C2IS&(QN"E5W
M1Y<8QAVADY!WNQ_E6X?Y:O+7!X1X;QD;2\Y'=R\8=F\N[6'AR,IG>>/B??/3
M_(^/_FK,5DVF+F[2#'TN$;,(]A;OY-GR)_Z7KZ2Z3B0U?;$2K"1RM5S34)W=
MFK).(TE+RFL6HYNP,[B%,\H!*T$(;*T<8NH.),(5[)DVW:-C85S83HVP<J.T
M8RPG*(=X[L4K[?Y2*:,G;=GV>1Y6/S;CQ+DS[JXL07*0XIPB(^_^T86\ER6&
M01?8FW:-HG!W['?ER%P)F6?<1^G],^,]AP:Q%UM,$K5-+1R=C\Q9BXK*-E.;
M5R#MB'7$WF1R02*>O[^B<HE(X<F;G!=*3Y:IE#8X+%)YZ!V_Y:99<R(6HI(F
MA(&<JI 7,.QZT)P/R$8Q%V,3W9@8.#LWE;L4M+&G4ECE>83XC;$QX'VC9G"<
M>)%(1,X$&SN;FYL^_8_:NILSIWS.13BU)O"Y_4:<<KY21SE3#X]8%/.4I9BY
M,9QT>>.DZB5D ;IXR@F$=.;W$F?P-6WI&%PC,P,>MNFG\IVTI1UBR0#'#&<<
MVP52J&4<S 7'OD;,9Q.\9<"[.G(SN3$&VW'96RXPSDFD"2'Q[@VP&2!R'EWJ
M560)=I&YB[/U(W9A<3Y;\MU+#KP4;G"B.$U#J9<@D+%Q&?X Z."V5Q<ET*L5
M)!:'L6G22#&8U><D9C5+A-T<F3 ..=R6PIG"VE[4&B)7E0C?=K%ZQP<2N#(+
M,![=)Y+$4_YVS.6S1N#_ )N_+?L\BF?'L]?'U^;$-(HB=S#?J].M+ S;;[#V
MR,;?G;<=NU^U0!4/2W5U1_=2%!949]%7VN!ZIX*:H,:T DSUP^;;=025[-"2
M]""!QLT5EHC2UBK2M6T^PA!7GO&U)0DV1-EFFZV\1?E/G!FWDWXM=>!Q'\WR
M1=)^QMF+EV<=NW&@Q#PM#M*'Y+YN<N,>W,J+3,1?G>67JMVONX\>WEV;8&'I
M.V$A8*8C**[*R=$-=P*B*LD#K(*;=SY ;$.-O)UXY U^Y5ZN!8QQ<*E4J:G8
M$+LI0I*?&UUTWEN#2D;B% $"*3YWBY3ET)6>22Q*+#.W'G:JM7D:1NGXX@[<
MXF;9VY.SN_E>-L-*P0!WQ$311582(H"Y<*ELK,;QOU7X&8NT<K]K%QW9FWV;
M=[FB6_3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(HSN?[H[+_ ('DW\H5
M95O*W[V_%4?R/^Y_P6CO)U MPG%#[B8?^\27^J'C(3_.?^'X,I0\G\?]F5C,
MM5Z81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*F_/V\GSCYQ.MF<PL+
M@HL]W:T%;4\W,K<O>G]RMRTG5% J_+8&%J2KW9_=&^0/R5] S-2%8X+TS2I*
M2ICC?(#>=CJXV;D,9[=(7>69R=A%H8F>23D1.PBSB+CN3LS.[;NS=JP<E8*K
M3FDCW>5V:*!F%R)YIB:./B(LY$[$3%Q9G=]MF9:96GEF_2V'</*[O_E=;7'<
M4#G7,BE>0UH/<@6<=YS)GFH(/'I124KFK98C>D=&Q\F,-D4%E@(W)F@3BZ/4
M@7M>TBU0>,!NZ>F('>EKU(;/4CI3UHA%K,8C-(03A&\3NSB!C('('V818NQE
MHVNN<=*.S<FJ].2]7LS$3U9#*",3KG(,K,[%)&49\#%G<C<=G=U>_?,2\J[Z
M??":Z)HXUK'K;O!RX^0.P)I>:)>PPB.BLQF6;<+$E#<R/,-TW&C+1HWY0A"Y
M,;6$Q>>FU[*3"*&DP.\J\N1O0 TI0P-8DC"N[%(72)MH@<F/?RN+/L3]C/XS
M^78=_6(L;0GD*()K#UHY9+#.,8=47WE-A*/;R,6W(6[=O%;R0E$^J_94SL'B
M9!VN/U2F=;Y;*[:YBPJFU_"8TOMF+[79HS/(3('"PF5QDM?.)E>-\J0-;+7D
MJT*-.XT3U8$><S6DYPF/$11QVY"*9QKO(X$SCVC$T+G'(+1DP2-U'!W*0'Y-
MN,1,Q,T$>8EDEI1L,+/9:)C%V+=BEZS#+&3RBYQ/TF(1&,_%=V*07VWB>&]1
MWD''*4@MWRAVB-Q6"7PKF,[D+8Q+A1N"HYP7RNI2GC%L_B:-]:HRU2"N6B:N
MCM.%8W"'%MS8T.B U;%&]4N<$TQXRN4\D ,<,;WAC%R;D?3:I/-M&;BY$,I
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M$G"3ENO0 G.+4D$*"MBV4H)+.+V(LPH6RS0!,!L11P0&E"V$6M[+-  P&_\
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M?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY
M?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9
M:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)
M[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/
M!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UG
MZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY
M ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[
M9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A
M)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>
M/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4U
MGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/F
MY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;
M[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/
MA)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@
M>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4
MUGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/
MFY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.
M;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U
M/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'
M@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA
M4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3
M/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT
M.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7
MU/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7
M'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*G
MA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U
M3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_IC
MT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]
M7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS
M7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*
MGA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9
MU3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_I
MCT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6
M]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?H
MS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^
M*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q
M9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_
MICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?
M6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?
MHS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:
M^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[
MQ9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!
M_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ
M?6]7U/A+)(I_:2.IO'WE*Y/,KJ&=("# #/CTEJ5D0MBTO6];&4<IABJ*/97G
MA\NM#3.Q(@[\F]>7R>3<4O<\TU(#B$-J G\DD5N0B;_5FG:8/^X.I8>ZQJ^*
M1CDGHV1;RQ348Q O]'>N\$C?P-EZ6N"W64J#J.TQ;4"=6$NH.2$9K&4/#S6J
MEVTZLDN9$K4<2OE%</9Q*-2XI$1II)CU&W%*6]L!:HH99[\VDJ7H'F.IM(6]
M/&$X2=]XZ61@"RP<#BD?=QBL SDPN3,_"07X&[.SM&3L#^SZ-U[1U6!UCB[Q
MRT,3R25'/G'/&.S%-4D=A(A%W9Y(3%I(N3;/*#/(L7SEEVZ\7_49M>1VQS!N
M0]]<%2I#7\I=:JBC>>:,Q,QQZ!NK@U#0MQ8M[TG3+Y![>D:@L'^$QT?'!3_S
MG[SZ,TC2CI:>QHQBS/8KA=E)F[3DMBTO(O.XQE'$S_\ 1&+?4OD?7F1FR6J\
MP<I.XU+<F.@!W=QCAHF5?B#/Y&.4)9B;R/)*;_6J/YTBX]6IX1\91<R.4]/\
M9PS75="M=[=6;4T%'=RS3#[,B[[)/6-QW3Y&MN?I_8OJ?HO;C?Z/UGUCTAGH
M?0&ZS,Y+YHQEO(]'OCO4!/H]3I<^4@1[=3A)QVY[[\"WVV[-]VW.GL1\_9FA
MB.^.]>_9#C[XZ77Z7&&27?I=2'GOT^.W4#;???LV?90^=(SCW+V#D@AXI]1N
M'\A[IXOU]8-FV)33QQOLNF%6XQ5BS2";^RIC)Y(]LJ]P;U^RVQ&6A3JVY6YJ
MV\M0Z-[>LTYE\Z&JK\,F.?*:>EQ]/)V(*U>X&2JW6ZMIN4'.&*,#$2'QBY.)
M"+$[ 1#Q772:'Q<\>6#"ZK@RN0P]6U<M4),3;Q[]&D7"QPL3321D0%L \6("
M,@9S$2YMKNMGBN7!ZSXD2^"2&RK)FG*&/2%R%7ZCCO9\#)87YJ>F1F:8Y7$S
M?R#V3D%M\->/(-VK,D](TK2TK8K+&K<T@=[^KD^M9RL4\=>O#C)(QZ[9"K.Y
M@0&9R6(8WYT.##^99V<Q=R;L$MN5NX9JU3"3UI;=NQF(I3[U?%7*S12!)&$<
M52Q*SQY3J/)VG39QC)A MR,5@5K\3.4%$GQ=-<W'FYZN/FZHMOAP)S6\MC?V
MG<S=EA T,0G1J3A='G0CB0F,Z,1KF4(XD)J0&S2]"GJY3&W6E>G?IV6A9RF>
M"S#+TA;?QY.!OQ#L?8WV%]GV?L=8UW"9C&O"U_%Y"F]DF&NUFI/#UC?;\G'S
M!N<G:V\8[FV[;CVLNZ<N$_,AF:%;^\<3^2+2S(9.VPM:XN=(V4@2I9>\K4+:
MT1E0-5&BO1/CFY.C8V(&P>M*U;DY-S>04-8N2DFV#F,09M&&4QQF413"(W:Q
M.\("1'*S-(^\8B!$1MXHB)$[LS.[2'I[/1QE*>$RP1C,-<C/'6Q89S(0"%]X
M6VD,S !!_&(S$6;D3,^(2;C/R,AEFLE+2VAKBC=P28I&?&ZM>JUF+=8,B(<?
M6/43V&'J6<M_>25>T:P*<UM0*2S1HUA8!;&E/"7-'D<?-6.Y%>IR5(W=I+(6
M82KQN.W)CF8WC!VY#NQ$VV[>=ECS8C*U[D>/GQM^&_,PO%3DJ3A:E8]^+QP%
M&TLC%Q+9P%V?B3?\K[=S,>(W*JO9O$:TG'&V]8I8=@&&$P*$/M43ENE4Y.)T
M#9Y$.8E#&!QE!R?T@ J"6-.O,3C%HLX(!_X<LBRN+G@ELPY&C+7KLSSSA:@*
M*!GWV>:1CXQ,^S[=1QWVW926,'FJMB"I9Q.2@M6MVK5Y*5D)K+MMNT$3Q\YG
M;=MVC8G9^Q]G5E*'Z;5P6C#^2DLLU'.>/P:&XLV1R?CC?8%4R%*=;#56SA[(
M<X^QC?'**&MB8UU H;CY,0ED"=O6ICDPVM0: 80ZZ]J*I6EQT59X+_?V4KXR
M0J]J-VJE8'F,A],96)V#8FC=XW(79V-F6WQND[]V#+3VQLXOYMPUO,1#:I2B
M]T*A<#BC>0X7!G-G!YF&5A)G9P=V51NSQ?\ Z2M"O[C;@T;=!?IJ=+W6<TT.
MUR=E)5'IJU#MEUN=%>@7(C_21?VH#T*M*;YWF'E"'M>_Z/\ F?\ .U/\GV6_
M\S#_ )5]W;:SX_Y#M$F_*\>UG;ZG6C^:\GO4;YNO;Y#_ -!_E+'^=[&?_*?D
M_P#,]A"_Y'GV$S_6RR>6<0^5D$GT4JJ8\;+VC=F3P"@R#0!VJB<I)A-0)"1G
MK!1"/&,>G23:1$EF#6^Q$R[U/11OK/HME&:#'%E<7/!+:BR-&2M!MU[ 6X'A
MAW[&ZTC2<(M_^7FX[[MMONRFGP>:K6H:5C$Y**Y99WK53I6&GL,+;D\$73YS
M<6WY=-BX[/RVV=1Q/ZDM.J=QL-H5Q.:Z',&3<EBA4YBKY%#Y%'O7U;7I]9B'
MQ"A.<6@;B@6HRW%* Q(:>E/++-%LL7DG@M5;74[VL06.B?3E>"4)6CDXL7 W
M BXEQ(7XOL^SLL2S1NTNEWY4LU'GCZL+689('EBY$'4C:01<@YB0\F9VW%VW
M[%(C7Q&Y4OE6FW>S<;KT=J<(0JG4VT6VJ9PM@06A#Z72YY^U2=C,9A,J'9!P
M%KN%9MM1C*,+4JBA@$'4!97&!::D>1HC<<F!JI6H&G<RVXATG/GS+=N(<>1;
M]C.LH,'FI*;Y&/$Y(Z#"1O<"E9*MP'?E)UFC>/ICL[%)RX"[.SDSLN3 N'?+
M6TVQA>JUXP\@9XRRIF>9%%WJ(T]8#^SR5ACJ\EI?G>/.K9'U*!Z;FAV4IFEP
M5MBA42E=5*9M-$%:H)('2?+8JL4@6,E0@.(PCE"6W7C.,Y!<HPD$I&(",6<A
M8F9W%G)NQG=5K8+-W BDJ8?*68YHY)89(*%J6.:*(F"62(PB<9 C-V B!W9C
M=@?QG9GQFM>-_(2Y9))H=4E&VY9DLA0%)DQC4$KN6RI]BFD:D]$I#)&IE:5B
MUD-+7)E"#T+D2F.$O),0@ )6'9.26,A0J1QS6KM2M%-MT9)[$44<N[,3=,S,
M1/<78MQ=_%??R=JBJ8G*7Y9H*..O7)Z^[SPUJL\TL'%W%^J$8$4;L0N.QLS\
MF<6;EV*?^<'"9QX5G<:$CM.3IBX\A.,-;<C%C<JAA\+6U^JGXG4I37ZY,ID#
MZ>[K(Z>U&$*7DTIB,5&B$68Q(!DB"+!PN9',-D2"%HAH9.SCF)IFF&=J_!VL
M"[1@PC(QL[ SGLW_ #ENMGJ+3QZ>?$#)9><\IAZF5('KO7*J]GFSU29Y9'D*
M)P=GD=HG=^QXQV7$FG"^0D0#B2]TQ_?->%F<GXC8,F-JEDXPV]'U4>.@9R U
M2BKJ4K$#@V<@4&V8]Q>GZ05HD/;8BF:Q ?-E^M%& 0YB-[&5"YWG2K8R6O'W
MT>3J2-(T[%L]B(2$J!<V  CLNQ3.?B>1U;8P$K5<))C_ )PR-S,0VI7I1X>]
M$43UG%W&I.0F&4'IN<DLM,7"NP;2[<FVP5+P?YFK5D(;TG$_D<H766UJWROD
MI5+6(,^9,R!.F6+W:.%ZCOG.K<B1+4*Y6M2>E3ID*Y"M., E6)CC<A\SB!:8
MGRF.8:Q,%A^_:^T)D[L(2_E/$)W$A82V=R$A9MQ=FQFT]GR*N(X3+.5L"DJB
MV/MN]B,6%R.%NE^4 1(2(AW81(2=V$F=\,A?&7D;8UAR&I(#0UPS&T8B8M+E
MU=QRMY>[32)C;E.D3AJ41M&T&NT>]16B"C5[>$J(*=6,"8W8#QA!N6;(X^O!
M':GO5(:TW'I6)+,(0R\FY#TI2-@DY#XP\'?<>UNSM4%?$96W:EHU<;?GN0<N
MO5BJ3G8@X/Q+K1"#G%Q+Q2Z@CL3L+]KLR^)7&[D,=;&J&+HNWA7<(S9?]T/]
MW$O#96MA2;<!#%"1-&I& D#=K;B-0-N"0!OUM<(S236SM5?(T&J]_/=J=Y>7
MOOOB'O;\[C_Q^?3_ #O%9N6[EXOE[%1L3E'N_-K8V]\X^3O'O2?OO\WGOWOT
M^KMP\=WX;,'C;\>U3'7_  @NQ3<]55G?-97[Q]C%D68&L3IT\<;[9E[BW/I)
M7K+JWQN -+,@D-AR9K2[+5F0Z+G&OAR8T"@LK1(@C%ASYJDU.U9HV:%^2O6[
MZ: ,C4A$H]]A*2<S*.O&3L[--*S SMMONL^MI[(/?IU,E4R>+AMW.\WLR8F]
M8()6;<PBJQQC+:F!MG>O"[R.S[LVW:NB7<,>03_8<_BE(TS?-W16)W3.J38Y
MS'*%LUN#(I/#%+DH$U.<=/95JZ%38Z+(02Q[KE_5!E,1;C3@OB<H*)0HU(.8
MH1UZ\MVY1I2S4X+AP2WJQ=..9A;D,G,1FA:4ND%B-NE*3-P=^3,HRP&4EM68
M,=0R61A@R%G'QV8L9<#JS5W-^!Q/&15[#PCUY*DI=: '?J,W%W4<MW&WD*[V
MRJH5LHRW%]W(33B5]1):[EIUDH!)TA:]0)="P-.Y"C)3MYQ3@>H4MY1!* TM
M<88%*,)N\@LA0"JUX[M0:1,SC;>Q"U8MW<6XSN?3+<F<69B=W)N+=O8L0,3E
M#NOC0QUXLB+NQ41JSO;%V%B?E7X=46878G<A9F%^3NP]JX5E<?KXIE(@<+>I
M6V*M;G5X?(\U.-B5W+H8WNC]&3PII$S-BZ1-#<E<'1B4""2\(49QREN,$$"L
MLH0@ZW=7OT;CD-2Y5M$ !(8U[$4Q"$K.\9DT9DXC(S.X$[,Q,S\7=6V\7DL>
M(E>Q]ZD)G)$!6ZD]<3DA?:6,"EC!B.-^R01=W!^PF9<Z"<:^1%HL2*4UM1%Q
M3V+.+N[L""40^M9C(HTK?(^RG21^9R) TLRIH,=&2.IU#\[H K-J6UF(-<UA
M1*(L9VK9\CCZQO%8O4X)1 )"BFLPQR-'(;1@;QF;&P'([1@6VQ&_%G<NQ75L
M3E;D8S5,;?LPG(<0S05)Y82DBC>62-I0C>/G'$+R&/+<(V<R9A;=3'=O$-?
M7/B_&JF<+7NJ:<D:(KZV2(</C=:M:OS=*)LE4J5$%KY!)DBI7>#"VA3"]E6G
M7R8^(2PK1JAFULH@S>L2GE1G#)2VFJTX<=>L5'F^<:MB,HH'%FGL%&[#2D+E
MX]6P[30OLQ^5EG9#!E6+#Q4CNY"QEL;5O-7^:;M20)K N3UJHS"3Y*,-O$NU
M&>"=MWC[&6>\>.G!>MI<Q:5X?W;%K'XL2*Z3)*)G?[0J>2IE)#?&X=(Y6:Z-
MD8?E4,,DB(XR/^R##T#T00C4*_/,.&:G$D-Q\AJ&E5Q%S+4I:^3CI]/G'6MQ
MNSE)-'%Q*6-IFC)F/FS$#N3-V-L^[96*TIDKN>Q^"R$-O#2Y!YNG+<I3,[##
M7EG<PAE*N\HN\7!W&1F%RW=W=N+P->/$GD)Q^(,D5C4Y;$6K5PE#O&X99\MK
M:5Q.&SCV>K7EH%K$\.R$+4H]N-R UY;$J=R5B5MGGK$1JQ&4)5O.I96A?=HZ
M]NK+9&())JT5F*6:#DP\AD "YMP(N!.XML783,[[+6Y'!Y3&,\MNA=AJ%,<,
M%R>I/!7L<2)A*.0QX/U!%Y 9C?D'C"Y"VZC"L*CM2[96G@E.5O.;4FBM,H6I
MXI7L5>YA(!H4GF>N+_9+ B7K0($>C2]K%QA(4B4(P"4'%A%K>9-FU5IQ//;L
M0586=F>6Q*$,;$_D'G(0CR?9]AWW?ZF=8=.C=R$[5J%2S=L$SDT%6&2>5Q';
MD7"(2+B.[<B=N([]KLKI\8.G-9MX7!>])VP9,N-,WHWC/9W(UQ8K!JQ[^T;J
MGKO[/;31DZ-OKQ"G!G3R4M^],CD^]N*<@I+Z0AJ<BU&AE:?):AK4JE&Y5Z.2
MANY*MCA.O:#I@]CJ;R=0 F$WCX;%%XKN[[.0[=O08?2ES(W\ECKKV,18QV(N
M94H[5*3JFU7I<87BDDKE&TS2;C-X[,S;L!L_9@LWX7R)/!^)CK3&KFO&RN3D
M)FTM-JQEXQ6]'ED?/A9B,Y6@KN1K4#@WW\VA9S'!Y>I-6J0]IC"9L&%WV7I0
M68&>',1O-E1N=YTJV-FAB[Z/)U)&-IMV8K$8D)4"Y\0".R['*Y>)OL[+&L8"
M5J^$/']_Y&WF*]B=Z4>'OQ%$]?B[C5F(2#*!TW.22:F+A"P/U-M]U%3WQ6Y
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ML/#&0'A9;2VB"Z5PH7$I3)8UK$BEI+4Z-\F8U;.8NQ4J7'O4X MU^^0":W7
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M,=BO3L30LX_GMU(XR%W#RGL[\&[2V95]+).-. G**,,/,,"2606 0SC#ABT
M!0"PZV,9@Q[T ( AV(0MZ#K6][\F9[OMVOV,W:[O]2U;,[NS,V[OV,S=KN[^
M1F93U:'%+D[2479)O<?'FZZLATC-(3L<IL&L9E$&!R5*21J4R-.[/S,A1;7*
M4I9BI,A&<%6>E -242,@.S-8-;*8V[(<-/(4[4L;.YQ5[,,QBS/LY.,9D7%G
M=F<MMF?L=]UL[F%S&.ACL7\7D*4$KLT<UJG8@B,B9W86.6,1Y.+.3#OR<6W9
MMNU<F9<1N5-=UVCMR?<;KUA=6N!*!2DL24U3.&&%F)G41(&E2*2.;&F:24[N
M)01II//5%E.GIBMH!J-##O=(<KC+%@JD&1HS6A<F>O%:@DF9PWYMTA-S=PV?
MGLWB;>-LJSX/,U:HWK.)R5>F;"XVIJ5F*N['MP?JG&P,TF[=-W)F/=N+ONI6
MH[@'R*M.W:;KZ;57<--PNUK+I^OU5L2^GID3&HLFNI\3-$,D0PO),8;W<AZ(
M-4.4>1@?VX$D3I#MMZ_16AJ"\6[G<?6J7)X;52Y-5K7+#58K<+R2O2C<YH_$
M>4@<'9AD?IETW=N0[]BSL;IG*W;U"K8I7Z%>[;HU2O3T)VA@;(2,%>5^HT(R
M-(SN<0]4.JS/Q+;M6#<F>)MG\;Y];[.OC,ZD-3UC?MD\?6F^5%>2"-UU.);7
M4DD3$>D;7H[;K'$TA7I(VX/!D232AW<FY,0L",Y46A/59-CLI6R$%0QD@CM6
M:%;(%1:Q')8@AL1QFSD#<9'C$I!!I7B 2=V[&Y,RQ<OA+F)M7HSAL2TJ>3MX
ML,D]66*I9GJ32QN(2/SB:4AA*1X&FD,&8NTF%R4*6%6%E5(_%Q6U:]G%9R<Y
MK0/94<L&)OT-?C69U (UK=RVB1(&UP&V.18!F(%X4^TJL !B3FF!#O>LV"S6
MM \M6Q!9C8B!Y*\L<T;&#[$'.,B'D+]A#ONWULL"U3MT96ANU;-.9P&1HK4$
MM>5XSWX2-'*($X'L_$MN);/L[K!LF6,I?H&UI'1]S5Q:D5<%3<ZQ"4-ZTP:0
MX9(US*K$)LDK&H$7O0AM\BCBUU87,CR^12W.*H@7[#-Y@Y.E'D<?<HRLSA9K
MR1]K;\3<=XY&W[.4<C!(#_40L_U+:87(S8G+8_(P$025+44K\=_'CY,,T3[>
M4)H7.(V^L#)OK7O!SY=7VHO%SU*F-1'>H5S<:E*#39YO*B]%R-&$G2<LMI>+
M'D+PRC()"$ "TRAH7H5"8)8=%^KFE^C_ ,'FY]+Z<)CP&%=GY-\UT!=]]_&"
MM&!-^\2%V?S.VR^.=71E'JG40F/%WS62-F?_ *)+<L@/^X@,2;_1V5)<W*YU
M;0.C _,<8ZG?$I]DCRTQYC;II*#7!Y?'%&TM2$HRM)L0 Q8XKSDZ1*6,\THD
M SS@!$:867K>QC#K?-ZO Y=-Y4(P*0RAC80 7,R?OB%]F$6=W[&W[&78:!DC
MAU?@Y)9 BC"Q*Y22$( +=Z6&W(B=A9MW9NUV[77I:=;!LF*1KGQKG?9G :)\
M1[#IFZ6&):X]R^!1SD1.'QV>!FUTRI#JN7-[[)UCJRF+BWUE=QN8GIV4I$BY
M"L9U<A /SD*]>67!?,E;/2Y6O<IR2_.$4\F/@C -K!NUIB")@/CTS#CP%G<2
M$VC7KDEJW#%J;_$ES3,&#MT,A' V+GK196S(<F]6,7ID,DQ21N32QR.;R&0B
M0D!2JOW%R]^/M?N_0<<+'L*OV,YGXP<M(6U2E\>&-4TU1:\QW%6V$.DS"<J$
M7&]K]C<61"H>0I"@*G<DXXU.E >L3[#*4;\X:X&O7G/GDL5,40!(QVJL3&4P
MP[-O)Q\4R8-WX@[-N^POK,/DL76/N;%;M58R##YRN$TDD9!1NV.@%8[&Y?DN
M7CQBY\>TV=W86<FC%^27-QHX&674W45OB-6?=-P\V>-\MXQ1YTO!GNN5,Q46
MM"*O-E6VWNA+Z^JHM!G^'IWY" Q4:UEHSG(Y*Y-S.X2G1*O(C>GDL[6M:?HR
MUZ=3#9&+)2!2.G$;RUI0JU"%P!I9XYGC)V;FY,+.)&,6[84HW\1IJY1U3DX;
MF0OZAQ,^'B+(AD9@:&Y!)<O ;22%#6EK]46<N'%SV,(SG9BL=;7,^;(N477?
M1,7)UV)B<;XC1A5Q^2M]LBW'F"7DU/' [64X22^;;6N4!<W5Y5&JX4$AX$]G
MGN!IHG0H*@O75</"^,T.1XP'EDRLC7W*I^4DB>U)XMS<.1Q.(@S#/N'!F%FX
M/L^UO9^P&9[I(Q9@V@BP<)8Q@O/THK#486<J#-+P"9CDD)RK[2=5W-WYMNNF
MJ&=-=V3KH_R21\H7&/V\T\ N0)CG)6FQ:])MNQIX1N$M[)3R^Q+*12LF&R>8
MMJMZ-W(75,7)_9J![+;'% M<#G,J^W 5*#5L<>,&2H6=H<8SKV'J5X'ZQ';&
MO7>)YHH38-HQ?I<B#D)"+"]E&S'?LZ%FES)17@TQD^<HVZK7;=EN]QCH%:N#
M,T$U@2D?JF/6X!(P$)$YM*2J;QQL;^DFBFIT3K:55GU )@38$'?>6[?RJE=4
MI76'3E:F36-<R^0NA>G!R+TD<5Z!,I1,+&:I1LP4R-Q2*49.,T$A%JMX1FL1
M6<#"]><,26+BM.,T+.]>FT8/Q%W<6)V(Y-B/DXDSOF%8B -#C8>"I/4U/.UJ
MO)G!S4U(3@LD+6\@4I^.;<3,6<8HW<8]A(7%J;\4>:":3\R.L5/N5\X%?%60
M/C]RACT*K"6V E11R65E'K:-4H:;K72E4)K;6641YK):TJ&,HU 51"D3D)(Y
M*##1J-OE,.\>(TC!BX>\;4]_&R36HJ[E)%9DJ,Q7+.S<B..0G)RE=MG;CN+,
MVVAPNH!FS^O+.:L_.5*MB\S%7ISVA:&>G%>=QH5-RX#'-$# (PB_)GY;$[[O
M:N(VM2P^IHS<O@WI$Y+5',G@#*8CPY)E=EQ^OR^.]PIT$"(%Q[4/36G7IJ%7
MG($\C(CDB]A%*2WJ2R-E0I)/(TZX;OJY:ES_  V6)[QECM8C/139AXJTECYP
MIN4[_. @;B5\=WC>6/GMPBC,GBC<6#=07<>^KX\[\Y0RTL_IB># ]>W%5;%7
MQ&LWS6\@,0XTG!I6BEZ>_4FFC$9I6)SR&&6J[U=9/3OIGD%$:LJ-T;^7\HLN
M-(K&Z@ROEUR#A$?_ +F+097MV>7HZN2(G%Z@E*QS0;0:<+D$M/D:E*%+$E!I
M*XYBCEJC9KZ@N4);5L2Q$=:0J^ ^::$\G?=8P  [X>62W$(OR8:;,T;.[RLS
MCSE@NG2MZ5Q^3@I4"'.S6XAM:H+.92M'WA<CD.0WJ-!#1G<PX<K[D\I#Q@=V
M)XO)=SRO^U>0O*.XY+:%ER*R0L%F6/&H,<[O9SLS1F#HYT_F,D<A:71QC8R1
M1*2;Z5M;&0I.VZT<-266,T\PXSU3!T*N/QE2*M6CK<Z]>29@!@.29X(V.29]
MN1RN[;$1NY=FWD;9>):ER=W*9F_+<N2VVBN6X:SR2/)'#6&S*\<5=MW".%F?
M< C9@[=V;=W=_9GQ66QZMYKQ8]J6N1:5-NG!]MAT>Y%6'S)KJ*UZZO0X,X'#
MHRM.'4(%$F54JC"9)Z15*ITS2%X:6%&%K=GT^1LC>>=Y!E&DLPY3C5>K<'-'
M,>/KX>Q+8$.N+=^V<O,TI,TKOV10'&!R/R"-HS)F][PI15;&&Y7FNX\].C!'
ME;6>J0U9#[V)_FVI@*_0C=X6;=YK,<L@1MPDE>6,'?4VR<FY?5G'/^SOP2O;
MS<H$VF7O/M7M%HM8 H^5[-0\EZ[0HD5K-;<Z)M@9/L[)IF5MMEA(6M4UN3P(
MY.:GV<(/4R8V*SD.Z!/8HC.34:W>,LM?J/R+&V7)ZI$+[GU(X7Y1/R8A#9V?
M9<5'EYZ>*[EE>KDCK ^3M?.4,-KI-P'+U!$;H ;?D^E-8;A.W!P.3=G;=6EG
M+Y);D@O5>I'@I=\-KGED[=1;=PNJUAN"/5'([(X]"B<61@-AME#?H^E/:VB9
MI)"]/PT+^0F3$&N!#BJT*8)4;GK8(XJDVEKN;I36,4&GN\Q:2I);CK9#JR/^
M6K-'([$<)1Q@Q1N[NPN+?D7<=Q8DFOU]:X[3F1@J9N357?YE%?BHRVL5T819
MX+?4B8@CL-+)+QE9F9R8GWG89-6O7UEP9?:/"!0MM:&71+VK@33[/8MAP63M
M<L8I+8"613<4J>B75J.,*'I\=#3WLCTP$YYJ-Q3*1)RP'@UG3:&AZ-7-,-6:
MG">>N'7KSQ%#)'7>.#I X$V[<!9@?;=F<7;=]EQW=,GZ]W3KE=KY"P&FJ,=N
MU6E":.:T,MGK2,8.[?E3WD;?9W$V?;9ULYX9V97#99']G:/<K A+>3#*$YTI
M)@<NE;$D*B:MVKI<0U)9*8>O+ Q*'([>B6\ETVE,6&[T6F"8/>M9S67K62K]
MT%AKSD\UW!E"PQ2.\K#9%R>-F'QV%NTG'=F;M==A@;=0+?<K<[5<6KXW4@SN
M4T8M YTR8&F=R;IN;]@L?%R?L;=5-2<X[U%TG&B1&<J["W<I_5F(9E3N.WW?
M^\;=1;@PI6-M$IV^?:(NNOMB44X;2:$&-^OA"G\ST?\ D9MGPE%M5G&V+K]Y
M_P"%G)@[T#O?OOOCI<MN'3[XZ.X[_P#$X[O_ *K2#J+(OHF.9\U:[_?6S 4G
M?\G??>/>SS<'+J]9JO79CVWZ7)MO)V+8K908_,^7G6'EM/6:MLB0.PN&):/C
MA4G)FK>,9%PL+;3D!V^SUYY!N1 I*ACD!6J'L;PC@LQC1!XBGQAE1ZTR3-Q)
M'/5NI#B-(PW*PUXP^>'?(V\;:R3TS*Y/P@&@+]-Y+ L# 5B&5V;A)$PM$3OU
M-MH[&<UY/1N%;E/Y@8<31R]+#M?B#'U>I9DRAL\PQ5G>1S&M/"+[2QSN?6!A
MRRRKEK)TY:3%@@-YU%6E_7MT7H'5O'>[B;B3/L/:;A33BTU[U#VR^ESBO<U$
MG5EK(8Z-<L=7(V7."!G0207K3N8@)5QUZED<5#)/1MV:%'6,]K(4GIN$Q5'@
MK"$Q4&$0:(=IA.$!:(2,H^P&)VFMWZAYNQ%5R-&ID\CW/ZM+%9!K[20!?:S=
M.2N&3(R)YB8JYA.9O.0@$OC'Q8HN3ALFMZPZ'[?R8ON)VW/(1SNGZ*<6<3::
M.R6-H3I/M(<CCCQ;"E>H12)=#6Q2B8G=:8ZK$[(M2F1D*XT#('>9#][V;.M"
MQM&6K!-@Z[P5N]7K&;NT;/(%5A8HQF)GD!N#.8NTO%N:PQ[[J4^YX.7R4%ZS
M7U+:&S<:Z-N.-AZSC%)><G&4H <8S)S)HR;H\GZ:HW?'(]\K#IU=00=,7<J@
ML[EW7%O-62HKFP=Q^9O%=+V-M=BW1K51UU2OQL5<'=B:C/:S<9IM6C2 3B4F
ME",*'NZ&."SG\#WY2:>"'1%%MK$'4A"P,I X$T@N'5$)#\0O&%GWV;RKGLEE
MI*>E-3OC\B]>S/W1<D3%4M=*P=0XP-C HC:7HF<8/U ?@6VV[L[L^PJ=73!I
M9RWYCQ*NN0%:UQRIY#=,3C[&J'NERL!DBZ4V?-Q<M56#%$ME)E>BH_.'_P!-
M$34YA*TE[0"8 .R4 36 H1.@@I3Q8G#S6*%BQC,?J2_+>I#7.1V@)XQ@F>L[
M;R01[2L[.+@74XOV&^_3V<A6GSF>@JY.G4S.5T?BXL;D3M1PCWT+3O:@&X+_
M )*S+R@<78FE'I<Q[8FVUD=71KM9@Z8G3%CUX7 R7K:C!.>2[++K%8)Z&T4*
MY6V25.D1QXRPP*%9<M<X,U@00E[<BEBTLAX8%K8%<MTA];.Z/2A53U)J62E4
M.C5DAQIPUY(.]2%BB=WD[WV9XAG/E. NP[A()<1Y<6Y#7 78M(:/BR-Z/)78
MK&8CGMQ6FNB1#,+#$]IG=ICK!QKRDQ&S21$/,N/)XEA/)N=43T%&EHI:Y%M;
M63,.H0_QN5)85+"F.P%%8NM+N#HY$;"W*R9(W1MU?8\PIW!<DTF3KPD::5"D
MQ*L4I#\N;&PW=<F=RF-BM%I\)(GFAYUVLA= 1?QA>,I!"21Q%]W'\YF9Q9VP
M:^8LXWN:QQX^^52W8U1+#,U>=H[3TSQYF;>(33!$<L43&0[,6W3=W8G%]K-1
M7#4Z&_\ @BSH[7KF)VO*>@-$Z8HJ>/$J9$[57W)=T;&L4?;7)[VI-3Q.5!;T
M+VC)+7#3.0AFF,)*8Y:])DBCF;=.T5#.&]6Q+5BU[-=O0!$;G8QHD[2$$>V\
MT3D0$_%G'9NH[L(.[=I0O4AR6F8QNU8;LW<R@Q^-LR31L%7+G''T@.3=V@FX
MC(+<MC[7B87*1A>$N,P.3]!\O^EM7G.WF?7L_D,;L+D3*TM.OLL@EB3JB65V
MJBR6_4CL/D.F<WEQ5MT^4JFW4:B[S,%Z )!2=*WEE"CH$B/+R7S;?Q&IK&#P
MUB".2OCXGN!%/7AO&%JN73KT'$!8J[,75E"$2W=W)WZG(M?B/GG&9[1M74FH
M*MJ6*UE9AH2SUK5G&QG2M@TMK*,<AN-IR!H89+!#LS"#-T6$:K2SD?)[FZ7?
M5?;K=NM=8LGUS3K)YKAIFT[^T+LF:U5I,X7,V M;JY*5*2/E-J< /58VG*9D
M#>7L!!*=-L>M[*+'QT]2Z6*I3&O%\SV0LG#!TP<FJGP:<Q%F>3D_ED=S(O*[
MNM-/EIK^CM:A>R!6YO\ $%.2H%FSU9&![D?-ZP2&[M$P"W9"S1B#;,S"H[Z.
M;PO?N-G4IHFD;$8*OYJ7#7%/@X_/3I.&RMG^21^+2Q_6V?#X1.'1P:2F5]=&
M9:D2F$DNK>:IVO0.AIY"&/+')LR=7 (9'3EZ[7DLX:I8N/? 82LQQR2P@-6:
M> !-SC Q<MW$F;B0;.4@B>+H.0I,3JW&XZU'3U!?J4/FR0[(5)98H9Y2N05K
M!G&T<I1DS.S&#ER W=AB(PO?2TFM:N^35DP3E[S'JV^K5A?1LOJ#KSD*N#^O
MU0YNJV$*VFC9?;+8: 5NV,B.*<G)6N='A^?3QKC''2Q6)Y./-TER*K8QM:?$
MXBU1JSZOHSBSM/M:$6F8[L50O_25R;B(B 1AL+#LS S-T>.FNU<Q;K9S/T\G
M<KZ#R5<G$J[E2,WK.&.GO!L]ZT+L1D1R2RNY.?)WD=WS[AQ9=<-EM_V>12XV
M!"6]/#>-W,]#+SULK8DI,46N=<.Q#:CDAIZ\L#$J<#A!)0IW024U6:()9 #!
M[UK(,M6LE4[H##7G)YLAARA9HI'>41M1N11LP^.PMVNX[LS=KK*P-NH%[N6.
M=JN+5\5J 9W*:,6@(Z<C TSN3=-S?L%CXN3]C;JE5:\EI3<O3 O,=YW:NL.=
M)>I_24CC9%BSSV])&UA5.T+5/*R-I'YS4.#;%TYJAS,&6T%$,3=ZRX^B+3A4
M*_/W%G&Q4]2TN\:35X'TW=CD[W@X1D;!,P#(X"PE*^PMN;N9;#N[[,N?IY:;
M(:.RGSCD"M61U=CI86M6>K*$925GD*$9#<PA;<W=HV:,.1[,W(M]C%M3#^]R
M[^N-3/$BXH7%.85ONO#EYIV3-=IQV!.EB5U#:ZK/5@QFO++,?&U F6H40)(V
MO)25[1A$*0IDJQ00G]<6-O/5(>]*6BK>5J32XFH.8"W$562<:]B:Q9[WEL5F
MC(G$GZ9 [@6W3(A9WV8NKO6._LCW1:&#OUX<[?/ '0E"[#6.U5KU*??4-6V\
M@"Q"/6"1FE%ORHL3BW(AB"CFJZE?(Z[(I=O.I!R5Y-UAT\(; BJPHVQ*9HN9
M6$<L?'9P>>-;[RJ=&)<O=WROE 4SW,;$8WE).5KC*6EV<)1I0T.C;O,NG3;'
M4I:6$+'8VSJ":=[-ZM<NPP;1@(9(,6$@B 6.V.&N8/ (QD(Q;&)+7XX,@^6R
M,.1U(.6R]32U>MWGC[5#'3VG*0RDQ$F:.(BDDJOM)/:CD:P1SB93L02 K>L5
MEU\GYD=(Y^>Y;6T=-BW%CF+#IR%/R%;KR0061)(HS(D\%DEX.\A=39>^-2W:
MUJ$ZKG@Y,Z.I+E]GQG-@4^\U1UK#X?5D8169&ER>(F@=\>5(IXRF<GFCI#&'
M2C(68F!@9P#CU&8MUOHKE5L_H>62>I%T<-G8+&V4#(C6E&&,6KS9$Y3>>0"W
M!S(W8S8^GN.R\DW3#GY5:=03B'*ETR^P;"1?5;(95(CW\4::B(NY2AM1O:60
MNHE2-*5'5B,T1#R6Y'A:S$0C-.&MIM&;UZGJ2![.!RT0P]>1Z-DHHVCZAO*,
M1%&\8;.[R,3,X<6Y<MN/;LO$-'VFJ:GP<Q6.]HFR509I7EZ(-"<P#(,I\A%H
MB%]I&-^#COR[-UZ +.NRX>,=5=?B7-MY$Q>Z95R4I:449)X[;4?DLP%4%CWF
M]EQXZOG5HD+NM;2T%02GU$EM:34SM &Y1I*)*P+6\L*;A*]*IDK.A(BI/+3B
MQUV*[%)4DCA:W7HQ\VG XP$M[<7+D6X3DV[/()/OZ=<R%_#T>Z9..1:#(39>
MA-CIHKT4UCO&WDC:-ZIQRR$'&C,X\ =CK"^VT1"VW"XMRJ)6;5?0+0S#D\15
M$S2V1U#Y',;$*DD$<9\URB23F9NK6E=5%B()2RLLBL]:K$U-CY+6-6K6*GOU
MQA])(C6E2&[)Q35K.NRBQKVH7KZ?CAKO'.,!Q1P0@;@U<HC..L+<R"(V%A#:
M3:-C968::"Y2[F8SYAJ5AKFJI9[335BM!/+9L& F]L9HXY;A/P"2>,B(I-XM
MY7!U8*W)6E1<8^/49L5(U5O8<-ZR?&Z<R2OYGS-:.7EDQ6(GKFP@R=S^<>WG
M!OA.G90XG*SXM'B&B+Q]K=&YT.2)7.3.IBC7U(G+)9"2NY6:\NC\C!'8APQ8
MFO+*W)V@KP=,2FXL+,TLCG+(0D#$X1 S;6].(XC%16Q"I:KZ]Q-B6M8S\>=M
MPP.0-WS9L=4QK-(Y.3P1-'!$!@?%CF-W\ZW40E4 4]6+D-,7D]OE]9!Y2!>W
MXQF4)7MMD$.2O[0I?"4!Z,TY(XDKFHE8G+]"<,H_8_,T+]N\] T_%.VE\?"#
M%#9^;& .;.!1S/&3 Y,[,XN).S]K;LO*]4S57UME)Y'&>G\\]25XW:0):[2@
M\C"XN[$Q Q,VSONO5JV2:Z ]0+D3R.=^857NG3ZNWBP^-O'J*!Y!1=1%9*N)
MK"*B0,\-J(V0:W'G^-.[7*W=YDA;(AV:4Z'(1N!KA)%C2G\O**G\Q8_'!B+(
MYZEE +(2]X2-+$W?,O(YK;1_E(Y *( C<RV86?BPQB;^TA-?_P 3Y7+'GJ9Z
M7R&&E#%P_.D+PRDU.%QC@HO+^2DBD"<Y)6C'=C<>;E*4;0QQMM,B8<;^F3->
M*K+$97&..M,1-DN1:MZA>N(\!I"UXX2A,L]9R#IQ)$I0NGL:F[TE=G=4[^P)
M*L>V1U7FEL!34ZE.CGF9&J\.0U)#DSEBDR%R4Z8MI_YVGNU9.356Q]QYHA@E
MA!Q!AZD; 8"W/F+@.OQ-T9\3I"QA8Z\\.+Q\$=\BU2V#K8V]$P]^'E* P3%9
MAL2,9O)TYBDC,GZ+ ;')R.+=HZON$'A88+34VJU/SDO&S"7WA_S><Z+LGBR[
M/UF.SDML>6L-BM5)M%X5L[!6KI?!E2II !? G!I9U-9B6)E")$R=9J,P\Y[D
M%I\)2K/'E\(%VMDQCK +5H9*YW3I61V:*<6)]IQ,VL\78GKAKOSG7?IUZ%BF
MVH\C;:7!:A/'6\,<MPS>U/%;CQP9&I)R*>L1 W*L01E4<A<1I3*I[Q\@O'/G
MNF?+O:^0M?(>L#0LX?9.ZN43<I5;=>M+U7;M8CUMLC*9L;9B 11+^T.4EC+&
M0PR=2E/>$1!*=R 5K<1P7Y\C@W"D5"=])78 B$91BJ6""P%>/E([E#L[QD,<
MA]2)G8'=W'=<_-:Q=;%:G:3(AE:PZYQ=F28R@.:]5CEJ26I.$0@%CL:6,Y88
MFBF<7D%F$]ELB0'7?*>474EN@7,FM[DXB7+P7N)\H*JH=>:*<Z B;X)$"DD@
M9ZG;UZI-!44$*,?6.2R8"5 !T=YHWA/$O<7]9[/YTFIQ8S3M+YHL5,M3S=0+
MUJ:B\'C%/,[QG:(6><I_R9QQ[EQ"%]N(QCRZP"R$V9U9D/G^I?P5_3EZ3&4H
M,D-AF$:T#-*%$3(:S5FZL<TW$6,[ [N1RDP:^(KRFD<'>_[.U!(9?JJ)0 N)
MQTJYHU&['"R1L6E\MBS(O1VFWMSLG0&D CYKBD*1RXL1*!&L=!IBB/7%@S-_
M)BXYPU_/-0:6=Y97IR25W.3Q8)3$JI$#DS]3B[E#VD[!N[[#MR\&9EK2=RRM
M!DW@K-#&U^&*WTXO&GAC(;H ;"[=)S%AG;81(^+-R+>T$-GL)LBK.9E.<:&E
M#9%S,G55Y-V7/:WKCFJW<*IM)8,\SJ4"A-KLEB(R#03Z -2#3,VC9$KD0W%K
M6E.[$Z4+6QH(5ZR:O/7M8>WD2>O3/2^-K06+.%+,P13A!%UJIUGV>"<RYES<
M7)V-P?82-QW%>S7MTM04<3&-O(1ZTS%NU4J:A'3UB:M)9F[WO1VA9VLU@!HP
MZ8FP,4;2-N0 Q?:R[ID/)5HZD=+<9+&X^U'U!GYHXMIE[W2?)P]R#;,6K(P9
M$K;8YR&E4$HO:Z;QJ/G*HY.RVE+MJ;-GDLBN3#"XNA;72O2#&GIVYDJ]^U@8
MRR;L%W&\>]9;+?DBDQ\4][C#(;#)!R?D6W4:)N(.5;>0ERP:LQ^(MXNCJB0,
M,)28_,.;7H:?9,$64FK8WE9AC(HK/3'@#NT13>,;!J/ZY4F=GJN>F@RS2XH;
M=UKPSC*]QBVYI#YRU6$2KG;6Z1EO>Q.<F:UBSVRX^O(51"I_4&"'(U254] .
M4A5[/'U>BXQ"?49PTYJ56;)C+5AF@.N[0$!D'&(A'@.SL[1LWY-G8-FVV7$=
MT68Y*>D([%^#(W:^(EBO6(+,=IBL@< R<YHR+J%R$F>5WWE<7DW?ENI^I6U&
MY9TP^F?-)[92.45!QHYV('+E?"W"S&Y8Z,U0)KCCQ$$;Y#6:Y_\ ;\RBT?V=
M'G-IB:%B>"&YE3IUJ5N2M28Q4FP;=4FU+J.&"N\5O)8,@Q4S5B$3ME4DZQ1V
M1CZ<,A[&)RE(#D;N+DYOL^RQUT2TAI*Q9MC-0Q&I /-USN 1QT&O0M6&6F4O
M4L01.\1A ,<C#&S$P-&SDUS[#76Q5$\ZLG)#EER<@=F<#.1/'VXXWQHAZ>^8
M[8;-9D@GRMM.HUDJVN4$A<S6)WA,9TNBZMR2-+5HA:MW(TJA>U)%\@;]-7&K
M:@TKCL5C9ZV<QV0IR9*9Z,E<ZT<#$UX[5@HP8PGEVE8',W=AZ3LQ.,9]!:*]
M2LZVRV;S%:WIK*XN_#B(&R45J.Y+:<'QT=.H,IO%)6AY0N8@&Q'UF<@8I1TO
M= ZP&FL>9MBS%UDL?B@VKB;?!S,YR1Q:VYO'("$L;6-",(G<XE&K5*%276R&
M\7I!J_1C+T28'S@YV.N:YVL17A&.25CRM%C&,2(NFY2,;^(SNS,S]I>1O.N
M[FED*>?MSG-% X83)/&<I  ]5AB*,?RCL)$[MV#V\MMMG6Q'IN\D9+R4X-\F
MH4Y2647_ ,WY;R7C,]F$9=N91O%.Z+2IAL@D48HH;&[J=P*%3Q'J]?6E[ ?
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M*.6?.:W>7Z&K(O,8Y5-95?232^-%44U1L%)KRKH."4+$CA)UK2Q>T'EP-<I
ML0(E#DK<GE=L1R<1R<"<Y8X&*XL5A:F)*U)#):LV;I@=JY=G>Q9GZ3.,0F?$
M!88V(F%A =F?9]V86:;-ZCO9T:<,\5*G3QX2!2Q^.K-5I5^L3',01<I"<Y2$
M7,CD+M;=F9R)RIGFX6@3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7/
M:G1>R.C:]-2@2-T:%Z-T;58 EC&E7MZ@M6C4  : PH8B%!19H0F%C+%L.M#
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6_P!1@'_0#_\ :'_TUGS.OL=?K"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g838337g77r31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g77r31.jpg
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M@% * 4 H"JJ4.%3&$TY\0LK)KR&<*+O@I1,X29,)IER2E![MAR/[,YINENK
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M:S@X>'CN["PO6B>6WLSKS".PS:*"HJ)-<6LB3""&?,A#GT+!X-X@M#()X?#
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M02"(":3#P*.2"$*Y8%4H(ZBHYP-/ Q#*8&DE,,8@V%(%<P@/9: 4 H!0"@%
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ML3)&L; ^-%QP+7SRPROF%G:V-[6[M <:,\2W1 E<MB<V:C@ID=-!D2=C)A6
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M5H\L@* QJ[X<\'8+[0E'\,4KSFPI[X=;>5XWH0SW)W.^\E@V\FI;[6.1)KX
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M8L:&CVHYJN8KV)C(CFJK;41R+G,.7]: XBW_ (;JU_IJ_P#_ )=K=/L:U?\
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M,I@XU?F5B'[437Y35ZK=NE/!RKO+<7F$8O5N#O#RNODC"]<R1F^JG!ZC"@%
M* L<X4O/28/1N0?R>JUN+ /ODT3\SI?U=,%7MV)O$UBY5JWZZE#6)5]CQP%
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M:GXX@7,,W;]D79+X-/.NVH#W]H7E:CN>03HJS^#58>0Z6YA,'R@:M$4K% *
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M<*7GI,'HW(/Y/5:W%@'WR:)^9TOZNF"KV[$WB:Q<JU;]=2AK$J^QXX"@% *
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MQ_59>'QZ7-Q?]18;_P" :?ES6GX5=]4D/NH]C>I'P!"^O4M]_+=@=1I:+@A
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M]J=_J@_.MP^?M]%_A^JO]#.AQ;P=(^A9Y$) C+<+=!KN],+GRA%8"4=553,
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MX@#WE-SH4B:I<2>$V^QE05"=R =<;I<XRULA+C@R;&$*-^[,+#LHTN.2)',
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M 7PS2N;)JK*)* !H)JFDG)>6"R#FA6(6;Z8>%2$3%/2K!DL!$ZG0"@% * Y
MISBP$*:&[ K@.*+??;V:!QX1^(LIA@BV9!!131X)U-MFN83_ -K6'PSB!8FX
MG(S<10EXNU5@BY")-02"JX:1P*XY@@MYQ>@N*'[QG*<U0T?=CNF+5:1H,^BP
M&QFIL]K2XNNO!O8FW"L-\F<: [E=2WFP9*.#FT0@U5APP[L"G*L>'<5QS"2+
M:JK:B+98MMRI^.#CSIHF%KEJNP(J*-22E:/FTWY\562#>116HM.HW'C?D!ZE
MT=>F@6)&0KK9QFQLE/M_$AEQRB,)NMD=YFBQ%3=.2J?"Q'L,*MO#]-^BWCL3
MZ. ES0P* 4 H!0"@% 5H;P>7#.Z*"^]SM<K+M?0AQ/OU=*D@M-_,]?I6M_<I
MU1??JZ5),NU]"$K:@3% * 4 H!0"@% * 4!Q#8B5W5"$5K4GM2(7G.8[8/H0
MJU'$:X9GI)56T>6":8MGF"W[$3(#L<J(5.?.X#8.J#;**9(F>N*Y$S(#"XPR
MB6\-A 1)NE39+-I0E1!QV%U7W:@]J1)%J^R;N%R-R <SI8TLR'$D@HZ *'9/
M(2,[B1=2*; E4=O+S?>K*2(UD+)G'6Q'9U2&5S)9<J+GT\2ZN)..TFY#&MB-
M#[B6GD>DR7)C>:FUT-@I[MF5Q-]PKK9CMMGU-51F2C&6VTV@"<*X*:N<4%EU
MNDNY)(>)O!/&>SW<F2,C^(#"K;P(GBTDCJ&!0"@% * KSX@2M+$=HT+S@PI]
M7H*8,;R2$ASNI (3-=#*#CJ3PBS127[(C=>":+@H-",9'R9"L]#20XV*IH,5
MJTEN,N\T$=) / C*<*6>+5UI=?:MF8C'&R1M)LL\"$VM1I&M6),6F\>;!3;]
MCH;=<$*;108EJ^*4C*3^UDDIY(LML9ZV)K:E(VL"@Y2D@_0_$N9R<CR5H^>"
M_'3P$K41++TOLX47AL6S.G'=;J12UN(8D9T),5-8+)!4LD\H845556W IF5Y
MVO!TKIT95<[V>KC/99J#C=[J63)M77UD[GX0T=,Y8 !%20)4F7$56TZ;0P*
M4!Q)PL>05&?8VD!,/Q:'&S98$B-UTIZQ'XRG+IAPN50:)IO"LJ1\5@ )L-/
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)67D7+C+;<?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g838337g78f41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g78f41.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #  F # 1$
M A$! Q$!_\0 'P !  $#!0$!              4&!P@" P0)"@L!_\0 8!
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M_+>"S<S6)YB3F'#;<=EU!:4D4LYYHADG\@JG;2G>/$XB)BXPCAP*BI6$<Q:
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M[[<_F4]](Z2O[0#>;Z2^8O;#3O5IGJ^R]UA_!3OMJOK/4/?;G\RGOI'25_:
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M.-V,@%NY. 0>0!)Y5GYU]D=X]3O).'<W5O)_UA/&$Z)T8/*SRRH@B+748!+
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M>U>=+!/7L2Y>PDDF\;E>-#-P<-#-3*M$%P5 =Q:3O.DAD14>*>6!MA)5N&V
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M&$!W$20\8*NS=&>$@WDUL7L=-NX]]F9(&:2_,1))1UL[*PE9")Y\QQM-)<<
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MS=[1T:O*$8.8UQ9XZ[N8%1\$+W9[V'-TB(JX.:L62"N.+5',K$M%J3#9)X6
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MT$H-O':Q18O=9=)?FQM(;K?T8I-=SP2++%-*(P(4B#<6%#$RI,_":6'C22[
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M?2.1Y64K59:RU=E(5U6Y5_EJ^N'C"W15I7*>4B.QO&G>30^]B?ILI78RQ,A
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M-4--*4TI32E-*4TI32E-*4TI32E-*4TI32E:TS'(<ADC'*H4Y3)F3$0.4X"
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M664PNM*%/&+PA@D5+?G([T#0SH1<Q)@<F5 8QP(KL!XM5A%1(PZTW==@6^F
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MN \+)&P<J4@D;C6\'$V2%&9@98(S%Q @PDA0K&%RRB]L6)(BT8PMC2*ESO\
M#U:8U>@LWEBF'L1#,HR.GHE@["-=.E45I)&/L\RBX<'_ $4HN:'DIAO(2U3I
M[^ PC=S,DJ$KB9BTA"@$DE21G'82B_2.84@.X;/6R@5X7"MFW0)$"[%5"AE!
MP3S(#L,_K=4MED0KD%K&K*II2FE*:4JJ:C_&:O\ ,E?[9OI2OC#U;(F0*,F\
M1I5ZN-/1D3HJR"56L\W7TWRC<JA6ZCPD2^:%<G0*JJ5$ZX',D510""4#FX^V
MO%')C?&CX[-Z*V/JR#BO DDDCSPY'3/;L9ESCLS@C.,U[(O<=BRSF^[_ -PX
M55<.'%:V[K+KK*'56665F<SG5555.)CJ*J',8ZBAS&.<YA,81$1'7&]V(Q'I
MX'(![@ #R=6&NZ[AOTFI?X+7_P!4]>Q['.W*DXVRUF#-+&:O%EN>89!@NZ&Z
MV9:R15 A6;)D1S3L7,7+<AJ=4IN:9C:I^*07=&E)]1L9=SW+@ZW&0W+76J7%
MW96-@T=O#!8JP'1XA$]S(S,1/>,">//'&W!B<A=D0.!ODE>3JK'0[2QU+4]5
M26[GNM3="W2IS/'9Q(B!K73T8?V6VEE7I$T:EN),5RW#A@CBV<@;8<3Y.M4I
M;;BQG)![,PO<608(6&2CXA9,M8MM.2?]C8JH'+(MZ[>++'HJ@OV<!?)NSMCO
MF3)RWK;:O>VD*0P-&JQR<16,2LX\=#<;=S Y4RV\3$8SU2N=K,#2\T#3K^XD
MN;E9G:6+A.@GD2(CH]S:A]B$'>(+N= <[>N&*ET1ECX/:9AB ,D=G$SBZK9M
M7XUDM(6B:?*L82I!6TJG -#KNC"G$5QG4H)E'H&YUEDVSEU).'\G*2K][?)K
M5_(,,\8!,CL%B10TDW%,TA &-\K32,QY %@$"HB*MD7<YI<.-L<S%5@12]Q*
MQ2*VX'1H5RW*.!;:%$',D*S2,\DDCO2\3L9VZ1*EL.%4D9).[5XU3L;::GI&
M4;2-9,K:ENXKM%TH<'[0G?M96J9Y,7SI.(>M*\1P6NP=?BHJ5^Z'5'$(XRKT
M>7CQ&.-4*S8A'$!4#:W]GA8[=H,BM*1Q9)7?'C[DM$C-P>CR2"Z@-M.LLTDB
MO;DW!X+!B=ZCI<Z@R;V$3K &X$,$<=0T[:#@NB7R*R17*T];VR#%$8J1<S+]
MZLVZFHQ]$*5=TY44D)1,:I"P44",P]D$$3PZ,FV30F)&>D)>*?6]0N;=[665
M6A?.]0BJ#F9[CDHPB>.DD?,:H3Q"C91(ECGM>YK2;.[2^@@9;B+;PW:5W*[;
M:.S&68EY!T:*&/;([J.$)%"RO,\F3FM36^II2FE*:4JF[E78>WU"U5.Q,PD:
M_9ZW.5V=CQ7<M0?0\U%NHV39BY9+-GC<'3)RNAU[1P@Y1Y^L0625*0Y;E9D9
M74X9&#*< X93D'!R#@CL((\]6NBR(\;C<CJR.O,95@589&#S!(Y$&NB;Q??H
MA/J?LO/9N/\ VP:W/A'K/ST^PMOR:YOP9T/YE_O-W_,4\7WZ(3ZG[+SV;C_V
MP:>$>L_/3["V_)IX,Z'\R_WF[_F*>+[]$)]3]EY[-Q_[8-/"/6?GI]A;?DT\
M&=#^9?[S=_S%/%]^B$^I^R\]FX_]L&GA'K/ST^PMOR:>#.A_,O\ >;O^8IXO
MOT0GU/V7GLW'_M@T\(]9^>GV%M^33P9T/YE_O-W_ #%/%]^B$^I^R\]FX_\
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M4/Z_K_/LJ8TJ:FE*X3Z.9228)/6Y5R%$1)Q$Y#D$P<HBFJF8BI!$/C$AR\>
M#\90X:[4M)T[6(5@U*U2YC1BR;FDC>-F7:3'-"\<L9([2CKG"GM52,FUO+FR
M<R6TS1,P ; 5E8 Y 9'#(V#V;E..?G-?K%@SC6Y6K%NFV0*8Y^0G'RG./,<Y
MSF$QU%##_C'.8QAX  CP  "[3=+T_2+5;+3;6.TME9Y.''N.Z21MTDDCN6DE
MD<_*DE=W( !;"@"ES=7%Y*9[F5II2JKN;')4&%554!451V*H"CGRR37,UGUC
MTTI32E-*4TI32E6RM6'L>W>^4K(MMKD;8K#CZO7.N54LTQ82D;&M[U,X_G)J
M118OVCDJ4VB]QK6PC)5N=!RP;FDT4Q,#XPIRI-)'')$C%5D9&?:2">&LBJ,@
MCJXE;(/(\O-4+V\4DL<TB*[Q)(B;@&"B5HF8@$'K9A3##! SYZQ_L&Q7"]H.
MJ>:D<@KBT>6%Y3!;6=O&KXS-8F>44UBT)]&1#21C5XF7RY9;379:4>3,] V"
M-J2D=+(Q=6B8I#)6_G7L$?,*'RI(EV&''$!8@Y6%48 *K*7R-SEJQ&TRV?Y1
MEY%S'A\&'>)\\(A05VM</(C$LZ.L>&"HJBZU=V^5&EXZM^+*+/76C5*U1=EC
MFB-5FF<9)TA:UO["_DYFB3/<I:2@II$U@!O$NU7#].'1A(-6.;MWK5T[>PM<
MN\B2ND;NC*274D/M"@+(-V&7J\P,9).2>6)TM(XXGAC>2.-U=0$8*8][.S-&
MP7*ME\*<G:%7:!@DVR0V64!O&1<:C?,H,QB:K%U-N]@G= J#CL]3-?W&-I=!
MM3,>5V)BI[%LIDRV3M-D(&-B2K3KB+E;>WM;J!A#L)C?R$DF.(Y<OAA*_P O
MAB49>5F*RB)%<,3U00A0,V81IT0"@23#:@0%3''\CB\%@(XD56A,SM&5"]8A
MI Y5<2U,V@8^ICRH.TK/>9I.HHU-L$=(]X<7$V)#'D];;9C8EBC:;0ZJU54H
MEMO=MM,6[B"0[V<GY@TC>'-L58178;9+V20.-D:[]_,<0LID5$EVEY'/C$C1
M#G(55Q&$R<W1V$49C(>1N'L&T\,*XB9WAWJD:#Q4DCR*5VEG;,A?"XRNUAUG
M4TI32E-*4TI54U'^,U?YDK_;-]*5\G/PR]%I]0W=C_\ V$TG_H7UZ]P-4]8V
MO_VUOY^O$^D:1ZMO/_NB?_QU>L;W++==J5MMV]$FVO &7<)NF-<P4:WN,G[B
MX+.R5B;N)/*H0J,,WA\"X7-6E(Q1&3.^6<+V )4KYJ1-&-%@<[WDNZJ.[1++
MI-S%."T^SAVQM]I BSG-Q/OSRQ\G&/+GEVG<?)9N]_T6UFMR%MMYENEN=X)F
MV[0MM;[,<\YW;LCLQS]ANN.KN*:4II2FE*:4II2FE*:4II2N*^_S)Y_-7']D
M?2E6ATK'II2FE*:4II2FE*:4II2H"MIE2CG!2D(0!G[6H($AY*" 3+6B86.<
M64LX=.ESJ&.)U)A)0L;8E#&L$,W:0\FQ:(J?_']?UV=E3^E*:4II2FE*:4II
M2FE*@%DRC:(]7E()BP$PF!^X\DH<I3R,&82A8"."P[,AA3 30[EHI)20D*]8
MN$&L5()N%/Z_K^O/]-3^E*:4II2FE*:4II2FE*:4J ATRDD+48"D**T^@H82
MP\E&"<P5BN(\RCQ^X7:V$X%2*0)B&3:1J)"$@5&YI>$E7;I3S?UY34_I2FE*
M:4II2FE*:4II2FE*@*\F5)M( 4I"<T_/J"!(>2A0$RDL[.8QD)1PY6>G.(\Q
MIAJ9.-F!$9&,;MV+A!$BE3^E*:4II2FE*:4II2FE*I^S)E5C$BF(4X!-5E3@
M>'DITH"E9(E4INPQ+AJ[3,0Q .25.J:/@3E+.2[=W$QSUJLJY?E"IC2IJ:4I
MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4JJ:C_ !FK_,E?
M[9OI2OD*;:-J#7<;$3;T^=L08DE6]^H6-ZM"Y.F7,(6V66]L;7+-"'F^I&$J
MD:1C3I)DRG[6\BZV\L[R&KS^9A1DDY GLEU=FV91P)I@8Y)6:(!MBQE >KG<
MYRX)5 6"@L%.,5X9:V8N@W]I@A;B11(LS%=[R!V'6P5C7$; .Y5"^U2RYS7J
MR]R+5XU1S)TD54.^:RAZPWP?7CR;$1%E(FA;3F^-,^9B(B(M78MA<-Q$1$4E
M"<1$?+KE.Z]M\&FO@C>9VP>T;D@.#](SBNR[B5V3ZJF0=@MUR.P[7N!D?0<<
MJ]M[F8B63^,BGDI'-)2:%X$/&N7K9!_+#'( ZD C&:JI'#\6+80</ :IJ]F0
M$%EN1,>;7$!'97=49DCV[W"DJFXX7>P&%W'DN2,GD.==\TL:O'&TB+)+NX4;
M.H>38-S\-2=S[%YMM!VCF<"M;.3C9 KL["08OB,'CJ/?'9NT')63]D;D>,79
MD5#@W>-#_!=-EA(L@;X*I"#Y-&1EQN5EW*&7<"-RM\EAD<U;R$<CY*+)&X8H
MZ.$9D<JP8*Z'#HV"=K*>3*<%3V@5"DO%*4B&$^2X5<\#*R"<5&39+!$FB)&4
M6<J,THUA) [%F\D%7:*S5-FW64<'<I*(%3%4ABA)T>XWM'P)N(BEWCX3[U0
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M"*>""Y +$*"N6(4%CC. "3RJX=V.H,K,MC;E4 +L!,50,0H+$/A06(4$XR2
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M0C?A6ZP'B6EM?/X]KD1$P6UW$\BH[L2'$0D 0OFSK0UU5-*4TI32E8T[T/\
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MIXAD+DMPX$W.'#L>&86>(;V*-*^UD!;=TG:WE:&FE*:4II2FE*:4II2MT/\
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M>?\ 2RY^W?G]W947%4B&4EK4N9[=0/W52: 4<@991;=2>MP!Q.W;R5E)$&4
MRA@!_64NYZ:H'2.N6P(S8%IQ&[,)VY_1Q_\ ';G'+L[/M-7&,<N;]F/TDG9D
M^9NWZ>WZ>RI;P>P'4(-^Z%XZMNJ*R9O"=DKKS'$1'@NY[[.TN4N(^1!RJJ@
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MR^%!(K AW0FZ@HG#>A'8H%5B9#M0 9+G.W"^<[N7+R\JU[2(H<LZ@1#=(20
MBA=Q+'R +ULGR<ZH8<^81(T9/ULM8\:,I)^[BX]R^ML(P2?/V"<:H^;-3/7B
M +G9$F8@7@I\Q&HRL:5<R9WS8JLO1KC)'!E) !(",< YP3@'MVMCSX/FJ+I=
MM@'I$(!)4$R*,D;<@9(SC<N?-N&>T5QB;A\$J=W.&7\=%[VGS>+G^MML*CW'
ME'96RC2,?]<[)V>2=IO&BK5@IP=N$7395%$Z:Z1C.BW/5\1+UQE>H>8':1R[
M!@\^RG2[7K?VB'J$*_C%&UCC"G)Y$Y&!VG(J9:9GQ$_G(BM,<G4)[/V!K%O8
M"*:6R#</)QK.183<(M#IHO3]TRS$*(3,6#(5S2$2(230JK+]/JA@G"LYBD"K
MD,2C87:=K;N7+:PVG/8>1YU<+FW+*@GB+L%**)%)8.NY2HSUMR]9<9RO,<N=
M7+U#4U-*4TI32E-*4TI32E-*4TI32E-*4TI54U'^,U?YDK_;-]*5\O#HP6U7
ME:+D.,G,J[<J],L<LXSLU.H>XE_B%% ;;%L9II"9!QRSR7)Q+QW:8<9)]'.6
M#4\]4I<5(9K<*A/G;016OJNJEUDC*Q7+ PRJ\EL)L["06CD,0("G ()VNO6*
M.N6KQO20C)*&FM5830O''=&$#>-P66(2LN77)! +(<KQ(WPF._;W*"D9'<;T
MHZ)YA_8CI3&)TC6"4,F>3G3)WK/!33$B9%!LD9_)B O7ADFS=,7"Z@D02*()
MET/=8<VNE':%R)3M'8OBX.J,Y.!V#F:Z7N,&+G5QN+8, W'F6Q)<]8_2>T_3
M7:YO=PUO=RQNTG-TN'</Q4O";'0QH7 32RWFU5*ZY!?QKEEDK<8IBNC,*#8(
M>^MLPU"4;8",K-W*BI=IJRZD,K*G5,!MGW/W_<_9:+'H]]?21R=T/2^^;16\
M,UO:HRM::6+RX>YC>V:QG1M2\7;W)Q,!)L &.8[K-+[K-1[I)NZ'3-+BEB[D
MN@=YEGO+BVN[UT9+_7#IUFEG-%>#5+:1=&S+=68W6Y,1E)K6T:9QDMN?22;9
M*]MZW(063-R>6-\EOQ%<7F.UX/'DA#Y4BYJ4I:,C>GTJT;5UU:V[<T V.^11
M2:2LLQ1<N6Y%#N$C-IRZKW*ZM+J>E2VFE67<[!>P+="2Y5[-HTN"MNJ,95@)
MXI"DED1B%.,$BZL^B=W6@P:+KL-_KNI=UMUIET]BT-D\6H12R6H>[>1! UR%
M,*EP LDB!F )(PPR#M/R_.,<B7J"V;9,# =]6W8UC%&W3P<0S2Q4;)^3-D^W
MK#N.<JO\9'=IH4:*?9:Q_DQDG=SI-5:P>4+=G:C&/G495QOK;6K&-K6WDUVT
M[Y6W>::]U3I;M%<6=IK^J7UU9+=[2;EULKFT;HX+";:;<;GC,=<O>=SFIS)?
M7<7<O?\ >:\\(X-.T,V,2S6FH7_<IHNEV.HO8%@+1'U&ROT%V0IMS)THE$F$
MC=AF(,*9 @]^&W.RI[=+G69G&^/LC57<?E:9JU::T:^34_ARC,&N=*[F:#E3
M6')%INEHK%;QWX++.M+,ZG!Q4U:U*S6I=FSEY#F+[4+:3N<U2'OI!,EU<VLV
MEV<<TQN+:.*^N&.G2V$B<*UA@AEENNF0[&FD>.#BRH6C3M=,TJ]B[L-$N!HE
MU;RV-E?6VN:C+;6ZVEY+-IEHBZO!JD,G&OKBZN+>"Q[WW!D2VACFN>CP2JDC
M]XFO/J]9II2FE*:4II2K*;E+G.8XVYY^R'6%&Z-EH>%,J7.O+.VY';1*<J]%
MG9R)4=-%!!-TW3?L6YEFYQ BZ8&3,/*8=36R++<01O\ )DFB1L'!VNZJ<'R<
MCVUCW<C0VMS*F \5O-(F1D;DC9ER/*,@<O+7SVZET]G38WRA3.4:?&42PX[K
MUYIV-9NXQV#8)6"C+WD SLE.K+MZ9X0B<C.J,U4FP#Q12549).E6ZDC'E<^A
M/W/:%'(L3\19&1Y%0W#[BD>-[ >90<GZ,XS@X\Q3NCU^2-I4V-$DD<3.MLA5
M9)<\-2<<BVT@?3@'FRYX@]/WTT8.\I,>S8\[9A1DXD<J-PPE7Q4I;)KD"M8K
M<.)0 >CS$2R'<:Q5#=C%T;NI-,R@443'6)7P=T/$1\9B<@1'I#]<F-I>7_TT
M9^>.2GRU3PEUW,R[H\VX)F'1X_%@2I =W_U9$3ZV'DR:I&%]T<=+?84I->(L
M&(724/!O;&^4-B*L-2EAHYTT8O7;87D@W[>9!V];("T8=J>G.H/5MS@FJ)+V
M[F=&7&4F&6"CQ[GK$$@''9R&<G JQ>ZG6FW$20G:NYO$1\ER!GGV\R.0YU$^
M,I]*]SI)]\>*>L<*%10)X$HCG65.BDX(DD7KN*BAVZZ"Y2$ QC(K)*@ D4(8
M:^"^C\^I+R[?'MR[>W[#]AJWPKUGTL//_P#MX_A](^VJAA?=%'2^V*$LMCA)
M+%DC"U!G&2%B?-\,UWDCF<Q/1%7C5Q2.](X=%<V">A8L 9).3IN9-D"Q4R+D
M.-K=S6BJRJRRAGSM!G?GM4L?H&%5CSQV'S5<O=1K;*[+)"5C +D01\@65!]?
M695Y9YD5<_"W3A=.7N)+:#86A<<7\:8^K458D8K$E*;.FDS<E9I"I0+9I*S<
M>ZEK!95Z[-MX. AT7\Q)N(UPW9L55@*0T4^@Z!;;..9(]X8KF:0@JFW>Q(!"
MJ@92S-A0""34UOW0=T-UOZ/PY=A0-M@BY-)N"*,D;F<JP55RS$$ &K6V7W1;
MTO5/5;H666Q3$KN(UC+ BXPW7#JMF<DJY19]T4T'RIXMXJLS=(GC9(&DD@L@
MHDX:)'+RZE3N:T5\E%E8 E>4[\R,$X\XYCF,CGR-1/W4:W'@/)$I(#8,$?8<
M]OF/(\C@C',53Y_=*O2N)@Y%2RXG(#-1))V)\*0Y0:JK"((IN1,N'4**B4P)
M$5Y3*"40* B ZN\%]'Y=27GV>/;G]56>%>L^EA]WC^%<1#W27TJ\4D\0/:\8
M@#9\[6>&DL/Q[E9FYE7KI_V599Z[45:HE4661C6)C)HLF*"+!BBDT:(HIO!?
M1^74EY]GCVY_53PKUCTL/N\?U>:GC,O2F_//#GF=@/6M5\%M(]'-[=Z>%>L>
MEA]A'\*>,R]*;\\\.>9V ]:T\%M(]'-[=Z>%>L>EA]A'\*>,R]*;\\\.>9V
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MFGG[UB#/5SI$4L>VFC,0==O&6-T)("XDSLW,>JIP,D,05',XJ2.Z@E$Q1]W
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MB&VB,JEIN56L.*2/JW>XRM5&7/"6 :K=D+U%U.D&K].]UCA!WQM J+(-J[
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M(F9R8$A4JLFKQH^2,LR=-GB)'+QF=5JNDX2([CG:\?(-3*)&.0KEB_;.63Q
M1!5L[;KMEBD624(52J6/D;'J=H<4A2]TU.Z,TV2KNHGM$(6T-4I)1@C'*.(
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3A^<3M CF$4H3GR?U@?#/[Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g838337g84w86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g84w86.jpg
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MW95_V"^9&I9L3<*B$XP-=-UG09V4+APJM7+%5NK7!<EV1>/K\''R<?5@J<X
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M :&?IEXV[>K!B6CT0*>:O&2VKD:Q6XW:I"K*P[C\,DI*AEV,:?F,$J5[9W;
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MO"5.GB+L,%1@&F_B*_Z?7>O]S?L[_1.;X)6*XUYS<?CX./DX^K!!S@# & ,
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M!@'HV] /T'.H?[N%.?8('G@#7COSUJ_6'3'M\\[39NYY'@H/11MWG5C., 8
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M@*56_,KO3CZ)Z5=:5J2C+ZPY>^([24Z (C.U*P]^T=[&74).1B03IB"DLH]
M"Q+::WW;$L]BPV;JX%J&"HP"OGQ#8!V"LVMA$(H A*!A^41GL=&6Q&*2,O$5
MA$_D_5>Z0%0G)))PRS9P"B@V>$67"9A5;5(-/74 -H^UD!C%VU$JFW=Y[^@U
M2TJ_Q*8"Z33KF9R"IZ4>2NW9<YCI>4@^U4VJZOS%># 4=CJJDZBTZM&;2J*V
M"-,W#"(] )).!+]O)5*J<!'+ "#'&A-5MIYJWO8J<6P[_.Z_[U=@^H76Z0E'
M,A@O8XA9OKLF<&C=A+U""@XZ1BK$<0"G[24 ,@4IFU;5LRED,!VH!%F0\\D)
MJ++2,<L^*,T W(BY-K9AL;I7%<W-<2?1E&VY4E[15\X+68\ 3&0]R)1-F$DM
M2S+5@49K]2:5+&.OL8%$)_)9/R)E96(Q<!.TA*;OCD8:-7BB*Y;"WJC/D&UY
MMB6;;]W%3(LEP0, 8 P!@# & , 8 P#H#^U:S%O):/)SZ(CWL"Y ZS9L]D Q
MJK$^90FDM'>)#JNYTY$\FTG#=4;P]]I\[371W1]EJJGSL%#J/OD:&\_>#-K8
M@Z;MB@BNMJJ>9))J;+NBC31FT744U1?$^%1+C?84RW7(ZMW(EWRU\U-AUGPF
MCR/O*7U4 EM+W*\] .O<+#UY](V@EWJ;)-8>B!8274^V&".'K\B/>!B;%X,5
M'MW/I7AQJF-X=*:[ZZA1Y;N4Q#;L[UX=(C%T;HK;G0RV7>B_92X+KL_9-$E%
M7CYIKR[_ /L#V?"*Z;H@C[-B@NV<MU'&J[=9/013X^.-&8,7]2,>+; #EL0
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g838337g94e00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g94e00.jpg
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M8FIE8W1S('=E<F4@8VAA;F=E9"!T;R!G<F%Y<V-A;&4N)B-X03LF(WA!.^*
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M\SUE2^D?AP(6HZ)>/$Q/.1$@P 8 >.G71T].NC^WI\W]GZ_^/FP&8\X , &
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MAD;RMCU455.%PG"J815+%<A<PLYZ8CI,DBED%/EIR5*Y0YJV>Z-5:M,%9(F
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M1M8)#$90JCR\!;TWM#LS/:AC="S#.S Z)42A28V+P'$F]0*LLA0$PHSJZT(
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MEQ==H-YM-E68B9IS;9^LF9.EMR:XG4$HN1;(VTZZBUN3V%D8ZAC' %GBC!F
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M09 OFSW]YGK*E](_#@0M1T2\>)B><B)!@ P 8 , & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # "D&Y?2U97KQ)_:ZO+RW%W%P%![S[SXBT7C'Z#
M(%\V>_O,]94OI'X<"%J.B7CQ,3SD1(, & # !@ P 8 , & # !@ P 8 , &
M# !@ P 8 , & # !@ P 8 4@W+Z6K*]>)/[75Y>6XNXN H/>?>?$6B\8_09
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M3"%:(XERV9L].2$?GYVC(+ !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
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M4ZL]@D+I(4$+0.;7&$RAJG$HC:8+2@>'F0.2<D2!E2&'!5/"T0E0SS #+*&
MDODF(JYBIN9U?&4ZMB,MM+:GE)4Z9+8:=/74A#:3^LLR+)"=F6\]I]WPI:R;
MS#];:RTLHDS&G%NICI6ADC1(>:+42XXZLBU6TYZSBCSS//+86;V?%&PA@ P
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M:?Q8G^><,:^U%M^E8^Z1QZ\T>>QE%\._]]DBUW-6&Z!@ P 8 , & # !@ P
M8 , & %(-R^EJRO7B3^UU>7EN+N+@*#WGWGQ%HO&/T&0+YL]_>9ZRI?2/PX$
M+4=$O'B8G0\\A*0<I4G%)TR<HP]0H/, 20002#9AIQQIFPEE%%%A$,PP8@@
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M]^?>][\^][_7FW(Z"?\ RIX$/[=X>/.@HS/:9T]89F?7_P!"8$@9(?8# !@
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6L0A;WL6][_7O>]].][W_ %[W@!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g838337g96o97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g96o97.jpg
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M&1HC07BVN-,D,C8Y459767&6H<G5UM<S-6&8U$)#4V-RAI.4E?_$ !T! 0$
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MZ;($Z\YRI^Y;;$B7NF^R".Y$*+8D.B6'9#$;<-^LLUIFJSQ]A@:-$6'+4#'
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M[?N)\,,'PO(,DRC$:AJEE9@W7+<1:QTX])(<KTD*Q-C4[)#7193R23*1(C,
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MPZGE:RNS D5Q([P[]Q)KD7;^*39#LOS*J$GX%UPO8C5."J-^(8+Y"%WG3?\
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M\<7H_P";'^[SM'+9OXFN>TO]8!J$/X[!]"?U86IJ/(G5WIQIJ*C\7-3*[)]
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M&'@PS+"JQ8NXO#L4&,PWX>$VJ<K?9"<Y4V!30?5$03[1H5447954E0>7+4M
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M(820D5G)TN0)@OM (N.=0DY17=":/;G#E<6SFU_PANK_ -_S]_;?^C^Y&/\
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@IQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIK_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
